|
|
|
Scientific Literature, PPAR
-
Aasum E, Khalid AM, Gudbrandsen OA, How OJ, Berge RK, Larsen TS. Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.
J. Mol. Cell. Cardiol. 44: 201-209 (2008).
-
Abbott BD. Review of the expression of peroxisome proliferators activated receptors alpha (PPARalpha), beta (PPARbeta), and gamma (PPARgamma) in rodent and human development.
Reprod. Toxicol. 27: 246-257 (2009).
-
Abbott BD, Wolf CJ, Schmid JE, Das KP, Zehr RD, Helfant L, Nakayama S, Lindstrom AB, Strynar MJ, Lau CS. Perfluorooctanoic acid (PFOA)-induced developmental toxicity in the mouse is dependent on expression of peroxisome proliferator activated receptor-alpha (PPARalpha).
Toxicol. Sci. 98: 571-581 (2007).
*
-
Abedin M, Lim J, Tang TB, Park D, Demer LL, Tintut Y. n-3 Fatty acids inhibit vascular calcification via the p38-MAPK and peroxisome proliferator-activated receptor-gamma pathways.
Circ. Res. 98: 727-729 (2006).
*
-
Abedin SA, Thorne JL, Battaglia S, Maguire O, Hornung L, Doherty AP, Mills IG, Campbell MJ. Elevated NCOR1 disrupts a network of dietary-sensing nuclear receptors in bladder cancer cells.
Carcinogenesis 30: 449-456 (2009).
*
-
Aberle J, Hopfer I, Beil FU, Seedorf U. Association of peroxisome proliferator-activated receptor delta +294T/C with body mass index and interaction with peroxisome proliferator-activated receptor alpha L162V.
Int. J. Obes. (Lond.) 30: 1709-1713 (2006).
-
Aceves C, Garcia-Solis P, Arroyo-Helguera O, Vega-Riveroll L, Delgado G, Anguiano B. Antineoplastic effect of iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).
Mol. Cancer 8: 33 (2009).
-
Ackert-Bicknell C, Rosen C. The genetics of PPARG and the skeleton.
PPAR Res. 2006: 93258 (2006).
*
-
Adachi M, Kurotani R, Morimura K, Shah Y, Sanford M, Madison BB, Gumucio DL, Marin HE, Peters JM, Young HA, Gonzalez FJ. PPARgamma in colonic epithelial cells protects against experimental inflammatory bowel disease.
Gut 55: 1104-1113 (2006).
*
-
Adamiec R, Gacka M, Dobosz T, Szymaniec S, Bednarska-Chabowska D, Sadakierska-Chudy A. Stimulation of the peroxisome proliferator-activated receptor gamma (PPARgamma) and the expression of selected blood monocyte cytokine genes in diabetic macroangiopathy.
Atherosclerosis 194: e108-e115 (2007).
-
Adamkiewicz J, Kaddatz K, Rieck M, Wilke B, Muller-Brusselbach S, Muller R. Proteomic profile of mouse fibroblasts with a targeted disruption of the peroxisome proliferator activated receptor-beta/delta gene.
Proteomics 7: 1208-1216 (2007).
*
-
Adamo KB, Dent R, Langefeld CD, Cox M, Williams K, Carrick KM, Stuart JS, Sundseth SS, Harper ME, McPherson R, Tesson F. Peroxisome proliferator-activated receptor gamma 2 and acyl-CoA synthetase 5 polymorphisms influence diet response.
Obesity (Silver Spring) 15: 1068-1075 (2007).
*
-
Adida A, Spener F. Adipocyte-type fatty acid-binding protein as inter-compartmental shuttle for peroxisome proliferator activated receptor gamma agonists in cultured cell.
Biochim. Biophys. Acta 1761: 172-181 (2006).
*
-
Afif H, Benderdour M, Mfuna-Endam L, Martel-Pelletier J, Pelletier JP, Duval N, Fahmi H. Peroxisome proliferator-activated receptor gamma1 expression is diminished in human osteoarthritic cartilage and is down-regulated by interleukin-1beta in articular chondrocytes.
Arthritis Res. Ther. 9: R31 (2007).
*
-
Agassandian M, Miakotina OL, Andrews M, Mathur SN, Mallampalli RK. P. aeruginosa and sPLA2 IB stimulate ABCA1-mediated phospholipid efflux via ERK-activation of PPARalpha/RXR.
Biochem. J. 403: 409-420 (2007).
*
-
Aggelidou E, Iordanidou P, Demetriades C, Piltsi O, Hadzopoulou-Cladaras M. Functional characterization of hepatocyte nuclear factor-4alpha dimerization interface mutants.
FEBS J. 273: 1948-1958 (2006).
*
-
Ahlawat P, Srinivas NR. Allometric prediction of the human pharmacokinetic parameters for naveglitazar.
Eur. J. Drug Metab. Pharmacokinet. 33: 187-190 (2008).
-
Ahmed I, Furlong K, Flood J, Treat VP, Goldstein BJ. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes.
Am. J. Ther. 14: 49-62 (2007).
-
Ahmed RA, Murao K, Imachi H, Yu X, Li J, Wong NC, Ishida T. Human scavenger receptor class B type 1 is regulated by activators of peroxisome proliferators-activated receptor-gamma in hepatocytes.
Endocrine 35: 233-242 (2009).
-
Ahmed W, Orasanu G, Nehra V, Asatryan L, Rader DJ, Ziouzenkova O, Plutzky J. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha. A candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion.
Circ. Res. 98: 490-498 (2006).
*
-
Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, Kanda T, Orasanu G, Sharlach M, Zandbergen F, Plutzky J. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
J. Intern. Med. 262: 184-198 (2007).
*
-
Ahmetov II, Mozhayskaya IA, Flavell DM, Astratenkova IV, Komkova AI, Lyubaeva EV, Tarakin PP, Shenkman BS, Vdovina AB, Netreba AI, Popov DV, Vinogradova OL, Montgomery HE, Rogozkin VA. PPARalpha gene variation and physical performance in Russian athletes.
Eur. J. Appl. Physiol. 97: 103-108 (2006).
-
Ahmetov II, Mozhayskaya IA, Lyubaeva EV, Vinogradova OL, Rogozkin VA. PPARG gene polymorphism and locomotor activity in humans.
Bull. Exp. Biol. Med. 146: 630-632 (2008).
-
Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, Freedman ND, Abnet CC, Huang WY, Kibel AS, Crawford ED, Weinstein SJ, Chanock SJ, Schatzkin A, Hayes RB; for the Prostate, Lung, Colorectal, and Ovarian (PLCO) Trial Project Team. Vitamin D-related genes, serum vitamin D concentrations, and prostate cancer risk.
Carcinogenesis 30: 769-776 (2009).
*
-
Ahn JH, Shin MS, Jung SH, Kang SK, Kim KR, Rhee SD, Jung WH, Yang SD, Kim SJ, Woo JR, Lee JH, Cheon HG, Kim SS. Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists.
J. Med. Chem. 49: 4781-4784 (2006).
*
-
Ahn KO, Lim SW, Yang HJ, Li C, Sugawara A, Ito S, Choi BS, Kim YS, Kim J, Yang CW. Induction of PPAR gamma mRNA and protein expression by rosiglitazone in chronic cyclosporine nephropathy in the rat.
Yonsei. Med. J. 48: 308-316 (2007).
*
-
Ahsan MK, Okuyama H, Hoshino Y, Oka SI, Masutani H, Yodoi J, Nakamura H. Thioredoxin-binding protein-2 deficiency enhances methionine-choline deficient diet-induced hepatic steatosis but inhibits steatohepatitis in mice.
Antioxid. Redox Signal. May 18 [Epub ahead of print] (2009).
-
Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, Genua M, Vigneri R, Belfiore A. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells.
Endocrinology 147: 4463-4475 (2006).
*
-
Ajmo JM, Liang X, Rogers CQ, Pennock B, You M. Resveratrol alleviates alcoholic fatty liver in mice.
Am. J. Physiol. Gastrointest. Liver Physiol. 295: G833-G842 (2008).
*
-
Akahori T, Sho M, Hamada K, Suzaki Y, Kuzumoto Y, Nomi T, Nakamura S, Enomoto K, Kanehiro H, Nakajima Y. Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice.
J. Hepatol. 47: 784-792 (2007).
*
-
Akbiyik F, Cinar K, Demirpence E, Ozsullu T, Tunca R, Haziroglu R, Yurdaydin C, Uzunalimoglu O, Bozkaya H. Ligand-induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver.
Eur. J. Clin. Invest. 34: 429-435 (2004).
-
Akiyama TE, Baumann CT, Sakai S, Hager GL, Gonzalez FJ. Selective intranuclear redistribution of PPAR isoforms by RXR alpha.
Mol. Endocrinol. 16: 707-721 (2002).
*
-
Akiyama TE, Meinke PT, Berger JP. PPAR ligands: potential therapies for metabolic syndrome.
Curr. Diab. Rep. 5: 45-52 (2005).
-
Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB Jr, Gonzalez FJ. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux.
Mol. Cell. Biol. 22: 2607-2619 (2002).
*
-
Akkiz H. Hepatocellular carcinoma pathogenesis: does PPAR alpha polymorphism have a role in hepatocarcinogenesis associated with HBV and HCV infections?
Turk. J. Gastroenterol. 19: 231-233 (2008).
*
-
Al-Hasani H, Joost HG. Nutrition-/diet-induced changes in gene expression in white adipose tissue.
Best Pract. Res. Clin. Endocrinol. Metab. 19: 589-603 (2005).
-
Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A. Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle.
Mol. Endocrinol. 20: 3364-3375 (2006).
*
-
Alarcon de la Lastra C, Sanchez-Fidalgo S, Villegas I, Motilva V. New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists.
Curr. Pharm. Des. 10: 3505-3524 (2004).
-
Alarcon-Aguilar FJ, Almanza-Perez J, Blancas G, Angeles S, Garcia-Macedo R, Roman R, Cruz M. Glycine regulates the production of pro-inflammatory cytokines in lean and monosodium glutamate-obese mice.
Eur. J. Pharmacol. 599: 152-158 (2008).
*
-
Alaynick WA. Nuclear receptors, mitochondria and lipid metabolism.
Mitochondrion 8: 329-337 (2008).
-
Aleksunes LM, Yeager RL, Klaassen CD. Application of multivariate statistical procedures to identify transcription factors that correlate with MRP2, 3, and 4 mRNA in adult human livers.
Xenobiotica 39: 514-522 (2009).
*
-
Aleman G, Torres N, Tovar AR. Peroxisome proliferator-activated receptors (PPARs) in obesity and insulin resistance development.
Rev. Invest. Clin. 56: 351-367 (2004).
-
Aleshin S, Grabeklis S, Hanck T, Sergeeva M, Reiser G. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Mol. Pharmacol. 76: 414-424 (2009).
*
-
Alevizaki M, Mantzou E, Cimponeriu A, Saltiki K, Philippou G, Wiersinga W. The Pro(12)Ala PPARgamma gene polymorphism: possible modifier of the activity and severity of thyroid associated orbitopathy (TAO).
Clin. Endocrinol. (Oxf.) 70: 464-468 (2009).
*
-
Alexis JD, Wang N, Che W, Lerner-Marmarosh N, Sahni A, Korshunov VA, Zou Y, Ding B, Yan C, Berk BC, Abe JI. Bcr kinase activation by angiotensin II inhibits peroxisome proliferator-activated receptor gamma transcriptional activity in vascular smooth muscle cells.
Circ. Res. 104: 69-78 (2009).
*
-
Ali F, Ali NS, Bauer A, Boyle JJ, Hamdulay SS, Haskard DO, Randi AM, Mason JC. PPARdelta and PGC1alpha act cooperatively to induce heme oxygenase-1 and enhance vascular endothelial cell resistance to stress.
Cardiovasc. Res. Nov 10 [Epub ahead of print] (2009).
-
Ali FY, Davidson SJ, Moraes LA, Traves SL, Paul-Clark M, Bishop-Bailey D, Warner TD, Mitchell JA. Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARbeta.
FASEB J. 20: 326-328 (2006).
*
-
Ali FY, Hall MG, Desvergne B, Warner TD, Mitchell JA. PPARbeta/delta agonists modulate platelet function via a mechanism involving PPAR receptors and specific association/repression of PKCalpha.
Arterioscler. Thromb. Vasc. Biol. 29: 1871-1873 (2009).
-
Ali SB, Yahia FB, Sediri Y, Kallel A, Ftouhi B, Feki M, Elasmi M, Haj-Taieb S, Souheil O, Sanhagi H, Slimane H, Jemaa R, Kaabachi N. Gender specific effect of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma-2 gene on obesity risk and leptin levels in a Tunisian population.
Clin. Biochem. 42: 1642-1647 (2009).
*
-
Alibin CP, Kopilas MA, Anderson HD. Suppression of cardiac myocyte hypertrophy by conjugated linoleic acid: role of peroxisome proliferator-activated receptors alpha and gamma.
J. Biol. Chem. 283: 10707-10715 (2008).
*
-
Aligeti VR, Gandhi M, Braden R, Rezk A, Elam MB. Effect of combination lipid-modifying therapy on the triglyceride lowering effect of fish oil.
Am. J. Med. Sci. 333: 168-172 (2007).
-
Aljada A, Shah KA, Mousa SA. Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?
PPAR Res. 2009: 460764 (2009).
*
-
Allahtavakoli M, Shabanzadeh A, Roohbakhsh A, Pourshanazari A. Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats.
Basic Clin. Pharmacol. Toxicol. 101: 309-314 (2007).
*
-
Allen T, Zhang F, Moodie SA, Clemens LE, Smith A, Gregoire F, Bell A, Muscat GE, Gustafson TA. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
Diabetes 55: 2523-2533 (2006).
*
-
Alleva DG, Johnson EB, Lio FM, Boehme SA, Conlon PJ, Crowe PD. Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma.
J. Leukoc. Biol. 71: 677-685 (2002).
*
-
Alleva LM, Cai C, Clark IA. Using complementary and alternative medicines to target the host response during severe influenza.
Evid. Based Complement. Alternat. Med. Sep 24 [Epub ahead of print] (2009).
-
Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease.
Aliment. Pharmacol. Ther. 18 Suppl. 2: 10-14 (2003).
*
-
Allgayer H, Kruis W. PPAR-ligands: a clinically important regulatory system with multiple options in the treatment of diabetes mellitus, inflammatory bowel disease and in the chemoprevention of colon cancer?
Z. Gastroenterol. 41: 1035-1038 (2003).
-
Allred CD, Talbert DR, Southard RC, Wang X, Kilgore MW. PPARgamma1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells.
J. Nutr. 138: 250-256 (2008).
*
-
Almad A, McTigue DM. Chronic expression of PPAR-delta by oligodendrocyte lineage cells in the injured rat spinal cord.
J. Comp. Neurol. 518: 785-799 (2009).
-
Almanza-Perez JC, Alarcon-Aguilar FJ, Blancas-Flores G, Campos-Sepulveda AE, Roman-Ramos R, Garcia-Macedo R, Cruz M. Glycine regulates inflammatory markers modifying the energetic balance through PPAR and UCP-2.
Biomed. Pharmacother. Oct 17 [Epub ahead of print] (2009).
-
Almeida M, Ambrogini E, Han L, Manolagas SC, Jilka RL. Increased lipid oxidation causes oxidative stress, increased PPARgamma expression and diminished pro-osteogenic Wnt signaling in the skeleton.
J. Biol. Chem. 284: 27438-27448 (2009).
*
-
Almeida PE, Silva AR, Maya-Monteiro CM, Torocsik D, Avila HD, Dezso B, Magalhaes KG, Castro-Faria-Neto HC, Nagy L, Bozza PT. Mycobacterium bovis Bacillus Calmette-Guerin infection induces TLR2-dependent peroxisome proliferator-activated receptor gamma expression and activation: functions in inflammation, lipid metabolism, and pathogenesis.
J. Immunol. 183: 1337-1345 (2009).
-
Almendro V, Fuster G, Busquets S, Ametller E, Figueras M, Argiles JM, Lopez-Soriano FJ. Effects of IL-15 on rat brown adipose tissue: uncoupling proteins and PPARs.
Obesity (Silver Spring) 16: 285-289 (2008).
*
-
Alnouti Y, Klaassen CD. Regulation of sulfotransferase enzymes by prototypical microsomal enzyme inducers in mice.
J. Pharmacol. Exp. Ther. 324: 612-621 (2008).
*
-
Alnouti Y, Klaassen CD. Tissue distribution, ontogeny, and regulation of aldehyde dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme inducers in mice.
Toxicol. Sci. 101: 51-64 (2008).
*
-
Alsarra IA, Brockmann WG, Cunningham ML, Badr MZ. Hepatocellular proliferation in response to agonists of peroxisome proliferator-activated receptor alpha: a role for Kupffer cells?
J. Carcinog. 5: 26 (2006).
*
-
Altmann R, Hausmann M, Spottl T, Gruber M, Bull AW, Menzel K, Vogl D, Herfarth H, Scholmerich J, Falk W, Rogler G. 13-Oxo-ODE is an endogenous ligand for PPARgamma in human colonic epithelial cells.
Biochem. Pharmacol. 74: 612-622 (2007).
*
-
Alvaro A, Rosales R, Masana L, Vallve JC. Polyunsaturated fatty acids down-regulate in vitro expression of the key intestinal cholesterol absorption protein NPC1L1: no effect of monounsaturated nor saturated fatty acids.
J. Nutr. Biochem. May 13 [Epub ahead of print] (2009).
*
-
Alwayn IP, Andersson C, Lee S, Arsenault DA, Bistrian B, Gura KM, Nose V, Zauscher B, Moses MA, Puder M. Inhibition of matrix metalloproteinases increases PPAR-alpha and IL-6 and prevents dietary-induced hepatic steatosis and injury in a murine model.
Am. J. Physiol. Gastrointest. Liver Physiol. 291: G1011-G1019 (2006).
*
-
Aly HH, Shimotohno K, Hijikata M. 3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV.
Biochem. Biophys. Res. Commun. 379: 330-334 (2009).
*
-
Ambrosio AL, Dias SM, Polikarpov I, Zurier RB, Burstein SH, Garratt RC. Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma.
J. Biol. Chem. 282: 18625-18633 (2007).
*
-
Ameen C, Edvardsson U, Ljungberg A, Asp L, Akerblad P, Tuneld A, Olofsson SO, Linden D, Oscarsson J. Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver.
J. Biol. Chem. 280: 1224-1229 (2005).
*
-
Amengual J, Ribot J, Bonet ML, Palou A. Retinoic acid treatment increases lipid oxidation capacity in skeletal muscle of mice.
Obesity (Silver Spring) 16: 585-591 (2008).
*
-
Amin RH, Mathews ST, Camp HS, Ding L, Leff T. Selective activation of PPARgamma in skeletal muscle induces endogenous production of adiponectin and protects mice from diet-induced insulin resistance.
Am. J. Physiol. Endocrinol. Metab. Oct 20 [Epub ahead of print] (2009).
*
-
Amoruso A, Bardelli C, Fresu LG, Palma A, Vidali M, Ferrero V, Ribichini F, Vassanelli C, Brunelleschi S. Enhanced PPAR-gamma expression in monocyte/macrophages from coronary artery disease patients and possible gender differences.
J. Pharmacol. Exp. Ther. 331: 531-538 (2009).
*
-
Amoruso A, Bardelli C, Gunella G, Fresu LG, Ferrero V, Brunelleschi S. Quantification of PPAR-gamma protein in monocyte/macrophages from healthy smokers and non-smokers: a possible direct effect of nicotine.
Life Sci. 81: 906-915 (2007).
*
-
Amoruso A, Bardelli C, Gunella G, Ribichini F, Brunelleschi S. A novel activity for substance P: stimulation of peroxisome proliferator-activated receptor-gamma protein expression in human monocytes and macrophages.
Br. J. Pharmacol. 154: 144-152 (2008).
*
-
Amoruso A, Gunella G, Rondano E, Bardelli C, Fresu L, Ferrero V, Ribichini F, Vassanelli C, Brunelleschi S. Tobacco smoke affects expression of peroxisome proliferator-activated receptor-gamma in monocyte/macrophages of patients with coronary heart disease.
Br. J. Pharmacol. 158: 1276-1284 (2009).
*
-
Amsaguine-Safir S, Bianchi A, Collet P, Huin-Schohn C, Jeanvoine A, Becuwe P, Kremarik-Bouillaud P, Domenjoud L, Keller JM, Schohn H, Dauca M. Induction of the expression of the peroxisome proliferator-activated receptor alpha (PPARalpha) by clofibrate in jerboa tissues.
Microsc. Res. Tech. 61: 185-190 (2003).
*
-
Anderson AL, Harris TB, Houston DK, Tylavsky FA, Lee JS, Sellmeyer DE, Sahyoun NR. Relationships of dietary patterns with body composition in older adults differ by gender and PPAR-gamma Pro12Ala genotype.
Eur. J. Nutr. Feb 21 [Epub ahead of print] (2010).
-
Anderson SP, Dunn C, Laughter A, Yoon L, Swanson C, Stulnig TM, Steffensen KR, Chandraratna RA, Gustafsson JA, Corton JC. Overlapping transcriptional programs regulated by the nuclear receptors peroxisome proliferator-activated receptor alpha, retinoid X receptor and liver X receptor in mouse liver.
Mol. Pharmacol. 66: 1440-1452 (2004).
*
-
Anderson SP, Dunn CS, Cattley RC, Corton JC. Hepatocellular proliferation in response to a peroxisome proliferator does not require TNFalpha signaling.
Carcinogenesis 22: 1843-1851 (2001).
*
-
Anderson SP, Howroyd P, Liu J, Qian X, Bahnemann R, Swanson C, Kwak MK, Kensler TW, Corton JC. The transcriptional response to a peroxisome proliferator-activated receptor alpha agonist includes increased expression of proteome maintenance genes.
J. Biol. Chem. 279: 52390-52398 (2004).
*
-
Anderson SP, Yoon L, Richard EB, Dunn CS, Cattley RC, Corton JC. Delayed liver regeneration in peroxisome proliferator-activated receptor-alpha-null mice.
Hepatology 36: 544-554 (2002).
*
-
Andersson C, Zaman MM, Jones AB, Freedman SD. Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages.
J. Cyst. Fibros. 7: 68-78 (2008).
-
Andreeva-Gateva P. Peroxisome proliferator activated receptors PPARs: their role in carbohydrate and lipid metabolism.
Ann. Biol. Clin. (Paris) 61: 295-303 (2003).
-
Andrulionyte L, Kuulasmaa T, Chiasson JL, Laakso M. Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
Diabetes 56: 1181-1186 (2007).
*
-
Andrulionyte L, Peltola P, Chiasson JL, Laakso M. Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial.
Diabetes 55: 2148-2152 (2006).
*
-
Andrulionyte L, Zacharova J, Chiasson JL, Laakso M; for the STOP-NIDDM Study Group. Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial.
Diabetologia 47: 2176-2184 (2004).
*
-
Anghel SI, Wahli W. Fat poetry: a kingdom for PPARgamma.
Cell Res. 17: 486-511 (2007).
*
-
Annicotte JS, Culine S, Fajas L. Role of PPARgamma in the control of prostate cancer growth: a new approach for therapy.
Bull. Cancer 94: 135-137 (2007).
-
Antoun J, Goulitquer S, Amet Y, Dreano Y, Salaun JP, Corcos L, Plee-Gautier E. CYP4F3B is induced by PGA1 in human liver cells: a regulation of the 20-HETE synthesis.
J. Lipid Res. 49: 2135-2141 (2008).
*
-
Aoki T, Asaki T, Hamamoto T, Sugiyama Y, Ohmachi S, Kuwabara K, Murakami K, Todo M. Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Bioorg. Med. Chem. Lett. 18: 2128-2132 (2008).
*
-
Aoki Y, Maeno T, Aoyagi K, Ueno M, Aoki F, Aoki N, Nakagawa J, Sando Y, Shimizu Y, Suga T, Arai M, Kurabayashi M. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis.
Respiration 77: 311-319 (2009).
-
Aouabdi S, Gibson GG, Plant N. Transcriptional regulation of the PXR gene: identification and characterization of a functional PPARalpha-binding site within the proximal promoter of the PXR gene.
Drug Metab. Dispos. 34: 138-144 (2006).
*
-
Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha).
J. Biol. Chem. 273: 5678-5684 (1998).
*
-
Aprahamian T, Bonegio RG, Richez C, Yasuda K, Chiang LK, Sato K, Walsh K, Rifkin IR. The peroxisome proliferator-activated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin.
J. Immunol. 182: 340-346 (2009).
*
-
Arai T, Kim HJ, Chiba H, Matsumoto A. Anti-obesity effect of fish oil and fish oil-fenofibrate combination in female KK mice.
J. Atheroscler. Thromb. 16: 674-683 (2009).
-
Araki E, Igata M, Motoshima H, Tsuruzoe K. Polymorphisms of PPARs and metabolic disorders.
Nippon Rinsho 63: 617-622 (2005).
-
Araki H, Tamada Y, Imoto S, Dunmore B, Sanders D, Humphrey S, Nagasaki M, Doi A, Nakanishi Y, Yasuda K, Tomiyasu Y, Tashiro K, Print C, Charnock-Jones DS, Kuhara S, Miyano S. Analysis of PPARalpha-dependent and PPARalpha-independent transcript regulation following fenofibrate treatment of human endothelial cells.
Angiogenesis 12: 221-229 (2009).
-
Araki M, Nozaki Y, Motojima K. Transcriptional regulation of metabolic switching PDK4 gene under various physiological conditions.
Yakugaku Zasshi 127: 153-162 (2007).
-
Araki O, Ying H, Furuya F, Zhu X, Cheng SY. Thyroid hormone receptor beta mutants: dominant negative regulators of peroxisome proliferator-activated receptor gamma action.
Proc. Natl. Acad. Sci. U.S.A. 102: 16251-16256 (2005).
*
-
Araya Y, Kasuga JI, Toyota K, Hirakawa Y, Oyama T, Makishima M, Morikawa K, Hashimoto Y, Miyachi H. Structure-based design and synthesis of fluorescent PPARalpha/delta co-agonist and its application as a probe for fluorescent polarization assay of PPARdelta ligands.
Chem. Pharm. Bull. (Tokyo) 56: 1357-1359 (2008).
-
Are A, Aronsson L, Wang S, Greicius G, Lee YK, Gustafsson JA, Pettersson S, Arulampalam V. Enterococcus faecalis from newborn babies regulate endogenous PPARgamma activity and IL-10 levels in colonic epithelial cells.
Proc. Natl. Acad. Sci. U.S.A. 105: 1943-1948 (2008).
*
-
Argmann C, Dobrin R, Heikkinen S, Auburtin A, Pouilly L, Cock TA, Koutnikova H, Zhu J, Schadt EE, Auwerx J. Ppargamma2 is a key driver of longevity in the mouse.
PLoS Genet. 5: e1000752 (2009).
*
-
Aronis A, Aharoni-Simon M, Madar Z, Tirosh O. Triacylglycerol-induced impairment in mitochondrial biogenesis and function in J774.2 and mouse peritoneal macrophage foam cells.
Arch. Biochem. Biophys. 492: 74-81 (2009).
*
-
Aronoff DM, Serezani CH, Carstens JK, Marshall T, Gangireddy SR, Peters-Golden M, Reddy RC. Stimulatory effects of peroxisome proliferator-activated receptor-gamma on Fcgamma receptor-mediated phagocytosis by alveolar macrophages.
PPAR Res. 2007: 52546 (2007).
*
-
Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, et al. Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.
Proc. Natl. Acad. Sci. U.S.A. 106: 262-267 (2009).
*
-
Artmann A, Petersen G, Hellgren LI, Boberg J, Skonberg C, Nellemann C, Hansen SH, Hansen HS. Influence of dietary fatty acids on endocannabinoid and N-acylethanolamine levels in rat brain, liver and small intestine.
Biochim. Biophys. Acta 1781: 200-212 (2008).
*
-
Arulmozhi DK, Dwyer DS, Bodhankar SL. Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice.
Life Sci. 79: 1865-1872 (2006).
*
-
Arundel C, Lewis JH. Drug-induced liver disease in 2006.
Curr. Opin. Gastroenterol. 23: 244-254 (2007).
-
Arzuaga X, Reiterer G, Majkova Z, Kilgore MW, Toborek M, Hennig B. PPARalpha ligands reduce PCB-induced endothelial activation: possible interactions in inflammation and atherosclerosis.
Cardiovasc. Toxicol. 7: 264-272 (2007).
*
-
Arzuaga X, Ren N, Stromberg A, Black EP, Arsenescu V, Cassis LA, Majkova Z, Toborek M, Hennig B. Induction of gene pattern changes associated with dysfunctional lipid metabolism induced by dietary fat and exposure to a persistent organic pollutant.
Toxicol. Lett. 189: 96-101 (2009).
*
-
Asai T, Okumura K, Takahashi R, Matsui H, Numaguchi Y, Murakami H, Murakami R, Murohara T. Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency.
Cardiovasc. Res. 70: 566-577 (2006).
*
-
Asakawa A, Toyoshima M, Harada KH, Fujimiya M, Inoue K, Koizumi A. The ubiquitous environmental pollutant perfluorooctanoicacid inhibits feeding behavior via peroxisome proliferator-activated receptor-alpha.
Int. J. Mol. Med. 21: 439-445 (2008).
*
-
Asaki T, Aoki T, Hamamoto T, Sugiyama Y, Ohmachi S, Kuwabara K, Murakami K, Todo M. Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Bioorg. Med. Chem. 16: 981-994 (2008).
*
-
Asano J, Kudo T, Shimizu T, Fan Y, Nanashima N, Yamana D, Miura T, Yamada T, Tsuchida S. Histone acetylation and steroid receptor coactivator expression during clofibrate-induced rat hepatocarcinogenesis.
Cancer Sci. Dec 8 [Epub ahead of print] (2009).
*
-
Asayama K, Sandhir R, Sheikh FG, Hayashibe H, Nakane T, Singh I. Increased peroxisomal fatty acid beta-oxidation and enhanced expression of peroxisome proliferator-activated receptor-alpha in diabetic rat liver.
Mol. Cell. Biochem. 194: 227-234 (1999).
-
Asnani S, Theuma P, Fonseca VA. PPARgamma agonists and vascular risk factors: potential effects on cardiovascular disease.
Metab. Syndr. Relat. Disord. 1: 23-32 (2003).
-
Atherton HJ, Bailey NJ, Zhang W, Taylor J, Major H, Shockcor J, Clarke K, Griffin JL. A combined 1H NMR spectroscopy and mass spectrometry-based metabolomic study of the PPAR-alpha null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome.
Physiol. Genomics 27: 178-186 (2006).
*
-
Atherton HJ, Gulston MK, Bailey NJ, Cheng KK, Zhang W, Clarke K, Griffin JL. Metabolomics of the interaction between PPAR-alpha and age in the PPAR-alpha-null mouse.
Mol. Syst. Biol. 5: 259 (2009).
*
-
Atherton HJ, Jones OA, Malik S, Miska EA, Griffin JL. A comparative metabolomic study of NHR-49 in Caenorhabditis elegans and PPAR-alpha in the mouse.
FEBS Lett. 582: 1661-1666 (2008).
*
-
Atkins KB, Irey B, Xiang N, Brosius 3rd FC. A rapid, PPARgamma-dependent, effect of pioglitazone on phosphorylation of myosin phosphatase targeting subunit - MYPT.
Am. J. Physiol. Cell. Physiol. 296: C1151-C1161 (2009).
*
-
Attakpa E, Hichami A, Simonin AM, Sanson EG, Dramane KL, Khan NA. Docosahexaenoic acid modulates the expression of T-bet and GATA-3 transcription factors, independently of PPARalpha, through suppression of MAP kinase activation.
Biochimie 91: 1359-1365 (2009).
-
Atug O, Tahan V, Eren F, Tiftikci A, Imeryuz N, Hamzaoglu HO, Tozun N. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene in inflammatory bowel disease.
J. Gastrointestin. Liver Dis. 17: 433-437 (2008).
*
-
August A, Mueller C, Weaver V, Polanco TA, Walsh ER, Cantorna MT. Nutrients, nuclear receptors, inflammation, immunity lipids, PPAR, and allergic asthma.
J. Nutr. 136: 695-699 (2006).
*
-
Aung CS, Faddy HM, Lister EJ, Monteith GR, Roberts-Thomson SJ. Isoform specific changes in PPARalpha and beta in colon and breast cancer with differentiation.
Biochem. Biophys. Res. Commun. 340: 656-660 (2006).
*
-
Auwerx J. Nuclear receptors. I. PPAR gamma in the gastrointestinal tract: gain or pain?
Am. J. Physiol. Gastrointest. Liver Physiol. 282: G581-G585 (2002).
*
-
Auwerx J, Cock TA, Knouff C. PPAR-gamma: a thrifty transcription factor.
Nucl. Recept. Signal. 1: e006 (2003).
*
-
Auwerx J, Schoonjans K, Fruchart JC, Staels B. Regulation of triglyceride metabolism by PPARs: fibrates and thiazolidinediones have distinct effects.
J. Atheroscler. Thromb. 3: 81-89 (1996).
-
Avallone R, Demers A, Rodrigue-Way A, Bujold K, Harb D, Anghel S, Wahli W, Marleau S, Ong H, Tremblay A. A growth hormone-releasing peptide that binds scavenger receptor CD36 and ghrelin receptor upregulates ABC sterol transporters and cholesterol efflux in macrophages through a PPARgamma-dependent pathway.
Mol. Endocrinol. 20: 3165-3178 (2006).
*
-
Awais M, Sato M, Umezawa Y. A fluorescent indicator to visualize ligand-induced receptor/coactivator interactions for screening of peroxisome proliferator-activated receptor gamma ligands in living cells.
Biosens. Bioelectron. 22: 2564-2569 (2007).
*
-
Awara WM, El-Sisi AE, El-Refaei M, El-Naa MM, El-Desoky K. Insulinotropic and anti-inflammatory effects of rosiglitazone in experimental autoimmune diabetes.
Rev. Diabet. Stud. 2: 146-156 (2005).
*
-
Ayoub SS, Botting RM, Joshi AN, Seed MP, Colville-Nash PR. Activation of macrophage peroxisome proliferator-activated receptor-gamma by diclofenac results in the induction of cyclooxygenase-2 protein and the synthesis of anti-inflammatory cytokines.
Mol. Cell. Biochem. 327: 101-110 (2009).
*
-
Azukizawa S, Kasai M, Takahashi K, Miike T, Kunishiro K, Kanda M, Mukai C, Shirahase H. Synthesis and biological evaluation of (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: a novel series of PPARgamma agonists.
Chem. Pharm. Bull. (Tokyo) 56: 335-345 (2008).
-
Azzi A, Gysin R, Kempna P, Munteanu A, Negis Y, Villacorta L, Visarius T, Zingg JM. Vitamin E mediates cell signaling and regulation of gene expression.
Ann. N. Y. Acad. Sci. 1031: 86-95 (2004).
*
-
Azzi A, Gysin R, Kempna P, Munteanu A, Villacorta L, Visarius T, Zingg JM. Regulation of gene expression by alpha-tocopherol.
Biol. Chem. 385: 585-591 (2004).
-
Baba MI, Kaul D, Grover A. Importance of blood cellular genomic profile in coronary heart disease.
J. Biomed. Sci. 13: 17-26 (2006).
*
-
Badawi AF, Badr MZ. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma.
Int. J. Oncol. 20: 1109-1122 (2002).
-
Badii R, Bener A, Zirie M, Al-Rikabi A, Simsek M, Al-Hamaq AO, Ghoussaini M, Froguel P, Wareham NJ. Lack of association between the Pro(12)Ala polymorphism of the PPAR-gamma2 gene and type 2 diabetes mellitus in the Qatari consanguineous population.
Acta Diabetol. 45: 15-21 (2008).
*
-
Badr MZ, Shnyra A, Zoubine M, Norkin M, Herndon B, Quinn T, Miranda RN, Cunningham ML, Molteni A. Phthalate-induced liver protection against deleterious effects of the Th1 response: a potentially serious health hazard.
PPAR Res. 2007: 49671 (2007).
*
-
Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view?
J. Hepatol. 51: 212-223 (2009).
-
Bahadir O, Uzunlulu M, Oguz A, Bahadir MA. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.
Hypertens. Res. 30: 49-53 (2007).
-
Bai JP, Lesko LJ, Burckart GJ. Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
Pharmacotherapy 30: 195-209 (2010).
-
Bai P, Houten SM, Huber A, Schreiber V, Watanabe M, Kiss B, de Murcia G, Auwerx J, Menissier-de Murcia J. PARP-2 controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the RXR/PPARgamma heterodimer.
J. Biol. Chem. 282: 37738-37746 (2007).
*
-
Bailey CJ. Drugs on the horizon for diabesity.
Curr. Diab. Rep. 5: 353-359 (2005).
-
Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, Defronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Diabetologia 50: 1723-1731 (2007).
*
-
Bajwa PJ, Lee JW, Straus DS, Lytle C. Activation of PPARgamma by rosiglitazone attenuates intestinal Cl- secretion.
Am. J. Physiol. Gastrointest. Liver Physiol. 297: G82-G89 (2009).
*
-
Baker AD, Malur A, Barna BP, Ghosh S, Kavuru MS, Malur AG, Thomassen MJ. Targeted PPARgamma deficiency in alveolar macrophages disrupts surfactant catabolism.
J. Lipid Res. Jan 11 [Epub ahead of print] (2010).
*
-
Baker AD, Malur A, Barna BP, Kavuru MS, Malur AG, Thomassen MJ. PPARgamma regulates the expression of cholesterol metabolism genes in alveolar macrophages.
Biochem. Biophys. Res. Commun. Feb 16 [Epub ahead of print] (2010).
-
Baker PR, Lin Y, Schopfer FJ, Woodcock SR, Groeger AL, Batthyany C, Sweeney S, Long MH, Iles KE, Baker LM, Branchaud BP, Chen YE, Freeman BA. Fatty acid transduction of nitric oxide signaling: identification of unsaturated fatty acid nitro derivatives and PPAR receptor-dependent signaling activity.
J. Biol. Chem. 280: 42464-42475 (2005).
*
-
Balakumar P, Arora MK, Singh M. Emerging role of PPAR ligands in the management of diabetic nephropathy.
Pharmacol. Res. 60: 170-173 (2009).
*
-
Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: are they opening Pandora's box?
Pharmacol. Res. 56: 91-98 (2007).
*
-
Balakumar P, Rose M, Singh M. PPAR ligands: are they potential agents for cardiovascular disorders?
Pharmacology 80: 1-10 (2007).
-
Balasubramaniyan N, Shahid M, Suchy FJ, Ananthanarayanan M. Multiple mechanisms of ontogenic regulation of nuclear receptors during rat liver development.
Am. J. Physiol. Gastrointest. Liver Physiol. 288: G251-G260 (2005).
*
-
Balcerzyk A, Zak I, Krauze J. Synergistic effect between polymorphisms of PPARA and ABCA1 genes on the premature coronary artery disease.
Acta Cardiol. 62: 233-238 (2007).
-
Baldan A, Relat J, Marrero PF, Haro D. Functional interaction between peroxisome proliferator-activated receptors-alpha and Mef-2C on human carnitine palmitoyltransferase 1beta (CPT1beta) gene activation.
Nucleic Acids Res. 32: 4742-4749 (2004).
*
-
Balint BL, Nagy L. Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases.
Endocr. Metab. Immune Disord. Drug Targets 6: 33-43 (2006).
-
Ban K, Kozar RA. Enteral glutamine: a novel mediator of PPARgamma in the postischemic gut.
J. Leukoc. Biol. 84: 595-599 (2008).
*
-
Banga A, Unal R, Tripathi P, Pokrovskaya I, Owens RJ, Kern PA, Ranganathan G. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids.
Am. J. Physiol. Endocrinol. Metab. 296: E480-E489 (2009).
*
-
Bao Y, Li R, Jiang J, Cai B, Gao J, Le K, Zhang F, Chen S, Liu P. Activation of peroxisome proliferator-activated receptor gamma inhibits endothelin-1-induced cardiac hypertrophy via the calcineurin/NFAT signaling pathway.
Mol. Cell. Biochem. 317: 189-196 (2008).
*
-
Barak Y, Sadovsky Y, Shalom-Barak T. PPAR signaling in placental development and function.
PPAR Res. 2008: 142082 (2008).
*
-
Baraka A, Abdelgawad H. Targeting apoptosis in the heart of streptozotocin-induced diabetic rats.
J. Cardiovasc. Pharmacol. Ther. Feb 4 [Epub ahead of print] (2010).
-
Baranova A. PPAR ligands as potential modifiers of breast carcinoma outcomes.
PPAR Res. 2008: 230893 (2008).
*
-
Baranowski M, Blachnio-Zabielska A, Gorski J. Peroxisome proliferator-activated receptor alpha activation induces unfavourable changes in fatty acid composition of myocardial phospholipids.
J. Physiol. Pharmacol. 60: 13-20 (2009).
*
-
Baranowski M, Blachnio-Zabielska A, Zabielski P, Gorski J. Pioglitazone induces lipid accumulation in the rat heart despite concomitant reduction in plasma free fatty acid availability.
Arch. Biochem. Biophys. 477: 86-91 (2008).
*
-
Barbera MJ, Schluter A, Pedraza N, Iglesias R, Villarroya F, Giralt M. Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell.
J. Biol. Chem. 276: 1486-1493 (2001).
*
-
Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme.
J. Biol. Chem. 278: 32852-32860 (2003).
*
-
Barbier O, Fontaine C, Fruchart JC, Staels B. Genomic and non-genomic interactions of PPARalpha with xenobiotic-metabolizing enzymes.
Trends Endocrinol. Metab. 15: 324-330 (2004).
*
-
Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis.
Arterioscler. Thromb. Vasc. Biol. 22: 717-726 (2002).
*
-
Barbier O, Trottier J, Kaeding J, Caron P, Verreault M. Lipid-activated transcription factors control bile acid glucuronidation.
Mol. Cell. Biochem. 326: 3-8 (2009).
*
-
Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C, Kosykh V, Fruchart JC, Guillemette C, Staels B. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene.
J. Biol. Chem. 278: 13975-13983 (2003).
*
-
Baregamian N, Mourot JM, Ballard AR, Evers BM, Chung DH. PPAR-gamma agonist protects against intestinal injury during necrotizing enterocolitis.
Biochem. Biophys. Res. Commun. 379: 423-427 (2009).
*
-
Barg E. Roles of PPARs in the origin of metabolic disturbances in children with low birth weight (below 2500 g).
Endokrynol. Diabetol. Chor. Przemiany Materii. Wieku Rozw. 15: 108-113 (2009).
-
Barish GD, Atkins AR, Downes M, Olson P, Chong LW, Nelson M, Zou Y, Hwang H, Kang H, Curtiss L, Evans RM, Lee CH. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis.
Proc. Natl. Acad. Sci. U.S.A. 105: 4271-4276 (2008).
*
-
Barish GD, Narkar VA, Evans RM. PPARdelta: a dagger in the heart of the metabolic syndrome.
J. Clin. Invest. 116: 590-597 (2006).
*
-
Barlic J, Zhang Y, Foley JF, Murphy PM. Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor gamma-dependent pathway.
Circulation 114: 807-819 (2006).
-
Barrera G, Toaldo C, Pizzimenti S, Cerbone A, Pettazzoni P, Dianzani MU, Ferretti C. The role of PPAR ligands in controlling growth-related gene expression and their interaction with lipoperoxidation products.
PPAR Res. 2008: 524671 (2008).
*
-
Barroso I, Luan J, Sandhu MS, Franks PW, Crowley V, Schafer AJ, O'Rahilly S, Wareham NJ. Meta-analysis of the Gly482Ser variant in PPARGC1A in type 2 diabetes and related phenotypes.
Diabetologia 49: 501-505 (2006).
*
-
Barter P. Managing diabetic dyslipidaemia-beyond LDL-C:HDL-C and triglycerides.
Atheroscler. Suppl. 7: 17-21 (2006).
-
Bartke A, Bonkowski M, Masternak M. THow diet interacts with longevity genes.
Hormones (Athens) 7: 17-23 (2008).
-
Bassaganya-Riera J, Hontecillas R. CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD.
Clin. Nutr. 25: 454-465 (2006).
-
Bassaganya-Riera J, Hontecillas R, Beitz DC. Colonic anti-inflammatory mechanisms of conjugated linoleic acid.
Clin. Nutr. 21: 451-459 (2002).
-
Bassaganya-Riera J, Misyak S, Guri AJ, Hontecillas R. PPAR gamma is highly expressed in F4/80(hi) adipose tissue macrophages and dampens adipose-tissue inflammation.
Cell. Immunol. 258: 138-146 (2009).
*
-
Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, Gonzalez F, Rohrer J, Benninghoff AU, Hontecillas R. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease.
Gastroenterology 127: 777-791 (2004).
*
-
Bassaganya-Riera J, Skoneczka J, Kingston DG, Krishnan A, Misyak SA, Guri AJ, Pereira A, Carter AB, Minorsky P, Tumarkin R, Hontecillas R. Mechanisms of action and medicinal applications of abscisic acid.
Curr. Med. Chem. Dec 17 [Epub ahead of print] (2009).
-
Bassols J, Ortega FJ, Moreno-Navarrete JM, Peral B, Ricart W, Fernandez-Real JM. Study of the proinflammatory role of human differentiated omental adipocytes.
J. Cell. Biochem. 107: 1107-1117 (2009).
*
-
Bastin J, Aubey F, Rotig A, Munnich A, Djouadi F. Activation of peroxisome proliferator activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components.
J. Clin. Endocrinol. Metab. 93: 1433-1441 (2008).
*
-
Basu-Modak S, Braissant O, Escher P, Desvergne B, Honegger P, Wahli W. Peroxisome proliferator-activated receptor beta regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures.
J. Biol. Chem. 274: 35881-35888 (1999).
*
-
Batheja P, Song Y, Wertz P, Michniak-Kohn B. Effects of growth conditions on the barrier properties of a human skin equivalent.
Pharm. Res. 26: 1689-1700 (2009).
*
-
Batista-Pinto C, Rocha E, Castro LF, Rodrigues P, Lobo-da-Cunha A. Seasonal and gender variation of peroxisome proliferator activated receptors expression in brown trout liver.
Gen. Comp. Endocrinol. 161: 146-152 (2009).
*
-
Baumgardner JN, Shankar K, Korourian S, Badger TM, Ronis MJ. Undernutrition enhances alcohol-induced hepatocyte proliferation in the liver of rats fed via total enteral nutrition.
Am. J. Physiol. Gastrointest. Liver Physiol. 293: G355-G364 (2007).
*
-
Beaven SW, Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia.
Annu. Rev. Med. 57: 313-329 (2006).
*
-
Beck F, Plummer S, Senior PV, Byrne S, Green S, Brammar WJ. The ontogeny of peroxisome-proliferator-activated receptor gene expression in the mouse and rat.
Proc. Biol. Sci. 247: 83-87 (1992).
-
Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?
Fundam. Clin. Pharmacol. 20: 429-447 (2006).
*
-
Becker J, Delayre-Orthez C, Frossard N, Pons F. Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inflammation.
Pulm. Pharmacol. Ther. 21: 324-330 (2008).
-
Bedu E, Desplanches D, Pequignot J, Bordier B, Desvergne B. Double gene deletion reveals the lack of cooperation between PPARalpha and PPARbeta in skeletal muscle.
Biochem. Biophys. Res. Commun. 357: 877-881 (2007).
*
-
Bedu E, Wahli W, Desvergne B. Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases.
Expert Opin. Ther. Targets 9: 861-873 (2005).
-
Beekum OV, Fleskens V, Kalkhoven E. Posttranslational modifications of PPAR-gamma: fine-tuning the metabolic master regulator.
Obesity (Silver Spring) 17: 213-219 (2009).
*
-
Behshad R, Cooper KD, Korman NJ. A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis.
Arch. Dermatol. 144: 84-88 (2008).
*
-
Beier K, Volkl A, Fahimi HD. TNF-alpha downregulates the peroxisome proliferator activated receptor-alpha and the mRNAs encoding peroxisomal proteins in rat liver.
FEBS Lett. 412: 385-387 (1997).
*
-
Beigneux AP, Davies BS, Bensadoun A, Fong LG, Young SG. GPIHBP1 - a GPI-anchored protein required for the lipolytic processing of triglyceride-rich lipoproteins.
J. Lipid Res. 50: S57-S62 (2009).
*
-
Beigneux AP, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. The acute phase response is associated with retinoid X receptor repression in rodent liver.
J. Biol. Chem. 275: 16390-16399 (2000).
*
-
Bektas M, Allende ML, Lee BG, Chen W, Amar MJ, Remaley AT, Saba JD, Proia RL. S1P lyase deficiency disrupts lipid homeostasis in liver.
J. Biol. Chem. Jan 24 [Epub ahead of print] (2010).
*
-
Belanger AJ, Luo Z, Vincent KA, Akita GY, Cheng SH, Gregory RJ, Jiang C. Hypoxia-inducible factor 1 mediates hypoxia-induced cardiomyocyte lipid accumulation by reducing the DNA binding activity of peroxisome proliferator-activated receptor alpha/retinoid X receptor.
Biochem. Biophys. Res. Commun. 364: 567-572 (2007).
*
-
Belfiore A, Genua M, Malaguarnera R. PPAR-gamma agonists and their effects on IGF-I receptor signaling: implications for cancer.
PPAR Res. 2009: 830501 (2009).
*
-
Bellosta S, Bernini F. Modulation of macrophage function and metabolism.
Handb. Exp. Pharmacol. 170: 665-695 (2005).
-
Beltowski J, Wojcicka G, Jamroz A. Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy.
Postepy. Hig. Med. Dosw. 57: 199-217 (2003).
-
Belvisi MG, Hele DJ. Peroxisome proliferator-activated receptors as novel targets in lung disease.
Chest 134: 152-157 (2008).
*
-
Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
Eur. J. Pharmacol. 533: 101-109 (2006).
*
-
Belvisi MG, Mitchell JA. Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease.
Br. J. Pharmacol. 158: 994-1003 (2009).
-
Bendinelli P, Piccoletti R, Maroni P. Leptin rapidly activates PPARs in C2C12 muscle cells.
Biochem. Biophys. Res. Commun. 332: 719-725 (2005).
*
-
Bendlova B, Vejralkova D, Vcelak J, Lukalova P, Burkonova D, Kunelova M, Vrbikova J, Dvorakova K, Vondra K, Vankova M. PPARgamma2 Pro12Ala polymorphism in relation to free fatty acids concentration and composition in lean healthy Czech individuals with and without family history of diabetes type 2.
Physiol. Res. 57 Suppl. 1: S77-S90 (2008).
*
-
Benigni A, Zoja C, Tomasoni S, Campana M, Corna D, Zanchi C, Gagliardini E, Garofano E, Rottoli D, Ito T, Remuzzi G. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
J. Am. Soc. Nephrol. 17: 1624-1632 (2006).
*
-
Bennett AJ, Sovio U, Ruokonen A, Martikainen H, Pouta A, Hartikainen AL, Franks S, Elliott P, Jarvelin MR, McCarthy MI. No evidence that established type 2 diabetes susceptibility variants in the PPARG and KCNJ11 genes have pleiotropic effects on early growth.
Diabetologia 51: 82-85 (2008).
*
-
Bentinger M, Turunen M, Zhang XX, Wan YJ, Dallner G. Involvement of retinoid X receptor alpha in coenzyme Q metabolism.
J. Mol. Biol. 326: 795-803 (2003).
*
-
Bento-Abreu A, Tabernero A, Medina JM. Peroxisome proliferator-activated receptor-alpha is required for the neurotrophic effect of oleic acid in neurons.
J. Neurochem. 103: 871-881 (2007).
-
Beraza N, Malato Y, Vander Borght S, Liedtke C, Wasmuth HE, Dreano M, de Vos R, Roskams T, Trautwein C. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis.
Gut 57: 655-663 (2008).
-
Bergamo P, Luongo D, Maurano F, Mazzarella G, Stefanile R, Rossi M. Conjugated linoleic acid enhances glutathione synthesis and attenuates pathological signs in MRL/lpr mice.
J. Lipid Res. 47: 2382-2391 (2006).
*
-
Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group.
Hepatology 40: 1013-1020 (2004).
*
-
Berge RK, Tronstad KJ, Berge K, Rost TH, Wergedahl H, Gudbrandsen OA, Skorve J. The metabolic syndrome and the hepatic fatty acid drainage hypothesis.
Biochimie 87: 15-20 (2005).
-
Berger A, Mutch DM, German JB, Roberts MA. Dietary effects of arachidonate-rich fungal oil and fish oil on murine hepatic and hippocampal gene expression.
Lipids Health Dis. 1: 2 (2002).
*
-
Berger A, Roberts MA, Hoff B. How dietary arachidonic- and docosahexaenoic- acid rich oils differentially affect the murine hepatic transcriptome.
Lipids Health Dis. 5: 10 (2006).
*
-
Berger J, Moller DE. The mechanisms of action of PPARs.
Annu. Rev. Med. 53: 409-435 (2002).
*
-
Berger J, Wagner JA. Physiological and therapeutic roles of peroxisome proliferator-activated receptors.
Diabetes Technol. Ther. 4: 163-174 (2002).
-
Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease.
Trends Pharmacol. Sci. 26: 244-251 (2005).
*
-
Bergeron R, Yao J, Woods JW, Zycband EI, Liu C, Li Z, Adams A, Berger JP, Zhang BB, Moller DE, Doebber TW. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in ZDF rats: a comparison to PPARgamma agonism.
Endocrinology 147: 4252-4262 (2006).
*
-
Bergman BC, Perreault L, Hunerdosse DM, Koehler MC, Samek AM, Eckel RH. Intramuscular lipid metabolism in the insulin resistance of smoking.
Diabetes 58: 2220-2227 (2009).
*
-
Bernardo A, Bianchi D, Magnaghi V, Minghetti L. Peroxisome proliferator-activated receptor-gamma agonists promote differentiation and antioxidant defenses of oligodendrocyte progenitor cells.
J. Neuropathol. Exp. Neurol. 68: 797-808 (2009).
-
Bernardo A, Minghetti L. Regulation of glial cell functions by PPAR-gamma natural and synthetic agonists.
PPAR Res. 2008: 864140 (2008).
*
-
Berruyer C, Pouyet L, Millet V, Martin FM, Legoffic A, Canonici A, Garcia S, Bagnis C, Naquet P, Galland F. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity.
J. Exp. Med. 203: 2817-2827 (2006).
*
-
Berry A, Balard P, Coste A, Olagnier D, Lagane C, Authier H, Benoit-Vical F, Lepert JC, Seguela JP, Magnaval JF, Chambon P, Metzger D, Desvergne B, Wahli W, Auwerx J, Pipy B. IL-13 induces expression of CD36 in human monocytes through PPARgamma activation.
Eur. J. Immunol. 37: 1642-1652 (2007).
*
-
Berry DC, Noy N. All-trans-retinoic acid represses obesity and insulin resistance by activating both peroxisome proliferation-activated receptor beta/delta and retinoic acid receptor.
Mol. Cell. Biol. 29: 3286-3296 (2009).
*
-
Berry DC, Noy N. Is PPARbeta/delta a retinoid receptor?
PPAR Res. 2007: 73256 (2007).
*
-
Berthiaume M, Laplante M, Festuccia WT, Berger JP, Thieringer R, Deshaies Y. Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats.
Int. J. Obes. (Lond.) 33: 601-604 (2009).
*
-
Bertolotti M, Gabbi C, Anzivino C, Mitro N, Godio C, De Fabiani E, Crestani M, Del Puppo M, Ricchi M, Carulli L, Rossi A, Loria P, Carulli N. Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis.
Eur. J. Clin. Invest. 36: 170-175 (2006).
-
Bertram JS, Vine AL. Cancer prevention by retinoids and carotenoids: independent action on a common target.
Biochim. Biophys. Acta 1740: 170-178 (2005).
*
-
Bertz J, Zang C, Liu H, Wachter M, Possinger K, Phillip Koeffler H, Elstner E. Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib.
Leuk. Res. 33: 686-692 (2009).
-
Besler C, Doerries C, Giannotti G, Luscher TF, Landmesse U. Pharmacological approaches to improve endothelial repair mechanisms.
Expert Rev. Cardiovasc. Ther. 6: 1071-1082 (2008).
-
Beuers U, Kullak-Ublick GA, Pusl T, Rauws ER, Rust C. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?
Clin. Rev. Allergy Immunol. 36: 52-61 (2009).
*
-
Beyer AM, Baumbach GL, Halabi CM, Modrick ML, Lynch CM, Gerhold TD, Ghoneim SM, de Lange WJ, Keen HL, Tsai YS, Maeda N, Sigmund CD, Faraci FM. Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.
Hypertension 51: 867-871 (2008).
-
Beyer TP, Chen Y, Porter RK, Lu D, Schmidt RJ, Mantlo NB, Konrad RJ, Cao G. Peroxisome proliferator-activated receptor alpha agonists regulate cholesterol ester transfer protein.
Lipids 43: 611-618 (2008).
-
Beyer TP, Schmidt RJ, Foxworthy P, Zhang Y, Dai J, Bensch WR, Kauffman RF, Gao H, Ryan TP, Jiang XC, Karathanasis SK, Eacho PI, Cao G. Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-alpha agonist in mice: effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo.
J. Pharmacol. Exp. Ther. 309: 861-868 (2004).
*
-
Beysen C, Murphy EJ, Nagaraja H, Decaris M, Riiff T, Fong A, Hellerstein MK, Boyle PJ. A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes.
J. Lipid Res. 49: 2657-2663 (2008).
*
-
Bhatia V, Viswanathan P. Insulin resistance and PPAR insulin sensitizers.
Curr. Opin. Investig. Drugs 7: 891-897 (2006).
-
Bhatt DL, Chew DP, Grines C, Mukherjee D, Leesar M, Gilchrist IC, Corbelli JC, Blankenship JC, Eres A, Steinhubl S, Tan WA, Resar JR, Almahameed A, Abdel-Latif A, Tang HW, Brennan D, McErlean E, Hazen SL, Topol EJ. Peroxisome proliferator-activated receptor gamma agonists for the prevention of adverse events following percutaneous coronary revascularization - results of the PPAR study.
Am. Heart J. 154: 137-143 (2007).
*
-
Bhattacharya S, Mathew G, Jayne DG, Pelengaris S, Khan M. 15-Lipoxygenase-1 in colorectal cancer: a review.
Tumour Biol. 30: 185-199 (2009).
-
Bhavsar SK, Singh S, Giri S, Jain MR, Santani DD. Effect of saponins from Helicteres isora on lipid and glucose metabolism regulating genes expression.
J. Ethnopharmacol. 124: 426-433 (2009).
-
Bhurruth-Alcor Y, Rost TH, Jorgensen MR, Rajender, Muller M, Skorve J, Berge RK, Miller AD. Novel phospholipid analogues of pan-PPAR activator tetradecylthioacetic acid are more PPARalpha selective.
Bioorg. Med. Chem. Lett. Dec 11 [Epub ahead of print] (2009).
*
-
Bianchi A, Moulin D, Sebillaud S, Koufany M, Galteau MM, Netter P, Terlain B, Jouzeau JY. Contrasting effects of peroxisome-proliferator-activated receptor (PPAR)gamma agonists on membrane-associated prostaglandin E2 synthase-1 in IL-1beta-stimulated rat chondrocytes.
Arthritis Res. Ther. 7: R1325-R1337 (2005).
*
-
Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel disease.
Curr. Gastroenterol. Rep. 5: 518-523 (2003).
-
Bighetti EJ, Patricio PR, Casquero AC, Berti JA, Oliveira HC. Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.
Lipids Health Dis. 8: 50 (2009).
*
-
Bilban M, Haslinger P, Prast J, Klinglmuller F, Woelfel T, Haider S, Sachs A, Otterbein LE, Desoye G, Hiden U, Wagner O, Knofler M. Identification of novel trophoblast invasion-related genes: heme oxygenase-1 controls motility via PPARgamma.
Endocrinology 150: 1000-1013 (2009).
*
-
Bility MT, Devlin-Durante MK, Blazanin N, Glick AB, Ward JM, Kang BH, Kennett MJ, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits chemically-induced skin tumorigenesis.
Carcinogenesis 29: 2406-2414 (2008).
*
-
Bility MT, Zhu B, Kang BH, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) enhances inhibition of skin tumorigenesis.
Toxicol. Sci. 113: 27-36 (2010).
*
-
Billiet L, Furman C, Larigauderie G, Copin C, Page S, Fruchart JC, Brand K, Rouis M. Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage.
J. Cell. Physiol. 214: 183-191 (2008).
*
-
Billin AN. PPAR-beta/delta agonists for type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home.
Expert Opin. Investig. Drugs 17: 1465-1471 (2008).
-
Billoni N, Buan B, Gautier B, Collin C, Gaillard O, Mahe YF, Bernard BA. Expression of peroxisome proliferator activated receptors (PPARs) in human hair follicles and PPAR alpha involvement in hair growth.
Acta Derm. Venereol. 80: 329-334 (2000).
-
Bionaz M, Baumrucker CR, Shirk E, Vanden Heuvel JP, Block E, Varga GA. Characterization of Madin-Darby bovine kidney cell line for peroxisome proliferator-activated receptors: temporal response and sensitivity to fatty acids.
J. Dairy Sci. 91: 2808-2813 (2008).
-
Biscetti F, Gaetani E, Flex A, Tamar A, Hopkins T, Straface G, Pecorini G, Stigliano E, Smith RC, Angelini F, Castellot JJ Jr, Pola R. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism.
Diabetes 57: 1394-1404 (2008).
*
-
Biscetti F, Straface G, Arena V, Stigliano E, Pecorini G, Rizzo P, De Angelis G, Iuliano L, Ghirlanda G, Flex A. Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPAR-gamma stimulation.
Cardiovasc. Diabetol. 8: 49 (2009).
-
Biscetti F, Straface G, Pitocco D, Zaccardi F, Ghirlanda G, Flex A. Peroxisome proliferator-activated receptors and angiogenesis.
Nutr. Metab. Cardiovasc. Dis. 19: 751-759 (2009).
-
Biserni A, Giannessi F, Sciarroni AF, Milazzo FM, Maggi A, Ciana P. In vivo imaging reveals selective peroxisome proliferator activated receptor modulator activity of the synthetic ligand 3-(1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886).
Mol. Pharmacol. 73: 1434-1443 (2008).
*
-
Bishop-Bailey D. PPAR receptor activation: experimental studies on cardiac structure and function.
Curr. Opin. Investig. Drugs 11: 283-288 (2010).
-
Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system.
Br. J. Pharmacol. 129: 823-834 (2000).
*
-
Bishop-Bailey D, Bystrom J. Emerging roles of peroxisome proliferator-activated receptor-beta/delta in inflammation.
Pharmacol. Ther. 124: 141-150 (2009).
*
-
Bishop-Bailey D, Wray J. Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation.
Prostaglandins Other Lipid Mediat. 71: 1-22 (2003).
-
Biyashev D, Veliceasa D, Kwiatek A, Sutanto MM, Cohen RN, Volpert OV. Natural angiogenesis inhibitor signals through Erk5 activation of peroxisome proliferator activated receptor gamma (PPARgamma).
J. Biol. Chem. Feb 25 [Epub ahead of print] (2010).
*
-
Black MH, Fingerlin TE, Allayee H, Zhang W, Xiang AH, Trigo E, Hartiala J, Lehtinen AB, Haffner SM, Bergman RN, McEachin RC, Kjos SL, Lawrence JM, Buchanan TA, Watanabe RM. Evidence of interaction between PPARG2 and HNF4A contributing to variation in insulin sensitivity in Mexican Americans.
Diabetes 57: 1048-1056 (2008).
*
-
Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation.
J. Steroid Biochem. Mol. Biol. 85: 267-273 (2003).
-
Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptor alpha (PPARalpha ) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes.
J. Biol. Chem. 277: 37254-37259 (2002).
*
-
Blanquart C, Mansouri R, Paumelle R, Fruchart JC, Staels B, Glineur C. The protein kinase C signalling pathway regulates a molecular switch between transactivation and transrepression activity of the peroxisome proliferator-activated receptor alpha (PPARalpha).
Mol. Endocrinol. 18: 1906-1918 (2004).
*
-
Blanquicett C, Roman J, Hart CM. Thiazolidinediones as anti-cancer agents.
Cancer Ther. 6(A): 25-34 (2008).
-
Blaschke F, Bruemmer D, Law RE. Will the potential of peroxisome proliferator-activated receptor agonists be realized in the clinical setting?
Clin. Cardiol. 27: IV3-IV10 (2004).
-
Blaschke F, Spanheimer R, Khan M, Law RE. Vascular effects of TZDs: new implications.
Vascul. Pharmacol. 45: 3-18 (2006).
-
Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
Arterioscler. Thromb. Vasc. Biol. 26: 28-40 (2006).
*
-
Blasi ER, Heyen J, Hemkens M, McHarg A, Ecelbarger CM, Tiwari S. Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy Sprague-Dawley rats.
PPAR Res. 2009: 237865 (2009).
*
-
Blavy P, Gondret F, Guillou H, Lagarrigue S, Martin PG, van Milgen J, Radulescu O, Siegel A. A minimal model for hepatic fatty acid balance during fasting: application to PPAR alpha-deficient mice.
J. Theor. Biol. 261: 266-278 (2009).
*
-
Blazovics A, Hagymasi K, Pronai L. Cytokines, prostaglandins, nutritive and non-nuitritive factors in inflammatory bowel diseases.
Orv. Hetil. 145: 2523-2529 (2004).
-
Boberg J, Metzdorff S, Wortziger R, Axelstad M, Brokken L, Vinggaard AM, Dalgaard M, Nellemann C. Impact of diisobutyl phthalate and other PPAR agonists on steroidogenesis and plasma insulin and leptin levels in fetal rats.
Toxicology 250: 75-81 (2008).
*
-
Bocca C, Bozzo F, Francica S, Colombatto S, Miglietta A. Involvement of PPARgamma and E-cadherin/beta-catenin pathway in the antiproliferative effect of conjugated linoleic acid in MCF-7 cells.
Int. J. Cancer 121: 248-256 (2007).
*
-
Bocca C, Bozzo F, Martinasso G, Canuto RA, Miglietta A. Involvement of PPARalpha in the growth inhibitory effect of arachidonic acid on breast cancer cells.
Br. J. Nutr. 100: 739-750 (2008).
*
-
Bocher V, Chinetti G, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control.
J. Soc. Biol. 196: 47-52 (2002).
-
Bocher V, Pineda-Torra I, Fruchart JC, Staels B. PPARs: transcription factors controlling lipid and lipoprotein metabolism.
Ann. N. Y. Acad. Sci. 967: 7-18 (2002).
*
-
Boden G, Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes.
Expert Opin. Investig. Drugs 15: 243-250 (2006).
-
Bodmer M, Meier C, Kraenzlin ME, Meier CR. Risk of fractures with glitazones: a critical review of the evidence to date.
Drug Saf. 32: 539-547 (2009).
-
Bogazzi F, Russo D, Locci MT, Chifenti B, Ultimieri F, Raggi F, Viacava P, Cecchetti D, Cosci C, Sardella C, Acerbi G, Gasperi M, Martino E. Peroxisome proliferator-activated receptor (PPAR)gamma is highly expressed in normal human pituitary gland.
J. Endocrinol. Invest. 28: 899-904 (2005).
-
Bogdanova K, Uherkova L, Poczatkova H, Rypka M, Vesely J. mRNA levels of peroxisome proliferator-activated receptors and their coactivators are affected by glucose deprivation and oleate in human hepatoma hepG2 cells.
Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 151: 237-245 (2007).
*
-
Bohme M, Nitz I, Doring F, Klapper M. Analysis of the transcriptional regulation of the FABP2 promoter haplotypes by PPARgamma/RXRalpha and Oct-1.
Biochim. Biophys. Acta 1779: 616-621 (2008).
*
-
Boitier E, Gautier JC, Roberts R. Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease.
Comp. Hepatol. 2: 3 (2003).
*
-
Bonfield TL, Thomassen MJ, Farver CF, Abraham S, Koloze MT, Zhang X, Mosser DM, Culver DA. Peroxisome proliferator-activated receptor-gamma regulates the expression of alveolar macrophage macrophage colony-stimulating factor.
J. Immunol. 181: 235-242 (2008).
*
-
Bongartz T, Coras B, Vogt T, Scholmerich J, Muller-Ladner U. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study.
Rheumatology (Oxford) 44: 126-129 (2005).
*
-
Bonilla S, Redonnet A, Noel-Suberville C, Groubet R, Pallet V, Higueret P. Effect of a pharmacological activation of PPAR on the expression of RAR and TR in rat liver.
J. Physiol. Biochem. 57: 1-8 (2001).
-
Bonilla S, Redonnet A, Noel-Suberville C, Pallet V, Garcin H, Higueret P. High-fat diets affect the expression of nuclear retinoic acid receptor in rat liver.
Br. J. Nutr. 83: 665-671 (2000).
*
-
Bonofiglio D, Cione E, Qi H, Pingitore A, Perri M, Catalano S, Vizza D, Panno ML, Genchi G, Fuqua SA, Ando S. Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells.
Am. J. Pathol. 175: 1270-1280 (2009).
*
-
Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile M, Middea E, Giordano F, Ando S. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells.
Clin. Cancer Res. 11: 6139-6147 (2005).
*
-
Bonora E. Protection of pancreatic beta-cells: is it feasible?
Nutr. Metab. Cardiovasc. Dis. 18: 74-83 (2007).
-
Bordet R, Ouk T, Petrault O, Gele P, Gautier S, Laprais M, Deplanque D, Duriez P, Staels B, Fruchart JC, Bastide M. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases.
Biochem. Soc. Trans. 34: 1341-1346 (2006).
*
-
Bordoni A, Di Nunzio M, Danesi F, Biagi PL. Polyunsaturated fatty acids: from diet to binding to PPARs and other nuclear receptors.
Genes Nutr. 1: 95-106 (2006).
*
-
Borel V, Gallot D, Marceau G, Sapin V, Blanchon L. Placental implications of peroxisome proliferator-activated receptors in gestation and parturition.
PPAR Res. 2008: 758562 (2008).
*
-
Boris M, Kaiser C, Golblatt A, Elice MW, Edelson SM, Adams JB, Feinstein DL. Effect of pioglitazone treatment on behavioral symptoms in autistic children.
J. Neuroinflammation 4: 3 (2007).
*
-
Borland MG, Foreman JE, Girroir EE, Zolfaghari R, Sharma AK, Amin SM, Gonzalez FJ, Ross AC, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell proliferation in human HaCaT keratinocytes.
Mol. Pharmacol. 74: 1429-1442 (2008).
*
-
Borniquel S, Jansson EA, Cole MP, Freeman BA, Lundberg JO. Nitrated oleic acid up-regulates PPAR-gamma and attenuates experimental inflammatory bowel disease.
Free Radic. Biol. Med. Nov 19 [Epub ahead of print] (2009).
-
Bosse Y, Weisnagel SJ, Bouchard C, Despres JP, Perusse L, Vohl MC. Combined effects of PPARgamma2 P12A and PPARalpha L162V polymorphisms on glucose and insulin homeostasis: the Quebec Family Study.
J. Hum. Genet. 48: 614-621 (2003).
*
-
Bougarne N, Paumelle R, Caron S, Hennuyer N, Mansouri R, Gervois P, Staels B, Haegeman G, De Bosscher K. PPARalpha blocks glucocorticoid receptor alpha-mediated transactivation but cooperates with the activated glucocorticoid receptor alpha for transrepression on NF-kappaB.
Proc. Natl. Acad. Sci. U.S.A. 106: 7397-7402 (2009).
*
-
Bouhlel MA, Brozek J, Derudas B, Zawadzki C, Jude B, Staels B, Chinetti-Gbaguidi G. Unlike PPARgamma, PPARalpha or PPARbeta/delta activation does not promote human monocyte differentiation toward alternative macrophages.
Biochem. Biophys. Res. Commun. 386: 459-462 (2009).
*
-
Boulanger A, McLemore P, Copeland NG, Gilbert DJ, Jenkins NA, Yu SS, Gentleman S, Redmond TM. Identification of beta-carotene 15, 15'-monooxygenase as a peroxisome proliferator-activated receptor target gene.
FASEB J. 17: 1304-1306 (2003).
*
-
Boulias K, Katrakili N, Bamberg K, Underhill P, Greenfield A, Talianidis I. Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP.
EMBO J. 24: 2624-2633 (2005).
*
-
Bouton D, Escriva H, de Mendonca RL, Glineur C, Bertin B, Noel C, Robinson-Rechavi M, de Groot A, Cornette J, Laudet V, Pierce RJ. A conserved retinoid X receptor (RXR) from the mollusk Biomphalaria glabrata transactivates transcription in the presence of retinoids.
J. Mol. Endocrinol. 34: 567-582 (2005).
*
-
Bouwens M, Afman LA, Muller M. Activation of peroxisome proliferator-activated receptor alpha in human peripheral blood mononuclear cells reveals an individual gene expression profile response.
BMC Genomics 9: 262 (2008).
*
-
Boyer JF, Balard P, Authier H, Faucon B, Bernad J, Mazieres B, Davignon JL, Cantagrel A, Pipy B, Constantin A. TNF alpha and adalimumab differentially regulate CD36 expression in human monocytes.
Arthritis Res. Ther. 9: R22 (2007).
*
-
Boyle PJ. Diabetes mellitus and macrovascular disease: mechanisms and mediators.
Am. J. Med. 120: S12-S17 (2007).
*
-
Bozkurt D, Taskin H, Sezak M, Bicak S, Sen S, Ok E, Duman S. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model.
Adv. Perit. Dial. 24: 32-38 (2008).
-
Bozzo F, Bocca C, Colombatto S, Miglietta A. Antiproliferative effect of conjugated linoleic acid in caco-2 cells: involvement of PPARgamma and APC/beta-catenin pathways.
Chem. Biol. Interact. 169: 110-121 (2007).
*
-
Brackenridge AL, Jackson N, Jefferson W, Stolinski M, Shojaee-Moradie F, Hovorka R, Umpleby AM, Russell-Jones D. Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with type 2 diabetes and normal lipids.
Diabet. Med. 26: 532-539 (2009).
-
Bragt MC, Popeijus HE. Peroxisome proliferator-activated receptors and the metabolic syndrome.
Physiol. Behav. 94: 187-197 (2008).
*
-
Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.
Endocrinology 137: 354-366 (1996).
*
-
Bright JJ, Kanakasabai S, Chearwae W, Chakraborty S. PPAR regulation of inflammatory signaling in CNS diseases.
PPAR Res. 2008: 658520 (2008).
*
-
Bright JJ, Walline CC, Kanakasabai S, Chakraborty S. Targeting PPAR as a therapy to treat multiple sclerosis.
Expert Opin. Ther. Targets 12: 1565-1575 (2008).
-
Brinckerhoff CE, Sporn MB. Retinoids and rexinoids for the 21st century: a brave new world for arthritis.
J. Rheumatol. 30: 211-213 (2003).
-
Brody F, Hill S, Celenski S, Kar R, Kluk B, Pinzone J, Fu S. Expression of ectonucleotide pyrophosphate phosphodiesterase and peroxisome proliferator activated receptor gamma in morbidly obese patients.
Surg. Endosc. 21: 941-944 (2007).
*
-
Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
Circulation 115: 518-533 (2007).
*
-
Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, Willson TM. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.
Diabetes 48: 1415-1424 (1999).
*
-
Brown PJ, Smith-Oliver TA, Charifson PS, Tomkinson NC, Fivush AM, Sternbach DD, Wade LE, Orband-Miller L, Parks DJ, Blanchard SG, Kliewer SA, Lehmann JM, Willson TM. Identification of peroxisome proliferator-activated receptor ligands from a biased chemical library.
Chem. Biol. 4: 909-918 (1997).
-
Brown PJ, Winegar DA, Plunket KD, Moore LB, Lewis MC, Wilson JG, Sundseth SS, Koble CS, Wu Z, Chapman JM, Lehmann JM, Kliewer SA, Willson TM. A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.
J. Med. Chem. 42: 3785-3788 (1999).
-
Browning SR, Briley JD, Briley LP, Chandra G, Charnecki JH, Ehm MG, Johansson KA, Jones BJ, Karter AJ, Yarnall DP, Wagner MJ. Case-control single-marker and haplotypic association analysis of pedigree data.
Genet. Epidemiol. 28: 110-122 (2005).
*
-
Bruck R, Weiss S, Aeed H, Pines M, Halpern Z, Zvibel I. Additive inhibitory effect of experimentally induced hepatic cirrhosis by agonists of peroxisome proliferator activator receptor gamma and retinoic acid receptor.
Dig. Dis. Sci. 54: 292-299 (2009).
*
-
Brune S, Kolsch H, Ptok U, Majores M, Schulz A, Schlosser R, Rao ML, Maier W, Heun R. Polymorphism in the peroxisome proliferator-activated receptor alpha gene influences the risk for Alzheimer's disease.
J. Neural. Transm. 110: 1041-1050 (2003).
*
-
Brunelleschi S, Bardelli C, Amoruso A, Gunella G, Ieri F, Romani A, Malorni W, Franconi F. Minor polar compounds extra-virgin olive oil extract (MPC-OOE) inhibits NF-kappaB translocation in human monocyte/macrophages.
Pharmacol. Res. 56: 542-549 (2007).
*
-
Brunelli L, Cieslik KA, Alcorn JL, Vatta M, Baldini A. Peroxisome proliferator-activated receptor-delta upregulates 14-3-3varepsilon in human endothelial cells via CCAAT/enhancer binding protein-beta.
Circ. Res. 100: e59-e71 (2007).
*
-
Brunmair B, Staniek K, Dorig J, Szocs Z, Stadlbauer K, Marian V, Gras F, Anderwald C, Nohl H, Waldhausl W, Furnsinn C. Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids.
Diabetologia 49: 2713-2722 (2006).
*
-
Bu PL, Zhao XQ, Wang LL, Zhao YX, Li CB, Zhang Y. Tong-xin-luo capsule inhibits left ventricular remodeling in spontaneously hypertensive rats by enhancing PPAR-gamma expression and suppressing NF-kappaB activity.
Chin. Med. J. (Engl.) 121: 147-154 (2008).
-
Bu SY, Mashek MT, Mashek DG. Suppression of long chain acyl-CoA synthetase 3 (ACSL3) decreases hepatic de novo fatty acid synthesis through decreased transcriptional activity.
J. Biol. Chem. 284: 30474-30483 (2009).
*
-
Buaud B, Esterle L, Vaysse C, Alfos S, Combe N, Higueret P, Pallet V. A high-fat diet induces lower expression of retinoid receptors and their target genes GAP-43/neuromodulin and RC3/neurogranin in the rat brain.
Br. J. Nutr. Jan 27 [Epub ahead of print] (2010).
*
-
Buckley DB, Klaassen CD. Induction of mouse UDP-glucuronosyltransferase mRNA expression in liver and intestine by activators of AhR, CAR, PXR, PPARalpha, and Nrf2.
Drug Metab. Dispos. 37: 847-856 (2009).
*
-
Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, Scholmerich J, Bollheimer LC. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types.
J. Mol. Endocrinol. 36: 485-501 (2006).
*
-
Bugge A, Grontved L, Aagaard MM, Borup R, Mandrup S. The PPARgamma2 A/B-domain plays a gene specific role in transactivation and co-factor recruitment.
Mol. Endocrinol. 23: 794-808 (2009).
*
-
Bujold K, Rhainds D, Jossart C, Febbraio M, Marleau S, Ong H. CD36-mediated cholesterol efflux is associated with PPARgamma activation via a MAPK-dependent COX-2 pathway in macrophages.
Cardiovasc. Res. 83: 457-464 (2009).
*
-
Bulhak AA, Jung C, Ostenson CG, Lundberg JO, Sjoquist PO, Pernow J. PPAR-alpha activation protects the type 2 diabetic myocardium against ischemia-reperfusion injury: involvement of the PI3-kinase/Akt and NO pathway.
Am. J. Physiol. Heart Circ. Physiol. 296: H719-H727 (2009).
*
-
Bulhak AA, Sjoquist PO, Xu CB, Edvinsson L, Pernow J. Protection against myocardial ischaemia/reperfusion injury by PPAR-alpha activation is related to production of nitric oxide and endothelin-1.
Basic Res. Cardiol. 101: 244-252 (2006).
-
Bull AW. The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease.
Arch. Pathol. Lab. Med. 127: 1121-1123 (2003).
*
-
Bundscherer A, Reichle A, Hafner C, Meyer S, Vogt T. Targeting the tumor stroma with peroxisome proliferator activated receptor (PPAR) agonists.
Anticancer Agents Med. Chem. 9: 816-821 (2009).
-
Bunger M, Hooiveld GJ, Kersten S, Muller M. Exploration of PPAR functions by microarray technology - a paradigm for nutrigenomics.
Biochim. Biophys. Acta 1771: 1046-1064 (2007).
*
-
Bunger M, van den Bosch HM, van der Meijde J, Kersten S, Hooiveld GJ, Muller M. Genome-wide analysis of PPARalpha activation in murine small intestine.
Physiol. Genomics 30: 192-204 (2007).
*
-
Burch LR, Zhou K, Donnelly LA, Doney AS, Brady J, Goddard C, Morris AD, Hansen MK, Palmer CN. A single nucleotide polymorphism on exon-4 of the gene encoding PPARdelta is associated with reduced height in adults and children.
J. Clin. Endocrinol. Metab. 94: 2587-2593 (2009).
*
-
Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M, Seger R. Interaction with MEK causes nuclear export and downregulation of PPARgamma.
Mol. Cell. Biol. 27: 803-817 (2007).
*
-
Burgermeister E, Schnoebelen A, Flament A, Benz J, Stihle M, Gsell B, Rufer A, Ruf A, Kuhn B, Marki HP, Mizrahi J, Sebokova E, Niesor E, Meyer M. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1 alpha (PGC1alpha), prevents triglyceride accumulation and potentiates insulin signaling in vitro.
Mol. Endocrinol. 20: 809-830 (2006).
*
-
Burns KA, Vanden Heuvel JP. Modulation of PPAR activity via phosphorylation.
Biochim. Biophys. Acta 1771: 952-960 (2007).
*
-
Buroker NE, Barboza J, Huang JY. The IkappaBalpha gene is a peroxisome proliferator-activated receptor cardiac target gene.
FEBS J. 276: 3247-3255 (2009).
*
-
Buroker NE, Young ME, Wei C, Serikawa K, Ge M, Ning XH, Portman MA. The dominant negative thyroid hormone receptor beta mutant Delta337T alters peroxisome proliferator-activated receptor alpha signaling in heart.
Am. J. Physiol. Endocrinol. Metab. 292: E453-E460 (2007).
*
-
Burrage PS, Schmucker AC, Ren Y, Sporn MB, Brinckerhoff CE. Retinoid X receptor and peroxisome proliferator-activated receptor-gamma agonists cooperate to inhibit matrix metalloproteinase gene expression.
Arthritis Res. Ther. 10: R139 (2008).
*
-
Burstein S. PPAR-gamma: a nuclear receptor with affinity for cannabinoids.
Life Sci. 77: 1674-1684 (2005).
*
-
Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Clin. Ther. 27: 1181-1195 (2005).
*
-
Bush CR, Havens JM, Necela BM, Su W, Chen L, Yanagisawa M, Anastasiadis PZ, Guerra R, Luxon BA, Thompson EA. Functional genomic analysis reveals crosstalk between peroxisome proliferator-activated receptor gamma (PPAR-gamma) and calcium signaling in human colorectal cancer cells.
J. Biol. Chem. 282: 23387-23401 (2007).
*
-
Butt C, Gladman D, Rahman P. PPAR-gamma gene polymorphisms and psoriatic arthritis.
J. Rheumatol. 33: 1631-1633 (2006).
*
-
Buzzetti R, Petrone A, Ribaudo MC, Alemanno I, Zavarella S, Mein CA, Maiani F, Tiberti C, Baroni MG, Vecci E, Arca M, Leonetti F, Mario UD. The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity.
Eur. J. Hum. Genet. 12: 1050-1054 (2004).
*
-
Cabrero A, Alegret M, Sanchez RM, Adzet T, Laguna JC, Vazquez M. Bezafibrate reduces mRNA levels of adipocyte markers and increases fatty acid oxidation in primary culture of adipocytes.
Diabetes 50: 1883-1890 (2001).
*
-
Cabrero A, Cubero M, Llaverias G, Alegret M, Sanchez R, Laguna JC, Vazquez-Carrera M. Leptin down-regulates peroxisome proliferator-activated receptor gamma (PPAR-gamma) mRNA levels in primary human monocyte-derived macrophages.
Mol. Cell. Biochem. 275: 173-179 (2005).
*
-
Cabrero A, Cubero M, Llaverias G, Jove M, Planavila A, Alegret M, Sanchez R, Laguna JC, Carrera MV. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages.
Metabolism 52: 652-657 (2003).
*
-
Cabrero A, Laguna JC, Vazquez M. Peroxisome proliferator-activated receptors and the control of inflammation.
Curr. Drug Targets Inflamm. Allergy 1: 243-248 (2002).
-
Caglayan E, Stauber B, Collins AR, Lyon CJ, Yin F, Liu J, Rosenkranz S, Erdmann E, Peterson LE, Ross RS, Tangirala RK, Hsueh WA. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis.
Diabetes 57: 2470-2479 (2008).
*
-
Calabro P, Samudio I, Safe SH, Willerson JT, Yeh ET. Inhibition of tumor-necrosis-factor-alpha-induced endothelial cell activation by a new class of PPAR-gamma agonists.
J. Vasc. Res. 42: 509-516 (2005).
*
-
Caldwell SH, Argo CK, Al-Osaimi AM. Therapy of NAFLD: insulin sensitizing agents.
J. Clin. Gastroenterol. 40 Suppl. 1: S61-S66 (2006).
-
Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, Thomas MC. Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse.
Atherosclerosis 195: 17-22 (2007).
-
Calkin AC, Giunti S, Jandeleit-Dahm KA, Allen TJ, Cooper ME, Thomas MC. PPAR-alpha and gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Nephrol. Dial. Transplant. 21: 2399-2405 (2006).
*
-
Calkin AC, Jandeleit-Dahm KA, Sebekova E, Allen TJ, Mizrahi J, Cooper ME, Tikellis C. PPARs and diabetes-associated atherosclerosis.
Curr. Pharm. Des. 13: 2736-2741 (2007).
-
Calkin AC, Thomas MC. PPAR agonists and cardiovascular disease in diabetes.
PPAR Res. 2008: 245410 (2008).
*
-
Calleja C, Messaddeq N, Chapellier B, Yang H, Krezel W, Li M, Metzger D, Mascrez B, Ohta K, Kagechika H, Endo Y, Mark M, Ghyselinck NB, Chambon P. Genetic and pharmacological evidence that a retinoic acid cannot be the RXR-activating ligand in mouse epidermis keratinocytes.
Genes Dev. 20: 1525-1538 (2006).
*
-
Calviello G, Resci F, Serini S, Piccioni E, Toesca A, Boninsegna A, Monego G, Ranelletti FO, Palozza P. Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2.
Carcinogenesis 28: 1202-1209 (2007).
*
-
Campbell IW. The clinical significance of PPAR gamma agonism.
Curr. Mol. Med. 5: 349-363 (2005).
-
Campbell SE, Musich PR, Whaley SG, Stimmel JB, Leesnitzer LM, Dessus-Babus S, Duffourc M, Stone W, Newman RA, Yang P, Krishnan K. Gamma tocopherol upregulates the expression of 15-S-HETE and induces growth arrest through a PPAR gamma-dependent mechanism in PC-3 human prostate cancer cells.
Nutr. Cancer 61: 649-662 (2009).
-
Campolongo P, Roozendaal B, Trezza V, Cuomo V, Astarita G, Fu J, McGaugh JL, Piomelli D. Fat-induced satiety factor oleoylethanolamide enhances memory consolidation.
Proc. Natl. Acad. Sci. U.S.A. 106: 8027-8031 (2009).
*
-
Canaple L, Rambaud J, Dkhissi-Benyahya O, Rayet B, Tan NS, Michalik L, Delaunay F, Wahli W, Laudet V. Reciprocal regulation of BMAL1 and PPARalpha defines a novel positive feedback loop in the rodent liver circadian clock.
Mol. Endocrinol. 20: 1715-1727 (2006).
*
-
Canton RF, Peijnenburg AA, Hoogenboom RL, Piersma AH, van der Ven LT, van den Berg M, Heneweer M. Subacute effects of hexabromocyclododecane (HBCD) on hepatic gene expression profiles in rats.
Toxicol. Appl. Pharmacol. 231: 267-272 (2008).
*
-
Cao LQ, Chen XL, Wang Q, Huang XH, Zhen MC, Zhang LJ, Li W, Bi J. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells.
Acta Pharmacol. Sin. 28: 879-887 (2007).
*
-
Capeau J. The story of adiponectin and its receptors AdipoR1 and R2: to follow.
J. Hepatol. 47: 736-738 (2007).
-
Capeau J, Magre J, Lascols O, Caron M, Bereziat V, Vigouroux C, Bastard JP. Diseases of adipose tissue: genetic and acquired lipodystrophies.
Biochem. Soc. Trans. 33: 1073-1077 (2005).
*
-
Capobianco E, Martínez N, Higa R, White V, Jawerbaum A. The effects of maternal dietary treatments with natural PPAR ligands on lipid metabolism in fetuses from control and diabetic rats.
Prostaglandins Leukot. Essent. Fatty Acids 79: 191-199 (2008).
*
-
Capobianco E, White V, Higa R, Martínez N, Jawerbaum A. Effects of natural ligands of PPARgamma on lipid metabolism in placental tissues from healthy and diabetic rats.
Mol. Hum. Reprod. 14: 491-499 (2008).
*
-
Cardell LO, Hagge M, Uddman R, Adner M. Downregulation of peroxisome proliferator-activated receptors (PPARs) in nasal polyposis.
Respir. Res. 6: 132 (2005).
*
-
Carey AL, Petersen EW, Bruce CR, Southgate RJ, Pilegaard H, Hawley JA, Pedersen BK, Febbraio MA. Discordant gene expression in skeletal muscle and adipose tissue of patients with type 2 diabetes: effect of interleukin-6 infusion.
Diabetologia 49: 1000-1007 (2006).
*
-
Carfi' M, Croera C, Ferrario D, Campi V, Bowe G, Pieters R, Gribaldo L. TBTC induces adipocyte differentiation in human bone marrow long term culture.
Toxicology 249: 11-18 (2008).
*
-
Cariello NF, Romach EH, Colton HM, Ni H, Yoon L, Falls JG, Casey W, Creech D, Anderson SP, Benavides GR, Hoivik DJ, Brown R, Miller RT. Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver.
Toxicol. Sci. 88: 250-264 (2005).
*
-
Carlberg C, Dunlop TW. An integrated biological approach to nuclear receptor signaling in physiological control and disease.
Crit. Rev. Eukaryot. Gene Expr. 16: 1-22 (2006).
-
Carmel JF, Tarnus E, Cohn JS, Bourdon E, Davignon J, Bernier L. High expression of apolipoprotein E impairs lipid storage and promotes cell proliferation in human adipocytes.
J. Cell. Biochem. 106: 608-617 (2009).
*
-
Carmena R. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.
Am. Heart J. 150: 859-870 (2005).
*
-
Carmena R, Betteridge DJ. Statins and diabetes.
Semin. Vasc. Med. 4: 321-332 (2004).
-
Carmona MC, Louche K, Lefebvre B, Pilon A, Hennuyer N, Audinot-Bouchez V, Fievet C, Torpier G, Formstecher P, Renard P, Lefebvre P, Dacquet C, Staels B, Casteilla L, Penicaud L. S 26948, a new specific PPARgamma modulator (SPPARM) with potent antidiabetic and antiatherogenic effects.
Diabetes 56: 2797-2808 (2007).
*
-
Caron-Dorval D, Paquet P, Paradis AM, Rudkowska I, Lemieux S, Couture P, Vohl MC. Effect of the PPAR-Alpha L162V polymorphism on the cardiovascular disease risk factor in response to n-3 polyunsaturated fatty acids.
J. Nutrigenet. Nutrigenomics 1: 205-212 (2008).
-
Carter AB, Misyak SA, Hontecillas R, Bassaganya-Riera J. Dietary modulation of inflammation-induced colorectal cancer through PPARgamma.
PPAR Res. 2009: 498352 (2009).
*
-
Carter JC, Church FC. Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-gamma and plasminogen activator inhibitor-1.
PPAR Res. 2009: 345320 (2009).
*
-
Carvajal K, Hernandez-Esquivel Mde L, Moreno-Sanchez R. PPARs, metabolic syndrome and cardiac diseases.
Arch. Cardiol. Mex. 77 Suppl. 4: S4-S66-S76 (2007).
-
Casals-Casas C, Feige JN, Desvergne B. Interference of pollutants with PPARs: endocrine disruption meets metabolism.
Int. J. Obes. (Lond.) 32 Suppl. 6: S53-S61 (2008).
*
-
Casey WM, Brodie T, Yoon L, Ni H, Jordan HL, Cariello NF. Correlation analysis of gene expression and clinical chemistry to identify biomarkers of skeletal myopathy in mice treated with PPAR agonist GW610742X.
Biomarkers 13: 364-376 (2008).
-
Casimiro-Garcia A, Bigge CF, Davis JA, Padalino T, Pulaski J, Ohren JF, McConnell P, Kane CD, Royer LJ, Stevens KA, Auerbach B, Collard W, McGregor C, Song K. Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists.
Bioorg. Med. Chem. 17: 7113-7125 (2009).
-
Cassuto H, Kochan K, Chakravarty K, Cohen H, Blum B, Olswang Y, Hakimi P, Xu C, Massillon D, Hanson RW, Reshef L. Glucocorticoids regulate transcription of the gene for phosphoenolpyruvate carboxykinase (GTP) in the liver via an extended glucocorticoid regulatory unit.
J. Biol. Chem. 280: 33873-33884 (2005).
*
-
Casteilla L, Cousin B, Carmona M. PPARs and adipose cell plasticity.
PPAR Res. 2007: 68202 (2007).
*
-
Castelein H, Declercq PE, Baes M. DNA binding preferences of PPAR alpha/RXR alpha heterodimers.
Biochem. Biophys. Res. Commun. 233: 91-95 (1997).
*
-
Castrillo A, Tontonoz P. PPARs in atherosclerosis: the clot thickens.
J. Clin. Invest. 114: 1538-1540 (2004).
*
-
Castriota G, Thompson GM, Lin Y, Scherer PE, Moller DE, Berger JP. Peroxisome proliferator-activated receptor gamma agonists inhibit adipocyte expression of alpha1-acid glycoprotein.
Cell Biol. Int. 31: 586-591 (2007).
*
-
Catalano M, Cortelazzo A, Santi R, Contino L, Demicheli M, Yilmaz Y, Zorzetto M, Campo I, Lanati N, Emanuele E. The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease.
Clin. Biochem. 41: 981-985 (2008).
*
-
Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Emerging molecular therapies of advanced thyroid cancer.
Mol. Aspects Med. Feb 19 [Epub ahead of print] (2010).
-
Cauchi S, Nead KT, Choquet H, Horber F, Potoczna N, Balkau B, Marre M, Charpentier G, Froguel P, Meyre D. The genetic susceptibility to type 2 diabetes may be modulated by obesity status: implications for association studies.
BMC Med. Genet. 9: 45 (2008).
*
-
Cavalieri D, Calura E, Romualdi C, Marchi E, Radonjic M, van Ommen B, Muller M. Filling gaps in PPAR-alpha signaling through comparative nutrigenomics analysis.
BMC Genomics 10: 596 (2009).
*
-
Cazzola M, Matera MG, Rogliani P, Page C. Treating systemic effects of COPD.
Trends Pharmacol. 28: 544-550 (2007).
*
-
Cecil JE, Watt P, Palmer CN, Hetherington M. Energy balance and food intake: the role of PPARgamma gene polymorphisms.
Physiol. Behav. 88: 227-233 (2006).
*
-
Celinski K, Madro A, Prozorow-Krol B, Korolczuk A, Cichoz-Lach H, Slomka M, Korobowicz E. Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-gamma)-specific agonist, as a modulator in experimental acute pancreatitis.
Med. Sci. Monit. 15: BR21-BR29 (2009).
*
-
Ceni E, Crabb DW, Foschi M, Mello T, Tarocchi M, Patussi V, Moraldi L, Moretti R, Milani S, Surrenti C, Galli A. Acetaldehyde inhibits PPARgamma via H(2)O(2)-mediated c-Abl activation in human hepatic stellate cells.
Gastroenterology 131: 1235-1252 (2006).
*
-
Ceperuelo-Mallafre V, Miranda M, Chacon MR, Vilarrasa N, Megia A, Gutierrez C, Fernandez-Real JM, Gomez JM, Caubet E, Fruhbeck G, Vendrell J. Adipose tissue expression of the glycerol channel aquaporin-7 gene is altered in severe obesity but not in type 2 diabetes.
J. Clin. Endocrinol. Metab. 92: 3640-3645 (2007).
*
-
Cesario RM, Stone J, Yen WC, Bissonnette RP, Lamph WW. Differentiation and growth inhibition mediated via the RXR:PPARgamma heterodimer in colon cancer.
Cancer Lett. 240: 225-233 (2006).
*
-
Cha DR, Zhang X, Zhang Y, Wu J, Su DM, Han JY, Fang X, Yu B, Breyer MD, Guan Y. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
Diabetes 56: 2036-2045 (2007).
*
-
Chae SJ, Kim JJ, Choi YM, Kim JM, Cho YM, Moon SY. Peroxisome proliferator-activated receptor-gamma and its coactivator-1alpha gene polymorphisms in Korean women with polycystic ovary syndrome.
Gynecol. Obstet. Invest. 70: 1-7 (2010).
-
Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, Turk J, Semenkovich CF. "New" hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis.
Cell. Metab. 1: 309-322 (2005).
*
-
Chalasani N, Teal E, Hall SD. Effect of rosiglitazone on serum liver biochemistries in diabetic patients with normal and elevated baseline liver enzymes.
Am. J. Gastroenterol. 100: 1317-1321 (2005).
*
-
Chambers KT, Weber SM, Corbett JA. PGJ2 stimulated beta-cell apoptosis is associated with prolonged UPR activation.
Am. J. Physiol. Endocrinol. Metab. 292: E1052-E1061 (2007).
*
-
Chambrier C, Bastard JP, Rieusset J, Chevillotte E, Bonnefont-Rousselot D, Therond P, Hainque B, Riou JP, Laville M, Vidal H. Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma.
Obes. Res. 10: 518-525 (2002).
*
-
Chan BY, Gartland A, Wilson PJ, Buckley KA, Dillon JP, Fraser WD, Gallagher JA. PPAR agonists modulate human osteoclast formation and activity in vitro.
Bone 40: 149-159 (2007).
*
-
Chan E, Tan CS, Deurenberg-Yap M, Chia KS, Chew SK, Tai ES. The V227A polymorphism at the PPARA locus is associated with serum lipid concentrations and modulates the association between dietary polyunsaturated fatty acid intake and serum high density lipoprotein concentrations in Chinese women.
Atherosclerosis 187: 309-315 (2006).
-
Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy.
Endocr. Pract. Jan 9 [Epub ahead of print] (2010).
*
-
Chan LS, Wells RA. Cross-talk between PPARs and the partners of RXR: a molecular perspective.
PPAR Res. 2009: 925309 (2009).
*
-
Chan LS, Wells RA. Manipulation of reciprocal salt bridges at the heterodimerization interface alters the dimerization properties of mouse RXRalpha and PPARgamma1.
Biochem. Biophys. Res. Commun. 358: 1080-1085 (2007).
*
-
Chan MM, Evans KW, Moore AR, Fong D. Peroxisome proliferator-activated receptor (PPAR): balance for survival in parasitic infections.
J. Biomed. Biotechnol. 2010: 828951 (2010).
*
-
Chan SH, Wu CA, Wu KL, Ho YH, Chang AY, Chan JY. Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension.
Circ. Res. 105: 886-896 (2009).
-
Chan SS, Schedlich LJ, Twigg SM, Baxter RC. Inhibition of adipocyte differentiation by insulin-like growth factor binding protein-3.
Am. J. Physiol. Endocrinol. Metab. 296: E654-E663 (2009).
*
-
Chanda D, Lee CH, Kim YH, Noh JR, Kim DK, Park JH, Hwang JH, Lee MR, Jeong KH, Lee IK, Kweon GR, Shong M, Oh GT, Chiang JY, Choi HS. Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner.
Hepatology 50: 880-892 (2009).
-
Chandalia A, Clarke HJ, Clemens LE, Pandey B, Vicena V, Lee P, Lavan BE, Gregoire FM. MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-gamma agonist lowers triglyceride independently of PPAR-alpha activation.
PPAR Res. 2009: 706852 (2009).
*
-
Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F. Structure of the intact PPAR-gamma-RXR-alpha nuclear receptor complex on DNA.
Nature 456: 350-356 (2008).
*
-
Chang AJ, Song DH, Wolfe MM. Attenuation of peroxisome proliferator activated receptor gamma (PPARgamma) mediates gastrin-stimulated colorectal cancer cell proliferation.
J. Biol. Chem. 281: 14700-14710 (2006).
*
-
Chang F, Jaber LA, Berlie HD, O'Connell MB. Evolution of peroxisome proliferator-activated receptor agonists.
Ann. Pharmacother. 41: 973-983 (2007).
-
Chang HJ, Lee JH, Hwang KJ, Kim MR, Chang KH, Park DW, Min CK. Transforming growth factor (TGF)-beta1-induced human endometrial stromal cell decidualization through extracellular signal-regulated kinase and Smad activation in vitro: peroxisome proliferator-activated receptor gamma acts as a negative regulator …
Fertil. Steril. 90: S1357-S1365 (2008).
-
Chang SC, Rashid A, Gao YT, Andreotti G, Shen MC, Wang BS, Han TQ, Zhang BH, Sakoda LC, Leitzmann MF, Chen BE, Rosenberg P, Chen J, Chanock S, Hsing AW. Polymorphism of genes related to insulin sensitivity and the risk of biliary tract cancer and biliary stone: a population-based case-control study in Shanghai, China.
Carcinogenesis 29: 944-948 (2008).
*
-
Chang XH, Zhang L, Yang R, Feng J, Cheng YX, Cheng HY, Ye X, Fu TY, Cui H. Screening for genes associated with ovarian cancer prognosis.
Chin. Med. J. (Engl.) 122: 1167-1172 (2009).
-
Chao C, Youssef J, Rezaiekhaleigh M, Birnbaum LS, Badr M. Senescence-associated decline in hepatic peroxisomal enzyme activities corresponds with diminished levels of retinoid X receptor alpha, but not peroxisome proliferator-activated receptor alpha.
Mech. Ageing Dev. 123: 1469-1476 (2002).
-
Chao HH, Liu JC, Hong HJ, Lin JW, Chen CH, Cheng TH. L-Carnitine reduces doxorubicin-induced apoptosis through a prostacyclin-mediated pathway in neonatal rat cardiomyocytes.
Int. J. Cardiol. Jun 22 [Epub ahead of print] (2009).
-
Chao PM, Yang MF, Tseng YN, Chang KM, Lu KS, Huang CJ. Peroxisome proliferation in liver of rats fed oxidized frying oil.
J. Nutr. Sci. Vitaminol. (Tokyo) 51: 361-368 (2005).
-
Charbonnel B. PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
Lancet 374: 96-88 (2009).
*
-
Chaturvedi D, Ray S, Srivastava AK, Chander R. Omega-(2-naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.
Bioorg. Med. Chem. 16: 2489-2498 (2008).
*
-
Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L, Starkov A, Kiaei M, Cannella M, Sassone J, Ciammola A, Squitieri F, Beal MF. Impaired PGC-1alpha function in muscle in Huntington's disease.
Hum. Mol. Genet. 18: 3048-3065 (2009).
-
Chaturvedi RK, Flint Beal M. PPAR: a therapeutic target in Parkinson's disease.
J. Neurochem. 106: 506-518 (2008).
*
-
Chaudhary N, Pfluger PT. Metabolic benefits from Sirt1 and Sirt1 activators.
Curr. Opin. Clin. Nutr. Metab. Care 12: 431-437 (2009).
-
Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Dietary fatty acid intakes and the risk of ovulatory infertility.
Am. J. Clin. Nutr. 85: 231-237 (2007).
*
-
Chearwae W, Bright JJ. PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells.
Br. J. Cancer 99: 2044-2053 (2008).
*
-
Cheatham WW. Peroxisome proliferator-activated receptor translational research and clinical experience.
Am. J. Clin. Nutr. 91: 262S-266S (2010).
*
-
Chegary M, Te Brinke H, Doolaard M, Ijlst L, Wijburg FA, Wanders RJ, Houten SM. Characterization of L-aminocarnitine, an inhibitor of fatty acid oxidation.
Mol. Genet. Metab. 93: 403-410 (2008).
*
-
Chello M, Spadaccio C, Lusini M, Covino E, Blarzino C, De Marco F, Di Domenico F, Coccia R. Advanced glycation end products in diabetic patients with optimized glycaemic control and their effects on endothelial reactivity: possible implications in venous graft failure.
Diabetes Metab. Res. Rev. 25: 420-426 (2009).
-
Chemin J, Patel A, Duprat F, Zanzouri M, Lazdunski M, Honore E. Lysophosphatidic acid-operated K+ channels.
J. Biol. Chem. 280: 4415-4421 (2005).
*
-
Chen AB, Hamamura K, Wang G, Xing W, Mohan S, Yokota H, Liu Y. Model-based comparative prediction of transcription-factor binding motifs in anabolic responses in bone.
Genomics Proteomics Bioinformatics 5: 158-165 (2007).
-
Chen C, Xu S, Wang WX, Ding YM, Yu KH, Wang B, Chen XY. Rosiglitazone attenuates the severity of sodium taurocholate-induced acute pancreatitis and pancreatitis-associated lung injury.
Arch. Med. Res. 40: 79-88 (2009).
-
Chen CH, Wang PH, Liu BH, Hsu HH, Mersmann HJ, Ding ST. Serum amyloid A protein regulates the expression of porcine genes related to lipid metabolism.
J. Nutr. 138: 674-679 (2008).
*
-
Chen D, Jin G, Wang Y, Wang H, Liu H, Liu Y, Fan W, Ma H, Miao R, Hu Z, Sun W, Qian J, Jin L, Wei Q, Shen H, Huang W, Lu D. Genetic variants in peroxisome proliferator-activated receptor-gamma gene are associated with risk of lung cancer in a Chinese population.
Carcinogenesis 29: 342-350 (2008).
*
-
Chen GG, Xu H, Lee JF, Subramaniam M, Leung KL, Wang SH, Chan UP, Spelsberg TC. 15-Hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferator-activated receptor gamma-dependent pathway.
Int. J. Cancer 107: 837-843 (2003).
*
-
Chen H, He YW, Liu WQ, Zhang JH. Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum.
World J. Gastroenterol. 14: 2905-2911 (2008).
*
-
Chen HH, Chen TW, Lin H. Prostacyclin-induced peroxisome proliferator-activated receptor alpha translocation attenuates NF-kappaB and TNF-alpha activation after renal ischemia-reperfusion injury.
Am. J. Physiol. Renal Physiol. 297: F1109-F1118 (2009).
*
-
Chen HH, Lee WJ, Fann CS, Bouchard C, Pan WH. Severe obesity is associated with novel single nucleotide polymorphisms of the ESR1 and PPARgamma locus in Han Chinese.
Am. J. Clin. Nutr. 90: 255-262 (2009).
*
-
Chen HJ, Chen JZ, Wang XX, Yu M. PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats.
Zhejiang Da Xue Xue Bao Yi Xue Ban 36: 470-476 (2007).
-
Chen J, Mehta JL. Angiotensin II-mediated oxidative stress and pro-collagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone.
Am. J. Physiol. Heart Circ. Physiol. 291: H1738-H1745 (2006).
*
-
Chen J, Raymond K. Treatment effect of rifampicin on cholestasis.
The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml) (2006). *
-
Chen L, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ, Fields AP, Thompson EA. Peroxisome proliferator-activated receptor-gamma promotes epithelial to mesenchymal transformation by Rho GTPase activation of ERK1/2.
J. Biol. Chem. 281: 24575-24587 (2006).
*
-
Chen N, Bezzina R, Hinch E, Lewandowski PA, Cameron-Smith D, Mathai ML, Jois M, Sinclair AJ, Begg DP, Wark JD, Weisinger HS, Weisinger RS. Green tea, black tea, and epigallocatechin modify body composition, improve glucose tolerance, and differentially alter metabolic gene expression in rats fed a high-fat diet.
Nutr. Res. 29: 784-793 (2009).
-
Chen P, Li C, Pang W, Zhao Y, Dong W, Wang S, Zhang J. The protective role of Per2 against carbon tetrachloride-induced hepatotoxicity.
Am. J. Pathol. 174: 63-70 (2009).
*
-
Chen Q, Sun X, Chen J, Cheng L, Wang J, Wang Y, Sun Z. Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells.
Reprod. Biol. Endocrinol. 7: 147 (2009).
-
Chen R, Liang F, Moriya J, Yamakawa JI, Takahashi T, Shen L, Kanda T. Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful?
Int. J. Cardiol. 130: 131-139 (2008).
-
Chen S, Li Y, Li S, Yu C. A Val227Ala substitution in the peroxisome proliferator activated receptor alpha (PPAR alpha) gene associated with non-alcoholic fatty liver disease and decreased waist circumference and waist-to-hip ratio.
J. Gastroenterol. Hepatol. 23: 1415-1418 (2008).
*
-
Chen TJ, Ji CY, Zheng XY, Hu YH. Association of beta3 adrenergic receptor and peroxisome proliferator-activated receptor gamma 2 polymorphisms with insulin sensitivity: a twin study.
Biomed. Environ. Sci. 20: 99-105 (2007).
-
Chen X, Matthews J, Zhou L, Pelton P, Liang Y, Xu J, Yang M, Cryan E, Rybczynski P, Demarest K. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.
Metabolism 57: 1516-1525 (2008).
*
-
Chen XD, Chen YL, Wang SB, Lei T, Gan L, Yang ZQ. Molecular characterization and functional analysis of porcine macrophage migration inhibitory factor (MIF) gene.
Cytokine Jan 19 [Epub ahead of print] (2010).
-
Chen XR, Besson VC, Beziaud T, Plotkine M, Marchand-Leroux C. Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury.
J. Pharmacol. Exp. Ther. 326: 966-974 (2008).
*
-
Chene G, Dubourdeau M, Balard P, Escoubet-Lozach L, Orfila C, Berry A, Bernad J, Aries MF, Charveron M, Pipy B. n-3 and n-6 Polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells.
Biochim. Biophys. Acta 1771: 576-589 (2007).
*
-
Cheng AY, Leiter LA. PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease.
Diabetes Obes. Metab. 10: 691-698 (2008).
-
Cheng G, Zhang X, Gao D, Jiang X, Dong W. Resveratrol inhibits MMP-9 expression by up-regulating PPAR alpha expression in an oxygen glucose deprivation-exposed neuron model.
Neurosci. Lett. 451: 105-108 (2009).
-
Cheng PT, Mukherjee R. PPARs as targets for metabolic and cardiovascular diseases.
Mini. Rev. Med. Chem. 5: 741-753 (2005).
-
Cheng S, Afif H, Martel-Pelletier J, Benderdour M, Pelletier JP, Hilal G, Haraoui P, Raynauld JP, Choquette D, Fahmi H. Association of polymorphisms in the peroxisome proliferator-activated receptor gamma gene and osteoarthritis of the knee.
Ann. Rheum. Dis. 65: 1394-1397 (2006).
*
-
Cheng W, Cheng NS, Xiong XZ, Xia QJ, Chen OY, Yan NH, Jing J. Expression of PPAR-gamma in human hilar bile duct carcinoma cell line QBC939 and the effects of PPAR-Y activated by its ligand on the growth of QBC939.
Sichuan Da Xue Xue Bao Yi Xue Ban 37: 745-749 (2006).
-
Cheng X, Klaassen CD. Perfluorocarboxylic acids induce cytochrome p450 enzymes in mouse liver through activation of PPARalpha and CAR transcription factors.
Toxicol. Sci. 106: 29-36 (2008).
*
-
Cheng X, Klaassen CD. Critical role of PPARalpha in perfluorooctanoic acid- and perfluorodecanoic acid-induced down-regulation of Oatp uptake transporters in mouse livers.
Toxicol. Sci. 106: 37-45 (2008).
*
-
Cheng X, Maher JM, Dieter MZ, Klaassen CD. Regulation of mouse organic anion transporting polypeptides (Oatps) in liver by prototypical microsome enzyme inducers that activate distinct transcription factor pathways.
Drug Metab. Dispos. 33: 1276-1282 (2005).
*
-
Cheng Y, Ping J, Xu LM. Effects of curcumin on peroxisome proliferator-activated receptor gamma expression and nuclear translocation/redistribution in culture-activated rat hepatic stellate cells.
Chin. Med. J. (Engl.) 120: 794-801 (2007).
-
Cheon CW, Kim DH, Kim DH, Cho YH, Kim JH. Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells.
World J. Gastroenterol. 15: 310-320 (2009).
*
-
Cheon Y, Nara TY, Band MR, Beever JE, Wallig MA, Nakamura MT. Induction of overlapping genes by fasting and a peroxisome proliferator in pigs: evidence of functional PPAR alpha in non-proliferating species.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 288: R1525-R1535 (2005).
*
-
Cherkaoui-Malki M, Meyer K, Cao WQ, Latruffe N, Yeldandi AV, Rao MS, Bradfield CA, Reddy JK. Identification of novel peroxisome proliferator-activated receptor alpha (PPARalpha) target genes in mouse liver using cDNA microarray analysis.
Gene Expr. 9: 291-304 (2001).
-
Cherry J, Jones HM, Karschner VA, Pekala PH. Post transcriptional control of C/EBPbeta expression: formation of a nuclear HuR-C/EBPbeta mRNA complex determines the amount of message reaching the cytosol.
J. Biol. Chem. 283: 30812-30820 (2008).
*
-
Chess DJ, Lei B, Hoit BD, Azimzadeh AM, Stanley WC. Effects of a high saturated fat diet on cardiac hypertrophy and dysfunction in response to pressure overload.
J. Card. Fail. 14: 82-88 (2008).
-
Chetty VT, Sharma AM. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
Vascul. Pharmacol. 45: 46-53 (2006).
*
-
Cheung C, Akiyama TE, Ward JM, Nicol CJ, Feigenbaum L, Vinson C, Gonzalez FJ. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha.
Cancer Res. 64: 3849-3854 (2004).
*
-
Chiang JY. Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms.
J. Hepatol. 40: 539-551 (2004).
*
-
Chiang JYL, Li T, Jahan A. Mechanisms of bile acid inhibition of genes in bile acid synthesis.
Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 23. June 18-19 (2004). *
-
Chiba T, Ueki S, Ito W, Kato H, Takeda M, Kayaba H, Furue M, Chihara J. 15-Deoxy-Delta(12,14)-prostaglandin J2 induces IL-8 and GM-CSF in a human airway epithelial cell line (NCI-H292).
Int. Arch. Allergy Immunol. 149 Suppl. 1: 77-82 (2009).
-
Chiche F, Le Guillou M, Chetrite G, Lasnier F, Dugail I, Carpene C, Moldes M, Feve B. The antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes.
Mol. Pharmacol. 75: 1052-1061 (2009).
*
-
Chikahisa S, Tominaga K, Kawai T, Kitaoka K, Oishi K, Ishida N, Rokutan K, Sei H. Bezafibrate, a PPARs agonist, decreases body temperature and enhances electroencephalogram delta-oscillation during sleep in mice.
Endocrinology 149: 5262-5271 (2008).
*
-
Childs S, Carter F, Lynch CO, Sreenan JM, Lonergan P, Hennessy AA, Kenny DA. Embryo yield and quality following dietary supplementation of beef heifers with n-3 polyunsaturated fatty acids (PUFA).
Theriogenology 70: 992-1003 (2008).
-
Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall.
Z. Kardiol. 90 Suppl. 3: 125-132 (2001).
-
Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation.
Inflamm. Res. 49: 497-505 (2000).
*
-
Chinetti G, Fruchart JC, Staels B. Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR.
Biochem. Soc. Trans. 34: 1128-1131 (2006).
*
-
Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications.
Int. J. Obes. Relat. Metab. Disord. 27 Suppl. 3: S41-S45 (2003).
-
Chinetti G, Zawadski C, Fruchart JC, Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.
Biochem. Biophys. Res. Commun. 314: 151-158 (2004).
*
-
Chinetti-Gbaguidi G, Fruchart JC, Staels B. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy.
Curr. Opin. Pharmacol. 5: 177-183 (2005).
-
Chinetti-Gbaguidi G, Fruchart JC, Staels B. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
Biomarkers 10 Suppl. 1: 30-36 (2005).
-
Chinetti-Gbaguidi G, Rigamonti E, Helin L, Mutka AL, Lepore M, Fruchart JC, Clavey V, Ikonen E, Lestavel S, Staels B. Peroxisome proliferator-activated receptor-alpha controls cellular cholesterol trafficking in macrophages.
J. Lipid Res. 46: 2717-2725 (2005).
*
-
Chinetti-Gbaguidi G, Staels B. Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
Pharmacogenomics 8: 1567-1580 (2007).
-
Chintalgattu V, Harris GS, Akula SM, Katwa LC. PPAR-gamma agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts.
Cardiovasc. Res. 74: 140-150 (2007).
*
-
Chintharlapalli S, Papineni S, Jutooru I, McAlees A, Safe S. Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor gamma agonists in colon cancer cells.
Mol. Cancer Ther. 6: 1588-1598 (2007).
-
Chintharlapalli S, Papineni S, Safe S. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes inhibit colon cancer cell and tumor growth through PPARgamma-dependent and PPARgamma-independent pathways.
Mol. Cancer Ther. 5: 1362-1370 (2006).
-
Chira EC, McMillen TS, Wang S, Haw A 3rd, O'Brien KD, Wight TN, Chait A. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.
Atherosclerosis 195: 100-109 (2007).
-
Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis.
Semin. Liver Dis. 21: 27-41 (2001).
-
Cho KH, Kim HJ, Kamanna VS, Vaziri ND. Niacin improves renal lipid metabolism and slows progression in chronic kidney disease.
Biochim. Biophys. Acta 1800: 6-15 (2010).
*
-
Cho MC, Lee HS, Kim JH, Choe YK, Hong JT, Paik SG, Yoon do Y. A simple ELISA for screening ligands of peroxisome proliferator-activated receptor-gamma.
J. Biochem. Mol. Biol. 36: 207-213 (2003).
*
-
Cho MC, Lee K, Paik SG, Yoon DY. Peroxisome proliferators-activated receptor (PPAR) modulators and metabolic disorders.
PPAR Res. 2008: 679137 (2008).
*
-
Cho MC, Lee S, Choi HS, Yang Y, Tae Hong J, Kim SJ, Yoon DY. Optimization of an enzyme-linked immunosorbent assay to screen ligand of peroxisome proliferator-activated receptor alpha.
Immunopharmacol. Immunotoxicol. 31: 459-467 (2009).
-
Cho MC, Yoon HE, Kang JW, Park SW, Yang Y, Hong JT, Song EY, Paik SG, Kim SH, Yoon DY. A simple method to screen ligands of peroxisome proliferator-activated receptor delta.
Eur. J. Pharm. Sci. 29: 355-360 (2006).
*
-
Cho N, Momose Y. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Curr. Top. Med. Chem. 8: 1483-1507 (2008).
-
Choi IK, Kim YH, Kim JS, Seo JH. PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo.
Invest. New Drugs 26: 283-288 (2008).
-
Choi JS, Bae JY, Kim DS, Li J, Kim JL, Lee YJ, Kang YH. Dietary compound quercitrin dampens VEGF induction and PPARgamma activation in oxidized LDL-exposed murine macrophages: association with scavenger receptor CD36.
J. Agric. Food Chem. Nov 23 [Epub ahead of print] (2009).
*
-
Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Biochem. Biophys. Res. Commun. 336: 747-753 (2005).
*
-
Choi SJ, Chung SS, Rho EJ, Lee HW, Lee MH, Choi HS, Seol JH, Baek SH, Bang OS, Chung CH. Negative modulation of RXRalpha transcriptional activity by small ubiquitin-related modifier (SUMO) modification and its reversal by SUMO-specific protease SUSP1.
J. Biol. Chem. 281: 30669-30677 (2006).
*
-
Choi SY, Chung JH, Kim DH, Chung SW, Kim JY, Yu BP, Chung HY. Peroxisome proliferator-activated receptor gamma agonist action of 3-methyl-1,2-cyclopentanedione.
Biochim. Biophys. Acta 1770: 1612-1619 (2007).
*
-
Chopra B, Georgopoulos NT, Nicholl A, Hinley J, Oleksiewicz MB, Southgate J. Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.
Cell Prolif. 42: 688-700 (2009).
*
-
Chopra B, Hinley J, Oleksiewicz MB, Southgate J. Trans-species comparison of PPAR and RXR expression by rat and human urothelial tissues.
Toxicol. Pathol. 36: 485-495 (2008).
*
-
Chou WL, Chuang LM, Khoo KH, Wang AH, Lawson JA, Fitzgerald GA, Chang ZF. Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of PPARgamma activation.
J. Biol. Chem. 282: 18162-18172 (2007).
*
-
Chou YC, Prakash E, Huang CF, Lien TW, Chen X, Su IJ, Chao YS, Hsieh HP, Hsu JT. Bioassay-guided purification and identification of PPARalpha/gamma agonists from Chlorella sorokiniana.
Phytother. Res. 22: 605-613 (2008).
-
Chowanadisai W, Bauerly KA, Tchaparian E, Wong A, Cortopassi GA, Rucker RB. Pyrroloquinoline quinone stimulates mitochondrial biogenesis through CREB phosphorylation and increased PGC-1alpha expression.
J. Biol. Chem. 285: 142-152 (2010).
*
-
Christensen KB, Minet A, Svenstrup H, Grevsen K, Zhang H, Schrader E, Rimbach G, Wein S, Wolffram S, Kristiansen K, Christensen LP. Identification of plant extracts with potential antidiabetic properties: effect on human peroxisome proliferator-activated receptor (PPAR), adipocyte differentiation and insulin-stimulated glucose uptake.
Phytother. Res. 23: 1316-1325 (2009).
-
Christianson JL, Nicoloro S, Straubhaar J, Czech MP. Stearoyl CoA desaturase 2 is required for PPARgamma expression and adipogenesis in cultured 3T3-L1 cells.
J. Biol. Chem. 283: 2906-2916 (2008).
*
-
Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man.
J. Clin. Endocrinol. Metab. 94: 3594-3601 (2009).
-
Christodoulides C, Vidal-Puig A. PPARs and adipocyte function.
Mol. Cell. Endocrinol. Sep 19 [Epub ahead of print] (2009).
-
Chu R, Lim H, Brumfield L, Liu H, Herring C, Ulintz P, Reddy JK, Davison M. Protein profiling of mouse livers with peroxisome proliferator-activated receptor alpha activation.
Mol. Cell. Biol. 24: 6288-6297 (2004).
*
-
Chuang CC, Yang RS, Tsai KS, Ho FM, Liu SH. Hyperglycemia enhances adipogenic induction of lipid accumulation: involvement of extracellular signal-regulated protein kinase 1/2, phosphoinositide 3-kinase/Akt and peroxisome proliferator-activated receptor-gamma (PPARgamma) signaling.
Endocrinology 148: 4267-4275 (2007).
*
-
Chuang JH, Wang PW, Tai MH. An adipocentric view of liver fibrosis and cirrhosis.
Chang Gung Med. J. 27: 855-868 (2004).
-
Chung C, Doll JA, Stellmach VM, Gonzales J, Surapureddi S, Cornwell M, Reddy JK, Crawford SE. Pigment epithelium-derived factor is an angiogenesis and lipid regulator that activates peroxisome proliferator-activated receptor alpha.
Adv. Exp. Med. Biol. 617: 591-597 (2008).
-
Chung JH, Seo AY, Chung SW, Kim MK, Leeuwenburgh C, Yu BP, Chung HY. Molecular mechanism of PPAR in the regulation of age-related inflammation.
Ageing Res. Rev. 7: 126-136 (2008).
-
Chung S, Lapoint K, Martinez K, Kennedy A, Boysen Sandberg M, McIntosh MK. Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes.
Endocrinology 147: 5340-5351 (2006).
*
-
Chung SS, Choi HH, Cho YM, Lee HK, Park KS. Sp1 mediates repression of the resistin gene by PPARgamma agonists in 3T3-L1 adipocytes.
Biochem. Biophys. Res. Commun. 348: 253-258 (2006).
*
-
Chung SS, Kim M, Youn BS, Lee NS, Park JW, Lee IK, Lee YS, Kim JB, Cho YM, Lee HK, Park KS. Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells.
Mol. Cell. Biol. 29: 20-30 (2009).
*
-
Chung SW, Kang BY, Kim SH, Pak YK, Cho D, Trinchieri G, Kim TS. Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B.
J. Biol. Chem. 275: 32681-32687 (2000).
*
-
Chung SW, Kang BY, Kim TS. Inhibition of interleukin-4 production in CD4+ T cells by peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: involvement of physical association between PPAR-gamma and the nuclear factor of activated T cells transcription factor.
Mol. Pharmacol. 64: 1169-1179 (2003).
*
-
Churi SB, Abdel-Aleem OS, Tumber KK, Scuderi-Porter H, Taylor BK. Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats.
J. Pain 9: 639-649 (2008).
-
Ciana P, Biserni A, Tatangelo L, Tiveron C, Sciarroni AF, Ottobrini L, Maggi A. A novel PPRE-luciferase reporter mouse reveals gender specificity of peroxisome proliferators activated receptor activity in liver.
Mol. Endocrinol. 21: 388-400 (2007).
*
-
Cianferotti L, Demay MB. VDR-mediated inhibition of DKK1 and SFRP2 suppresses adipogenic differentiation of murine bone marrow stromal cells.
J. Cell. Biochem. 101: 80-88 (2007).
*
-
Cimini A, Ceru MP. Emerging roles of peroxisome proliferator-activated receptors (PPARs) in the regulation of neural stem cells proliferation and differentiation.
Stem Cell Rev. 4: 293-303 (2008).
-
Cimini A, Cristiano L, Benedetti E, D'Angelo B, Ceru MP. PPARs expression in adult mouse neural stem cells: modulation of PPARs during astroglial differentiaton of NSC.
PPAR Res. 2007: 48242 (2007).
*
-
Cindoruk M, Kerem M, Karakan T, Salman B, Akin O, Alper M, Erdem O, Unal S. Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study.
BMC Gastroenterol. 7: 44 (2007).
*
-
Clark RB. The role of PPARs in inflammation and immunity.
J. Leukoc. Biol. 71: 388-400 (2002).
*
-
Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses.
J. Immunol. 164: 1364-1371 (2000).
*
-
Clarke HJ, Gregoire F, Ma F, Martin R, Zhao S, Lavan BE. Cross-species differential plasma protein binding of MBX-102/JNJ39659100: a novel PPAR-gamma agonist.
PPAR Res. 2008: 465715 (2008).
*
-
Clarke SD, Jump D. Polyunsaturated fatty acids regulate lipogenic and peroxisomal gene expression by independent mechanisms.
Prostaglandins Leukot. Essent. Fatty Acids 57: 65-69 (1997).
-
Clarke SD, Jump DB. Polyunsaturated fatty acid regulation of hepatic gene transcription.
Lipids 31: S7-S11 (1996).
-
Clarke SD, Thuillier P, Baillie RA, Sha X. Peroxisome proliferator-activated receptors: a family of lipid-activated transcription factors.
Am. J. Clin. Nutr. 70: 566-571 (1999).
*
-
Claudel T, Leibowitz MD, Fievet C, Tailleux A, Wagner B, Repa JJ, Torpier G, Lobaccaro JM, Paterniti JR, Mangelsdorf DJ, Heyman RA, Auwerx J. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.
Proc. Natl. Acad. Sci. U.S.A. 98: 2610-2615 (2001).
*
-
Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A, Bohm C, Hartge M, Gust R, Staels B, Unger T, Kintscher U. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan.
Diabetes 57: 1405-1413 (2008).
*
-
Cluny NL, Keenan CM, Lutz B, Piomelli D, Sharkey KA. The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice.
Neurogastroenterol. Motil. 21: 420-429 (2009).
-
Cock TA, Houten SM, Auwerx J. Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm.
EMBO Rep. 5: 142-147 (2004).
*
-
Coleman JD, Prabhu KS, Thompson JT, Reddy PS, Peters JM, Peterson BR, Reddy CC, Vanden Heuvel JP. The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta).
Free Radic. Biol. Med. 42: 1155-1164 (2007).
-
Coletta DK, Balas B, Chavez AO, Baig M, Abdul-Ghani M, Kashyap S, Folli F, Tripathy D, Mandarino LJ, Cornell JE, Defronzo RA, Jenkinson CP. Effect of acute physiologic hyperinsulinemia on gene expression in human skeletal muscle in vivo.
Am. J. Physiol. Endocrinol. Metab. 294: E910-E917 (2008).
*
-
Colin S, Bourguignon E, Boullay AB, Tousaint JJ, Huet S, Caira F, Staels B, Lestavel S, Lobaccaro JM, Delerive P. Intestine-specific regulation of PPARalpha gene transcription by liver X receptors.
Endocrinology 149: 5128-5135 (2008).
*
-
Coll T, Rodriguez-Calvo R, Barroso E, Serrano L, Eyre E, Palomer X, Vazquez-Carrera M. Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome.
Curr. Mol. Pharmacol. 2: 46-55 (2009).
-
Collin M, Murch O, Thiemermann C. Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia.
Crit. Care Med. 34: 1131-1138 (2006).
-
Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C, Danni O, Thiemermann C, Fantozzi R. Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643.
Free Radic. Biol. Med. 41: 579-589 (2006).
-
Collino M, Patel NS, Thiemermann C. PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.
Ther. Adv. Cardiovasc. Dis. 2: 179-197 (2008).
-
Combarros O, Rodriguez-Rodriguez E, Mateo I, Vazquez-Higuera JL, Infante J, Berciano J, Sanchez-Juan P. APOE dependent-association of PPAR-gamma genetic variants with Alzheimer's disease risk.
Neurobiol. Aging Aug 4 [Epub ahead of print] (2009).
-
Commerford SR, Vargas L, Dorfman SE, Mitro N, Rocheford EC, Mak PA, Li X, Kennedy P, Mullarkey TL, Saez E. Dissection of the insulin-sensitizing effect of liver X receptor ligands.
Mol. Endocrinol. 21: 3002-3112 (2007).
*
-
Compe E, Drane P, Laurent C, Diderich K, Braun C, Hoeijmakers JH, Egly JM. Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations.
Mol. Cell. Biol. 25: 6065-6076 (2005).
*
-
Conaway HH, Persson E, Halen M, Granholm S, Svensson O, Pettersson U, Lie A, Lerner UH. Retinoids inhibit differentiation of hematopoetic osteoclast progenitors.
FASEB J. 23: 3526-3538 (2009).
*
-
Constantin-Teodosiu D, Baker DJ, Constantin D, Greenhaff PL. PPARdelta agonism inhibits skeletal muscle PDC activity, mitochondrial ATP production and force generation during prolonged contraction.
J. Physiol. 587: 231-239 (2009).
*
-
Contestabile A. Benefits of caloric restriction on brain aging and related pathological states: understanding mechanisms to devise novel therapies.
Curr. Med. Chem. 16: 350-361 (2009).
-
Cook WS, Yeldandi AV, Rao MS, Hashimoto T, Reddy JK. Less extrahepatic induction of fatty acid beta-oxidation enzymes by PPAR alpha.
Biochem. Biophys. Res. Commun. 278: 250-257 (2000).
*
-
Cooley MA, Whittall C, Rolph MS. Pseudomonas signal molecule 3-oxo-C12-homoserine lactone interferes with binding of rosiglitazone to human PPARgamma.
Microbes Infect. Jan 11 [Epub ahead of print] (2010).
*
-
Coppola G, Marmolino D, Lu D, Wang Q, Cnop M, Rai M, Acquaviva F, Cocozza S, Pandolfo M, Geschwind DH. Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARgamma pathway as a therapeutic target in Friedreich's ataxia.
Hum. Mol. Genet. 18: 2452-2461 (2009).
*
-
Coras R, Holsken A, Seufert S, Hauke J, Eyupoglu IY, Reichel M, Trankle C, Siebzehnrubl FA, Buslei R, Blumcke I, Hahnen E. The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion.
Mol. Cancer Ther. 6: 1745-1754 (2007).
*
-
Cornick CL, Strongitharm BH, Sassano G, Rawlins C, Mayes AE, Joseph AN, O'Dowd J, Stocker C, Wargent E, Cawthorne MA, Brown AL, Arch JR. Identification of a novel agonist of peroxisome proliferator-activated receptors alpha and gamma that may contribute to the anti-diabetic activity of guggulipid in Lep(ob)/Lep(ob) mice.
J. Nutr. Biochem. 20: 806-815 (2009).
*
-
Cornwell PD, De Souza AT, Ulrich RG. Profiling of hepatic gene expression in rats treated with fibric acid analogs.
Mutat. Res. 549: 131-145 (2004).
-
Cornwell PD, Ulrich RG. Investigating the mechanistic basis for hepatic toxicity induced by an experimental chemokine receptor 5 (CCR5) antagonist using a compendium of gene expression profiles.
Toxicol. Pathol. 35: 576-588 (2007).
*
-
Corton JC, Anderson SP, Stauber A. Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators.
Annu. Rev. Pharmacol. Toxicol. 40: 491-518 (2000).
*
-
Corton JC, Brown-Borg HM. Peroxisome proliferator-activated receptor gamma coactivator 1 in caloric restriction and other models of longevity.
J. Gerontol. A. Biol. Sci. Med. Sci. 60: 1494-1509 (2005).
-
Corton JC, Lapinskas PJ, Gonzalez FJ. Central role of PPARalpha in the mechanism of action of hepatocarcinogenic peroxisome proliferators.
Mutat. Res. 448: 139-151 (2000).
-
Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors.
Pain 139: 541-550 (2008).
-
Costa CD, Hammes TO, Rohden F, Margis R, Bortolotto JW, Padoin AV, Mottin CC, Guaragna RM. SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis.
Obes. Surg. Dec 22 [Epub ahead of print] (2009).
-
Costa V, Casamassimi A, Esposito K, Villani A, Capone M, Iannella R, Schisano B, Ciotola M, Di Palo C, Corrado FC, Santangelo F, Giugliano D, Ciccodicola A. Characterization of a novel polymorphism in PPARG regulatory region associated with type 2 diabetes and diabetic retinopathy in Italy.
J. Biomed. Biotechnol. 2009: 126917 (2009).
*
-
Costa V, Foti D, Paonessa F, Chiefari E, Palaia L, Brunetti G, Gulletta E, Fusco A, Brunetti A. The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-gamma (PPARgamma) and thiazolidinedione-PPARgamma agonists.
Endocr. Relat. Cancer 15: 325-335 (2008).
-
Cox SL. Tesaglitazar: a promising approach in type 2 diabetes.
Drugs Today (Barc.) 42: 139-146 (2006).
-
Coyle AT, O'keeffe MB, Kinsella BT. 15-Deoxy delta-prostaglandin J suppresses transcription by promoter 3 of the human thromboxane A receptor gene through peroxisome proliferator-activated receptor gamma in human erythroleukemia cells.
FEBS J. 272: 4754-4773 (2005).
*
-
Coyne GS, Kenny DA, Childs S, Sreenan JM, Waters SM. Dietary n-3 polyunsaturated fatty acids alter the expression of genes involved in prostaglandin biosynthesis in the bovine uterus.
Theriogenology 70: 772-782 (2008).
-
Crabb DW. Alcohol deranges hepatic lipid metabolism via altered transcriptional regulation.
Trans. Am. Clin. Climatol. Assoc. 115: 273-287 (2004).
*
-
Crabb DW, Galli A, Fischer M, You M. Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha.
Alcohol 34: 35-38 (2004).
*
-
Crabb DW, Liangpunsakul S. Alcohol and lipid metabolism.
J. Gastroenterol. Hepatol. 21 Suppl. 3: S56-S60 (2006).
*
-
Crabb DW, Pinaire J, Chou WY, Sissom S, Peters JM, Harris RA, Stewart M. Peroxisome proliferator-activated receptors (PPAR) and the mitochondrial aldehyde dehydrogenase (ALDH2) promoter in vitro and in vivo.
Alcohol Clin. Exp. Res. 25: 945-952 (2001).
-
Cree MG, Newcomer BR, Read LK, Sheffield-Moore M, Paddon-Jones D, Chinkes D, Aarsland A, Wolfe RR. Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment.
Mech. Ageing Dev. 128: 558-565 (2007).
-
Cresci S. The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics.
Expert Opin. Pharmacother. 6: 2577-2591 (2005).
-
Cresci S. Pharmacogenetics of the PPAR genes and cardiovascular disease.
Pharmacogenomics 8: 1581-1595 (2007).
-
Cresci S. PPAR genomics and pharmacogenomics: implications for cardiovascular disease.
PPAR Res. 2008: 374549 (2008).
*
-
Crisafulli C, Bruscoli S, Esposito E, Mazzon E, Di Paola R, Genovese T, Bramanti P, Migliorati G, Cuzzocrea S. PPAR-alpha contributes to the anti-inflammatory activity of 17beta-estradiol.
J. Pharmacol. Exp. Ther. 331: 796-807 (2009).
*
-
Crisafulli C, Cuzzocrea S. The role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha (PPAR-alpha) in the regulation of inflammation in macrophages.
Shock 32: 62-73 (2009).
-
Crisafulli C, Cuzzocrea S. The role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha (PPAR-alpha) in the regulation of inflammation in macrophages.
Shock 32: 62-73 (2009).
-
Cristiano L, Cimini A, Moreno S, Ragnelli AM, Paola Ceru M. Peroxisome proliferator-activated receptors (PPARs) and related transcription factors in differentiating astrocyte cultures.
Neuroscience 131: 577-587 (2005).
*
-
Crosby MB, Svenson J, Gilkeson GS, Nowling TK. A novel PPAR response element in the murine iNOS promoter.
Mol. Immunol. 42: 1303-1310 (2005).
*
-
Crowe DL, Chandraratna RA. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands.
Breast Cancer Res. 6: R546-R555 (2004).
*
-
Csaki C, Matis U, Mobasheri A, Ye H, Shakibaei M. Chondrogenesis, osteogenesis and adipogenesis of canine mesenchymal stem cells: a biochemical, morphological and ultrastructural study.
Histochem. Cell Biol. 128: 507-520 (2007).
-
Cui Y, Lu Z, Bai L, Shi Z, Zhao WE, Zhao B. beta-Carotene induces apoptosis and up-regulates peroxisome proliferator-activated receptor gamma expression and reactive oxygen species production in MCF-7 cancer cells.
Eur. J. Cancer 43: 2590-2601 (2007).
*
-
Cullingford TE, Bhakoo K, Peuchen S, Dolphin CT, Patel R, Clark JB. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system.
J. Neurochem. 70: 1366-1375 (1998).
-
Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention.
Neurology 69: 1622-1634 (2007).
-
Cunard R. The potential use of PPARalpha agonists as immunosuppressive agents.
Curr. Opin. Investig. Drugs 6: 467-472 (2005).
-
Cunard R, DiCampli D, Archer DC, Stevenson JL, Ricote M, Glass CK, Kelly CJ. WY14,643, a PPAR alpha ligand, has profound effects on immune responses in vivo.
J. Immunol. 169: 6806-6812 (2002).
*
-
Cunard R, Ricote M, DiCampli D, Archer DC, Kahn DA, Glass CK, Kelly CJ. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors.
J. Immunol. 168: 2795-2802 (2002).
*
-
Cuzzocrea S. Peroxisome proliferator-activated receptors and acute lung injury.
Curr. Opin. Pharmacol. 6: 263-270 (2006).
-
Cuzzocrea S, Bruscoli S, Mazzon E, Crisafulli C, Donato V, Di Paola R, Velardi E, Esposito E, Nocentini G, Riccardi C. Peroxisome proliferator-activated receptor-alpha contributes to the anti-inflammatory activity of glucocorticoids.
Mol. Pharmacol. 73: 323-337 (2008).
*
-
Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, Caputi AP. WY 14643, a potent exogenous PPAR-alpha ligand, reduces intestinal injury associated with splanchnic artery occlusion shock.
Shock 22: 340-346 (2004).
*
-
Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muia C, Centorrino T, Caputi AP. Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice.
Lab. Invest. 84: 1643-1654 (2004).
*
-
Cuzzocrea S, Mazzon E, Di Paola R, Peli A, Bonato A, Britti D, Genovese T, Mui C, Crisafulli C, Caputi AP. The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation.
J. Leukoc. Biol. 79: 999-1010 (2006).
*
-
Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.
Br. J. Pharmacol. 140: 366-376 (2003).
*
-
Cwinn MA, Jones SP, Kennedy SW. Exposure to perfluorooctane sulfonate or fenofibrate causes PPAR-alpha dependent transcriptional responses in chicken embryo hepatocytes.
Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 148: 165-171 (2008).
*
-
d'Abramo C, Zingg JM, Pizzuti A, Argellati F, Pronzato MA, Ricciarelli R. In vitro effect of PPAR-gamma2 Pro12Ala polymorphism on the deposition of Alzheimer's amyloid-beta peptides.
Brain Res. 1173: 1-5 (2007).
-
D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Mattace Raso G, Cuzzocrea S, Lo Verme J, Piomelli D, Meli R, Calignano A. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous PPAR-alpha agonist, modulates carrageenan-induced paw edema in mice.
J. Pharmacol. Exp. Ther. 322: 1137-1143 (2007).
*
-
D'Agostino G, La Rana G, Russo R, Sasso O, Iacono A, Esposito E, Mattace Raso G, Cuzzocrea S, Loverme J, Piomelli D, Meli R, Calignano A. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia.
Eur. J. Pharmacol. 613: 54-59 (2009).
-
D'Eon TM, Souza SC, Aronovitz M, Obin MS, Fried SK, Greenberg AS. Estrogen regulation of adiposity and fuel partitioning: evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways.
J. Biol. Chem. 280: 36334-36341 (2005).
*
-
Da Silva Morais A, Abarca-Quinones J, Horsmans Y, Starkel P, Leclercq IA. Peroxisome proliferated-activated receptor gamma ligand, pioglitazone, does not prevent hepatic fibrosis in mice.
Int. J. Mol. Med. 19: 105-112 (2007).
*
-
Da Silva Morais A, Lebrun V, Abarca-Quinones J, Brichard S, Hue L, Guigas B, Viollet B, Leclercq IA. Prevention of steatohepatitis by pioglitazone: implication of adiponectin-dependent inhibition of SREBP-1c and inflammation.
J. Hepatol. 50: 489-500 (2009).
-
Dahten A, Koch C, Ernst D, Schnoller C, Hartmann S, Worm M. Systemic PPARgamma ligation inhibits allergic immune response in the skin.
J. Invest. Dermatol. 128: 2211-2218 (2008).
*
-
Dai X, Sayama K, Shirakata Y, Hanakawa Y, Yamasaki K, Tokumaru S, Yang L, Wang X, Hirakawa S, Tohyama M, Yamauchi T, Takashi K, Kagechika H, Hashimoto K. STAT5a/PPARgamma pathway regulates involucrin expression in keratinocyte differentiation.
J. Invest. Dermatol. 127: 1728-1735 (2007).
*
-
Dai X, Sayama K, Shirakata Y, Tokumaru S, Yang L, Tohyama M, Hirakawa S, Hanakawa Y, Hashimoto K. PPARgamma is an important transcription factor in 1alpha,25-dihydroxyvitamin D3-induced involucrin expression.
J. Dermatol. Sci. 50: 53-60 (2008).
-
Dai X, Souza AT, Dai H, Lewis DL, Lee CK, Spencer AG, Herweijer H, Hagstrom JE, Linsley PS, Bassett DE, Ulrich RG, He YD. PPARalpha siRNA-treated expression profiles uncover the causal sufficiency network for compound-induced liver hypertrophy.
PLoS Comput. Biol. 3: e30 (2007).
*
-
Dallaire P, Bellmann K, Laplante M, Gelinas S, Centeno-Baez C, Penfornis P, Peyot ML, Latour MG, Lamontagne J, Trujillo ME, Scherer PE, Prentki M, Deshaies Y, Marette A. Obese mice lacking iNOS are sensitized to the metabolic actions of PPARgamma agonism.
Diabetes 57: 1999-2011 (2008).
*
-
Danesi F, Di Nunzio M, Boschetti E, Bordoni A. Green tea extract selectively activates peroxisome proliferator-activated receptor beta/delta in cultured cardiomyocytes.
Br. J. Nutr. 101: 1736-1739 (2009).
*
-
Dang CN, Trainer P. Pharmacological management of Cushing's syndrome: an update.
Arq. Bras. Endocrinol. Metabol. 51: 1339-1348 (2007).
*
-
Daoud G, Simoneau L, Masse A, Rassart E, Lafond J. Expression of cFABP and PPAR in trophoblast cells: effect of PPAR ligands on linoleic acid uptake and differentiation.
Biochim. Biophys. Acta 1687: 181-194 (2005).
*
-
Darimont C, Avanti O, Zbinden I, Leone-Vautravers P, Mansourian R, Giusti V, Mace K. Liver X receptor preferentially activates de novo lipogenesis in human preadipocytes.
Biochimie 88: 309-318 (2006).
-
Das KK, Bajpai M, Kong Y, Liu J, Geng X, Das KM. Mesalamine suppresses the expression of a novel tropomyosin isoform, TC22, associated with colonic neoplasia.
Mol. Pharmacol. 76: 183-191 (2009).
*
-
Das SK, Chakrabarti R. Role of PPAR in cardiovascular diseases.
Recent Patents Cardiovasc. Drug Discov. 1: 193-209 (2006).
-
Das UN. A defect in the activity of Delta(6) and Delta(5) desaturases may be a factor predisposing to the development of insulin resistance syndrome.
Prostaglandins Leukot. Essent. Fatty Acids 72: 343-350 (2005).
*
-
Das UN. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.
Lipids Health Dis. 7: 37 (2008).
*
-
Das UN, Rao AA. Gene expression profile in obesity and type 2 diabetes mellitus.
Lipids Health Dis. 6: 35 (2007).
*
-
Dasgupta S, Roy A, Jana M, Hartley DM, Pahan K. Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha.
Mol. Pharmacol. 72: 934-946 (2007).
*
-
Dat NT, Lee K, Hong YS, Ho Kim Y, Van Minh C, Joon Lee J. A peroxisome proliferator-activated receptor-gamma agonist and other constituents from Chromolaena odorata.
Planta Med. 75: 803-807 (2009).
-
Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids.
Am. J. Cardiol. 98: S27-S33 (2006).
-
Davies BS, Waki H, Beigneux AP, Farber E, Weinstein MM, Wilpitz DC, Tai LJ, Evans RM, Fong LG, Tontonoz P, Young SG. The expression of GPIHBP1, an endothelial cell binding site for lipoprotein lipase and chylomicrons, is induced by PPARgamma.
Mol. Endocrinol. 22: 2496-2504 (2008).
*
-
Dawson MI, Ye M, Cao X, Farhana L, Hu QY, Zhao Y, Xu LP, Kiselyuk A, Correa RG, Yang L, Hou T, Reed JC, Itkin-Ansari P, Levine F, Sanner MF, Fontana JA, Zhang XK. Derivation of a retinoid X receptor scaffold from peroxisome proliferator-activated receptor gamma ligand 1-di(1H-indol-3-yl)methyl-4-trifluoromethylbenzene.
ChemMedChem. 4: 1106-1119 (2009).
*
-
Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity.
Nat. Rev. Immunol. 2: 748-759 (2002).
*
-
De Backer O, Elinck E, Priem E, Leybaert L, Lefebvre RA. PPARgamma activation alleviates postoperative ileus in mice by inhibition of Egr-1 expression and its downstream target genes.
J. Pharmacol. Exp. Ther. 331: 496-503 (2009).
*
-
de Boer RA, Martens FM, Kuipers I, Boomsma F, Visseren FL. The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus.
J. Hum. Hypertens. 24: 74-76 (2010).
-
De Cavanagh EM, Piortkowski B, Fraga CG. The interaction between the renin-angiotensin system and peroxisome proliferator activated receptors: a hypothesis including the participation of mitochondria in aging.
Front. Biosci. 12: 1049-1062 (2007).
-
De Cosmo S, Motterlini N, Prudente S, Pellegrini F, Trevisan R, Bossi A, Remuzzi G, Trischitta V, Ruggenenti P; on behalf of the BENEDICT Study Group. Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from Benedict.
Diabetes 58: 2920-2929 (2009).
-
De Gottardi A, Hadengue A, Dumonceau JM. Retinoids, bile acids and PPARs in Barrett's oesophagus.
Gut 57: 137 (2008).
*
-
De Gottardi A, Pazienza V, Pugnale P, Bruttin F, Rubbia-Brandt L, Juge-Aubry CE, Meier CA, Hadengue A, Negro F. Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection.
Aliment. Pharmacol.Ther. 23: 107-114 (2006).
*
-
de Kort S, Hokken-Koelega A. The PPAR-gamma Pro12Ala polymorphism associates with weight gain during GH-treatment in short children born small for gestational age.
Eur. J. Endocrinol. 162: 49-52 (2010).
-
de Lange P, Lombardi A, Silvestri E, Goglia F, Lanni A, Moreno M. Peroxisome proliferator-activated receptor delta: a conserved director of lipid homeostasis through regulation of the oxidative capacity of muscle.
PPAR Res. 2008: 172676 (2008).
*
-
de Oliveira Silva-Junior G, da Silva Torres T, de Souza Mendonca L, Alberto Mandarim-de-Lacerda C. Rosiglitazone (peroxisome proliferator-activated receptor-gamma) counters hypertension and adverse cardiac and vascular remodeling in 2K1C hypertensive rats.
Exp. Toxicol. Pathol. Sep 21 [Epub ahead of print] (2009).
*
-
De Pascale MC, Bassi AM, Patrone V, Villacorta L, Azzi A, Zingg JM. Increased expression of transglutaminase-1 and PPARgamma after vitamin E treatment in human keratinocytes.
Arch. Biochem. Biophys. 447: 97-106 (2006).
*
-
de Rooij SR, Painter RC, Phillips DI, Osmond C, Tanck MW, Defesche JC, Bossuyt PM, Michels RP, Bleker OP, Roseboom TJ. The effects of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene on glucose/insulin metabolism interact with prenatal exposure to famine.
Diabetes Care 29: 1052-1057 (2006).
*
-
De Souza AT, Cornwell PD, Dai X, Caguyong MJ, Ulrich RG. Agonists of the peroxisome proliferator activated receptor alpha induce a fiber-type selective transcriptional response in rat skeletal muscle.
Toxicol. Sci. 92: 578-586 (2006).
*
-
De Souza AT, Dai X, Spencer AG, Reppen T, Menzie A, Roesch PL, He Y, Caguyong MJ, Bloomer S, Herweijer H, Wolff JA, Hagstrom JE, Lewis DL, Linsley PS, Ulrich RG. Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice.
Nucleic Acids Res. 34: 4486-4494 (2006).
*
-
de Ubago MM, Garcia-Oya I, Perez-Perez A, Canfran-Duque A, Quintana-Portillo R, de Fonseca FR, Gonzalez-Yanes C, Sanchez-Margalet V. Oleoylethanolamide, a natural ligand for PPAR-alpha, inhibits insulin receptor signalling in HTC rat hepatoma cells.
Biochim. Biophys. Acta 1791: 740-745 (2009).
*
-
de Vogel-van den Bosch HM, Bunger M, de Groot PJ, Bosch-Vermeulen H, Hooiveld GJ, Muller M. PPARalpha-mediated effects of dietary lipids on intestinal barrier gene expression.
BMC Genomics 9: 231 (2008).
*
-
de Wilde J, Smit E, Snepvangers FJ, de Wit NW, Mohren R, Hulshof MF, Mariman EC. Adipophilin protein expression in muscle - a possible protective role against insulin resistance.
FEBS J. Dec 22 [Epub ahead of print] (2009).
*
-
de Wit NJ, Bosch-Vermeulen H, de Groot PJ, Hooiveld GJ, Grootte Bromhaar MM, Jansen J, Muller M, van der Meer R. The role of the small intestine in the development of dietary fat-induced obesity and insulin resistance in C57BL/6J mice.
BMC Med. Genomics 1: 14 (2008).
*
-
Debard C, Cozzone D, Ricard N, Vouillarmet J, Disse E, Husson B, Laville M, Vidal H. Short-term activation of peroxisome proliferator-activated receptor beta/delta increases fatty acid oxidation but does not restore insulin action in muscle cells from type 2 diabetic patients.
J. Mol. Med. 84: 747-752 (2006).
*
-
Debril MB, Renaud JP, Fajas L, Auwerx J. The pleiotropic functions of peroxisome proliferator-activated receptor gamma.
J. Mol. Med. 79: 30-47 (2001).
*
-
Decochez K, Rippley RK, Miller JL, De Smet M, Yan KX, Matthijs Z, Riffel KA, Song H, Zhu H, Maynor HO, Tanaka W, Johnson-Levonas AO, Davies MJ, Gottesdiener KM, Keymeulen B, Wagner JA. A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects.
Drugs R. D. 7: 99-110 (2006).
-
Deeg MA, Tan MH. Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies.
PPAR Res. 2008: 520465 (2008).
*
-
Defaux A, Zurich MG, Braissant O, Honegger P, Monnet-Tschudi F. Effects of the PPAR-beta agonist GW501516 in an in vitro model of brain inflammation and antibody-induced demyelination.
J. Neuroinflammation 6: 15 (2009).
*
-
DeFronzo RA. Dysfunctional fat cells, lipotoxicity and type 2 diabetes.
Int. J. Clin. Pract. Suppl. 143: 9-21 (2004).
-
Degenhardt T, Matilainen M, Herzig KH, Dunlop TW, Carlberg C. The insulin-like growth factor binding protein 1 gene is a primary target of peroxisome proliferator-activated receptors.
J. Biol. Chem. 281: 39607-39619 (2006).
*
-
Degenhardt T, Saramaki A, Malinen M, Rieck M, Vaisanen S, Huotari A, Herzig KH, Muller R, Carlberg C. Three members of the human pyruvate dehydrogenase kinase gene family are direct targets of the peroxisome proliferator-activated receptor beta/delta.
J. Mol. Biol. 372: 341-355 (2007).
*
-
Degenhardt T, Vaisanen S, Rakhshandehroo M, Kersten S, Carlberg C. Peroxisome proliferator-activated receptor alpha controls hepatic heme biosynthesis through ALAS1.
J. Mol. Biol. 388: 225-238 (2009).
*
-
Del V Cano M, Gehlbach PL. PPAR-alpha ligands as potential therapeutic agents for wet age-related macular degeneration.
PPAR Res. 2008: 821592 (2008).
*
-
Delage B, Rullier A, Capdepont M, Rullier E, Cassand P. The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers.
Nutr. J. 6: 20 (2007).
*
-
Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1.
J. Biol. Chem. 274: 32048-32054 (1999).
*
-
Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control.
J. Endocrinol. 169: 453-459 (2001).
*
-
Delerive P, Furman C, Teissier E, Fruchart J, Duriez P, Staels B. Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner.
FEBS Lett. 471: 34-38 (2000).
*
-
Delerive P, Gervois P, Fruchart JC, Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators.
J. Biol. Chem. 275: 36703-36707 (2000).
*
-
DeLuca JG, Doebber TW, Kelly LJ, Kemp RK, Molon-Noblot S, Sahoo SP, Ventre J, Wu MS, Peters JM, Gonzalez FJ, Moller DE. Evidence for peroxisome proliferator-activated receptor (PPAR)alpha-independent peroxisome proliferation: effects of PPARgamma/delta-specific agonists in PPARalpha-null mice.
Mol. Pharmacol. 58: 470-476 (2000).
*
-
Demerjian M, Choi EH, Man MQ, Chang S, Elias PM, Feingold KR. Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis.
Exp. Dermatol. 18: 643-649 (2009).
-
Demerjian M, Man MQ, Choi EH, Brown BE, Crumrine D, Chang S, Mauro T, Elias PM, Feingold KR. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model.
Exp. Dermatol. 15: 154-160 (2006).
*
-
Demers A, Rodrigue-Way A, Tremblay A. Hexarelin signaling to PPARgamma in metabolic diseases.
PPAR Res. 2008: 364784 (2008).
*
-
Demizieux L. Control and regulation of mitochondrial oxidation of long-chained fatty acids.
J. Soc. Biol. 199: 143-155 (2005).
-
Deng QG, She H, Cheng JH, French SW, Koop DR, Xiong S, Tsukamoto H. Steatohepatitis induced by intragastric overfeeding in mice.
Hepatology 42: 905-914 (2005).
*
-
Deng T, Shan S, Li ZB, Wu ZW, Liao CZ, Ko B, Lu XP, Cheng J, Ning ZQ. A new retinoid-like compound that activates peroxisome proliferator-activated receptors and lowers blood glucose in diabetic mice.
Biol. Pharm. Bull. 28: 1192-1196 (2005).
*
-
Denning GM, Stoll LL. Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease?
Pediatr. Pulmonol. 41: 23-34 (2006).
-
Dentelli P, Trombetta A, Togliatto G, Zeoli A, Rosso A, Uberti B, Orso F, Taverna D, Pegoraro L, Brizzi MF. Formation of STAT5/PPARgamma transcriptional complex modulates angiogenic cell bioavailability in diabetes.
Arterioscler. Thromb. Vasc. Biol. 29: 114-120 (2009).
-
Derecka K, Sheldrick EL, Wathes DC, Abayasekara DR, Flint AP. A PPAR-independent pathway to PUFA-induced COX-2 expression.
Mol. Cell. Endocrinol. 287: 65-71 (2008).
-
Derlacz RA, Hyc K, Usarek M, Jagielski AK, Drozak J, Jarzyna R. PPAR-gamma-independent inhibitory effect of rosiglitazone on glucose synthesis in primary cultured rabbit kidney-cortex tubules.
Biochem. Cell. Biol. 86: 396-404 (2008).
-
Desch M, Schreiber A, Schweda F, Madsen K, Friis UG, Weatherford ET, Sigmund CD, Sequeira Lopez ML, Gomez RA, Todorov VT. Increased renin production in mice with deletion of peroxisome proliferator-activated receptor-gamma in juxtaglomerular cells.
Hypertension Jan 11 [Epub ahead of print] (2010).
-
Desouza CV, Gerety M, Hamel FG. Effects of a PPAR-gamma agonist, on growth factor and insulin stimulated endothelial cells.
Vascul. Pharmacol. 51: 162-168 (2009).
-
Desreumaux P, Dubuquoy L, Nutten S, Peuchmaur M, Englaro W, Schoonjans K, Derijard B, Desvergne B, Wahli W, Chambon P, Leibowitz MD, Colombel JF, Auwerx J. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies.
J. Exp. Med. 193: 827-838 (2001).
*
-
Desvergne B. RXR: from partnership to leadership in metabolic regulations.
Vitam. Horm. 75: 1-32 (2007).
-
Desvergne B, Feige JN, Casals-Casas C. PPAR-mediated activity of phthalates: a link to the obesity epidemic?
Mol. Cell. Endocrinol. 304: 43-48 (2009).
-
Desvergne B, IJpenberg A, Devchand PR, Wahli W. The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling.
J. Steroid Biochem. Mol. Biol. 65: 65-74 (1998).
-
Devchand PR, Ijpenberg A, Devesvergne B, Wahli W. PPARs: nuclear receptors for fatty acids, eicosanoids, and xenobiotics.
Adv. Exp. Med. Biol. 469: 231-236 (1999).
-
Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control.
Nature 384: 39-43 (1996).
*
-
Dewitt JC, Shnyra A, Badr MZ, Loveless SE, Hoban D, Frame SR, Cunard R, Anderson SE, Meade BJ, Peden-Adams MM, Luebke RW, Luster MI. Immunotoxicity of perfluorooctanoic acid and perfluorooctane sulfonate and the role of peroxisome proliferator-activated receptor alpha.
Crit. Rev. Toxicol. 39: 76-94 (2009).
-
Dharancy S, Lemoine M, Mathurin P, Serfaty L, Dubuquoy L. Peroxisome proliferator-activated receptors in HCV-related infection.
PPAR Res. 2009: 357204 (2009).
*
-
Dharancy S, Louvet A, Hollebecque A, Desreumaux P, Mathurin P, Dubuquoy L. Nuclear receptor PPAR and hepatology: pathophysiological and therapeutical aspects.
Gastroenterol. Clin. Biol. 32: 339-350 (2008).
-
Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, Podevin P, Conti F, Canva V, Philippe D, Gambiez L, Mathurin P, Paris JC, Schoonjans K, Calmus Y, Pol S, Auwerx J, Desreumaux P. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.
Gastroenterology 128: 334-342 (2005).
*
-
Di Nunzio M, Danesi F, Bordoni A. n-3 PUFA as regulators of cardiac gene transcription: a new link between PPAR activation and fatty acid composition.
Lipids Oct 27 [Epub ahead of print] (2009).
-
Di Paola R, Cuzzocrea S. Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.
Naunyn. Schmiedebergs Arch. Pharmacol. 375: 157-175 (2007).
*
-
Di Paola R, Esposito E, Mazzon E, Genovese T, Muia C, Crisafulli C, Malleo G, Sessa E, Meli R, Cuzzocrea S. Absence of peroxisome proliferators-activated receptors (PPAR) alpha enhanced the multiple organ failure induced by zymosan.
Shock 26: 477-484 (2006).
*
-
Di Paola R, Mazzon E, Maiere D, Zito D, Britti D, De Majo M, Genovese T, Cuzzocrea S. Rosiglitazone reduces the evolution of experimental periodontitis in the rat.
J. Dent. Res. 85: 156-161 (2006).
-
Di ZL, Niu XL, Wei J, Li YQ, Chen GL, Wang NP. Expression of peroxisome proliferator-activated receptors Y changes with age in vascular smooth muscle cells of spontaneously hypertensive rat.
Sichuan Da Xue Xue Bao Yi Xue Ban 37: 204-207 (2006).
-
Di-Poi N, Desvergne B, Michalik L, Wahli W. Transcriptional repression of peroxisome proliferator-activated receptor beta/delta in murine keratinocytes by CCAAT/enhancer-binding proteins.
J. Biol. Chem. 280: 38700-38710 (2005).
*
-
Di-Poi N, Michalik L, Desvergne B, Wahli W. Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis.
Lipids 39: 1093-1099 (2004).
-
Diab A, Hussain RZ, Lovett-Racke AE, Chavis JA, Drew PD, Racke MK. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis.
J. Neuroimmunol. 148: 116-126 (2004).
-
Ding G, Cheng L, Qin Q, Frontin S, Yang Q. PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes.
J. Mol. Cell. Cardiol. 40: 821-828 (2006).
*
-
Ding G, Fu M, Qin Q, Lewis W, Kim HW, Fukai T, Bacanamwo M, Chen EY, Schneider MD, Mangelsdorf DJ, Evans RM, Yang Q. Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage.
Cardiovasc. Res. 76: 269-279 (2007).
*
-
Ding J, Woo JT, Nagai K. The effects of retinoic acid on reversing the adipocyte differentiation into an osteoblastic tendency in ST2 cells, a murine bone marrow-derived stromal cell line.
Cytotechnology 36: 125-136 (2001).
*
-
Ding L, Liang X, Zhu D, Lou Y. Peroxisome proliferator-activated receptor alpha is involved in cardiomyocyte differentiation of murine embryonic stem cells in vitro.
Cell Biol. Int. 31: 1002-1009 (2007).
*
-
Ding Q, Jin T, Wang Z, Chen Y. Catalase potentiates retinoic acid-induced THP-1 monocyte differentiation into macrophage through inhibition of peroxisome proliferator-activated receptor gamma.
J. Leukoc. Biol. 81: 1568-1576 (2007).
*
-
Ding X, Lichti K, Kim I, Gonzalez FJ, Staudinger JL. Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha.
J. Biol. Chem. 281: 26540-26551 (2006).
*
-
Diradourian C, Girard J, Pegorier JP. Phosphorylation of PPARs: from molecular characterization to physiological relevance.
Biochimie 87: 33-38 (2005).
-
DiRenzo J, Soderstrom M, Kurokawa R, Ogliastro MH, Ricote M, Ingrey S, Horlein A, Rosenfeld MG, Glass CK. Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors.
Mol. Cell. Biol. 17: 2166-2176 (1997).
*
-
Dirkx R, Vanhorebeek I, Martens K, Schad A, Grabenbauer M, Fahimi D, Declercq P, Van Veldhoven PP, Baes M. Absence of peroxisomes in mouse hepatocytes causes mitochondrial and ER abnormalities.
Hepatology 41: 868-878 (2005).
*
-
Djouadi F, Aubey F, Schlemmer D, Bastin J. Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 (CPT2) deficiency in human muscle cells.
J. Clin. Endocrinol. Metab. 90: 1791-1797 (2005).
*
-
Djouadi F, Bastin J. PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders.
J. Inherit. Metab. Dis. 31: 217-225 (2008).
*
-
Djouadi F, Lecarpentier Y, Hebert JL, Charron P, Bastin J, Coirault C. A potential link between PPAR signaling and the pathogenesis of arrhythmogenic right ventricular cardiomyopathy (ARVC).
Cardiovasc. Res. 84: 83-90 (2009).
-
Djouadi F, Weinheimer CJ, Saffitz JE, Pitchford C, Bastin J, Gonzalez FJ, Kelly DP. A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice.
J. Clin. Invest. 102: 1083-1091 (1998).
*
-
Dobrosi N, Toth BI, Nagy G, Dozsa A, Geczy T, Nagy L, Zouboulis CC, Paus R, Kovacs L, Bíro T. Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling.
FASEB J. 22: 3685-3695 (2008).
*
-
Doggrell SA. Muraglitazar: beneficial or detrimental in the treatment of type 2 diabetes?
Expert Opin. Pharmacother. 7: 1229-1233 (2006).
-
Doi S, Masaki T, Arakawa T, Takahashi S, Kawai T, Nakashima A, Naito T, Kohno N, Yorioka N. Protective effects of peroxisome proliferator-activated receptor gamma ligand on apoptosis and hepatocyte growth factor induction in renal ischemia-reperfusion injury.
Transplantation 84: 207-213 (2007).
-
Doi T, Sakoda T, Akagami T, Naka T, Mori Y, Tsujino T, Masuyama T, Ohyanagi M. Aldosterone induces interleukin-18 through endothelin-1, angiotensin-II, Rho/Rho-kinase, and PPARs in cardiomyocytes.
Am. J. Physiol. Heart Circ. Physiol. 295: H1279-H1287 (2008).
*
-
Dolezalova R, Haluzik M, Bosanska L, Lacinova Z, Stulc T, Haluzik M. Effect of PPAR-gama agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus.
Physiol. Res. 56: 741-748 (2007).
*
-
Dong C, He L, Li J, Ye F, He M, Wang Y. Association of the Pro12Ala and C1431T polymorphism of the PPAR gamma2 gene and their haplotypes with obesity and type 2 diabetes.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi 25: 447-451 (2008).
-
Dong YW, Wang XP, Wu K. Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition.
World J. Gastroenterol. 15: 441-448 (2009).
*
-
Dongol B, Shah Y, Kim I, Gonzalez FJ, Hunt MC. The acyl-CoA thioesterase I is regulated by PPARalpha and HNF4alpha via a distal response element in the promoter.
J. Lipid Res. 48: 1781-1791 (2007).
*
-
Dongxia L, Qi H, Lisong L, Jincheng G. Association of peroxisome proliferator-activated receptor-gamma gene Pro12Ala and C161T polymorphisms with metabolic syndrome.
Circ. J. 72: 551-557 (2008).
*
-
Donkor J, Sparks LM, Xie H, Smith SR, Reue K. Adipose tissue lipin-1 expression is correlated with PPARalpha gene expression and insulin sensitivity in healthy young men.
J. Clin. Endocrinol. Metab. 93: 233-239 (2008).
*
-
Donkor J, Zhang P, Wong S, O'Loughlin L, Dewald J, Kok BP, Brindley DN, Reue K. A conserved serine residue is required for the phosphatidate phosphatase activity but not transcriptional coactivator functions of lipin-1 and lipin-2.
J. Biol. Chem. 284: 29968-29978 (2009).
*
-
Donnelly R, Wang B, Qu X. Type 2 diabetes in China: partnerships in education and research to evaluate new antidiabetic treatments.
Br. J. Clin. Pharmacol. 61: 702-705 (2006).
*
-
Donthamsetty S, Bhave VS, Mitra MS, Latendresse JR, Mehendale HM. Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARalpha with clofibrate.
Toxicol. Appl. Pharmacol. 230: 327-337 (2008).
*
-
Doonan F, Wallace DM, O'Driscoll C, Cotter TG. Rosiglitazone acts as a neuro-protectant in retinal cells via up-regulation of sestrin-1 and SOD-2.
J. Neurochem. 109: 631-643 (2009).
-
Dorfmeister B, Brandlhofer S, Schaap FG, Hermann M, Furnsinn C, Hagerty BP, Stangl H, Patsch W, Strobl W. Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats.
Diabetologia 49: 1324-1332 (2006).
*
-
Dos Santos Mendes S, Candi A, Vansteenbrugge M, Pignon MR, Bult H, Boudjeltia KZ, Munaut C, Raes M. Microarray analyses of the effects of NFkappaB or PI3K pathway inhibitors on the LPS-induced gene expression profile in RAW264.7 cells. Synergistic effects of rapamycin on LPS induced MMP9-overexpression.
Cell Signal. 21: 1109-1122 (2009).
*
-
Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT, Ehnholm C, Buchanan TA, Bergman RN, Collins FS, Boehnke M, Tuomilehto J. The peroxisome proliferator-activated receptor-gamma2 Pro12A1a variant: association with type 2 diabetes and trait differences.
Diabetes 50: 886-890 (2001).
*
-
Downie MM, Sanders DA, Maier LM, Stock DM, Kealey T. Peroxisome proliferator-activated receptor and farnesoid X receptor ligands differentially regulate sebaceous differentiation in human sebaceous gland organ cultures in vitro.
Br. J. Dermatol. 151: 766-775 (2004).
*
-
Dreijerink KM, Varier RA, van Beekum O, Jeninga EH, Hoppener JW, Lips CJ, Kummer JA, Kalkhoven E, Timmers HT. The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates PPARgamma-dependent adipocyte differentiation.
Mol. Cell Biol. 29: 5060-5069 (2009).
*
-
Drew PD, Storer PD, Xu J, Chavis JA. Hormone regulation of microglial cell activation: relevance to multiple sclerosis.
Brain Res. Brain Res. Rev. 48: 322-327 (2005).
-
Drew PD, Xu J, Racke MK. PPAR-gamma: therapeutic potential for multiple sclerosis.
PPAR Res. 2008: 627463 (2008).
*
-
Drew PD, Xu J, Storer PD, Chavis JA, Racke MK. Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders.
Neurochem. Int. 49: 183-189 (2006).
-
Dreyer C, Keller H, Mahfoudi A, Laudet V, Krey G, Wahli W. Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR).
Biol. Cell 77: 67-76 (1993).
-
Drover VA, Abumrad NA. CD36-dependent fatty acid uptake regulates expression of peroxisome proliferator activated receptors.
Biochem. Soc. Trans. 33: 311-315 (2005).
*
-
Duan SZ, Ivashchenko CY, Usher MG, Mortensen RM. PPAR-gamma in the cardiovascular system.
PPAR Res. 2008: 745804 (2008).
*
-
Duan SZ, Usher MG, Mortensen RM. PPARs: the vasculature, inflammation and hypertension.
Curr. Opin. Nephrol. Hypertens. 18: 128-133 (2009).
-
Dubois M, Vantyghem MC, Schoonjans K, Pattou F. Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma).
Ann. Endocrinol. (Paris) 63: 511-523 (2002).
-
DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers.
Carcinogenesis 19: 49-53 (1998).
*
-
Dubois SG, Heilbronn LK, Smith SR, Albu JB, Kelley DE, Ravussin E. Decreased expression of adipogenic genes in obese subjects with type 2 diabetes.
Obesity (Silver Spring) 14: 1543-1552 (2006).
*
-
Dubrac S, Schmuth M. (P)PARsing epidermal development.
J. Invest. Dermatol. 126: 241-242 (2006).
*
-
Dubrac S, Stoitzner P, Pirkebner D, Elentner A, Schoonjans K, Auwerx J, Saeland S, Hengster P, Fritsch P, Romani N, Schmuth M. Peroxisome proliferator-activated receptor-alpha activation inhibits Langerhans cell function.
J. Immunol. 178: 4362-4372 (2007).
*
-
Dubuquoy L, Bourdon C, Peuchmaur M, Leibowitz MD, Nutten S, Colombel JF, Auwerx J, Desreumaux P. Peroxisome proliferator-activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease.
Gastroenterol. Clin. Biol. 24: 719-724 (2000).
-
Dubuquoy L, Dharancy S, Nutten S, Pettersson S, Auwerx J, Desreumaux P. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases.
Lancet 360: 1410-1418 (2002).
*
-
Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF, Auwerx J, Pettersson S, Desreumaux P. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis.
Gastroenterology 124: 1265-1276 (2003).
*
-
Dubuquoy L, Louvet A, Hollebecque A, Mathurin P, Dharancy S. Peroxisome proliferator-activated receptors in HBV-related infection.
PPAR Res. 2009: 145124 (2009).
*
-
Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, Fruchart JC, Fievet C, Wright SD, Staels B. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice.
J. Biol. Chem. 277: 48051-48057 (2002).
*
-
Duez H, Fruchart JC, Staels B. PPARS in inflammation, atherosclerosis and thrombosis.
J. Cardiovasc. Risk 8: 187-194 (2001).
-
Duez H, Lefebvre B, Poulain P, Pineda Torra I, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Fruchart JC, Fievet C, Lefebvre P, Staels B. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
Arterioscler. Thromb. Vasc. Biol. 25: 585-591 (2005).
*
-
Duffy D, Rader DJ. Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport.
Curr. Opin. Cardiol. 20: 301-306 (2005).
-
Duffy DL. Genetic determinants of diabetes are similarly associated with other immune-mediated diseases.
Curr. Opin. Allergy Clin. Immunol. 7: 468-474 (2007).
-
Duhaney TA, Cui L, Rude MK, Lebrasseur NK, Ngoy S, De Silva DS, Siwik DA, Liao R, Sam F. Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.
Hypertension 49: 1084-1094 (2007).
-
Dullens SP, Mensink RP, Mariman EC, Plat J. Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-I production in the small intestine.
Eur. J. Gastroenterol. Hepatol. 21: 642-649 (2009).
-
Dumasia R, Eagle KA, Kline-Rogers E, May N, Cho L, Mukherjee D. Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective.
Curr. Drug Targets Cardiovasc. Haemato. Disord. 5: 377-386 (2005).
-
Duncan JG, Fong JL, Medeiros DM, Finck BN, Kelly DP. Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway.
Circulation 115: 909-917 (2007).
*
-
Duncan RE, Archer MC. Farnesol decreases serum triglycerides in rats: identification of mechanisms including up-regulation of PPARalpha and down-regulation of fatty acid synthase in hepatocytes.
Lipids 43: 619-627 (2008).
-
Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D(3) and its nuclear receptor.
J. Mol. Biol. 349: 248-260 (2005).
*
-
Dunn SE, Ousman SS, Sobel RA, Zuniga L, Baranzini SE, Youssef S, Crowell A, Loh J, Oksenberg J, Steinman L. Peroxisome proliferator-activated receptor (PPAR) alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity.
J. Exp. Med. 204: 321-330 (2007).
*
-
Dupont J, Chabrolle C, Rame C, Tosca L, Coyral-Castel S. Role of the peroxisome proliferator-activated receptors, adenosine monophosphate-activated kinase, and adiponectin in the ovary.
PPAR Res. 2008: 176275 (2008).
*
-
Dushkin MI, Khoshchenko OM, Chasovsky MA, Pivovarova EN. The content of PPAR, LXR, and RXR and the PPAR DNA-binding activity in macrophages over the course of inflammation in mice.
Bull. Exp. Biol. Med. 147: 345-348 (2009).
-
Duval C, Fruchart JC, Staels B. PPAR alpha, fibrates, lipid metabolism and inflammation.
Arch. Mal. Coeur. Vaiss. 97: 665-672 (2004).
-
Duy SN, Baes M, Van Veldhoven PP. Degradation of very long chain dicarboxylic polyunsaturated fatty acids in mouse hepatocytes, a peroxisomal process.
Biochim. Biophys. Acta 1781: 400-405 (2008).
*
-
Dyroy E, Rost TH, Pettersen RJ, Halvorsen B, Gudbrandsen OA, Ueland T, Muna Z, Muller F, Nordrehaug JE, Aukrust P, Berge RK. Tetradecylselenoacetic acid, a PPAR ligand with antioxidant, antiinflammatory, and hypolipidemic properties.
Arterioscler. Thromb. Vasc. Biol. 27: 628-634 (2007).
*
-
Dyroy E, Yndestad A, Ueland T, Halvorsen B, Damas JK, Aukrust P, Berge RK. Antiinflammatory effects of tetradecylthioacetic acid involve both peroxisome proliferator-activated receptor alpha-dependent and -independent pathways.
Arterioscler. Thromb. Vasc. Biol. 25: 1364-1369 (2005).
*
-
Eastham LL, Mills CN, Niles RM. PPARalpha/gamma expression and activity in mouse and human melanocytes and melanoma cells.
Pharm. Res. 25: 1327-1333 (2008).
*
-
Eder K, Gutgesell A, Ringseis R, Schmidt E, Brandsch C, Stangl G. Down-regulation of peroxisome proliferator-activated receptor alpha and its coactivators in liver and skeletal muscle mediates the metabolic adaptations during lactation in mice.
J. Mol. Endocrinol. 43: 241-250 (2009).
*
-
Edgar AD, Tomkiewicz C, Costet P, Legendre C, Aggerbeck M, Bouguet J, Staels B, Guyomard C, Pineau T, Barouki R. Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway.
Toxicol. Lett. 98: 13-23 (1998).
-
Edgerton DS, Johnson KM, Cherrington AD. Current strategies for the inhibition of hepatic glucose production in type 2 diabetes.
Front. Biosci. 14: 1169-1181 (2009).
-
Edvardsson U, Alexandersson M, Brockenhuus von Lowenhielm H, Nystrom AC, Ljung B, Nilsson F, Dahllof B. A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14,643.
Electrophoresis 20: 935-942 (1999).
*
-
Edwards IJ, O'Flaherty JT. Omega-3 fatty acids and PPARgamma in cancer.
PPAR Res. 2008: 358052 (2008).
*
-
Edwards IJ, Sun H, Hu Y, Berquin IM, O'Flaherty JT, Cline JM, Rudel LL, Chen YQ. In vivo and in vitro regulation of syndecan 1 in prostate cells by n-3 polyunsaturated fatty acids.
J. Biol. Chem. 283: 18441-18449 (2008).
*
-
Eeckhoute J, Briche I, Kurowska M, Formstecher P, Laine B. Hepatocyte nuclear factor 4 alpha ligand binding and F domains mediate interaction and transcriptional synergy with the pancreatic islet LIM HD transcription factor Isl1.
J. Mol. Biol. 364: 567-581 (2006).
*
-
Efrati S, Berman S, Chachashvili A, Cohen N, Siman-Tov Y, Averbukh Z, Weissgarten J. Rosiglitazone treatment attenuates renal tissue inflammation generated by urinary tract obstruction.
Nephrology (Carlton) 14: 189-197 (2009).
-
Egerod FL, Svendsen JE, Hinley J, Southgate J, Bartels A, Brunner N, Oleksiewicz MB. PPARalpha and PPARgamma coactivation rapidly induces Egr-1 in the nuclei of the dorsal and ventral urinary bladder and kidney pelvis urothelium of rats.
Toxicol. Pathol. 37: 947-958 (2009).
*
-
Ehrenborg E, Krook A. Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta.
Pharmacol. Rev. 61: 373-393 (2009).
*
-
Ehrmann J Jr, Vavrusova N, Collan Y, Kolar Z. Peroxisome proliferator-activated receptors (PPARs) in health and disease.
Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 146: 11-14 (2002).
*
-
Eibl G. The role of PPAR-gamma and its interaction with COX-2 in pancreatic cancer.
PPAR Res. 2008: 326915 (2008).
*
-
Eibl G, Reber HA, Hines OJ, Go VL. COX and PPAR: possible interactions in pancreatic cancer.
Pancreas 29: 247-253 (2004).
-
Eichele K, Ramer R, Hinz B. R(+)-Methanandamide-induced apoptosis of human cervical carcinoma cells involves a cyclooxygenase-2-dependent pathway.
Pharm. Res. 26: 346-355 (2009).
*
-
Einstein M, Akiyama T, Castriota G, Wang C, McKeever B, Mosley R, Becker J, Moller D, Meinke P, Wood H, Berger J. The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.
Mol. Pharmacol. 73: 62-74 (2008).
*
-
Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus.
Diabetologia 44: 2220-2226 (2001).
*
-
El Gawly HW, Tawfik MK, Rashwan ME, Baruzaig AS. The effect of pioglitazone on the liver of streptozotocin-induced diabetic albino Wistar rats.
Eur. Rev. Med. Pharmacol. Sci. 13: 443-451 (2009).
-
El Kebbaj Z, Andreoletti P, Mountassif D, Kabine M, Schohn H, Dauca M, Latruffe N, El Kebbaj MS, Cherkaoui-Malki M. Differential regulation of peroxisome proliferator-activated receptor (PPAR)-alpha1 and truncated PPARalpha2 as an adaptive response to fasting in the control of hepatic peroxisomal fatty acid beta-oxidation in the hibernating mammal.
Endocrinology 150: 1192-1201 (2009).
*
-
El Midaoui A, Wu L, Wang R, de Champlain J. Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats.
Am. J. Hypertens. 19: 407-412 (2006).
-
Elangbam CS, Tyler RD, Lightfoot RM. Peroxisome proliferator-activated receptors in atherosclerosis and inflammation - an update.
Toxicol. Pathol. 29: 224-231 (2001).
*
-
Eletto D, Leone A, Bifulco M, Tecce MF. Effect of unsaturated fat intake from Mediterranean diet on rat liver mRNA expression profile: selective modulation of genes involved in lipid metabolism.
Nutr. Metab. Cardiovasc. Dis. 15: 13-23 (2005).
-
Elholm M, Dam I, Jorgensen C, Krogsdam AM, Holst D, Kratchmarova I, Gottlicher M, Gustafsson JA, Berge R, Flatmark T, Knudsen J, Mandrup S, Kristiansen K. Acyl-CoA esters antagonize the effects of ligands on peroxisome proliferator-activated receptor alpha conformation, DNA binding, and interaction with co-factors.
J. Biol. Chem. 276: 21410-21416 (2001).
*
-
Elias AN, Lizotte P, Hofflich H. Evidence of acute pancreatitis in a patient with radioresistant-differentiated thyroid cancer.
J. Natl. Med. Assoc. 100: 285-287 (2008).
-
Elrod HA, Sun SY. PPARgamma and apoptosis in cancer.
PPAR Res. 2008: 704165 (2008).
*
-
Enders GA. Cyclooxygenase-2 overexpression abrogates the antiproliferative effects of TGF-beta.
Br. J. Cancer 97: 1388-1392 (2007).
*
-
Endresen MJ. The role of fatty acids in gene regulation. An example of an important nutritional factor which may influence our genes.
Tidsskr. Nor. Laegeforen. 115: 2084-2086 (1995).
-
Engdahl R, Monroy MA, Daly JM. 15-Deoxy-Delta(12,14)-prostaglandin J2 (15d-PGJ2) mediates repression of TNF-alpha by decreasing levels of acetylated histone H3 and H4 at its promoter.
Biochem. Biophys. Res. Commun. 359: 88-93 (2007).
*
-
Engle SK, Solter PF, Credille KM, Bull CM, Adams S, Berna MJ, Schultze AE, Rothstein EC, Cockman MD, Pritt ML, Liu H, Lu Y, Chiang AY, Watson DE. Detection of left ventricular hypertrophy in rats administered a peroxisome proliferator-activated receptor alpha/gamma dual agonist using natriuretic peptides and imaging.
Toxicol. Sci. Dec 31 [Epub ahead of print] (2009).
*
-
Enoki T, Ohnogi H, Nagamine K, Kudo Y, Sugiyama K, Tanabe M, Kobayashi E, Sagawa H, Kato I. Antidiabetic activities of chalcones isolated from a Japanese herb, Angelica keiskei.
J. Agric. Food Chem. 55: 6013-6017 (2007).
*
-
Eny KM, El-Sohemy A, Cornelis MC, Sung YK, Bae SC. Catalase and PPARgamma2 genotype and risk of systemic lupus erythematosus in Koreans.
Lupus 14: 351-355 (2005).
-
Epple R, Azimioara M, Russo R, Bursulaya B, Tian SS, Gerken A, Iskandar M. 1,3,5-Trisubstituted aryls as highly selective PPARdelta agonists.
Bioorg. Med. Chem. Lett. 16: 2969-2973 (2006).
-
Epple R, Cow C, Xie Y, Azimioara M, Russo R, Wang X, Wityak J, Karanewsky DS, Tuntland T, Nguyen-Tran VT, Cuc Ngo C, Huang D, Saez E, Spalding T, Gerken A, Iskandar M, Seidel HM, Tian SS. Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
J. Med. Chem. Nov 20 [Epub ahead of print] (2009).
*
-
Epple R, Russo R, Azimioara M, Cow C, Xie Y, Wang X, Wityak J, Karanewsky D, Gerken A, Iskandar M, Saez E, Martin Seidel H, Tian SS. 3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists: part 1.
Bioorg. Med. Chem. Lett. 16: 4376-4380 (2006).
-
Epstein S, Leroith D. Diabetes and fragility fractures - a burgeoning epidemic?
Bone 43: 3-6 (2008).
-
Erdogan M, Karadeniz M, Eroglu Z, Tezcanli B, Selvi N, Yilmaz C. The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy.
Diabetes Res. Clin. Pract. 78: 355-359 (2007).
-
Ereqat S, Nasereddin A, Azmi K, Abdeen Z, Amin R. Impact of the Pro12Ala polymorphism of the PPAR-gamma 2 gene on metabolic and clinical characteristics in the Palestinian type 2 diabetic patients.
PPAR Res. 2009: 874126 (2009).
*
-
Eriksson JG. The role of genes in growth and later health.
Nestle Nutr. Workshop Ser. Pediatr. Program 61: 69-77 (2008).
-
Erol A. PPARalpha activators may be good candidates as antiaging agents.
Med. Hypotheses 65: 35-38 (2005).
-
Erol A. The functions of PPARs in aging and longevity.
PPAR Res. 2007: 39654 (2007).
*
-
Escher P, Wahli W. Peroxisome proliferator-activated receptors: insight into multiple cellular functions.
Mutat. Res. 448: 121-138 (2000).
-
Escribano L, Simon AM, Perez-Mediavilla A, Salazar-Colocho P, Río JD, Frechilla D. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model.
Biochem. Biophys. Res. Commun. 379: 406-410 (2009).
*
-
Esposito E, Cuzzocrea S, Meli R. Peroxisome proliferator-activated receptors and shock state.
ScientificWorldJournal 6: 1770-1782 (2006).
-
Esteves J, Laranjeira AF, Roggia MF, Dalpizol M, Scocco C, Kramer CK, Azevedo MJ, Canani LH. Diabetic retinopathy risk factors.
Arq. Bras. Endocrinol. Metabol. 52: 431-441 (2008).
-
Eun CS, Han DS, Lee SH, Jeon YC, Sohn JH, Kim YS, Lee J. Probiotics may reduce inflammation by enhancing peroxisome proliferator activated receptor gamma activation in HT-29 cells.
Korean J. Gastroenterol. 49: 139-146 (2007).
-
Eun CS, Han DS, Lee SH, Paik CH, Chung YW, Lee J, Hahm JS. Attenuation of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on Toll-like receptor pathway.
Dig. Dis. Sci. 51: 693-697 (2006).
*
-
Evans D, Aberle J, Wendt D, Wolf A, Beisiegel U, Mann WA. A polymorphism, L162V, in the peroxisome proliferator-activated receptor alpha (PPARalpha) gene is associated with lower body mass index in patients with non-insulin-dependent diabetes mellitus.
J. Mol. Med. 79: 198-204 (2001).
*
-
Evans JL, Lin JJ, Goldfine ID. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
Curr. Diabetes Rev. 1: 299-307 (2005).
-
Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez RV, Vlasuk GP, Harnish DC. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
Am. J. Physiol. Gastrointest. Liver Physiol. 296: G543-G552 (2009).
*
-
Evans NP, Misyak SA, Schmelz EM, Guri AJ, Hontecillas R, Bassaganya-Riera J. Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma.
J. Nutr. Jan 20 [Epub ahead of print] (2010).
-
Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity.
Nat. Med. 10: 355-361 (2004).
*
-
Evans-Molina C, Robbins RD, Kono T, Tersey SA, Vestermark GL, Nunemaker CS, Garmey JC, Deering TG, Keller SR, Maier B, Mirmira RG. PPAR-gamma activation restores islet function in diabetic mice through reduction of ER stress and maintenance of euchromatin structure.
Mol. Cell. Biol. 29: 2053-2067 (2009).
*
-
Ewaschuk J, Endersby R, Thiel D, Diaz H, Backer J, Ma M, Churchill T, Madsen K. Probiotic bacteria prevent hepatic damage and maintain colonic barrier function in a mouse model of sepsis.
Hepatology 46: 841-850 (2007).
*
-
Eynon N, Meckel Y, Sagiv M, Yamin C, Amir R, Sagiv M, Goldhammer E, Duarte JA, Oliveira J. Do PPARGC1A and PPARalpha polymorphisms influence sprint or endurance phenotypes?
Scand. J. Med. Sci. Sports Apr 20 [Epub ahead of print] (2009).
-
Fagerberg B, Schuster H, Birketvedt GS, Tonstad S, Ohman KP, Gause-Nilsson I; On Behalf Of The Sir Study Group. Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARa/g agonist, tesaglitazar.
Diab. Vasc. Dis. Res. 4: 174-180 (2007).
-
Fainaru O, Shay T, Hantisteanu S, Goldenberg D, Domany E, Groner Y. TGFbeta-dependent gene expression profile during maturation of dendritic cells.
Genes Immun. 8: 239-244 (2007).
*
-
Faiola B, Falls JG, Peterson RA, Bordelon NR, Brodie TA, Cummings CA, Romach EH, Miller RT. PPAR alpha, more than PPAR delta, mediates the hepatic and skeletal muscle alterations induced by the PPAR agonist GW0742.
Toxicol. Sci. 105: 384-394 (2008).
*
-
Faisy C, Pinto FM, Blouquit-Laye S, Danel C, Naline E, Buenestado A, Delyle SG, Burgel PR, Chapelier A, Advenier C, Candenas ML, Devillier P. beta(2)-Agonist modulates epithelial gene expression involved in the T and B-cell chemotaxis and induces airway sensitization in human isolated bronchi.
Pharmacol. Res. Aug 12 [Epub ahead of print] (2009).
*
-
Fakhrudin N, Ladurner A, Atanasov AG, Heiss EH, Baumgartner L, Markt P, Schuster D, Ellmerer EP, Wolber G, Rollinger JM, Stuppner H, Dirsch VM. Computer-aided discovery, validation and mechanistic characterisation of novel neolignan activators of PPARgamma.
Mol. Pharmacol. Jan 11 [Epub ahead of print] (2010).
*
-
Falcetti E, Flavell DM, Staels B, Tinker A, Haworth SG, Clapp LH. IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues.
Biochem. Biophys. Res. Commun. 360: 821-827 (2007).
*
-
Fan B, Ikuyama S, Gu JQ, Wei P, Oyama JI, Inoguchi T, Nishimura J. Oleic acid-induced ADRP expression requires both AP-1 and PPAR-response elements, and is reduced by pycnogenol through mRNA degradation in NMuLi liver cells.
Am. J. Physiol. Endocrinol. Metab. 297: E112-E123 (2009).
*
-
Fan H, Zingarelli B, Harris V, Tempel GE, Halushka PV, Cook JA. Lysophosphatidic acid inhibits bacterial endotoxin-induced pro-inflammatory response: potential anti-inflammatory signaling pathways.
Mol. Med. 14: 422-428 (2008).
*
-
Fan P, Zhang B, Kuroki S, Saku K. Pitavastatin, a potent hydroxymethylglutaryl coenzyme A reductase inhibitor, increases cholesterol 7 alpha-hydroxylase gene expression in HepG2 cells.
Circ. J. 68: 1061-1066 (2004).
*
-
Fan W, Imamura T, Sonoda N, Sears DD, Patsouris D, Kim JJ, Olefsky JM. FOXO1 transrepresses PPARgamma transactivation, coordinating an insulin-induced feed-forward response in adipocytes.
J. Biol. Chem. 284: 12188-12197 (2009).
*
-
Fan W, Yanase T, Morinaga H, Mu YM, Nomura M, Okabe T, Goto K, Harada N, Nawata H. Activation of peroxisome proliferator activated receptor gamma and retinoid X receptor inhibits aromatase transcription via NF-kappaB.
Endocrinology 146: 85-92 (2005).
*
-
Fan Y, Wang Y, Tang Z, Zhang H, Qin X, Zhu Y, Guan Y, Wang X, Staels B, Chien S, Wang N. Suppression of proinflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells.
Arterioscler. Thromb. Vasc. Biol. 28: 315-321 (2008).
-
Fan YY, Spencer TE, Wang N, Moyer MP, Chapkin RS. Chemopreventive n-3 fatty acids activate RXRalpha in colonocytes.
Carcinogenesis 24: 1541-1548 (2003).
*
-
Fang C, Yoon S, Tindberg N, Jarvelainen HA, Lindros KO, Ingelman-Sundberg M. Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure.
Biochem. Pharmacol. 67: 1389-1397 (2004).
*
-
Fang F, Kang Z, Wong C. Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors.
Mol. Nutr. Food Res. Oct 28 [Epub ahead of print] (2009).
*
-
Fang HL, Strom SC, Cai H, Falany CN, Kocarek TA, Runge-Morris M. Regulation of human hepatic hydroxysteroid sulfotransferase gene expression by the peroxisome proliferator-activated receptor alpha transcription factor.
Mol. Pharmacol. 67: 1257-1267 (2005).
*
-
Fang X, Dillon JS, Hu S, Harmon SD, Yao J, Anjaiah S, Falck JR, Spector AA. 20-Carboxy-arachidonic acid is a dual activator of peroxisome proliferator-activated receptors alpha and gamma.
Prostaglandins Other Lipid Mediat. 82: 175-184 (2007).
-
Fang X, Feng Y, Wang J, Dai J. Perfluorononanoic acid-induced apoptosis in rat spleen involves oxidative stress and the activation of caspase-independent death pathway.
Toxicology 267: 54-59 (2010).
*
-
Fang X, Hu S, Xu B, Snyder G, Harmon S, Yao J, Liu Y, Sangras B, Falck J, Weintraub NL, Spector AA. 14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator activated receptor alpha.
Am. J. Physiol. Heart Circ. Physiol. 290: H55-H63 (2006).
*
-
Fang X, Zhang L, Feng Y, Zhao Y, Dai J. Immunotoxic effects of perfluorononanoic acid on BALB/c mice.
Toxicol. Sci. 105: 312-321 (2008).
*
-
Fatehi-Hassanabad Z, Chan CB. Expression of PPARalpha modifies fatty acid effects on insulin secretion in uncoupling protein-2 knockout mice.
Nutr. Metab. (Lond.) 4: 6 (2007).
*
-
Fatehi-Hassanabad Z, Chan CB. Transcriptional regulation of lipid metabolism by fatty acids: a key determinant of pancreatic beta-cell function.
Nutr. Metab. (Lond.) 2: 1 (2005).
*
-
Fediuc S, Pimenta AS, Gaidhu MP, Ceddia RB. Activation of AMP-activated protein kinase, inhibition of pyruvate dehydrogenase activity, and redistribution of substrate partitioning mediate the acute insulin-sensitizing effects of troglitazone in skeletal muscle cells.
J. Cell Physiol. 215: 392-400 (2008).
*
-
Fehrenbacher JC, Loverme J, Clarke W, Hargreaves KM, Piomelli D, Taylor BK. Rapid pain modulation with nuclear receptor ligands.
Brain Res. Rev. 60: 114-124 (2009).
-
Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions.
Prog. Lipid Res. 45: 120-159 (2006).
*
-
Feige JN, Gelman L, Rossi D, Zoete V, Metivier R, Tudor C, Anghel SI, Grosdidier A, Lathion C, Engelborghs Y, Michielin O, Wahli W, Desvergne B. The endocrine disruptor mono-ethyl-hexyl-phthalate is a selective PPARgamma modulator which promotes adipogenesis.
J. Biol. Chem. 282: 19152-19166 (2007).
*
-
Feige JN, Gelman L, Tudor C, Engelborghs Y, Wahli W, Desvergne B. Fluorescence imaging reveals the nuclear behavior of PPAR/RXR heterodimers in the absence and presence of ligand.
J. Biol. Chem. 280: 17880-17890 (2005).
*
-
Feige JN, Gerber A, Casals-Casas C, Yang Q, Winkler C, Bedu E, Bueno M, Gelman L, Auwerx J, Gonzalez FJ, Desvergne B. The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms.
Environ. Health Perspect. 118: 234-241 (2010).
-
Feingold K, Kim MS, Shigenaga J, Moser A, Grunfeld C. Altered expression of nuclear hormone receptors and coactivators in mouse heart during the acute-phase response.
Am. J. Physiol. Endocrinol. Metab. 286: E201-E207 (2004).
*
-
Feingold KR, Moser A, Patsek SM, Shigenaga JK, Grunfeld C. Infection decreases fatty acid oxidation and nuclear hormone receptors in the diaphragm.
J. Lipid Res. May 14 [Epub ahead of print] (2009).
*
-
Feingold KR, Wang Y, Moser A, Shigenaga JK, Grunfeld C. LPS decreases fatty acid oxidation and nuclear hormone receptors in the kidney.
J. Lipid Res. 49: 2179-2187 (2008).
*
-
Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Russo CD. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?
Biochem. Pharmacol. 70: 177-188 (2005).
*
-
Feldman PL, Lambert MH, Henke BR. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?
Curr. Top. Med. Chem. 8: 728-749 (2008).
-
Feldon SE, O'loughlin CW, Ray DM, Landskroner-Eiger S, Seweryniak KE, Phipps RP. Activated human T lymphocytes express cyclooxygenase-2 and produce proadipogenic prostaglandins that drive human orbital fibroblast differentiation to adipocytes.
Am. J. Pathol. 169: 1183-1193 (2006).
*
-
Feng D, Zhang Y, Chen G. Cortical expression of peroxisome proliferator-activated receptor-alpha after human brain contusion.
J. Int. Med. Res. 36: 783-791 (2008).
-
Ferguson HE, Kulkarni A, Lehmann GM, Garcia-Bates TM, Thatcher TH, Huxlin KR, Phipps RP, Sime PJ. Electrophilic peroxisome proliferator activated receptor-gamma ligands have potent anti-fibrotic effects in human lung fibroblasts.
Am. J. Respir. Cell. Mol. Biol. 41: 722-730 (2009).
*
-
Ferguson HE, Thatcher TH, Olsen KC, Garcia-Bates TM, Baglole CJ, Kottmann RM, Strong ER, Phipps RP, Sime PJ. Peroxisome proliferator activated receptor-gamma (PPARgamma) ligands induce heme oxygenase-1 in lung fibroblasts by a PPARgamma-independent, glutathione-dependent mechanism.
Am. J. Physiol. Lung Cell. Mol. Physiol. 297: L912-L919 (2009).
*
-
Ferguson LR. Dissecting the nutrigenomics, diabetes, and gastrointestinal disease interface: from risk assessment to health intervention.
OMICS 12: 237-244 (2008).
-
Fernandes-Santos C, Carneiro RE, Mendonca LD, Aguila MB, Mandarim-de-Lacerda CA. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
Nutrition 25: 818-827 (2009).
*
-
Fernandes-Santos C, Evangelista Carneiro R, de Souza Mendonca L, Barbosa Aguila M, Alberto Mandarim-de-Lacerda C. Rosiglitazone aggravates nonalcoholic fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
Pancreas 38: e80-e86 (2009).
-
Fernandez AZ. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome.
Curr. Opin. Investig. Drugs 5: 936-940 (2004).
-
Fernandez AZ. Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis.
PPAR Res. 2008: 285842 (2008).
*
-
Fernandez PL. Stress and inflammatory bowell disease (I.B.D). Therapeutic strategies.
An. R. Acad. Nac. Med. (Madr.) 123: 219-229 (2006).
-
Fernandez-Espejo E, Ramiro-Fuentes S, de Fonseca FR. The absence of a functional peroxisome proliferator-activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine.
Neuroscience 164: 667-675 (2009).
-
Fernandez-Veledo S, Nieto-Vazquez I, Vila-Bedmar R, Garcia-Guerra L, Alonso-Chamorro M, Lorenzo M. Molecular mechanisms involved in obesity-associated insulin resistance: therapeutical approach.
Arch. Physiol. Biochem. 115: 227-239 (2009).
-
Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, Skrede S, Gudbrandsen OA, Waage J, Lunder N, Mork S, Berge RK, Jorgensen HA, Steen VM. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver.
Psychopharmacology (Berl.) 203: 73-84 (2009).
-
Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity.
Diabetes 53 Suppl. 1: S43-S50 (2004).
*
-
Fesinmeyer MD, Stanford JL, Brentnall TA, Mandelson MT, Farin FM, Srinouanprachanh S, Afsharinejad Z, Goodman GE, Barnett MJ, Austin MA. Association between the peroxisome proliferator-activated receptor gamma Pro12Ala variant and haplotype and pancreatic cancer in a high-risk cohort of smokers: a pilot study.
Pancreas 38: 631-637 (2009).
-
Festuccia WT, Blanchard PG, Turcotte V, Laplante M, Sariahmetoglu M, Brindley DN, Richard D, Deshaies Y. The PPARgamma agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 296: R1327-R1335 (2009).
*
-
Festuccia WT, Oztezcan S, Laplante M, Berthiaume M, Michel C, Dohgu S, Denis RG, Brito MN, Brito NA, Miller DS, Banks WA, Bartness TJ, Richard D, Deshaies Y. Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status.
Endocrinology 149: 2121-2130 (2008).
*
-
Fiatte C, Huin C, Bertin I, Lesuffleur T, Pluvinet A, Touche N, Plenat F, Dauca M, Domenjoud L, Schohn H. Genetic analysis of peroxisome proliferator-activated receptor gamma1 splice variants in human colorectal cell lines.
Int. J. Oncol. 29: 1601-1610 (2006).
*
-
Fidaleo M, Berardi E, Sartori C. Differential modulation of PPARalpha and gamma target gene expression in the liver and kidney of rats treated with aspirin.
Exp. Toxicol. Pathol. 59: 391-397 (2008).
*
-
Fievet C, Fruchart JC, Staels B. Genetically-engineered animals as research models for atherosclerosis : their use for the characterization of PPAR agonists in the treatment of cardiometabolic disorders.
Front. Biosci. 12: 4132-4156 (2007).
-
Fievet C, Fruchart JC, Staels B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Curr. Opin. Pharmacol. 6: 606-614 (2006).
-
Fievet C, Staels B. Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease.
Curr. Atheroscler. Rep. 11: 281-288 (2009).
-
Filzen GF, Bratton L, Cheng XM, Erasga N, Geyer A, Lee C, Lu G, Pulaski J, Sorenson RJ, Unangst PC, Trivedi BK, Xu X. Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.
Bioorg. Med. Chem. Lett. 17: 3630-3635 (2007).
-
Finck BN. Effects of PPARalpha on cardiac glucose metabolism: a transcriptional equivalent of the glucose-fatty acid cycle?
Expert Rev. Cardiovasc. Ther. 4: 161-171 (2006).
-
Finck BN. The PPAR regulatory system in cardiac physiology and disease.
Cardiovasc. Res. 73: 269-277 (2007).
*
-
Finck BN, Gropler MC, Chen Z, Leone TC, Croce MA, Harris TE, Lawrence JC Jr, Kelly DP. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway.
Cell Metab. 4: 199-210 (2006).
*
-
Finn AV, John M, Nakazawa G, Polavarapu R, Karmali V, Xu X, Cheng Q, Davis T, Raghunathan C, Acampado E, Ezell T, Lajoie S, Eppihimer M, Kolodgie FD, Virmani R, Gold HK. Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists. Requirement for mTOR/Akt2 in PPARgamma activation.
Circ. Res. 105: 1003-1012 (2009).
-
Fionda C, Nappi F, Piccoli M, Frati L, Santoni A, Cippitelli M. Inhibition of TRAIL gene expression by cyclopentenonic prostaglandin 15-deoxy-delta12,14-prostaglandin J2 in T lymphocytes.
Mol. Pharmacol. 72: 1246-1257 (2007).
*
-
Fiorito M, Torrente I, De Cosmo S, Guida V, Colosimo A, Prudente S, Flex E, Menghini R, Miccoli R, Penno G, Pellegrini F, Tassi V, Federici M, Trischitta V, Dallapiccola B. Interaction of DIO2 T92A and PPARgamma2 P12A polymorphisms in the modulation of metabolic syndrome.
Obesity (Silver Spring) 15: 2889-2895 (2007).
*
-
Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Antonio M, Pruzanski M, Pelllicciari R. Cross-talk between farnesoid X-receptor (FXR) and peroxisome proliferator-activated receptor (PPAR) gamma contributes to the anti-fibrotic activity of FXR ligands in rodent models of liver cirrhosis.
J. Pharmacol. Exp. Ther. 315: 58-68 (2005).
*
-
Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice.
J. Biol. Chem. 278: 27997-28004 (2003).
*
-
Fisher CD, Jackson JP, Lickteig AJ, Augustine LM, Cherrington NJ. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis.
Arch. Toxicol. 82: 959-964 (2008).
*
-
Fitzgerald ML, Moore KJ, Freeman MW. Nuclear hormone receptors and cholesterol trafficking: the orphans find a new home.
J. Mol. Med. 80: 271-281 (2002).
*
-
Flachs P, Horakova O, Brauner P, Rossmeisl M, Pecina P, Franssen-van Hal N, Ruzickova J, Sponarova J, Drahota Z, Vlcek C, Keijer J, Houstek J, Kopecky J. Polyunsaturated fatty acids of marine origin upregulate mitochondrial biogenesis and induce beta-oxidation in white fat.
Diabetologia 48: 2365-2375 (2005).
*
-
Flachs P, Rossmeisl M, Bryhn M, Kopecky J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism.
Clin. Sci. (Lond.) 116: 1-16 (2009).
*
-
Flavell DM, Ireland H, Stephens JW, Hawe E, Acharya J, Mather H, Hurel SJ, Humphries SE. Peroxisome proliferator-activated receptor alpha gene variation influences age of onset and progression of type 2 diabetes.
Diabetes 54: 582-586 (2005).
*
-
Flavell DM, Jamshidi Y, Hawe E, Pineda Torra I, Taskinen MR, Frick MH, Nieminen MS, Kesaniemi YA, Pasternack A, Staels B, Miller G, Humphries SE, Talmud PJ, Syvanne M. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease.
Circulation 105: 1440-1445 (2002).
*
-
Flavell DM, Pineda Torra I, Jamshidi Y, Evans D, Diamond JR, Elkeles RS, Bujac SR, Miller G, Talmud PJ, Staels B, Humphries SE. Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects.
Diabetologia 43: 673-680 (2000).
*
-
Fletcher HA, Keyser A, Bowmaker M, Sayles PC, Kaplan G, Hussey G, Hill AV, Hanekom WA. Transcriptional profiling of mycobacterial antigen-induced responses in infants vaccinated with BCG at birth.
BMC Med. Genomics 2: 10 (2009).
*
-
Flores AM, Li L, Aneskievich BJ. Isolation and functional analysis of a keratinocyte-derived, ligand-regulated nuclear receptor comodulator.
J. Invest. Dermatol. 123: 1092-1101 (2004).
*
-
Florez JC, Jablonski KA, Sun MW, Bayley N, Kahn SE, Shamoon H, Hamman RF, Knowler WC, Nathan DM, Altshuler D. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.
J. Clin. Endocrinol. Metab. 92: 1502-1509 (2007).
*
-
Flowers MT, Keller MP, Choi Y, Lan H, Kendziorski CM, Ntambi JM, Attie AD. Liver gene expression analysis reveals endoplasmic reticulum stress and metabolic dysfunction in SCD1-deficient mice fed a very low-fat diet.
Physiol. Genomics 33: 361-372 (2008).
*
-
Floyd ZE, Wang ZQ, Kilroy G, Cefalu WT. Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol.
Metabolism 57: S32-S38 (2008).
*
-
Fogari R, Zoppi A, Ferrari I, Mugellini A, Preti P, Lazzari P, Derosa G. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients.
Horm. Metab. Res. 41: 893-898 (2009).
-
Folch-Puy E, Granell S, Iovanna JL, Barthet M, Closa D. Peroxisome proliferator-activated receptor gamma agonist reduces the severity of post-ERCP pancreatitis in rats.
World J. Gastroenterol. 12: 6458-6463 (2006).
*
-
Fong WH, Tsai HD, Chen YC, Wu JS, Lin TN. Anti-apoptotic actions of PPAR-gamma against ischemic stroke.
Mol. Neurobiol. Feb 3 [Epub ahead of print] (2010).
-
Foreman JE, Chang SC, Ehresman DJ, Butenhoff JL, Anderson CR, Palkar PS, Kang BH, Gonzalez FJ, Peters JM. Differential hepatic effects of perfluorobutyrate (PFBA) mediated by mouse and human PPARalpha.
Toxicol. Sci. 110: 204-211 (2009).
*
-
Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta.
Proc. Natl. Acad. Sci. U.S.A. 94: 4312-4317 (1997).
*
-
Foucher C, Rattier S, Flavell DM, Talmud PJ, Humphries SE, Kastelein JJ, Ayyobi A, Pimstone S, Frohlich J, Ansquer JC, Steiner G; for the DAIS investigators. Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.
Pharmacogenetics 14: 823-829 (2004).
-
Fourcade S, Savary S, Albet S, Gauthe D, Gondcaille C, Pineau T, Bellenger J, Bentejac M, Holzinger A, Berger J, Bugaut M. Fibrate induction of the adrenoleukodystrophy-related gene (ABCD2): promoter analysis and role of the peroxisome proliferator-activated receptor PPARalpha.
Eur. J. Biochem. 268: 3490-3500 (2001).
*
-
Fournier T, Handschuh K, Tsatsaris V, Evain-Brion D. Involvement of PPARgamma in human trophoblast invasion.
Placenta 28 Suppl. A: S76-S81 (2007).
-
Fournier T, Handschuh K, Tsatsaris V, Guibourdenche J, Evain-Brion D. Role of nuclear receptors and their ligands in human trophoblast invasion.
J. Reprod. Immunol. 77: 161-170 (2008).
-
Fournier T, Therond P, Handschuh K, Tsatsaris V, Evain-Brion D. PPARgamma and early human placental development.
Curr. Med. Chem. 15: 3011-3024 (2008).
-
Fournier T, Tsatsaris V, Handschuh K, Evain-Brion D. PPARs and the placenta.
Placenta 28: 65-76 (2007).
-
Fracchiolla G, Laghezza A, Piemontese L, Tortorella P, Mazza F, Montanari R, Pochetti G, Lavecchia A, Novellino E, Pierno S, Conte Camerino D, Loiodice F. New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.
J. Med. Chem. 52: 6382-6393 (2009).
*
-
Frances F, Verdu F, Portoles O, Castello A, Sorlí JV, Guillen M, Corella D. PPAR-alpha L162V and PGC-1 G482S gene polymorphisms, but not PPAR-gamma P12A, are associated with alcohol consumption in a Spanish Mediterranean population.
Clin. Chim. Acta 398: 70-74 (2008).
*
-
Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism.
Annu. Rev. Physiol. 65: 261-311 (2003).
*
-
Francis GA, Li G, Casey R, Wang J, Cao H, Leff T, Hegele RA. Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3).
BMC Med. Genet. 7: 3 (2006).
*
-
Francois M, Richette P, Corvol MT. Peroxisome proliferator-activated receptor gamma and its ligands in controlling interleukin-1beta target gene expression: a confusing story.
Drug News Perspect. 18: 257-261 (2005).
-
Francois M, Richette P, Tsagris L, Fitting C, Lemay C, Benallaoua M, Tahiri K, Corvol MT. Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes.
Arthritis Rheum. 54: 1233-1245 (2006).
*
-
Franks PW, Ekelund U, Brage S, Luan J, Schafer AJ, O'Rahilly S, Barroso I, Wareham NJ. PPARGC1A coding variation may initiate impaired NEFA clearance during glucose challenge.
Diabetologia 50: 569-573 (2007).
*
-
Franks PW, Jablonski KA, Delahanty L, Hanson RL, Kahn SE, Altshuler D, Knowler WC, Florez JC; Diabetes Prevention Program Research Group. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program.
Diabetologia 50: 2451-2460 (2007).
*
-
Fredenrich A, Grimaldi P. PPAR delta: an uncompletely known nuclear receptor.
Diabetes Metab. 31: 23-27 (2005).
*
-
Friedmann PS, Cooper HL, Healy E. Peroxisome proliferator-activated receptors and their relevance to dermatology.
Acta Derm. Venereol. 85: 194-202 (2005).
*
-
Fritah A, Steel JH, Nichol D, Parker N, Williams S, Price A, Strauss L, Ryder TA, Mobberley MA, Poutanen M, Parker M, White A. Elevated expression of the metabolic regulator RIP140 results in cardiac hypertrophy and impaired cardiac function.
Cardiovasc. Res. Jan 18 [Epub ahead of print] (2010).
*
-
Frode TS, da Silva Buss Z, Dos Reis GO, Santos Medeiros Y. Evidence of anti-inflammatory effects of pioglitazone in the murine pleurisy model induced by carrageenan.
Int. Immunopharmacol. 9: 1394-1400 (2009).
-
Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease.
Atherosclerosis 205: 1-8 (2009).
-
Fruchart JC. Novel peroxisome proliferator activated receptor-alpha agonists.
Am. J. Cardiol. 100: S41-S46 (2007).
*
-
Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Drugs Today (Barc.) 42: 39-64 (2006).
-
Fruchart JC, Duriez P, Staels B. Molecular mechanism of action of the fibrates.
J. Soc. Biol. 193: 67-75 (1999).
-
Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis.
Curr. Opin. Lipidol. 10: 245-257 (1999).
-
Fruchart JC, Staels B, Duriez P. PPARS, metabolic disease and atherosclerosis.
Pharmacol. Res. 44: 345-352 (2001).
*
-
Fu J, Oveisi F, Gaetani S, Lin E, Piomelli D. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats.
Neuropharmacology 48: 1147-1153 (2005).
*
-
Fu L, Xiong X, Wang L, Gao X, Ye Y, Jia J, Hu H, Li L, Shen J, Mei C. Antitumor efficacy of two novel non-thiazolidinedione compounds as peroxisome proliferator-activated receptor-gamma agonists in human osteosarcoma cells in vitro.
Chemotherapy 55: 468-476 (2009).
-
Fu Y, Zheng S, Lin J, Ryerse J, Chen A. Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation.
Mol. Pharmacol. 73: 399-409 (2008).
*
-
Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez GR, Inestrosa NC, Bronfman M. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis.
J. Biol. Chem. 282: 37006-37015 (2007).
*
-
Fuenzalida KM, Aguilera MC, Piderit DG, Ramos PC, Contador D, Quinones V, Rigotti A, Bronfman FC, Bronfman M. Peroxisome proliferator-activated receptor gamma is a novel target of the nerve growth factor signaling pathway in PC12 cells.
J. Biol. Chem. 280: 9604-9609 (2005).
*
-
Fujii H. PPARs-mediated intracellular signal transduction.
Nippon Rinsho 63: 565-571 (2005).
-
Fujii H. Anti-inflammatory action of PPARs.
Nippon Rinsho 63: 609-615 (2005).
-
Fujii H. Nuclear receptor PPARs and magnesium.
Clin. Calcium 15: 1814-1826 (2005).
-
Fujimori K, Ueno T, Nagata N, Kashiwagi K, Aritake K, Amano F, Urade Y. Suppression of adipocyte differentiation by aldo-keto reductase 1B3 acting as prostaglandin F2alpha synthase.
J. Biol. Chem. Jan 21 [Epub ahead of print] (2010).
*
-
Fujimura T, Kimura C, Oe T, Takata Y, Sakuma H, Aramori I, Mutoh S. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
J. Pharmacol. Exp. Ther. 318: 863-871 (2006).
*
-
Fujishiro K, Fukui Y, Sato O, Kawabe K, Seto K, Motojima K. Analysis of tissue-specific and PPARalpha-dependent induction of FABP gene expression in the mouse liver by an in vivo DNA electroporation method.
Mol. Cell. Biochem. 239: 165-172 (2002).
*
-
Fukuda LE, Davel AP, Verissimo-Filho S, Lopes LR, Cachofeiro V, Lahera V, Rossoni LV. Fenofibrate and pioglitazone do not ameliorate the altered vascular reactivity in aorta of isoproterenol-treated rats.
J. Cardiovasc. Pharmacol. 52: 413-421 (2008).
-
Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity.
J. Biol. Chem. 280: 23653-23659 (2005).
*
-
Fukui N, Honda K, Ito E, Ishikawa K. Peroxisome proliferator-activated receptor-gamma negatively regulates allergic rhinitis in mice.
Allergol. Int. 58: 247-253 (2009).
-
Furnsinn C, Willson TM, Brunmair B. Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport.
Diabetologia 50: 8-17 (2007).
*
-
Futter M, Diekmann H, Schoenmakers E, Sadiq O, Chatterjee K, Rubinsztein DC. Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors.
J. Med. Genet. 46: 438-446 (2009).
*
-
Fyffe SA, Alphey MS, Buetow L, Smith TK, Ferguson MA, Sorensen MD, Bjorkling F, Hunter WN. Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids.
J. Mol. Biol. 356: 1005-1013 (2006).
*
-
Gacka M, Adamiec R. Mutations of peroxisome proliferator-activated receptor gamma (PPARgamma): clinical implications.
Postepy. Hig. Med. Dosw. (Online) 58: 483-489 (2004).
-
Gacka M, Bednarska-Chabowska D, Dobosz T, Szymaniec S, Jakobsche U, Lebioda A, Adamiec R. The Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma and immunological processes in patients with type 2 diabetes and insulin resistance.
Przegl. Lek. 64: 393-397 (2007).
-
Gaetani S, Kaye WH, Cuomo V, Piomelli D. Role of endocannabinoids and their analogues in obesity and eating disorders.
Eat. Weight Disord. 13: e42-e48 (2008).
-
Gaetano C, Colussi C, Capogrossi MC. PEDF, PPAR-gamma, p53: deadly circuits arise when worlds collide.
Cardiovasc. Res. 76: 195-196 (2007).
*
-
Galan-Rodriguez B, Suarez J, Gonzalez-Aparicio R, Bermudez-Silva FJ, Maldonado R, Robledo P, Rodriguez de Fonseca F, Fernandez-Espejo E. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons.
Neuropharmacology 56: 653-664 (2009).
-
Gale SE, Frolov A, Han X, Bickel PE, Cao L, Bowcock A, Schaffer JE, Ory DS. A regulatory role for 1-acylglycerol-3-phosphate-O-acyltransferase 2 in adipocyte differentiation.
J. Biol. Chem. 281: 11082-11089 (2006).
*
-
Gallardo-Soler A, Gomez-Nieto C, Luisa Campo M, Marathe C, Tontonoz P, Castrillo A, Corraliza I. Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-gamma/delta-mediated effect that links lipid metabolism and immunity.
Mol. Endocrinol. 22: 1394-1402 (2008).
*
-
Galli A, Ceni E, Crabb DW, Mello T, Salzano R, Grappone C, Milani S, Surrenti E, Surrenti C, Casini A. Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.
Gut 53: 1688-1697 (2004).
*
-
Galli A, Mello T, Ceni E, Surrenti E, Surrenti C. The potential of antidiabetic thiazolidinediones for anticancer therapy.
Expert Opin. Investig. Drugs 15: 1039-1049 (2006).
-
Galli A, Pinaire J, Fischer M, Dorris R, Crabb DW. The transcriptional and DNA binding activity of peroxisome proliferator-activated receptor alpha is inhibited by ethanol metabolism. A novel mechanism for the development of ethanol-induced fatty liver.
J. Biol. Chem. 276: 68-75 (2001).
*
-
Gallicchio L, Kalesan B, Huang HY, Strickland P, Hoffman SC, Helzlsouer KJ. Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in Washington county, Maryland.
PPAR Res. 2008: 276581 (2008).
*
-
Gambero A, Marostica M, Abdalla Saad MJ, Pedrazzoli J. Mesenteric adipose tissue alterations resulting from experimental reactivated colitis.
Inflamm. Bowel Dis. 13: 1357-1364 (2007).
*
-
Gampe RT Jr, Montana VG, Lambert MH, Miller AB, Bledsoe RK, Milburn MV, Kliewer SA, Willson TM, Xu HE. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors.
Mol. Cell 5: 545-555 (2000).
*
-
Gan Q, Huang J, Zhou R, Niu J, Zhu X, Wang J, Zhang Z, Tong T. PPARgamma accelerates cellular senescence by inducing p16INK4alpha expression in human diploid fibroblasts.
J. Cell. Sci. 121: 2235-2245 (2008).
*
-
Gani OA. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
Cardiovasc. Diabetol. 7: 6 (2008).
*
-
Gani OA, Sylte I. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
J. Mol. Graph Model. 27: 217-224 (2008).
*
-
Garcia-Bates TM, Baglole CJ, Bernard MP, Murant TI, Simpson-Haidaris PJ, Phipps RP. Peroxisome proliferator-activated receptor gamma ligands enhance human B cell antibody production and differentiation.
J. Immunol. 183: 6903-6912 (2009).
-
Garcia-Bueno B, Caso JR, Perez-Nievas BG, Lorenzo P, Leza JC. Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats.
Neuropsychopharmacology 32: 1251-1260 (2007).
-
Garcia-Bueno B, Madrigal JL, Perez-Nievas BG, Leza JC. Stress mediators regulate brain prostaglandin synthesis and peroxisome proliferator-activated receptor-gamma activation after stress in rats.
Endocrinology 149: 1969-1978 (2008).
*
-
Garcia-Rojas P, Antaramian A, Gonzalez-Davalos L, Villarroya F, Shimada A, Varela-Echavarria A, Mora O. Induction of PPARgamma and PGC-1alpha by unsaturated fatty acids, retinoic acid, and carotenoids in preadipocytes obtained from bovine white adipose tissue.
J. Anim. Sci. Feb 12 [Epub ahead of print] (2010).
*
-
Garcia-Verdugo I, Tattermusch S, Leduc D, Dif F, Touqui L. Regulation of MUC5AC expression by arachidonic acid metabolites.
Rev. Mal. Respir. 25: 1187 (2008).
-
Gardner OS, Dewar BJ, Graves LM. Activation of mitogen-activated protein kinases by peroxisome proliferator-activated receptor ligands: an example of non-genomic signaling.
Mol. Pharmacol. 68: 933-941 (2005).
*
-
Garenc C, Aubert S, Laroche J, Girouard J, Vohl MC, Bergeron J, Rousseau F, Julien P. Population prevalence of APOE, APOC3 and PPAR-alpha mutations associated to hypertriglyceridemia in French Canadians.
J. Hum. Genet. 49: 691-700 (2004).
*
-
Garzon B, Gayarre J, Gharbi S, Diez-Dacal B, Sanchez-Gomez FJ, Timms JF, Perez-Sala D. A biotinylated analog of the anti-proliferative prostaglandin A(1) allows assessment of PPAR-independent effects and identification of novel cellular targets for covalent modification.
Chem. Biol. Interact. 183: 212-221 (2010).
*
-
Gatfield D, Le Martelot G, Vejnar CE, Gerlach D, Schaad O, Fleury-Olela F, Ruskeepaa AL, Oresic M, Esau CC, Zdobnov EM, Schibler U. Integration of microRNA miR-122 in hepatic circadian gene expression.
Genes Dev. 23: 1313-1326 (2009).
*
-
Gatica A, Aguilera MC, Contador D, Loyola G, Pinto CO, Amigo L, Tichauer JE, Zanlungo S, Bronfman M. The cytochromes P450 CYP2C epoxygenase and CYP4A omega-hydroxylase mediate ciprofibrate-induced PPAR alpha-dependent peroxisomal proliferation in isolated rat liver cells.
J. Lipid Res. 48: 924-934 (2007).
*
-
Gaudel C, Schwartz C, Giordano C, Abumrad NA, Grimaldi P. Pharmacological activation of PPARbeta promotes rapid and calcineurin-dependent fiber remodeling and angiogenesis in mouse skeletal muscle.
Am. J. Physiol. Endocrinol. Metab. 295: E297-E304 (2008).
*
-
Gaudel CL, Grimaldi PA. Metabolic functions of peroxisome proliferator-activated receptor beta/delta in skeletal muscle.
PPAR Res. 2007: 86394 (2007).
*
-
Gauglitz GG, Herndon DN, Jeschke MG. Insulin resistance postburn: underlying mechanisms and current therapeutic strategies.
J. Burn Care Res. 29: 683-694 (2008).
-
Gaulton KJ, Willer CJ, Li Y, Scott LJ, Conneely KN, Jackson AU, Duren WL, Chines PS, Narisu N, Bonnycastle LL, Luo J, Tong M, Sprau AG, Pugh EW, Doheny KF, Valle TT, Abecasis GR, Tuomilehto J, Bergman RN, Collins FS, Boehnke M, Mohlke KL. Comprehensive association study of type 2 diabetes and related quantitative traits with 222 candidate genes.
Diabetes 57: 3136-3144 (2008).
*
-
Gayathri SB, Radha V, Vimaleswaran KS, Mohan V. Association of the PPARGC1A gene polymorphism with diabetic nephropathy in an Asian Indian population (CURES-41).
Metab. Syndr. Relat. Disord. Nov 9 [Epub ahead of print] (2009).
-
Gbaguidi GF, Agellon LB. The atypical interaction of peroxisome proliferator-activated receptor alpha with liver X receptor alpha antagonizes the stimulatory effect of their respective ligands on the murine cholesterol 7alpha-hydroxylase gene promoter.
Biochim. Biophys. Acta 1583: 229-236 (2002).
*
-
Gbaguidi GF, Agellon LB. The inhibition of the human cholesterol 7alpha-hydroxylase gene (CYP7A1) promoter by fibrates in cultured cells is mediated via the liver X receptor alpha and peroxisome proliferator-activated receptor alpha heterodimer.
Nucleic Acids Res. 32: 1113-1121 (2004).
*
-
Ge K, Cho YW, Guo H, Hong TB, Guermah M, Ito M, Yu H, Kalkum M, Roeder RG. Alternative mechanisms by which mediator subunit MED1/TRAP220 regulates peroxisome proliferator-activated receptor gamma-stimulated adipogenesis and target gene expression.
Mol. Cell. Biol. 28: 1081-1091 (2008).
*
-
Gealekman O, Burkart A, Chouinard M, Nicoloro S, Straubhaar J, Corvera S. Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production.
Am. J. Physiol. Endocrinol. Metab. 295: E1056-E1064 (2008).
*
-
Geese WJ, Achanzar W, Rubin C, Hariharan N, Cheng P, Tomlinson L, Ordway N, Dracopoli NC, Delmonte T, Hui L, Krishnan B, Cosma G, Ranade K. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
Pharmacogenet. Genomics 18: 903-910 (2008).
-
Geldenhuys WJ, Funk MO, Barnes KF, Carroll RT. Structure-based design of a thiazolidinedione which targets the mitochondrial protein mitoNEET.
Bioorg. Med. Chem. Lett. Jan 4 [Epub ahead of print] (2010).
*
-
Gelinas DS, McLaurin J. PPAR-alpha expression inversely correlates with inflammatory cytokines IL-1beta and TNF-alpha in aging rats.
Neurochem. Res. 30: 1369-1375 (2005).
*
-
Gelinas R, Labarthe F, Bouchard B, Janie MD, Guy C, Young ME, Des Rosiers C. Alterations in carbohydrate metabolism and its regulation in PPAR alpha null mouse hearts.
Am. J. Physiol. Heart Circ. Physiol. 294: H1571-H1580 (2008).
*
-
Gelman L, Feige JN, Desvergne B. Molecular basis of selective PPARgamma modulation for the treatment of type 2 diabetes.
Biochim. Biophys. Acta 1771: 1094-1107 (2007).
*
-
Gelman L, Fruchart JC, Auwerx J. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer.
Cell. Mol. Life Sci. 55: 932-943 (1999).
*
-
Gelman L, Michalik L, Desvergne B, Wahli W. Kinase signaling cascades that modulate peroxisome proliferator-activated receptors.
Curr. Opin. Cell Biol. 17: 216-222 (2005).
*
-
Genini D, Carbone GM, Catapano CV. Multiple interactions between peroxisome proliferators-activated receptors and the ubiquitin-proteasome system and implications for cancer pathogenesis.
PPAR Res. 2008: 195065 (2008).
*
-
Genini D, Catapano CV. Block of nuclear receptor ubiquitination. A mechanism of ligand-dependent control of peroxisome proliferator-activated receptor delta activity.
J. Biol. Chem. 282: 11776-11785 (2007).
*
-
Genini D, Catapano CV. Control of peroxisome proliferator-activated receptor fate by the ubiquitin-proteasome system.
J. Recept. Signal Transduct. Res. 26: 679-692 (2006).
-
Genolet R, Wahli W, Michalik L. PPARs as drug targets to modulate inflammatory responses?
Curr. Drug Targets Inflamm. Allergy 3: 361-375 (2004).
-
Genovese T, Esposito E, Mazzon E, Crisafulli C, Paterniti I, Di Paola R, Galuppo M, Bramanti P, Cuzzocrea S. PPAR-alpha modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma.
Pharmacol. Res. 59: 338-350 (2009).
*
-
Genovese T, Esposito E, Mazzon E, Di Paola R, Meli R, Bramanti P, Piomeli D, Calignano A, Cuzzocrea S. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury.
J. Pharmacol. Exp. Ther. 326: 12-23 (2008).
*
-
Genovese T, Mazzon E, Di Paola R, Muia C, Crisafulli C, Caputi AP, Cuzzocrea S. Role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor-alpha in the development of bleomycin-induced lung injury.
Shock 24: 547-555 (2005).
*
-
Genovese T, Mazzon E, Di Paola R, Muia C, Crisafulli C, Malleo G, Esposito E, Cuzzocrea S. Role of peroxisome proliferator-activated receptor-alpha in acute pancreatitis induced by cerulein.
Immunology 118: 559-570 (2006).
*
-
George J, Liddle C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets.
Mol. Pharm. 5: 49-59 (2008).
*
-
Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis.
World J. Gastroenterol. 15: 942-954 (2009).
*
-
Gerhold DL, Liu F, Jiang G, Li Z, Xu J, Lu M, Sachs JR, Bagchi A, Fridman A, Holder DJ, Doebber TW, Berger J, Elbrecht A, Moller DE, Zhang BB. Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists.
Endocrinology 143: 2106-2118 (2002).
*
-
Gerin I, Bommer GT, Lidell ME, Cederberg A, Enerback S, Macdougald OA. On the role of FOX transcription factors in adipocyte differentiation and insulin-stimulated glucose uptake.
J. Biol. Chem. 284: 10755-10763 (2009).
*
-
Gervois P, Chopin-Delannoy S, Fadel A, Dubois G, Kosykh V, Fruchart JC, Najïb J, Laudet V, Staels B. Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element.
Mol. Endocrinol. 13: 400-409 (1999).
*
-
Gervois P, Fruchart JC, Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
Nat. Clin. Pract. Endocrinol. Metab. 3: 145-156 (2007).
*
-
Gervois P, Fruchart JC, Staels B. Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARalpha and PPARgamma agonists.
Int. J. Clin. Pract. Suppl. 143: 22-29 (2004).
-
Gervois P, Kleemann R, Pilon A, Percevault F, Koenig W, Staels B, Kooistra T. Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate.
J. Biol. Chem. 279: 16154-1660 (2004).
*
-
Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators.
Clin. Chem. Lab. Med. 38: 3-11 (2000).
-
Ghanaat-Pour H, Sjoholm A. Gene expression regulated by pioglitazone and exenatide in normal and diabetic rat islets exposed to lipotoxicity.
Diabetes Metab. Res. Rev. 25: 163-184 (2009).
-
Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, Varga J. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator.
FASEB J. 23: 2968-2977 (2009).
*
-
Ghosh AK, Wei J, Wu M, Varga J. Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptor-gamma.
Biochem. Biophys. Res. Commun. 374: 231-236 (2008).
*
-
Ghosh M, Ai Y, Narko K, Wang Z, Peters JM, Hla T. PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer.
Prostaglandins Other Lipid Mediat. 88: 97-100 (2009).
-
Ghosh M, Wang H, Ai Y, Romeo E, Luyendyk JP, Peters JM, Mackman N, Dey SK, Hla T. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation.
J. Exp. Med. 204: 2053-2061 (2007).
*
-
Ghoussaini M, Meyre D, Lobbens S, Charpentier G, Clement K, Charles MA, Tauber M, Weill J, Froguel P. Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population.
BMC Med. Genet. 6: 11 (2005).
*
-
Giaginis C, Giagini A, Theocharis S. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis.
Pharmacol. Res. 60: 160-169 (2009).
*
-
Giaginis C, Katsamangou E, Tsourouflis G, Zizi-Serbetzoglou D, Kouraklis G, Theocharis S. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival.
Med. Sci. Monit. 15: BR148-BR156 (2009).
-
Giaginis C, Margeli A, Theocharis S. Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis.
Expert Opin. Investig. Drugs 16: 1561-1572 (2007).
-
Giaginis C, Spanopoulou E, Theocharis S. PPAR-gamma signaling pathway in placental development and function: a potential therapeutic target in the treatment of gestational diseases.
Expert Opin. Ther. Targets 12: 1049-1063 (2008).
-
Giaginis C, Theocharis S, Tsantili-Kakoulidou A. Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 857: 181-187 (2007).
-
Giaginis C, Theocharis S, Tsantili-Kakoulidou A. Quantitative structure-activity relationships for PPAR-gamma binding and gene transactivation of tyrosine-based agonists using multivariate statistics.
Chem. Biol. Drug Des. 72: 257-264 (2008).
-
Giaginis C, Theocharis S, Tsantili-Kakoulidou A. Structural basis for the design of PPAR-gamma ligands: a survey on quantitative structure-activity relationships.
Mini Rev. Med. Chem. 9: 1075-1083 (2009).
-
Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptor-gamma ligands as bone turnover modulators.
Expert Opin. Investig. Drugs 16: 195-207 (2007).
-
Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
Fundam. Clin. Pharmacol. 21: 231-244 (2007).
*
-
Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptor-gamma ligands: potential pharmacological agents for targeting the angiogenesis signaling cascade in cancer.
PPAR Res. 2008: 431763 (2008).
*
-
Giaginis C, Tsourouflis G, Theocharis S. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury.
Curr. Mol. Med. 8: 562-579 (2008).
-
Giercksky KE. COX-2 inhibition and prevention of cancer.
Best Pract. Res. Clin. Gastroenterol. 15: 821-833 (2001).
*
-
Gilde AJ, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors at the crossroads of obesity, diabetes, and cardiovascular disease.
J. Am. Coll. Cardiol. 48: A24-A32 (2006).
-
Gilde AJ, Van Bilsen M. Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle.
Acta Physiol. Scand. 178: 425-434 (2003).
*
-
Gilles S, Mariani V, Bryce M, Mueller MJ, Ring J, Jakob T, Pastore S, Behrendt H, Traidl-Hoffmann C. Pollen-derived E1-phytoprostanes signal via PPAR-gamma and NF-kappaB-dependent mechanisms.
J. Immunol. 182: 6653-6658 (2009).
-
Gillio-Meina C, Phang S, Mather J, Knight B, Kennedy T. Expression patterns and role of prostaglandin-endoperoxide synthases, prostaglandin E synthases, prostacyclin synthase, prostacyclin receptor, peroxisome proliferator-activated receptor delta (PPARD) and retinoid X receptor alpha (RXRA) in rat …
Reproduction 137: 537-552 (2009).
-
Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, Kliewer SA, Lehmann JM, Morris DC. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
Mol. Pharmacol. 50: 1087-1094 (1996).
*
-
Giordano TJ, Au AY, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG Jr, Vinco M, Misek DE, Sanders D, Zhu Z, Ciampi R, Hanash S, Chinnaiyan A, Clifton-Bligh RJ, Robinson BG, Nikiforov YE, Koenig RJ. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.
Clin. Cancer Res. 12: 1983-1993 (2006).
*
-
Giral H, Villa-Bellosta R, Catalan J, Sorribas V. Cytotoxicity of peroxisome proliferator-activated receptor alpha and gamma agonists in renal proximal tubular cell lines.
Toxicol. In Vitro 21: 1066-1076 (2007).
-
Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM. Synergy between PPARgamma ligands and platinum-based drugs in cancer.
Cancer Cell 11: 395-406 (2007).
*
-
Giros A, Grzybowski M, Sohn VR, Pons E, Fernandez-Morales J, Xicola RM, Sethi P, Grzybowski J, Goel A, Boland CR, Gassull MA, Llor X. Regulation of colorectal cancer cell apoptosis by the n-3 polyunsaturated fatty acids docosahexaenoic and eicosapentaenoic.
Cancer Prev. Res. (Phila. Pa) 2: 732-742 (2009).
-
Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, Sevestre H, Krimpenfort P, Corsini A, Rochette J, Glineur C, Fruchart JC, Torpier G, Staels B. PPARalpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16.
J. Clin. Invest. 115: 3228-3238 (2005).
*
-
Gizard F, Bruemmer D. Transcriptional control of vascular smooth muscle cell proliferation by peroxisome proliferator-activated receptor-gamma: therapeutic implications for cardiovascular diseases.
PPAR Res. 2008: 429123 (2008).
*
-
Gizard F, Nomiyama T, Zhao Y, Findeisen HM, Heywood EB, Jones KL, Staels B, Bruemmer D. The PPARalpha/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation.
Circ. Res. 103: 1155-1163 (2008).
*
-
Glass CK, Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity.
Nat. Rev. Immunol. 6: 44-55 (2006).
*
-
Gloerich J, Ijlst L, Wanders RJ, Ferdinandusse S. Bezafibrate induces FALDH in human fibroblasts; implications for Sjogren-Larsson syndrome.
Mol. Genet. Metab. 89: 111-115 (2006).
*
-
Gloerich J, van den Brink DM, Ruiter JP, van Vlies N, Vaz FM, Wanders RJ, Ferdinandusse S. Metabolism of phytol to phytanic acid in the mouse and the role of PPARalpha in its regulation.
J. Lipid Res. 48: 77-85 (2007).
*
-
Gocke AR, Hussain RZ, Yang Y, Peng H, Weiner J, Ben LH, Drew PD, Stuve O, Lovett-Racke AE, Racke MK. Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-alpha agonists in autoimmune disease.
J. Immunol. 182: 4479-4487 (2009).
-
Goetzman ES. The regulation of acyl-CoA dehydrogenases in adipose tissue by rosiglitazone.
Obesity (Silver Spring) 17: 196-198 (2009).
*
-
Goetzman ES, Tian L, Wood PA. Differential induction of genes in liver and brown adipose tissue regulated by peroxisome proliferator-activated receptor-alpha during fasting and cold exposure in acyl-CoA dehydrogenase-deficient mice.
Mol. Genet. Metab. 84: 39-47 (2005).
*
-
Gogolak P, Rethi B, Szatmari I, Lanyi A, Dezso B, Nagy L, Rajnavolgyi E. Differentiation of CD1a- and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPARgamma.
Blood 109: 643-652 (2007).
*
-
Gohlke JM, Thomas R, Zhang Y, Rosenstein MC, Davis AP, Murphy C, Becker KG, Mattingly CJ, Portier CJ. Genetic and environmental pathways to complex diseases.
BMC Syst. Biol. 3: 46 (2009).
*
-
Goke B, Gause-Nilsson I, Persson A; On Behalf Of The Gallant 8 Study Group. The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes.
Diab. Vasc. Dis. Res. 4: 204-213 (2007).
-
Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP. Effect of tesaglitazar, a dual PPARalpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
Curr. Med. Res. Opin. 22: 2575-2590 (2006).
-
Golembesky AK, Gammon MD, North KE, Bensen JT, Schroeder JC, Teitelbaum SL, Neugut AI, Santella RM. Peroxisome proliferator-activated receptor-alpha (PPARA) genetic polymorphisms and breast cancer risk: a Long Island ancillary study.
Carcinogenesis 29: 1944-1949 (2008).
*
-
Gollamudi R, Gupta D, Goel S, Mani S. Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism.
Curr. Drug Metab. 9: 611-613 (2008).
-
Golledge J, Cullen B, Rush C, Moran CS, Secomb E, Wood F, Daugherty A, Campbell JH, Norman PE. Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm.
Atherosclerosis Oct 29 [Epub ahead of print] (2009).
-
Gomes Mde B. Glitazones and the metabolic syndrome: mechanism of action, pathophysiology and therapeutic indications.
Arq. Bras. Endocrinol. Metabol. 50: 271-280 (2006).
-
Gong H, Xie W. Orphan nuclear receptors, PXR and LXR: new ligands and therapeutic potential.
Expert Opin. Ther. Targets 8: 49-54 (2004).
-
Gong X, Tsai SW, Yan B, Rubin LP. Cooperation between MEF2 and PPARgamma in human intestinal beta,beta-carotene 15,15'-monooxygenase gene expression.
BMC Mol. Biol. 7: 7 (2006).
*
-
Gong Z, Huang C, Sheng X, Zhang Y, Li Q, Wang MW, Peng L, Zang YQ. The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism.
Endocrinology 150: 104-113 (2009).
*
-
Gong Z, Xie D, Deng Z, Bostick RM, Muga SJ, Hurley TG, Hebert JR. The PPARgamma Pro12Ala polymorphism and risk for incident sporadic colorectal adenomas.
Carcinogenesis 26: 579-585 (2005).
*
-
Gonthier MP, Hoareau L, Festy F, Matias I, Valenti M, Bes-Houtmann S, Rouch C, Robert-Da Silva C, Chesne S, Lefebvre d'Hellencourt C, Cesari M, Di Marzo V, Roche R. Identification of endocannabinoids and related compounds in human fat cells.
Obesity (Silver Spring) 15: 837-845 (2007).
*
-
Gonzalez FJ. Recent update on the PPAR alpha-null mouse.
Biochimie 79: 139-144 (1997).
-
Gonzalez FJ, Cheung C. Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment.
J. Pharmacol. Exp. Ther. 327: 288-299 (2008).
*
-
Gonzalez FJ, Fernandez-Salguero P, Lee SS, Pineau T, Ward JM. Xenobiotic receptor knockout mice.
Toxicol. Lett. 82-83: 117-121 (1995).
-
Gonzalez FJ, Shah YM. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators.
Toxicology 246: 2-8 (2008).
*
-
Gonzalez R, Collado JA, Nell S, Briceno J, Tamayo MJ, Fraga E, Bernardos A, Lopez-Cillero P, Pascussi JM, Rufian S, Vilarem MJ, Mata Mde L, Brigelius-Flohe R, Maurel P, Muntane J. Cytoprotective properties of alpha-tocopherol are related to gene regulation in cultured D-galactosamine-treated human hepatocytes.
Free Radic. Biol. Med. 43: 1439-1452 (2007).
-
Gonzalez-Periz A, Planaguma A, Gronert K, Miquel R, Lopez-Parra M, Titos E, Horrillo R, Ferre N, Deulofeu R, Arroyo V, Rodes J, Claria J. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA.
FASEB J. 20: 2537-2539 (2006).
*
-
Gopinathan L, Hannon DB, Peters JM, Vanden Heuvel JP. Regulation of peroxisome proliferator-activated receptor-alpha by MDM2.
Toxicol. Sci. 108: 48-58 (2009).
*
-
Gopinathan L, Hannon DB, Smith Iii RW, Peters JM, Vanden Heuvel JP. Regulation of peroxisome proliferator-activated receptors by E6-associated protein.
PPAR Res. 2008: 746935 (2008).
*
-
Gordon JN, Sabatino AD, Macdonald TT. The pathophysiologic rationale for biological therapies in inflammatory bowel disease.
Curr. Opin. Gastroenterol. 21: 431-437 (2005).
-
Gorla-Bajszczak A, Juge-Aubry C, Pernin A, Burger AG, Meier CA. Conserved amino acids in the ligand-binding and tau(i) domains of the peroxisome proliferator-activated receptor alpha are necessary for heterodimerization with RXR.
Mol. Cell. Endocrinol. 147: 37-47 (1999).
-
Goto T, Takahashi N, Kato S, Egawa K, Ebisu S, Moriyama T, Fushiki T, Kawada T. Phytol directly activates peroxisome proliferator-activated receptor alpha (PPARalpha) and regulates gene expression involved in lipid metabolism in PPARalpha-expressing HepG2 hepatocytes.
Biochem. Biophys. Res. Commun. 337: 440-445 (2005).
*
-
Gotoh S, Ohgari Y, Nakamura T, Osumi T, Taketani S. Heme-binding to the nuclear receptor retinoid X receptor alpha (RXRalpha) leads to the inhibition of the transcriptional activity.
Gene 423: 207-214 (2008).
*
-
Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis.
Am. J. Epidemiol. Feb 23 [Epub ahead of print] (2010).
-
Gould Rothberg BE, Sundseth SS, DiPippo VA, Brown PJ, Winegar DA, Gottshalk WK, Shenoy SG, Rothberg JM. The characterization of PPAR alpha ligand drug action in an in vivo model by comprehensive differential gene expression profiling.
Funct. Integr. Genomics 1: 294-304 (2001).
*
-
Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W. The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls.
Atherosclerosis 183: 336-341 (2005).
-
Gouni-Berthold I, Krone W. Peroxisome proliferator-activated receptor alpha (PPARalpha) and athero-sclerosis.
Curr. Drug Targets Cardiovasc. Haematol. Disord. 5: 513-523 (2005).
-
Goyenechea E, Dolores Parra M, Alfredo Martinez J. Weight regain after slimming induced by an energy-restricted diet depends on interleukin-6 and peroxisome-proliferator-activated-receptor-gamma2 gene polymorphisms.
Br. J. Nutr. 96: 965-972 (2006).
*
-
Grabacka M, Plonka PM, Urbanska K, Reiss K. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt.
Clin. Cancer Res. 12: 3028-3036 (2006).
*
-
Grabacka M, Reiss K. Anticancer properties of PPARalpha - effects on cellular metabolism and inflammation.
PPAR Res. 2008: 930705 (2008).
*
-
Graham A. Curcumin adds spice to the debate: lipid metabolism in liver disease.
Br. J. Pharmacol. 157: 1352-1353 (2009).
*
-
Grau R, Diaz-Munoz MD, Cacheiro-Llaguno C, Fresno M, Iniguez MA. Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.
PPAR Res. 2008: 352437 (2008).
*
-
Gray SL, Dalla Nora E, Vidal-Puig AJ. Mouse models of PPAR-gamma deficiency: dissecting PPAR-gamma's role in metabolic homoeostasis.
Biochem. Soc. Trans. 33: 1053-1058 (2005).
*
-
Green S. PPAR: a mediator of peroxisome proliferator action.
Mutat. Res. 333: 101-109 (1995).
-
Green S, Wahli W. Peroxisome proliferator-activated receptors: finding the orphan a home.
Mol. Cell. Endocrinol. 100: 149-153 (1994).
*
-
Greger DL, Gropp F, Morel C, Sauter S, Blum JW. Nuclear receptor and target gene mRNA abundance in duodenum and colon of dogs with chronic enteropathies.
Domest. Anim. Endocrinol. 31: 327-329 (2006).
*
-
Gregoire FM, Zhang F, Clarke HJ, Gustafson TA, Sears DD, Favelyukis S, Lenhard J, Rentzeperis D, Clemens LE, Mu Y, Lavan BE. MBX-102/JNJ39659100, a novel peroxisome proliferator activated receptor-gamma ligand with weak transactivation activity retains full anti-diabetic properties in the absence of side effects.
Mol. Endocrinol. 23: 975-988 (2009).
*
-
Gremlich S, Nolan C, Roduit R, Burcelin R, Peyot ML, Delghingaro-Augusto V, Desvergne B, Michalik L, Prentki M, Wahli W. Pancreatic islet adaptation to fasting is dependent on PPARalpha transcriptional up-regulation of fatty acid oxidation.
Endocrinology 146: 375-382 (2005).
*
-
Grenier E, Schwalm Maupas F, Beaulieu JF, Seidman EG, Delvin E, Sane AT, Tremblay E, Garofalo C, Levy E. Effect of retinoic acid on cell proliferation and differentiation as well as on lipid synthesis, lipoprotein secretion and apolipoprotein biogenesis.
Am. J. Physiol. Gastrointest. Liver Physiol. 293: G1178-G1189 (2007).
*
-
Gressner OA, Gao C, Rehbein K, Lahme B, Siluschek M, Berg T, Muller T, Gressner AM. Elevated concentrations of 15-deoxy-delta12,14-prostaglandin J2 in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor gamma-inducing drugs.
Liver Int. 29: 730-735 (2009).
*
-
Grey A. Thiazolidinedione-induced skeletal fragility - mechanisms and implications.
Diabetes Obes. Metab. 11: 275-284 (2009).
*
-
Griesbacher T, Pommer V, Schuligoi R, Tiran B, Peskar BA. Anti-inflammatory actions of perfluorooctanoic acid and peroxisome proliferator-activated receptors (PPAR) alpha and gamma in experimental acute pancreatitis.
Int. Immunopharmacol. 8: 325-329 (2008).
-
Grimaldi PA. Regulatory functions of PPARbeta in metabolism: implications for the treatment of metabolic syndrome.
Biochim. Biophys. Acta 1771: 983-990 (2007).
*
-
Grimaldi PA. Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives.
Cell. Mol. Life Sci. 64: 2459-2464 (2007).
*
-
Grobe JL, Venegas-Pont MR, Sigmund CD, Ryan MJ. The PPARgamma agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 296: R1325-R1326 (2009).
*
-
Gross B, Staels B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
Best Pract. Res. Clin. Endocrinol. Metab. 21: 687-710 (2007).
-
Grozovsky R, Ribich S, Rosene ML, Mulcahey MA, Huang SA, Patti ME, Bianco AC, Kim BW. Type 2 deiodinase expression is induced by PPAR-gamma agonists in skeletal myocytes.
Endocrinology 150: 1976-1983 (2009).
*
-
Grun F, Watanabe H, Zamanian Z, Maeda L, Arima K, Chubacha R, Gardiner DM, Kanno J, Iguchi T, Blumberg B. Endocrine disrupting organotin compounds are potent inducers of adipogenesis in vertebrates.
Mol. Endocrinol. 20: 2141-2155 (2006).
*
-
Gu BH, Baek KH. Pro12Ala and His447His polymorphisms of PPAR-gamma are associated with polycystic ovary syndrome.
Reprod. Biomed. Online 18: 644-650 (2009).
-
Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.
J. Am. Soc. Nephrol. 15: 2801-2815 (2004).
*
-
Guan Y. Targeting peroxisome proliferator-activated receptors (PPARs) in kidney and urologic disease.
Minerva Urol. Nefrol. 54: 65-79 (2002).
-
Guan Y, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease.
Kidney Int. 60: 14-30 (2001).
*
-
Guan Y, Zhang Y, Breyer MD. The role of PPARs in the transcriptional control of cellular processes.
Drug News Perspect. 15: 147-154 (2002).
-
Gudbrandsen OA, Rodríguez E, Wergedahl H, Mørk S, Reseland JE, Skorve J, Palou A, Berge RK. Trans-10, cis-12-conjugated linoleic acid reduces the hepatic triacylglycerol content and the leptin mRNA level in adipose tissue in obese Zucker fa/fa rats.
Br. J. Nutr. 102: 803-815 (2009).
*
-
Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G, Staels B. PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance.
Diabetes 50: 2809-2814 (2001).
*
-
Guettier JM, Park JY, Cochran EK, Poitou C, Basdevant A, Meier M, Clement K, Magre J, Gorden P. Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation.
Clin. Endocrinol. (Oxf.) 68: 547-554 (2008).
*
-
Gui Y, Cai Z, Silha JV, Murphy LJ. Variations in parametrial white adipose tissue mass during the mouse estrous cycle: relationship with the expression of peroxisome proliferator-activated receptor-gamma and retinoic acid receptor-alpha.
Can. J. Physiol. Pharmacol. 84: 887-892 (2006).
-
Guignabert C, Alvira CM, Alastalo TP, Sawada H, Hansmann G, Zhao M, Wang L, El-Bizri N, Rabinovitch M. Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF-receptor beta-dependant pulmonary arterial muscularization.
Am. J. Physiol. Lung Cell. Mol. Physiol. 297: L1082-L1090 (2009).
*
-
Guilherme A, Tesz GJ, Guntur KV, Czech MP. Tumor necrosis factor-alpha induces caspase-mediated cleavage of peroxisome proliferator-activated receptor gamma in adipocytes.
J. Biol. Chem. 284: 17082-17091 (2009).
*
-
Guillot N, Debard C, Calzada C, Vidal H, Lagarde M, Vericel E. Effects of docosahexaenoic acid on some megakaryocytic cell gene expression of some enzymes controlling prostanoid synthesis.
Biochem. Biophys. Res. Commun. 372: 924-928 (2008).
*
-
Guillou H, Martin P, Jan S, D'Andrea S, Roulet A, Catheline D, Rioux V, Pineau T, Legrand P. Comparative effect of fenofibrate on hepatic desaturases in wild-type and peroxisome proliferator-activated receptor alpha-deficient mice.
Lipids 37: 981-989 (2002).
-
Gundling F, Schumm-Draeger PM, Schepp W. Hepatogenous diabetes - diagnostics and treatment.
Z. Gastroenterol. 47: 436-445 (2009).
-
Gundling F, Seidl H, Loffler N, Strassen I, Schepp W. Metabolic disturbances in liver cirrhosis (part 2), hepatogenous diabetes.
Dtsch. Med. Wochenschr. 135: 22-24 (2010).
-
Gunther T, Schule R. Fat or bone? A non-canonical decision.
Nat. Cell Biol. 9: 1229-1231 (2007).
*
-
Guntur KV, Guilherme A, Xue L, Chawla A, Czech MP. Map4k4 negatively regulates PPARgamma protein translation by suppressing the mTOR signaling pathway in cultured adipocytes.
J. Biol. Chem. Dec 28 [Epub ahead of print] (2009).
*
-
Guo CB, Li S. Advances in the study of anti-atherosclerosis drugs.
Yao Xue Xue Bao 42: 231-235 (2007).
-
Guo D, Sarkar J, Ahmed MR, Viswakarma N, Jia Y, Yu S, Sambasiva Rao M, Reddy JK. Peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP) but not PPAR-interacting protein (PRIP) is required for nuclear translocation of constitutive androstane receptor in mouse liver.
Biochem. Biophys. Res. Commun. 347: 485-495 (2006).
*
-
Guo D, Sarkar J, Suino-Powell K, Xu Y, Matsumoto K, Jia Y, Yu S, Khare S, Haldar K, Rao MS, Foreman JE, Monga SP, Peters JM, Xu HE, Reddy JK. Induction of nuclear translocation of constitutive androstane receptor by peroxisome proliferator-activated receptor alpha synthetic ligands in mouse liver.
J. Biol. Chem. 282: 36766-36776 (2007).
*
-
Guo GL, Choudhuri S, Klaassen CD. Induction profile of rat organic anion transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme inducers that activate gene expression through ligand-activated transcription factor pathways.
J. Pharmacol. Exp. Ther. 300: 206-212 (2002).
*
-
Guo H, Zhang XJ, Wang F, Wang Y, Shen Y, Zhao JJ, Gao L. Suppression effects of AICAR on insulin secretion involved in peroxisome proliferator-activated receptor gamma changes in INS-1 cells.
J. Endocrinol. Invest. Jan 22 [Epub ahead of print] (2010).
-
Guo L, Fang H, Collins J, Fan XH, Dial S, Wong A, Mehta K, Blann E, Shi L, Tong W, Dragan YP. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.
BMC Bioinformatics 7: S18 (2006).
*
-
Guo L, Hu WR, Lian JH, Ji W, Deng T, Qian M, Gong BQ. Anti-hyperlipidemic properties of CM108 (a flavone derivative) in vitro and in vivo.
Eur. J. Pharmacol. 551: 80-86 (2006).
*
-
Guo L, Zhang L, Sun Y, Muskhelishvili L, Blann E, Dial S, Shi L, Schroth G, Dragan YP. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells.
Mol. Divers. 10: 349-360 (2006).
-
Guo Q, Wang G, Namura S. Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice.
J. Cereb. Blood Flow Metab. Sep 2 [Epub ahead of print] (2009).
-
Gupta D, Jetton TL, Mortensen RM, Zhong Duan S, Peshavaria M, Leahy JL. In vivo and in vitro studies of a functional peroxisome proliferator-activated receptor gamma response element in the mouse PDX-1 promoter.
J. Biol. Chem. 283: 32462-32470 (2008).
*
-
Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer.
Proc. Natl. Acad. Sci. U.S.A. 97: 13275-13280 (2000).
*
-
Guri AJ, Hontecillas R, Bassaganya-Riera J. Dietary modulators of peroxisome proliferator-activated receptors: implications for the prevention and treatment of metabolic syndrome.
J. Nutrigenet. Nutrigenomics 1: 126-135 (2008).
-
Gurley C, Nichols J, Liu S, Phulwani NK, Esen N, Kielian T. Microglia and astrocyte activation by Toll-like receptor ligands: modulation by PPAR-gamma agonists.
PPAR Res. 2008: 453120 (2008).
*
-
Gurnell M. 'Striking the right balance' in targeting PPARgamma in the metabolic syndrome: novel insights from human genetic studies.
PPAR Res. 2007: 83593 (2007).
*
-
Gurnell M, Chatterjee VK. Nuclear receptors in disease: thyroid receptor beta, peroxisome-proliferator-activated receptor gamma and orphan receptors.
Essays Biochem. 40: 169-189 (2004).
-
Gurnell M, Wentworth JM, Agostini M, Adams M, Collingwood TN, Provenzano C, Browne PO, Rajanayagam O, Burris TP, Schwabe JW, Lazar MA, Chatterjee VK. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.
J. Biol. Chem. 275: 5754-5759 (2000).
*
-
Gustafsson MC, Knight D, Palmer CN. Ligand modulated antagonism of PPARgamma by genomic and non-genomic actions of PPARdelta.
PLoS One 4: e7046 (2009).
*
-
Gutgesell A, Ringseis R, Brandsch C, Stangl GI, Hirche F, Eder K. Peroxisome proliferator-activated receptor alpha and enzymes of carnitine biosynthesis in the liver are down-regulated during lactation in rats.
Metabolism 58: 226-232 (2009).
*
-
Gutierrez PT, Folch-Puy E, Bulbena O, Closa D. Oxidized lipids present in ascitic fluid interferes the regulation of the macrophages during acute pancreatitis, promoting an exacerbation of the inflammatory response.
Gut 57: 642-648 (2008).
-
Guyton KZ, Chiu WA, Bateson TF, Jinot J, Scott CS, Brown RC, Caldwell JC. A reexamination of the PPAR-alpha activation mode of action as a dasis for assessing human cancer risks of environmental contaminants.
Environ. Health Perspect. 117: 1664-1672 (2009).
*
-
Guzman M, Lo Verme J, Fu J, Oveisi F, Blazquez C, Piomelli D. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha).
J. Biol. Chem. 279: 27849-27854 (2004).
*
-
Gyamfi MA, Wan YJ. Mechanisms of resistance of hepatocyte retinoid X receptor alpha-null mice to WY-14,643-induced hepatocyte proliferation and cholestasis.
J. Biol. Chem. 284: 9321-9330 (2009).
*
-
Gyongyosi A, Nagy L. Potential therapeutic use of PPARgamma-programed human monocyte-derived dendritic cells in cancer vaccination therapy.
PPAR Res. 2008: 473804 (2008).
*
-
Hafstad AD, Khalid AM, Hagve M, Lund T, Larsen TS, Severson DL, Clarke K, Berge RK, Aasum E. Cardiac PPARalpha activation causes increased fatty acid oxidation, reducing efficiency and post-ischemic functional loss.
Cardiovasc. Res. 83: 519-526 (2009).
-
Hall JM, McDonnell DP. The molecular mechanisms underlying the pro-inflammatory actions of thiazolidinediones (TZDs) in human macrophages.
Mol. Endocrinol. 21: 1756-1768 (2007).
*
-
Hall MG, Quignodon L, Desvergne B. Peroxisome proliferator-activated receptor beta/delta in the brain: facts and hypothesis.
PPAR Res. 2008: 780452 (2008).
*
-
Haluzik M. Peroxisome proliferator activated receptors (PPAR) and insulin sensitivity: experimental studies.
Cesk. Fysiol. 55: 163-168 (2006).
-
Haluzik M, Anderlova K, Dolelalova R, Adamikova A, Haluzikova D, Housova J, Svacina S, Haluzik M. Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment.
Physiol. Res. 58: 93-99 (2009).
*
-
Haluzik MM, Haluzik M. PPAR-alpha and insulin sensitivity.
Physiol. Res. 55: 115-122 (2006).
*
-
Haluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A, Vernerova Z, Kumstyrova T, Haluzik M. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
Endocrinology 147: 4517-4524 (2006).
*
-
Halvorsen B, Heggen E, Ueland T, Smith C, Sandberg W, Damas J, Otterdal K, Tonstad S, Aukrust P. Treatment with the PPAR-gamma agonist rosiglitazone down-regulates interleukin-1 receptor antagonist in individuals with metabolic syndrome.
Eur. J. Endocrinol. Nov 19 [Epub ahead of print] (2009).
-
Ham SA, Kim HJ, Kim HJ, Kang ES, Eun SY, Kim GH, Park MH, Woo IS, Kim HJ, Chang KC, Lee JH, Seo HG. PPARdelta promotes wound healing by upregulating TGF-beta1-dependent or -independent expression of extracellular matrix proteins.
J. Cell. Mol. Med. Jun 16 [Epub ahead of print] (2009).
*
-
Hamada T, Kotani K, Tsuzaki K, Sano Y, Murata T, Tabata M, Sato S, Sakane N. Association of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene with small dense low-density lipoprotein in the general population.
Metabolism 56: 1345-1349 (2007).
*
-
Hamada Y. Diabetes and bone health. The relationship between insulin resistance and bone metabolism.
Clin. Calcium 19: 1269-1274 (2009).
-
Hamblin M, Chang L, Fan Y, Zhang J, Chen YE. PPARs and the cardiovascular system.
Antioxid. Redox Signal. 11: 1415-1452 (2009).
-
Hamilton G, Proitsi P, Jehu L, Morgan A, Williams J, O'Donovan MC, Owen MJ, Powell JF, Lovestone S. Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci.
Am. J. Med. Genet. B. Neuropsychiatr. Genet. 144: 508-16 (2007).
-
Hammarstedt A, Andersson CX, Rotter Sopasakis V, Smith U. The effect of PPARgamma ligands on the adipose tissue in insulin resistance.
Prostaglandins Leukot. Essent. Fatty Acids 73: 65-75 (2005).
*
-
Hamza MS, Pott S, Vega VB, Thomsen JS, Kandhadayar GS, Ng PW, Chiu KP, Pettersson S, Wei CL, Ruan Y, Liu ET. De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis.
PLoS ONE 4: e4907 (2009).
*
-
Han CY, Kargi AY, Omer M, Chan CK, Wabitsch M, O'Brien KD, Wight TN, Chait A. Differential effect of saturated and unsaturated free fatty acids on the generation of monocyte adhesion and chemotactic factors by adipocytes: dissociation of adipocyte hypertrophy from inflammation.
Diabetes Nov 23 [Epub ahead of print] (2009).
-
Han H, Shin SW, Seo CY, Kwon HC, Han JY, Kim IH, Kwak JY, Park JI. 15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ (2)) sensitizes human leukemic HL-60 cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through Akt downregulation.
Apoptosis 12: 2101-2114 (2007).
*
-
Han JK, Lee HS, Yang HM, Hur J, Jun SI, Kim JY, Cho CH, Koh GY, Peters JM, Park KW, Cho HJ, Lee HY, Kang HJ, Oh BH, Park YB, Kim HS. Peroxisome proliferator-activated receptor-delta agonist enhances vasculogenesis by regulating endothelial progenitor cells through genomic and nongenomic activations of the phosphatidylinositol 3-kinase/Akt pathway.
Circulation 118: 1021-1033 (2008).
*
-
Han JL, Ding RY, Zhao L, Ren Z, Jiang XJ. Rosiglitazone attenuates allergic inflammation and inhibits expression of galectin-3 in a mouse model of allergic rhinitis.
J. Int. Med. Res. 36: 830-836 (2008).
-
Han JY, Kim YJ, Kim L, Choi SJ, Park IS, Kim JM, Chu YC, Cha DR. PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis.
J. Korean Med. Sci. 25: 35-41 (2010).
*
-
Han K, Song H, Moon I, Augustin R, Moley K, Rogers M, Lim H. Utilization of DR1 as true RARE in regulating the Ssm, a novel retinoic acid-target gene in the mouse testis.
J. Endocrinol. 192: 539-551 (2007).
*
-
Han KL, Choi JS, Lee JY, Song J, Joe MK, Jung MH, Hwang JK. Therapeutic potential of peroxisome proliferators-activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
Diabetes 57: 737-745 (2008).
*
-
Han S, Ritzenthaler JD, Zheng Y, Roman J. PPARbeta/delta agonist stimulates human lung carcinoma cell growth through inhibition of PTEN expression: the involvement of PI3-K and NF-kappaB signals.
Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L1238-L1249 (2008).
*
-
Han S, Roman J. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways.
Mol. Cancer Ther. 5: 430-437 (2006).
-
Han S, Sun X, Ritzenthaler JD, Roman J. Fish oil inhibits human lung carcinoma cell growth by suppressing integrin-linked kinase.
Mol. Cancer Res. 7: 108-117 (2009).
*
-
Han SH, Quon MJ, Koh KK. Beneficial vascular and mtabolic effects of peroxisome proliferator-activated receptor-alpha activators.
Hypertension 46: 1086-1092 (2005).
-
Han SW, Roman J. Activated PPARgamma targets surface and intracellular signals that inhibit the proliferation of lung carcinoma cells.
PPAR Res. 2008: 254108 (2008).
*
-
Han X, Benight N, Osuntokun B, Loesch K, Frank S, Denson L. Tumour necrosis factor alpha blockade induces an anti- inflammatory growth hormone signalling pathway in experimental colitis.
Gut 56: 73-81 (2007).
*
-
Han X, Kitamoto S, Lian Q, Boisvert WA. Interleukin-10 facilitates both cholesterol uptake and efflux in macrophages.
J. Biol. Chem. 284: 32950-32958 (2009).
*
-
Han X, Osuntokun B, Benight N, Loesch K, Frank SJ, Denson LA. Signal transducer and activator of transcription 5b promotes mucosal tolerance in pediatric Crohn's disease and murine colitis.
Am. J. Pathol. 169: 1999-2013 (2006).
*
-
Hancock CR, Han DH, Chen M, Terada S, Yasuda T, Wright DC, Holloszy JO. High-fat diets cause insulin resistance despite an increase in muscle mitochondria.
Proc. Natl. Acad. Sci. U.S.A. 105: 7815-7820 (2008).
*
-
Handeli S, Simon JA. A small-molecule inhibitor of Tcf/beta-catenin signaling down-regulates PPARgamma and PPARdelta activities.
Mol. Cancer Ther. 7: 521-529 (2008).
*
-
Hanley K, Jiang Y, Crumrine D, Bass NM, Appel R, Elias PM, Williams ML, Feingold KR. Activators of the nuclear hormone receptors PPARalpha and FXR accelerate the development of the fetal epidermal permeability barrier.
J. Clin. Invest. 100: 705-712 (1997).
*
-
Hansen L, Ekstrom CT, Palacios RT, Anant M, Wassermann K, Reinhardt RR. The Pro12Ala variant of the PPARG gene is a risk factor for PPARgamma/alpha agonist induced edema in type 2 diabetic patients.
J. Clin. Endocrinol. Metab. 91: 3446-3450 (2006).
*
-
Hansen MK, Connolly TM. Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis.
Curr. Opin. Investig. Drugs 9: 247-255 (2008).
-
Hao CY, Moore DH, Wong P, Bennington JL, Lee NM, Chen LC. Alteration of gene expression in macroscopically normal colonic mucosa from individuals with a family history of sporadic colon cancer.
Clin. Cancer Res. 11: 1400-1407 (2005).
*
-
Hao J, Shen W, Yu G, Jia H, Li X, Feng Z, Wang Y, Weber P, Wertz K, Sharman E, Liu J. Hydroxytyrosol promotes mitochondrial biogenesis and mitochondrial function in 3T3-L1 adipocytes.
J. Nutr. Biochem. Jul 1 [Epub ahead of print] (2009).
*
-
Hao K, Liu S, Niu T. A sparse marker extension tree algorithm for selecting the best set of haplotype tagging single nucleotide polymorphisms.
Genet. Epidemiol. 29: 336-352 (2005).
-
Harada K, Isse K, Kamihira T, Shimoda S, Nakanuma Y. Th1 cytokine-induced downregulation of PPARgamma in human biliary cells relates to cholangitis in primary biliary cirrhosis.
Hepatology 41: 1329-1338 (2005).
*
-
Harada K, Nakanuma Y. Biliary innate immunity and cholangiopathy.
Hepatol. Res. 37 Suppl. 3: S430-S437 (2007).
*
-
Haraguchi G, Kosuge H, Maejima Y, Suzuki JI, Imai T, Yoshida M, Isobe M. Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis.
Intensive Care Med. 34: 1304-1312 (2008).
*
-
Haraguchi T, Takasaki K, Naito T, Hayakawa K, Katsurabayashi S, Mishima K, Iwasaki K, Fujiwara M. Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor gamma-dependent mechanism.
Neurosci. Lett. 464: 151-155 (2009).
-
Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, Mimani M, Hirasawa T, Itoh Y, Okanoue T. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
Liver Int. 26: 613-620 (2006).
*
-
Hardisty JF, Elwell MR, Ernst H, Greaves P, Kolenda-Roberts H, Malarkey DE, Mann PC, Tellier PA. Histopathology of hemangiosarcomas in mice and hamsters and liposarcomas/fibrosarcomas in rats associated with PPAR agonists.
Toxicol. Pathol. 35: 928-941 (2007).
*
-
Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases.
Cell Cycle 7: 1020-1035 (2008).
*
-
Harmon GS, Dumlao DS, Ng DT, Barrett KE, Dennis EA, Dong H, Glass CK. Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice.
Nat. Med. Feb 14 [Epub ahead of print] (2010).
*
-
Harnack K, Andersen G, Somoza V. Quantitation of alpha-linolenic acid elongation to eicosapentaenoic and docosahexaenoic acid as affected by the ratio of n6/n3 fatty acids.
Nutr. Metab. (Lond.) 6: 8 (2009).
*
-
Harries MJ, Paus R. Scarring alopecia and the PPAR-gamma connection.
J. Invest. Dermatol. 129: 1066-1070 (2009).
*
-
Harrington WW, S Britt C, G Wilson J, O Milliken N, G Binz J, C Lobe D, R Oliver W, C Lewis M, M Ignar D. The effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan agonists on body weight, body mass, and serum lipid profiles in diet-induced obese AKR/J mice.
PPAR Res. 2007: 97125 (2007).
*
-
Harris G, Ghazallah RA, Nascene D, Wuertz B, Ondrey FG. PPAR activation and decreased proliferation in oral carcinoma cells with 4-HPR.
Otolaryngol. Head Neck Surg. 133: 695-701 (2005).
-
Hart CM. The role of PPARgamma in pulmonary vascular disease.
J. Investig. Med. 56: 518-521 (2008).
-
Hart CM, Roman J, Reddy R, Sime PJ. PPARgamma: a novel molecular target in lung disease.
J. Investig. Med. 56: 515-517 (2008).
-
Haseeb A, Iliyas M, Chakrabarti S, Farooqui AA, Naik SR, Ghosh S, Suragani M, Ehtesham NZ. Single-nucleotide polymorphisms in peroxisome proliferator-activated receptor gamma and their association with plasma levels of resistin and the metabolic syndrome in a South Indian population.
J. Biosci. 34: 405-414 (2009).
*
-
Hasegawa Y, Kishimoto S, Takahashi H, Inotsume N, Takeuchi Y, Fukushima S. Altered expression of nuclear receptors affects the expression of metabolic enzymes and transporters in a rat model of cholestasis.
Biol. Pharm. Bull. 32: 2046-2052 (2009).
*
-
Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting.
J. Biol. Chem. 275: 28918-28928 (2000).
*
-
Hashimoto T, Fujita T, Usuda N, Cook W, Qi C, Peters JM, Gonzalez FJ, Yeldandi AV, Rao MS, Reddy JK. Peroxisomal and mitochondrial fatty acid beta-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor alpha and peroxisomal fatty acyl-CoA oxidase. Genotype correlation with fatty liver phenotype.
J. Biol. Chem. 274: 19228-19236 (1999).
*
-
Hatano Y, Man MQ, Uchida Y, Crumrine D, Mauro TM, Feingold KR, Elias PM, Holleran WM. Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators.
J. Allergy Clin. Immunol. Oct 7 [Epub ahead of print] (2009).
*
-
Hayashida K, Kume N, Minami M, Inui-Hayashida A, Mukai E, Toyohara M, Kita T. Peroxisome proliferator-activated receptor alpha ligands activate transcription of lectin-like oxidized low density lipoprotein receptor-1 gene through GC box motif.
Biochem. Biophys. Res. Commun. 323: 1116-1123 (2004).
*
-
Hayashida S, Arimoto A, Kuramoto Y, Kozako T, Honda SI, Shimeno H, Soeda S. Fasting promotes the expression of SIRT1, an NAD(+)-dependent protein deacetylase, via activation of PPARalpha in mice.
Mol. Cell. Biochem. Feb 11 [Epub ahead of print] (2010).
*
-
Hays T, Rusyn I, Burns AM, Kennett MJ, Ward JM, Gonzalez FJ, Peters JM. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis.
Carcinogenesis 26: 219-227 (2005).
*
-
Hazra S, M Dubinett S. Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells.
Prostaglandins Leukot. Essent. Fatty Acids 77: 51-58 (2007).
*
-
Hazra S, Peebles KA, Sharma S, Mao JT, Dubinett SM. The role of PPARgamma in the cyclooxygenase pathway in lung cancer.
PPAR Res. 2008: 790568 (2008).
*
-
He CQ, Ding NZ, Fan W. YY1 repressing peroxisome proliferator-activated receptor delta promoter.
Mol. Cell. Biochem. 308: 247-252 (2008).
*
-
He H, Yang D, Ma L, Luo Z, Ma S, Feng X, Cao T, Yan Z, Liu D, Tepel M, Zhu Z. Telmisartan prevents weight gain and obesity through activation of peroxisome proliferator-activated receptor-delta-dependent pathways.
Hypertension Feb 22 [Epub ahead of print] (2010).
-
He T, Lu T, d'Uscio LV, Lam CF, Lee HC, Katusic ZS. Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells.
Circ. Res. 103: 80-88 (2008).
*
-
He W. PPARgamma2 polymorphism and human health.
PPAR Res. 2009: 849538 (2009).
*
-
He Z, Hu Y, Feng L, Bao D, Wang L, Li Y, Wang J, Liu G, Xi Y, Wen L, Lucia A. Is there an association between PPARGC1A genotypes and endurance capacity in Chinese men?
Scand. J. Med. Sci. Sports 18: 195-204 (2008).
-
Hebbachi AM, Knight BL, Wiggins D, Patel DD, Gibbons GF. Peroxisome proliferator-activated receptor alpha-deficiency abolishes the response of lipogenic gene expression to re-feeding: restoration of the normal response by activation of liver X receptor alpha.
J. Biol. Chem. 283: 4866-4876 (2008).
*
-
Hee Kim Y, Jae Han H. High glucose-induced prostaglandin E2 and peroxisome proliferator-activated receptor delta promotes mouse embryonic stem cells proliferation.
Stem Cells 26: 745-755 (2008).
*
-
Hegele RA, Pollex RL. Genetic and physiological insights into the metabolic syndrome.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 289: R663-R669 (2005).
*
-
Heikkinen S, Auwerx J, Argmann CA. PPARgamma in human and mouse physiology.
Biochim. Biophys. Acta 1771: 999-1013 (2007).
*
-
Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity.
Curr. Pharm. Des. 14: 1225-1230 (2008).
-
Heimburger M, Palmblad J. The peroxisome proliferator-activated receptor alpha (PPARalpha) ligand WY 14,643 does not interfere with leukotriene B4 induced adhesion of neutrophils to endothelial cells.
Biochem. Biophys. Res. Commun. 249: 371-374 (1998).
*
-
Hein GJ, Bernasconi AM, Montanaro MA, Pellon-Maison M, Finarelli G, Chicco A, Lombardo YB, Brenner RR. Nuclear receptors and hepatic lipidogenic enzymes response to a dyslipidemic sucrose rich diet and its revertion by fish oil n-3 polyunsaturated fatty acids.
Am. J. Physiol. Endocrinol. Metab. Dec 1 [Epub ahead of print] (2009).
*
-
Heinaniemi M, Carlberg C. Screening for PPAR responsive regulatory modules in cancer.
PPAR Res. 2008: 749073 (2008).
*
-
Heinaniemi M, Uski JO, Degenhardt T, Carlberg C. Meta-analysis of primary target genes of peroxisome proliferator-activated receptors.
Genome Biol. 8: R147 (2007).
*
-
Helenius K, Yang Y, Alasaari J, Makela TP. Mat1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipocyte differentiation.
Mol. Cell. Biol. 29: 315-323 (2009).
*
-
Hellemans K, Kerckhofs K, Hannaert JC, Martens G, Van Veldhoven P, Pipeleers D. Peroxisome proliferator-activated receptor alpha-retinoid X receptor agonists induce beta-cell protection against palmitate toxicity.
FEBS J. 274: 6094-6105 (2007).
*
-
Hellemans KH, Hannaert JC, Denys B, Steffensen KR, Raemdonck C, Martens GA, Van Veldhoven PP, Gustafsson JA, Pipeleers D. Susceptibility of pancreatic beta cells to fatty acids is regulated by LXR/PPARalpha-dependent stearoyl-coenzyme A desaturase.
PLoS One 4: e7266 (2009).
*
-
Heneka MT, Landreth GE. PPARs in the brain.
Biochim. Biophys. Acta 1771: 1031-1045 (2007).
*
-
Heneka MT, Landreth GE, Hull M. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders.
Nat. Clin. Pract. Neurol. 3: 496-504 (2007).
-
Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW Jr, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook RA Jr, Noble SA, Oliver W Jr, et al. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.
J. Med. Chem. 41: 5020-5036 (1998).
*
-
Hennig B, Reiterer G, Majkova Z, Oesterling E, Meerarani P, Toborek M. Modification of environmental toxicity by nutrients: implications in atherosclerosis.
Cardiovasc. Toxicol. 5: 153-160 (2005).
-
Hennuyer N, Tailleux A, Torpier G, Mezdour H, Fruchart JC, Staels B, Fievet C. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Arterioscler. Thromb. Vasc. Biol. 25: 1897-1902 (2005).
*
-
Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study.
Lancet 374: 126-135 (2009).
*
-
Herken H, Erdal M, Aydin N, Sengul C, Karadag F, Barlas O, Akin F. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia.
DNA Cell Biol. 28: 515-519 (2009).
-
Hernandez-Trujillo Y, Rodriguez-Esparragon F, Macias-Reyes A, Caballero-Hidalgo A, Rodriguez-Perez JC. Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model.
Cardiovasc. Diabetol. 7: 3 (2008).
-
Herrmann J, Rubin D, Hasler R, Helwig U, Pfeuffer M, Auinger A, Laue C, Winkler P, Bell D, Schreiber S, Schrezenmeir J. Isomer-specific effects of CLA on gene expression in human adipose tissue depending on PPARgamma2 P12A polymorphism.
Lipids Health Dis. 8: 35 (2009).
*
-
Hertz R, Bar-Tana J. Peroxisome proliferator-activated receptor (PPAR) alpha activation and its consequences in humans.
Toxicol. Lett. 102-103: 85-90 (1998).
-
Hertz R, Berman I, Keppler D, Bar-Tana J. Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome-proliferators-activated receptor (PPAR).
Eur. J. Biochem. 235: 242-247 (1996).
*
-
Herzlich AA, Tuo J, Chan CC. Peroxisome proliferator-activated receptor and age-related macular degeneration.
PPAR Res. 2008: 389507 (2008).
*
-
Heul-Nieuwenhuijsen LV, Dits N, Van Ijcken W, de Lange D, Jenster G. The FOXF2 pathway in the human prostate stroma.
Prostate 69: 1538-1547 (2009).
-
Higa R, Gonzalez E, Pustovrh MC, White V, Capobianco E, Martinez N, Jawerbaum A. PPARdelta and its activator PGI2 are reduced in diabetic embryopathy: involvement of PPARdelta activation in lipid metabolic and signalling pathways in rat embryo early organogenesis.
Mol. Hum. Reprod. 13: 103-110 (2007).
*
-
Higashida K, Higuchi M, Terada S. Dissociation between PGC-1alpha and GLUT-4 expression in skeletal muscle of rats fed a high-fat diet.
J. Nutr. Sci. Vitaminol. (Tokyo) 55: 486-491 (2009).
*
-
Higashiyama H, Billin AN, Okamoto Y, Kinoshita M, Asano S. Expression profiling of peroxisome proliferator-activated receptor-delta (PPAR-delta) in mouse tissues using tissue microarray.
Histochem. Cell Biol. 127: 485-494 (2007).
*
-
Higgins LS, Depaoli AM. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.
Am. J. Clin. Nutr. 91: 267S-272S (2010).
*
-
Higuchi S, Wu R, Zhou M, Ravikumar TS, Wang P. Downregulation of hepatic cytochrome P-450 isoforms and PPAR-gamma: their role in hepatic injury and proinflammatory responses in a double-hit model of hemorrhage and sepsis.
J. Surg. Res. 137: 46-52 (2007).
*
-
Hihi AK, Michalik L, Wahli W. PPARs: transcriptional effectors of fatty acids and their derivatives.
Cell. Mol. Life Sci. 59: 790-798 (2002).
*
-
Hill MR, Clarke S, Rodgers K, Thornhill B, Peters JM, Gonzalez FJ, Gimble JM. Effect of peroxisome proliferator-activated receptor alpha activators on tumor necrosis factor expression in mice during endotoxemia.
Infect. Immun. 67: 3488-3493 (1999).
*
-
Hirai T, Fukui Y, Motojima K. PPARalpha agonists positively and negatively regulate the expression of several nutrient/drug transporters in mouse small intestine.
Biol. Pharm. Bull. 30: 2185-2190 (2007).
*
-
Hiromori Y, Nishikawa J, Yoshida I, Nagase H, Nakanishi T. Structure-dependent activation of peroxisome proliferator-activated receptor (PPAR) gamma by organotin compounds.
Chem. Biol. Interact. 180: 238-244 (2009).
*
-
Hirotani M, Tsukamoto T, Bourdeaux J, Sadano H, Osumi T. Stabilization of peroxisome proliferator-activated receptor alpha by the ligand.
Biochem. Biophys. Res. Commun. 288: 106-110 (2001).
*
-
Hoareau L, Buyse M, Festy F, Ravanan P, Gonthier MP, Matias I, Petrosino S, Tallet F, d'Hellencourt CL, Cesari M, Di Marzo V, Roche R. Anti-inflammatory effect of palmitoylethanolamide on human adipocytes.
Obesity (Silver Spring) 17: 431-438 (2009).
*
-
Hodgkinson CP, Ye S. Microarray analysis of peroxisome proliferator-activated receptor-gamma induced changes in gene expression in macrophages.
Biochem. Biophys. Res. Commun. 308: 505-510 (2003).
*
-
Hoeks J, Hesselink MK, Russell AP, Mensink M, Saris WH, Mensink RP, Schrauwen P. Peroxisome proliferator-activated receptor-gamma coactivator-1 and insulin resistance: acute effect of fatty acids.
Diabetologia 49: 2419-2426 (2006).
*
-
Hoekstra M, Out R, Kar Kruijt J, Van Eck M, Van Berkel TJ. Diet induced regulation of genes involved in cholesterol metabolism in rat liver parenchymal and Kupffer cells.
J. Hepatol. 42: 400-407 (2005).
*
-
Hojo M, Takada I, Kimura W, Fukuda K, Yasugi S. Expression patterns of the chicken peroxisome proliferator-activated receptors (PPARs) during the development of the digestive organs.
Gene Expr. Patterns 6: 171-179 (2006).
*
-
Holden PR, Tugwood JD. Peroxisome proliferator-activated receptor alpha: role in rodent liver cancer and species differences.
J. Mol. Endocrinol. 22: 1-8 (1999).
*
-
Holdsworth-Carson S, Lim R, Mitton A, Whitehead C, Rice G, Permezel M, Lappas M. Peroxisome proliferator-activated receptors are altered in pathologies of the human placenta: gestational diabetes mellitus, intrauterine growth restriction and preeclampsia.
Placenta Dec 30 [Epub ahead of print] (2009).
-
Holdsworth-Carson S, Permezel M, Rice G, Lappas M. Preterm and infection-driven preterm labour: the role of peroxisome proliferator-activated receptors and retinoid X receptor.
Reproduction 137: 1007-1015 (2009).
-
Holdsworth-Carson SJ, Permezel M, Riley C, Rice GE, Lappas M. Peroxisome proliferator-activated receptors and retinoid X receptor-alpha in term human gestational tissues: tissue specific and labour-associated changes.
Placenta 30: 176-186 (2009).
-
Holla VR, Mann JR, Shi Q, Dubois RN. Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer.
J. Biol. Chem. 281: 2676-2682 (2006).
*
-
Hollingshead HE, Borland MG, Billin AN, Willson TM, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooygenase-2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms.
Carcinogenesis 29: 169-176 (2008).
*
-
Hollingshead HE, Morimura K, Adachi M, Kennett MJ, Billin AN, Willson TM, Gonzalez FJ, Peters JM. PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism.
Dig. Dis. Sci. 52: 2912-2919 (2007).
*
-
Holloway GP, Gurd BJ, Snook LA, Lally J, Bonen A. Compensatory increases in nuclear PGC1alpha protein are primarily associated with subsarcolemmal mitochondrial adaptations in ZDF rats.
Diabetes Jan 26 [Epub ahead of print] (2010).
-
Holmes A, Mesa J, Neill B, Chung J, Carey A, Steinberg G, Kemp B, Southgate R, Lancaster G, Bruce C, Watt M, Febbraio M. Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARalpha and UCP2 expression in rats.
J. Endocrinol. 198: 367-374 (2008).
*
-
Holness MJ, Greenwood GK, Smith ND, Sugden MC. Peroxisome proliferator-activated receptor-alpha and glucocorticoids interactively regulate insulin secretion during pregnancy.
Diabetes 55: 3501-3508 (2006).
*
-
Holness MJ, Greenwood GK, Smith ND, Sugden MC. PPARalpha activation and increased dietary lipid oppose thyroid hormone signalling and rescue impaired glucose-stimulated insulin secretion in hyperthyroidism.
Am. J. Physiol. Endocrinol. Metab. 295: E1380-E1389 (2008).
*
-
Holst D, Luquet S, Nogueira V, Kristiansen K, Leverve X, Grimaldi PA. Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle.
Biochim. Biophys. Acta 1633: 43-50 (2003).
*
-
Holvoet P. Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease.
Verh. K. Acad. Geneeskd. Belg. 70: 193-219 (2008).
-
Holzapfel J, Heun R, Lutjohann D, Jessen F, Maier W, Kolsch H. PPARD haplotype influences cholesterol metabolism but is no risk factor of Alzheimer's disease.
Neurosci. Lett. 408: 57-61 (2006).
*
-
Honda K, Kamisoyama H, Tominaga Y, Yokota S, Hasegawa S. The molecular mechanism underlying the reduction in abdominal fat accumulation by licorice flavonoid oil in high fat diet-induced obese rats.
Anim. Sci. J. 80: 562-569 (2009).
-
Hondares E, Mora O, Yubero P, de la Concepcion MR, Iglesias R, Giralt M, Villarroya F. Thiazolidinediones and rexinoids induce PGC-1alpha gene transcription. An auto-regulatory loop controls PGC-1alpha expression in adipocytes via PPARgamma co-activation.
Endocrinology 147: 2829-2838 (2006).
*
-
Hong C, Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors.
Curr. Opin. Genet. Dev. 18: 461-467 (2008).
-
Hong KM, Belperio JB, Keane MP, Burdick MD, Strieter RM. Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator activated receptor-gamma.
J. Biol. Chem. 282: 22910-22920 (2007).
*
-
Honka MJ, Vanttinen M, Iozzo P, Virtanen KA, Lautamaki R, Hallsten K, Borra RJ, Takala T, Viljanen AP, Kemppainen J, Pihlajamaki J, Knuuti J, Nuutila P, Laakso M. The Pro12Ala polymorphism of the PPARgamma2 gene is associated with hepatic glucose uptake during hyperinsulinemia in subjects with type 2 diabetes mellitus.
Metabolism 58: 541-546 (2009).
-
Hontecillas R, Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis.
J. Immunol. 178: 2940-2949 (2007).
*
-
Hontecillas R, Diguardo M, Duran E, Orpi M, Bassaganya-Riera J. Catalpic acid decreases abdominal fat deposition, improves glucose homeostasis and upregulates PPAR alpha expression in adipose tissue.
Clin. Nutr. 27: 764-772 (2008).
-
Hontecillas R, O'Shea M, Einerhand A, Diguardo M, Bassaganya-Riera J. Activation of PPAR gamma and alpha by punicic acid ameliorates glucose tolerance and suppresses obesity-related inflammation.
J. Am. Coll. Nutr. 28: 184-195 (2009).
*
-
Hontecillas R, Wannemeulher MJ, Zimmerman DR, Hutto DL, Wilson JH, Ahn DU, Bassaganya-Riera J. Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid.
J. Nutr. 132: 2019-2027 (2002).
*
-
Hoo RL, Chow WS, Yau MH, Xu A, Tso AW, Tse HF, Fong CH, Tam S, Chan L, Lam KS. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
Arterioscler. Thromb. Vasc. Biol. 27: 2777-2782 (2007).
-
Hoon Lee J, Joe EH, Jou I. PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharide-activated rat glia.
Neuroreport 16: 829-833 (2005).
-
Hopkins TA, Sugden MC, Holness MJ, Kozak R, Dyck JR, Lopaschuk GD. Control of cardiac pyruvate dehydrogenase activity in peroxisome proliferator-activated receptor-alpha transgenic mice.
Am. J. Physiol. Heart Circ. Physiol. 285: H270-H276 (2003).
*
-
Horia E, Watkins BA. Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells.
Carcinogenesis 28: 809-815 (2007).
*
-
Horstman LL, Jy W, Ahn YS, Zivadinov R, Maghzi AH, Etemadifar M, Alexander JS, Minagar A. Role of platelets in neuroinflammation: a wide-angle perspective.
J. Neuroinflammation 7: 10 (2010).
-
Hosooka T, Noguchi T, Kotani K, Nakamura T, Sakaue H, Inoue H, Ogawa W, Tobimatsu K, Takazawa K, Sakai M, Matsuki Y, Hiramatsu R, Yasuda T, Lazar MA, Yamanashi Y, Kasuga M. Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation.
Nat. Med. 14: 188-193 (2008).
*
-
Hossain MA, Tsujita M, Gonzalez FJ, Yokoyama S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.
J. Cardiovasc. Pharmacol. 51: 258-266 (2008).
-
Hossain MG, Iwata T, Mizusawa N, Shima SW, Okutsu T, Ishimoto K, Yoshimoto K. Compressive force inhibits adipogenesis through COX-2-mediated down-regulation of PPARgamma2 and C/EBPalpha.
J. Biosci. Bioeng. 109: 297-303 (2010).
*
-
Hostetler HA, Kier AB, Schroeder F. Very-long-chain and branched-chain fatty acyl-CoAs are high affinity ligands for the peroxisome proliferator-activated receptor alpha (PPARalpha).
Biochemistry 45: 7669-7681 (2006).
*
-
Hostetler HA, McIntosh AL, Atshaves BP, Storey SM, Payne HR, Kier AB, Schroeder F. L-FABP directly interacts with PPARalpha in cultured primary hepatocytes.
J. Lipid Res. 50: 1663-1675 (2009).
*
-
Hostetler HA, Petrescu AD, Kier AB, Schroeder F. Peroxisome proliferator-activated receptor alpha interacts with high affinity and is conformationally responsive to endogenous ligands.
J. Biol. Chem. 280: 18667-18682 (2005).
*
-
Hostetler HA, Syler LR, Hall LN, Zhu G, Schroeder F, Kier AB. A novel high-throughput screening assay for putative antidiabetic agents through PPARalpha interactions.
J. Biomol. Screen 13: 855-861 (2008).
-
Hotta M, Nakata R, Katsukawa M, Hori K, Takahashi S, Inoue H. Carvacrol, a component of thyme oil, activates PPARalpha and gamma , and suppresses COX-2 expression.
J. Lipid Res. 51: 132-139 (2010).
*
-
Hounoki H, Sugiyama E, Mohamed SG, Shinoda K, Taki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Miyahara T. Activation of peroxisome proliferator-activated receptor gamma inhibits TNF-alpha-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression.
Bone 42: 765-774 (2008).
*
-
Houseknecht KL, Cole BM, Steele PJ. Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review.
Domest. Anim. Endocrinol. 22: 1-23 (2002).
*
-
Housley WJ, O'Conor CA, Nichols F, Puddington L, Lingenheld EG, Zhu L, Clark RB. PPARgamma regulates retinoic acid-mediated DC induction of Tregs.
J. Leukoc. Biol. 86: 293-301 (2009).
*
-
Houston MC. The role of mercury and cadmium heavy metals in vascular disease, hypertension, coronary heart disease, and myocardial infarction.
Altern. Ther. Health Med. 13: S128-S133 (2007).
-
Howarth AG, Jiang Y, Pannirselvam M, Wiehler WB, Berger JP, Severson DL, Anderson TJ, Triggle CR. A non-thiazolidinedione PPARgamma agonist reverses endothelial dysfunction in diabetic (db/db -/-) mice.
J. Pharmacol. Exp. Ther. 316: 364-370 (2006).
*
-
Howroyd P, Swanson C, Dunn C, Cattley RC, Corton JC. Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha).
Toxicol. Pathol. 32: 591-599 (2004).
*
-
Hsieh CC, Huang CJ, Lin BF. Low and high levels of alpha-tocopherol exert opposite effects on IL-2 possibly through the modulation of PPAR-gamma, IkappaBalpha, and apoptotic pathway in activated splenocytes.
Nutrition 22: 433-440 (2006).
*
-
Hsieh MC, Lin KD, Tien KJ, Tu ST, Hsiao JY, Chang SJ, Lin SR, Shing SJ, Chen HC. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus.
Metabolism Dec 30 [Epub ahead of print] (2009).
*
-
Hsieh PS, Jin JS, Chiang CF, Chan PC, Chen CH, Shih KC. COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver.
Obesity (Silver Spring) 17: 1150-1157 (2009).
*
-
Hsu MH, Savas U, Griffin KJ, Johnson EF. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells.
J. Biol. Chem. 276: 27950-27958 (2001).
*
-
Hsu SC, Huang CJ. Reduced fat mass in rats fed a high oleic acid-rich safflower oil diet is associated with changes in expression of hepatic PPARalpha and adipose SREBP-1c-regulated genes.
J. Nutr. 136: 1779-1785 (2006).
*
-
Hsun-Wei Huang T, Peng G, Qian Li G, Yamahara J, Roufogalis BD, Li Y. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha.
Toxicol. Appl. Pharmacol. 210: 225-235 (2006).
*
-
Hu C, Jia W, Fang Q, Zhang R, Wang C, Lu J, Xiang K. Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects.
Diabet. Med. 23: 1307-1312 (2006).
*
-
Hu T, Foxworthy P, Siesky A, Ficorilli JV, Gao H, Li S, Christe M, Ryan T, Cao G, Eacho P, Michael MD, Michael LF. Hepatic peroxisomal fatty acid beta oxidation is regulated by liver X receptor alpha (LXRalpha).
Endocrinology 146: 5380-5387 (2005).
*
-
Hu X, Feng Y, Liu X, Zhao XF, Yu JH, Yang YS, Sydow-Backman M, Horling J, Zierath JR, Leng Y. Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor alpha/gamma agonist on glucose uptake.
Diabetologia 50: 1048-1057 (2007).
*
-
Hu X, Feng Y, Shen Y, Zhao XF, Yu JH, Yang YS, Leng Y. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice.
Acta Pharmacol. Sin. 27: 1346-1352 (2006).
-
Hua Y, Xue J, Sun F, Zhu L, Xie M. Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes.
Pharmacology 83: 18-25 (2008).
-
Huang D, Yang C, Wang Y, Liao Y, Huang K. PARP-1 suppresses adiponectin expression through poly(ADP-ribosyl)ation of PPARgamma in cardiac fibroblasts.
Cardiovasc. Res. 81: 98-107 (2009).
*
-
Huang H, Wu D, Fu J, Chen G. Multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid.
Leuk. Lymphoma 50: 966-973 (2009).
-
Huang JC. The role of peroxisome proliferator-activated receptors in the development and physiology of gametes and preimplantation embryos.
PPAR Res. 2008: 732303 (2008).
*
-
Huang TH, Li Y, Razmovski-Naumovski V, Tran VH, Li GQ, Duke CC, Roufogalis BD. Gypenoside XLIX isolated from Gynostemma pentaphyllum inhibits nuclear factor-kappaB activation via a PPAR-alpha-dependent pathway.
J. Biomed. Sci. 13: 535-548 (2006).
*
-
Huang TH, Peng G, Kota BP, Li GQ, Yamahara J, Roufogalis BD, Li Y. Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids.
Br. J. Pharmacol. 145: 767-774 (2005).
*
-
Huang TH, Teoh AW, Lin BL, Lin DS, Roufogalis B. The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome.
Pharmacol. Res. 60: 195-206 (2009).
*
-
Huang TH, Tran VH, Roufogalis BD, Li Y. Gypenoside XLIX, a naturally occurring gynosaponin, PPAR-alpha dependently inhibits LPS-induced tissue factor expression and activity in human THP-1 monocytic cells.
Toxicol. Appl. Pharmacol. 218: 30-36 (2007).
*
-
Huang TH, Tran VH, Roufogalis BD, Li Y. Gypenoside XLIX, a naturally occurring PPAR-alpha activator, inhibits cytokine-induced vascular cell adhesion molecule-1 expression and activity in human endothelial cells.
Eur. J. Pharmacol. 565: 158-165 (2007).
*
-
Huang W, Eum SY, Andras IE, Hennig B, Toborek M. PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities.
FASEB J. 23: 1596-1606 (2009).
*
-
Huang W, Rha GB, Han MJ, Eum SY, Andras IE, Zhong Y, Hennig B, Toborek M. PPARalpha and PPARgamma effectively protect against HIV-induced inflammatory responses in brain endothelial cells.
J. Neurochem. 107: 497-509 (2008).
-
Huang WP, Yin WH, Chen JW, Jen HL, Young MS, Lin SJ. Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study.
Eur. J. Clin. Invest. 39: 775-783 (2009).
-
Hui Y, Yu-Yuan L, Yu-Qiang N, Wei-Hong S, Yan-Lei D, Xiao-Bo L, Yong-Jian Z. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people.
Liver Int. 28: 385-392 (2008).
*
-
Humar B, D'Orazio D, Albrecht C, Bauerfeind P, Muller H, Dobbie Z, Bendik I. Expression of putative anticancer targets in familial adenomatous polyposis and its association with the APC mutation status.
Int. J. Oncol. 19: 1179-1186 (2001).
-
Hummasti S, Tontonoz P. The peroxisome proliferator-activated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis.
Mol. Endocrinol. 20: 1261-1275 (2006).
*
-
Hummasti S, Tontonoz P. Adopting new orphans into the family of metabolic regulators.
Mol. Endocrinol. 22: 1743-1753 (2008).
*
-
Hummasti S, Tontonoz P. HRASLS3 is a PPARgamma-selective target gene that promotes adipocyte differentiation.
J. Lipid Res. 49: 2535-2544 (2008).
*
-
Hung SH, Yeh CH, Huang HT, Wu P, Ho ML, Chen CH, Wang C, Chao D, Wang GJ. Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway.
Life Sci. 82: 561-569 (2008).
*
-
Hunt M, O'Byrne J, Solaas K, Frode Kase B, Alexson SEH. New insights into bile acid amidation.
Falk Symposium 141. XVIII International Bile Acid Meeting: Bile Acid Biology and its Therapeutic Implications. Stockholm (Sweden). p. 24. June 18-19 (2004). *
-
Hunt MC, Yang YZ, Eggertsen G, Carneheim CM, Gafvels M, Einarsson C, Alexson SE. The peroxisome proliferator-activated receptor alpha (PPARalpha) regulates bile acid biosynthesis.
J. Biol. Chem. 275: 28947-28953 (2000).
*
-
Hunter J, Kassam A, Winrow CJ, Rachubinski RA, Capone JP. Crosstalk between the thyroid hormone and peroxisome proliferator-activated receptors in regulating peroxisome proliferator-responsive genes.
Mol. Cell. Endocrinol. 116: 213-221 (1996).
-
Hunter RL, Choi DY, Ross SA, Bing G. Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats.
Neurosci. Lett. 432: 198-201 (2008).
-
Huss JM, Kelly DP. Nuclear receptor signaling and cardiac energetics.
Circ. Res. 95: 568-578 (2004).
*
-
Huss JM, Torra IP, Staels B, Giguere V, Kelly DP. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle.
Mol. Cell Biol. 24: 9079-9091 (2004).
*
-
Hutchins H. Omega-3 fatty acids: recommendations for therapeutics and prevention.
MedGenMed. 7: 18 (2005).
*
-
Hwang D. Fatty acids and immune responses - a new perspective in searching for clues to mechanism.
Annu. Rev. Nutr. 20: 431-456 (2000).
*
-
Hwang J, Kleinhenz DJ, Rupnow HL, Campbell AG, Thule PM, Sutliff RL, Hart CM. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
Vascul. Pharmacol. 46: 456-462 (2007).
*
-
Hwang JT, Lee MS, Kim HJ, Sung MJ, Kim HY, Kim MS, Kwon DY. Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways.
Phytother. Res. 23: 262-266 (2009).
-
Hwang SJ, Kang HJ, Song JJ, Kang JS, Woo JS, Chae SW, Lee HM. Up-regulation of peroxidase proliferator-activated receptor gamma in cholesteatoma.
Laryngoscope 116: 58-61 (2006).
-
Hyong A, Jadhav V, Lee S, Tong W, Rowe J, Zhang JH, Tang J. Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents.
Brain Res. 1215: 218-224 (2008).
-
Hyyti OM, Portman MA. Molecular mechanisms of cross-talk between thyroid hormone and peroxisome proliferator activated receptors: focus on the heart.
Cardiovasc. Drugs Ther. 20: 463-469 (2006).
-
Iankova I, Petersen RK, Annicotte JS, Chavey C, Hansen JB, Kratchmarova I, Sarruf D, Benkirane M, Kristiansen K, Fajas L. PPARgamma recruits the P-TEFb complex to activate transcription and promote adipogenesis.
Mol. Endocrinol. 20: 1494-1505 (2006).
*
-
Ibabe A, Herrero A, Cajaraville MP. Modulation of peroxisome proliferator-activated receptors (PPARs) by PPARalpha- and PPARgamma-specific ligands and by 17beta-estradiol in isolated zebrafish hepatocytes.
Toxicol. In Vitro 19: 725-735 (2005).
-
Ibarra-Lara L, Cervantes-Perez LG, Perez-Severiano F, Del Valle L, Rubio-Ruiz E, Soria-Castro E, Pastelín-Hernandez GS, Sanchez-Aguilar M, Martinez-Lazcano JC, Sanchez-Mendoza A. PPARalpha stimulation exerts a blood pressure lowering effect through different mechanisms in a time-dependent manner.
Eur. J. Pharmacol. Oct 23 [Epub ahead of print] (2009).
-
Ichihara S, Obata K, Yamada Y, Nagata K, Noda A, Ichihara G, Yamada A, Kato T, Izawa H, Murohara T, Yokota M. Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors.
J. Mol. Cell. Cardiol. 41: 318-329 (2006).
-
Icre G, Wahli W, Michalik L. Functions of the peroxisome proliferator-activated receptor (PPAR) alpha and beta in skin homeostasis, epithelial repair, and morphogenesis.
J. Investig. Dermatol. Symp. Proc. 11: 30-35 (2006).
-
Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Yatoh S, Iizuka Y, Tomita S, Ohashi K, Takahashi A, Sone H, Gotoda T, Osuga J, Ishibashi S, Yamada N. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling.
Mol. Endocrinol. 17: 1255-1267 (2003).
*
-
Ide T, Tsunoda M, Mochizuki T, Murakami K. Enhancement of insulin signaling through inhibition of tissue lipid accumulation by activation of peroxisome proliferator-activated receptor (PPAR) a in obese mice.
Med. Sci. Monit. 10: BR388-BR395 (2004).
*
-
Iglesias P, Diez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease.
Eur. J. Endocrinol. 154: 613-621 (2006).
*
-
Iglseder B, Oberkofler H, Felder TK, Klein K, Paulweber B, Krempler F, Tregouet DA, Patsch W. Associations of PPARGC1A haplotypes with plaque score but not with intima-media thickness of carotid arteries in middle-aged subjects.
Stroke 37: 2260-2265 (2006).
-
Ihm SH, Chang K, Kim HY, Baek SH, Youn HJ, Seung KB, Kim JH. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
Basic Res. Cardiol. Oct 23 [Epub ahead of print] (2009).
-
Ii M, Hoshiga M, Negoro N, Fukui R, Nakakoji T, Kohbayashi E, Shibata N, Furutama D, Ishihara T, Hanafusa T, Losordo DW, Ohsawa N. Adrenal androgen dehydroepiandrosterone sulfate inhibits vascular remodeling following arterial injury.
Atherosclerosis 206: 77-85 (2009).
-
Ijichi N, Ikeda K, Horie-Inoue K, Yagi K, Okazaki Y, Inoue S. Estrogen-related receptor alpha modulates the expression of adipogenesis-related genes during adipocyte differentiation.
Biochem. Biophys. Res. Commun. 358: 813-818 (2007).
*
-
IJpenberg A, Tan NS, Gelman L, Kersten S, Seydoux J, Xu J, Metzger D, Canaple L, Chambon P, Wahli W, Desvergne B. In vivo activation of PPAR target genes by RXR homodimers.
EMBO J. 23: 2083-2091 (2004).
*
-
Ikeda I, Konno R, Shimizu T, Ide T, Takahashi N, Kawada T, Nagao K, Inoue N, Yanagita T, Hamada T, Morinaga Y, Tomoyori H, Imaizumi K, Suzuki K. Campest-5-en-3-one, an oxidized derivative of campesterol, activates PPARalpha, promotes energy consumption and reduces visceral fat deposition in rats.
Biochim. Biophys. Acta 1760: 800-807 (2006).
*
-
Ikeda I, Tomimoto A, Wada K, Fujisawa T, Fujita K, Yonemitsu K, Nozaki Y, Endo H, Takahashi H, Yoneda M, Inamori M, Kubota K, Saito S, Nagashima Y, Nakagama H, Nakajima A. 5-Aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model.
Clin. Cancer Res. 13: 6527-6531 (2007).
*
-
Im SS, Kim JW, Kim TH, Song XL, Kim SY, Kim HI, Ahn YH. Identification and characterization of peroxisome proliferator response element in the mouse GLUT2 promoter.
Exp. Mol. Med. 37: 101-110 (2005).
*
-
Imai T. Functional genetic dissection of nuclear receptor signalling in obesity, diabetes and liver regeneration using spatiotemporally controlled somatic mutagenesis in the mouse.
Keio. J. Med. 52: 198-203 (2003).
*
-
Imamura K, Lu J, Kaminishi M. Roles of PPARs in carcinogenesis.
Nippon Rinsho 63: 584-588 (2005).
-
Imanishi T, Kobayashi K, Kuroi A, Ikejima H, Akasaka T. Pioglitazone inhibits angiotensin II-induced senescence of endothelial progenitor cell.
Hypertens. Res. 31: 757-765 (2008).
*
-
Imbimbo BP. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease.
Expert Opin. Investig. Drugs 18: 1147-1168 (2009).
-
Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21.
Cell. Metab. 5: 415-425 (2007).
*
-
Inamoto T, Azuma H, Ubai T, Katsuoka Y. Association of PPAR-gamma with BCG immunotherapy.
Med. Hypotheses 72: 231 (2009).
-
Inamoto T, Shah JB, Kamat AM. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.
Urol. Oncol. 27: 585-591 (2009).
-
Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling.
Exp. Cell Res. 304: 91-104 (2005).
*
-
Inestrosa NC, Toledo EM. The role of Wnt signaling in neuronal dysfunction in Alzheimer's disease.
Mol. Neurodegener. 3: 9 (2008).
-
Inoue H. Endogenous ligands for PPARs.
Nippon Rinsho 63: 578-583 (2005).
-
Inoue I. Hyperlipidemia and peroxisome proliferator-activated receptor (PPAR) - regulation of the PPARalpha gene by CLOCK: BMAL1.
Nippon Rinsho 63: 643-656 (2005).
-
Inoue I, Goto S, Matsunaga T, Nakajima T, Awata T, Hokari S, Komoda T, Katayama S. The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells.
Metabolism 50: 3-11 (2001).
*
-
Inoue I, Itoh F, Aoyagi S, Tazawa S, Kusama H, Akahane M, Mastunaga T, Hayashi K, Awata T, Komoda T, Katayama S. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.
Biochem. Biophys. Res. Commun. 290: 131-139 (2002).
*
-
Inoue I, Shino K, Noji S, Awata T, Katayama S. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells.
Biochem. Biophys. Res. Commun. 246: 370-374 (1998).
*
-
Inoue J, Satoh S, Kita M, Nakahara M, Hachimura S, Miyata M, Nishimaki-Mogami T, Sato R. PPARalpha gene expression is up-regulated by LXR and PXR activators in the small intestine.
Biochem. Biophys. Res. Commun. 371: 675-678 (2008).
*
-
Inoue S, Imamura M, Umezawa A, Tabata Y. Attachment, proliferation and adipogenic differentiation of adipo-stromal cells on self-assembled monolayers of different chemical compositions.
J. Biomater. Sci. Polym. Ed. 19: 893-914 (2008).
-
Inui S, Lee YF, Chang E, Shyr CR, Chang C. Differential and bi-directional regulation between TR2/TR4 orphan nuclear receptors and a specific ligand mediated-peroxisome proliferator-activated receptor alpha in human HaCaT keratinocytes.
J. Dermatol. Sci. 31: 65-71 (2003).
-
Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice.
Hepatology 39: 1286-1296 (2004).
*
-
Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice.
Hepatology 38: 123-132 (2003).
*
-
Iqbal M, Duffy P, Evans P, Cloughley G, Allan B, Lledó A, Verdaguer X, Riera A. The conjugate addition-Peterson olefination reaction for the preparation of cross-conjugated cyclopentenone, PPAR-gamma ligands.
Org. Biomol. Chem. 6: 4649-4661 (2008).
-
Iruretagoyena MI, Sepulveda SE, Lezana JP, Hermoso M, Bronfman M, Gutierrez MA, Jacobelli SH, Kalergis AM. Inhibition of NF-kappaB enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis.
J. Pharmacol. Exp. Ther. 318: 59-67 (2006).
*
-
Ishida N. Role of PPARalpha in the control of torpor through FGF21-NPY pathway: from circadian clock to seasonal change in mammals.
PPAR Res. 2009: 412949 (2009).
*
-
Ishiguro H, Okubo Y, Ohtsuki T, Yamakawa-Kobayashi K, Arinami T. Mutation analysis of the retinoid X receptor beta, nuclear-related receptor 1, and peroxisome proliferator-activated receptor alpha genes in schizophrenia and alcohol dependence.
Am. J. Med. Genet. 114: 15-23 (2002).
*
-
Ishii H, Horie Y, Ohshima S, Anezaki Y, Kinoshita N, Dohmen T, Kataoka E, Sato W, Goto T, Sasaki J, Sasaki T, Watanabe S, Suzuki A, Ohnishi H. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice.
J. Hepatol. 50: 562-571 (2009).
-
Ishizuka M, Sawada T, Okada T, Nagata H, Takagi K, Horie T, Kubota K. Influence of tumor peroxisome proliferator-activated receptor gamma and delta expression on postoperative mortality of patients undergoing colorectal cancer surgery.
J. Invest. Surg. 22: 105-111 (2009).
-
Islam KK, Knight BL, Frayn KN, Patel DD, Gibbons GF. Deficiency of PPARalpha disturbs the response of lipogenic flux and of lipogenic and cholesterogenic gene expression to dietary cholesterol in mouse white adipose tissue.
Biochim. Biophys. Acta 1734: 259-268 (2005).
*
-
Islinger M, Luers GH, Li KW, Loos M, Volkl A. Rat liver peroxisomes after fibrate treatment. A survey using quantitative mass spectrometry.
J. Biol. Chem. 282: 23055-23069 (2007).
*
-
Israelian-Konaraki Z, Reaven PD. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications.
Cardiology 103: 1-9 (2004).
-
Issemann I, Prince RA, Tugwood JD, Green S. The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs.
J. Mol. Endocrinol. 11: 37-47 (1993).
-
Ito O, Nakamura Y, Tan L, Ishizuka T, Sasaki Y, Minami N, Kanazawa M, Ito S, Sasano H, Kohzuki M. Expression of cytochrome P-450 4 enzymes in the kidney and liver: regulation by PPAR and species-difference between rat and human.
Mol. Cell. Biochem. 284: 141-148 (2006).
*
-
Ito Y, Yamanoshita O, Asaeda N, Tagawa Y, Lee CH, Aoyama T, Ichihara G, Furuhashi K, Kamijima M, Gonzalez FJ, Nakajima T. Di(2-ethylhexyl)phthalate induces hepatic tumorigenesis through a peroxisome proliferator-activated receptor alpha-independent pathway.
J. Occup. Health 49: 172-182 (2007).
-
Ito Y, Yamanoshita O, Kurata Y, Kamijima M, Aoyama T, Nakajima T. Induction of peroxisome proliferator-activated receptor alpha (PPARalpha)-related enzymes by di(2-ethylhexyl) phthalate (DEHP) treatment in mice and rats, but not marmosets.
Arch. Toxicol. 81: 219-226 (2007).
*
-
Itoh H. PPARs and hypertension
Nippon Rinsho 63: 631-642 (2005).
-
Itoh T, Murota I, Yoshikai K, Yamada S, Yamamoto K. Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents.
Bioorg. Med. Chem. 14: 98-108 (2005).
*
-
Itoh T, Yamamoto K. Peroxisome proliferator activated receptor gamma and oxidized docosahexaenoic acids as new class of ligand.
Naunyn. Schmiedebergs. Arch. Pharmacol. 377: 541-547 (2008).
*
-
Itoi Y, Takatori M, Hyakusoku H, Mizuno H. Comparison of readily available scaffolds for adipose tissue engineering using adipose-derived stem cells.
J. Plast. Reconstr. Aesthet. Surg. Apr 13 [Epub ahead of print] (2009).
-
Iwashita A, Muramatsu Y, Yamazaki T, Muramoto M, Kita Y, Yamazaki S, Mihara K, Moriguchi A, Matsuoka N. Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.
J. Pharmacol. Exp. Ther. 320: 1087-1096 (2007).
*
-
Izzo AA, Piscitelli F, Capasso R, Marini P, Cristino L, Petrosino S, Di Marzo V. Basal and fasting/refeeding-regulated tissue levels of endogenous PPAR-alpha ligands in Zucker rats.
Obesity (Silver Spring) 18: 55-62 (2010).
*
-
Jagannath K, Chaluvadi MR, Mullangi R, Mamidi NV, Srinivas NR. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
Biopharm. Drug Dispos. 25: 323 (2004).
*
-
Jahnke VE, Sabido O, Freyssenet DG. Control of mitochondrial biogenesis, ROS level and cytosolic Ca2+ concentration during the cell cycle and the onset of differentiation in L6E9 myoblasts.
Am. J. Physiol. Cell Physiol. 296: C1185-C1194 (2009).
*
-
Jahoor A, Patel R, Bryan A, Do C, Krier J, Watters C, Wahli W, Li G, Williams SC, Rumbaugh KP. Peroxisome proliferator activated receptors mediate host cell pro-inflammatory responses to P. aeruginosa autoinducer.
J. Bacteriol. 190: 4408-4415 (2008).
*
-
Jain S, Pulikuri S, Zhu Y, Qi C, Kanwar YS, Yeldandi AV, Rao MS, Reddy JK. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPAR-binding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse.
Am. J. Pathol. 153: 349-354 (1998).
*
-
Jakel H, Nowak M, Helleboid-Chapman A, Fruchart-Najib J, Fruchart JC. Is apolipoprotein A5 a novel regulator of triglyceride-rich lipoproteins?
Ann. Med. 38: 2-10 (2006).
-
Jakobsen MA, Petersen RK, Kristiansen K, Lange M, Lillevang ST. Peroxisome proliferator-activated receptor alpha, delta, gamma1 and gamma2 expressions are present in human monocyte-derived dendritic cells and modulate dendritic cell maturation by addition of subtype-specific ligands.
Scand. J. Immunol. 63: 330-337 (2006).
*
-
Jalouli M, Carlsson L, Ameen C, Linden D, Ljungberg A, Michalik L, Eden S, Wahli W, Oscarsson J. Sex difference in hepatic peroxisome proliferator-activated receptor alpha expression: influence of pituitary and gonadal hormones.
Endocrinology 144: 101-109 (2003).
*
-
James SY, Lin F, Kolluri SK, Dawson MI, Zhang XK. Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells.
Cancer Res. 63: 3531-3538 (2003).
*
-
Jamshidi Y, Flavell DM, Hawe E, MacCallum PK, Meade TW, Humphries SE. Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial.
Atherosclerosis 163: 183-192 (2002).
-
Jan HJ, Lee CC, Lin YM, Lai JH, Wei HW, Lee HM. Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells.
Cancer Lett. 277: 141-148 (2009).
-
Jana M, Jana A, Liu X, Ghosh S, Pahan K. Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of IkappaBalpha in anti-inflammatory effect of gemfibrozil in microglia.
J. Immunol. 179: 4142-4152 (2007).
*
-
Jandeleit-Dahm KA, Calkin A, Tikellis C, Thomas M. Direct antiatherosclerotic effects of PPAR agonists.
Curr. Opin. Lipidol. 20: 24-29 (2009).
-
Jang JY, Lee JH, Shin HK, Choi YH, Lee JD, Choi BT. Partially purified Asiasari radix inhibits melanogenesis through extracellular signal-regulated kinase signaling in B16F10 cells.
Int. J. Mol. Med. 25: 287-292 (2010).
-
Jansen S, Cashman K, Thompson J, Pantaleon M, Kaye P. Glucose deprivation, oxidative stress and peroxisome proliferator activated receptor alpha (PPAR-alpha) cause peroxisome proliferation in preimplantation mouse embryos.
Reproduction 138: 493-505 (2009).
-
Jansson EA. Pivotal role of the nuclear receptor PPARgamma in colon epithelial cells.
Ph.D. Thesis, Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden (2004). *
-
Jarrar MH, Baranova A. PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling.
J. Cell. Mol. Med. 11: 71-87 (2007).
*
-
Jaudszus A, Krokowski M, Mockel P, Darcan Y, Avagyan A, Matricardi P, Jahreis G, Hamelmann E. cis-9,trans-11-Conjugated linoleic acid inhibits allergic sensitization and airway inflammation via a PPARgamma-related mechanism in mice.
J. Nutr. 138: 1336-1342 (2008).
*
-
Jay MA, Ren J. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
Curr. Diabetes Rev. 3: 33-39 (2007).
-
Jaziri R, Lobbens S, Aubert R, Pean F, Lahmidi S, Vaxillaire M, Porchay I, Bellili N, Tichet J, Balkau B, Froguel P, Marre M, Fumeron F. The PPARG Pro12Ala polymorphism is associated with a decreased risk of developing hyperglycemia over 6 years and combines with the effect of the APM1 G-11391A single nucleotide polymorphism: the data from an epidemiological study …
Diabetes 55: 1157-1162 (2006).
*
-
Jazurek M, Dobrzyn P, Dobrzyn A. Regulation of gene expression by long-chain fatty acids.
Postepy. Biochem. 54: 242-250 (2008).
-
Jeffery B, Choudhury AI, Horley N, Bruce M, Tomlinson SR, Roberts RA, Gray TJ, Barrett DA, Shaw PN, Kendall D, Bell DR. Peroxisome proliferator activated receptor alpha regulates a male-specific cytochrome P450 in mouse liver.
Arch. Biochem. Biophys. 429: 231-236 (2004).
*
-
Jeninga EH, Bugge A, Nielsen R, Kersten S, Hamers N, Dani C, Wabitsch M, Berger R, Stunnenberg HG, Mandrup S, Kalkhoven E. Peroxisome proliferator-activated receptor gamma regulates expression of the anti-lipolytic G-protein-coupled receptor 81 (GPR81/Gpr81).
J. Biol. Chem. 284: 26385-26393 (2009).
*
-
Jeninga EH, Gurnell M, Kalkhoven E. Functional implications of genetic variation in human PPARgamma.
Trends Endocrinol. Metab. 20: 380-387 (2009).
*
-
Jeninga EH, van Beekum O, van Dijk AD, Hamers N, Hendriks-Stegeman BI, Bonvin AM, Berger R, Kalkhoven E. Impaired PPARgamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy.
Mol. Endocrinol. 21: 1049-1065 (2007).
*
-
Jennewein C, Kuhn AM, Schmidt MV, Meilladec-Jullig V, von Knethen A, Gonzalez FJ, Brune B. Sumoylation of peroxisome proliferator-activated receptor gamma by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from kappaB binding sites mediating transrepression of proinflammatory cytokines.
J. Immunol. 181: 5646-5652 (2008).
*
-
Jennewein C, von Knethen A, Schmid T, Bruene B. MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA destabilization.
J. Biol. Chem. Feb 17 [Epub ahead of print] (2010).
*
-
Jeon EJ, Lee SK, Park YS, Kim DH, Yum JH, Park CS. The effects of peroxisome proliferator-activated receptor-gamma agonist on a murine model of experimental allergic rhinitis.
Otolaryngol. Head Neck Surg. 139: 124-130 (2008).
-
Ji CG, Zhang JZ. Protein polarization is critical to stabilizing AF-2 and helix-2' domains in ligand binding to PPAR-gamma.
J. Am. Chem. Soc. 130: 17129-17133 (2008).
*
-
Ji JD, Kim HJ, Rho YH, Choi SJ, Lee YH, Cheon HJ, Sohn J, Song GG. Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandin J2.
Rheumatology (Oxford) 44: 983-988 (2005).
*
-
Ji SL, Huang QY. PPARgamma variants and complex diseases.
Yi Chuan 28: 993-1002 (2006).
-
Ji Y, Liu J, Wang Z, Liu N, Gou W. PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway.
Lab. Invest. 89: 887-902 (2009).
*
-
Ji YY, Liu JT, Liu N, Wang ZD, Liu CH. PPARalpha activator fenofibrate modulates angiotensin II-induced inflammatory responses in vascular smooth muscle cells via the TLR4-dependent signaling pathway.
Biochem. Pharmacol. 78: 1186-1197 (2009).
*
-
Ji-Rong Y, Bi-Rong D, Chang-Quan H, Zhen-Chan L, Hong-Mei W, Yan-Ling Z, Mattis TA. Pro12Ala polymorphism in PPARgamma2 associated with depression in Chinese nonagenarians/centenarians.
Arch. Med. Res. 40: 411-415 (2009).
-
Jia Y, Qi C, Kashireddi P, Surapureddi S, Zhu YJ, Rao MS, Le Roith D, Chambon P, Gonzalez FJ, Reddy JK. Transcription coactivator PBP, the peroxisome proliferator-activated receptor (PPAR)-binding protein, is required for PPARalpha-regulated gene expression in liver.
J. Biol. Chem. 279: 24427-24434 (2004).
*
-
Jia Y, Qi C, Zhang Z, Zhu YT, Rao SM, Zhu YJ. Peroxisome proliferator-activated receptor-binding protein null mutation results in defective mammary gland development.
J. Biol. Chem. 280: 10766-10773 (2005).
*
-
Jiang B, Liang P, Zhang B, Huang X, Xiao X. Enhancement of PPAR-beta activity by repetitive low-grade H2O2 stress protects human umbilical vein endothelial cells from subsequent oxidative stress-induced apoptosis.
Free Radic. Biol. Med. 46: 555-563 (2009).
-
Jiang B, Liang P, Zhang B, Song J, Huang X, Xiao X. Role of PPAR-beta in hydrogen peroxide-induced apoptosis in human umbilical vein endothelial cells.
Atherosclerosis 204: 353-358 (2009).
-
Jiang J, Gajalakshmi V, Wang J, Kuriki K, Suzuki S, Nakamura S, Akasaka S, Ishikawa H, Tokudome S. Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma on colorectal cancer in an Indian population.
Cancer Sci. 96: 507-512 (2005).
*
-
Jiang WG, Davies G, Kynaston H, Mason MD, Fodstad O. Does the PGC-1/PPARgamma pathway play a role in Com-1/p8 mediated cell growth inhibition in prostate cancer?
Int. J. Mol. Med. 18: 1169-1175 (2006).
*
-
Jiang Y, Mishima H, Sakai S, Liu YK, Ohyabu Y, Uemura T. Gene expression analysis of major lineage-defining factors in human bone marrow cells: effect of aging, gender, and age-related disorders.
J. Orthop. Res. 26: 910-917 (2008).
-
Jiang YD, Xiong JT, Cao J, Li GZ, Wang SR. Effects of peroxisome proliferators activated receptors on caveolin-1 expression in foam cells.
Zhonghua Xin Xue Guan Bing Za Zhi 35: 661-665 (2007).
-
Jiang YJ, Barish G, Lu B, Evans RM, Crumrine D, Schmuth M, Elias PM, Feingold KR. PPARdelta activation promotes stratum corneum formation and epidermal permeability barrier development during late gestation.
J. Invest. Dermatol. Aug 13 [Epub ahead of print] (2009).
*
-
Jiang YJ, Kim P, Elias PM, Feingold KR. LXR and PPAR activators stimulate cholesterol sulfotransferase (SULT2B1b) in human keratinocytes.
J. Lipid Res. 46: 2657-2666 (2005).
*
-
Jiang YJ, Lu B, Kim P, Elias PM, Feingold KR. Regulation of ABCA1 expression in human keratinocytes and murine epidermis.
J. Lipid Res. 47: 2248-2258 (2006).
*
-
Jiang YJ, Lu B, Kim P, Paragh G, Schmitz G, Elias PM, Feingold KR. PPAR and LXR activators regulate ABCA12 expression in human keratinocytes.
J. Invest. Dermatol. 128: 104-109 (2008).
*
-
Jiang YJ, Uchida Y, Lu B, Kim P, Mao C, Akiyama M, Elias PM, Holleran WM, Grunfeld C, Feingold KR. Ceramide stimulates ABCA12 expression via peroxisome proliferator-activated peceptor delta in human keratinocytes.
J. Biol. Chem. 284: 18942-18952 (2009).
*
-
Jin S, Mathis AS, Rosenblatt J, Minko T, Friedman GS, Gioia K, Serur DS, Knipp GT. Insights into cyclosporine A-induced atherosclerotic risk in transplant recipients: macrophage scavenger receptor regulation.
Transplantation 77: 497-504 (2004).
-
Jing L, Li WM, Zhou LJ, Li S, Kou JJ, Song J. Expression of renin-angiotensin system and peroxisome proliferator-activated receptors in alcoholic cardiomyopathy.
Alcohol Clin. Exp. Res. 32: 1999-2007 (2008).
*
-
Jo SH, Yang C, Miao Q, Marzec M, Wasik MA, Lu P, Wang YL. Peroxisome proliferator-activated receptor gamma promotes lymphocyte survival through its actions on cellular metabolic activities.
J. Immunol. 177: 3737-3745 (2006).
*
-
Jobgen W, Fu WJ, Gao H, Li P, Meininger CJ, Smith SB, Spencer TE, Wu G. High fat feeding and dietary L-arginine supplementation differentially regulate gene expression in rat white adipose tissue.
Amino Acids 37: 187-198 (2009).
*
-
Johansen A, Jensen DP, Bergholdt R, Mortensen HB, Pociot F, Nerup J, Hansen T, Pedersen O; The Danish Society of Childhood Diabetes. IRS1, KCNJ11, PPARgamma2 and HNF-1alpha: do amino acid polymorphisms in these candidate genes support a shared aetiology between type 1 and type 2 diabetes?
Diabetes Obes. Metab. 8: 75-82 (2006).
-
Johmura Y. Characterization of novel genes regulating adipocyte differentiation.
Yakugaku Zasshi 127: 135-142 (2007).
-
Johnson DR, Stebulis JA, Rossetti RG, Burstein SH, Zurier RB. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid.
J. Cell. Biochem. 100: 184-190 (2007).
*
-
Johnson EF, Hsu MH, Savas U, Griffin KJ. Regulation of P450 4A expression by peroxisome proliferator activated receptors.
Toxicology 181-182: 203-206 (2002).
*
-
Johnson EF, Palmer CN, Griffin KJ, Hsu MH. Role of the peroxisome proliferator-activated receptor in cytochrome P450 4A gene regulation.
FASEB J. 10: 1241-1248 (1996).
*
-
Johnson TE, Zhang X, Shi S, Umbenhauer DR. Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment.
Toxicol. Appl. Pharmacol. 208: 210-221 (2005).
*
-
Johnson W, Harris SE, Starr JM, Whalley LJ, Deary IJ. PPARG Pro12Ala genotype and risk of cognitive decline in elders? Maybe with diabetes.
Neurosci. Lett. 434: 50-55 (2008).
-
Johnston TP, Waxman DJ. Circulating free fatty acids are increased independently of PPAR-gamma activity after administration of poloxamer 407 to mice.
Can. J. Physiol. Pharmacol. 86: 643-649 (2008).
-
Jones DC, Ding X, Daynes RA. Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent.
J. Biol. Chem. 277: 6838-6845 (2002).
*
-
Jones DC, Manning BM, Daynes RA. A role for the peroxisome proliferator-activated receptor alpha in T-cell physiology and ageing immunobiology.
Proc. Nutr. Soc. 61: 363-369 (2002).
*
-
Jones JR, Barrick C, Kim KA, Lindner J, Blondeau B, Fujimoto Y, Shiota M, Kesterson RA, Kahn BB, Magnuson MA. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance.
Proc. Natl. Acad. Sci. U.S.A. 102: 6207-6212 (2005).
*
-
Jones KS, Alimov AP, Rilo HL, Jandacek RP, Woollett LA, Penberthy WT. A high throughput live transparent animal bioassay to identify non-toxic small molecules or genes that regulate vertebrate fat metabolism for obesity drug development.
Nutr. Metab. (Lond.) 5: 23 (2008).
*
-
Jorsal A, Tarnow L, Lajer M, Ek J, Hansen T, Pedersen O, Parving HH. The PPARgamma2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy.
Mol. Genet. Metab. 94: 347-351 (2008).
*
-
Jouzeau JY, Moulin D, Koufany M, Sebillaud S, Bianchi A, Netter P. Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists.
J. Soc. Biol. 202: 289-312 (2008).
-
Jozkowicz A, Was H, Taha H, Kotlinowski J, Mleczko K, Cisowski J, Weigel G, Dulak J. 15d-PGJ2 upregulates synthesis of IL-8 in endothelial cells through induction of oxidative stress.
Antioxid. Redox Signal. 10: 2035-2046 (2008).
-
Jucker B, Yang D, Casey W, Olzinski A, Williams C, Lenhard S, Legos J, Hawk T, Sarkar S, Newsholme S. Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study.
Am. J. Physiol. Endocrinol. Metab. 293: E1256-E1264 (2007).
*
-
Juge-Aubry CE, Gorla-Bajszczak A, Pernin A, Lemberger T, Wahli W, Burger AG, Meier CA. Peroxisome proliferator-activated receptor mediates cross-talk with thyroid hormone receptor by competition for retinoid X receptor. Possible role of a leucine zipper-like heptad repeat.
J. Biol. Chem. 270: 18117-18122 (1995).
*
-
Jump DB. Dietary polyunsaturated fatty acid regulation of hepatic gene transcription.
Scand. J. Nutr. 46: 59-67 (2002). *
-
Jump DB. Fatty acid regulation of gene transcription.
Crit. Rev. Clin. Lab. Sci. 41: 41-78 (2004).
-
Jump DB. Dietary polyunsaturated fatty acids and regulation of gene transcription.
Curr. Opin. Lipidol. 13: 155-164 (2002).
-
Jump DB, Botolin D, Wang Y, Xu J, Christian B, Demeure O. Fatty acid regulation of hepatic gene transcription.
J. Nutr. 135: 2503-2506 (2005).
*
-
Jump DB, Botolin D, Wang Y, Xu J, Demeure O, Christian B. Docosahexaenoic acid (DHA) and hepatic gene transcription.
Chem. Phys. Lipids 153: 3-13 (2008).
*
-
Jump DB, Clarke SD, Thelen A, Liimatta M, Ren B, Badin MV. Dietary fat, genes, and human health.
Adv. Exp. Med. Biol. 422: 167-176 (1997).
-
Jump DB, Thelen A, Mater M. Dietary polyunsaturated fatty acids and hepatic gene expression.
Lipids 34: S209-S112 (1999).
-
Jump DB, Thelen A, Ren B, Mater M. Multiple mechanisms for polyunsaturated fatty acid regulation of hepatic gene transcription.
Prostaglandins Leukot. Essent. Fatty Acids 60: 345-349 (1999).
-
Jung D, Fried M, Kullak-Ublick GA. Human apical sodium-dependent bile salt transporter gene (SLC10A2) is regulated by the peroxisome proliferator-activated receptor alpha.
J. Biol. Chem. 277: 30559-30566 (2002).
*
-
Jung SH, Park SY, Kim-Pak Y, Lee HK, Park KS, Shin KH, Ohuchi K, Shin HK, Keum SR, Lim SS. Synthesis and PPAR-gamma ligand-binding activity of the new series of 2'-hydroxychalcone and thiazolidinedione derivatives.
Chem. Pharm. Bull. (Tokyo) 54: 368-371 (2006).
*
-
Jung TW, Lee MW, Lee YJ, Kim SM, Lee KT, Whang WK, Cheon HJ, Jeong YT, Chung KW, Cho JM, Kim DH, Jung TW. Regulation of adiponectin receptor 2 expression via PPAR-alpha in NIT-1 cells.
Endocr. J. 56: 377-382 (2009).
*
-
Kacerovsky-Bielesz G, Chmelik M, Ling C, Pokan R, Szendroedi J, Farukuoye M, Kacerovsky M, Schmid AI, Gruber S, Wolzt M, Moser E, Pacini G, Smekal G, Groop L, Roden M. Short-term exercise training does not stimulate skeletal muscle ATP synthesis in relatives of humans with type 2 diabetes.
Diabetes 58: 1333-1341 (2009).
*
-
Kadotani A, Tsuchiya Y, Hatakeyama H, Katagiri H, Kanzaki M. Different impacts of saturated and unsaturated free fatty acids on COX-2 expression in C2C12 myotubes.
Am. J. Physiol. Endocrinol. Metab. 297: E1291-E1303 (2009).
*
-
Kadowaki K, Fukino K, Negishi E, Ueno K. Sex differences in PPARgamma expressions in rat adipose tissues.
Biol. Pharm. Bull. 30: 818-820 (2007).
*
-
Kadowaki T. Recent advances in PPARs research - basic and clinical aspects.
Nippon Rinsho 63: 539-548 (2005).
-
Kadowaki T, Hara K, Yamauchi T, Terauchi Y, Tobe K, Nagai R. Molecular mechanism of insulin resistance and obesity.
Exp. Biol. Med. (Maywood) 228: 1111-1117 (2003).
*
-
Kagechika H, Miyachi H. PPARs as molecular targets for drug discovery.
Nippon Rinsho 63: 549-555 (2005).
-
Kaidashev IP, Rasin AM, Shlykova OA, Gorbas' IM, Smirnova IP, Petrushov AV, Rasin MS. Frequency of the Pro 12Ala gene polymorphism PPARgamma2 in Ukrainian population and its possible role in metabolic syndrome development.
Tsitol. Genet. 41: 43-47 (2007).
-
Kaimal R, Song X, Yan B, King R, Deng R. Differential modulation of farnesoid X receptor signaling pathway by thiazolidinediones.
J. Pharmacol. Exp. Ther. 330: 125-134 (2009).
*
-
Kainuma M, Kasuga JI, Hosoda S, Wakabayashi KI, Tanatani A, Nagasawa K, Miyachi H, Makishima M, Hashimoto Y. Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands.
Bioorg. Med. Chem. Lett. 16: 3213-3218 (2006).
*
-
Kaipainen A, Kieran MW, Huang S, Butterfield C, Bielenberg D, Mostoslavsky G, Mulligan R, Folkman J, Panigrahy D. PPARalpha deficiency in inflammatory cells suppresses tumor growth.
PLoS ONE 2: e260 (2007).
*
-
Kakiuchi-Kiyota S, Vetro JA, Suzuki S, Varney ML, Han HY, Nascimento M, Pennington KL, Arnold LL, Singh RK, Cohen SM. Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: differences between human and mouse.
Toxicol. Appl. Pharmacol. 237: 83-90 (2009).
*
-
Kalinowska A, Gorski J, Harasim E, Harasiuk D, Bonen A, Chabowski A. Differential effects of chronic, in vivo, PPAR's stimulation on the myocardial subcellular redistribution of FAT/CD36 and FABPpm.
FEBS Lett. 583: 2527-2534 (2009).
*
-
Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.
World J. Gastroenterol. 14: 22-28 (2008).
*
-
Kambia N, Renault N, Dilly S, Farce A, Dine T, Gressier B, Luyckx M, Brunet C, Chavatte P. Molecular modelling of phthalates: PPARs interactions.
J. Enzyme Inhib. Med. Chem. 23: 611-616 (2008).
-
Kamijo Y, Hora K, Kono K, Takahashi K, Higuchi M, Ehara T, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T. PPARalpha protects proximal tubular cells from acute fatty acid toxicity.
J. Am. Soc. Nephrol. 18: 3089-3100 (2007).
*
-
Kamijo Y, Hora K, Nakajima T, Kono K, Takahashi K, Ito Y, Higuchi M, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T. Peroxisome proliferator-activated receptor alpha protects against glomerulonephritis induced by long-term exposure to the plasticizer di-(2-ethylhexyl)phthalate.
J. Am. Soc. Nephrol. 18: 176-188 (2007).
*
-
Kaminishi M. Diversity of gastric carcinogenesis.
Oncology 69 Suppl. 1: 1-8 (2005).
-
Kanayama T, Kobayashi N, Mamiya S, Nakanishi T, Nishikawa JI. Organotin compounds promote adipocyte differentiation as agonists of the peroxisome proliferator-activated receptor (PPAR) gamma / retinoid X receptor (RXR) pathway.
Mol. Pharmacol. 67: 766-774 (2005).
*
-
Kanda S, Nakashima R, Takahashi K, Tanaka J, Ogawa J, Ogata T, Yachi M, Araki K, Ohsumi J. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
J. Pharmacol. Sci. 111: 155-166 (2009).
*
-
Kanda Y, Shimoda M, Hamamoto S, Tawaramoto K, Kawasaki F, Hashiramoto M, Nakashima K, Matsuki M, Kaku K. Molecular mechanism by which pioglitazone preserves pancreatic beta cells in obese diabetic mice: evidence for acute and chronic actions as a PPARgamma agonist.
Am. J. Physiol. Endocrinol. Metab. Nov 17 [Epub ahead of print] (2009).
*
-
Kane CD, Francone OL, Stevens KA. Differential regulation of the cynomolgus, human, and rat acyl-CoA oxidase promoters by PPARalpha.
Gene 380: 84-94 (2006).
*
-
Kanfi Y, Peshti V, Gil R, Naiman S, Nahum L, Levin E, Kronfeld-Schor N, Cohen HY. SIRT6 protects against pathological damage caused by diet-induced obesity.
Aging Cell Dec 28 [Epub ahead of print] (2009).
-
Kang HJ, Cinn YG, Hwang SJ, Won Chae S, Woo JS, Lee SH, Lee HM. Up-regulation of peroxisome proliferator-activated receptor gamma in perennial allergic rhinitis.
Arch. Otolaryngol. Head Neck Surg. 132: 1196-1200 (2006).
-
Kang HW, Bhimidi GR, Odom DP, Brun PJ, Fernandez ML, McGrane MM. Altered lipid catabolism in the vitamin A deficient liver.
Mol. Cell. Endocrinol. 271: 18-27 (2007).
-
Kang HY, Chung E, Lee M, Cho Y, Kang WH. Expression and function of peroxisome proliferator-activated receptors in human melanocytes.
Br. J. Dermatol. 150: 462-468 (2004).
*
-
Kang HY, Lee JY, Lee JS, Choi YM. Peroxisome proliferator-activated receptors-gamma activator, ciglitazone, inhibits human melanocyte growth through induction of apoptosis.
Arch. Dermatol. Res. 297: 472-476 (2006).
*
-
Kang JH, Cho HJ, Lee IS, Kim M, Lee IK, Chang YC. Comparative proteome analysis of TGF-beta1-induced fibrosis processes in normal rat kidney interstitial fibroblast cells in response to ascofuranone.
Proteomics 9: 4445-4456 (2009).
*
-
Kang JH, Tsuyoshi G, Han IS, Kawada T, Kim YM, Yu R. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
Obesity (Silver Spring) Oct 1 [Epub ahead of print] (2009).
*
-
Kang K, Hatano B, Lee CH. PPARdelta agonists and metabolic diseases.
Curr. Atheroscler. Rep. 9: 72-77 (2007).
-
Kang KW, Lee SJ, Kim SG. Molecular mechanism of Nrf2 activation by oxidative stress.
Antioxid. Redox Signal. 7: 1664-1673 (2005).
-
Kang MS, Hirai S, Goto T, Kuroyanagi K, Lee JY, Uemura T, Ezaki Y, Takahashi N, Kawada T. Dehydroabietic acid, a phytochemical, acts as ligand for PPARs in macrophages and adipocytes to regulate inflammation.
Biochem. Biophys. Res. Commun. 369: 333-338 (2008).
*
-
Kang Q, Chen A. Curcumin inhibits SREBP-2 expression in activated hepatic stellate cells in vitro by reducing the activity of specificity protein-1.
Endocrinology 150: 5384-5394 (2009).
*
-
Kang SA, Hong K, Jang KH, Kim YY, Choue R, Lim Y. Altered mRNA expression of hepatic lipogenic enzyme and PPARalpha in rats fed dietary levan from Zymomonas mobilis.
J. Nutr. Biochem. 17: 419-426 (2006).
*
-
Kang X, Zhong W, Liu J, Song Z, McClain CJ, Kang YJ, Zhou Z. Zinc supplementation reverses alcohol-induced steatosis in mice through reactivating hepatocyte nuclear factor-4alpha and peroxisome proliferator-activated receptor-alpha.
Hepatology 50: 1241-1250 (2009).
-
Kanjanabuch T, Ma LJ, Chen J, Pozzi A, Guan Y, Mundel P, Fogo AB. PPAR-gamma agonist protects podocytes from injury.
Kidney Int. 71: 1232-1239 (2007).
*
-
Kannisto K, Chibalin A, Glinghammar B, Zierath JR, Hamsten A, Ehrenborg E. Differential expression of peroxisomal proliferator activated receptors alpha and delta in skeletal muscle in response to changes in diet and exercise.
Int. J. Mol. Med. 17: 45-52 (2006).
*
-
Kao YH, Hsieh HP, Chitlimalla SK, Pan WY, Kuo CC, Tsai YC, Lin WH, Chuang SE, Chang JY. A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells.
Anticancer Drugs 19: 151-158 (2008).
-
Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.
Front. Biosci. 13: 1813-1826 (2008).
-
Kaplins'kyi SP, Shysh AM, Nahibin VS, Dosenko VIe, Klimashevs'kyi VM, Moibenko OO. Omega-3 polyunsaturated fatty acids elevate the expression of PPAR target genes.
Fiziol. Zh. 55: 37-43 (2009).
-
Kapoor A, Collino M, Castiglia S, Fantozzi R, Thiemermann C. Activation of peroxisome proliferator-activated receptor-beta/delta attenuates myocardial ischemia/reperfusion injury in the rat.
Shock Dec 7 [Epub ahead of print] (2009).
-
Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ, Leask A. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis.
Arthritis Rheum. 60: 2822-2829 (2009).
*
-
Kappert K, Tsuprykov O, Kaufmann J, Fritzsche J, Ott I, Goebel M, Bahr IN, HaBle PL, Gust R, Fleck E, Unger T, Stawowy P, Kintscher U. Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation.
Hypertension 54: 738-743 (2009).
-
Karaliota S, Siafaka-Kapadai A, Gontinou C, Psarra K, Mavri-Vavayanni M. Anandamide increases the differentiation of rat adipocytes and causes PPARgamma and CB1 receptor upregulation.
Obesity (Silver Spring) 17: 1830-1838 (2009).
*
-
Karger S, Berger K, Eszlinger M, Tannapfel A, Dralle H, Paschke R, Fuhrer D. Evaluation of peroxisome proliferator-activated receptor-gamma expression in benign and malignant thyroid pathologies.
Thyroid 15: 997-1003 (2005).
-
Karlsen TH. Genome-wide association studies reach hepatology.
J. Hepatol. 50: 1278-1280 (2009).
-
Karlsson HK, Ahlsen M, Zierath JR, Wallberg-Henriksson H, Koistinen HA. Insulin signaling and glucose transport in skeletal muscle from first-degree relatives of type 2 diabetic patients.
Diabetes 55: 1283-1288 (2006).
*
-
Karnati S, Baumgart-Vogt E. Peroxisomes in mouse and human lung: their involvement in pulmonary lipid metabolism.
Histochem. Cell Biol. 130: 719-740 (2008).
-
Karnik P, Tekeste Z, McCormick TS, Gilliam AC, Price VH, Cooper KD, Mirmirani P. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia.
J. Invest. Dermatol. 129: 1243-1257 (2009).
*
-
Karpen SJ, Trauner M. The new therapeutic frontier - nuclear receptors and the liver.
J. Hepatol. Dec 24 [Epub ahead of print] (2009).
*
-
Kasai S, Inoue T, Yoshitomi H, Hihara T, Matsuura F, Harada H, Shinoda M, Tanaka I. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
J. Pharmacol. Sci. 108: 40-48 (2008).
*
-
Kasai T, Miyauchi K, Yokoyama T, Aihara K, Daida H. Efficacy of peroxisome proliferative activated receptor (PPAR)-alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models.
Atherosclerosis 188: 274-280 (2006).
-
Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis.
Gut 54: 117-121 (2005).
*
-
Kashireddy PV, Rao MS. Lack of peroxisome proliferator-activated receptor a in mice enhances methionine and choline deficient diet-induced steatohepatitis.
Hepatol. Res. 30: 104-110 (2004).
-
Kassam A, Hunter J, Rachubinski RA, Capone JP. Subtype- and response element-dependent differences in transactivation by peroxisome proliferator-activated receptors alpha and gamma.
Mol. Cell. Endocrinol. 141: 153-162 (1998).
-
Kassam A, Winrow CJ, Fernandez-Rachubinski F, Capone JP, Rachubinski RA. The peroxisome proliferator response element of the gene encoding the peroxisomal beta-oxidation enzyme enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase is a target for constitutive androstane receptor beta/9-cis-retinoic acid receptor-mediated …
J. Biol. Chem. 275: 4345-4350 (2000).
*
-
Kasuga JI, Ishida S, Yamasaki D, Makishima M, Doi T, Hashimoto Y, Miyachi H. Novel biphenylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) delta selective antagonists.
Bioorg. Med. Chem. Lett. 19: 6595-6599 (2009).
-
Kasuga JI, Makishima M, Hashimoto Y, Miyachi H. Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.
Bioorg. Med. Chem. Lett. 16: 554-558 (2006).
*
-
Kasuga JI, Nakagome I, Aoyama A, Sako K, Ishizawa M, Ogura M, Makishima M, Hirono S, Hashimoto Y, Miyachi H. Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.
Bioorg. Med. Chem. 15: 5177-5190 (2007).
*
-
Kasuga JI, Oyama T, Nakagome I, Aoyama A, Sako K, Makishima M, Hirono S, Morikawa K, Hashimoto Y, Miyachi H. Design and synthesis of peroxisome proliferator-activated receptor (PPAR) delta agonists and its implication to the driving force to elicit PPAR delta selectivity.
Yakugaku Zasshi 129: 709-718 (2009).
-
Kasuga JI, Yamasaki D, Araya Y, Nakagawa A, Makishima M, Doi T, Hashimoto Y, Miyachi H. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
Bioorg. Med. Chem. 14: 8405-8414 (2006).
-
Katayama K, Wada K, Nakajima A, Mizuguchi H, Hayakawa T, Nakagawa S, Kadowaki T, Nagai R, Kamisaki Y, Blumberg RS, Mayumi T. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model.
Gastroenterology 124: 1315-1324 (2003).
*
-
Kaul D, Anand PK, Khanna A. Functional genomics of PPAR-gamma in human immunomodulatory cells.
Mol. Cell. Biochem. 290: 211-215 (2006).
*
-
Kaul D, Gautam A, Sikand K. Importance of LXR-alpha transcriptome in the modulation of innate immunity.
Mol. Cell. Biochem. 292: 53-57 (2006).
*
-
Kawachi H, Moriya NH, Korai T, Tanaka SY, Watanabe M, Matsui T, Kawada T, Yano H. Nitric oxide suppresses preadipocyte differentiation in 3T3-L1 culture.
Mol. Cell. Biochem. 300: 61-67 (2007).
*
-
Kawada T. Lipid metabolism related nuclear receptor - the structure, function, expression and classification of peroxisome proliferation-activated receptor (PPAR).
Nippon Rinsho 56: 1722-1728 (1998).
-
Kawada T, Goto T, Hirai S, Kang MS, Uemura T, Yu R, Takahashi N. Dietary regulation of nuclear receptors in obesity-related metabolic syndrome.
Asia Pac. J. Clin. Nutr. 17 Suppl. 1: 126-130 (2008).
-
Kawada T, Kamei Y, Fujita A, Hida Y, Takahashi N, Sugimoto E, Fushiki T. Carotenoids and retinoids as suppressors on adipocyte differentiation via nuclear receptors.
Biofactors 13: 103-109 (2000).
-
Kawai M, Namba N, Mushiake S, Etani Y, Nishimura R, Makishima M, Ozono K. Growth hormone stimulates adipogenesis of 3T3-L1 cells through activation of the Stat5A/5B-PPARgamma pathway.
J. Mol. Endocrinol. 38: 19-34 (2007).
*
-
Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, Kohno N, Yorioka N. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta.
Lab. Invest. 89: 47-58 (2009).
*
-
Kawashima A, Harada T, Imada K, Yano T, Mizuguchi K. Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma.
Prostaglandins Leukot. Essent. Fatty Acids 79: 59-65 (2008).
*
-
Keech A. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, a randomized, placebo-controlled trial: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
Cardiovasc. Diabetol. 4: 13 (2005).
*
-
Keen HL, Halabi CM, Beyer AM, de Lange WJ, Liu X, Maeda N, Faraci FM, Casavant TL, Sigmund CD. Bioinformatic analysis of gene sets regulated by ligand-activated and dominant-negative peroxisome proliferator-activated receptor gamma in mouse aorta.
Arterioscler. Thromb. Vasc. Biol. Dec 17 [Epub ahead of print] (2009).
-
Keller H, Devchand PR, Perroud M, Wahli W. PPAR alpha structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents.
Biol. Chem. 378: 651-655 (1997).
-
Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers.
Proc. Natl. Acad. Sci. U.S.A. 90: 2160-2164 (1993).
*
-
Keller H, Mahfoudi A, Dreyer C, Hihi AK, Medin J, Ozato K, Wahli W. Peroxisome proliferator-activated receptors and lipid metabolism.
Ann. N. Y. Acad. Sci. 684: 157-173 (1993).
*
-
Keller JM, Collet P, Bianchi A, Huin C, Bouillaud-Kremarik P, Becuwe P, Schohn H, Domenjoud L, Dauca M. Implications of peroxisome proliferator-activated receptors (PPARS) in development, cell life status and disease.
Int. J. Dev. Biol. 44: 429-442 (2000).
*
-
Kelly D, Campbell JI, King TP, Grant G, Jansson EA, Coutts AG, Pettersson S, Conway S. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA.
Nat. Immunol. 5: 104-112 (2004).
*
-
Kelly KJ, Wu P, Patterson CE, Temm CJ, Dominguez JH. LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes.
Am. J. Physiol. Renal Physiol. 294: F1136-F1145 (2008).
*
-
Kempna P, Hofer G, Mullis PE, Fluck CE. Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2.
Mol. Pharmacol. 71: 787-798 (2007).
*
-
Kennedy A, Martinez K, Chuang CC, Lapoint K, McIntosh M. Saturated fatty acid-mediated inflammation and insulin resistance in adipose tissue: mechanisms of action and implications.
J. Nutr. 139: 1-4 (2009).
*
-
Kennedy A, Overman A, Lapoint K, Hopkins R, West T, Chuang CC, Martinez K, Bell D, McIntosh MK. Conjugated linoleic acid-mediated inflammation and insulin resistance in human adipocytes are attenuated by resveratrol.
J. Lipid Res. 50: 225-232 (2009).
*
-
Kepez A, Oto A, Dagdelen S. Peroxisome proliferator-activated receptor-gamma: novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis.
BioDrugs 20: 121-135 (2006).
-
Kershaw EE, Schupp M, Guan HP, Gardner NP, Lazar MA, Flier JS. PPARgamma regulates adipose triglyceride lipase in adipocytes in vitro and in vivo.
Am. J. Physiol. Endocrinol. Metab. 293: E1736-E1745 (2007).
*
-
Kersten S. Peroxisome proliferator activated receptors and obesity.
Eur. J. Pharmacol. 440: 223-234 (2002).
*
-
Kersten S. Peroxisome proliferator activated receptors and lipoprotein metabolism.
PPAR Res. 2008: 132960 (2008).
*
-
Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease.
Nature 405: 421-424 (2000).
*
-
Kersten S, Mandard S, Escher P, Gonzalez FJ, Tafuri S, Desvergne B, Wahli W. The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism.
FASEB J. 15: 1971-1978 (2001).
*
-
Kersten S, Mandard S, Tan NS, Escher P, Metzger D, Chambon P, Gonzalez FJ, Desvergne B, Wahli W. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene.
J. Biol. Chem. 275: 28488-28493 (2000).
*
-
Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting.
J. Clin. Invest. 103: 1489-1498 (1999).
*
-
Kersten S, Wahli W. Peroxisome proliferator activated receptor agonists.
EXS 89: 141-151 (2000).
-
Keshava N, Caldwell JC. Key issues in the role of peroxisome proliferator-activated receptor agonism and cell signaling in trichloroethylene toxicity.
Environ. Health Perspect. 114: 1464-1470 (2006).
*
-
Ketsawatsomkron P, Pelham CJ, Groh S, Keen HL, Faraci FM, Sigmund CD. Does peroxisome proliferator-activated receptor gamma (PPARgamma) protect from hypertension directly through effects in the vasculature?
J. Biol. Chem. Feb 3 [Epub ahead of print] (2010).
*
-
Khan QH, Pontefract DE, Iyengar S, Ye S. Evidence of differing genotypic effects of PPARalpha in women and men.
J. Med. Genet. 41: e79 (2004).
*
-
Khanna AK. Enhanced susceptibility of cyclin kinase inhibitor p21 knockout mice to high fat diet induced atherosclerosis.
J. Biomed. Sci. 16: 66 (2009).
*
-
Kharroubi I, Lee CH, Hekerman P, Darville MI, Evans RM, Eizirik DL, Cnop M. BCL-6: a possible missing link for anti-inflammatory PPAR-delta signalling in pancreatic beta cells.
Diabetologia 49: 2350-2358 (2006).
*
-
Khateeb J, Gantman A, Kreitenberg AJ, Aviram M, Fuhrman B. Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-gamma pathway.
Atherosclerosis Sep 6 [Epub ahead of print] (2009).
-
Khodadadi I, Griffin B, Thumser A. Differential effects of long-chain fatty acids and clofibrate on gene expression profiles in cardiomyocytes.
Arch. Iran. Med. 11: 42-49 (2008).
-
Kholaifi AA, Amer A, Jeffery B, Gray TJ, Roberts RA, Bell DR. Species-specific kinetics and zonation of hepatic DNA synthesis induced by ligands of PPARalpha.
Toxicol. Sci. 104: 74-85 (2008).
*
-
Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host.
J. Lipid Res. 45: 1169-1196 (2004).
*
-
Kiaei M. Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease.
PPAR Res. 2008: 418765 (2008).
*
-
Kiaei M, Kipiani K, Chen J, Calingasan NY, Beal MF. Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis.
Exp. Neurol. 191: 331-336 (2005).
-
Kiec-Wilk B, Dembinska-Kiec A, Olszanecka A, Bodzioch M, Kawecka-Jaszcz K. The selected pathophysiological aspects of PPARs activation.
J. Physiol. Pharmacol. 56: 149-162 (2005).
*
-
Kielian T, Syed MM, Liu S, Phulwani NK, Phillips N, Wagoner G, Drew PD, Esen N. The synthetic peroxisome proliferator-activated receptor-gamma agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses.
J. Immunol. 180: 5004-5016 (2008).
*
-
Kilgore KS, Billin AN. PPARbeta/delta ligands as modulators of the inflammatory response.
Curr. Opin. Investig. Drugs 9: 463-469 (2008).
-
Kilpealinen TO, Lakka TA, Laaksonen DE, Lindstorm J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Lindi V, Tuomilehto J, Uusitupa M, Laakso M. SNPs in PPARg associate with type 2 diabetes and interact with physical activity.
Med. Sci. Sports Exerc. 40: 25-33 (2008).
-
Kilroy GE, Zhang X, Floyd ZE. PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal.
Obesity (Silver Spring) 17: 665-673 (2009).
*
-
Kilter H, Werner M, Roggia C, Reil JC, Schafers HJ, Kintscher U, Bohm M. The PPAR-gamma agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation.
Diabetes Obes. Metab. 11: 1060-1067 (2009).
-
Kim DJ, Oh B, Kim YY. Splicing factor ASF/SF2 and transcription factor PPAR-gamma cooperate to directly regulate transcription of uncoupling protein-3.
Biochem. Biophys. Res. Commun. 378: 877-882 (2009).
*
-
Kim DY, Yuan HD, Chung IK, Chung SH. Compound K, intestinal metabolite of ginsenoside, attenuates hepatic lipid accumulation via AMPK activation in human hepatoma cells.
J. Agric. Food Chem. 57: 1532-1537 (2009).
*
-
Kim E, Chen F, Wang CC, Harrison LE. CDK5 is a novel regulatory protein in PPARgamma ligand-induced antiproliferation.
Int. J. Oncol. 28: 191-194 (2006).
*
-
Kim E, Li K, Lieu C, Tong S, Kawai S, Fukutomi T, Zhou Y, Wands J, Li J. Expression of apolipoprotein C-IV is regulated by Ku antigen/peroxisome proliferator-activated receptor gamma complex and correlates with liver steatosis.
J. Hepatol. 49: 787-798 (2008).
*
-
Kim EK, Kwon KB, Koo BS, Han MJ, Song MY, Song EK, Han MK, Park JW, Ryu DG, Park BH. Activation of peroxisome proliferator-activated receptor-gamma protects pancreatic beta-cells from cytokine-induced cytotoxicity via NFkappaB pathway.
Int. J. Biochem. Cell Biol. 39: 1260-1275 (2007).
*
-
Kim GS, Lee GY, Nedumaran B, Park YY, Kim KT, Park SC, Lee YC, Kim JB, Choi HS. The orphan nuclear receptor DAX-1 acts as a novel transcriptional corepressor of PPARgamma.
Biochem. Biophys. Res. Commun. 370: 264-268 (2008).
*
-
Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.
Diabetes 52: 1770-1778 (2003).
*
-
Kim H, Haluzik M, Gavrilova O, Yakar S, Portas J, Sun H, Pajvani UB, Scherer PE, Leroith D. Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes.
Diabetologia 47: 2215-2225 (2004).
*
-
Kim HG, Han EH, Jeong HG. Effect of troglitazone on CYP1A1 induction.
Toxicology 246: 166-171 (2008).
*
-
Kim HI, Koh YK, Kim TH, Kwon SK, Im SS, Choi HS, Kim KS, Ahn YH. Transcriptional activation of SHP by PPAR-gamma in liver.
Biochem. Biophys. Res. Commun. 360: 301-306 (2007).
*
-
Kim HJ, Ham SA, Kim SU, Hwang JY, Kim JH, Chang KC, Yabe-Nishimura C, Kim JH, Seo HG. Transforming growth factor-beta1 is a molecular target for the peroxisome proliferator-activated receptor delta.
Circ. Res. 102: 193-200 (2008).
*
-
Kim HJ, Jung TW, Kang ES, Kim DJ, Ahn CW, Lee KW, Lee HC, Cha BS. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model.
Metabolism 56: 676-685 (2007).
*
-
Kim HJ, Kim MY, Jin H, Kim HJ, Kang SS, Kim HJ, Lee JH, Chang KC, Hwang JY, Yabe-Nishimura C, Kim JH, Seo HG. Peroxisome proliferator-activated receptor delta regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-beta1/Smad3.
Circ. Res. 105: 16-24 (2009).
-
Kim HY, Kim JR, Kim HS. Upregulation of lipopolysaccharide-induced interleukin-10 by prostaglandin A1 in mouse peritoneal macrophages.
J. Microbiol. Biotechnol. 18: 1170-1178 (2008).
*
-
Kim J, Ahn JH, Kim JH, Yu YS, Kim HS, Ha J, Shinn SH, Oh YS. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway.
Exp. Eye Res. 84: 886-893 (2007).
*
-
Kim J, Han DC, Kim JM, Lee SY, Kim SJ, Woo JR, Lee JW, Jung SK, Yoon KS, Cheon HG, Kim SS, Hong SH, Kwon BM. PPAR gamma partial agonist, KR-62776, inhibits adipocyte differentiation via activation of ERK.
Cell. Mol. Life Sci. 66: 1766-1781 (2009).
*
-
Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis.
Diabetes 53: 2748-2756 (2004).
*
-
Kim JJ, Li P, Huntley J, Chang JP, Arden KC, Olefsky JM. FoxO1 haploinsufficiency protects against high fat diet-induced insulin resistance with enhanced PPARgamma activation in adipose tissue.
Diabetes 58: 1275-1282 (2009).
*
-
Kim JY, Song EH, Lee HJ, Oh YK, Choi KH, Yu DY, Park SI, Seong JK, Kim WH. HBx-induced hepatic steatosis and apoptosis are regulated by TNFR1 and NF-kB-dependent pathway.
J. Mol. Biol. Feb 12 [Epub ahead of print] (2010).
*
-
Kim JY, Tillison K, Lee JH, Rearick DA, Smas C. The adipose tissue triglyceride lipase ATGL/PNPLA2 is downregulated by insulin and TNFalpha in 3T3-L1 adipocytes and is a target for transactivation by PPARgamma.
Am. J. Physiol. Endocrinol. Metab. 291: E115-E127 (2006).
*
-
Kim K, Lee S, Valentine RJ. Association of Pro12Ala polymorphism in the peroxisome proliferative-activated receptor gamma2 gene with obesity and hypertension in Korean women.
J. Nutr. Sci. Vitaminol. (Tokyo) 53: 239-246 (2007).
*
-
Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, Kim HH, Yang US, Yu DY, Cheong J. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma.
Gastroenterology 132: 1955-1967 (2007).
*
-
Kim KY, Ahn JH, Cheon HG. Apoptotic action of PPARgamma activation in human non-small cell lung cancer is mediated via proline oxidase-induced ROS formation.
Mol. Pharmacol. 72: 674-685 (2007).
*
-
Kim KY, Cho HS, Jung WH, Kim SS, Cheon HG. Phosphatase and tensin homolog deleted on chromosome 10 suppression is an important process in peroxisome proliferator-activated receptor-gamma signaling in adipocytes and myotubes.
Mol. Pharmacol. 71: 1554-1562 (2007).
*
-
Kim KY, Kim JK, Jeon JH, Yoon SR, Choi I, Yang Y. c-Jun N-terminal kinase is involved in the suppression of adiponectin expression by TNF-alpha in 3T3-L1 adipocytes.
Biochem. Biophys. Res. Commun. 327: 460-467 (2005).
*
-
Kim MJ, Deplewski D, Ciletti N, Michel S, Reichert U, Rosenfield RL. Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development.
Mol. Genet. Metab. 74: 362-369 (2001).
*
-
Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Arch. Pharm. Res. 32: 721-727 (2009).
*
-
Kim MK, Chae YN, Son MH, Kim SH, Kim JK, Moon HS, Park CS, Bae MH, Kim E, Han T, Choi HH, Shin YA, Ahn BN, Lee CH, Lim JI, Shin CY. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Eur. J. Pharmacol. 595: 119-125 (2008).
*
-
Kim MS, Sweeney 1 TR, Shigenaga JK, Chui LG, Moser A, Grunfeld C, Feingold KR. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells.
Metabolism 56: 267-279 (2007).
*
-
Kim N, Choi S, Lim C, Lee H, Oh J. Albumin mediates PPAR-gamma or C/EBP-alpha -induced phenotypic changes in pancreatic stellate cells.
Biochem. Biophys. Res. Commun. Nov 20 [Epub ahead of print] (2009).
*
-
Kim S, Hong I, Hwang JS, Choi JK, Rho HS, Kim DH, Chang I, Lee SH, Lee MO, Hwang JS. Phytosphingosine stimulates the differentiation of human keratinocytes and inhibits TPA-induced inflammatory epidermal hyperplasia in hairless mouse skin.
Mol. Med. 12: 17-24 (2006).
*
-
Kim S, Sohn I, Lee YS, Lee YS. Hepatic gene expression profiles are altered by genistein supplementation in mice with diet-induced obesity.
J. Nutr. 135: 33-41 (2005).
*
-
Kim SH, Nam GW, Lee HK, Moon SJ, Chang IS. The effects of Musk T on peroxisome proliferator-activated receptor [PPAR]-alpha activation, epidermal skin homeostasis and dermal hyaluronic acid synthesis.
Arch. Dermatol. Res. 298: 273-282 (2006).
*
-
Kim SL, Kim EM, Cheong SJ, Lee CM, Kim DW, Jeong HJ, Lim ST, Sohn MH, Yim CY. The effect of PPAR-gamma agonist on 18F-FDG uptake in tumor and macrophages and tumor cells.
Nucl. Med. Biol. 36: 427-433 (2009).
-
Kim SR, Lee KS, Park HS, Park SJ, Min KH, Jin SM, Lee YC. Involvement of IL-10 in PPARgamma-mediated anti-inflammatory response in asthma.
Mol. Pharmacol. 68: 1568-1575 (2005).
*
-
Kim TH, Kim H, Park JM, Im SS, Bae JS, Kim MY, Yoon HG, Cha JY, Kim KS, Ahn YH. Interrelationship between LXRalpha, SREBP-1c, PPARgamma and SHP in the transcriptional regulation of glucokinase gene expression in liver.
J. Biol. Chem. 284: 15071-15083 (2009).
*
-
Kim WK, Lee CY, Kang MS, Kim MH, Ryu YH, Bae KH, Shin SJ, Lee SC, Ko Y. Effects of leptin on lipid metabolism and gene expression of differentiation-associated growth factors and transcription factors during differentiation and maturation of 3T3-L1 preadipocytes.
Endocr. J. 55: 827-837 (2008).
*
-
Kimura H, Li X, Torii K, Okada T, Takahashi N, Fujii H, Ishihara S, Yoshida H. A natural PPAR-gamma agonist, 15-deoxy-delta 12,14-prostaglandin J2, may act as an enhancer of PAI-1 in human proximal renal tubular cells under hypoxic and inflammatory conditions.
Nephrol. Dial. Transplant. 23: 2496-2503 (2008).
-
Kino T, Chrousos GP. Combating atherosclerosis with LXRalpha and PPARalpha agonists: is rational multitargeted polypharmacy the future of therapeutics in complex diseases?
Mol. Interv. 4: 254-257 (2004).
*
-
Kino T, Rice KC, Chrousos GP. The PPARdelta agonist GW501516 suppresses interleukin-6-mediated hepatocyte acute phase reaction via STAT3 inhibition.
Eur. J. Clin. Invest. 37: 425-433 (2007).
*
-
Kinoshita H, Azma T, Iranami H, Nakahata K, Kimoto Y, Dojo M, Yuge O, Hatano Y. Synthetic peroxisome proliferator-activated receptor-gamma agonists restore impaired vasorelaxation via ATP-sensitive K+ channels by high glucose.
J. Pharmacol. Exp. Ther. 318: 312-318 (2006).
*
-
Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RA, Graf K, Fleck E, Hsueh WA, Law RE. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes.
Eur. J. Pharmacol. 401: 259-270 (2000).
*
-
Kirchmair J, Ristic S, Eder K, Markt P, Wolber G, Laggner C, Langer T. Fast and efficient in silico 3D screening: toward maximum computational efficiency of pharmacophore-based and shape-based approaches.
J. Chem. Inf. Model. 47: 2182-2196 (2007).
*
-
Kirchner S, Kieu T, Chow C, Casey S, Blumberg B. Prenatal exposure to the environmental obesogen tributyltin predisposes multipotent stem cells to become adipocytes.
Mol. Endocrinol. Feb 16 [Epub ahead of print] (2010).
-
Kita R, Kita-Sasai Y, Hanaoka I, Kimura T, Kokuryu H, Takamatsu S, Osaki Y, Tomono N, Hachiya T, Shimizu T. Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports).
Am. J. Gastroenterol. 97: 1849-1851 (2002).
*
-
Kitajima K, Miura SI, Mastuo Y, Uehara Y, Saku K. Newly developed PPAR-alpha agonist (R)-K-13675 inhibits the secretion of inflammatory markers without affecting cell proliferation or tube formation.
Atherosclerosis 203: 75-81 (2009).
-
Kitson AP, Stroud CK, Stark KD. Elevated production of docosahexaenoic acid in females: potential molecular mechanisms.
Lipids Feb 12 [Epub ahead of print] (2010).
-
Kitz Kramer D, Al-Khalili L, Guigas B, Leng Y, Garcia-Roves PM, Krook A. Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle.
J. Biol. Chem. 282: 19313-19320 (2007).
*
-
Kiyomizu M, Kitawaki J, Obayashi H, Ohta M, Koshiba H, Ishihara H, Honjo H. Association of two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene with adenomyosis, endometriosis, and leiomyomata in Japanese women.
J. Soc. Gynecol. Investig. 13: 372-377 (2006).
-
Klaassen CD, Slitt AL. Regulation of hepatic transporters by xenobiotic receptors.
Curr. Drug Metab. 6: 309-328 (2005).
-
Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, Fenner-Crisp PA. PPARalpha agonist-induced rodent tumors: modes of action and human relevance.
Crit. Rev. Toxicol. 33: 655-780 (2003).
-
Klebl FH, Bregenzer N, Rogler G, Straub RH, Scholmerich J, Andus T. Treatment of pouchitis with dehydroepiandrosterone (DHEA) - a case report.
Z. Gastroenterol. 41: 1087-1090 (2003).
-
Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation.
Blood 101: 545-551 (2003).
*
-
Kleemann R, Verschuren L, van Erk MJ, Nikolsky Y, Cnubben NH, Verheij ER, Smilde AK, Hendriks HF, Zadelaar S, Smith GJ, Kaznacheev V, Nikolskaya T, Melnikov A, Hurt-Camejo E, van der Greef J, van Ommen B, Kooistra T. Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis.
Genome Biol. 8: R200 (2007).
*
-
Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.
Proc. Natl. Acad. Sci. U.S.A. 91: 7355-7359 (1994).
*
-
Kliewer SA, Lehmann JM, Milburn MV, Willson TM. The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways.
Recent Prog. Horm. Res. 54: 345-367 (1999).
-
Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.
Cell 83: 813-819 (1995).
*
-
Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma.
Proc. Natl. Acad. Sci. U.S.A. 94: 4318-4323 (1997).
*
-
Kliewer SA, Willson TM. The nuclear receptor PPARgamma - bigger than fat.
Curr. Opin. Genet. Dev. 8: 576-581 (1998).
-
Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology.
Recent Prog. Horm. Res. 56: 239-263 (2001).
*
-
Klopper JP, Sharma V, Berenz A, Hays WR, Loi M, Pugazhenthi U, Said S, Haugen BR. Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression.
Mol. Cancer 8: 16 (2009).
*
-
Klopper JP, Sharma V, Bissonnette R, Haugen BR. Combination PPARgamma and RXR agonist treatment in melanoma cells: functional importance of S100A2.
PPAR Res. 2010: 729876 (2010).
*
-
Klotz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, Hucke S, Alferink J, Novak N, Beyer M, Mayer G, Langhans B, Klockgether T, Waisman A, Eberl G, Schultze J, Famulok M, Kolanus W, Glass C, Kurts C, Knolle PA. The nuclear receptor PPARgamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity.
J. Exp. Med. 206: 2079-2089 (2009).
*
-
Klotz L, Dani I, Edenhofer F, Nolden L, Evert B, Paul B, Kolanus W, Klockgether T, Knolle P, Diehl L. Peroxisome proliferator-activated receptor gamma control of dendritic cell function contributes to development of CD4+ T cell anergy.
J. Immunol. 178: 2122-2131 (2007).
*
-
Klotz L, Hucke S, Thimm D, Classen S, Gaarz A, Schultze J, Edenhofer F, Kurts C, Klockgether T, Limmer A, Knolle P, Burgdorf S. Increased antigen cross-presentation but impaired cross-priming after activation of peroxisome proliferator-activated receptor gamma is mediated by up-regulation of B7H1.
J. Immunol. 183: 129-136 (2009).
-
Klotz L, Schmidt S, Heun R, Klockgether T, Kolsch H. Association of the PPARgamma gene polymorphism Pro12Ala with delayed onset of multiple sclerosis.
Neurosci. Lett. 449: 81-83 (2009).
-
Knapp P, Jarzabek K, Blachnio A, Zbroch T. The role of peroxisome proliferator-activated receptors (PPAR) in carcinogenesis.
Ginekol. Pol. 77: 643-651 (2006).
-
Knauf C, Rieusset J, Foretz M, Cani PD, Uldry M, Hosokawa M, Martinez E, Bringart M, Waget A, Kersten S, Desvergne B, Gremlich S, Wahli W, Seydoux J, Delzenne NM, Thorens B, Burcelin R. Peroxisome proliferator-activated receptor-alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass. Role in liver and brain.
Endocrinology 147: 4067-4078 (2006).
*
-
Knebel B, Janssen OE, Hahn S, Jacob S, Gleich J, Kotzka J, Muller-Wieland D. Increased low grade inflammatory serum markers in patients with polycystic ovary syndrome (PCOS) and their relationship to PPARgamma gene variants.
Exp. Clin. Endocrinol. Diabetes 116: 481-486 (2008).
-
Knight BL, Hebbachi A, Hauton D, Brown AM, Wiggins D, Patel DD, Gibbons GF. A role for PPAR-alpha in the control of SREBP activity and lipid synthesis in the liver.
Biochem. J. 389: 413-421 (2005).
*
-
Knight BL, Patel DD, Humphreys SM, Wiggins D, Gibbons GF. Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice.
J. Lipid Res. 44: 2049-2058 (2003).
*
-
Knight TR, Choudhuri S, Klaassen CD. Induction of hepatic glutathione S-transferases in male mice by prototypes of various classes of microsomal enzyme inducers.
Toxicol. Sci. 106: 329-338 (2008).
*
-
Knoch B, Barnett MP, Zhu S, Park ZA, Nones K, Dommels YE, Knowles SO, McNabb WC, Roy NC. Genome-wide analysis of dietary eicosapentaenoic acid- and oleic acid-induced modulation of colon inflammation in interleukin-10 gene-deficient mice.
J. Nutrigenet. Nutrigenomics 2: 9-28 (2009).
-
Knouff C, Auwerx J. PPARgamma calls for activation in moderation: lessons from genetics and pharmacology.
Endocr. Rev. 25: 899-918 (2004).
*
-
Ko GJ, Kang YS, Han SY, Lee MH, Song HK, Han KH, Kim HK, Han JY, Cha DR. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
Nephrol. Dial. Transplant. 23: 2750-2760 (2008).
-
Kobayashi S, Fukuhara A, Taguchi T, Matsuda M, Tochino Y, Otsuki M, Shimomura I. Identification of a new secretory factor, CCDC3, in adipocytes and endothelial cells.
Biochem. Biophys. Res. Commun. Dec 28 [Epub ahead of print] (2009).
*
-
Kobuke T, Tazuma S, Hyogo H, Chayama K. A ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma.
Dig. Dis. Sci. 51: 1650-1657 (2006).
*
-
Kocdor H, Kocdor M, Canda T, Gurel D, Cehreli R, Yilmaz O, Alakavuklar M, Guner G. Chemopreventive efficacies of rosiglitazone, fenretinide and their combination against rat mammary carcinogenesis.
Clin.Transl. Oncol. 11: 243-249 (2009).
-
Koch A, Konig B, Stangl GI, Eder K. PPARalpha mediates transcriptional upregulation of novel organic cation transporters-2 and -3 and enzymes involved in hepatic carnitine synthesis.
Exp. Biol. Med. (Maywood) 233: 356-365 (2008).
*
-
Kociecka B, Surazynski A, Miltyk W, Palka J. The effect of telmisartan on collagen biosynthesis depends on the status of estrogen activation in breast cancer cells.
Eur. J. Pharmacol. Nov 26 [Epub ahead of print] (2009).
-
Kockx M, Gervois PP, Poulain P, Derudas B, Peters JM, Gonzalez FJ, Princen HM, Kooistra T, Staels B. Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.
Blood 93: 2991-2998 (1999).
*
-
Koeck T, Willard B, Crabb JW, Kinter M, Stuehr DJ, Aulak KS. Glucose-mediated tyrosine nitration in adipocytes: targets and consequences.
Free Radic. Biol. Med. 46: 884-892 (2009).
-
Koh KK, Quon MJ, Rosenson RS, Chung WJ, Han SH. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.
Int. J. Cardiol. 124: 149-159 (2008).
-
Koh WP, Yuan JM, Van Den Berg D, Ingles SA, Yu MC. Peroxisome proliferator-activated receptor (PPAR) gamma gene polymorphisms and colorectal cancer risk among Chinese in Singapore.
Carcinogenesis 27: 1797-1802 (2006).
*
-
Koh YJ, Park BH, Park JH, Han J, Lee IK, Park JW, Koh GY. Activation of PPARgamma induces profound multilocularization of adipocytes in adult mouse white adipose tissues.
Exp. Mol. Med. Sep 11 [Epub ahead of print] (2009).
*
-
Kohalmy K, Tamasi V, Kobori L, Sarvary E, Pascussi JM, Porrogi P, Rozman D, Prough RA, Meyer UA, Monostory K. Dehydroepiandrosterone induces human CYP2B6 through the constitutive androstane receptor.
Drug Metab. Dispos. 35: 1495-1501 (2007).
*
-
Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada M, Yada R, Harada N, Takayanagi R, Nakamuta M. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.
Int. J. Mol. Med. 20: 351-358 (2007).
*
-
Kohno H, Suzuki R, Sugie S, Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands.
BMC Cancer 5: 46 (2005).
*
-
Koika V, Marioli D, Saltamavros A, Vervita V, Koufogiannis K, Adonakis G, Decavalas G, Georgopoulos N. Association of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor 2 (PPARgamma2) with decreased basic metabolic rate (BMR) in women with polycystic ovary syndrome (PCOS).
Eur. J. Endocrinol. 161: 317-322 (2009).
-
Koirala K, Wan YL, Liu YC, Wang X, Cui W, Wang CL, Chen HN, Wang HY, Zhu J. Effects of peroxisome proliferator-activated receptor-gamma ligand troglitazone on colon cancer cell growth.
Beijing Da Xue Xue Bao 38: 385-388 (2006).
-
Koivisto AM, Helisalmi S, Pihlajamaki J, Hiltunen M, Koivisto K, Moilanen L, Kuusisto J, Helkala EL, Hanninen T, Kervinen K, Kesaniemi YA, Laakso M, Soininen H. Association analysis of peroxisome proliferator-activated receptor gamma polymorphisms and late onset Alzheimer's disease in the Finnish population.
Dement. Geriatr. Cogn. Disord. 22: 449-453 (2006).
-
Kok T, Bloks VW, Wolters H, Havinga R, Jansen PL, Staels B, Kuipers F. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice.
Biochem. J. 369: 539-547 (2003).
*
-
Kok T, Wolters H, Bloks VW, Havinga R, Jansen PL, Staels B, Kuipers F. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse.
Gastroenterology 124: 160-171 (2003).
*
-
Komatsu A, Node K. Effects of PPARgamma agonist on dyslipidemia and atherosclerosis.
Nippon Rinsho 68: 294-298 (2010).
-
Komeda T. Obesity and NASH in Japan.
Hepatol. Res. 33: 83-86 (2005).
-
Kondoh K, Tsuji N, Asanuma K, Kobayashi D, Watanabe N. Inhibition of estrogen receptor beta-mediated human telomerase reverse transcriptase gene transcription via the suppression of mitogen-activated protein kinase signaling plays an important role in 15-deoxy-Delta(12,14)-prostaglandin J(2)-induced …
Exp. Cell Res. 313: 3486-3496 (2007).
*
-
Kong J, Li YC. Molecular mechanism of 1,25-dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells.
Am. J. Physiol. Endocrinol. Metab. 290: E916-E924 (2006).
*
-
Kong W, Yen JH, Vassiliou E, Adhikary S, Toscano MG, Ganea D. Docosahexaenoic acid prevents dendritic cell maturation and in vitro and in vivo expression of the IL-12 cytokine family.
Lipids Health Dis. 9: 12 (2010).
*
-
Konig B, Koch A, Giggel K, Dordschbal B, Eder K, Stangl GI. Monocarboxylate transporter (MCT)-1 is up-regulated by PPARalpha.
Biochim. Biophys. Acta 1780: 899-904 (2008).
*
-
Konig B, Spielmann J, Haase K, Brandsch C, Kluge H, Stangl GI, Eder K. Effects of fish oil and conjugated linoleic acids on expression of target genes of PPARalpha and sterol regulatory element-binding proteins in the liver of laying hens.
Br. J. Nutr. 100: 355-363 (2008).
*
-
Kono K, Kamijo Y, Hora K, Takahashi K, Higuchi M, Kiyosawa K, Shigematsu H, Gonzalez FJ, Aoyama T. PPARalpha attenuates the proinflammatory response in activated mesangial cells.
Am. J. Physiol. Renal Physiol. 296: F328-F336 (2009).
*
-
Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W, Schober WD, Wang RY, Chism D, Kornblau SM, Younes A, Collins SJ, Koeffler HP, Andreeff M. Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.
Mol. Cancer Ther. 3: 1249-1262 (2004).
-
Konturek PC, Brzozowski T, Engel M, Burnat G, Gaca P, Kwiecien S, Pajdo R, Konturek SJ. Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves.
J. Physiol. Pharmacol. 60: 41-47 (2009).
*
-
Konturek PC, Kania J, Raithel M, Ocker M, Rembiasz K, Hahn EG, Konturek SJ. Implication of peroxisome proliferator-activated receptor gamma and proinflammatory cytokines in gastric carcinogenesis: link to Helicobacter pylori-infection.
J. Pharmacol. Sci. 96: 134-143 (2005).
*
-
Kopij M, Rapak A. The role of nuclear receptors in cell death.
Postepy. Hig. Med. Dosw. (Online) 62: 571-581 (2008).
-
Koppen A, Houtman R, Pijnenburg D, Jeninga EH, Ruijtenbeek R, Kalkhoven E. Nuclear receptor-coregulator profiling identifies TRIP3 as a novel PPARgamma cofactor.
Mol. Cell. Proteomics 8: 2212-2226 (2009).
*
-
Kornbluth A. What happened to drug trials in ulcerative colitis? Problems, PPARs, placebos, and (possible) progress.
Am. J. Gastroenterol. 96: 3232-3234 (2001).
*
-
Korner A, Kiess W, Stumvoll M, Kovacs P. Polygenic contribution to obesity: genome-wide strategies reveal new targets.
Front. Horm. Res. 36: 12-36 (2008).
-
Kostadinova R, Wahli W, Michalik L. PPARs in diseases: control mechanisms of inflammation.
Curr. Med. Chem. 12: 2995-3009 (2005).
-
Kostiuk MA, Keller BO, Berthiaume LG. Palmitoylation of ketogenic enzyme HMGCS2 enhances its interaction with PPARalpha and transcription at the Hmgcs2 PPRE.
FASEB J. Feb 2 [Epub ahead of print] (2010).
*
-
Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs.
Pharmacol. Res. 51: 85-94 (2005).
*
-
Kotronen A, Yki-Jarvinen H, Aminoff A, Bergholm R, Pietilainen K, Westerbacka J, Talmud P, Humphries S, Hamsten A, Isomaa B, Groop L, Orho-Melander M, Ehrenborg E, Fisher R. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts.
Eur. J. Endocrinol. 160: 593-602 (2009).
-
Koufany M, Moulin D, Bianchi A, Muresan M, Sebillaud S, Netter P, Weryha G, Jouzeau JY. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
Arthritis Res. Ther. 10: R6 (2008).
*
-
Kouidhi S, Seugnet I, Decherf S, Guissouma H, Elgaaied AB, Demeneix B, Clerget-Froidevaux MS. Peroxisome proliferator-activated receptor-gamma (PPARgamma) modulates hypothalamic Trh regulation in vivo.
Mol. Cell. Endocrinol. Nov 6 [Epub ahead of print] (2009).
-
Kourtidis A, Srinivasaiah R, Carkner RD, Brosnan MJ, Conklin DS. PPARgamma protects ERBB2-positive breast cancer cells from palmitate toxicity.
Breast Cancer Res. 11: R16 (2009).
*
-
Koutsogiannaki S, Evangelinos N, Koliakos G, Kaloyianni M. Cytotoxic mechanisms of Zn(2+) and Cd(2+) involve Na(+)/H(+) exchanger (NHE) activation by ROS.
Aquat. Toxicol. 78: 315-324 (2006).
-
Krag MB, Rasmussen LM, Hansen TK, Frystyk J, Flyvbjerg A, Moller N, Jorgensen JO. Peroxisome proliferator-activated receptor gamma agonism reduces the insulin-stimulated increase in circulating interleukin-6 in growth hormone (GH) replaced GH-deficient adults.
Clin. Endocrinol. (Oxf.) 71: 363-368 (2009).
*
-
Kramer DK, Ahlsen M, Norrbom J, Jansson E, Hjeltnes N, Gustafsson T, Krook A. Human skeletal muscle fibre type variations correlate with PPARalpha, PPARdelta and PGC-1alpha mRNA.
Acta Physiol. (Oxf.) 188: 207-216 (2006).
*
-
Kratzner R, Frohlich F, Lepler K, Schroder M, Roher K, Dickel C, Tzvetkov MV, Quentin T, Oetjen E, Knepel W. A peroxisome proliferator-activated receptor gamma-retinoid X receptor heterodimer physically interacts with the transcriptional activator PAX6 to inhibit glucagon gene transcription.
Mol. Pharmacol. 73: 509-517 (2008).
*
-
Krause WF, DuBois RN. The molecular basis for prevention of colorectal cancer.
Clin. Colorectal Cancer 1: 47-54 (2001).
*
-
Kreisler A, Gele P, Wiart JF, Lhermitte M, Destee A, Bordet R. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Brain Res. 1135: 77-84 (2007).
-
Kreutzer J, Jeske I, Hofmann B, Blumcke I, Fahlbusch R, Buchfelder M, Buslei R. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.
Clin. Neuropathol. 28: 430-439 (2009).
-
Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay.
Mol. Endocrinol. 11: 779-791 (1997).
*
-
Kristiansen G, Jacob J, Buckendahl AC, Grutzmann R, Alldinger I, Sipos B, Kloppel G, Bahra M, Langrehr JM, Neuhaus P, Dietel M, Pilarsky C. Peroxisome proliferator-activated receptor gamma is highly expressed in pancreatic cancer and is associated with shorter overall survival times.
Clin. Cancer Res. 12: 6444-6451 (2006).
*
-
Kronke G, Kadl A, Ikonomu E, Bluml S, Furnkranz A, Sarembock IJ, Bochkov VN, Exner M, Binder BR, Leitinger N. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors.
Arterioscler. Thromb. Vasc. Biol. 27: 1276-1282 (2007).
*
-
Krskova-Tybitanclova K, Macejova D, Brtko J, Baculikova M, Krizanova O, Zorad S. Short term 13-cis-retinoic acid treatment at therapeutic doses elevates expression of leptin, GLUT4, PPARgamma and aP2 in rat adipose tissue.
J. Physiol. Pharmacol. 59: 731-743 (2008).
*
-
Krzystyniak KL. Current strategies for anticancer chemoprevention and chemoprotection.
Acta Pol. Pharm. 59: 473-478 (2002).
-
Kuenzli S, Saurat JH. Peroxisome proliferator-activated receptors in cutaneous biology.
Br. J. Dermatol. 149: 229-236 (2003).
*
-
Kuenzli S, Saurat JH. Peroxisome proliferator-activated receptors as new molecular targets in psoriasis.
Curr. Drug Targets Inflamm. Allergy 3: 205-211 (2004).
-
Kuliczkowska J, Filus A, Trzmiel A, Tworowska U, Demissie M, Jedrzejuk D, Milewicz A. PPAR-gamma2 Pro12Ala polymorphism in the population of obese and non-obese men of the city of Wroclaw.
Endokrynol. Pol. 59: 312-315 (2008).
-
Kumar AP, Piedrafita FJ, Reynolds WF. Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism.
J. Biol. Chem. 279: 8300-8315 (2004).
*
-
Kumar PM, Hemalatha R, Mahajan SC, Karthikeyan C, Moorthy NS, Trivedi P. Quantitative structure activity analysis of 2-alkoxydihydrocinnamates as PPARalpha/gamma dual agonist.
Med. Chem. 4: 273-277 (2008).
-
Kumari R, Willing LB, Patel SD, Krady JK, Zavadoski WJ, Gibbs EM, Vannucci SJ, Simpson IA. The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse.
J. Cereb. Blood Flow Metab. Oct 28 [Epub ahead of print] (2009).
-
Kumei S, Motomura W, Yoshizaki T, Takakusaki K, Okumura T. Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells.
Biochem. Biophys. Res. Commun. 380: 614-619 (2009).
*
-
Kummer MP, Heneka MT. PPARs in Alzheimer's disease.
PPAR Res. 2008: 403896 (2008).
*
-
Kuniyasu H. The roles of dietary PPARgamma ligands for metastasis in colorectal cancer.
PPAR Res. 2008: 529720 (2008).
*
-
Kuriki K, Hirose K, Matsuo K, Wakai K, Ito H, Kanemitsu Y, Hirai T, Kato T, Hamajima N, Takezaki T, Suzuki T, Saito T, Tanaka R, Tajima K. Meat, milk, saturated fatty acids, the Pro12Ala and C161T polymorphisms of the PPARgamma gene and colorectal cancer risk in Japanese.
Cancer Sci. 97: 1226-1235 (2006).
*
-
Kuroda M, Mimaki Y, Honda S, Tanaka H, Yokota S, Mae T. Phenolics from Glycyrrhiza glabra roots and their PPAR-gamma ligand-binding activity.
Bioorg. Med. Chem. Nov 26 [Epub ahead of print] (2009).
*
-
Kuroda T, Hirota H, Fujio Y, Sugiyama S, Masaki M, Hiramoto Y, Shioyama W, Okamoto K, Hori M, Yamauchi-Takihara K. Carbacyclin induces carnitine palmitoyltransferase-1 in cardiomyocytes via peroxisome proliferator-activated receptor (PPAR) delta independent of the IP receptor signaling pathway.
J. Mol. Cell. Cardiol. 43: 54-62 (2007).
*
-
Kusu R, Oishi A, Kakizawa K, Kimura T, Toda C, Hashizume K, Ueda K, Kojima N. Effects of phthalate ester derivatives including oxidized metabolites on coactivator recruiting by PPARalpha and PPARgamma.
Toxicol. In Vitro 22: 1534-1538 (2008).
-
Kuusisto J, Andrulionyte L, Laakso M. Atherosclerosis and cardiovascular risk reduction with PPAR agonists.
Curr. Atheroscler. Rep. 9: 274-280 (2007).
-
Kwak H, Hwang I, Kim JH, Kim MY, Yang JS, Jeong S. Modulation of transcription by the peroxisome proliferator-activated receptor delta-binding RNA aptamer in colon cancer cells.
Mol. Cancer Ther. 8: 2664-2673 (2009).
-
Kyoko U, Seiji U, Shinichi I, Masakazu T, Shinji K, Tohru F, Masunori M. Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia.
Am. J. Physiol. Heart Circ. Physiol. 291: H2522-H2532 (2006).
*
-
Labinskyy V, Bellomo M, Chandler MP, Young ME, Lionetti V, Qanud K, Bigazzi F, Sampietro T, Stanley WC, Recchia FA. Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure.
J. Pharmacol. Exp. Ther. 321: 165-171 (2007).
*
-
Lacour S, Gautier JC, Pallardy M, Roberts R. Cytokines as potential biomarkers of liver toxicity.
Cancer Biomark. 1: 29-39 (2005).
-
Lacroix L, Mian C, Barrier T, Talbot M, Caillou B, Schlumberger M, Bidart JM. PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues.
Eur. J. Endocrinol. 151: 367-374 (2004).
*
-
Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, Tontonoz P. Autoregulation of the human liver X receptor alpha promoter.
Mol. Cell Biol. 21: 7558-7568 (2001).
*
-
Lagou V, Scott RA, Manios Y, Chen TL, Wang G, Grammatikaki E, Kortsalioudaki C, Liarigkovinos T, Moschonis G, Roma-Giannikou E, Pitsiladis YP. Impact of peroxisome proliferator-activated receptors gamma and delta on adiposity in toddlers and preschoolers in the GENESIS study.
Obesity (Silver Spring) 16: 913-918 (2008).
*
-
Lahiri S, Sen T, Palit G. Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats.
Eur. J. Pharmacol. 609: 118-125 (2009).
*
-
Lai DY. Rodent carcinogenicity of peroxisome proliferators and issues on human relevance.
J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev. 22: 37-55 (2004).
-
Lai PH, Wang WL, Ko CY, Lee YC, Yang WM, Shen TW, Chang WC, Wang JM. HDAC1/HDAC3 modulates PPARG2 transcription through the sumoylated CEBPD in hepatic lipogenesis.
Biochim. Biophys. Acta 1783: 1803-1814 (2008).
*
-
Laidler P, Dulinska J, Mrozicki S. Does the inhibition of c-myc expression mediate the anti-tumor activity of PPAR's ligands in prostate cancer cell lines?
Arch. Biochem. Biophys. 462: 1-12 (2007).
*
-
Lakatos HF, Thatcher TH, Kottmann RM, Garcia TM, Phipps RP, Sime PJ. The role of PPARs in lung fibrosis.
PPAR Res. 2007: 71323 (2007).
*
-
Lalloyer F, Vandewalle B, Percevault F, Torpier G, Kerr-Conte J, Oosterveer M, Paumelle R, Fruchart JC, Kuipers F, Pattou F, Fievet C, Staels B. Peroxisome proliferator-activated receptor alpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets.
Diabetes 55: 1605-1613 (2006).
*
-
Lampen A, Leifheit M, Voss J, Nau H. Molecular and cellular effects of cis-9, trans-11-conjugated linoleic acid in enterocytes: effects on proliferation, differentiation, and gene expression.
Biochim. Biophys. Acta 1735: 30-40 (2005).
*
-
Lampen A, Meyer S, Nau H. Phytanic acid and docosahexaenoic acid increase the metabolism of all-trans-retinoic acid and CYP26 gene expression in intestinal cells.
Biochim. Biophys. Acta 1521: 97-106 (2001).
*
-
Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F; Bellvitge Colorectal Cancer Study Group. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer.
Cancer Res. 63: 3560-3566 (2003).
*
-
Landreth G. Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease.
Curr. Alzheimer Res. 4: 159-164 (2007).
-
Landrier JF, Gouranton E, Yazidi CE, Malezet C, Balaguer P, Borel P, Amiot MJ. Adiponectin expression is induced by vitamin E via a peroxisome proliferator-activated receptor gamma-dependent mechanism.
Endocrinology 150: 5318-5325 (2009).
*
-
Landrier JF, Thomas C, Grober J, Duez H, Percevault F, Souidi M, Linard C, Staels B, Besnard P. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is PPARalpha-dependent.
J. Biol. Chem. 279: 45512-45518 (2004).
*
-
Landrier JF, Thomas C, Grober J, Zaghini I, Petit V, Poirier H, Niot I, Besnard P. The gene encoding the human ileal bile acid-binding protein (I-BABP) is regulated by peroxisome proliferator-activated receptors.
Biochim. Biophys. Acta 1735: 41-49 (2005).
*
-
Lapinskas PJ, Brown S, Leesnitzer LM, Blanchard S, Swanson C, Cattley RC, Corton JC. Role of PPARalpha in mediating the effects of phthalates and metabolites in the liver.
Toxicology 207: 149-163 (2005).
*
-
Laplante M, Festuccia WT, Soucy G, Blanchard PG, Renaud A, Berger JP, Olivecrona G, Deshaies Y. Tissue-specific postprandial clearance is the major determinant of PPARgamma-induced triglyceride lowering in the rat.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 296: R57-R66 (2009).
*
-
Lappas M, Permezel M, Rice GE. 15-Deoxy-delta(12,14)-prostaglandin J(2) and troglitazone regulation of the release of phospholipid metabolites, inflammatory cytokines and proteases from human gestational tissues.
Placenta 27: 1060-1072 (2006).
-
Larsen LN, Granlund L, Holmeide AK, Skattebol L, Nebb HI, Bremer J. Sulfur-substituted and alpha-methylated fatty acids as peroxisome proliferator-activated receptor activators.
Lipids 40: 49-57 (2005).
-
Larsen PJ, Lykkegaard K, Larsen LK, Fleckner J, Sauerberg P, Wassermann K, Wulff EM. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
Eur. J. Pharmacol. 596: 173-179 (2008).
-
Larsen ST, Nielsen GD. The adjuvant effect of di-(2-ethylhexyl) phthalate is mediated through a PPARalpha-independent mechanism.
Toxicol. Lett. 170: 223-228 (2007).
*
-
Larter CZ, Yeh MM, Cheng J, Williams J, Brown S, Dela Pena A, Bell-Anderson KS, Farrell GC. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
J. Gastroenterol. Hepatol. 23: 267-275 (2008).
*
-
Latini G, Del Vecchio A, Massaro M, Verrotti A, DE Felice C. In utero exposure to phthalates and fetal development.
Curr. Med. Chem. 13: 2527-2534 (2006).
-
Latini G, Scoditti E, Verrotti A, De Felice C, Massaro M. Peroxisome proliferator-activated receptors as mediators of phthalate-induced effects in the male and female reproductive tract: epidemiological and experimental evidence.
PPAR Res. 2008: 359267 (2008).
*
-
Latruffe N, Cherkaoui Malki M, Nicolas-Frances V, Clemencet MC, Jannin B, Berlot JP. Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases.
Biochem. Pharmacol. 60: 1027-1032 (2000).
*
-
Latruffe N, Cherkaoui Malki M, Nicolas-Frances V, Jannin B, Clemencet MC, Hansmannel F, Passilly-Degrace P, Berlot JP. Peroxisome-proliferator-activated receptors as physiological sensors of fatty acid metabolism: molecular regulation in peroxisomes.
Biochem. Soc. Trans. 29: 305-309 (2001).
*
-
Latruffe N, Vamecq J. Peroxisome proliferators and peroxisome proliferator activated receptors (PPARs) as regulators of lipid metabolism.
Biochimie 79: 81-94 (1997).
-
Latruffe N, Vamecq J, Cherkaoui Malki M. Genetic-dependency of peroxisomal cell functions - emerging aspects.
J. Cell. Mol. Med. 7: 238-248 (2003).
*
-
Laurent D, Gounarides JS, Gao J, Boettcher BR. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Diabetes Obes. Metab. 11: 632-636 (2009).
-
Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR, Moller DE, Zhou G. Differential gene regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) alpha.
J. Biol. Chem. 276: 31521-31527 (2001).
*
-
Lazennec G, Canaple L, Saugy D, Wahli W. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators.
Mol. Endocrinol. 14: 1962-1975 (2000).
*
-
Le Jossic-Corcos C, Duclos S, Ramirez LC, Zaghini I, Chevillard G, Martin P, Pineau T, Bournot P. Effects of peroxisome proliferator-activated receptor alpha activation on pathways contributing to cholesterol homeostasis in rat hepatocytes.
Biochim. Biophys. Acta 1683: 49-58 (2004).
*
-
le Maire A, Grimaldi M, Roecklin D, Dagnino S, Vivat-Hannah V, Balaguer P, Bourguet W. Activation of RXR-PPAR heterodimers by organotin environmental endocrine disruptors.
EMBO Rep. 10: 367-373 (2009).
*
-
Le May C, Cauzac M, Diradourian C, Perdereau D, Girard J, Burnol AF, Pegorier JP. Fatty acids induce L-CPT I gene expression through a PPARalpha-independent mechanism in rat hepatoma cells.
J. Nutr. 135: 2313-2319 (2005).
*
-
Le May C, Pineau T, Bigot K, Kohl C, Girard J, Pegorier JP. Reduced hepatic fatty acid oxidation in fasting PPARalpha null mice is due to impaired mitochondrial hydroxymethylglutaryl-CoA synthase gene expression.
FEBS Lett. 475: 163-166 (2000).
*
-
Le Mee S, Hennebert O, Ferrec C, Wulfert E, Morfin R. 7beta-Hydroxy-epiandrosterone-mediated regulation of the prostaglandin synthesis pathway in human peripheral blood monocytes.
Steroids 73: 1148-1159 (2008).
-
Leahy JL. Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis.
Curr. Diab. Rep. 9: 215-220 (2009).
-
Leaver MJ, Ezaz MT, Fontagne S, Tocher DR, Boukouvala E, Krey G. Multiple peroxisome proliferator-activated receptor beta subtypes from Atlantic salmon (Salmo salar).
J. Mol. Endocrinol. 38: 391-400 (2007).
*
-
Lebovic DI, Mwenda JM, Chai DC, Mueller MD, Santi A, Fisseha S, D'Hooghe T. PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study.
Fertil. Steril. 88: 1108-1119 (2007).
*
-
Lebovitz H. Diabetes: assessing the pipeline.
Atheroscler. Suppl. 7: 43-49 (2006).
-
Lebovitz HE. Insulin resistance - a common link between type 2 diabetes and cardiovascular disease.
Diabetes Obes. Metab. 8: 237-249 (2006).
-
Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, Reid IR, Grey A, Rosen CJ. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the IGF regulatory system in vitro and in vivo.
Endocrinology 148: 903-911 (2007).
*
-
Lecka-Czernik B, Suva LJ. Resolving the two "bony" faces of PPAR-gamma.
PPAR Res. 2006: 27489 (2006).
*
-
Leclercq IA. Pathogenesis of steatohepatitis: insights from the study of animal models.
Acta Gastroenterol. Belg. 70: 25-31 (2007).
-
Leclercq IA, Lebrun VA, Starkel P, Horsmans YJ. Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPARgamma agonist pioglitazone.
Lab. Invest. 87: 56-65 (2007).
*
-
Lecomte J, Flament S, Salamone S, Boisbrun M, Mazerbourg S, Chapleur Y, Grillier-Vuissoz I. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Breast Cancer Res. Treat. 112: 437-451 (2008).
-
Lee BC, Doo HK, Ahn SY, Byun SH, Kim SI, Park HK, Hong M, Ha E, Yim SV, Yin C, Leem KH, Ahn YM. Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism is associated with the susceptibility to ischemic stroke in Taeeumin classified by Sasang medicine.
Neurol. Res. 29 Suppl. 1: 32-37 (2007).
-
Lee BC, Lee HJ, Chung JH. Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes.
Neurosci. Lett. 410: 141-145 (2006).
*
-
Lee BC, Lee KC, Lee H, Mach RH, Katzenellenbogen JA. Synthesis and binding affinity of a fluorine-substituted peroxisome proliferator-activated gamma (PPARgamma) ligand as a potential positron emission tomography (PET) imaging agent.
Bioconjug. Chem. 18: 507-513 (2007).
*
-
Lee CH, Chawla A, Urbiztondo N, Liao D, Boisvert WA, Evans RM, Curtiss LK. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta.
Science 302: 453-457 (2003).
*
-
Lee CH, Kang K, Mehl IR, Nofsinger R, Alaynick WA, Chong LW, Rosenfeld JM, Evans RM. Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage.
Proc. Natl. Acad. Sci. U.S.A. 103: 2434-2439 (2006).
*
-
Lee CH, Kim HD, Shin SM, Kim SG. A novel mechanism of PPARgamma regulation of TGFbeta1: implication in cancer biology.
PPAR Res. 2008: 762398 (2008).
*
-
Lee CH, Olson P, Hevener A, Mehl I, Chong LW, Olefsky JM, Gonzalez FJ, Ham J, Kang H, Peters JM, Evans RM. PPARdelta regulates glucose metabolism and insulin sensitivity.
Proc. Natl. Acad. Sci. U.S.A. 103: 3444-3449 (2006).
*
-
Lee E, Ahn MY, Kim HJ, Kim IY, Han SY, Kang TS, Hong JH, Park KL, Lee BM, Kim HS. Effect of di(n-butyl) phthalate on testicular oxidative damage and antioxidant enzymes in hyperthyroid rats.
Environ. Toxicol. 22: 245-255 (2007).
-
Lee GY, Kim NH, Zhao ZS, Cha BS, Kim YS. Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level.
Biochem. J. 378: 983-990 (2004).
*
-
Lee H, Kang R, Kim YS, Chung SI, Yoon Y. Platycodin D inhibits adipogenesis of 3T3-L1 cells by modulating Kruppel-like factor 2 and peroxisome proliferator-activated receptor gamma.
Phytother. Res. Dec 18 [Epub ahead of print] (2009).
-
Lee HJ, Ju J, Paul S, So JY, Decastro A, Smolarek A, Lee MJ, Yang CS, Newmark HL, Suh N. Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma.
Clin. Cancer Res. 15: 4242-4249 (2009).
*
-
Lee HJ, Su Y, Yin PH, Lee HC, Chi CW. PPARgamma/PGC-1alpha pathway in E-cadherin expression and motility of HepG2 cells.
Anticancer Res. 29: 5057-5063 (2009).
-
Lee HK, Lee BH, Park SA, Kim CW. The proteomic analysis of an adipocyte differentiated from human mesenchymal stem cells using two-dimensional gel electrophoresis.
Proteomics 6: 1223-1229 (2006).
*
-
Lee IK, Lee JH, Yun BS. Polychlorinated compounds with PPAR-gamma agonistic effect from the medicinal fungus Phellinus ribis.
Bioorg. Med. Chem. Lett. 18: 4566-4568 (2008).
*
-
Lee J, Hong EM, Byun HW, Choi MH, Jang HJ, Eun CS, Kae SH, Choi HS. The effect of PPARalpha and PPARgamma ligands on inflammation and ABCA1 expression in cultured gallbladder epithelial cells.
Dig. Dis. Sci. 53: 1707-1715 (2008).
*
-
Lee J, Hong EM, Koh DH, Choi MH, Jang HJ, Kae SH, Choi HS. HMG-CoA reductase inhibitors (statins) activate expression of PPARalpha/PPARgamma and ABCA1 in cultured gallbladder epithelial cells.
Dig. Dis. Sci. Feb 19 [Epub ahead of print] (2009).
*
-
Lee J, Jung E, Lee J, Huh S, Kim YS, Kim YW, Kim YS, Park D. Anti-adipogenesis by 6-thioinosine is mediated by downregulation of PPAR gamma through JNK-dependent upregulation of iNOS.
Cell. Mol. Life Sci. Nov 26 [Epub ahead of print] (2009).
*
-
Lee J, Jung E, Lee J, Kim S, Huh S, Kim Y, Kim Y, Byun SY, Kim YS, Park D. Isorhamnetin represses adipogenesis in 3T3-L1 cells.
Obesity (Silver Spring) 17: 226-232 (2009).
*
-
Lee JH, Banerjee A, Ueno Y, Ramaiah SK. Potential relationship between hepatobiliary osteopontin and peroxisome proliferator-activated receptor alpha expression following ethanol-associated hepatic injury in vivo and in vitro.
Toxicol. Sci. 106: 290-299 (2008).
*
-
Lee JH, Yu SM, Yoon EK, Lee WK, Jung JC, Kim SJ. 15-Deoxy-delta(12,14)-prostaglandinJ2 regulates dedifferentiation through peroxisome proliferator-activated receptor-gamma-dependent pathway but not COX-2 expression in articular chondrocytes.
J. Korean Med. Sci. 22: 891-897 (2007).
*
-
Lee JH, Zhou J, Xie W. PXR and LXR in hepatic steatosis: a new dog and an old dog with new tricks.
Mol. Pharm. 5: 60-66 (2008).
*
-
Lee JI, Paik YH, Lee KS, Lee JW, Kim YS, Jeong S, Kwon KS, Lee DH, Kim HG, Shin YW, Kim MA. A peroxisome-proliferator activated receptor-gamma ligand could regulate the expression of leptin receptor on human hepatic stellate cells.
Histochem. Cell Biol. 127: 495-502 (2007).
*
-
Lee JS, Choi YM, Kang HY. PPAR-gamma agonist, ciglitazone, increases pigmentation and migration of human melanocytes.
Exp. Dermatol. 16: 118-123 (2007).
*
-
Lee JW, Bajwa PJ, Carson MJ, Jeske DR, Cong Y, Elson CO, Lytle C, Straus DS. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice.
Gastroenterology 133: 108-123 (2007).
*
-
Lee KJ, Ha ES, Kim MK, Lee SH, Suh JS, Lee SH, Park KH, Park JH, Kim DJ, Kang D, Kim BC, Jeoung D, Kim YK, Kim HD, Hahn JH. CD36 signaling inhibits the translation of heat shock protein 70 induced by oxidized low density lipoprotein through activation of peroxisome proliferators-activated receptor gamma.
Exp. Mol. Med. 40: 658-668 (2008).
*
-
Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, Lee MK, Kim UH, Lee YC. Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice.
J. Allergy Clin. Immunol. 118: 120-127 (2006).
*
-
Lee KS, Park JH, Lee S, Lim HJ, Park HY. PPARdelta activation inhibits angiotensin II induced cardiomyocyte hypertrophy by suppressing intracellular Ca(2+) signaling pathway.
J. Cell. Biochem. 106: 823-834 (2009).
*
-
Lee KS, Park SJ, Hwang PH, Yi HK, Song CH, Chai OH, Kim JS, Lee MK, Lee YC. PPAR-gamma modulates allergic inflammation through up-regulation of PTEN.
FASEB J. 19: 1033-1035 (2005).
*
-
Lee SJ, Yang EK, Kim SG. Peroxisome proliferator-activated receptor-gamma and retinoic acid X receptor alpha represses the TGFbeta1 gene via PTEN-mediated S6K1 inhibition: role for Zf9 dephosphorylation.
Mol. Pharmacol. 70: 415-425 (2006).
*
-
Lee SK, Kim HJ, Chi SG, Jang JY, Nam KD, Kim NH, Joo KR, Dong SH, Kim BH, Chang YW, Lee JI, Chang R. Saccharomyces boulardii activates expression of peroxisome proliferator-activated receptor-gamma in HT-29 cells.
Korean J. Gastroenterol. 45: 328-334 (2005).
-
Lee SK, Kim YW, Chi SG, Joo YS, Kim HJ. The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis.
Dig. Dis. Sci. 54: 255-263 (2009).
*
-
Lee SS, Chan WY, Lo CK, Wan DC, Tsang DS, Cheung WT. Requirement of PPARalpha in maintaining phospholipid and triglyceride homeostasis during energy deprivation.
J. Lipid Res. 45: 2025-2037 (2004).
*
-
Lee SY, Kang EJ, Hur GY, Jung KH, Jung HC, Lee SY, Kim JH, Shin C, In KH, Kang KH, Yoo SH, Shim JJ. Peroxisome proliferator activated receptor gamma (PPARgamma) inhibits cigarette smoke solution-induced mucin production in human airway epithelial (NCI-H292) cells.
Am. J. Physiol. Lung Cell. Mol. Physiol. 291: L84-L90 (2006).
*
-
Lee TI, Kao YH, Chen YC, Chen YJ. Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors.
Eur. J. Clin. Invest. 39: 23-30 (2009).
*
-
Lee TS, Lin CY, Tsai JY, Wu YL, Su KH, Lu KY, Hsiao SH, Pan CC, Kou YR, Hsu YP, Ho LT. Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages.
Life Sci. 84: 97-104 (2009).
*
-
Lee WJ, Jung HD, Lee HJ, Kim BS, Lee SJ, Kim DW. Influence of substance-P on cultured sebocytes.
Arch. Dermatol. Res. 300: 311-316 (2008).
*
-
Lee Y, Thompson JT, de Lera AR, Vanden Heuvel JP. Isomer-specific effects of conjugated linoleic acid on gene expression in RAW 264.7.
J. Nutr. Biochem. 20: 848-859.e1-e5 (2009).
*
-
Lee Y, Yu X, Gonzales F, Mangelsdorf DJ, Wang MY, Richardson C, Witters LA, Unger RH. PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue.
Proc. Natl. Acad. Sci. U.S.A. 99: 11848-11853 (2002).
*
-
Lee YJ, Suh HN, Han HJ. Effect of BSA-induced ER stress on SGLTs protein expression levels and alpha-MG uptake in renal proximal tubule cells.
Am. J. Physiol. Renal Physiol. 296: F1405-F1416 (2009).
*
-
Lee YK, Lee WS, Hwang JT, Kwon DY, Surh YJ, Park OJ. Curcumin exerts antidifferentiation effect through AMPKalpha-PPAR-gamma in 3T3-L1 adipocytes and antiproliferatory effect through AMPKalpha-COX-2 in cancer cells.
J. Agric. Food Chem. 57: 305-310 (2009).
*
-
Lee YR, Yu HN, Noh EM, Kim JS, Song EK, Han MK, Kim BS, Lee SH, Park J. Peroxisome proliferator-activated receptor gamma and retinoic acid receptor synergistically up-regulate the tumor suppressor PTEN in human promyeloid leukemia cells.
Int. J. Hematol. 85: 231-237 (2007).
-
Lefterova MI, Steger DJ, Zhuo D, Qatanani M, Mullican SE, Tuteja G, Manduchi E, Grant GR, Lazar MA. Cell-specific determinants of PPARgamma function in adipocytes and macrophages.
Mol. Cell. Biol. Feb 22 [Epub ahead of print] (2010).
*
-
Lefterova MI, Zhang Y, Steger DJ, Schupp M, Schug J, Cristancho A, Feng D, Zhuo D, Stoeckert CJ Jr, Liu XS, Lazar MA. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale.
Genes Dev. 22: 2941-2952 (2008).
*
-
Legendre C, Causse E, Chaput E, Salvayre R, Pineau T, Edgar AD. Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARalpha-mediated effect.
Biochem. Biophys. Res. Commun. 295: 1052-1056 (2002).
*
-
Lehmann GM, Garcia-Bates TM, Smith TJ, Feldon SE, Phipps RP. Regulation of lymphocyte function by PPARgamma: relevance to thyroid eye disease-related inflammation.
PPAR Res. 2008: 895901 (2008).
*
-
Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs.
J. Biol. Chem. 272: 3406-3410 (1997).
*
-
Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).
J. Biol. Chem. 270: 12953-12956 (1995).
*
-
Lehrke M, Pascual G, Glass CK, Lazar MA. Gaining weight: the Keystone Symposium on PPAR and LXR.
Genes Dev. 19: 1737-1742 (2005).
*
-
Leibovitz E, Schiffrin EL. PPAR activation: a new target for the treatment of hypertension.
J. Cardiovasc. Pharmacol. 50: 120-125 (2007).
-
Leisewitz AV, Urrutia CR, Martinez GR, Loyola G, Bronfman M. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
J. Cell. Physiol. 217: 367-376 (2008).
*
-
Lelliott CJ, Ljungberg A, Ahnmark A, William-Olsson L, Ekroos K, Elmgren A, Arnerup G, Shoulders CC, Oscarsson J, Linden D. Hepatic PGC-1beta overexpression induces combined hyperlipidemia and modulates the response to PPARalpha activation.
Arterioscler. Thromb. Vasc. Biol. 27: 2707-2713 (2007).
-
Lemann M. Treatment of chronic inflammatory bowel diseases.
Bull. Acad. Natl. Med. 191: 1125-1141 (2007).
-
Lemay DG, Hwang DH. Genome-wide identification of peroxisome proliferator response elements using integrated computational genomics.
J. Lipid Res. 47: 1583-1587 (2006).
*
-
Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology.
Annu. Rev. Cell. Dev. Biol. 12: 335-363 (1996).
-
Lemberger T, Saladin R, Vazquez M, Assimacopoulos F, Staels B, Desvergne B, Wahli W, Auwerx J. Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm.
J. Biol. Chem. 271: 1764-1769 (1996).
*
-
Lemoine CM, McClelland GB, Lyons CN, Mathieu-Costello O, Moyes CD. Control of mitochondrial gene expression in the aging rat myocardium.
Biochem. Cell. Biol. 84: 191-198 (2006).
-
Lemoine M, Barbu V, Girard PM, Kim M, Bastard JP, Wendum D, Paye F, Housset C, Capeau J, Serfaty L. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients.
AIDS 20: 387-395 (2006).
*
-
Lemoine M, Capeau J, Serfaty L. PPAR and liver injury in HIV-infected patients.
PPAR Res. 2009: 906167 (2009).
*
-
Lenhard JM. PPAR gamma/RXR as a molecular target for diabetes.
Receptors Channels 7: 249-258 (2001).
-
Lennon R, Welsh GI, Singh A, Satchell SC, Coward RJ, Tavare JM, Mathieson PW, Saleem MA. Rosiglitazone enhances glucose uptake in glomerular podocytes using the glucose transporter GLUT1.
Diabetologia 52: 1944-1952 (2009).
*
-
Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders.
Proc. Natl. Acad. Sci. U.S.A. 96: 7473-7478 (1999).
*
-
Leslie DS, Dascher CC, Cembrola K, Townes MA, Hava DL, Hugendubler LC, Mueller E, Fox L, Roura-Mir C, Moody DB, Vincent MS, Gumperz JE, Illarionov PA, Besra GS, Reynolds CG, Brenner MB. Serum lipids regulate dendritic cell CD1 expression and function.
Immunology 125: 289-301 (2008).
*
-
Leuenberger N, Pradervand S, Wahli W. Sumoylated PPARalpha mediates sex-specific gene repression and protects the liver from estrogen-induced toxicity in mice.
J. Clin. Invest. 119: 3138-3148 (2009).
*
-
Leung WK, Bai AH, Chan VY, Yu J, Chan MW, To KF, Wu JR, Chan KK, Fu YG, Chan FK, Sung JJ. Effect of peroxisome proliferator activated receptor gamma ligands on growth and gene expression profiles of gastric cancer cells.
Gut 53: 331-338 (2004).
*
-
Levy E, Spahis S, Sinnett D, Peretti N, Maupas-Schwalm F, Delvin E, Lambert M, Lavoie MA. Intestinal cholesterol transport proteins: an update and beyond.
Curr. Opin. Lipidol. 18: 310-318 (2007).
-
Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis.
Am. J. Gastroenterol. 96: 3323-3328 (2001).
*
-
Lewis SN, Bassaganya-Riera J, Bevan DR. Virtual screening as a technique for PPAR modulator discovery.
PPAR Res. 2010: 861238 (2010).
*
-
Leyvraz C, Suter M, Verdumo C, Calmes JM, Paroz A, Darimont C, Gaillard RC, Pralong FP, Giusti V. Selective effects of PPARgamma agonists and antagonists on human pre-adipocyte differentiation.
Diabetes Obes. Metab. Nov 5 [Epub ahead of print] (2009).
-
Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma.
J. Clin. Invest. 114: 1564-1576 (2004).
*
-
Li AC, Glass CK. PPAR and LXR-dependent pathways controlling lipid metabolism and development of atherosclerosis.
J. Lipid Res. 45: 2161-2173 (2004).
*
-
Li AC, Palinski W. Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis.
Annu. Rev. Pharmacol. Toxicol. 46: 1-39 (2006).
*
-
Li B, Reynolds JM, Stout RD, Bernlohr DA, Suttles J. Regulation of Th17 differentiation by epidermal fatty acid-binding protein.
J. Immunol. 182: 7625-7633 (2009).
-
Li CB, Li XX, Chen YG, Zhang C, Zhang MX, Zhao XQ, Hao MX, Hou XY, Gong ML, Zhao YX, Bu PL, Zhang Y. Effects and mechanisms of PPARalpha activator fenofibrate on myocardial remodeling in hypertension.
J. Cell. Mol. Med. Aug 27 [Epub ahead of print] (2008).
*
-
Li F, Tan W, Kang Z, Wong CW. Tocotrienol enriched palm oil prevents atherosclerosis through modulating the activities of peroxisome proliferators-activated receptors.
Atherosclerosis Jan 25 [Epub ahead of print] (2010).
-
Li H, Pauza CD. Effects of 15-deoxy-delta-prostaglandin J2 (15d-PGJ2) and rosiglitazone on human Vdelta2 T cells.
PLoS One 4: e7726 (2009).
*
-
Li H, Ruan XZ, Powis SH, Fernando R, Mon WY, Wheeler DC, Moorhead JF, Varghese Z. EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism.
Kidney Int. 67: 867-874 (2005).
*
-
Li J, Wang N. Peroxisome proliferator-activated receptor-gamma in vascular biology.
Cardiovasc. Hematol. Disord. Drug Targets 7: 109-117 (2007).
-
Li L, Cheng LX, Nsenga R, He MA, Wu TC. Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population.
Clin. Cardiol. 29: 300-304 (2006).
-
Li L, Gao PJ, Xi R, Wu CF, Zhu DL, Yan J, Lu GP. Pioglitazone inhibits homocysteine-induced migration of vascular smooth musclecells through a peroxisome proliferator-activated receptor gamma-independentmechanism.
Clin. Exp. Pharmacol. Physiol. 35: 1471-1476 (2008).
*
-
Li L, Nelson ED, Seburg RA, Reed RA. Nucleophilic group transfer reactivity for fibric acid derived drug molecules.
J. Pharm. Sci. 95: 1954-1966 (2006).
*
-
Li L, Prabhakaran K, Zhang X, Borowitz JL, Isom GE. PPARalpha-mediated up-regulation of uncoupling protein-2 switches cyanide-induced apoptosis to necrosis in primary cortical cells.
Toxicol. Sci. 93: 136-145 (2006).
*
-
Li LL, Ma XL, Ran JX, Sun XF, Xu LM, Ren J, Mao XM. Genetic polymorphism of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala on ethnic susceptibility to diabetes in Uygur, Kazak and Han subjects.
Clin. Exp. Pharmacol Physiol. 35: 187-191 (2008).
-
Li M, Indra AK, Warot X, Brocard J, Messaddeq N, Kato S, Metzger D, Chambon P. Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis.
Nature 407: 633-636 (2000).
*
-
Li M, Lee TW, Yim AP, Mok TS, Chen GG. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells.
J. Cell. Physiol. 209: 428-438 (2006).
*
-
Li M, Li Z, Sun X, Yang L, Fang P, Liu Y, Li W, Xu J, Lu J, Xie M, Zhang D. Heme oxygenase-1/p21(WAF1) mediates peroxisome proliferator-activated receptor-gamma signaling inhibition of proliferation of rat pulmonary artery smooth muscle cells.
FEBS J. Feb 13 [Epub ahead of print] (2010).
*
-
Li MY, Hsin MK, Yip J, Mok TS, Underwood MJ, Chen GG. PPARgamma activation extinguishes smoking carcinogen by inhibiting NNK-mediated proliferation.
Am. J. Respir. Cell. Mol. Biol. 42: 113-122 (2010).
*
-
Li R, Zheng W, Pi R, Gao J, Zhang H, Wang P, Le K, Liu P. Activation of peroxisome proliferator-activated receptor-alpha prevents glycogen synthase 3beta phosphorylation and inhibits cardiac hypertrophy.
FEBS Lett. 581: 3311-3316 (2007).
*
-
Li RJ, Qiu SD, Chen HX, Tian H, Wang HX. The immunotherapeutic effects of Astragalus polysaccharide in type 1 diabetic mice.
Biol. Pharm. Bull. 30: 470-476 (2007).
*
-
Li RW, Douglas TD, Maiyoh GK, Adeli K, Theriault AG. Green tea leaf extract improves lipid and glucose homeostasis in a fructose-fed insulin-resistant hamster model.
J. Ethnopharmacol. 104: 24-31 (2006).
-
Li S, Gokden N, Okusa MD, Bhatt R, Portilla D. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF.
Am. J. Physiol. Renal Physiol. 289: F469-F480 (2005).
*
-
Li SY, Chang CQ, Ma FY, Yu CL. Modulating effects of chlorogenic acid on lipids and glucose metabolism and expression of hepatic peroxisome proliferator-activated receptor-alpha in golden hamsters fed on high fat diet.
Biomed. Environ. Sci. 22: 122-129 (2009).
-
Li T, Chiang JY. Regulation of bile acid and cholesterol metabolism by PPARs.
PPAR Res. 2009: 501739 (2009).
*
-
Li T, Jahan A, Chiang JY. Bile acids and cytokines inhibit the human cholesterol 7 alpha-hydroxylase gene via the JNK/c-Jun pathway in human liver cells.
Hepatology 43: 1202-1210 (2006).
*
-
Li WM, Jing L, Song J, Zhou LJ. Role of renin-angiotensin system, PPARalpha, PPARgamma in the development of alcoholic cardiomyopathy.
Zhonghua Xin Xue Guan Bing Za Zhi 36: 630-635 (2008).
-
Li X, Han de W, Zhao LF, Yin L. Effect of endotoxin on the expression of peroxisome proliferator-activated receptor alpha in the development of nonalcoholic steatohepatitis in rats.
Zhonghua Gan Zang Bing Za Zhi 13: 89-91 (2005).
-
Li X, Hansen PA, Xi L, Chandraratna RA, Burant CF. Distinct mechanisms of glucose lowering by specific agonists for peroxisomal proliferator activated receptor-gamma (PPARgamma) and retinoic acid X receptors (RXR).
J. Biol. Chem. 280: 38317-38327 (2005).
*
-
Li X, Kimura H, Hirota K, Sugimoto H, Kimura N, Takahashi N, Fujii H, Yoshida H. Hypoxia reduces the expression and anti-inflammatory effects of peroxisome proliferator-activated receptor-gamma in human proximal renal tubular cells.
Nephrol. Dial. Transplant. 22: 1041-1051 (2007).
*
-
Li X, Yang X, Xu Y, Jiang X, Li X, Nan F, Tang H. Troglitazone inhibits cell proliferation by attenuation of epidermal growth factor receptor signaling independent of peroxisome proliferator-activated receptor gamma.
Cell Res. 19: 720-732 (2009).
-
Li XH, Zou HJ, Wu AH, Ye YL, Shen JH. Structure-based drug design of a novel family of chalcones as PPARalpha agonists: virtual screening, synthesis, and biological activities in vitro.
Acta Pharmacol. Sin. 28: 2040-2052 (2007).
*
-
Li Y, Kovach A, Suino-Powell K, Martynowski D, Xu HE. Structural and biochemical basis for the binding selectivity of PPARgamma to PGC-1alpha.
J. Biol. Chem. 283: 19132-19139 (2008).
*
-
Li Y, Nara TY, Nakamura MT. Peroxisome proliferator activated receptor is required for feedback regulation of highly unsaturated fatty acid synthesis.
J. Lipid Res. 46: 2423-2431 (2005).
*
-
Li Y, Qi Y, Huang TH, Yamahara J, Roufogalis BD. Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties.
Diabetes Obes. Metab. 10: 10-17 (2008).
-
Li Y, Wen X, Spataro BC, Hu K, Dai C, Liu Y. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists.
J. Am. Soc. Nephrol. 17: 54-65 (2006).
*
-
Li Z, Liao C, Ko BC, Shan S, Tong EH, Yin Z, Pan D, Wong VK, Shi L, Ning ZQ, Hu W, Zhou J, Chung SS, Lu XP. Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.
Bioorg. Med. Chem. Lett. 14: 3507-3511 (2004).
*
-
Li Z, Zhu XY, Li M, Bai YL, Hu J. Protective effect of ghrelin on left ventricular remodeling in spontaneously hypertensive rats is associated with the peroxisome proliferator-activated receptor gamma-dependent pathway.
Chin. Med. J. (Engl.) 121: 2299-2304 (2008).
-
Liang C, Ren Y, Tan H, He Z, Jiang Q, Wu J, Zhen Y, Fan M, Wu Z. Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products.
Br. J. Pharmacol. 158: 1865-1873 (2009).
*
-
Liang HJ, Suk FM, Wang CK, Hung LF, Liu DZ, Chen NQ, Chen YC, Chang CC, Liang YC. Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice.
Chem. Biol. Interact. 181: 309-315 (2009).
*
-
Liang HL, Ouyang Q. A clinical trial of rosiglitazone and 5-aminosalicylate combination for ulcerative colitis.
Zhonghua Nei Ke Za Zhi 45: 548-551 (2006).
-
Liang YJ, Liu YC, Chen CY, Lai LP, Shyu KG, Juang SJ, Wang BW, Leu JG. Comparison of PPARdelta and PPARgamma in inhibiting the pro-inflammatory effects of C-reactive protein in endothelial cells.
Int. J. Cardiol. Apr 21 [Epub ahead of print] (2009).
-
Liangpunsakul S, Wou SE, Wineinger KD, Zeng Y, Cyganek I, Jayaram HN, Crabb D. Effects of WY-14,643 on the phosphorylation and activation of AMP-dependent protein kinase.
Arch. Biochem. Biophys. 485: 10-15 (2009).
*
-
Liao C, Liu B, Shi L, Zhou J, Lu XP. Construction of a virtual combinatorial library using SMILES strings to discover potential structure-diverse PPAR modulators.
Eur. J. Med. Chem. 40: 632-640 (2005).
*
-
Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
Am. J. Cardiol. 99: 27-40 (2007).
-
Lichtor T, Spagnolo A, Glick RP, Feinstein DL. PPAR-gamma thiazolidinedione agonists and immunotherapy in the treatment of brain tumors.
PPAR Res. 2008: 547470 (2008).
*
-
Lickteig AJ, Cheng X, Augustine LM, Klaassen CD, Cherrington NJ. Tissue distribution, ontogeny and induction of the transporters multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice.
Life Sci. 83: 59-64 (2008).
-
Lieber CS, Leo MA, Wang X, Decarli LM. Effect of chronic alcohol consumption on hepatic SIRT1 and PGC-1alpha in rats.
Biochem. Biophys. Res. Commun. 370: 44-48 (2008).
*
-
Lillycrop KA, Phillips ES, Jackson AA, Hanson MA, Burdge GC. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring.
J. Nutr. 135: 1382-1386 (2005).
*
-
Lim HJ, Lee S, Park JH, Lee KS, Choi HE, Chung KS, Lee HH, Park HY. PPARdelta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle.
Atherosclerosis 202: 446-454 (2009).
-
Lim SW, Hong SP, Jeong SW, Kim B, Bak H, Ryoo HC, Lee SH, Ahn SK. Simultaneous effect of ursolic acid and oleanolic acid on epidermal permeability barrier function and epidermal keratinocyte differentiation via peroxisome proliferator-activated receptor-alpha.
J. Dermatol. 34: 625-634 (2007).
-
Lin BC, Sullivan R, Lee Y, Moran S, Glover E, Bradfield CA. Deletion of the aryl hydrocarbon receptor associated protein 9 leads to cardiac malformation and embryonic lethality.
J. Biol. Chem. 282: 35924-35932 (2007).
*
-
Lin CL, Wang MH, Qin YF, Fang M, Xie BB, Zhong XY. Differentiation of SWO-38 glioma cells induced by CDA-2 is mediated by peroxisome proliferator-activated receptor gamma.
J. Neurooncol. 95: 29-36 (2009).
-
Lin CY, Gurlo T, Haataja L, Hsueh WA, Butler PC. Activation of peroxisome proliferator-activated receptors-gamma (PPAR-gamma) by rosiglitazone prevents human islet cells against human-islet amyloid polypeptide toxicity by a PI3 kinase-dependent pathway.
J. Clin. Endocrinol. Metab. 90: 6678-6686 (2005).
*
-
Lin HY, Yu IC, Wang RS, Chen YT, Liu NC, Altuwaijri S, Hsu CL, Ma WL, Jokinen J, Sparks JD, Yeh S, Chang C. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor.
Hepatology 47: 1924-1935 (2008).
*
-
Lin MS, Chen WC, Bai X, Wang YD. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
J. Dig. Dis. 8: 82-88 (2007).
-
Lin Q, Ruuska SE, Shaw NS, Dong D, Noy N. Ligand selectivity of the peroxisome proliferator-activated receptor alpha.
Biochemistry 38: 185-190 (1999).
*
-
Lin TH, Tang CH, Hung SY, Liu SH, Lin YM, Fu WM, Yang RS. Upregulation of heme oxygenase-1 inhibits the maturation and mineralization of osteoblasts.
J. Cell. Physiol. 222: 757-768 (2009).
*
-
Linard C, Gremy O, Benderitter M. Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-ASA agonist.
J. Pharmacol. Exp. Ther. 324: 911-920 (2008).
*
-
Ling C, Del Guerra S, Lupi R, Ronn T, Granhall C, Luthman H, Masiello P, Marchetti P, Groop L, Del Prato S. Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion.
Diabetologia 51: 615-622 (2008).
*
-
Ling C, Wegner L, Andersen G, Almgren P, Hansen T, Pedersen O, Groop L, Vaag A, Poulsen P. Impact of the peroxisome proliferator activated receptor-gamma coactivator-1beta (PGC-1beta) Ala203Pro polymorphism on in vivo metabolism, PGC-1beta expression and fibre type composition in human skeletal muscle.
Diabetologia 50: 1615-1620 (2007).
*
-
Linsalata M, Giannini R, Notarnicola M, Cavallini A. Peroxisome proliferator-activated receptor gamma and spermidine/spermine N1-acetyltransferase gene expressions are significantly correlated in human colorectal cancer.
BMC Cancer 6: 191 (2006).
*
-
Linz W, Wohlfart P, Baader M, Breitschopf K, Falk E, Schafer HL, Gerl M, Kramer W, Rutten H. The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.
Acta Pharmacol. Sin. 30: 935-946 (2009).
-
Liou JY, Ghelani D, Yeh S, Wu KK. Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3{varepsilon}.
Cancer Res. 67: 3185-3191 (2007).
*
-
Liou JY, Lee S, Ghelani D, Matijevic-Aleksic N, Wu KK. Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation.
Arterioscler. Thromb. Vasc. Biol. 26: 1481-1487 (2006).
-
Liou JY, Wu CC, Chen BR, Yen LB, Wu KK. Nonsteroidal anti-inflammatory drugs induced endothelial apoptosis by perturbing PPAR-delta transcriptional pathway.
Mol. Pharmacol. 74: 1399-1406 (2008).
*
-
Lipozencic J. The 1st world congress on gender-specific medicine men, women and medicine a new view of the biology of sex/gender differences and aging.
Acta Dermatovenerol. Croat. 14: 132-134 (2006).
-
Lira FS, Rosa JC, Yamashita AS, Koyama CH, Batista ML Jr, Seelaender M. Endurance training induces depot-specific changes in IL-10/TNF-alpha ratio in rat adipose tissue.
Cytokine 45: 80-85 (2009).
-
Liu D, Zeng BX, Shang Y. Decreased expression of peroxisome proliferator-activated receptor-gamma in endotoxin-induced acute lung injury.
Physiol. Res. 55: 291-299 (2006).
*
-
Liu DS, Liu WJ, Chen L, Ou XM, Wang T, Feng YL, Zhang SF, Xu D, Chen YJ, Wen FQ. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates acrolein-induced airway mucus hypersecretion in rats.
Toxicology 260: 112-119 (2009).
*
-
Liu G, Moon TW, Metcalfe CD, Lee LE, Trudeau VL. A teleost in vitro reporter gene assay to screen for agonists of the peroxisome proliferator-activated receptors.
Environ. Toxicol. Chem. 24: 2260-2266 (2005).
-
Liu GH, Qu J, Shen X. Thioredoxin-mediated negative autoregulation of peroxisome proliferator-activated receptor alpha transcriptional activity.
Mol. Biol. Cell. 17: 1822-1833 (2006).
*
-
Liu HR, Tao L, Gao E, Qu Y, Lau WB, Lopez BL, Christopher TA, Koch W, Yue TL, Ma XL. Rosiglitazone inhibits hypercholesterolemia-induced myeloperoxidase upregulation - a novel mechanism for the cardioprotective effects of PPAR agonists.
Cardiovasc. Res. 81: 344-352 (2009).
*
-
Liu J, Xia Q, Zhang Q, Li H, Zhang J, Li A, Xiu R. Peroxisome proliferator-activated receptor-gamma ligands 15-deoxy-delta-prostaglandin J2 and pioglitazone inhibit H2O2-induced tumor necrosis factor-alpha and lipopolysaccharide-induced CXC chemokine expression in neonatal rat cardiac myocytes.
Shock 32: 317-324 (2009).
-
Liu JJ, Guo YW, Fang ZG, Si XN, Wu XY, Liu PQ, Lin DJ, Xiao RZ, Xu Y, Wang CZ, Li XD, He Y, Huang RW. Activation of peroxisome proliferator-activated receptor-gamma induces apoptosis on acute promyelocytic leukemia cells via downregulation of XIAP.
Int. J. Mol. Med. 24: 623-632 (2009).
-
Liu JJ, Hu T, Wu XY, Wang CZ, Xu Y, Zhang Y, Xiao RZ, Lin DJ, Huang RW, Liu Q. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone-induced apoptosis in leukemia K562 cells and its mechanisms of action.
Int. J. Toxicol. 28: 123-131 (2009).
-
Liu JJ, Liu PQ, Lin DJ, Xiao RZ, Huang M, Li XD, He Y, Huang RW. Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro.
Ann. Hematol. 86: 173-183 (2007).
*
-
Liu K, Xu L, Berger JP, Macnaul KL, Zhou G, Doebber TW, Forrest MJ, Moller DE, Jones AB. Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
J. Med. Chem. 48: 2262-2265 (2005).
*
-
Liu L, Zheng T, Wang F, Wang N, Song Y, Li M, Li L, Jiang J, Zhao W. Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetes.
Diabetes Care Oct 16 [Epub ahead of print] (2009).
-
Liu M, Guo HW, Wan WT, Luo X, Zhang SX, Xue K, Ma YY. Association of peroxisome proliferator-activated-receptors-gamma C161-->T gene polymorphism with metabolic syndrome and dietary predisposition.
Zhonghua Yu Fang Yi Xue Za Zhi 42: 494-498 (2008).
-
Liu MH, Li J, Shen P, Husna B, Tai ES, Yong EL. A natural polymorphism in peroxisome proliferator-activated receptor-alpha hinge region attenuates transcription due to defective release of nuclear receptor corepressor from chromatin.
Mol. Endocrinol. 22: 1078-1092 (2008).
*
-
Liu WJ, Li WC, Xu ZB, Feng YL. Effect of peroxisome proliferators activated receptor gamma and its ligand on airway mucus hypersecretion in rats.
Zhonghua Jie He He Hu Xi Za Zhi 32: 282-286 (2009).
-
Liu XF, Li H. Regulation of fat metabolism by PPARs.
Yi Chuan. 28: 243-248 (2006).
-
Liu Y, Lou SY, He YM. Effects of berberine on cell proliferation, peroxisome proliferation activated receptor gamma, CAAT/enhancer binding protein mRNA and protein expression in 3T3-L1 pre-adipocytes.
Zhongguo Zhong Xi Yi Jie He Za Zhi 28: 1005-1009 (2008).
-
Liu Y, Yuan Z, Liu Y, Zhang J, Yin P, Wang D, Wang Y, Kishimoto C, Ma A. PPARgamma gene C161T substitution is associated with reduced risk of coronary artery disease and decreased proinflammatory cytokine expression.
Am. Heart J. 154: 718-724 (2007).
*
-
Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, Shyy JY. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase.
Proc. Natl. Acad. Sci. U.S.A. 102: 16747-16752 (2005).
*
-
Ljungberg A, Linden D, Ameen C, Bergstrom G, Oscarsson J. Importance of PPARalpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
Growth Horm. IGF Res. 17: 154-164 (2007).
-
Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the antiinflammatory actions of palmitoylethanolamide.
Mol. Pharmacol. 67: 15-19 (2005).
*
-
Loane DJ, Deighan BF, Clarke RM, Griffin RJ, Lynch AM, Lynch MA. Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain.
Neurobiol. Aging 30: 920-931 (2009).
-
Lobaccaro JM, Repa JJ, Lu TT, Caira F, Henry-Berger J, Volle DH, Mangelsdorf DJ. Regulation of lipid metabolism by the orphan nuclear receptors.
Ann. Endocrinol. (Paris) 62: 239-247 (2001).
-
Lockyer P, Schisler JC, Patterson C, Willis MS. Minireview: won't get fooled again: the nonmetabolic roles of peroxisome proliferator-activated receptors (PPARs) in the heart.
Mol. Endocrinol. Dec 16 [Epub ahead of print] (2009).
*
-
Loffler M, Bilban M, Reimers M, Waldhausl W, Stulnig T. Blood glucose lowering nuclear receptor agonists only partially normalize hepatic gene expression in db/db mice.
J. Pharmacol. Exp. Ther. 316: 797-804 (2006).
*
-
Loichot C, Jesel L, Tesse A, Tabernero A, Schoonjans K, Roul G, Carpusca I, Auwerx J, Andriantsitohaina R. Deletion of peroxisome proliferator-activated receptor-alpha induces an alteration of cardiac functions.
Am. J. Physiol. Heart Circ. Physiol. 291: H161-H166 (2006).
*
-
Long GG, Reynolds VL, Dochterman LW, Ryan TE. Neoplastic and non-neoplastic changes in F-344 rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist.
Toxicol. Pathol. 37: 741-753 (2009).
-
Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event.
Toxicol. Pathol. 36: 218-231 (2008).
*
-
Long MJ, Sairam MR, Komar CM. Initiation of the expression of peroxisome proliferator - activated receptor gamma (PPAR gamma) in the rat ovary and the role of FSH.
Reprod. Biol. Endocrinol. 7: 145 (2009).
*
-
Long YC, Glund S, Garcia-Roves PM, Zierath JR. Calcineurin regulates skeletal muscle metabolism via coordinated changes in gene expression.
J. Biol. Chem. 282: 1607-1614 (2007).
*
-
Looze C, Yui D, Leung L, Ingham M, Kaler M, Yao X, Wu WW, Shen RF, Daniels MP, Levine SJ. Proteomic profiling of human plasma exosomes identifies PPARgamma as an exosome-associated protein.
Biochem. Biophys. Res. Commun. 378: 433-438 (2009).
*
-
Lopez D, McLean MP. Activation of the rat scavenger receptor class B type I gene by PPARalpha.
Mol. Cell. Endocrinol. 251: 67-77 (2006).
-
Lopez V, Saraff K, Medh JD. Down-regulation of lipoprotein lipase increases glucose uptake in L6 muscle cells.
Biochem. Biophys. Res. Commun. 389: 34-39 (2009).
*
-
Lopez-Parra M, Claria J, Titos E, Planaguma A, Parrizas M, Masferrer JL, Jimenez W, Arroyo V, Rivera F, Rodes J. The selective cyclooxygenase-2 inhibitor celecoxib modulates the formation of vasoconstrictor eicosanoids and activates PPARgamma. Influence of albumin.
J. Hepatol. 42: 75-81 (2005).
*
-
Lopez-Soriano J, Chiellini C, Maffei M, Grimaldi PA, Argiles JM. Roles of skeletal muscle and PPARs in the development and treatment of obesity.
Endocr. Rev. 27: 318-329 (2006).
*
-
Lorente-Cebrian S, Perez-Matute P, Martinez JA, Marti A, Moreno-Aliaga MJ. Effects of eicosapentaenoic acid (EPA) on adiponectin gene expression and secretion in primary cultured rat adipocytes.
J. Physiol. Biochem. 62: 61-69 (2006).
-
Louet JF, Coste A, Amazit L, Tannour-Louet M, Wu RC, Tsai SY, Tsai MJ, Auwerx J, O'Malley BW. Oncogenic steroid receptor coactivator-3 is a key regulator of the white adipogenic program.
Proc. Natl. Acad. Sci. U.S.A. 103: 17868-17873 (2006).
*
-
Lovas K, Rost TH, Skorve J, Ulvik RJ, Gudbrandsen OA, Bohov P, Wensaas AJ, Rustan AC, Berge RK, Husebye ES. Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation.
Diabetes Obes. Metab. 11: 304-314 (2009).
*
-
Loverme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor.
Life Sci. 77: 1685-1698 (2005).
*
-
Loverme J, Russo R, La Rana G, Fu J, Farthing J, Raso G, Meli R, Hohmann A, Calignano A, Piomelli D. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha.
J. Pharmacol. Exp. Ther. 319: 1051-1061 (2006).
*
-
Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, Chavis JA, Diab A, Drew PD, Racke MK. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease.
J. Immunol. 172: 5790-5798 (2004).
*
-
Lowe DB, Bifulco N, Bullock WH, Claus T, Coish P, Dai M, Dela Cruz FE, Dickson D, Fan D, Hoover-Litty H, Li T, Ma X, Mannelly G, Monahan MK, Muegge I, O'Connor S, Rodriguez M, Shelekhin T, Stolle A, Sweet L, Wang M, Wang Y, Zhang C, Zhang HJ, et al. Substituted indanylacetic acids as PPAR-alpha-gamma activators.
Bioorg. Med. Chem. Lett. 16: 297-301 (2006).
*
-
Lu B, Moser AH, Shigenaga JK, Feingold KR, Grunfeld C. Type II nuclear hormone receptors, coactivator, and target gene repression in adipose tissue in the acute-phase response.
J. Lipid Res. 47: 2179-2190 (2006).
*
-
Lu C, Cheng SY. Thyroid hormone receptors regulate adipogenesis and carcinogenesis via cross-talk signaling with peroxisome proliferator-activated receptors.
J. Mol. Endocrinol. Sep 9 [Epub ahead of print] (2009).
*
-
Lu H, Lei X, Klaassen C. Gender differences in renal nuclear receptors and aryl hydrocarbon receptor in 5/6 nephrectomized rats.
Kidney Int. 70: 1920-1928 (2006).
*
-
Lu IL, Huang CF, Peng YH, Lin YT, Hsieh HP, Chen CT, Lien TW, Lee HJ, Mahindroo N, Prakash E, Yueh A, Chen HY, Goparaju CM, Chen X, Liao CC, Chao YS, Hsu JT, Wu SY. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
J. Med. Chem. 49: 2703-2712 (2006).
*
-
Lu J, Chen M, Stanley SE, Li E. Effect of heterodimer partner RXRalpha on PPARgamma activation function-2 helix in solution.
Biochem. Biophys. Res. Commun. 365: 42-46 (2008).
*
-
Lu J, Dawson MI, Hu QY, Xia Z, Dambacher JD, Ye M, Zhang XK, Li E. The effect of antagonists on the conformational exchange of the retinoid X receptor alpha ligand-binding domain.
Magn. Reson. Chem. 47: 1071-1080 (2009).
*
-
Lu RH, Ji H, Chang ZG, Su SS, Yang GS. Mitochondrial development and the influence of its dysfunction during rat adipocyte differentiation.
Mol. Biol. Rep. Aug 20 [Epub ahead of print] (2009).
*
-
Lu Z, Dong B, Mo X, Chen T, Wu H, Zhang Y, Xiao H. Pro12Ala polymorphism in PPAR gamma 2 associated with essential hypertension in Chinese nonagenarians/centenarians.
Exp. Gerontol. 43: 1108-1113 (2008).
-
Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.
Int. J. Cancer 123: 2254-2259 (2008).
*
-
Luc G, Jacob N, Bouly M, Fruchart JC, Staels B, Giral P. Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism.
J. Cardiovasc. Pharmacol. 43: 452-453 (2004).
-
Luci S, Geissler S, Konig B, Koch A, Stangl GI, Hirche F, Eder K. PPARalpha agonists up-regulate organic cation transporters in rat liver cells.
Biochem. Biophys. Res. Commun. 350: 704-708 (2006).
*
-
Luci S, Hirche F, Eder K. Fasting and caloric restriction increases mRNA concentrations of novel organic cation transporter-2 and carnitine concentrations in rat tissues.
Ann. Nutr. Metab. 52: 58-67 (2008).
-
Luciani A, Villella VR, Vasaturo A, Giardino I, Pettoello Mantovani M, Guido S, Cexus ON, Peake N, Londei M, Quaratino S, Maiuri L. Lysosomal accumulation of gliadin p31-43 peptide induces oxidative stress and tissue transglutaminase mediated PPARgamma downregulation in intestinal epithelial cells and coeliac mucosa.
Gut Dec 1 [Epub ahead of print] (2009).
-
Luciani A, Villella VR, Vasaturo A, Giardino I, Raia V, Pettoello-Mantovani M, D'Apolito M, Guido S, Leal T, Quaratino S, Maiuri L. SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation.
J. Immunol. 183: 2775-2784 (2009).
-
Luconi M, Cantini G, Serio M. Peroxisome proliferator-activated receptor-gamma (PPARgamma): is the genomic activity the only answer?
Steroids Nov 6 [Epub ahead of print] (2009).
-
Ludovico O, Pellegrini F, Di Paola R, Minenna A, Mastroianno S, Cardellini M, Marini MA, Andreozzi F, Vaccaro O, Sesti G, Trischitta V. Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk.
Obesity (Silver Spring) 15: 1076-1081 (2007).
*
-
Ludtke A, Buettner J, Schmidt HH, Worman HJ. New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
J. Med. Genet. 44: e88 (2007).
-
Ludtke A, Buettner J, Wu W, Muchir A, Schroeter A, Zinn-Justin S, Spuler S, Schmidt HH, Worman HJ. Peroxisome proliferator-activated receptor gamma C190S mutation causes partial lipodystrophy.
J. Clin. Endocrinol. Metab. 92: 2248-2255 (2007).
*
-
Lui WO, Zeng L, Rehrmann V, Deshpande S, Tretiakova M, Kaplan EL, Leibiger I, Leibiger B, Enberg U, Hoog A, Larsson C, Kroll TG. CREB3L2-PPARgamma fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis.
Cancer Res. 68: 7156-7164 (2008).
*
-
Lundasen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, Alexson SE, Rudling M. PPARalpha is a key regulator of hepatic FGF21.
Biochem. Biophys. Res. Commun. 360: 437-440 (2007).
*
-
Lunde IG, Ekmark M, Rana ZA, Buonanno A, Gundersen K. PPARdelta expression is influenced by muscle activity and induces slow muscle properties in adult rat muscles after somatic gene transfer.
J. Physiol. 582: 1277-1287 (2007).
*
-
Luo HF, Wei HK, Huang FR, Zhou Z, Jiang SW, Peng J. The effect of linseed on intramuscular fat content and adipogenesis related genes in skeletal muscle of pigs.
Lipids Oct 2 [Epub ahead of print] (2009).
-
Luo Y, Yin W, Signore AP, Zhang F, Hong Z, Wang S, Graham SH, Chen J. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
J. Neurochem. 97: 435-448 (2006).
-
Luquet S, Gaudel C, Holst D, Lopez-Soriano J, Jehl-Pietri C, Fredenrich A, Grimaldi PA. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes.
Biochim. Biophys. Acta 1740: 313-317 (2005).
*
-
Luquet S, Lopez-Soriano J, Holst D, Gaudel C, Jehl-Pietri C, Fredenrich A, Grimaldi PA. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.
Biochimie 86: 833-837 (2004).
-
Lymboussaki A, Gemelli C, Testa A, Facchini G, Ferrari F, Mavilio F, Grande A. PPARdelta is a ligand dependent negative regulator of vitamin D3 induced monocyte differentiation.
Carcinogenesis 30: 230-237 (2009).
*
-
Lyssenko V, Almgren P, Anevski D, Orho-Melander M, Sjogren M, Saloranta C, Tuomi T, Groop L; Botnia Study Group. Genetic prediction of future type 2 diabetes.
PLoS Med. 2: e345 (2005).
*
-
Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L. Clinical risk factors, DNA variants, and the development of type 2 diabetes.
N. Engl. J. Med. 359: 2220-2232 (2008).
*
-
Lytle C, Tod TJ, Vo KT, Lee JW, Atkinson RD, Straus DS. The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency.
Inflamm. Bowel Dis. 11: 231-243 (2005).
*
-
Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, Gonzalez FJ. Rifaximin is a gut-specific human pregnane X receptor activator.
J. Pharmacol. Exp. Ther. 322: 391-398 (2007).
*
-
Ma XM, Yu H, Huai N. Peroxisome proliferator-activated receptor-gamma is essential in the pathogenesis of gastric carcinoma.
World J. Gastroenterol. 15: 3874-3883 (2009).
*
-
Macdonald N, Holden PR, Roberts RA. Addition of peroxisome proliferator-activated receptor alpha to guinea pig hepatocytes confers increased responsiveness to peroxisome proliferators.
Cancer Res. 59: 4776-4780 (1999).
*
-
Macejova D, Krizanova O, Brtko J. Different mRNA expression profiling of nuclear retinoid, thyroid, estrogen and PPARgamma receptors, their coregulators and selected genes in rat liver and spleen in response to short-term in vivo administration of 13-cis retinoic acid.
Toxicol. Lett. 184: 114-120 (2009).
*
-
Macias-Gonzalez M, Cardona F, Queipo-Ortuno M, Bernal R, Martin M, Tinahones FJ. PPARgamma mRNA expression is reduced in peripheral blood mononuclear cells after fat overload in patients with metabolic syndrome.
J. Nutr. 138: 903-907 (2008).
*
-
Macic-Dzankovic A, Dzankovic F, Pojskic B, Velija-Asimi Z. Evaluation of risk markers fluctuation during an initial therapy with rosiglitazon in patients suffering from metabolic syndrome.
Bosn. J. Basic Med. Sci. 9: 320-328 (2009).
-
Mackellar J, Cushman SW, Periwal V. Waves of adipose tissue growth in the genetically obese Zucker fatty rat.
PLoS One 5: e8197 (2010).
*
-
Mackenzie PI, Hu DG, Gardner-Stephen DA. The regulation of UDP-glucuronosyltransferase genes by tissue-specific and ligand-activated transcription factors.
Drug Metab. Rev. 42: 95-105 (2010).
*
-
MacLaren LA, Guzeloglu A, Michel F, Thatcher WW. Peroxisome proliferator-activated receptor (PPAR) expression in cultured bovine endometrial cells and response to omega-3 fatty acid, growth hormone and agonist stimulation in relation to series 2 prostaglandin production.
Domest. Anim. Endocrinol. 30: 155-169 (2006).
*
-
Maclennan NK, Rahib L, Shin C, Fang Z, Horvath S, Dean J, Liao JC, McCabe ER, Dipple KM. Targeted disruption of glycerol kinase gene in mice: expression analysis in liver shows alterations in network partners related to glycerol kinase activity.
Hum. Mol. Genet. 15: 405-415 (2006).
*
-
Madhavan GR, Chakrabarti R, Anantha Reddy K, Rajesh BM, Balraju V, Bheema Rao P, Rajagopalan R, Iqbal J. Dual PPAR-alpha and -gamma activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential.
Bioorg. Med. Chem. 14: 584-591 (2006).
*
-
Madrazo JA, Kelly DP. The PPAR trio: regulators of myocardial energy metabolism in health and disease.
J. Mol. Cell. Cardiol. 44: 968-975 (2008).
*
-
Madsen L, Petersen RK, Sorensen MB, Jorgensen C, Hallenborg P, Pridal L, Fleckner J, Amri EZ, Krieg P, Furstenberger G, Berge RK, Kristiansen K. Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during the initial stages of the differentiation process.
Biochem. J. 375: 539-549 (2003).
*
-
Maeda T, Kiguchi N, Fukazawa Y, Yamamoto A, Ozaki M, Kishioka S. Peroxisome proliferator-activated receptor gamma activation relieves expression of behavioral sensitization to methamphetamine in mice.
Neuropsychopharmacology 32: 1133-1140 (2007).
-
Maeda T, Kishioka S. Chapter 13. PPAR and pain.
Int. Rev. Neurobiol. 85: 165-177 (2009).
-
Maeda T, Wakasawa T, Funabashi M, Fukushi A, Fujita M, Motojima K, Tamai I. Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha.
Biol. Pharm. Bull. 31: 1230-1236 (2008).
*
-
Maeyama K, Emi M, Chihara K. Role of PPARgamma in inflammatory response related to mast cells.
Nippon Yakurigaku Zasshi 122: 325-330 (2003).
-
Maeyama K, Emi M, Tachibana M. Nuclear receptors as targets for drug development: peroxisome proliferator-activated receptor gamma in mast cells: its roles in proliferation and differentiation.
J. Pharmacol. Sci. 97: 190-194 (2005).
*
-
Magae J, Tsuruga M, Maruyama A, Furukawa C, Kojima S, Shimizu H, Ando K. Relationship between peroxisome proliferator-activated receptor-gamma activation and the ameliorative effects of ascochlorin derivatives on type II diabetes.
J. Antibiot. (Tokyo) 62: 365-369 (2009).
-
Magee TR, Han G, Cherian B, Khorram O, Ross MG, Desai M. Down-regulation of transcription factor peroxisome proliferator-activated receptor in programmed hepatic lipid dysregulation and inflammation in intrauterine growth-restricted offspring.
Am. J. Obstet. Gynecol. 199: 271.e1-e5 (2008).
-
Maggi LB Jr, Sadeghi H, Weigand C, Scarim AL, Heitmeier MR, Corbett JA. Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression.
Diabetes 49: 346-355 (2000).
*
-
Maher AC, Fu MH, Isfort RJ, Varbanov AR, Qu XA, Tarnopolsky MA. Sex differences in global mRNA content of human skeletal muscle.
PLoS One 4: e6335 (2009).
*
-
Maher J, Aleksunes L, Dieter M, Tanaka Y, Peters J, Manautou J, Klaassen C. Nrf2 and PPARalpha-mediated regulation of hepatic Mrp transporters after exposure to perfluorooctanoic acid and perfluorodecanoic acid.
Toxicol. Sci. 106: 319-328 (2008).
*
-
Maher JM, Cheng X, Slitt AL, Dieter MZ, Klaassen CD. Induction of the Mrp family of transporters by chemical activators of receptor-mediated pathways in mouse liver.
Drug Metab. Dispos. 33: 956-962 (2005).
*
-
Mahindroo N, Huang CF, Peng YH, Wang CC, Liao CC, Lien TW, Chittimalla SK, Huang WJ, Chai CH, Prakash E, Chen CP, Hsu TA, Peng CH, Lu IL, Lee LH, Chang YW, Chen WC, Chou YC, Chen CT, Goparaju CM, Chen YS, Lan SJ, Yu MC, Chen X, Chao YS, Wu SY, Hsieh HP. Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities.
J. Med. Chem. 48: 8194-8208 (2005).
*
-
Mahindroo N, Wang CC, Liao CC, Huang CF, Lu IL, Lien TW, Peng YH, Huang WJ, Lin YT, Hsu MC, Lin CH, Tsai CH, Hsu JT, Chen X, Lyu PC, Chao YS, Wu SY, Hsieh HP. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
J. Med. Chem. 49: 1212-1216 (2006).
*
-
Maia-Fernandes T, Roncon-Albuquerque R Jr, Leite-Moreira AF. Cardiovascular actions of adiponectin: pathophysiologic implications.
Rev. Port. Cardiol. 27: 1431-1449 (2008).
-
Maiuri L, Luciani A, Giardino I, Raia V, Villella VR, D'Apolito M, Pettoello-Mantovani M, Guido S, Ciacci C, Cimmino M, Cexus ON, Londei M, Quaratino S. Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation.
J. Immunol. 180: 7697-7705 (2008).
*
-
Majai G, Sarang Z, Csomos K, Zahuczky G, Fesus L. PPARgamma-dependent regulation of human macrophages in phagocytosis of apoptotic cells.
Eur. J. Immunol. 37: 1343-1354 (2007).
*
-
Makino N, Maeda T, Oyama JI, Higuchi Y, Mimori K. Improving insulin sensitivity via activation of PPAR-gamma increases telomerase activity in the heart of OLETF rats.
Am. J. Physiol. Heart Circ. Physiol. 297: H2188-H2195 (2009).
*
-
Makowski L, Noland RC, Koves TR, Xing W, Ilkayeva OR, Muehlbauer MJ, Stevens RD, Muoio DM. Metabolic profiling of PPARalpha-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation.
FASEB J. 23: 586-604 (2009).
*
-
Malchiodi-Albedi F, Matteucci A, Bernardo A, Minghetti L. PPAR-gamma, microglial cells, and ocular inflammation: new venues for potential therapeutic approaches.
PPAR Res. 2008: 295784 (2008).
*
-
Malecki MT, Cyganek K, Mirkiewicz-Sieradzka B, Wolkow PP, Wanic K, Skupien J, Solnica B, Sieradzki J. Alanine variant of the Pro12Ala polymorphism of the PPARgamma gene might be associated with decreased risk of diabetic retinopathy in type 2 diabetes.
Diabetes Res. Clin. Pract. 80: 139-145 (2008).
-
Malur A, McCoy AJ, Arce S, Barna BP, Kavuru MS, Malur AG, Thomassen MJ. Deletion of PPARgamma in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response.
J. Immunol. 182: 5816-5822 (2009).
-
Mamnoor PK, Hegde P, Datla SR, Damarla RK, Rajagopalan R, Chakrabarti R. Antihypertensive effect of ragaglitazar: a novel PPARalpha and gamma dual activator.
Pharmacol. Res. 54: 129-135 (2006).
*
-
Man MQ, Barish GD, Schmuth M, Crumrine D, Barak Y, Chang S, Jiang Y, Evans RM, Elias PM, Feingold KR. Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation.
J. Invest. Dermatol. 128: 370-377 (2008).
*
-
Man MQ, Choi EH, Schmuth M, Crumrine D, Uchida Y, Elias PM, Holleran WM, Feingold KR. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing.
J. Invest. Dermatol. 126: 386-392 (2006).
*
-
Mandard S, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes.
Cell. Mol. Life Sci. 61: 393-416 (2004).
*
-
Mandard S, Stienstra R, Escher P, Tan NS, Kim I, Gonzalez FJ, Wahli W, Desvergne B, Muller M, Kersten S. Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors.
Cell. Mol. Life Sci. 64: 1145-1157 (2007).
*
-
Mandard S, Zandbergen F, Tan NS, Escher P, Patsouris D, Koenig W, Kleemann R, Bakker A, Veenman F, Wahli W, Muller M, Kersten S. The direct PPAR target FIAF/PGAR/ANGPTL4 is present in blood plasma as a truncated protein that is increased by fenofibrate treatment.
J. Biol. Chem. 279: 34411-34420 (2004).
*
-
Mangan S, Clancy P, Golledge J. Modulation of endothelial cell thrombomodulin by PPAR ligands - variation according to environment.
Thromb. Res. 121: 827-834 (2008).
*
-
Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H, Mann DA. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis.
Gastroenterology 138: 705-714.e4 (2010).
*
-
Manni A, Xu H, Washington S, Aliaga C, Cooper T, Richie JP Jr, Bruggeman R, Prokopczyk B, Calcagnotto A, Trushin N, Mauger D, Verderame MF, El-Bayoumy K. The impact of fish oil on the chemopreventive efficacy of tamoxifen against development of N-methyl-N-nitrosourea-induced rat mammary carcinogenesis.
Cancer Prev. Res. (Phila. Pa) 3: 322-330 (2010).
-
Mansouri R, Bauge E, Staels B, Gervois P. Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute phase response.
Endocrinology 149: 3215-3223 (2008).
*
-
Mansure JJ, Nassim R, Kassouf W. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target.
Cancer Biol. Ther. 8: 6-15 (2009).
-
Mao Z, Ong AC. Peroxisome proliferator-activated receptor gamma agonists in kidney disease - future promise, present fears.
Nephron. Clin. Pract. 112: c230-c241 (2009).
-
Maraldi NM, Capanni C, Mattioli E, Columbaro M, Squarzoni S, Parnaik WK, Wehnert M, Lattanzi G. A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome.
Acta Biomed. 78 Suppl. 1: 207-215 (2007).
-
Marathe C, Bradley MN, Hong C, Chao L, Wilpitz D, Salazar J, Tontonoz P. Preserved glucose tolerance in high fat diet-fed C57BL/6 mice transplanted with PPARgamma -/-, PPARdelta -/-, PPARgamma delta -/- or LXRalpha beta -/- bone marrow.
J. Lipid Res. 50: 214-224 (2009).
*
-
Marchesini G, Suppini A, Forlani G. NAFLD treatment: cognitive-behavioral therapy has entered the arena.
J. Hepatol. 43: 926-928 (2005).
*
-
Marcos M, Pastor I, Gonzalez-Sarmiento R, Laso FJ. A functional polymorphism of the NFKB1 gene increases the risk for alcoholic liver cirrhosis in patients with alcohol dependence.
Alcohol Clin. Exp. Res. 33: 1857-1862 (2009).
*
-
Marcus SL, Miyata KS, Rachubinski RA, Capone JP. Transactivation by PPAR/RXR heterodimers in yeast is potentiated by exogenous fatty acid via a pathway requiring intact peroxisomes.
Gene Expr. 4: 227-239 (1995).
-
Marian E, Baraldo S, Visentin A, Papi A, Saetta M, Fabbri LM, Maestrelli P. Up-regulated membrane and nuclear leukotriene B4 receptors in COPD.
Chest 129: 1523-1530 (2006).
*
-
Marie PJ. Transcription factors controlling osteoblastogenesis.
Arch. Biochem. Biophys. 473: 98-105 (2008).
*
-
Marin HE, Peraza MA, Billin AN, Willson TM, Ward JM, Kennett MJ, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis.
Cancer Res. 66: 4394-4401 (2006).
*
-
Marion-Letellier R, Butler M, Dechelotte P, Playford RJ, Ghosh S. Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells.
Am. J. Clin. Nutr. 87: 939-948 (2008).
*
-
Marion-Letellier R, Dechelotte P, Iacucci M, Ghosh S. Dietary modulation of peroxisome proliferator-activated receptor gamma.
Gut 58: 586-593 (2009).
-
Mark M, Kastner P, Ghyselinck NB, Krezel W, Dupe V, Chambon P. Genetic control of the development by retinoic acid.
C. R. Seances Soc. Biol. Fil. 191: 77-90 (1997).
-
Markt P, Petersen RK, Flindt EN, Kristiansen K, Kirchmair J, Spitzer G, Distinto S, Schuster D, Wolber G, Laggner C, Langer T. Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening.
J. Med. Chem. 51: 6303-6317 (2008).
*
-
Markt P, Schuster D, Kirchmair J, Laggner C, Langer T. Pharmacophore modeling and parallel screening for PPAR ligands.
J. Comput. Aided Mol. Des. 21: 575-590 (2007).
*
-
Marmolino D, Acquaviva F. Friedreich's ataxia: from the (GAA)(n) repeat mediated silencing to new promising molecules for therapy.
Cerebellum 8: 245-259 (2009).
-
Marmolino D, Acquaviva F, Pinelli M, Monticelli A, Castaldo I, Filla A, Cocozza S. PPAR-gamma agonist azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich's ataxia therapy.
Cerebellum 8: 98-103 (2009).
-
Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, Gentilini P. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells.
Gastroenterology 119: 466-478 (2000).
*
-
Marrapodi M, Chiang JY. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription.
J. Lipid Res. 41: 514-520 (2000).
*
-
Marshall TG, Lee RE, Marshall FE. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b.
Theor. Biol. Med. Model. 3: 1 (2006).
*
-
Marsillach J, Camps J, Ferre N, Beltran R, Rull A, Mackness B, Mackness M, Joven J. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease.
BMC Gastroenterol. 9: 3 (2009).
*
-
Martens FM, Rabelink TJ, Op 't Roodt J, de Koning EJ, Visseren FL. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone.
Eur. Heart J. 27: 1605-1609 (2006).
-
Martin G, Poirier H, Hennuyer N, Crombie D, Fruchart JC, Heyman RA, Besnard P, Auwerx J. Induction of the fatty acid transport protein 1 and acyl-CoA synthase genes by dimer-selective rexinoids suggests that the peroxisome proliferator-activated receptor-retinoid X receptor heterodimer is their molecular target.
J. Biol. Chem. 275: 12612-12618 (2000).
*
-
Martin GG, Atshaves BP, McIntosh AL, Payne HR, Mackie JT, Kier AB, Schroeder F. Liver fatty acid binding protein gene ablation enhances age-dependent weight gain in male mice.
Mol. Cell. Biochem. 324: 101-115 (2009).
*
-
Martin H. Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components.
Mutat. Res. 669: 1-7 (2009).
-
Martin MT, Brennan R, Hu W, Ayanoglu E, Lau C, Ren H, Wood CR, Corton JC, Kavlock RJ, Dix DJ. Toxicogenomic study of triazole fungicides and perfluoroalkyl acids in rat livers predicts toxicity and categorizes chemicals based on mechanisms of toxicity.
Toxicol. Sci. 97: 595-613 (2007).
*
-
Martin PG, Guillou H, Lasserre F, Dejean S, Lan A, Pascussi JM, Sancristobal M, Legrand P, Besse P, Pineau T. Novel aspects of PPARalpha-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study.
Hepatology 45: 767-777 (2007).
*
-
Martin PG, Lasserre F, Calleja C, Van Es A, Roulet A, Concordet D, Cantiello M, Barnouin R, Gauthier B, Pineau T. Transcriptional modulations by RXR agonists are only partially subordinated to PPARalpha signaling and attest additional, organ-specific, molecular cross-talks.
Gene Expr. 12: 177-192 (2005).
-
Martinez N, Capobianco E, White V, Pustovrh M, Higa R, Jawerbaum A. Peroxisome proliferator-activated receptor alpha activation regulates lipid metabolism in the feto-placental unit from diabetic rats.
Reproduction 136: 95-103 (2008).
*
-
Martinez-Augustin O, Lopez-Posadas R, Gonzalez R, Suarez MD, Zarzuelo A, Sanchez de Medina F. Genomic analysis of sulfasalazine effect in experimental colitis is consistent primarily with the modulation of NF-kappaB but not PPAR-gamma signaling.
Pharmacogenet. Genomics 19: 363-372 (2009).
-
Martinez-Jimenez CP, Kyrmizi I, Cardot P, Gonzalez FJ, Talianidis I. HNF4alpha coordinates a transcription factor network regulating hepatic fatty acid metabolism.
Mol. Cell. Biol. Nov 23 [Epub ahead of print] (2009).
*
-
Martinsen TC, Bakke I, Chen D, Sandvik AK, Zahlsen K, Aamo T, Waldum HL. Ciprofibrate stimulates the gastrin-producing cell by acting luminally on antral PPARalpha.
Am. J. Physiol. Gastrointest. Liver Physiol. 289: G1052-G1060 (2005).
*
-
Martres P, Faucher N, Laroze A, Pineau O, Fouchet MH, Potvain F, Grillot D, Beneton V. The discovery of equipotent PPARalpha/gamma dual activators.
Bioorg. Med. Chem. Lett. 18: 6251-6254 (2008).
-
Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
Circ. Res. 94: 1168-1178 (2004).
*
-
Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V, Libby P, Plutzky J. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.
Circ. Res. 90: 703-710 (2002).
*
-
Marx N, Walcher D. Vascular effects of PPARgamma activators - from bench to bedside.
Prog. Lipid Res. 46: 283-296 (2007).
*
-
Mas E, Danjoux M, Garcia V, Carpentier S, Segui B, Levade T. IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis.
PLoS One 4: e7929 (2009).
*
-
Masamune A, Kikuta K, Satoh M, Sakai Y, Satoh A, Shimosegawa T. Ligands of peroxisome proliferator-activated receptor-gamma block activation of pancreatic stellate cells.
J. Biol. Chem. 277: 141-147 (2002).
*
-
Mascrez B, Ghyselinck NB, Watanabe M, Annicotte JS, Chambon P, Auwerx J, Mark M. Ligand-dependent contribution of RXRbeta to cholesterol homeostasis in Sertoli cells.
EMBO Rep. 5: 285-290 (2004).
*
-
Massip-Salcedo M, Zaouali MA, Padrissa-Altes S, Casillas-Ramirez A, Rodes J, Rosello-Catafau J, Peralta C. Activation of peroxisome proliferator-activated receptor-alpha inhibits the injurious effects of adiponectin in rat steatotic liver undergoing ischemia-reperfusion.
Hepatology 47: 461-472 (2008).
*
-
Masternak MM, Al-Regaiey KA, Del Rosario Lim MM, Bonkowski MS, Panici JA, Przybylski GK, Bartke A. Caloric restriction results in decreased expression of peroxisome proliferator-activated receptor superfamily in muscle of normal and long-lived growth hormone receptor/binding protein knockout mice.
J. Gerontol. A. Biol. Sci. Med. Sci. 60: 1238-1245 (2005).
-
Masternak MM, Al-Regaiey KA, Del Rosario Lim MM, Jimenez-Ortega V, Panici JA, Bonkowski MS, Kopchick JJ, Bartke A. Effects of caloric restriction and growth hormone resistance on the expression level of peroxisome proliferator-activated receptors superfamily in liver of normal and long-lived growth hormone receptor/binding protein knockout mice.
J. Gerontol. A. Biol. Sci. Med. Sci. 60: 1394-1398 (2005).
-
Masternak MM, Bartke A. PPARs in calorie restricted and genetically long-lived mice.
PPAR Res. 2007: 28436 (2007).
*
-
Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
Drug Metab. Pharmacokinet. 21: 347-356 (2006).
*
-
Mathis AS, Jin S, Friedman GS, Peng F, Carl SM, Knipp GT. The pharmacodynamic effects of sirolimus and sirolimus-calcineurin inhibitor combinations on macrophage scavenger and nuclear hormone receptors.
J. Pharm. Sci. 96: 209-222 (2007).
*
-
Mathur SK, Rathore R, Chandra S, Sharma BB, Sharma L, Mathur P, Mathur M. Primary pioglitazone failure in Asian Indian diabetics is not related to common Pro12Ala polymorph of PPAR-gamma gene.
Indian J. Physiol. Pharmacol. 53: 175-180 (2009).
-
Mathur SN, Watt KR, Field FJ. Regulation of intestinal NPC1L1 expression by dietary fish oil and docosahexaenoic acid.
J. Lipid Res. 48: 395-404 (2007).
*
-
Matias I, Gonthier MP, Petrosino S, Docimo L, Capasso R, Hoareau L, Monteleone P, Roche R, Izzo AA, Di Marzo V. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells.
Br. J. Pharmacol. 152: 676-690 (2007).
*
-
Matin A, Gavande N, Kim MS, Yang NX, Salam NK, Hanrahan JR, Roubin RH, Hibbs DE. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and gamma (PPARalpha and gamma) dual agonists.
J. Med. Chem. 52: 6835-6850 (2009).
*
-
Matsui T, Yamagishi SI, Takeuchi M, Ueda S, Fukami K, Okuda S. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation.
Biochem. Biophys. Res. Commun. 385: 269-272 (2009).
*
-
Matsumoto K, Huang J, Viswakarma N, Bai L, Jia Y, Zhu YT, Yang G, Borensztajn J, Rao MS, Zhu YJ, Reddy JK. Transcription coactivator PBP/MED1 deficient hepatocytes are not susceptible to diethylnitrosamine-induced hepatocarcinogenesis in the mouse.
Carcinogenesis Dec 14 [Epub ahead of print] (2009).
*
-
Matsumoto K, Yu S, Jia Y, Ahmed MR, Viswakarma N, Sarkar J, Kashireddy PV, Rao MS, Karpus W, Gonzalez FJ, Reddy JK. Critical role for transcription coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein/TRAP220 in liver regeneration and PPARalpha ligand-induced liver tumor development.
J. Biol. Chem. 282: 17053-17060 (2007).
*
-
Matsumoto T, Kobayashi T, Kamata K. Relationships among ET-1, PPARgamma, oxidative stress and endothelial dysfunction in diabetic animals.
J. Smooth Muscle Res. 44: 41-55 (2008).
*
-
Matsuo K, Arai H, Muto K, Fukaya M, Sato T, Mizuno A, Sakuma M, Yamanaka-Okumura H, Sasaki H, Yamamoto H, Taketani Y, Doi T, Takeda E. The anti-obesity effect of the palatinose-based formula Inslow is likely due to an increase in the hepatic PPAR-alpha and adipocyte PPAR-gamma gene expressions.
J. Clin. Biochem. Nutr. 40: 234-241 (2007).
*
-
Matsuyama M, Yoshimura R. Peroxisome proliferator-activated receptor-gamma is a potent target for prevention and treatment in human prostate and testicular cancer.
PPAR Res. 2008: 249849 (2008).
*
-
Matsuyama M, Yoshimura R. The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer.
Biologics 2: 725-732 (2008).
*
-
Mattevi VS, Zembrzuski VM, Hutz MH. Effects of a PPARG gene variant on obesity characteristics in Brazil.
Braz. J. Med. Biol. Res. 40: 927-932 (2007).
*
-
Matthews RP, Lorent K, Mañoral-Mobias R, Huang Y, Gong W, Murray IV, Blair IA, Pack M. TNFalpha-dependent hepatic steatosis and liver degeneration caused by mutation of zebrafish S-adenosylhomocysteine hydrolase.
Development 136: 865-875 (2009).
*
-
Matthiessen MW, Pedersen G, Albrektsen T, Adamsen S, Fleckner J, Brynskov J. Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas.
Scand. J. Gastroenterol. 40: 198-205 (2005).
*
-
Maurin AC, Chavassieux PM, Meunier PJ. Expression of PPARgamma and beta/delta in human primary osteoblastic cells: influence of polyunsaturated fatty acids.
Calcif. Tissue Int. 76: 385-392 (2005).
*
-
Maurois P, Rocchi S, Pages N, Bac P, Stables JP, Gressens P, Vamecq J. The PPARgamma agonist FMOC-l-leucine protects both mature and immature brain.
Biomed. Pharmacother. 62: 259-263 (2008).
-
Maver A, Medica I, Salobir B, Tercelj-Zorman M, Sabovic M, Petrovic D, Peterlin B. Peroxisome proliferator-activated receptor gamma/Pro12Ala polymorphism and peroxisome proliferator-activated receptor gamma coactivator-1 alpha/Gly482Ser polymorphism in patients with sarcoidosis.
Sarcoidosis Vasc. Diffuse Lung Dis. 25: 29-35 (2008).
-
Mazid MA, Chowdhury AA, Nagao K, Nishimura K, Jisaka M, Nagaya T, Yokota K. Endogenous 15-deoxy-Delta(12,14)-prostaglandin J(2) synthesized by adipocytes during maturation phase contributes to upregulation of fat storage.
FEBS Lett. 580: 6885-6890 (2006).
*
-
Mazzon E, Crisafulli C, Galuppo M, Cuzzocrea S. Role of peroxisome proliferators activated receptor alpha (PPAR-alpha) in ileum tight junction alteration in mouse model of restraint stress.
Am. J. Physiol. Gastrointest. Liver Physiol. 297: G488-G505 (2009).
*
-
Mazzucotelli A, Viguerie N, Tiraby C, Annicotte JS, Mairal A, Klimcakova E, Lepin E, Delmar P, Dejean S, Tavernier G, Lefort C, Hidalgo J, Pineau T, Fajas L, Clement K, Langin D. The transcriptional coactivator peroxisome proliferator activated receptor (PPAR)gamma coactivator-1 alpha and the nuclear receptor PPAR alpha control the expression of glycerol kinase and metabolism genes…
Diabetes 56: 2467-2475 (2007).
*
-
McCarty MF. Nutraceutical resources for diabetes prevention - an update.
Med. Hypotheses 64: 151-158 (2005).
-
McCarty MF, Barroso-Aranda J, Contreras F. The "rejuvenatory" impact of lipoic acid on mitochondrial function in aging rats may reflect induction and activation of PPAR-gamma coactivator-1alpha.
Med. Hypotheses 72: 29-33 (2009).
-
McClelland S, Shrivastava R, Medh JD. Regulation of translational efficiency by disparate 5' UTRs of PPARgamma splice variants.
PPAR Res. 2009: 193413 (2009).
*
-
McDonough PM, Agustin RM, Ingermanson RS, Loy PA, Buehrer BM, Nicoll JB, Prigozhina NL, Mikic I, Price JH. Quantification of lipid droplets and associated proteins in cellular models of obesity via high-content/high-throughput microscopy and automated image analysis.
Assay Drug Dev. Technol. 7: 440-460 (2009).
-
McFarlane SI, Provilus A, Shin JJ. Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.
J. Cardiometab. Syndr. 2: 149-150 (2007).
-
McNeal CL, Raymond MI, Taylor WE. Testosterone inhibits adipogenic transcription factors PPAR-gamma2 and C/EBP-alpha through TCF4 transcription factor.
Ethn. Dis. 15:S4-S6 (2005).
-
McNeil CJ, Hay SM, Rucklidge GJ, Reid M, Duncan G, Maloney CA, Rees WD. Disruption of lipid metabolism in the liver of the pregnant rat fed folate-deficient and methyl donor-deficient diets.
Br. J. Nutr. 99: 262-271 (2008).
*
-
McTigue DM. Potential therapeutic targets for PPARgamma after spinal cord injury.
PPAR Res. 2008: 517162 (2008).
*
-
Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, Curtis RK, Jimenez-Linan M, Blount M, Yeo GS, Lopez M, Seppanen-Laakso T, Ashcroft FM, Oresic M, Vidal-Puig A. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism.
PLoS Genet. 3: e64 (2007).
*
-
Mei CL, He P, Cheng B, Liu W, Wang YF, Wan JJ. Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma-dependent pathways.
Cell Biol. Int. 33: 301-308 (2009).
*
-
Meier C, Bodmer M, Meier CR, Kraenzlin ME. Thiazolidinediones and skeletal health.
Rev. Med. Suisse. 5: 1309-1310, 1312-1313 (2009).
-
Melis M, Pillolla G, Luchicchi A, Muntoni AL, Yasar S, Goldberg SR, Pistis M. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors.
J. Neurosci. 28: 13985-13994 (2008).
-
Mello T, Polvani S, Galli A. Peroxisome proliferator-activated receptor and retinoic X receptor in alcoholic liver disease.
PPAR Res. 2009: 748174 (2009).
*
-
Melnick RL. Is peroxisome proliferation an obligatory precursor step in the carcinogenicity of di(2-ethylhexyl)phthalate (DEHP)?
Environ. Health Perspect. 109: 437-442 (2001).
*
-
Meng H, Li H, Zhao JG, Gu ZL. Differential expression of peroxisome proliferator-activated receptors alpha and gamma gene in various chicken tissues.
Domest. Anim. Endocrinol. 28: 105-110 (2005).
*
-
Mercader J, Ribot J, Murano I, Feddersen S, Cinti S, Madsen L, Kristiansen K, Bonet ML, Palou A. Haploinsufficiency of the retinoblastoma protein gene reduces diet-induced obesity, insulin resistance and hepatosteatosis in mice.
Am. J. Physiol. Endocrinol. Metab. 297: E184-E193 (2009).
*
-
Meredith D, Panchatcharam M, Miriyala S, Tsai YS, Morris AJ, Maeda N, Stouffer GA, Smyth SS. Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling.
Arterioscler. Thromb. Vasc. Biol. 29: 465-471 (2009).
-
Mestre L, Docagne F, Correa F, Loría F, Hernangomez M, Borrell J, Guaza C. A cannabinoid agonist interferes with the progression of a chronic model of multiple sclerosis by downregulating adhesion molecules.
Mol. Cell. Neurosci. 40: 258-266 (2009).
-
Meyer S, Vogt T, Landthaler M, Berand A, Reichle A, Bataille F, Marx AH, Menz A, Hartmann A, Kunz-Schughart LA, Wild PJ. Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma.
PPAR Res. 2009: 848645 (2009).
*
-
Meyer UA, Gut J. Genomics and the prediction of xenobiotic toxicity.
Toxicology 181-182: 463-466 (2002).
*
-
Mezei O, Li Y, Mullen E, Ross-Viola JS, Shay NF. Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha dependent and independent mechanisms.
Physiol. Genomics 26: 8-14 (2006).
*
-
Miceli I, Burt D, Tarabra E, Camussi G, Cavallo Perin P, Gruden G. Stretch reduces nephrin expression via an angiotensin II-AT1-dependent mechanism in human podocytes: effect of rosiglitazone.
Am. J. Physiol. Renal Physiol. Nov 11 [Epub ahead of print] (2009).
*
-
Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors.
Pharmacol. Rev. 58: 726-741 (2006).
*
-
Michalik L, Desvergne B, Tan NS, Basu-Modak S, Escher P, Rieusset J, Peters JM, Kaya G, Gonzalez FJ, Zakany J, Metzger D, Chambon P, Duboule D, Wahli W. Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice.
J. Cell Biol. 154: 799-814 (2001).
*
-
Michalik L, Feige JN, Gelman L, Pedrazzini T, Keller H, Desvergne B, Wahli W. Selective expression of a dominant negative form of PPAR in keratinocytes leads to impaired epidermal healing.
Mol. Endocrinol. 19: 2335-2348 (2005).
*
-
Michalik L, Wahli W. Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions.
Curr. Opin. Biotechnol. 10: 564-570 (1999).
-
Michalik L, Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair.
J. Clin. Invest. 116: 598-606 (2006).
*
-
Michalik L, Wahli W. Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease.
Biochim. Biophys. Acta 1771: 991-998 (2007).
*
-
Michalik L, Wahli W. Guiding ligands to nuclear receptors.
Cell 129: 649-651 (2007).
*
-
Michalik L, Wahli W. PPARs mediate lipid signaling in inflammation and cancer.
PPAR Res. 2008: 134059 (2008).
*
-
Michiels JF, Perrin C, Leccia N, Massi D, Grimaldi P, Wagner N. PPARbeta activation inhibits melanoma cell proliferation involving repression of the Wilms' tumour suppressor WT1.
Pflugers. Arch. Jan 12 [Epub ahead of print] (2010).
*
-
Migita H, Morser J. 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) signals through retinoic acid receptor-related orphan receptor-alpha but not peroxisome proliferator-activated receptor-gamma in human vascular endothelial cells: the effect of 15d-PGJ2 on tumor necrosis …
Arterioscler. Thromb. Vasc. Biol. 25: 710-716 (2005).
*
-
Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R. PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss.
Neurochem. Int. 55: 496-504 (2009).
-
Mikael LG, Genest J Jr, Rozen R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease.
Circ. Res. 98: 564-571 (2006).
*
-
Miksa M, Wu R, Cui X, Dong W, Das P, Simms HH, Ravikumar TS, Wang P. Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activated receptor-gamma.
J. Immunol. 179: 6263-6272 (2007).
*
-
Milewicz A, Tworowska-Bardzinska U, Dunajska K, Jedrzejuk D, Lwow F. Relationship of PPARgamma2 polymorphism with obesity and metabolic syndrome in postmenopausal Polish women.
Exp. Clin. Endocrinol. Diabetes 117: 628-632 (2009).
-
Millar JS, Duffy D, Gadi R, Bloedon LT, Dunbar RL, Wolfe ML, Movva R, Shah A, Fuki IV, McCoy M, Harris CJ, Wang MD, Howey DC, Rader DJ. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome.
Arterioscler. Thromb. Vasc. Biol. 29: 140-146 (2009).
-
Miller RT, Scappino LA, Long SM, Corton JC. Role of thyroid hormones in hepatic effects of peroxisome proliferators.
Toxicol. Pathol. 29: 149-155 (2001).
*
-
Min G. Different modulation of ER-mediated transactivation by xenobiotic nuclear receptors depending on the estrogen response elements and estrogen target cell types.
Ann. N. Y. Acad. Sci. 1091: 244-257 (2006).
*
-
Min Q, Bai YT, Jia G, Wu J, Xiang JZ. High glucose enhances angiotensin II mediated peroxisome proliferation activated receptor-gamma inactivation in human coronary artery endothelial cells.
Exp. Mol. Pathol. Sep 28 [Epub ahead of print] (2009).
-
Ming M, Yu JP, Meng XZ, Zhou YH, Yu HG, Luo HS. Effect of ligand troglitazone on peroxisome proliferator-activated receptor gamma expression and cellular growth in human colon cancer cells.
World J. Gastroenterol. 12: 7263-7270 (2006).
*
-
Minge CE, Robker RL, Norman RJ. PPAR gamma: coordinating metabolic and immune contributions to female fertility.
PPAR Res. 2008: 243791 (2008).
*
-
Minoura H, Takeshita S, Kimura C, Hirosumi J, Takakura S, Kawamura I, Seki J, Manda T, Mutoh S. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
Diabetes Obes. Metab. 9: 369-378 (2007).
*
-
Minutoli L, Antonuccio P, Polito F, Bitto A, Squadrito F, Irrera N, Nicotina PA, Fazzari C, Montalto AS, Di Stefano V, Romeo C, Altavilla D. Peroxisome proliferator activated receptor beta/delta activation prevents extracellular regulated kinase 1/2 phosphorylation and protects the testis from ischemia and reperfusion injury.
J. Urol. 181: 1913-1921 (2009).
-
Miranda M, Escote X, Ceperuelo-Mallafre V, Megia A, Caubet E, Naf S, Gomez JM, Gonzalez-Clemente JM, Vicente V, Vendrell J. Relation between human LPIN1, hypoxia and endoplasmic reticulum stress genes in subcutaneous and visceral adipose tissue.
Int. J. Obes. (Lond.) Jan 26 [Epub ahead of print] (2010).
*
-
Mishra A, Chaudhary A, Sethi S. Oxidized omega-3 fatty acids inhibit NF-kappaB activation via a PPARalpha-dependent pathway.
Arterioscler. Thromb. Vasc. Biol. 24: 1621-1627 (2004).
*
-
Mishra P, Younossi ZM. Current treatment strategies for non-alcoholic fatty liver disease (NAFLD).
Curr. Drug Discov. Technol. 4: 133-140 (2007).
-
Missiou A, Wolf D, Platzer I, Ernst S, Walter C, Rudolf P, Zirlik KM, Kostlin N, Willecke FK, Münkel C, Schonbeck U, Libby P, Bode C, Varo N, Zirlik A. CD40L induces inflammation and adipogenesis in adipose cells - a potential link between metabolic and cardiovascular disease.
Thromb. Haemost. Feb 19 [Epub ahead of print] (2010).
-
Mistry NF, Cresci S. PPAR transcriptional activator complex polymorphisms and the promise of individualized therapy for heart failure.
Heart Fail. Rev. Nov 8 [Epub ahead of print] (2008).
-
Mitchell JA, Ali F, Bailey L, Moreno L, Harrington LS. Role of nitric oxide and prostacyclin as vasoactive hormones released by the endothelium.
Exp. Physiol. 93: 141-147 (2008).
-
Mitra SK, Varma SR, Godavarthi A, Nandakumar KS. Liv.52 regulates ethanol induced PPARgamma and TNF alpha expression in HepG2 cells.
Mol. Cell. Biochem. 315: 9-15 (2008).
*
-
Mitsuyoshi H, Yasui K, Harano Y, Endo M, Tsuji K, Minami M, Itoh Y, Okanoue T, Yoshikawa T. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease.
Hepatol. Res. 39: 366-373 (2009).
*
-
Miura M, Satoh S, Kagaya H, Saito M, Inoue T, Ohkubo T, Habuchi T, Suzuki T. Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients.
J. Clin. Pharm. Ther. 34: 683-692 (2009).
-
Miura P, Chakkalakal JV, Boudreault L, Belanger G, Hebert RL, Renaud JM, Jasmin BJ. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice.
Hum. Mol. Genet. 18: 4640-4649 (2009).
-
Miyachi H. Recent progress of the research on peroxisome proliferator-activated receptor alpha-selective ligands.
IDrugs 7: 746-754 (2004).
-
Miyachi H. Design and synthesis of subtype- and species-selective peroxisome proliferator-activated receptor (PPAR) alpha ligands.
Yakugaku Zasshi 124: 803-813 (2004).
-
Miyachi H. Design, synthesis, and structure-activity relationship study of peroxisome proliferator-activated receptor (PPAR) delta-selective ligands.
Curr. Med. Chem. 14: 2335-2343 (2007).
-
Miyachi H, Hashimoto Y. Structural development studies of subtype-selective ligands for peroxisome proliferator-activated receptors (PPARs) based on the 3,4-disubstituted phenylpropanoic acid scaffold as a versatile template.
PPAR Res. 2008: 689859 (2008).
*
-
Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, Anania FA, Willson TM, Tsukamoto H. Peroxisome proliferator-activated receptors and hepatic stellate cell activation.
J. Biol. Chem. 275: 35715-35722 (2000).
*
-
Miyata KS, McCaw SE, Meertens LM, Patel HV, Rachubinski RA, Capone JP. Receptor-interacting protein 140 interacts with and inhibits transactivation by, peroxisome proliferator-activated receptor alpha and liver-X-receptor alpha.
Mol. Cell. Endocrinol. 146: 69-76 (1998).
-
Miyata KS, McCaw SE, Patel HV, Rachubinski RA, Capone JP. The orphan nuclear hormone receptor LXR alpha interacts with the peroxisome proliferator-activated receptor and inhibits peroxisome proliferator signaling.
J. Biol. Chem. 271: 9189-9192 (1996).
*
-
Miyawaki K, Inoue H, Keshavarz P, Mizuta K, Sato A, Sakamoto Y, Moritani M, Kunika K, Tanahashi T, Itakura M. Transgenic expression of a mutated cyclin-dependent kinase 4 (CDK4/R24C) in pancreatic beta-cells prevents progression of diabetes in db/db mice.
Diabetes Res. Clin. Pract. 82: 33-41 (2008).
-
Mizutani N, Sakurai T, Shibata T, Uchida K, Fujita J, Kawashima R, Kawamura YI, Toyama-Sorimachi N, Imai T, Dohi T. Dose-dependent differential regulation of cytokine secretion from macrophages by fractalkine.
J. Immunol. 179: 7478-7487 (2007).
*
-
Mo C, Chearwae W, Bright JJ. PPARgamma regulates LIF-induced growth and self-renewal of mouse ES cells through Tyk2-Stat3 pathway.
Cell. Signal. 22: 495-500 (2010).
*
-
Mochizuki K, Mochizuki H, Kawai H, Ogura Y, Shimada M, Takase S, Goda T. Possible role of fatty acids in milk as the regulator of the expression of cytosolic binding proteins for fatty acids and vitamin A through PPARalpha in developing rats.
J. Nutr. Sci. Vitaminol. (Tokyo) 53: 515-521 (2008).
*
-
Mochizuki K, Suruga K, Fukami H, Kiso Y, Takase S, Goda T. Selectivity of fatty acid ligands for PPARalpha which correlates both with binding to cis-element and DNA binding-independent transactivity in Caco-2 cells.
Life Sci. 80: 140-145 (2006).
*
-
Mochizuki K, Suruga K, Kitagawa M, Takase S, Goda T. Modulation of the expression of peroxisome proliferator-activated receptor-dependent genes through disproportional expression of two subtypes in the small intestine.
Arch. Biochem. Biophys. 389: 41-48 (2001).
*
-
Mochizuki K, Suruga K, Yagi E, Takase S, Goda T. The expression of PPAR-associated genes is modulated through postnatal development of PPAR subtypes in the small intestine.
Biochim. Biophys. Acta 1531: 68-76 (2001).
*
-
Mochizuki K, Yorita S, Goda T. Gene expression changes in the jejunum of rats during the transient suckling-weaning period.
J. Nutr. Sci. Vitaminol. (Tokyo) 55: 139-148 (2009).
*
-
Moffett SP, Feingold E, Barmada MM, Damcott CM, Marshall JA, Hamman RF, Ferrell RE. The C161-->T polymorphism in peroxisome proliferator-activated receptor gamma, but not P12A, is associated with insulin resistance in Hispanic and non-Hispanic white women: evidence for another functional variant in PPARgamma.
Metabolism 54: 1552-1556 (2005).
*
-
Moffit JS, Aleksunes LM, Maher JM, Scheffer GL, Klaassen CD, Manautou J. Induction of hepatic transporters Mrp3 and Mrp4 by clofibrate is regulated by PPARalpha.
J. Pharmacol. Exp. Ther. 317: 537-545 (2006).
*
-
Mogilenko DA, Dizhe EB, Shavva VS, Lapikov IA, Orlov SV, Perevozchikov AP. Role of the nuclear receptors HNF4alpha, PPARalpha and LXRs in the TNFalpha-mediated inhibition of human apolipoprotein A-I gene expression in HepG2 cells.
Biochemistry 48: 11950-11960 (2009).
*
-
Mohamed MB, Mtiraoui N, Ezzidi I, Chaieb M, Mahjoub T, Almawi WY. Association of the peroxisome proliferator-activated receptor-gamma2 Pro12Ala but not the C1431T gene variants with lower body mass index in Type 2 diabetes.
J. Endocrinol. Invest. 30: 937-943 (2007).
-
Mohan R, Heyman RA. Orphan nuclear receptor modulators.
Curr. Top. Med. Chem. 3: 1637-1647 (2003).
-
Mohapatra SK, Cole LE, Evans C, Sobral BW, Bassaganya-Riera J, Hontecillas R, Vogel SN, Crasta OR. Modulation of hepatic PPAR expression during Ft LVS LPS-induced protection from Francisella tularensis LVS infection.
BMC Infect. Dis. 10: 10 (2010).
*
-
Mohler DL, Shen G. The synthesis of tethered ligand dimers for PPARgamma-RXR protein heterodimers.
Org. Biomol. Chem. 4: 2082-2087 (2006).
*
-
Moibi JA, Gupta D, Jetton TL, Peshavaria M, Desai R, Leahy JL. Peroxisome proliferator-activated receptor-gamma regulates expression of PDX-1 and NKX6.1 in INS-1 cells.
Diabetes 56: 88-95 (2007).
*
-
Moise AR, Alvarez S, Dominguez M, Alvarez R, Golczak M, Lobo GP, von Lintig J, de Lera AR, Palczewski K. Activation of retinoic acid receptors by dihydroretinoids.
Mol. Pharmacol. 76: 1228-1237 (2009).
*
-
Moise AR, Lobo GP, Erokwu B, Wilson DL, Peck D, Alvarez S, Domínguez M, Alvarez R, Flask CA, de Lera AR, von Lintig J, Palczewski K. Increased adiposity in the retinol saturase-knockout mouse.
FASEB J. Nov 25 [Epub ahead of print] (2009).
*
-
Molavi B, Chen J, Mehta JL. Cardioprotective effects of rosiglitazone are associated with selective over-expression of type 2 angiotensin receptors and inhibition of P42/44 MAPK.
Am. J. Physiol. Heart Circ. Physiol. 291: H687-H693 (2006).
*
-
Mollah ML, Kim GS, Moon HK, Chung SK, Cheon YP, Kim JK, Kim KS. Antiobesity effects of wild ginseng (Panax ginseng C.A. Meyer) mediated by PPAR-gamma, GLUT4 and LPL in ob/ob mice.
Phytother. Res. 23: 220-225 (2009).
-
Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation.
Int. J. Obes. Relat. Metab. Disord. 27 Suppl. 3: S17-S21 (2003).
-
Molnar F, Matilainen M, Carlberg C. Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators.
J. Biol. Chem. 280: 26543-26556 (2005).
*
-
Monajemi H, Zhang L, Li G, Jeninga EH, Cao H, Maas M, Brouwer CB, Kalkhoven E, Stroes E, Hegele RA, Leff T. Familial partial lipodystrophy phenotype resulting from a single-base mutation in DNA binding domain of peroxisome proliferator-activated receptor gamma.
J. Clin. Endocrinol. Metab. 92: 1606-1612 (2007).
*
-
Monami M, Lamanna C, Marchionni N, Mannucci E. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials.
Diabetes Care 31: 1455-1460 (2008).
*
-
Monden T, Hosoya T, Nakajima Y, Kishi M, Satoh T, Hashimoto K, Kasai K, Yamada M, Mori M. Herbal medicine, Hachimi-jio-gan, and its component Cinnamomi cortex activate the peroxisome proliferator-activated receptor alpha in renal cells.
Endocr. J. 55: 529-533 (2008).
*
-
Monden T, Kishi M, Hosoya T, Satoh T, Wondisford FE, Hollenberg AN, Yamada M, Mori M. p120 acts as a specific coactivator for 9-cis-retinoic acid receptor (RXR) on peroxisome proliferator-activated receptor-gamma/RXR heterodimers.
Mol. Endocrinol. 13: 1695-1703 (1999).
*
-
Monroy MA, Opperman KK, Pucciarelli M, Yerrum S, Berg DA, Daly JM. The PPARgamma ligand 15d-PGJ2 modulates macrophage activation after injury in a murine trauma model.
Shock 28: 186-191 (2007).
*
-
Montagnana M, Fava C, Nilsson PM, Engstrom G, Hedblad B, Lippi G, Minuz P, Berglund G, Melander O. The Pro12Ala polymorphism of the PPARG gene is not associated with the metabolic syndrome in an urban population of middle-aged Swedish individuals.
Diabet. Med. 25: 902-908 (2008).
*
-
Montagnani M, Abrahamsson A, Galman C, Eggertsen G, Marschall HU, Ravaioli E, Einarsson C, Dawson PA. Analysis of ileal sodium/bile acid cotransporter and related nuclear receptor genes in a family with multiple cases of idiopathic bile acid malabsorption.
World J. Gastroenterol. 12: 7710-7714 (2006).
*
-
Montanari R, Saccoccia F, Scotti E, Crestani M, Godio C, Gilardi F, Loiodice F, Fracchiolla G, Laghezza A, Tortorella P, Lavecchia A, Novellino E, Mazza F, Aschi M, Pochetti G. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
J. Med. Chem. 51: 7768-7776 (2008).
*
-
Montanaro MA, Gonzalez MS, Bernasconi AM, Brenner RR. Role of liver X receptor, insulin and peroxisome proliferator activated receptor alpha on in vivo desaturase modulation of unsaturated fatty acid biosynthesis.
Lipids 42: 197-210 (2007).
-
Monte MJ, Rosales RR, Macias RI, Iannota V, Martinez-Fernandez A, Romero MR, Hofmann AF, Marin JJ. Cytosol-nucleus traffic and colocalization with FXR of conjugated bile acids in rat hepatocytes.
Am. J. Physiol. Gastrointest. Liver Physiol. 295: G54-G62 (2008).
*
-
Montessuit C, Papageorgiou I, Lerch R. Nuclear receptors agonists improve insulin responsiveness in cultured cardiomyocytes through enhanced signaling and preserved cytoskeletal architecture.
Endocrinology 149: 1064-1074 (2008).
*
-
Mook-Kanamori DO, Steegers EA, Uitterlinden AG, Moll HA, van Duijn CM, Hofman A, Jaddoe VW. Breastfeeding modifies the association of PPARgamma-2 polymorphism Pro12Ala with growth in early life.
Diabetes 58: 992-998 (2009).
*
-
Moon Y, Yang H, Park SH. Hypo-responsiveness of interleukin-8 production in human embryonic epithelial intestine 407 cells independent of NF-kappaB pathway: new lessons from endotoxin and ribotoxic deoxynivalenol.
Toxicol. Appl. Pharmacol. 231: 94-102 (2008).
*
-
Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation.
Pharmacol. Ther. 110: 371-385 (2006).
*
-
Moraes LA, Spyridon M, Kaiser WJ, Jones CI, Sage T, Atherton RE, Gibbinsm JM. Nongenomic effects of PPARgamma ligands: inhibition of GPVI-stimulated platelet activation.
J. Thromb. Haemost. Dec 21 [Epub ahead of print] (2009).
-
Moraes LA, Swales KE, Wray JA, Damazo A, Gibbins JM, Warner TD, Bishop-Bailey D. Non-genomic signalling of the retinoid X receptor through binding and inhibiting Gq in human platelets.
Blood 109: 3741-3744 (2007).
*
-
Moran CS, Clancy P, Biros E, Blanco-Martin B, McCaskie P, Palmer LJ, Coomans D, Norman PE, Golledge J. Association of PPARgamma allelic variation, osteoprotegerin and abdominal aortic aneurysm.
Clin. Endocrinol. (Oxf.) Apr 25 [Epub ahead of print] (2009).
*
-
Moras D. Structure of full-length PPARgamma-RXRalpha: a snapshot of a functional complex?
Cell Metab. 9: 8-10 (2009).
*
-
Morash AJ, Bureau DP, McClelland GB. Effects of dietary fatty acid composition on the regulation of carnitine palmitoyltransferase (CPT) I in rainbow trout (Oncorhynchus mykiss).
Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 152: 85-93 (2009).
*
-
Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis.
J. Am. Coll. Cardiol. 44: 2293-2300 (2004).
-
Morgenweck J, Abdel-Aleem OS, McNamara KC, Donahue RR, Badr MZ, Taylor BK. Activation of peroxisome proliferator activated receptor gamma in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema.
Neuropharmacology Nov 2 [Epub ahead of print] (2009).
-
Mori Y, Hirano T, Nagashima M, Shiraishi Y, Fukui T, Adachi M. Decreased peroxisome proliferator-activated receptor alpha gene expression is associated with dyslipidemia in a rat model of chronic renal failure.
Metabolism 56: 1714-1718 (2007).
*
-
Mori Y, Tokutate Y, Oana F, Matsuzawa A, Akahane S, Tajima N. Bezafibrate-induced changes over time in the expression of uncoupling protein (UCP) mRNA in the tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.
J. Atheroscler. Thromb. 11: 224-231 (2004).
*
-
Morihara N, Ide N, Weiss N. Aged garlic extract inhibits CD36 expression in human macrophages via modulation of the PPARgamma pathway.
Phytother. Res. Jan 20 [Epub ahead of print] (2010).
-
Morimura K, Cheung C, Ward JM, Reddy JK, Gonzalez FJ. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis.
Carcinogenesis 27: 1074-1080 (2006).
*
-
Morin C, Sirois M, Echave V, Albadine R, Rousseau E. 17,18-EpETE targets PPARgamma and p38MAPK to mediate its anti-inflammatory effect in lung: role of sEH.
Am. J. Respir. Cell. Mol. Biol. Dec 14 [Epub ahead of print] (2009).
*
-
Morise A, Thomas C, Landrier JF, Besnard P, Hermier D. Hepatic lipid metabolism response to dietary fatty acids is differently modulated by PPARalpha in male and female mice.
Eur. J. Nutr. 48: 465-473 (2009).
*
-
Moriya T, Naito H, Ito Y, Nakajima T. "Hypothesis of seven balances": molecular mechanisms behind alcoholic liver diseases and association with PPARalpha.
J. Occup. Health. 51: 391-403 (2009).
*
-
Morris RT, Laye MJ, Lees SJ, Rector RS, Thyfault JP, Booth FW. Exercise-induced attenuation of obesity, hyperinsulinemia, and skeletal muscle lipid peroxidation in the OLETF rat.
J. Appl. Physiol. 104: 708-715 (2008).
*
-
Morrison JA, Glueck CJ, Wang P. Dietary trans fatty acid intake is associated with increased fetal loss.
Fertil. Steril. 90: 385-390 (2008).
-
Moseley RH. Progress in understanding the pathogenesis of nonalcoholic fatty liver disease.
Hepatology 41: 204 (2005).
*
-
Mossner R, Kaiser R, Matern P, Kruger U, Westphal GA, Brockmoller J, Ziegler A, Neumann C, Konig IR, Reich K. Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis.
Arch. Dermatol. Res. 296: 1-5 (2004).
*
-
Mossner R, Meyer P, Jankowski F, Konig IR, Kruger U, Kammerer S, Westphal G, Boettger MB, Berking C, Schmitt C, Brockmoller J, Ziegler A, Stapelmann H, Kaiser R, Volkenandt M, Reich K. Variations in the peroxisome proliferator-activated receptor-gamma gene and melanoma risk.
Cancer Lett. 246: 218-223 (2007).
*
-
Mostyn A, Symonds ME. Early programming of adipose tissue function: a large-animal perspective.
Proc. Nutr. Soc. 68: 393-400 (2009).
*
-
Motani A, Wang Z, Weiszmann J, McGee LR, Lee G, Liu Q, Staunton J, Fang Z, Fuentes H, Lindstrom M, Liu J, Biermann DH, Jaen J, Walker NP, Learned RM, Chen JL, Li Y. INT131: a selective modulator of PPAR gamma.
J. Mol. Biol. 386: 1301-1311 (2009).
-
Motawi TM, Hashem RM, Rashed LA, El-Razek SM. Comparative study between the effect of the peroxisome proliferator activated receptor-alpha ligands fenofibrate and n-3 polyunsaturated fatty acids on activation of 5'-AMP-activated protein kinase-alpha1 in high-fat fed rats.
J. Pharm. Pharmacol. 61: 1339-1346 (2009).
-
Motojima K. Differential effects of PPARalpha activators on induction of ectopic expression of tissue-specific fatty acid binding protein genes in the mouse liver.
Int. J. Biochem. Cell. Biol. 32: 1085-1092 (2000).
*
-
Motojima K. PPAR-mediated diverse responses in various tissues of mouse.
Cell. Biochem. Biophys. 32: 205-211 (2000).
-
Motojima K. Peroxisome proliferator-activated receptor (PPAR)-dependent and -independent transcriptional modulation of several non-peroxisomal genes by peroxisome proliferators.
Biochimie 79: 101-106 (1997).
-
Motojima K, Hirai T. Peroxisome proliferator-activated receptor a plays a vital role in inducing a detoxification system against plant compounds with crosstalk with other xenobiotic nuclear receptors.
FEBS J. 273: 292-300 (2006).
*
-
Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner.
J. Biol. Chem. 273: 16710-16714 (1998).
*
-
Motojima K, Peters JM, Gonzalez FJ. PPAR alpha mediates peroxisome proliferator-induced transcriptional repression of nonperoxisomal gene expression in mouse.
Biochem. Biophys. Res. Commun. 230: 155-158 (1997).
*
-
Mousavinasab F, Tahtinen T, Jokelainen J, Koskela P, Vanhala M, Oikarinen J, Laakso M, Keinanen-Kiukaanniemi S. The Pro12Ala polymorphism of the PPAR gamma 2 gene influences sex hormone-binding globulin level and its relationship to the development of the metabolic syndrome in young Finnish men.
Endocrine 30: 185-190 (2006).
-
Mouthiers A, Baillet A, Delomenie C, Porquet D, Mejdoubi-Charef N. PPARalpha physically interacts with C/EBPbeta to inhibit C/EBPbeta-responsive alpha1-acid glycoprotein gene expression.
Mol. Endocrinol. 19: 1135-1146 (2005).
*
-
Moya-Camarena SY, Van den Heuvel JP, Belury MA. Conjugated linoleic acid activates peroxisome proliferator-activated receptor alpha and beta subtypes but does not induce hepatic peroxisome proliferation in Sprague-Dawley rats.
Biochim. Biophys. Acta 1436: 331-342 (1999).
-
Moyes KM, Drackley JK, Morin DE, Bionaz M, Rodriguez-Zas SL, Everts RE, Lewin HA, Loor JJ. Gene network and pathway analysis of bovine mammary tissue challenged with Streptococcus uberis reveals induction of cell proliferation and inhibition of PPAR-gamma signaling as potential mechanism for the negative relationships between immune response ..
BMC Genomics 10: 542 (2009).
*
-
Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, Matoulek M, Dostalova I, Humenanska V, Haluzik M. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.
Clin. Endocrinol. (Oxf.) 71: 369-375 (2009).
*
-
Mrowka P, Glodkowska E, Mlynarczuk-Bialy I, Bialy L, Kuckelkorn U, Nowis D, Makowski M, Legat M, Golab J. Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome.
Acta Biochim. Pol. 55: 75-84 (2008).
*
-
Mrowka P, Glodkowska E, Nowis D, Legat M, Issat T, Makowski M, Szokalska A, Janowska S, Stoklosa T, Jakobisiak M, Golab J. Ciglitazone, an agonist of peroxisome proliferator-activated receptor gamma, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin.
Int. J. Oncol. 32: 249-255 (2008).
*
-
Mueller M, Jungbauer A. Peroxisome proliferator-activated receptor gamma is constitutively activated in yeast.
Anal. Biochem. 385: 365-367 (2009).
*
-
Mueller M, Lukas B, Novak J, Simoncini T, Genazzani AR, Jungbauer A. Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists.
J. Agric. Food Chem. 56: 11621-11630 (2008).
*
-
Muia C, Mazzon E, Crisafulli C, Paola RD, Genovese T, Caputi AP, Cuzzocrea S. Role of endogenous peroxisome proliferator-activated receptor-alpha (PPAR-alpha) ligands in the development of gut ischemia and reperfusion in mice.
Shock 25: 17-22 (2006).
*
-
Muise ES, Azzolina B, Kuo DW, El-Sherbeini M, Tan Y, Yuan X, Mu J, Thompson JR, Berger JP, Wong KK. Adipose fibroblast growth factor 21 is up-regulated by PPARgamma and altered metabolic states.
Mol. Pharmacol. 74: 403-412 (2008).
*
-
Mukherjee R, Locke KT, Miao B, Meyers D, Monshizadegan H, Zhang R, Search D, Grimm D, Flynn M, O'Malley KM, Zhang L, Li J, Shi Y, Kennedy LJ, Blanar M, Cheng PT, Tino J, Srivastava R. Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist.
J. Pharmacol. Exp. Ther. 327: 716-726 (2008).
*
-
Mukundan L, Odegaard JI, Morel CR, Heredia JE, Mwangi JW, Ricardo-Gonzalez RR, Goh YP, Eagle AR, Dunn SE, Awakuni JU, Nguyen KD, Steinman L, Michie SA, Chawla A. PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance.
Nat. Med. 15: 1266-1272 (2009).
*
-
Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with Wnt/beta-catenin/Tcf signalling: Wnt you like to know?
Endocr. Rev. 26: 898-915 (2005).
*
-
Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB. The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome.
Clin. Endocrinol. (Oxf.) 64: 519-522 (2006).
*
-
Muller M. Transcriptional control of hepatocanalicular transporter gene expression.
Semin. Liver Dis. 20: 323-337 (2000).
-
Munekata K, Sakamoto K. Forkhead transcription factor Foxo1 is essential for adipocyte differentiation.
In Vitro Cell Dev. Biol. Anim. Jul 8 [Epub ahead of print] (2009).
-
Munhoz CD, Garcia-Bueno B, Madrigal JL, Lepsch LB, Scavone C, Leza JC. Stress-induced neuroinflammation: mechanisms and new pharmacological targets.
Braz. J. Med. Biol. Res. 41: 1037-1046 (2008).
*
-
Muoio DM, MacLean PS, Lang DB, Li S, Houmard JA, Way JM, Winegar DA, Corton JC, Dohm GL, Kraus WE. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta.
J. Biol. Chem. 277: 26089-26097 (2002).
*
-
Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA, Kraus WE, Dohm GL. Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells.
Diabetes 51: 901-909 (2002).
*
-
Murad H, Collet P, Brunner E, Schohn H, Becuwe P, Devignes MD, Dauca M, Domenjoud L. Immunoselection and characterization of a human genomic PPAR binding fragment located within POTE genes.
Biochimie 89: 329-336 (2007).
-
Murad H, Collet P, Huin-Schohn C, Al-Makdissy N, Kerjan G, Chedotal A, Donner M, Devignes MD, Becuwe P, Schohn H, Domenjoud L, Dauca M. Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells.
Int. J. Oncol. 28: 977-984 (2006).
*
-
Murad H, Fiatte C, Brunner E, Huin-Schohn C, Schohn H, Becuwe P, Domenjoud L, Dauca M. PPARs and cell-cell or cell-extracellular matrix interactions.
Med. Sci. (Paris) 23: 515-518 (2007).
-
Murakami K, Bujo H, Unoki H, Saito Y. Effect of PPARalpha activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes.
Eur. J. Pharmacol. 561: 206-213 (2007).
*
-
Murakami K, Ide T, Suzuki M, Mochizuki T, Kadowaki T. Evidence for direct binding of fatty acids and eicosanoids to human peroxisome proliferators-activated receptor alpha.
Biochem. Biophys. Res. Commun. 260: 609-613 (1999).
*
-
Murch O, Collin M, Thiemermann C. Lysophosphatidic acid reduces the organ injury caused by endotoxemia - a role for G-protein-coupled receptors and peroxisome proliferator-activated receptor-gamma.
Shock 27: 48-54 (2007).
*
-
Murphy GJ, Holder JC. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer.
Trends Pharmacol. Sci. 21: 469-474 (2000).
*
-
Muscat GE, Dressel U. Cardiovascular disease and PPARdelta: targeting the risk factors.
Curr. Opin. Investig. Drugs 6: 887-894 (2005).
-
Musiek ES, Brooks JD, Joo M, Brunoldi E, Porta A, Zanoni G, Vidari G, Blackwell TS, Montine TJ, Milne GL, McLaughlin B, Morrow JD. Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid.
J. Biol. Chem. 283: 19927-19935 (2008).
*
-
Musiek ES, Gao L, Milne GL, Han W, Everhart MB, Wang D, Backlund MG, Dubois RN, Zanoni G, Vidari G, Blackwell TS, Morrow JD. Cyclopentenone isoprostanes inhibit the inflammatory response in macrophages.
J. Biol. Chem. 280: 35562-35570 (2005).
*
-
Mutoh M, Niho N, Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice.
Biol. Chem. 387: 381-385 (2006).
-
Myers KA, Lambe KG, Aldridge TC, Macdonald N, Tugwood JD. Amino acid residues in both the DNA-binding and ligand-binding domains influence transcriptional activity of the human peroxisome proliferator-activated receptor alpha.
Biochem. Biophys. Res. Commun. 239: 522-526 (1997).
*
-
Myerson M, Ngai C, Jones J, Holleran S, Ramakrishnan R, Berglund L, Ginsberg HN. Treatment with high dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
J. Lipid Res. 46: 2735-2744 (2005).
*
-
Mysiorek C, Culot M, Dehouck L, Derudas B, Staels B, Bordet R, Cecchelli R, Fenart L, Berezowski V. Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier.
Curr. Neurovasc. Res. 6: 181-193 (2009).
-
Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Chayama K. Deletion of angiotensin II type I receptor reduces hepatic steatosis.
J. Hepatol. 50: 1226-1235 (2009).
-
Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration.
Toxicol. Appl. Pharmacol. 223: 277-287 (2007).
*
-
Nagao K, Yanagita T. Bioactive lipids in metabolic syndrome.
Prog. Lipid Res. 47: 127-146 (2008).
*
-
Nagao Y, French BA, Cai Y, French SW, Wan YJ. Inhibition of PPAR alpha/RXR alpha-mediated direct hyperplasia pathways during griseofulvin-induced hepatocarcinogenesis.
J. Cell. Biochem. 69: 189-200 (1998).
*
-
Nagasawa K, Miyaki J, Kido Y, Higashi Y, Nishida K, Fujimoto S. Possible involvement of PPARgamma in regulation of basal channel opening of P2X7 receptor in cultured mouse astrocytes.
Life Sci. 84: 825-831 (2009).
*
-
Nagasawa M, Hara T, Kashino A, Akasaka Y, Ide T, Murakami K. Identification of a functional peroxisome proliferator-activated receptor (PPAR) response element (PPRE) in the human apolipoprotein A-IV gene.
Biochem. Pharmacol. 78: 523-530 (2009).
*
-
Nagasawa T, Inada Y, Nakano S, Tamura T, Takahashi T, Maruyama K, Yamazaki Y, Kuroda J, Shibata N. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.
Eur. J. Pharmacol. 536: 182-191 (2006).
*
-
Nagata D, Yoshihiro H, Nakanishi M, Naruyama H, Okada S, Ando R, Tozawa K, Kohri K. Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer.
Cancer Detect. Prev. 32: 259-266 (2008).
-
Nagatomo F, Gu N, Fujino H, Takeda I, Tsuda K, Ishihara A. Skeletal muscle characteristics of rats with obesity, diabetes, hypertension, and hyperlipidemia.
J. Atheroscler. Thromb. 16: 576-585 (2009).
*
-
Nagothu KK, Bhatt R, Kaushal GP, Portilla D. Fibrate prevents cisplatin-induced proximal tubule cell death.
Kidney Int. 68: 2680-2693 (2005).
*
-
Naito H, Kamijima M, Yamanoshita O, Nakahara A, Katoh T, Tanaka N, Aoyama T, Gonzalez FJ, Nakajima T. Differential effects of aging, drinking and exercise on serum cholesterol levels dependent on the PPARA-V227A polymorphism.
J. Occup. Health 49: 353-362 (2007).
*
-
Naito H, Yamanoshita O, Kamijima M, Katoh T, Matsunaga T, Lee CH, Kim H, Aoyama T, Gonzalez FJ, Nakajima T. Association of V227A PPARalpha polymorphism with altered serum biochemistry and alcohol drinking in Japanese men.
Pharmacogenet. Genomics 16: 569-577 (2006).
-
Nakachi Y, Yagi K, Nikaido I, Bono H, Tonouchi M, Schonbach C, Okazaki Y. Identification of novel PPARgamma target genes by integrated analysis of ChIP-on-chip and microarray expression data during adipocyte differentiation.
Biochem. Biophys. Res. Commun. 372: 362-366 (2008).
*
-
Nakahata Y, Akashi M, Trcka D, Yasuda A, Takumi T. The in vitro real-time oscillation monitoring system identifies potential entrainment factors for circadian clocks.
BMC Mol. Biol. 7: 5 (2006).
*
-
Nakajima A, Katayama K, Mayumi T. PPARgamma-gene therapy using an adenovirus vector for inflammatory bowel disease.
Nippon Yakurigaku Zasshi 122: 309-316 (2003).
-
Nakajima A, Wada K, Katayama K, Saubermann L, Osawa E, Nagase H, Ueno N, Matsuhashi N, Aburatani H. Gene expression profile after peroxisome proliferator activator receptor-gamma ligand administration in dextran sodium sulfate mice.
J. Gastroenterol. 37 Suppl. 14: 62-66 (2002).
-
Nakajima A, Yoneda M, Takahashi H, Fujisawa N, Wada K. The roles of PPARs in digestive diseases.
Nippon Rinsho 63: 665-671 (2005).
-
Nakajima T, Kamijo Y, Tanaka N, Sugiyama E, Tanaka E, Kiyosawa K, Fukushima Y, Peters JM, Gonzalez FJ, Aoyama T. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage.
Hepatology 40: 972-980 (2004).
*
-
Nakajima T, Kamijo Y, Usuda N, Liang Y, Fukushima Y, Kametani K, Gonzalez FJ, Aoyama T. Sex-dependent regulation of hepatic peroxisome proliferation in mice by trichloroethylene via peroxisome proliferator-activated receptor alpha (PPARalpha).
Carcinogenesis 21: 677-682 (2000).
*
-
Nakajima T, Tanaka N, Kanbe H, Hara A, Kamijo Y, Zhang X, Gonzalez FJ, Aoyama T. Bezafibrate at clinically-relevant doses decreases serum/liver triglycerides via down-regulation of SREBP-1c in mice: a novel PPARalpha-independent mechanism.
Mol. Pharmacol. 75: 782-792 (2009).
*
-
Nakajima T, Tanaka N, Sugiyama E, Kamijo Y, Hara A, Hu R, Li G, Li Y, Nakamura K, Gonzalez FJ, Aoyama T. Cholesterol-lowering effect of bezafibrate is independent of peroxisome proliferator-activated receptor activation in mice.
Biochem. Pharmacol. 76: 108-119 (2008).
*
-
Nakamachi T, Nomiyama T, Gizard F, Heywood EB, Jones KL, Zhao Y, Fuentes L, Takebayashi K, Aso Y, Staels B, Inukai T, Bruemmer D. PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes.
Diabetes 56: 1662-1670 (2007).
*
-
Nakamura K, Inoue I, Takahashi S, Komoda T, Katayama S. Cryptochrome and period proteins are regulated by the CLOCK/BMAL1 gene: crosstalk between the PPARs/RXRalpha-regulated and CLOCK/BMAL1-regulated systems.
PPAR Res. 2008: 348610 (2008).
*
-
Nakamura MT, Cheon Y, Li Y, Nara TY. Mechanisms of regulation of gene expression by fatty acids.
Lipids 39: 1077-1083 (2004).
*
-
Nakamura T, Ito Y, Yanagiba Y, Ramdhan DH, Kono Y, Naito H, Hayashi Y, Li Y, Aoyama T, Gonzalez FJ, Nakajima T. Microgram-order ammonium perfluorooctanoate may activate mouse peroxisome proliferator-activated receptor alpha, but not human PPARalpha.
Toxicology 265: 27-33 (2009).
*
-
Nakamura T, Kawachi K, Saito Y, Saito T, Morishita K, Hoshino J, Hosoi T, Iwasaki T, Ohyama Y, Kurabayashi M. Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension.
Int. Heart J. 50: 501-512 (2009).
-
Nakamura Y, Suzuki T, Sugawara A, Arai Y, Sasano H. Peroxisome proliferator-activated receptor gamma in human prostate carcinoma.
Pathol. Int. 59: 288-293 (2009).
*
-
Nakamura YK, Omaye ST. Conjugated linoleic acid isomers' roles in the regulation of PPAR-gamma and NF-kappaB DNA binding and subsequent expression of antioxidant enzymes in human umbilical vein endothelial cells.
Nutrition 25: 800-811 (2009).
*
-
Nakamuta M, Fujino T, Yada R, Yasutake K, Yoshimoto T, Harada N, Yada M, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nishinakagawa T, Machida K, Matsunaga K, Nakashima M, Kotoh K, Enjoji M. Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.
Int. J. Clin. Pharmacol. Ther. 48: 22-28 (2010).
-
Nakamuta M, Kohjima M, Morizono S, Kotoh K, Yoshimoto T, Miyagi I, Enjoji M. Evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.
Int. J. Mol. Med. 16: 631-635 (2005).
-
Nakano A, Hattori Y, Aoki C, Jojima T, Kasai K. Telmisartan inhibits cytokine-induced nuclear factor-kappaB activation independently of the peroxisome proliferator-activated receptor-gamma.
Hypertens. Res. 32: 765-769 (2009).
-
Nakano R, Kurosaki E, Shimaya A, Shibasaki M. The novel hypoglycemic agent YM440 improves hepatic insulin resistance in obese Zucker fatty rats.
J. Pharmacol. Sci. 101: 311-317 (2006).
*
-
Nakaya H, Summers BD, Nicholson AC, Gotto AM Jr, Hajjar DP, Han J. Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone.
Am. J. Pathol. 174: 2007-2014 (2009).
*
-
Nakaya K, Ayaori M, Hisada T, Sawada S, Tanaka N, Iwamoto N, Ogura M, Yakushiji E, Kusuhara M, Nakamura H, Ohsuzu F. Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma.
J. Atheroscler. Thromb. 14: 133-141 (2007).
-
Nam DH, Ramachandran S, Song DK, Kwon KY, Jeon DS, Shin SJ, Kwon SH, Cha SD, Bae I, Cho CH. Growth inhibition and apoptosis induced in human leiomyoma cells by treatment with the PPAR gamma ligand ciglitizone.
Mol. Hum. Reprod. 13: 829-836 (2007).
-
Namgaladze D, Morbitzer D, von Knethen A, Brune B. Phospholipase A2-modified low-density lipoprotein activates macrophage peroxisome proliferator-activated receptors.
Arterioscler. Thromb. Vasc. Biol. Nov 30 [Epub ahead of print] (2009).
-
Nanji AA, Dannenberg AJ, Jokelainen K, Bass NM. Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-alpha (PPARalpha)-regulated genes and is ameliorated by PPARalpha activation.
J. Pharmacol. Exp. Ther. 310: 417-424 (2004).
*
-
Napal L, Marrero PF, Haro D. An intronic peroxisome proliferator-activated receptor-binding sequence mediates fatty acid induction of the human carnitine palmitoyltransferase 1A.
J. Mol. Biol. 354: 751-759 (2005).
*
-
Napimoga MH, Souza GR, Cunha TM, Ferrari LF, Clemente-Napimoga JT, Parada CA, Verri Jr WA, Cunha FQ, Ferreira SH. 15d-Prostaglandin J2 inhibits inflammatory hypernociception: involvement of peripheral opioid receptor.
J. Pharmacol. Exp. Ther. 324: 313-321 (2007).
*
-
Napimoga MH, Vieira SM, Dal-Secco D, Freitas A, Souto FO, Mestriner FL, Alves-Filho JC, Grespan R, Kawai T, Ferreira SH, Cunha FQ. Peroxisome proliferator-activated receptor-gamma ligand, 15-deoxy-delta12,14-prostaglandin J2, reduces neutrophil migration via a nitric oxide pathway.
J. Immunol. 180: 609-617 (2008).
*
-
Narala VR, Smith MR, Adapala RK, Ranga R, Panati K, Moore BB, Leff T, Reddy VD, Kondapi AK, Reddy RC. Curcumin is not a ligand for peroxisome proliferator-activated receptor-gamma.
Gene Ther. Mol. Biol. 13: 20-25 (2009).
*
-
Narayanan NK, Narayanan BA, Reddy BS. A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors.
Int. J. Oncol. 26: 785-792 (2005).
-
Narravula S, Colgan SP. Hypoxia-inducible factor 1-mediated inhibition of peroxisome proliferator-activated receptor alpha expression during hypoxia.
J. Immunol. 166: 7543-7548 (2001).
*
-
Naruhn S, Meissner W, Adhikary T, Kaddatz K, Klein T, Watzer B, Muller-Brusselbach S, Muller R. 15-Hydroxyeicosatetraenoic acid (15-HETE) is a preferential PPARbeta/delta agonist.
Mol. Pharmacol. Nov 10 [Epub ahead of print] (2009).
*
-
Narvaez CJ, Matthews D, Broun E, Chan M, Welsh J. Lean phenotype and resistance to diet-induced obesity in VDR knockout mice correlates with induction of uncoupling protein-1 in white adipose tissue.
Endocrinology 150: 651-661 (2009).
*
-
Nasrallah R, Clark J, Corinaldi J, Paris G, Miura P, Jasmin BJ, Hebert RL. Thiazolidinediones alter growth and epithelial cell integrity, independent of PPARgamma and MAPK activation, in mouse M1 cortical collecting duct cells.
Am. J. Physiol. Renal Physiol. Feb 17 [Epub ahead of print] (2010).
*
-
Nasrollahzadeh J, Siassi F, Doosti M, Eshraghian MR, Shokri F, Modarressi MH, Mohammadi-Asl J, Abdi K, Nikmanesh A, Karimian SM. The influence of feeding linoleic, gamma-linolenic and docosahexaenoic acid rich oils on rat brain tumor fatty acids composition and fatty acid binding protein 7 mRNA expression.
Lipids Health Dis. 7: 45 (2008).
*
-
Natarajan C, Bright JJ. Peroxisome proliferator-activated receptor-gamma agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation.
Genes Immun. 3: 59-70 (2002).
*
-
Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, Chen AS, Ruderman NB, Chen H, Rossetti L, Scherer PE. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to PPARgamma-agonists.
J. Biol. Chem. 281: 2654-2660 (2006).
*
-
Necela BM, Su W, Thompson EA. Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor gamma and nuclear factor-kappaB in macrophages.
Immunology 125: 344-358 (2008).
*
-
Necela BM, Su W, Thompson EA. Peroxisome proliferator activated receptor gamma downregulates follistatin in intestinal epithelial cells through Sp1.
J. Biol. Chem. 283: 29784-29794 (2008).
*
-
Necela BM, Thompson EA. Pathophysiological roles of PPARgamma in gastrointestinal epithelial cells.
PPAR Res. 2008: 148687 (2008).
*
-
Neess D, Kiilerich P, Sandberg MB, Helledie T, Nielsen R, Mandrup S. ACBP - a PPAR and SREBP modulated housekeeping gene.
Mol. Cell. Biochem. 284: 149-157 (2006).
*
-
Negishi K, Noiri E, Maeda R, Portilla D, Sugaya T, Fujita T. Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury.
Kidney Int. 73: 1374-1384 (2008).
*
-
Nehlin JO, Mogensen JP, Petterson I, Jeppesen L, Fleckner J, Wulff EM, Sauerberg P. Selective PPAR agonists for the treatment of type 2 diabetes.
Ann. N. Y. Acad. Sci. 1067: 448-453 (2006).
*
-
Nelson TL, Fingerlin TE, Moss L, Barmada MM, Ferrell RE, Norris JM. The peroxisome proliferator-activated receptor gamma coactivator-1 alpha gene (PGC-1alpha) is not associated with type 2 diabetes mellitus or body mass index among hispanic and non hispanic whites from Colorado.
Exp. Clin. Endocrinol. Diabetes 115: 268-275 (2007).
-
Nelson TL, Fingerlin TE, Moss L, Barmada MM, Ferrell RE, Norris JM. The PPARgamma Pro12Ala polymorphism is not associated with body mass index or waist circumference among hispanics from Colorado.
Ann. Nutr. Metab. 51: 252-257 (2007).
-
Nelson TL, Fingerlin TE, Moss LK, Barmada MM, Ferrell RE, Norris JM. Association of the peroxisome proliferator-activated receptor gamma gene with type 2 diabetes mellitus varies by physical activity among non-Hispanic whites from Colorado.
Metabolism 56: 388-393 (2007).
*
-
Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW, Keith RL. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor gamma.
Cancer Prev. Res. (Phila. Pa) 1: 349-356 (2008).
-
Neschen S, Morino K, Dong J, Wang-Fischer Y, Cline GW, Romanelli AJ, Rossbacher JC, Moore IK, Regittnig W, Munoz DS, Kim JH, Shulman GI. n-3 Fatty acids preserve insulin sensitivity in vivo in a PPARalpha-dependent manner.
Diabetes 56: 1034-1041 (2007).
*
-
Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S, Gillum M, Shulman GI. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice.
Diabetes 55: 924-928 (2006).
*
-
Neugebauer P, Goldbergova-Pavkova M, Kala P, Bocek O, Jerabek P, Poloczek M, Vytiska M, Parenica J, Mikulik R, Jarkovsky J, Semrad B, Spinar J, Vasku A. Nuclear receptors gene polymorphisms and risk of restenosis and clinical events following coronary stenting.
Vnitr. Lek. 55: 1135-1140 (2009).
-
Neumeier M, Weigert J, Schaffler A, Weiss TS, Schmidl C, Buttner R, Bollheimer C, Aslanidis C, Scholmerich J, Buechler C. Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro.
Biochem. Biophys. Res. Commun. 350: 731-735 (2006).
*
-
Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.
Hepatology 38: 1008-10017 (2003).
*
-
Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis.
J. Hepatol. 38: 434-440 (2003).
*
-
Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.
Circulation 103: 207-212 (2001).
*
-
Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis.
Biochem. Pharmacol. 60: 1245-1250 (2000).
*
-
Newaz M, Blanton A, Fidelis P, Oyekan A. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)alpha-mediated cardiovascular effects.
Mutat. Res. 579: 163-171 (2005).
-
Newaz M, Ranganna K, Truong LD, Oyekan A. Effect of peroxisome proliferator-activated receptor-alpha siRNA on hypertension and renal injury in the rat following nitric oxide withdrawal and high salt diet.
J. Hypertens. Oct 14 [Epub ahead of print] (2009).
-
Newaz M, Yousefipour Z, Oyekan A. Role of PPAR-gamma on the pathogenesis and vascular changes in glycerol-induced acute renal failure.
Pharmacol. Res. 54: 234-240 (2006).
*
-
Ng SC, Kamm MA. Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis.
Aliment. Pharmacol. Ther. 28: 815-829 (2008).
*
-
Ng VY, Huang Y, Reddy LM, Falck JR, Lin ET, Kroetz DL. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha (PPARalpha).
Drug Metab. Dispos. 35: 1126-1134 (2007).
*
-
Nguyen KA, Carbone JM, Silva VM, Chen C, Hennig GE, Whiteley HE, Manautou JE. The PPAR activator docosahexaenoic acid prevents acetaminophen hepatotoxicity in male CD-1 mice.
J. Toxicol. Environ. Health A. 58: 171-186 (1999).
-
Ni HX, Yu NJ, Yang XH. The study of ginsenoside on PPARgamma expression of mononuclear macrophage in type 2 diabetes.
Mol. Biol. Rep. Oct 10 [Epub ahead of print] (2009).
*
-
Ni J, Zhang YZ, Xue SL. The expressions of PPAR-gamma, COX-2 in the lesions of patients with condyloma acuminatum and bowenoid papulosis.
Sichuan Da Xue Xue Bao Yi Xue Ban 40: 439-441 (2009).
-
Nie W, Sweetser S, Rinella M, Green RM. Transcriptional regulation of murine Slc22a11 (Oct1) by peroxisome-proliferator agonist receptor (PPAR)-alpha and -gamma.
Am. J. Physiol. Gastrointest. Liver Physiol. 288: G207-G212 (2005).
*
-
Nielsen R, Grontved L, Stunnenberg HG, Mandrup S. Peroxisome proliferator-activated receptor subtype- and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery.
Mol. Cell. Biol. 26: 5698-5714 (2006).
*
-
Nielsen R, Pedersen TA, Hagenbeek D, Moulos P, Siersbaek R, Megens E, Denissov S, Borgesen M, Francoijs KJ, Mandrup S, Stunnenberg HG. Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis.
Genes Dev. 22: 2953-2967 (2008).
*
-
Niemoller TD, Bazan NG. Docosahexaenoic acid neurolipidomics.
Prostaglandins Other Lipid Mediat. Oct 2 [Epub ahead of print] (2009).
-
Nigro J, Potter-Perigo S, Ivey ME, de Dios ST, Evanko SP, Wight TN, Little PJ. The effect of PPAR ligands to modulate glucose metabolism alters the incorporation of metabolic precursors into proteoglycans synthesized by human vascular smooth muscle cells.
Arch. Physiol. Biochem. 114: 171-177 (2008).
*
-
Niho N, Mutoh M, Takahashi M, Tsutsumi K, Sugimura T, Wakabayashi K. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice.
Proc. Natl. Acad. Sci. U.S.A. 102: 2970-2974 (2005).
*
-
Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T, Sugimura T, Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands.
Cancer Res. 63: 6090-6095 (2003).
*
-
Niino M. Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis.
Mini. Rev. Med. Chem. 7: 1129-1135 (2007).
-
Nilmeier J, Jacobson M. Multiscale Monte Carlo sampling of protein sidechains: application to binding pocket flexibility.
J. Chem. Theory Comput. 4: 835-846 (2008).
-
Nilsson E, Poulsen P, Sjogren M, Ling C, Ridderstrale M, Groop L, Vaag A. Regulation of skeletal muscle PPAR delta mRNA expression in twins.
J. Physiol. 584: 1011-1017 (2007).
*
-
Nisbet RE, Sutliff RL, Hart CM. The role of peroxisome proliferator-activated receptors in pulmonary vascular disease.
PPAR Res. 2007: 18797 (2007).
*
-
Nishii N, Takasu M, Soe OK, Maeda S, Ohba Y, Inoue-Murayama M, Kitagawa H. Cloning, expression and investigation for polymorphisms of canine peroxisome proliferator-activated receptors.
Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 147: 690-697 (2007).
*
-
Nishimaki-Mogami T, Tamehiro N, Sato Y, Okuhira KI, Sai K, Kagechika H, Shudo K, Abe-Dohmae S, Yokoyama S, Ohno Y, Inoue K, Sawada JI. The RXR agonists PA024 and HX630 have different abilities to activate LXR/RXR and to induce ABCA1 expression in macrophage cell lines.
Biochem. Pharmacol. 76: 1006-1013 (2008).
*
-
Nishimura J, Masaki T, Arakawa M, Seike M, Yoshimatsu H. Isoleucine prevents the accumulation of tissue triglycerides and upregulates the expression of PPARalpha and uncoupling protein in diet-induced obese mice.
J. Nutr. Jan 20 [Epub ahead of print] (2010).
-
Nishimura R, Hata K, Ichida F. Roles of PPAR family in bone metabolisms.
Nippon Rinsho 63: 591-596 (2005).
-
Nishimura-Sakurai Y, Sakamoto N, Mogushi K, Nagaie S, Nakagawa M, Itsui Y, Tasaka-Fujita M, Onuki-Karakama Y, Suda G, Mishima K, Yamamoto M, Ueyama M, Funaoka Y, Watanabe T, Azuma S, Sekine-Osajima Y, Kakinuma S, Tsuchiya K, Enomoto N, Tanaka H, et al. Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells.
J. Gastroenterol. Dec 17 [Epub ahead of print] (2009).
*
-
Nishioka T, Hyogo H, Numata Y, Yamaguchi A, Kobuke T, Komichi D, Nonaka M, Inoue M, Nabeshima Y, Ogi M, Iwamoto K, Ishitobi T, Ajima T, Chayama K, Tazuma S. A nuclear receptor-mediated choleretic action of fibrates is associated with enhanced canalicular membrane fluidity and transporter activity mediating bile acid-independent bile secretion.
J. Atheroscler. Thromb. 12: 211-217 (2005).
*
-
Nitz I, Ewert A, Klapper M, Doring F. Analysis of PGC-1alpha variants Gly482Ser and Thr612Met concerning their PPARgamma2-coactivation function.
Biochem. Biophys. Res. Commun. 353: 481-486 (2007).
*
-
Nivitabishekam SN, Asad M, Prasad VS. Pharmacodynamic interaction of Momordica charantia with rosiglitazone in rats.
Chem. Biol. Interact. 177: 247-253 (2009).
*
-
Nizamutdinova IT, Kim YM, Kim HJ, Seo HG, Lee JH, Chang KC. Carbon monoxide (from CORM-2) inhibits high glucose-induced ICAM-1 expression via AMP-activated protein kinase and PPAR-gamma activations in endothelial cells.
Atherosclerosis 207: 405-411 (2009).
-
Nofziger C, Brown KK, Smith CD, Harrington W, Murray D, Bisi J, Ashton TT, Maurio FP, Kalsi K, West TA, Baines DL, Blazer-Yost BL. PPARgamma agonists inhibit vasopressin mediated anion transport in the MDCK-C7 cell line.
Am. J. Physiol. Renal Physiol. 297: F55-F62 (2009).
*
-
Nohara A, Kawashiri MA, Claudel T, Mizuno M, Tsuchida M, Takata M, Katsuda S, Miwa K, Inazu A, Kuipers F, Kobayashi J, Koizumi J, Yamagishi M, Mabuchi H. High frequency of a retinoid X receptor gamma gene variant in familial combined hyperlipidemia that associates with atherogenic dyslipidemia.
Arterioscler. Thromb. Vasc. Biol. 27: 923-928 (2007).
-
Nomura H, Yamawaki H, Mukohda M, Okada M, Hara Y. Mechanisms underlying pioglitazone-mediated relaxation in isolated blood vessel.
J. Pharmacol. Sci. 108: 258-265 (2008).
*
-
Nomura S, Nakajima A, Ishimine S, Matsuhashi N, Kadowaki T, Kaminishi M. Differential expression of peroxisome proliferator-activated receptor in histologically different human gastric cancer tissues.
J. Exp. Clin. Cancer Res. 25: 443-448 (2006).
-
Norel X. Prostanoid receptors in the human vascular wall.
ScientificWorldJournal 7: 1359-1374 (2007).
*
-
Noshiro M, Usui E, Kawamoto T, Kubo H, Fujimoto K, Furukawa M, Honma S, Makishima M, Honma K, Kato Y. Multiple mechanisms regulate circadian expression of the gene for cholesterol 7alpha-hydroxylase (Cyp7a), a key enzyme in hepatic bile acid biosynthesis.
J. Biol. Rhythms 22: 299-311 (2007).
-
Nunez SB, Medin JA, Braissant O, Kemp L, Wahli W, Ozato K, Segars JH. Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor.
Mol. Cell. Endocrinol. 127: 27-40 (1997).
-
Nunez-Anita RE, Arroyo-Helguera O, Cajero-Juarez M, Lopez-Bojorquez L, Aceves C. A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplasic effect of iodine in mammary cancer.
Prostaglandins Other Lipid Mediat. 89: 34-42 (2009).
-
Nunn AV, Bell J, Barter P. The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balance.
Nucl. Recept. 5: 1 (2007).
*
-
Nuver J, De Haas EC, Van Zweeden M, Gietema JA, Meijer C. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro.
Oncol. Rep. 23: 247-253 (2010).
-
Nyirenda MJ, Dean S, Lyons V, Chapman KE, Seckl JR. Prenatal programming of hepatocyte nuclear factor 4alpha in the rat: a key mechanism in the 'foetal origins of hyperglycaemia'?
Diabetologia 49: 1412-1420 (2006).
*
-
O'Brien ML, Spear BT, Glauert HP. Role of oxidative stress in peroxisome proliferator-mediated carcinogenesis.
Crit. Rev. Toxicol. 35: 61-88 (2005).
-
O'Connell MA, Rushworth SA. Curcumin: potential for hepatic fibrosis therapy?
Br. J. Pharmacol. 153: 403-405 (2008).
*
-
O'Flaherty JT, Rogers LC, Paumi CM, Hantgan RR, Thomas LR, Clay CE, High K, Chen YQ, Willingham MC, Smitherman PK, Kute TE, Rao A, Cramer SD, Morrow CS. 5-Oxo-ETE analogs and the proliferation of cancer cells.
Biochim. Biophys. Acta 1736: 228-236 (2005).
*
-
O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors.
Br. J. Pharmacol. 152: 576-582 (2007).
*
-
O'Sullivan SE, Kendall DA. Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease.
Immunobiology Oct 13 [Epub ahead of print] (2009).
-
Oben JE, Ngondi JL, Blum K. Inhibition of adipogenesis by Irvingia gabonensis seed extract (IGOB131) as mediated via down regulation of the PPAR gamma and leptin genes, and up-regulation of the adiponectin gene.
Lipids Health Dis. 7: 44 (2008).
*
-
Oberfield JL, Collins JL, Holmes CP, Goreham DM, Cooper JP, Cobb JE, Lenhard JM, Hull-Ryde EA, Mohr CP, Blanchard SG, Parks DJ, Moore LB, Lehmann JM, Plunket K, Miller AB, Milburn MV, Kliewer SA, Willson TM. A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation.
Proc. Natl. Acad. Sci. U.S.A. 96: 6102-6106 (1999).
*
-
Ogasawara N, Kojima T, Go M, Fuchimoto J, Kamekura R, Koizumi JI, Ohkuni T, Masaki T, Murata M, Tanaka S, Ichimiya S, Himi T, Sawada N. Induction of JAM-A during differentiation of human THP-1 dendritic cells.
Biochem. Biophys. Res. Commun. 389: 543-549 (2009).
*
-
Ogata M, Tsujita M, Hossain MA, Akita N, Gonzalez FJ, Staels B, Suzuki S, Fukutomi T, Kimura G, Yokoyama S. On the mechanism for PPAR agonists to enhance ABCA1 gene expression.
Atherosclerosis 205: 413-419 (2009).
-
Ogino M, Nagata K, Yamazoe Y. Selective suppressions of human CYP3A forms, CYP3A5 and CYP3A7, by troglitazone in HepG2 cells.
Drug Metab. Pharmacokinet. 17: 42-46 (2002).
*
-
Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL, Giovannucci EL, Fuchs CS. Colorectal cancer expression of peroxisome proliferator-activated receptor-gamma (PPARG, PPARgamma) is associated with good prognosis.
Gastroenterology 136: 1242-1250 (2009).
*
-
Oh SH, Park SM, Lee YH, Cha JY, Lee JY, Shin EK, Park JS, Park BL, Shin HD, Park CS. Association of peroxisome proliferator-activated receptor-gamma gene polymorphisms with the development of asthma.
Respir. Med. 103: 1020-1024 (2009).
-
Ohata M, Suzuki H, Sakamoto K, Hashimoto K, Nakajima H, Yamauchi M, Hokkyo K, Yamada H, Toda G. Pioglitazone prevents acute liver injury induced by ethanol and lipopolysaccharide through the suppression of tumor necrosis factor-alpha.
Alcohol Clin. Exp. Res. 28: 139S-144S (2004).
-
Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, Wada J, Shikata Y, Makino H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
Am. J. Physiol. Renal Physiol. 292: F1141-F1150 (2007).
*
-
Ohhira M, Motomura W, Fukuda M, Yoshizaki T, Takahashi N, Tanno S, Wakamiya N, Kohgo Y, Kumei S, Okumura T. Lipopolysaccharide induces adipose differentiation-related protein expression and lipid accumulation in the liver through inhibition of fatty acid oxidation in mice.
J. Gastroenterol. 42: 969-978 (2007).
*
-
Ohnishi T, Arnold LL, Clark NM, Wisecarver JL, Cohen SM. Comparison of endothelial cell proliferation in normal liver and adipose tissue in B6C3F1 mice, F344 rats, and humans.
Toxicol. Pathol. 35: 904-909 (2007).
*
-
Ohoka N, Kato S, Takahashi Y, Hayashi H, Sato R. The orphan nuclear receptor RORalpha restrains adipocyte differentiation through a reduction of C/EBPbeta activity and perilipin gene expression.
Mol. Endocrinol. 23: 759-771 (2009).
*
-
Oikari S, Ahtialansaari T, Heinonen MV, Mauriala T, Auriola S, Kiehne K, Folsch UR, Janne J, Alhonen L, Herzig KH. Downregulation of PPARs and SREBP by acyl-CoA-binding protein overexpression in transgenic rats.
Pflugers Arch. 456: 369-377 (2008).
*
-
Oishi K, Shirai H, Ishida N. CLOCK is involved in the circadian transactivation of peroxisome-proliferator-activated receptor alpha (PPARalpha) in mice.
Biochem. J. 386: 575-581 (2005).
*
-
Oishi Y, Manabe I, Tobe K, Ohsugi M, Kubota T, Fujiu K, Maemura K, Kubota N, Kadowaki T, Nagai R. SUMOylation of Kruppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-delta.
Nat. Med. 14: 656-666 (2008).
*
-
Oka SI, Masutani H, Liu W, Horita H, Wang D, Kizaka-Kondoh S, Yodoi J. Thioredoxin-binding protein-2 (TBP-2)-like inducible membrane protein (TLIMP) is a novel vitamin D3 and PPAR-gamma ligand target protein that regulates PPAR-gamma signaling.
Endocrinology 147: 733-743 (2006).
*
-
Oka SI, Yoshihara E, Bizen-Abe A, Liu W, Watanabe M, Yodoi J, Masutani H. Thioredoxin binding protein-2 (TBP-2)/Txnip is a critical regulator of insulin secretion and PPAR function.
Endocrinology 150: 1225-1234 (2009).
*
-
Okada K, Fujii T, Ohtsuka Y, Yamakawa Y, Izumi H, Yamashiro Y, Shimizu T. Overfeeding can cause NEC-like enterocolitis in premature rat pups.
Neonatology 97: 218-224 (2009).
-
Okada K, Yanagawa T, Warabi E, Yamastu K, Uwayama J, Takeda K, Utsunomiya H, Yoshida H, Shoda J, Ishii T. The alpha-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice.
Hepatol. Res. 39: 490-500 (2009).
*
-
Okada M, Yan SF, Pinsky DJ. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets.
FASEB J. 16: 1861-1868 (2002).
*
-
Okada T, Wada J, Hida K, Eguchi J, Hashimoto I, Baba M, Yasuhara A, Shikata K, Makino H. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
Diabetes 55: 1666-1677 (2006).
*
-
Okamoto H, Iwamoto T, Kotake S, Momohara S, Yamanaka H, Kamatani N. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis.
Clin. Exp. Rheumatol. 23: 323-330 (2005).
-
Okamoto Y, Higashiyama H, Inoue H, Kanematsu M, Kinoshita M, Asano S. Quantitative image analysis in adipose tissue using an automated image analysis system: differential effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist on white and brown adipose tissue morphology in AKR obese and db/db …
Pathol. Int. 57: 369-377 (2007).
*
-
Okauchi Y, Iwahashi H, Okita K, Yuan M, Matsuda M, Tanaka T, Miyagawa J, Funahashi T, Horikawa Y, Shimomura I, Yamagata K. PGC-1alpha Gly482Ser polymorphism is associated with the plasma adiponectin level in type 2 diabetic men.
Endocr. J. 55: 991-997 (2008).
*
-
Okaya T, Lentsch AB. Peroxisome proliferator-activated receptor-alpha regulates postischemic liver injury.
Am. J. Physiol. Gastrointest. Liver Physiol. 286: G606-G612 (2004).
*
-
Okazaki M, Iwasaki Y, Nishiyama M, Taguchi T, Tsugita M, Nakayama S, Kambayashi M, Hashimoto K, Terada Y. PPARbeta/delta regulates the human SIRT1 gene transcription via Sp1.
Endocr. J. Feb 17 [Epub ahead of print] (2010).
*
-
Oki K, Koide J, Nakanishi S, Nakashima R, Yamane K. Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia.
Endocr. J. 54: 431-435 (2007).
*
-
Oki Y, Watanabe S, Endo T, Kano K. Mature adipocyte-derived dedifferentiated fat cells can trans-differentiate into osteoblasts in vitro and in vivo only by all-trans retinoic acid.
Cell. Struct. Funct. 33: 211-222 (2008).
*
-
Okiyama W, Tanaka N, Nakajima T, Tanaka E, Kiyosawa K, Gonzalez FJ, Aoyama T. Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress.
J. Hepatol. 50: 1236-1246 (2009).
-
Oku H, Umino T. Molecular characterization of peroxisome proliferator-activated receptors (PPARs) and their gene expression in the differentiating adipocytes of red sea bream Pagrus major.
Comp. Biochem. Physiol. B. Biochem. Mol. Biol. 151: 268-277 (2008).
*
-
Oleksiewicz MB, Southgate J, Iversen L, Egerod FL. Rat urinary bladder carcinogenesis by dual-acting PPARalpha + gamma agonists.
PPAR Res. 2008: 103167 (2008).
*
-
Oliveira AC, Bertollo CM, Rocha LT, Nascimento EB Jr, Costa KA, Coelho MM. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.
Eur. J. Pharmacol. 561: 194-201 (2007).
*
-
Oliver E, McGillicuddy F, Phillips C, Toomey S, Roche HM. Postgraduate Symposium. The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA.
Proc. Nutr. Soc. Feb 17 [Epub ahead of print] (2010).
*
-
Oliver WR Jr, Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport.
Proc. Natl. Acad. Sci. U.S.A. 98: 5306-5311 (2001).
*
-
Ollero M, Junaidi O, Zaman MM, Tzameli I, Ferrando AA, Andersson C, Blanco PG, Bialecki E, Freedman SD. Decreased expression of peroxisome proliferator activated receptor gamma in CFTR-/- mice.
J. Cell Physiol. 200: 235-244 (2004).
*
-
Omura K, Kiyosawa N, Uehara T, Hirode M, Shimizu T, Miyagishima T, Ono A, Nagao T, Urushidani T. Gene expression profiling of rat liver treated with serum triglyceride-decreasing compounds.
J. Toxicol. Sci. 32: 387-399 (2007).
*
-
Ondracek CR, Rushing CN, Reese VC, Oropeza CE, McLachlan A. Peroxisome proliferator-activated receptor gamma coactivator 1alpha and small heterodimer partner differentially regulate nuclear receptor-dependent hepatitis B virus biosynthesis.
J. Virol. 83: 12535-12544 (2009).
-
Ondrey F. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention.
Clin. Cancer Res. 15: 2-8 (2009).
*
-
Ooi EM, Barrett PH, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.
Clin. Sci. (Lond.) 114: 611-624 (2008).
*
-
Orasanu G, Ziouzenkova O, Devchand PR, Nehra V, Hamdy O, Horton ES, Plutzky J. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
J. Am. Coll. Cardiol. 52: 869-881 (2008).
-
Orfila C, Lepert JC, Alric L, Carrera G, Beraud M, Pipy B. Immunohistochemical distribution of activated nuclear factor kappaB and peroxisome proliferator-activated receptors in carbon tetrachloride-induced chronic liver injury in rats.
Histochem. Cell. Biol. 123: 585-593 (2005).
-
Oshio H, Abe T, Onogawa T, Ohtsuka H, Sato T, Ii T, Fukase K, Muto M, Katayose Y, Oikawa M, Rikiyama T, Egawa S, Unno M. Peroxisome proliferator-activated receptor alpha activates cyclooxygenase-2 gene transcription through bile acid transport in human colorectal cancer cell lines.
J. Gastroenterol. 43: 538-549 (2008).
*
-
Ostberg T, Svensson S, Selen G, Uppenberg J, Thor M, Sundbom M, Sydow-Backman M, Gustavsson AL, Jendeberg L. A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects.
J. Biol. Chem. 279: 41124-41130 (2004).
*
-
Ouamrane L, Larrieu G, Gauthier B, Pineau T. RXR activators molecular signalling: involvement of a PPAR alpha-dependent pathway in the liver and kidney, evidence for an alternative pathway in the heart.
Br. J. Pharmacol. 138: 845-854 (2003).
*
-
Ouk T, Laprais M, Bastide M, Gautier S, Mostafa K, Bordet R. Withdrawal of fenofibrate treatment partially abrogates preventive neuroprotection in stroke via loss of vascular protection.
Vascul. Pharmacol. 51: 323-330 (2009).
-
Oyama T, Toyota K, Waku T, Hirakawa Y, Nagasawa N, Kasuga JI, Hashimoto Y, Miyachi H, Morikawa K. Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures.
Acta Crystallogr. D. Biol. Crystallogr. 65: 786-795 (2009).
*
-
Oyama Y, Akuzawa N, Nagai R, Kurabayashi M. PPARgamma ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells.
Circ. Res. 90: 348-355 (2002).
*
-
Ozbek E, Ilbey YO, Simsek A, Cekmen M, Mete F, Somay A. Rosiglitazone, peroxisome proliferator receptor-gamma agonist, ameliorates gentamicin-induced nephrotoxicity in rats.
Int. Urol. Nephrol. Sep 25 [Epub ahead of print] (2009).
-
Pace E, Ferraro M, Mody CH, Melis MR, Scafidi V, Bonanno A, Profita M, Giarratano A, Gjomarkaj M. Pleural mesothelial cells express both BLT2 and PPARalpha and mount an integrated response to pleural leukotriene B4.
J. Immunol. 181: 7292-7299 (2008).
*
-
Pachikian BD, Neyrinck AM, Cani PD, Portois L, Deldicque L, De Backer FC, Sohet FM, Bindels LB, Malaisse WJ, Francaux M, Carpentier YA, Delzenne NM. Hepatic steatosis in n-3 fatty acid depleted mice: focus on metabolic alterations related to tissue fatty acid composition.
BMC Physiol. 8: 21 (2008).
*
-
Pagel-Langenickel I, Schwartz DR, Arena RA, Minerbi DC, Johnson DT, Waclawiw MA, Cannon RO, Balaban RS, Tripodi DJ, Sack MM. A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in type 2 diabetes mellitus.
Am. J. Physiol. Heart Circ. Physiol. 293: H2659-H2666 (2007).
*
-
Paik YH, Kim JK, Lee JI, Kang SH, Kim DY, Ahn SH, Lee SJ, Lee DK, Han KH, Chon CY, Lee SI, Lee KS, Brenner D. Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats.
Gut 58: 1517-1527 (2009).
-
Paintlia AS, Paintlia MK, Singh I, Singh AK. IL-4-induced peroxisome proliferator-activated receptor gamma activation inhibits NF-kappaB trans activation in central nervous system (CNS) glial cells and protects oligodendrocyte progenitors under neuroinflammatory disease conditions.
J. Immunol. 176: 4385-4398 (2006).
*
-
Paintlia MK, Paintlia AS, Contreras MA, Singh I, Singh AK. Lipopolysaccharide-induced peroxisomal dysfunction exacerbates cerebral white matter injury: attenuation by N-acetyl cysteine.
Exp. Neurol. 210: 560-576 (2008).
-
Paintlia MK, Paintlia AS, Khan M, Singh I, Singh AK. Modulation of peroxisome proliferator-activated receptor-alpha activity by N-acetyl cysteine attenuates inhibition of oligodendrocyte development in lipopolysaccharide stimulated mixed glial cultures.
J. Neurochem. 105: 956-970 (2008).
-
Pal M, Pillarisetti S. HDL elevators and mimetics - emerging therapies for atherosclerosis.
Cardiovasc. Hematol. Agents Med. Chem. 5: 55-66 (2007).
-
Palicka V. Drugs influencing bone metabolism in diabetic patients.
Vnitr. Lek. 55: 368-370 (2009).
-
Pall H, Andersson C, Zaman MM, Freedman SD. Decreased PPAR alpha may explain the pathogenesis of primary sclerosing cholangitis.
Gastroenterology 126: A672 (2004).
-
Pall H, Zaman MM, Andersson C, Freedman SD. Decreased peroxisome proliferator activated receptor alpha is associated with bile duct injury in cystic fibrosis transmembrane conductance regulator-/- mice.
J. Pediatr. Gastroenterol. Nutr. 42: 275-281 (2006).
*
-
Pall H, Zielenski J, Jonas MM, Dasilva DA, Potvin KM, Yuan, XW, Huang Q, Freedman SD. Primary sclerosing cholangitis in childhood is associated with abnormalities in cystic fibrosis-mediated chloride channel function.
J. Pediatr. 151: 255-259 (2007).
*
-
Palmer CN, Doney AS, Ismail T, Lee SP, Murrie I, Macgregor DF, Mukhopadhyay S. PPARG locus haplotype variation and exacerbations in asthma.
Clin. Pharmacol. Ther. 81: 713-718 (2007).
*
-
Palmer CN, Hsu MH, Griffin HJ, Johnson EF. Novel sequence determinants in peroxisome proliferator signaling.
J. Biol. Chem. 270: 16114-16121 (1995).
*
-
Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF. Peroxisome proliferator activated receptor-alpha expression in human liver.
Mol. Pharmacol. 53: 14-22 (1998).
*
-
Palmer CN, Hsu MH, Muerhoff AS, Griffin KJ, Johnson EF. Interaction of the peroxisome proliferator-activated receptor alpha with the retinoid X receptor alpha unmasks a cryptic peroxisome proliferator response element that overlaps an ARP-1-binding site in the CYP4A6 promoter.
J. Biol. Chem. 269: 18083-18089 (1994).
*
-
Palut D, Kostka G, Strucinski P. The role of nuclear receptors in cytochrome P-450 induction by xenochemicals.
Rocz. Panstw. Zakl. Hig. 53: 321-332 (2002).
-
Pan DA, Mater MK, Thelen AP, Peters JM, Gonzalez FJ, Jump DB. Evidence against the peroxisome proliferator-activated receptor alpha (PPARalpha) as the mediator for polyunsaturated fatty acid suppression of hepatic L-pyruvate kinase gene transcription.
J. Lipid Res. 41: 742-751 (2000).
*
-
Pan GD, Cheng NS, Xiong XZ, Liu JW, Li SF, Zahng GF, Yan LN. A study on inflammatory regulation of human gallbladder epithelial cells by PPAR-gamma ligand.
Sichuan Da Xue Xue Bao Yi Xue Ban 35: 658-661 (2004).
-
Pan GD, Wu H, Liu JW, Cheng NS, Xiong XZ, Li SF, Zhang GF, Yan LN. Effect of peroxisome proliferator-activated receptor-gamma ligand on inflammation of human gallbladder epithelial cells.
World J. Gastroenterol. 11: 6061-6065 (2005).
*
-
Pan QR, Li WH, Wang H, Sun Q, Xiao XH, Brock B, Schmitz O. Glucose, metformin, and AICAR regulate the expression of G protein-coupled receptor members in INS-1 beta cell.
Horm. Metab. Res. 41: 799-804 (2009).
-
Pan X, Song X, Wang L, Li L, Ying B. Association of the Pro12Ala polymorphism in peroxisome proliferators activated receptor gamma gene with rheumatoid arthritis in Sichuan Province of China.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi 26: 87-90 (2009).
-
Panadero M, Bocos C, Herrera E. Relationship between lipoprotein lipase and peroxisome proliferator-activated receptor-alpha expression in rat liver during development.
J. Physiol. Biochem. 62: 189-198 (2006).
-
Panadero M, Herrera E, Bocos C. Different sensitivity of PPARalpha gene expression to nutritional changes in liver of suckling and adult rats.
Life Sci. 76: 1061-1072 (2005).
*
-
Pancani T, Phelps JT, Searcy JL, Kilgore MW, Chen KC, Porter NM, Thibault O. Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons.
J. Neurochem. 109: 1800-1811 (2009).
-
Panchapakesan U, Chen XM, Pollock CA. Drug insight: thiazolidinediones and diabetic nephropathy-relevance to renoprotection.
Nat. Clin. Pract. Nephrol. 1: 33-43 (2005).
*
-
Pandey NR, Benkirane K, Amiri F, Schiffrin EL. Effects of PPAR-gamma knock-down and hyperglycemia on insulin signaling in vascular smooth muscle cells from hypertensive rats.
J. Cardiovasc. Pharmacol. 49: 346-354 (2007).
-
Pandey NR, Renwick J, Misquith A, Sokoll K, Sparks DL. Linoleic acid-enriched phospholipids act through peroxisome proliferator-activated receptors alpha to stimulate hepatic apolipoprotein A-I secretion.
Biochemistry 47: 1579-1587 (2008).
*
-
Pang M, de la Monte SM, Longato L, Tong M, He J, Chaudhry R, Duan K, Ouh J, Wands JR. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair.
J. Hepatol. 50: 1192-1201 (2009).
-
Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnes CM, Fannon M, Laforme AM, Chaponis DM, Folkman J, Kieran MW. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.
Proc. Natl. Acad. Sci. U.S.A. 105: 985-990 (2008).
*
-
Panunti B, Fonseca V. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
Vascul. Pharmacol. 45: 29-35 (2006).
*
-
Paola RD, Cuzzocrea S. Peroxisome proliferator-activated receptors and acute lung injury.
PPAR Res. 2007: 63745 (2007).
*
-
Papadopoulos GA, Erkens T, Maes DG, Peelman LJ, van Kempen TA, Buyse J, Janssens GP. Peripartal feeding strategy with different n-6:n-3 ratios in sows: effect on gene expression in backfat white adipose tissue postpartum.
Br. J. Nutr. 101: 197-205 (2009).
*
-
Papi A, Rocchi P, Ferreri AM, Guerra F, Orlandi M. Enhanced effects of PPARgamma ligands and RXR selective retinoids in combination to inhibit migration and invasiveness in cancer cells.
Oncol. Rep. 21: 1083-1089 (2009).
-
Paquette A, Wang D, Jankowski M, Gutkowska J, Lavoie JM. Effects of ovariectomy on PPARalpha, SREBP-1c, and SCD-1 gene expression in the rat liver.
Menopause 15: 1169-1175 (2008).
-
Paragh G, Harangi M, Mark L. New trends in lipidology: the increasing role of HDL-cholesterol.
Orv. Hetil. 149: 1395-1404 (2008).
-
Parajuli P, Mathupala S, Mittal S, Sloan AE. Dendritic cell-based active specific immunotherapy for malignant glioma.
Expert Opin. Biol. Ther. 7: 439-448 (2007).
-
Parent R, Kolippakkam D, Booth G, Beretta L. Mammalian target of rapamycin activation impairs hepatocytic differentiation and targets genes moderating lipid homeostasis and hepatocellular growth.
Cancer Res. 67: 4337-4345 (2007).
*
-
Park BC, Thapa D, Lee JS, Park SY, Kim JA. Troglitazone inhibits vascular endothelial growth factor-induced angiogenic signaling via suppression of reactive oxygen species production and extracellular signal-regulated kinase phosphorylation in endothelial cells.
J. Pharmacol. Sci. 111: 1-12 (2009).
*
-
Park CW, Kim HW, Ko SH, Chung HW, Lim SW, Yang CW, Chang YS, Sugawara A, Guan Y, Breyer MD. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha.
Diabetes 55: 885-893 (2006).
*
-
Park CW, Zhang Y, Zhang X, Wu J, Chen L, Cha DR, Su D, Hwang MT, Fan X, Davis L, Striker G, Zheng F, Breyer M, Guan Y. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.
Kidney Int. 69: 1511-1517 (2006).
*
-
Park EY, Cho IJ, Kim SG. Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer.
Cancer Res. 64: 3701-3713 (2004).
*
-
Park JK, Ki MR, Lee HR, Hong IH, Ji AR, Ishigami A, Park SI, Kim JM, Chung HY, Yoo SE, Jeong KS. Vitamin C deficiency attenuates liver fibrosis by way of up-regulated peroxisome proliferator-activated receptor-gamma expression in senescence marker protein 30 knockout mice.
Hepatology Dec 9 [Epub ahead of print] (2009).
*
-
Park JY, Kawada T, Han IS, Kim BS, Goto T, Takahashi N, Fushiki T, Kurata T, Yu R. Capsaicin inhibits the production of tumor necrosis factor alpha by LPS-stimulated murine macrophages, RAW 264.7: a PPARgamma ligand-like action as a novel mechanism.
FEBS Lett. 572: 266-270 (2004).
*
-
Park KW, Waki H, Villanueva CJ, Monticelli LA, Hong C, Kang S, Macdougald OA, Goldrath AW, Tontonoz P. Inhibitor of DNA binding 2 is a small molecule-inducible modulator of peroxisome proliferator-activated receptor-gamma expression and adipocyte differentiation.
Mol. Endocrinol. 22: 2038-2048 (2008).
*
-
Park SJ, Lee KS, Kim SR, Min KH, Choe YH, Moon H, Chae HJ, Yoo WH, Lee YC. Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation.
J. Immunol. 183: 3259-3267 (2009).
-
Park SW, Yi JH, Miranpuri G, Satriotomo I, Bowen K, Resnick DK, Vemuganti R. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats.
J. Pharmacol. Exp. Ther. 320: 1002-1012 (2007).
*
-
Park SY, Shin HK, Lee JH, Kim CD, Lee WS, Rhim BY, Hong KW. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.
J. Pharmacol. Exp. Ther. 329: 571-579 (2009).
*
-
Parmenon C, Guillard J, Caignard DH, Hennuyer N, Staels B, Audinot-Bouchez V, Boutin JA, Dacquet C, Ktorza A, Viaud-Massuard MC. 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: synthesis and pharmacological evaluation of oxime and acidic head group structural variations.
Bioorg. Med. Chem. Lett. 19: 2683-2687 (2009).
*
-
Paruchuri S, Jiang Y, Feng C, Francis SA, Plutzky J, Boyce JA. Leukotriene E4 activates peroxisome proliferator activated receptor gamma and induces prostaglandin D2 generation by human mast cells.
J. Biol. Chem. 283: 16477-16487 (2008).
*
-
Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma.
Nature 437: 759-763 (2005).
*
-
Patel DD, Knight BL, Soutar AK, Gibbons GF, Wade DP. The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene.
Biochem. J. 351: 747-753 (2000).
*
-
Patel DD, Knight BL, Wiggins D, Humphreys SM, Gibbons GF. Disturbances in the normal regulation of SREBP-sensitive genes in PPAR alpha-deficient mice.
J. Lipid Res. 42: 328-337 (2001).
*
-
Patel H, Truant R, Rachubinski RA, Capone JP. Activity and subcellular compartmentalization of peroxisome proliferator-activated receptor alpha are altered by the centrosome-associated protein CAP350.
J. Cell. Sci. 118: 175-186 (2005).
*
-
Patel NS, di Paola R, Mazzon E, Britti D, Thiemermann C, Cuzzocrea S. Peroxisome-proliferator activated receptor-alpha contributes to the resolution of inflammation following renal ischemia/reperfusion injury.
J. Pharmacol. Exp. Ther. 328: 635-643 (2009).
*
-
Paterniti I, Esposito E, Mazzon E, Galuppo M, di Paola R, Bramanti P, Kapoor A, Thiemermann C, Cuzzocrea S. Evidence for the role of PPAR-beta/delta the development of spinal cord injury.
J. Pharmacol. Exp. Ther. Feb 22 [Epub ahead of print] (2010).
-
Pathak R, Asad M, Jagannath Hrishikeshavan H, Prasad S. Effect of peroxisome proliferator-activated receptor-alpha agonist (bezafibrate) on gastric secretion and gastric cytoprotection in rats.
Fundam. Clin. Pharmacol. 21: 291-296 (2007).
*
-
Patsouris D, Mandard S, Voshol PJ, Escher P, Tan NS, Havekes LM, Koenig W, Marz W, Tafuri S, Wahli W, Muller M, Kersten S. PPARalpha governs glycerol metabolism.
J. Clin. Invest. 114: 94-103 (2004).
*
-
Patsouris D, Reddy JK, Muller M, Kersten S. Peroxisome proliferator-activated receptor alpha mediates the effects of high fat diet on hepatic gene expression.
Endocrinology 147: 1508-1516 (2006).
*
-
Patterson AD, Slanar O, Krausz KK, Li F, Hofer CC, Perlík F, Gonzalez FJ, Idle JR. Human urinary metabolomic profile of PPAR induced fatty acid oxidation.
J. Proteome Res. 8: 4293-4300 (2009).
*
-
Paukkeri EL, Leppanen T, Sareila O, Vuolteenaho K, Kankaanranta H, Moilanen E. PPARalpha agonists inhibit nitric oxide production by enhancing iNOS degradation in LPS-treated macrophages.
Br. J. Pharmacol. 152: 1081-1091 (2007).
*
-
Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, Percevault F, Fruchart JC, Dombrowicz D, Glineur C, Staels B. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway.
Circ. Res. 98: 361-369 (2006).
*
-
Pavan L, Hermouet A, Tsatsaris V, Therond P, Sawamura T, Evain-Brion D, Fournier T. Lipids from oxidized low-density lipoprotein modulate human trophoblast invasion: involvement of nuclear liver X receptors.
Endocrinology 145: 4583-4591 (2004).
*
-
Pavankuamr VV, Vinu CA, Mullangi R, Srinivas NR. Preclinical pharmacokinetics and interspecies scaling of ragaglitazar, a novel biliary excreted PPAR dual activator.
Eur. J. Drug Metab. Pharmacokinet. 32: 29-37 (2007).
-
Pavlov TS, Levchenko V, Karpushev AV, Vandewalle A, Staruschenko A. Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.
Mol. Pharmacol. 76: 1333-1340 (2009).
*
-
Pawar A, Botolin D, Mangelsdorf DJ, Jump DB. The role of liver X receptor-alpha in the fatty acid regulation of hepatic gene expression.
J. Biol. Chem. 278: 40736-40743 (2003).
*
-
Pawar A, Jump DB. Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor alpha activity in rat primary hepatocytes.
J. Biol. Chem. 278: 35931-35939 (2003).
*
-
Pawar A, Xu J, Jerks E, Mangelsdorf DJ, Jump DB. Fatty acid regulation of liver X receptors (LXR) and peroxisome proliferator-activated receptor alpha (PPARalpha ) in HEK293 cells.
J. Biol. Chem. 277: 39243-39250 (2002).
*
-
Pedersen G, Brynskov J. Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity.
Am. J. Gastroenterol. Jan 19 [Epub ahead of print] (2010).
*
-
Pegorier JP. PPAR receptors and insulin sensitivity: new agonists in development.
Ann. Endocrinol. (Paris) 66: 10-17 (2005).
-
Pei L, Castrillo A, Chen M, Hoffmann A, Tontonoz P. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli.
J. Biol. Chem. 280: 29256-29262 (2005).
*
-
Pei L, Castrillo A, Tontonoz P. Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77.
Mol. Endocrinol. 20: 786-794 (2006).
*
-
Peiris M, Monteith GR, Roberts-Thomson SJ, Cabot PJ. A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for the characterisation of intervention therapies.
J. Neurosci. Methods 163: 245-254 (2007).
-
Pelton PD, Patel M, Demarest KT. Nuclear receptors as potential targets for modulating reverse cholesterol transport.
Curr. Top. Med. Chem. 5: 265-282 (2005).
-
Pena-Dos-Santos DR, Severino FP, Pereira SA, Rodrigues DB, Cunha FQ, Vieira SM, Napimoga MH, Clemente-Napimoga JT. Activation of peripheral kappa/delta opioid receptors mediates 15-deoxy-(Delta12,14)-prostaglandin J2 induced-antinociception in rat temporomandibular joint.
Neuroscience 163: 1211-1219 (2009).
-
Penberthy WT. Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease.
Curr. Drug Metab. 8: 245-266 (2007).
-
Penberthy WT. Nicotinic acid-mediated activation of both membrane and nuclear receptors towards therapeutic glucocorticoid mimetics for treating multiple sclerosis.
PPAR Res. 2009: 853707 (2009).
*
-
Penna F, Bonelli G, Baccino FM, Costelli P. Cytotoxic properties of clofibrate and other peroxisome proliferators: relevance to cancer progression.
Curr. Med. Chem. Dec 17 [Epub ahead of print] (2009).
-
Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR).
Toxicol. Sci. 90: 269-295 (2006).
*
-
Perelas A, Tsoulkani A, Perrea D. Effects of lipid-lowering drugs on adiponectin.
Curr. Vasc. Pharmacol. Feb 25 [Epub ahead of print] (2010).
-
Perera RJ, Marcusson EG, Koo S, Kang X, Kim Y, White N, Dean NM. Identification of novel PPARgamma target genes in primary human adipocytes.
Gene 369: 90-99 (2006).
-
Perez A, van Heeckeren AM, Nichols D, Gupta S, Eastman JF, Davis PB. Peroxisome proliferator-activated receptor gamma in cystic fibrosis lung epithelium.
Am. J. Physiol. Lung Cell. Mol. Physiol. 295: L303-L313 (2008).
*
-
Perez-Cano FJ, Ramirez-Santana C, Molero-Luis M, Castell M, Rivero M, Castellote C, Franch A. Mucosal IgA increase in rats by continuous CLA feeding during suckling and early infancy.
J. Lipid Res. 50: 467-476 (2009).
*
-
Perez-Echarri N, Perez-Matute P, Marcos-Gomez B, Marti A, Martinez JA, Moreno-Aliaga MJ. Down-regulation in muscle and liver lipogenic genes: EPA ethyl ester treatment in lean and overweight (high-fat-fed) rats.
J. Nutr. Biochem. 20: 705-714 (2009).
*
-
Perfetti R, D'Amico E. Rational drug design and PPAR agonists.
Curr. Diab. Rep. 5: 340-345 (2005).
-
Perreault M, Erbe DV, Tobin JF. PPARdelta agonism for the treatment of obesity and associated disorders: challenges and opportunities.
PPAR Res. 2008: 125387 (2008).
*
-
Perrone MG, Santandrea E, Dell'uomo N, Giannessi F, Milazzo FM, Sciarroni AF, Scilimati A, Tortorella V. Synthesis and biological evaluation of new clofibrate analogues as potential PPARalpha agonists.
Eur. J. Med. Chem. 40: 143-154 (2005).
*
-
Pershadsingh HA. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?
Expert Opin. Investig. Drugs 13: 215-228 (2004).
-
Pershadsingh HA. Dual peroxisome proliferator-activated receptor-alpha/gamma agonists in the treatment of type 2 diabetes mellitus and the metabolic syndrome.
Treat. Endocrinol. 5: 89-99 (2006).
-
Pershadsingh HA. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma.
Int. J. Biochem. Cell. Biol. 38: 766-781 (2006).
*
-
Peters JM, Aoyama T, Burns AM, Gonzalez FJ. Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice.
Biochim. Biophys. Acta 1632: 80-89 (2003).
*
-
Peters JM, Cheung C, Gonzalez FJ. Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?
J. Mol. Med. 83: 774-785 (2005).
*
-
Peters JM, Hennuyer N, Staels B, Fruchart JC, Fievet C, Gonzalez FJ, Auwerx J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice.
J. Biol. Chem. 272: 27307-27312 (1997).
*
-
Peters JM, Hollingshead HE, Gonzalez FJ. Role of peroxisome-proliferator-activated receptor beta/delta (PPARbeta/delta) in gastrointestinal tract function and disease.
Clin. Sci. (Lond.) 115: 107-127 (2008).
*
-
Peters JM, Park Y, Gonzalez FJ, Pariza MW. Influence of conjugated linoleic acid on body composition and target gene expression in peroxisome proliferator-activated receptor alpha-null mice.
Biochim. Biophys. Acta 1533: 233-242 (2001).
*
-
Peters JM, Rusyn I, Rose ML, Gonzalez FJ, Thurman RG. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis.
Carcinogenesis 21: 823-826 (2000).
*
-
Peters JM, Zhou YC, Ram PA, Lee SS, Gonzalez FJ, Waxman DJ. Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate.
Mol. Pharmacol. 50: 67-74 (1996).
-
Petrick JS, Klaassen CD. Importance of hepatic induction of constitutive androstane receptor and other transcription factors that regulate xenobiotic metabolism and transport.
Drug Metab. Dispos. 35: 1806-1815 (2007).
*
-
Petridou A, Tsalouhidou S, Tsalis G, Schulz T, Michna H, Mougios V. Long-term exercise increases the DNA binding activity of peroxisome proliferator-activated receptor gamma in rat adipose tissue.
Metabolism 56: 1029-1036 (2007).
*
-
Petrosino S, Cristino L, Karsak M, Gaffal E, Ueda N, Tuting T, Bisogno T, De Filippis D, D'Amico A, Saturnino C, Orlando P, Zimmer A, Iuvone T, Di Marzo V. Protective role of palmitoylethanolamide in contact allergic dermatitis.
Allergy Nov 11 [Epub ahead of print] (2009).
*
-
Petrovic MG, Kunej T, Peterlin B, Dovc P, Petrovic D. Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-gamma coactivator-1 gene might be a risk factor for diabetic retinopathy in Slovene population (Caucasians) with type 2 diabetes …
Diabetes Metab. Res. Rev. 21: 470-474 (2005).
-
Petrovic N, Shabalina IG, Timmons JA, Cannon B, Nedergaard J. Thermogenically competent non-adrenergic recruitment in brown predipocytes by a PPARgamma agonist.
Am. J. Physiol. Endocrinol. Metab. 295: E287-E296 (2008).
*
-
Petrovic N, Walden TB, Shabalina IG, Timmons JA, Cannon B, Nedergaard J. Chronic PPARgamma activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classical brown adipocytes.
J. Biol. Chem. Dec 22 [Epub ahead of print] (2009).
*
-
Pettersson S. A pivotal role for PPAR gamma in innate immune homeostasis?
J. Pediatr. Gastroenterol. Nutr. 40 Suppl. 1: S9 (2005).
*
-
Pettinelli P, Del Pozo T, Araya J, Rodrigo R, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Korn O, Maluenda F, Diaz JC, Rencoret G, Braghetto I, Castillo J, Poniachik J, Videla LA. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion.
Biochim. Biophys. Acta 1792: 1080-1086 (2009).
*
-
Pfab T, Poralla C, Richter CM, Godes M, Slowinski T, Priem F, Halle H, Hocher B. Fetal and maternal peroxisome proliferator-activated receptor gamma2 Pro12Ala does not influence birth weight.
Obesity (Silver Spring) 14: 1880-1885 (2006).
*
-
Pfutzner A, Weber MM, Forst T. Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.
Expert Opin. Pharmacother. 8: 1985-1998 (2007).
-
Phipps RP, Blumberg N. Statin islands and PPAR ligands in platelets.
Arterioscler. Thromb. Vasc. Biol. 29: 620-621 (2009).
-
Pialat JB, Cho TH, Beuf O, Joye E, Moucharaffie S, Langlois JB, Nemoz C, Janier M, Berthezene Y, Nighoghossian N, Desvergne B, Wiart M. MRI monitoring of focal cerebral ischemia in peroxisome proliferator-activated receptor (PPAR)-deficient mice.
NMR Biomed. 20: 335-342 (2007).
*
-
Pierzchalski P, Krawiec A, Gawelko J, Pawlik WW, Konturek SJ, Gonciarz M. Molecular mechanism of protection against chemically and gamma-radiation induced apoptosis in human colon cancer cells.
J. Physiol. Pharmacol. 59 Suppl. 2: 191-202 (2008).
*
-
Pierzchalski P, Pytko-Polonczyk J, Jaworek J, Konturek SJ, Gonciarz M. Only live Helicobacter pylori is capable of caspase-3 dependent apoptosis induction in gastric mucosa epithelial cells.
J. Physiol. Pharmacol. 60: 119-128 (2009).
*
-
Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
Mol. Endocrinol. 17: 259-272 (2003).
*
-
Pineda Torra I, Gervois P, Staels B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging.
Curr. Opin. Lipidol. 10: 151-159 (1999).
-
Pinelli A, Godio C, Laghezza A, Mitro N, Fracchiolla G, Tortorella V, Lavecchia A, Novellino E, Fruchart JC, Staels B, Crestani M, Loiodice F. Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.
J. Med. Chem. 48: 5509-5519 (2005).
*
-
Pingali H, Jain M, Shah S, Makadia P, Zaware P, Goel A, Patel M, Giri S, Patel H, Patel P. Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.
Bioorg. Med. Chem. 16: 7117-7127 (2008).
*
-
Pingali H, Jain M, Shah S, Patil P, Makadia P, Zaware P, Sairam KV, Jamili J, Goel A, Patel M, Patel P. Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety.
Bioorg. Med. Chem. Lett. 18: 6471-6475 (2008).
-
Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD, Bishop-Bailey D. Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis.
Arterioscler. Thromb. Vasc. Biol. 27: 63-69 (2007).
*
-
Piqueras L, Sanz MJ, Perretti M, Morcillo E, Norling L, Mitchell JA, Li Y, Bishop-Bailey D. Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release.
J. Leukoc. Biol. 86: 115-122 (2009).
*
-
Piraino G, Cook JA, O'Connor M, Hake PW, Burroughs TJ, Teti D, Zingarelli B. Synergistic effect of peroxisome proliferator-activated receptor-gamma and liver X receptor-alpha in the regulation of inflammation in macrophages.
Shock 26: 146-153 (2006).
*
-
Pitulis N, Papageorgiou E, Tenta R, Lembessis P, Koutsilieris M. IL-6 and PPARgamma signalling in human PC-3 prostate cancer cells.
Anticancer Res. 29: 2331-2337 (2009).
-
Piva R, Gianferretti P, Ciucci A, Taulli R, Belardo G, Santoro MG. 15-Deoxy-delta12,14-prostaglandin J2 induces apoptosis in human malignant B-cells: an effect associated with inhibition of NF-kappaB activity and down-regulation of anti-apoptotic proteins.
Blood 105: 1750-1758 (2005).
*
-
Plager DA, Leontovich AA, Henke SA, Davis MD, McEvoy MT, Sciallis GF 2nd, Pittelkow MR. Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications.
Exp. Dermatol. 16: 28-36 (2007).
*
-
Planaguma A, Claria J, Miquel R, Lopez-Parra M, Titos E, Masferrer JL, Arroyo V, Rodes J. The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation.
FASEB J. 19: 1120-1122 (2005).
*
-
Planavila A, Laguna JC, Vazquez-Carrera M. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappaB activation.
Biochim. Biophys. Acta 1687: 76-83 (2005).
*
-
Plaza-Zabala A, Berrendero F, Suarez J, Bermudez-Silva FJ, Fernandez-Espejo E, Serrano A, Pavon FJ, Parsons LH, De Fonseca FR, Maldonado R, Robledo P. Effects of the endogenous PPAR-alpha agonist, oleoylethanolamide on MDMA-induced cognitive deficits in mice.
Synapse 64: 379-389 (2010).
-
Plevy S, Mayer L. Meeting summary: signal transduction pathways in immune and inflammatory cells. November 30-December 3, 2000, Amelia Island, Florida, U.S.A.
Inflamm. Bowel Dis. 9: 28-33 (2003).
*
-
Plourde M, Vohl MC, Vandal M, Couture P, Lemieux S, Cunnane SC. Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE 4 but not by the common PPAR-alpha L162V polymorphism in men.
Br. J. Nutr. 102: 1121-1124 (2009).
*
-
Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms.
Curr. Atheroscler. Rep. 2: 327-335 (2000).
-
Pochetti G, Godio C, Mitro N, Caruso D, Galmozzi A, Scurati S, Loiodice F, Fracchiolla G, Tortorella P, Laghezza A, Lavecchia A, Novellino E, Mazza F, Crestani M. Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands.
J. Biol. Chem. 282: 17314-17324 (2007).
*
-
Poczatkova H, Bogdanova K, Uherkova L, Cervenkova K, Riegrova D, Rypka M, Vesely J. Dehydroepiandrosterone effects on the mRNA levels of peroxisome proliferator-activated receptors and their coactivators in human hepatoma HepG2 cells.
Gen. Physiol. Biophys. 26: 268-274 (2007).
*
-
Poeckel D, Greiner C, Pergola C, Henkel A, Popescu L, Rau O, Schubert-Zsilavecz M, Werz O. Interference of alpha-alkyl-substituted pirinixic acid derivatives with neutrophil functions and signalling pathways.
Eur. J. Pharmacol. 619: 1-7 (2009).
-
Poirier H, Braissant O, Niot I, Wahli W, Besnard P. 9-cis-Retinoic acid enhances fatty acid-induced expression of the liver fatty acid-binding protein gene.
FEBS Lett. 412: 480-484 (1997).
*
-
Poirier H, Niot I, Monnot MC, Braissant O, Meunier-Durmort C, Costet P, Pineau T, Wahli W, Willson TM, Besnard P. Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine.
Biochem. J. 355: 481-488 (2001).
*
-
Polak PE, Kalinin S, Dello Russo C, Gavrilyuk V, Sharp A, Peters JM, Richardson J, Willson TM, Weinberg G, Feinstein DL. Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis.
J. Neuroimmunol. 168: 65-75 (2005).
-
Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hegele RA, Hanley AJ. Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes.
J. Diabetes Complications 21: 166-171 (2007).
-
Ponferrada A, Caso JR, Alou L, Colon A, Sevillano D, Moro MA, Lizasoain I, Menchen P, Gomez-Lus ML, Lorenzo P, Cos E, Leza JC, Menchen L. The role of PPARgamma on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction.
Gastroenterology 132: 1791-1803 (2007).
*
-
Popescu L, Rau O, Bottcher J, Syha Y, Schubert-Zsilavecz M. Quinoline-based derivatives of pirinixic acid as dual PPAR alpha/gamma agonists.
Arch. Pharm. (Weinheim.) 340: 367-371 (2007).
-
Porksen S, Nielsen LB, Mortensen HB, Danne T, Kocova M, Castano L, Pociot F, Hougaard P, Ekstrom CT, Gammeltoft S, Knip M, Hansen L; the Hvidore Study Group on Childhood Diabetes. Variation within the PPARG gene is associated with residual beta-cell function and glycemic control in children and adolescents during the first year of clinical type 1 diabetes.
Pediatr. Diabetes 9: 297-302 (2008).
-
Porter DW, Wolfarth M, Young SH, Rao MK, Meighan T, Barger M, Andrew ME, Huffman LJ. PGJ2 inhibition of LPS-induced inflammatory mediator expression from rat alveolar macrophages.
J. Toxicol. Environ. Health A. 70: 1967-1976 (2007).
*
-
Portilla D. Energy metabolism and cytotoxicity.
Semin. Nephrol. 23: 432-438 (2003).
-
Portilla D, Li S, Nagothu KK, Megyesi J, Kaissling B, Schnackenberg L, Safirstein RL, Beger RD. Metabolomic study of cisplatin-induced nephrotoxicity.
Kidney Int. 69: 2194-2204 (2006).
*
-
Portincasa P, Grattagliano I, Palmieri VO, Palasciano G. Current pharmacological treatment of nonalcoholic fatty liver.
Curr. Med. Chem. 13: 2889-2900 (2006).
-
Posokhova EN, Khoshchenko OM, Chasovskikh MI, Pivovarova EN, Dushkin MI. Lipid synthesis in macrophages during inflammation in vivo: effect of agonists of peroxisome proliferator activated receptors alpha and gamma and of retinoid X receptors.
Biochemistry (Mosc.) 73: 296-304 (2008).
-
Post SM, Duez H, Gervois PP, Staels B, Kuipers F, Princen HM. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression.
Arterioscler. Thromb. Vasc. Biol. 21: 1840-1845 (2001).
*
-
Postea O, Koenen RR, Hristov M, Weber C, Ludwig A. Homocysteine upregulates vascular transmembrane chemokine CXCL16 and induces CXCR6(+) lymphocyte recruitment in vitro and in vivo.
J. Cell. Mol. Med. 12: 1700-1709 (2008).
*
-
Potula R, Ramirez SH, Knipe B, Leibhart J, Schall K, Heilman D, Morsey B, Mercer A, Papugani A, Dou H, Persidsky Y. Peroxisome proliferator-activated receptor-gamma activation suppresses HIV-1 replication in an animal model of encephalitis.
AIDS 22: 1539-1549 (2008).
-
Pourcet B, Pineda-Torra I, Derudas B, Staels B, Glineur C. SUMOylation of the human peroxisome proliferator-activated receptor alpha inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR.
J. Biol. Chem. Dec 2 [Epub ahead of print] (2009).
*
-
Powell E, Kuhn P, Xu W. Nuclear receptor cofactors in PPARgamma-mediated adipogenesis and adipocyte energy metabolism.
PPAR Res. 2007: 53843 (2007).
*
-
Poynter ME, Daynes RA. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging.
J. Biol. Chem. 273: 32833-32841 (1998).
*
-
Pozzi A, Capdevila JH. PPARalpha ligands as antitumorigenic and antiangiogenic agents.
PPAR Res. 2008: 906542 (2008).
*
-
Pozzi A, Ibanez MR, Gatica AE, Yang S, Wei S, Mei S, Falck JR, Capdevila JH. Peroxisomal proliferator activated receptor alpha-dependent inhibition of endothelial cell proliferation and tumorigenesis.
J. Biol. Chem. 282: 17685-17695 (2007).
*
-
Prasad KN, Saxena A, Ghoshal UC, Bhagat MR, Krishnani N. Analysis of Pro12Ala PPAR gamma polymorphism and Helicobacter pylori infection in gastric adenocarcinoma and peptic ulcer disease.
Ann. Oncol. 19: 1299-1303 (2008).
-
Prasad R, Giri S, Singh AK, Singh I. 15-Deoxy-delta12,14-prostaglandin J2 attenuates endothelial-monocyte interaction: implication for inflammatory diseases.
J. Inflamm. (Lond.) 5: 14 (2008).
*
-
Prasain JK, Carlson SH, Wyss JM. Flavonoids and age-related disease: risk, benefits and critical windows.
Maturitas Feb 22 [Epub ahead of print] (2010).
-
Prestwich GD, Xu Y, Qian L, Gajewiak J, Jiang G. New metabolically stabilized analogues of lysophosphatidic acid: agonists, antagonists and enzyme inhibitors.
Biochem. Soc. Trans. 33: 1357-1361 (2005).
*
-
Prieur X, Lesnik P, Moreau M, Rodríguez JC, Doucet C, Chapman MJ, Huby T. Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice.
Biochim. Biophys. Acta 1791: 764-771 (2009).
*
-
Prieur X, Roszer T, Ricote M. Lipotoxicity in macrophages: evidence from diseases associated with the metabolic syndrome.
Biochim. Biophys. Acta Sep 28 [Epub ahead of print] (2009).
*
-
Prost S, Le Dantec M, Auge S, Le Grand R, Derdouch S, Auregan G, Deglon N, Relouzat F, Aubertin AM, Maillere B, Dusanter-Fourt I, Kirszenbaum M. Nef and PPAR-gamma interact to suppress Stat5 expression in CD34+ progenitors from infected macaques.
Med. Sci. (Paris) 24: 551-554 (2008).
-
Prudente S, Ludovico O, Tassi V, Trischitta V. Heterogeneous effects of gene polymorphism on type 2 diabetes risk: lesson from the PPARgamma2 Pro12Ala.
Nutr. Metab. Cardiovasc. Dis. 17: 629-631 (2007).
-
Ptak-Belowska A, Pawlik MW, Krzysiek-Maczka G, Brzozowski T, Pawlik WW. Transcriptional upregulation of gastrin in response to peroxisome proliferator-activated recptor gamma agonist triggers cell survival pathways.
J. Physiol. Pharmacol. 58: 793-801 (2007).
*
-
Ptasinska A, Wang S, Zhang J, Wesley RA, Danner RL. Nitric oxide activation of peroxisome proliferator-activated receptor gamma through a p38 MAPK signaling pathway.
FASEB J. 21: 950-961 (2007).
*
-
Puddu P, Puddu GM, Muscari A. Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression?
Int. J. Cardiol. 90: 133-140 (2003).
-
Puigserver P. Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha.
Int. J. Obes. Relat. Metab. Disord. 29 Suppl. 1: S5-S9 (2005).
-
Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C, Callizot N, Ruiz M, Pampols T, Giros M, Mandel JL. Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy.
Hum. Mol. Genet. 13: 2997-3006 (2004).
*
-
Purohit V, Gao B, Song BJ. Molecular mechanisms of alcoholic fatty liver.
Alcohol Clin. Exp. Res. 33: 191-205 (2009).
*
-
Pustovrh MC, Capobianco E, Martínez N, Higa R, White V, Jawerbaum A. MMP/TIMP balance is modulated in vitro by 15dPGJ in fetuses and placentas from diabetic rats.
Eur. J. Clin. Invest. 39: 1082-1090 (2009).
*
-
Qi C, Zhu Y, Reddy JK. Peroxisome proliferator-activated receptors, coactivators, and downstream targets.
Cell. Biochem. Biophys. 32: 187-204 (2000).
-
Qi W, Chen X, Holian J, Tan CY, Kelly DJ, Pollock CA. Transcription factors Kruppel-like factor 6 and peroxisome proliferator-activated receptor-gamma mediate high glucose-induced thioredoxin-interacting protein.
Am. J. Pathol. 175: 1858-1867 (2009).
*
-
Qiao L, Dai Y, Gu Q, Chan KW, Ma J, Lan HY, Zou B, Rocken C, Ebert MP, Wong BC. Loss of XIAP sensitizes colon cancer cells to PPARgamma independent antitumor effects of troglitazone and 15-PGJ2.
Cancer Lett. 268: 260-271 (2008).
*
-
Qiao L, Zou C, Shao P, Schaack J, Johnson PF, Shao J. Transcriptional regulation of fatty acid translocase/CD36 expression by CCAAT/enhancer-binding protein alpha.
J. Biol. Chem. 283: 8788-8795 (2008).
*
-
Qin HD, Huang D, Weng XD, Xu F. Upregulation of peroxisome proliferator-activated receptor-gamma and NADPH oxidases are involved in restenosis after balloon injury.
J. Cell Physiol. 221: 387-393 (2009).
*
-
Qin S, Liu T, Kamanna VS, Kashyap ML. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha.
Arterioscler. Thromb. Vasc. Biol. 27: 2428-2434 (2007).
-
Qin S, Okawa Y, Atangan LI, Brown G, Chandraratna RA, Zhao Y. Integrities of A/B and C domains of RXR are required for rexinoid-induced caspase activations and apoptosis.
J. Steroid Biochem. Mol. Biol. 112: 25-31 (2008).
-
Qin X, Xie X, Fan Y, Tian J, Guan Y, Wang X, Zhu Y, Wang N. Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice.
Hepatology 48: 432-441 (2008).
*
-
Qiu Y, Michalak M. Transcriptional control of the calreticulin gene in health and disease.
Int. J. Biochem. Cell Biol. 41: 531-538 (2009).
*
-
Quinn CM, Jessup W, Wong J, Kritharides L, Brown AJ. Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPAR-gamma ligands.
Biochem. J. 385: 823-830 (2005).
*
-
Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson GV. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease.
J. Biol. Chem. 283: 25628-25637 (2008).
*
-
Rabkin SW, Lodha P. Stearic acid-induced cardiac lipotoxicity is independent of cellular lipid and is mitigated by the fatty acids oleic and capric but not by the PPAR agonist troglitazone.
Exp. Physiol. 94: 877-887 (2009).
-
Racke MK, Gocke AR, Muir M, Diab A, Drew PD, Lovett-Racke AE. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis.
J. Nutr. 136: 700-703 (2006).
*
-
Radha V, Mohan V. Genetic predisposition to type 2 diabetes among Asian Indians.
Indian J. Med. Res. 125: 259-274 (2007).
*
-
Radha V, Vimaleswaran KS, Babu HN, Abate N, Chandalia M, Satija P, Grundy SM, Ghosh S, Majumder PP, Deepa R, Rao SM, Mohan V. Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: evidence for heterogeneity.
Diabetes Care 29: 1046-1051 (2006).
*
-
Radha V, Vimaleswaran KS, Babu S, Deepa R, Anjana M, Ghosh S, Majumder PP, Rao MR, Mohan V. Lack of association between serum adiponectin levels and the Pro12Ala polymorphism in Asian Indians.
Diabet. Med. 24: 398-402 (2007).
*
-
Rageul J, Mottier S, Jarry A, Shah Y, Theoleyre S, Masson D, Gonzalez FJ, Laboisse CL, Denis MG. KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines.
Int. J. Cancer 125: 2802-2809 (2009).
*
-
Raikwar HP, Muthian G, Rajasingh J, Johnson C, Bright JJ. PPARgamma antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis.
J. Neuroimmunol. 167: 99-107 (2005).
-
Raikwar HP, Muthian G, Rajasingh J, Johnson CN, Bright JJ. PPARgamma antagonists reverse the inhibition of neural antigen-specific Th(1) response and experimental allergic encephalomyelitis by ciglitazone and 15-deoxy-delta(12,14)-prostaglandin J(2).
J. Neuroimmunol. 178: 76-86 (2006).
-
Raj SM, Howson JM, Walker NM, Cooper JD, Smyth DJ, Field SF, Stevens HE, Todd JA. No association of multiple type 2 diabetes loci with type 1 diabetes.
Diabetologia 52: 2109-2116 (2009).
*
-
Rajasingh J, Bright JJ. 15-Deoxy-delta(12,14)-prostaglandin J(2) regulates leukemia inhibitory factor signaling through JAK-STAT pathway in mouse embryonic stem cells.
Exp. Cell Res. 312: 2538-2546 (2006).
*
-
Rakhshandehroo M, Sanderson LM, Matilainen M, Stienstra R, Carlberg C, de Groot PJ, Muller M, Kersten S. Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling.
PPAR Res. 2007: 26839 (2007).
*
-
Rakic B, Sagan SM, Noestheden M, Belanger S, Nan X, Evans CL, Xie XS, Pezacki JP. Peroxisome proliferator-activated receptor alpha antagonism inhibits hepatitis C virus replication.
Chem. Biol. 13: 23-30 (2006).
*
-
Ram VJ. Therapeutic significance of peroxisome proliferator-activated receptor modulators in diabetes.
Drugs Today (Barc.) 39: 609-632 (2003).
-
Ram VJ. Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation.
Prog. Drug Res. 60: 93-132 (2003).
-
Ramachandran U, Kumar R, Mittal A. Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome.
Mini. Rev. Med. Chem. 6: 563-573 (2006).
-
Ramakers JD, Mensink RP, Schaart G, Plat J. Arachidonic acid but not eicosapentaenoic acid (EPA) and oleic acid activates NF-kappaB and elevates ICAM-1 expression in Caco-2 cells.
Lipids 42: 687-698 (2007).
-
Ramakers JD, Verstege MI, Thuijls G, Te Velde AA, Mensink RP, Plat J. The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis.
J. Clin. Immunol. 27: 275-283 (2007).
*
-
Ramanan S, Kooshki M, Zhao W, Hsu FC, Riddle DR, Robbins ME. The PPARalpha agonist fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain irradiation.
Int. J. Radiat. Oncol. Biol. Phys. 75: 870-877 (2009).
-
Ramanan S, Kooshki M, Zhao W, Hsu FC, Robbins ME. PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways.
Free Radic. Biol. Med. 45: 1695-1704 (2008).
-
Ramanan S, Zhao W, Riddle DR, Robbins ME. Role of PPARs in radiation-induced brain injury.
PPAR Res. 2010: 234975 (2010).
*
-
Ramaswamy G, Karim MA, Murti KG, Jackowski S. PPARalpha controls the intracellular coenzyme A concentration via regulation of PANK1alpha gene expression.
J. Lipid Res. 45: 17-31 (2004).
*
-
Ramos GC, Fernandes D, Charao CT, Souza DG, Teixeira MM, Assreuy J. Apoptotic mimicry: phosphatidylserine liposomes reduce inflammation through activation of peroxisome proliferator-activated receptors (PPARs) in vivo.
Br. J. Pharmacol. 151: 844-850 (2007).
*
-
Ramos-Nino ME, Maclean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones (TZDs): results from the Vermont Diabetes Information System.
BMC Med. 5: 17 (2007).
*
-
Randy LH, Guoying B. Agonism of peroxisome proliferator receptor-gamma may have therapeutic potential for neuroinflammation and Parkinson's disease.
Curr. Neuropharmacol. 5: 35-46 (2007).
-
Rangwala SM, Rhoades B, Shapiro JS, Rich AS, Kim JK, Shulman GI, Kaestner KH, Lazar MA. Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity.
Dev. Cell 5: 657-663 (2003).
*
-
Ranjith N, Pegoraro RJ, Naidoo DP, Shanmugam R, Rom L. Genetic variants associated with insulin resistance and metabolic syndrome in young Asian Indians with myocardial infarction.
Metab. Syndr. Relat. Disord. 6: 209-214 (2008).
-
Rao MS, Papreddy K, Musunuri S, Okonkwo A. Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor alpha ligand in rats.
In Vivo 16: 145-152 (2002).
-
Rao MS, Reddy JK. Peroxisomal beta-oxidation and steatohepatitis.
Semin. Liver Dis. 21: 43-55 (2001).
-
Raso GM, Esposito E, Iacono A, Pacilio M, Cuzzocrea S, Canani RB, Calignano A, Meli R. Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat.
Eur. J. Pharmacol. 604: 125-131 (2009).
-
Ratner RE, Parikh S, Tou C; On Behalf Of The Gallant 9 Study Group. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes.
Diab. Vasc. Dis. Res. 4: 214-221 (2007).
-
Rau O, Wurglics M, Dingermann T, Abdel-Tawab M, Schubert-Zsilavecz M. Screening of herbal extracts for activation of the human peroxisome proliferator-activated receptor.
Pharmazie 61: 952-956 (2006).
-
Rauwel B, Mariame B, Martin H, Nielsen R, Allart S, Pipy B, Mandrup S, Devignes MD, Evain-Brion D, Fournier T, Davrinche C. Activation of PPARgamma by human cytomegalovirus for de novo replication impairs migration and invasiveness of cytotrophoblast from early placenta.
J. Virol. Dec 30 [Epub ahead of print] (2009).
*
-
Ravaux L, Denoyelle C, Monne C, Limon I, Raymondjean M, Hadri KE. Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the proto-oncogene BCL-6.
Mol. Cell. Biol. 27: 8374-8387 (2007).
*
-
Ravingerova T, Adameova A, Kelly T, Antonopoulou E, Pancza D, Ondrejcakova M, Khandelwal VK, Carnicka S, Lazou A. Changes in PPAR gene expression and myocardial tolerance to ischaemia: relevance to pleiotropic effects of statins.
Can. J. Physiol. Pharmacol. 87: 1028-1036 (2009).
-
Ravnskjaer K, Boergesen M, Dalgaard LT, Mandrup S. Glucose-induced repression of PPARalpha gene expression in pancreatic beta-cells involves PP2A activation and AMPK inactivation.
J. Mol. Endocrinol. 36: 289-299 (2006).
*
-
Ravnskjaer K, Borgesen M, Rubi B, Larsen JK, Nielsen T, Fridriksson J, Maechler P, Mandrup S. Peroxisome proliferator-activated receptor alpha (PPARalpha) potentiates, whereas PPARgamma attenuates glucose-stimulated insulin secretion in pancreatic beta-cells.
Endocrinology 146: 3266-3276 (2005).
*
-
Ravnskjaer K, Frigerio F, Boergesen M, Nielsen T, Maechler P, Mandrup S. PPARdelta is a fatty acid sensor, which enhances mitochondrial oxidation in insulin-secreting cells and protects against fatty acid induced dysfunction.
J. Lipid Res. Nov 30 [Epub ahead of print] (2009).
*
-
Ray DM, Spinelli SL, O'Brien JJ, Blumberg N, Phipps RP. Platelets as a novel target for PPARgamma ligands: implications for inflammation, diabetes, and cardiovascular disease.
BioDrugs 20: 231-241 (2006).
-
Ray DM, Spinelli SL, Pollock SJ, Murant TI, O'Brien JJ, Blumberg N, Francis CW, Taubman MB, Phipps RP. Peroxisome proliferator-activated receptor gamma and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles.
Thromb. Haemost. 99: 86-95 (2008).
-
Razeghi P, Wang ME, Youker KA, Golfman L, Stepkowski S, Taegtmeyer H. Lack of NF-kappaB1 (p105/p50) attenuates unloading-induced downregulation of PPARalpha and PPARalpha-regulated gene expression in rodent heart.
Cardiovasc. Res. 74: 133-139 (2007).
*
-
Razquin C, Alfredo Martinez J, Martinez-Gonzalez MA, Corella D, Santos JM, Marti A. The Mediterranean diet protects against waist circumference enlargement in 12Ala carriers for the PPARgamma gene: 2 years' follow-up of 774 subjects at high cardiovascular risk.
Br. J. Nutr. 102: 672-679 (2009).
*
-
Read WL, Baggstrom MQ, Fracasso PM, Govindan R. A phase I study of bexarotene and rosiglitazone in patients with refractory cancers.
Chemotherapy 54: 236-241 (2008).
-
Reddy JK, Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system.
Annu. Rev. Nutr. 21: 193-230 (2001).
*
-
Reddy JK, Sambasiva Rao M. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.
Am. J. Physiol. Gastrointest. Liver Physiol. 290: G852-G858 (2006).
*
-
Reddy RC. Immunomodulatory role of PPAR-gamma in alveolar macrophages.
J. Investig. Med. 56: 522-527 (2008).
-
Reddy RC, Hao Y, Lee SH, Gangireddy SR, Owyang C, Dimagno MJ. Pioglitazone reverses insulin resistance and impaired CCK stimulated pancreatic secretion in eNOS (-/-) mice. Therapy for exocrine pancreatic disorders?
Am. J. Physiol. Gastrointest. Liver Physiol. 293: G112-G120 (2007).
*
-
Reddy RC, Narala VR, Keshamouni VG, Milam JE, Newstead MW, Standiford TJ. Sepsis-induced inhibition of neutrophil chemotaxis is mediated by activation of peroxisome proliferator-activated receptor-gamma.
Blood 112: 4250-4258 (2008).
*
-
Reddy RC, Srirangam A, Reddy K, Chen J, Gangireddy S, Kalemkerian GP, Standiford TJ, Keshamouni VG. Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer.
Neoplasia 10: 597-603 (2008).
-
Redondo S, Hristov M, Gumbel D, Tejerina T, Weber C. Biphasic effect of pioglitazone on isolated human endothelial progenitor cells: involvement of peroxisome proliferator-activated receptor-gamma and transforming growth factor-beta1.
Thromb. Haemost. 97: 979-987 (2007).
-
Redonnet A, Ferrand C, Bairras C, Higueret P, Noel-Suberville C, Cassand P, Atgie C. Synergic effect of vitamin A and high-fat diet in adipose tissue development and nuclear receptor expression in young rats.
Br. J. Nutr. 100: 722-730 (2008).
*
-
Redonnet A, Groubet R, Noel-Suberville C, Bonilla S, Martinez A, Higueret P. Exposure to an obesity-inducing diet early affects the pattern of expression of peroxisome proliferator, retinoic acid, and triiodothyronine nuclear receptors in the rat.
Metabolism 50: 1161-1167 (2001).
*
-
Rees WD, McNeil CJ, Maloney CA. The roles of PPARs in the fetal origins of metabolic health and disease.
PPAR Res. 2008: 459030 (2008).
*
-
Regieli JJ, Jukema JW, Doevendans PA, Zwinderman AH, van der Graaf Y, Kastelein JJ, Grobbee DE. A PPARgamma variant influences angiographic outcome and ten-year cardiovascular risk in male symptomatic coronary artery disease patients.
Diabetes Care 32: 839-844 (2009).
-
Rehan VK, Sakurai R, Wang Y, Santos J, Huynh K, Torday JS. Reversal of nicotine-induced alveolar lipofibroblast-to-myofibroblast transdifferentiation by stimulants of parathyroid hormone-related protein signaling.
Lung 185: 151-159 (2007).
-
Rehan VK, Wang Y, Sugano S, Santos J, Patel S, Sakurai R, Boros LW, Lee WP, Torday JS. In utero nicotine exposure alters fetal rat lung alveolar type II cell proliferation, differentiation, and metabolism.
Am. J. Physiol. Lung Cell. Mol. Physiol. 292: L323-L333 (2007).
*
-
Reiff C, Delday M, Rucklidge G, Reid M, Duncan G, Wohlgemuth S, Hormannsperger G, Loh G, Blaut M, Collie-Duguid E, Haller D, Kelly D. Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease.
Inflamm. Bowel Dis. 15: 1721-1736 (2009).
*
-
Reinhard W, Stark K, Sedlacek K, Fischer M, Baessler A, Neureuther K, Weber S, Kaess B, Wiedmann S, Mitsching S, Lieb W, Erdmann J, Meisinger C, Doering A, Tolle R, Jeron A, Riegger G, Hengstenberg C. Association between PPAR-alpha gene polymorphisms and myocardial infarction.
Clin. Sci. (Lond.) 115: 301-308 (2008).
*
-
Reiss AB, Vagell ME. PPARgamma activity in the vessel wall: anti-atherogenic properties.
Curr. Med. Chem. 13: 3227-3238 (2006).
-
Reiter E, Beck V, Medjakovic S, Jungbauer A. Isoflavones are safe compounds for therapeutical applications - evaluation of in vitro data.
Gynecol. Endocrinol. 25: 554-580 (2009).
-
Relic B, Benoit V, Franchimont N, Kaiser MJ, Hauzeur JP, Gillet P, Merville MP, Bours V, Malaise MG. Peroxisome proliferator-activated receptor-gamma 1 is dephosphorylated and degraded during BAY 11-7085-induced synovial fibroblast apoptosis.
J. Biol. Chem. 281: 22597-22604 (2006).
*
-
Relic B, Zeddou M, Desoroux A, Beguin Y, de Seny D, Malaise MG. Genistein induces adipogenesis but inhibits leptin induction in human synovial fibroblasts.
Lab. Invest. 89: 811-822 (2009).
*
-
Remels AH, Gosker HR, Schrauwen P, Langen RC, Schols AM. Peroxisome proliferator-activated receptors: a therapeutic target in COPD?
Eur. Respir. J. 31: 502-508 (2008).
-
Remels AH, Langen R, Gosker HR, Russell A, Spaapen F, Voncken W, Schrauwen P, Schols AM. PPAR-gamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle.
Am. J. Physiol. Endocrinol. Metab. 297: E174-E183 (2009).
*
-
Remels AH, Langen RC, Schrauwen P, Schaart G, Schols AM, Gosker HR. Regulation of mitochondrial biogenesis during myogenesis.
Mol. Cell. Endocrinol. Oct 2 [Epub ahead of print] (2009).
-
Remels AH, Schrauwen P, Broekhuizen R, Willems J, Kersten S, Gosker HR, Schols AM. Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD.
Eur. Respir. J. 30: 245-252 (2007).
*
-
Ren B, Thelen A, Jump DB. Peroxisome proliferator-activated receptor alpha inhibits hepatic S14 gene transcription. Evidence against the peroxisome proliferator-activated receptor alpha as the mediator of polyunsaturated fatty acid regulation of S14 gene transcription.
J. Biol. Chem. 271: 17167-17173 (1996).
*
-
Ren H, Aleksunes LM, Wood C, Vallanat B, George MH, Klaassen CD, Corton JC. Characterization of peroxisome proliferator-activated receptor alpha (PPARalpha) - independent effects of PPARalpha activators in the rodent liver: Di-(2-ethylhexyl) phthalate also activates the constitutive activated receptor.
Toxicol. Sci. 113: 45-59 (2010).
*
-
Ren H, Vallanat B, Nelson DM, Yeung LW, Guruge KS, Lam PK, Lehman-McKeeman LD, Corton JC. Evidence for the involvement of xenobiotic-responsive nuclear receptors in transcriptional effects upon perfluoroalkyl acid exposure in diverse species.
Reprod. Toxicol. 27: 266-277 (2009).
-
Ren Y, Sun C, Sun Y, Tan H, Wu Y, Cui B, Wu Z. PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation.
Vascul. Pharmacol. 51: 169-174 (2009).
*
-
Rendel M. Advances in diabetes for the millennium: nutritional therapy of type 2 diabetes.
MedGenMed. 6: 10 (2004).
*
-
Reverter-Gomez A, Hudson NJ, Nagaraj SH, Perez-Enciso M, Dalrymple BP. Regulatory impact factors: unraveling the transcriptional regulation of complex traits from expression data.
Bioinformatics Feb 9 [Epub ahead of print] (2010).
*
-
Reynders V, Loitsch SM, Steinhauer C, Wagner TO, Steinhilber D, Bargon J. Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes.
Respir. Res. 7: 104 (2006).
*
-
Reynolds CM, Draper E, Keogh B, Rahman A, Moloney AP, Mills KH, Loscher CE, Roche HM. A conjugated linoleic acid-enriched beef diet attenuates lipopolysaccharide-induced inflammation in mice in part through PPARgamma-mediated suppression of Toll-like receptor 4.
J. Nutr. 139: 2351-2357 (2009).
-
Reynolds WF, Kumar AP, Piedrafita FJ. The human myeloperoxidase gene is regulated by LXR and PPARalpha ligands.
Biochem. Biophys. Res. Commun. 349: 846-854 (2006).
*
-
Rezen T, Tamasi V, Lovgren Sandblom A, Bjorkhem I, Meyer UA, Rozman D. Effect of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse liver.
BMC Genomics 10: 384 (2009).
*
-
Rhee CK, Lee SY, Kang JY, Kim SJ, Kwon SS, Kim YK, Park SH. Effect of peroxisome proliferator-sctivated receptor-gamma on airway smooth muscle thickening in a murine model of chronic asthma.
Int. Arch. Allergy Immunol. 148: 289-296 (2009).
-
Rhee EJ, Kwon CH, Lee WY, Kim SY, Jung CH, Kim BJ, Sung KC, Kim BS, Oh KW, Kang JH, Park SW, Kim SW, Lee MH, Park JR. No association of Pro12Ala polymorphism of PPAR-gamma gene with coronary artery disease in Korean subjects.
Circ. J. 71: 338-342 (2007).
*
-
Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, Kang MI, Kim SW. Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome.
Arch. Med. Res. 37: 86-94 (2006).
-
Rhee EJ, Oh KW, Yun EJ, Jung CH, Park CY, Lee WY, Oh ES, Baek KH, Kang MI, Park SW, Kim SW. The association of Pro12Ala polymorphism of peroxisome proliferator-activated receptor-g gene with serum osteoprotegerin levels in healthy Korean women.
Exp. Mol. Med. 39: 696-704 (2007).
*
-
Riahi Y, Sin-Malia Y, Cohen G, Alpert E, Gruzman A, Eckel J, Staels B, Guichardant M, Sasson S. The natural protective mechanism against hyperglycemia in vascular endothelial cells: roles of the lipid peroxidation product 4-hydroxydodecadienal (4-HDDE) and PPARdelta.
Diabetes Jan 27 [Epub ahead of print] (2010).
-
Ribas V, Palomer X, Roglans N, Rotllan N, Fievet C, Tailleux A, Julve J, Laguna JC, Blanco-Vaca F, Escola-Gil JC. Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate.
Biochim. Biophys. Acta 1737: 130-137 (2005).
*
-
Ribot J, Felipe F, Bonet ML, Palou A. Changes of adiposity in response to vitamin A status correlate with changes of PPAR gamma 2 expression.
Obes. Res. 9: 500-509 (2001).
*
-
Riccardi L, Mazzon E, Bruscoli S, Esposito E, Crisafulli C, Di Paola R, Caminiti R, Riccardi C, Cuzzocrea S. PPAR-alpha modulates the anti-inflammatory effect of glucocorticoids in a model of inflammatory bowel disease in mice.
Shock 31: 308-316 (2009).
-
Richard CL, Blay J. Thiazolidinedione drugs down-regulate CXCR4 expression on human colorectal cancer cells in a peroxisome proliferator activated receptor gamma-dependent manner.
Int. J. Oncol. 30: 1215-1222 (2007).
*
-
Richard CL, Blay J. CXCR4 in cancer and its regulation by PPARgamma.
PPAR Res. 2008: 769413 (2008).
*
-
Richards DB, Bareille P, Lindo EL, Quinn D, Farrow SN. Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trial.
Respir. Med. Nov 25 [Epub ahead of print] (2009).
-
Richardson TA, Morgan E. Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice.
J. Pharmacol. Exp. Ther. 314: 703-709 (2005).
*
-
Richert L, Tuschl G, Abadie C, Blanchard N, Bonet A, Heyd B, Halkic N, Wimmer E, Dolgos H, Mueller S. Species differences in the response of liver drug metabolizing enzymes to EMD 392949 in vivo and in vitro.
Drug Metab. Dispos. 36: 702-714 (2008).
*
-
Richir MC, Ellger B, Teerlink T, Siroen MP, Visser M, Spreeuwenberg M, Girbes AR, van der Hoven B, van den Berghe G, Wilhelm AJ, de Vries TP, van Leeuwen PA. The effect of rosiglitazone on asymmetric dimethylarginine (ADMA) in critically ill patients.
Pharmacol. Res. 60: 519-524 (2009).
*
-
Ricote M, Glass CK. PPARs and molecular mechanisms of transrepression.
Biochim. Biophys. Acta 1771: 926-935 (2007).
*
-
Ricote M, Valledor AF, Glass CK. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis.
Arterioscler. Thromb. Vasc. Biol. 24: 230-239 (2004).
*
-
Rieck M, Meissner W, Ries S, Muller-Brusselbach S, Muller R. Ligand-mediated regulation of PPARbeta/delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic acid (atRA).
Mol. Pharmacol. 74: 1269-1277 (2008).
*
-
Rieck M, Wedeken L, Muller-Brusselbach S, Meissner W, Muller R. Expression level and agonist-binding affect the turnover, ubiquitination and complex formation of peroxisome proliferator activated receptor beta.
FEBS J. 274: 5068-5076 (2007).
*
-
Rigamonti E, Chinetti-Gbaguidi G, Staels B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men.
Arterioscler. Thromb. Vasc. Biol. 28: 1050-1059 (2008).
-
Rigamonti E, Fontaine C, Lefebvre B, Duhem C, Lefebvre P, Marx N, Staels B, Chinetti-Gbaguidi G. Induction of CXCR2 receptor by peroxisome proliferator-activated receptor gamma in human macrophages.
Arterioscler. Thromb. Vasc. Biol. 28: 932-939 (2008).
-
Ringseis R, Eder K. Influence of conjugated linoleic acids on functional properties of vascular cells.
Br. J. Nutr. 102: 1099-1116 (2009).
*
-
Ringseis R, Gutgesell A, Dathe C, Brandsch C, Eder K. Feeding oxidized fat during pregnancy up-regulates expression of PPARalpha-responsive genes in the liver of rat fetuses.
Lipids Health Dis. 6: 6 (2007).
*
-
Ringseis R, Luci S, Spielmann J, Kluge H, Fischer M, Geissler S, Wen G, Hirche F, Eder K. Clofibrate treatment up-regulates novel organic cation transporter (OCTN)-2 in tissues of pigs as a model of non-proliferating species.
Eur. J. Pharmacol. 583: 11-17 (2008).
*
-
Ringseis R, Wege N, Wen G, Rauer C, Hirche F, Kluge H, Eder K. Carnitine synthesis and uptake into cells are stimulated by fasting in pigs as a model of nonproliferating species.
J. Nutr. Biochem. 20: 840-847 (2009).
*
-
Rios FJ, Jancar S, Melo IB, Ketelhuth DF, Gidlund M. Role of PPAR-gamma in the modulation of CD36 and FcgammaRII induced by LDL with low and high degrees of oxidation during the differentiation of the monocytic THP-1 cell line.
Cell Physiol. Biochem. 22: 549-556 (2008).
*
-
Ripp SL, Fitzpatrick JL, Peters JM, Prough RA. Induction of CYP3A expression by dehydroepiandrosterone: involvement of the pregnane X receptor.
Drug Metab. Dispos. 30: 570-575 (2002).
*
-
Rippley RK, Yan KX, Matthews ND, Greenberg HE, Herman GA, Wagner JA. Human pharmacokinetics and interconversion of enantiomers of MK-0767, a dual PPARalpha/gamma agonist.
J. Clin. Pharmacol. 47: 323-333 (2007).
*
-
Riserus U, Sprecher D, Johnson T, Olson E, Hirschberg S, Liu A, Fang Z, Hegde P, Richards D, Sarov-Blat L, Strum JC, Basu S, Cheeseman J, Fielding BA, Humphreys SM, Danoff T, Moore NR, Murgatroyd P, O'Rahilly S, Sutton P, Willson T, Hassall D, et al. Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress and increases fatty acid oxidation in moderately obese men.
Diabetes 57: 332-339 (2008).
*
-
Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis.
J. Hepatol. 47: 571-579 (2007).
*
-
Rizzo G, Disante M, Mencarelli A, Renga B, Gioiello A, Pellicciari R, Fiorucci S. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo.
Mol. Pharmacol. 70: 1164-1173 (2006).
*
-
Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL. Increased hepatic oxidative metabolism distinguishes the action of peroxisome proliferator-activated receptor delta from peroxisome proliferator-activated receptor gamma in the Ob/Ob mouse.
Genome Med. 1: 115 (2009).
*
-
Robertson MD, Bickerton AS, Dennis AL, Vidal H, Jewell DP, Frayn KN. Enhanced metabolic cycling in subjects following colonic resection for ulcerative colitis.
J. Clin. Endocrinol. Metab. 90: 2747-2754 (2005).
*
-
Robinson CE, Wu X, Nawaz Z, Onate SA, Gimble JM. A corepressor and chicken ovalbumin upstream promoter transcriptional factor proteins modulate peroxisome proliferator-activated receptor-gamma2/retinoid X receptor alpha-activated transcription from the murine lipoprotein lipase promoter.
Endocrinology 140: 1586-1593 (1999).
*
-
Robinson E, Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.
Pharmacol. Ther. 122: 246-263 (2009).
*
-
Robinson JG. Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.
Curr. Atheroscler. Rep. 9: 64-71 (2007).
-
Robinson JG. Should we use PPAR agonists to reduce cardiovascular risk?
PPAR Res. 2008: 891425 (2008).
*
-
Robitaille J, Brouillette C, Houde A, Lemieux S, Perusse L, Tchernof A, Gaudet D, Vohl MC. Association between the PPARalpha-L162V polymorphism and components of the metabolic syndrome.
J. Hum. Genet. 49: 482-489 (2004).
*
-
Robitaille J, Gaudet D, Perusse L, Vohl MC. Features of the metabolic syndrome are modulated by an interaction between the peroxisome proliferator-activated receptor-delta -87T>C polymorphism and dietary fat in French-Canadians.
Int. J. Obes. (Lond.) 31: 411-417 (2007).
-
Rocchi S, Auwerx J. Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator.
Ann. Med. 31: 342-351 (1999).
-
Roche M, Kelly JP, O'Driscoll M, Finn DP. Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats.
Immunology 125: 263-271 (2008).
*
-
Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator activated receptor gamma independently of cannabinoid receptors 1 and 2.
Mol. Pharmacol. 70: 101-111 (2006).
*
-
Rodriguez A, Duran A, Selloum M, Champy MF, Diez-Guerra FJ, Flores JM, Serrano M, Auwerx J, Diaz-Meco MT, Moscat J. Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62.
Cell. Metab. 3: 211-222 (2006).
*
-
Rodriguez AM, Sanchez J, Tobaruela A, Priego T, Pico C, Palou A. Time-course effects of increased fatty acid supply on the expression of genes involved in lipid/glucose metabolism in muscle cells.
Cell. Physiol. Biochem. 25: 337-346 (2010).
*
-
Rodriguez-Ayala E, Anderstam B, Suliman ME, Seeberger A, Heimburger O, Lindholm B, Stenvinkel P. Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients.
Atherosclerosis 180: 333-340 (2005).
-
Rodriguez-Calvo R, Serrano L, Barroso E, Coll T, Palomer X, Camins A, Sanchez RM, Alegret M, Merlos M, Pallas M, Laguna JC, Vazquez-Carrera M. Peroxisome proliferator-activated receptor alpha down-regulation is associated with enhanced ceramide levels in age-associated cardiac hypertrophy.
J. Gerontol. A. Biol. Sci. Med. Sci. 62: 1326-1336 (2007).
-
Rodriguez-Calvo R, Serrano L, Coll T, Moullan N, Sanchez RM, Merlos M, Palomer X, Laguna JC, Michalik L, Wahli W, Vazquez-Carrera M. Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2.
Diabetes 57: 2149-2157 (2008).
*
-
Rodriguez-Cruz M, Tovar AR, del Prado M, Torres N. Molecular mechanisms of action and health benefits of polyunsaturated fatty acids.
Rev. Invest. Clin. 57: 457-472 (2005).
-
Rogers CQ, Ajmo JM, You M. Adiponectin and alcoholic fatty liver disease.
IUBMB Life 60: 790-797 (2008).
-
Roglans N, Bellido A, Rodriguez C, Cabrero A, Novell F, Ros E, Zambon D, Laguna JC. Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver.
Clin. Pharmacol. Ther. 72: 692-701 (2002).
*
-
Roglans N, Vazquez-Carrera M, Alegret M, Novell F, Zambon D, Ros E, Laguna JC, Sanchez RM. Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients.
Eur. J. Clin. Pharmacol. 59: 855-861 (2004).
*
-
Roglans N, Vila L, Farre M, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC. Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats.
Hepatology 45: 778-788 (2007).
*
-
Rogler G. Significance of anti-inflammatory effects of PPARgamma agonists?
Gut 55: 1067-1069 (2006).
*
-
Rohatagi S Ph D, Carrothers TJ, Jin JY, Jusko WJ, Khariton T, Walker J, Truitt K, Salazar DE. Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs.
J. Clin. Pharmacol. 48: 1420-1429 (2008).
*
-
Rohini A, Agrawal N, Chintan NK, Singh R. Molecular targets and regulators of cardiac hypertrophy.
Pharmacol. Res. Dec 4 [Epub ahead of print] (2009).
*
-
Rollins MD, Sudarshan S, Firpo MA, Etherington BH, Hart BJ, Jackson HH, Jackson JD, Emerson LL, Yang DT, Mulvihill SJ, Glasgow RE. Anti-inflammatory effects of PPAR-gamma agonists directly correlate with PPAR-gamma expression during acute pancreatitis.
J. Gastrointest. Surg. 10: 1120-1130 (2006).
-
Roman J. Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy.
J. Investig. Med. 56: 528-533 (2008).
-
Romanowska M, Al Yacoub N, Seidel H, Donandt S, Gerken H, Phillip S, Haritonova N, Artuc M, Schweiger S, Sterry W, Foerster J. PPARdelta enhances keratinocyte proliferation in psoriasis and induces heparin-binding EGF-like growth factor.
J. Invest. Dermatol. 128: 110-124 (2008).
*
-
Romera C, Hurtado O, Mallolas J, Pereira MP, Morales JR, Romera A, Serena J, Vivancos J, Nombela F, Lorenzo P, Lizasoain I, Moro MA. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection.
J. Cereb. Blood Flow Metab. 27: 1327-1338 (2007).
-
Romero-Prado MM, Barrera-Saldana HA, Castrillo-Diez JL. hGH-V gene expression and promoter activity under glucose and 5-azacytidine (5azaC) effects.
Gene Dec 14 [Epub ahead of print] (2009).
*
-
Romics L Jr, Kodys K, Dolganiuc A, Graham L, Velayudham A, Mandrekar P, Szabo G. Diverse regulation of NF-kappaB and peroxisome proliferator-activated receptors in murine nonalcoholic fatty liver.
Hepatology 40: 376-385 (2004).
*
-
Rong X, Kim MS, Su N, Wen S, Matsuo Y, Yamahara J, Murray M, Li Y. An aqueous extract of Salacia oblonga root, a herb-derived peroxisome proliferator-activated receptor-alpha activator, by oral gavage over 28 days induces gender-dependent hepatic hypertrophy in rats.
Food Chem. Toxicol. 46: 2165-2172 (2008).
*
-
Rong X, Li Y, Ebihara K, Zhao M, Aini W, Kusakabe T, Hirata M, Miyamoto L, Murray M, Nakao K. An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice.
J. Pharmacol. Exp. Ther. 331: 1096-1103 (2009).
*
-
Ronis MJ, Chen Y, Badeaux J, Badger TM. Dietary soy protein isolate attenuates metabolic syndrome in rats via effects on PPAR, LXR, and SREBP signaling.
J. Nutr. 139: 1431-1438 (2009).
-
Rosado EL, Bressan J, Martins MF, Cecon PR, Martinez JA. Polymorphism in the PPARgamma2 and beta2-adrenergic genes and diet lipid effects on body composition, energy expenditure and eating behavior of obese women.
Appetite 49: 635-643 (2007).
-
Rosen MB, Abbott BD, Wolf DC, Corton JC, Wood CR, Schmid JE, Das KP, Zehr RD, Blair ET, Lau C. Gene profiling in the livers of wild-type and PPARalpha-null mice exposed to perfluorooctanoic acid (PFOA).
Toxicol. Pathol. 36: 592-607 (2008).
*
-
Rosen MB, Lee JS, Ren H, Vallanat B, Liu J, Waalkes MP, Abbott BD, Lau C, Corton JC. Toxicogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPARalpha and CAR.
Toxicol. Sci. 103: 46-56 (2008).
*
-
Rosenfield RL, Deplewski D, Greene ME. Peroxisome proliferator-activated receptors and skin development.
Horm. Res. 54: 269-274 (2000).
-
Rosenfield RL, Deplewski D, Kentsis A, Ciletti N. Mechanisms of androgen induction of sebocyte differentiation.
Dermatology 196: 43-46 (1998).
-
Rosenson RS. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus.
Am. J. Cardiol. 99: 96-104 (2007).
*
-
Rosenson RS. Fenofibrate: treatment of hyperlipidemia and beyond.
Expert Rev. Cardiovasc. Ther. 6: 1319-1330 (2008).
-
Ross PK, Woods CG, Bradford BU, Kosyk O, Gatti DM, Cunningham ML, Rusyn I. Time-course comparison of xenobiotic activators of CAR and PPARalpha in mouse liver.
Toxicol. Appl. Pharmacol. 235: 199-207 (2009).
*
-
Rost TH, Moi LL, Berge K, Staels B, Mellgren G, Berge RK. A pan-PPAR ligand induces hepatic fatty acid oxidation in PPARalpha-/- mice possibly through PGC-1 mediated PPARdelta coactivation.
Biochim. Biophys. Acta 1791: 1076-1083 (2009).
*
-
Roth M, Black JL. Transcription factors in asthma: are transcription factors a new target for asthma therapy?
Curr. Drug Targets 7: 589-595 (2006).
-
Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, Metzger D, Wahli W, Desvergne B, Naccari GC, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma.
J. Exp. Med. 201: 1205-1215 (2005).
*
-
Rousseaux PC, Desreumaux P. The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPARgamma and IBD).
J. Soc. Biol. 200: 121-131 (2006).
-
Roy HK, Karolski WJ, Ratashak A. Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone.
Int. J. Cancer 92: 609-615 (2001).
*
-
Roy N, Barnett M, Knoch B, Dommels Y, McNabb W. Nutrigenomics applied to an animal model of inflammatory bowel diseases: transcriptomic analysis of the effects of eicosapentaenoic acid- and arachidonic acid-enriched diets.
Mutat. Res. 622: 103-116 (2007).
-
Rozo AV, Vijayvargia R, Weiss HR, Ruan H. Silencing Jnk1 and Jnk2 accelerates basal lipolysis and promotes fatty acid re-esterification in mouse adipocytes.
Diabetologia 51: 1493-1504 (2008).
*
-
Ruan X, Zheng F, Guan Y. PPARs and the kidney in metabolic syndrome.
Am. J. Physiol. Renal Physiol. 294: F1032-F1047 (2008).
*
-
Ruan XZ, Moorhead JF, Fernando R, Wheeler DC, Powis SH, Varghese Z. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway.
J. Am. Soc. Nephrol. 14: 593-600 (2003).
*
-
Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators.
Biochim. Biophys. Acta 1771: 1065-1081 (2007).
*
-
Rubic T, Lorenz RL. Downregulated CD36 and oxLDL uptake and stimulated ABCA1/G1 and cholesterol efflux as anti-atherosclerotic mechanisms of interleukin-10.
Cardiovasc. Res. 69: 527-535 (2006).
*
-
Rudkowska I, Caron-Dorval D, Verreault M, Couture P, Deshaies Y, Barbier O, Vohl MC. PPARalpha L162V polymorphism alters the potential of n-3 fatty acids to increase lipoprotein lipase activity.
Mol. Nutr. Food Res. Nov 24 [Epub ahead of print] (2009).
*
-
Rudkowska I, Garenc C, Couture P, Vohl MC. Omega-3 fatty acids regulate gene expression levels differently in subjects carrying the PPARalpha L162V polymorphism.
Genes Nutr. 4: 199-205 (2009).
*
-
Rudkowska I, Verreault M, Barbier O, Vohl MC. Differences in transcriptional activation by the two allelic (L162V polymorphic) variants of PPARalpha after omega-3 fatty acids treatment.
PPAR Res. 2009: 369602 (2009).
*
-
Rudolph MC, Neville MC, Anderson SM. Lipid synthesis in lactation: diet and the fatty acid switch.
J. Mammary Gland Biol. Neoplasia 12: 269-281 (2007).
*
-
Ruiz JJ, Labayen I, Ortega FB, Moreno LA, Gonzalez-Lamuno D, Marti A, Nova E, Garcia-Fuentes M, Redondo-Figuero C, Martinez JA, Sjostrom M, Castillo MJ. Birth weight and blood lipid levels in Spanish adolescents: influence of selected APOE, APOC3 and PPAR-gamma-2 gene polymorphisms. The AVENA Study.
BMC Med. Genet. 9: 98 (2008).
*
-
Ruiz-Narvaez E. Is the Ala12 variant of the PPARG gene an "unthrifty allele"?
J. Med. Genet. 42: 547-550 (2005).
*
-
Ruiz-Narvaez EA, Kraft P, Campos H. Ala12 variant of the peroxisome proliferator-activated receptor-gamma gene (PPARG) is associated with higher polyunsaturated fat in adipose tissue and attenuates the protective effect of polyunsaturated fat intake on the risk of myocardial infarction.
Am. J. Clin. Nutr. 86: 1238-1242 (2007).
*
-
Rull A, Rodríguez F, Aragones G, Marsillach J, Beltran R, Alonso-Villaverde C, Camps J, Joven J. Hepatic monocyte chemoattractant protein-1 is upregulated by dietary cholesterol and contributes to liver steatosis.
Cytokine 48: 273-279 (2009).
-
Rumi MA, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y. Can PPARgamma ligands be used in cancer therapy?
Curr. Med. Chem. Anti-Canc. Agents 4: 465-477 (2004).
-
Runge-Morris M, Kocarek TA. Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs.
PPAR Res. 2009: 728941 (2009).
*
-
Rupp H, Rupp TP, Alter P, Maisch B. Acute heart failure - basic pathomechanism and new drug targets.
Herz. 31: 727-735 (2006).
-
Ruschke K, Fishbein L, Dietrich A, Kloting N, Toenjes A, Oberbach A, Fasshauer M, Jenkner J, Schon M, Stumvoll M, Bluher M, Mantzoros C. Gene expression of PPARgamma and PGC-1alpha in human omental and subcutaneousadipose tissue is related to insulin resistance markers and mediates beneficial effects of physical training.
Eur. J. Endocrinol. Dec 4 [Epub ahead of print] (2009).
-
Rushmore TH, Kong AN. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes.
Curr. Drug Metab. 3: 481-490 (2002).
-
Russell AP. PGC-1alpha and exercise: important partners in combating insulin resistance.
Curr. Diabetes Rev. 1: 175-181 (2005).
-
Russo R, Loverme J, La Rana G, D'Agostino G, Sasso O, Calignano A, Piomelli D. Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647.
Eur. J. Pharmacol. 566: 117-119 (2007).
*
-
Rusyn I, Peters JM, Cunningham ML. Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver.
Crit. Rev. Toxicol. 36: 459-479 (2006).
*
-
Rutherford AE, Pratt DS. Cholestasis and cholestatic syndromes.
Curr. Opin. Gastroenterol. 22: 209-214 (2006).
*
-
Ryu JY, Whang J, Park H, Im JY, Kim J, Ahn MY, Lee J, Kim HS, Lee BM, Yoo SD, Kwack SJ, Oh JH, Park KL, Han SY, Kim SH. Di(2-ethylhexyl) phthalate induces apoptosis through peroxisome proliferators-activated receptor-gamma and ERK 1/2 activation in testis of Sprague-Dawley rats.
J. Toxicol. Environ. Health A. 70: 1296-1303 (2007).
*
-
Saad S, Agapiou DJ, Chen XM, Stevens V, Pollock CA. The role of Sgk-1 in the upregulation of transport proteins by PPAR-gamma agonists in human proximal tubule cells.
Nephrol. Dial. Transplant. 24: 1130-1141 (2009).
-
Saban MR, O'Donnell MA, Hurst RE, Wu XR, Simpson C, Dozmorov I, Davis CA, Saban R. Molecular networks discriminating mouse bladder responses to intravesical bacillus Calmette-Guerin (BCG), LPS, and TNF-alpha.
BMC Immunol. 9: 4 (2008).
*
-
Saez ME, Grilo A, Moron FJ, Manzano L, Martinez-Larrad MT, Gonzalez-Perez A, Serrano-Hernando FJ, Ruiz A, Ramirez-Lorca R, Serrano-Rios M. Interaction between calpain-5, peroxisome proliferator-activated receptor-gamma and Peroxisome proliferator-activated receptor-delta genes: a polygenic approach to obesity.
Cardiovasc. Diabetol. 7: 23 (2008).
-
Saga D, Sakatsume M, Ogawa A, Tsubata Y, Kaneko Y, Kuroda T, Sato F, Ajiro J, Kondo D, Miida T, Narita I, Gejyo F. Bezafibrate suppresses rat antiglomerular basement membrane crescentic glomerulonephritis.
Kidney Int. 67: 1821-1829 (2005).
*
-
Saha S, New LS, Kiat HH, Chui WK, Chan EC. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity.
Toxicol. Lett. 192: 141-149 (2010).
-
Saidi SA, Holland CM, Charnock-Jones DS, Smith SK. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer.
Mol. Cancer 5: 13 (2006).
*
-
Saika S, Yamanaka O, Okada Y, Miyamoto T, Kitano A, Flanders KC, Ohnishi Y, Nakajima Y, Kao WW, Ikeda K. Effect of overexpression of PPARgamma on the healing process of corneal alkali burn in mice.
Am. J. Physiol. Cell Physiol. 293: C75-C86 (2007).
*
-
Sainis I, Vareli K, Karavasilis V, Briasoulis E. PPARgamma: the portrait of a target ally to cancer chemopreventive agents.
PPAR Res. 2008: 436489 (2008).
*
-
Salam NK, Huang TH, Kota BP, Kim MS, Li Y, Hibbs DE. Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study.
Chem. Biol. Drug Des. 71: 57-70 (2008).
-
Salma N, Xiao H, Imbalzano AN. Temporal recruitment of CCAAT/enhancer-binding proteins to early and late adipogenic promoters in vivo.
J. Mol. Endocrinol. 36: 139-151 (2006).
*
-
Samarasinghe SP, Sutanto MM, Danos AM, Johnson DN, Brady MJ, Cohen RN. Altering PPARgamma ligand selectivity impairs adipogenesis by thiazolidinediones but not hormonal inducers.
Obesity (Silver Spring) 17: 965-972 (2009).
*
-
Sampath H, Flowers MT, Liu X, Paton CM, Sullivan R, Chu K, Zhao M, Ntambi JM. Skin-specific deletion of stearoyl-CoA desaturase-1 alters skin lipid composition and protects mice from high-fat diet-induced obesity.
J. Biol. Chem. 284: 19961-19973 (2009).
*
-
Sampath H, Ntambi JM. Polyunsaturated fatty acid regulation of gene expression.
Nutr. Rev. 62: 333-339 (2004).
-
Samuelsson AM, Matthews PA, Argenton M, Christie MR, McConnell JM, Jansen EH, Piersma AH, Ozanne SE, Twinn DF, Remacle C, Rowlerson A, Poston L, Taylor PD. Diet-induced obesity in female mice leads to offspring hyperphagia, adiposity, hypertension, and insulin resistance. A novel murine model of developmental programming.
Hypertension 51: 383-392 (2008).
-
San-Millan JL, Escobar-Morreale HF. The role of genetic variation in peroxisome proliferator-activated receptors in the polycystic ovary syndrome (PCOS): an original case-control study followed by systematic review and meta-analysis of existing evidence.
Clin. Endocrinol. (Oxf.) Aug 4 [Epub ahead of print] (2009).
*
-
Sanal MG. The blind men 'see' the elephant-the many faces of fatty liver disease.
World J. Gastroenterol. 14: 831-844 (2008).
*
-
Sanchez RA, Masnatta LD, Pesiney C, Fischer P, Ramirez AJ. Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.
J. Hypertens. 26: 2393-2398 (2008).
-
Sanchez-Hidalgo M, Martin AR, Villegas I, Alarcon De La Lastra C. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats.
Biochem. Pharmacol. 69: 1733-1744 (2005).
*
-
Sanchez-Hidalgo M, Martin AR, Villegas I, Alarcon de la Lastra C. Rosiglitazone, a PPARgamma ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats.
Eur. J. Pharmacol. 562: 247-258 (2007).
*
-
Sandberg MB, Bloksgaard M, Duran-Sandoval D, Duval C, Staels B, Mandrup S. The gene encoding acyl-CoA binding protein is subject to metabolic regulation by both sterol regulatory element-binding protein and peroxisome proliferator-activated receptor alpha in hepatocytes.
J. Biol. Chem. 280: 5258-5266 (2005).
*
-
Sanderson LM, Boekschoten MV, Desvergne B, Muller M, Kersten S. Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta/delta in regulation of gene expression in mouse liver.
Physiol. Genomics Dec 14 [Epub ahead of print] (2009).
*
-
Sanderson LM, de Groot PJ, Hooiveld GJ, Koppen A, Kalkhoven E, Muller M, Kersten S. Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics.
PLoS ONE 3: e1681 (2008).
*
-
Sanderson LM, Degenhardt T, Koppen A, Kalkhoven E, Desvergne B, Muller M, Kersten S. PPARbeta/delta but not PPARalpha serves as plasma free fatty acid sensor in liver.
Mol. Cell. Biol. 29: 6257-6267 (2009).
*
-
Sanghera DK, Ortega L, Han S, Singh J, Ralhan SK, Wander GS, Mehra NK, Mulvihill JJ, Ferrell RE, Nath SK, Kamboh MI. Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk.
BMC Med. Genet. 9: 59 (2008).
*
-
Sangiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina.
Prog. Retin. Eye Res. 24: 87-138 (2005).
-
Sanguino E, Bejarano R, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC. Sexual dimorphism in lipid metabolic phenotype associated with old age in Sprague-Dawley rats.
Exp. Gerontol. 39: 1295-1306 (2004).
*
-
Sanguino E, Roglans N, Alegret M, Sanchez RM, Vazquez-Carrera M, Laguna JC. Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4.
Br. J. Pharmacol. 145: 853-861 (2005).
*
-
Sano M, Izumi Y, Helenius K, Asakura M, Rossi DJ, Xie M, Taffet G, Hu L, Pautler RG, Wilson CR, Boudina S, Abel ED, Taegtmeyer H, Scaglia F, Graham BH, Kralli A, Shimizu N, Tanaka H, Makela TP, Schneider MD. Menage-a-trois 1 is critical for the transcriptional function of PPARgamma coactivator 1.
Cell. Metab. 5: 129-142 (2007).
*
-
Sapiro JM, Mashek MT, Greenberg AS, Mashek DG. Hepatic triacylglycerol hydrolysis regulates peroxisome proliferator-activated receptor alpha activity.
J. Lipid Res. 50: 1621-1629 (2009).
*
-
Sapone A, Peters JM, Sakai S, Tomita S, Papiha SS, Dai R, Friedman FK, Gonzalez FJ. The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants.
Pharmacogenetics 10: 321-333 (2000).
-
Sarkar J, Qi C, Guo D, Ahmed MR, Jia Y, Usuda N, Viswakarma N, Rao MS, Reddy JK. Transcription coactivator PRIP, the peroxisome proliferator-activated receptor (PPAR)-interacting protein, is redundant for the function of nuclear receptors PPARalpha and CAR, the constitutive androstane receptor, in mouse liver.
Gene Expr. 13: 255-269 (2007).
-
Sarov-Blat L, Kiss RS, Haidar B, Kavaslar N, Jaye M, Bertiaux M, Steplewski K, Hurle MR, Sprecher D, McPherson R, Marcel YL. Predominance of a proinflammatory phenotype in monocyte-derived macrophages from subjects with low plasma HDL-cholesterol.
Arterioscler. Thromb. Vasc. Biol. 27: 1115-1122 (2007).
-
Sarruf DA, Yu F, Nguyen HT, Williams DL, Printz RL, Niswender KD, Schwartz MW. Expression of PPARgamma in key neuronal subsets regulating glucose metabolism and energy homeostasis.
Endocrinology 150: 707-712 (2009).
*
-
Sartor RB. Immunomodulatory properties of the gut microflora.
Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 44 (2005). *
-
Sasa M, Inoue I, Shinoda Y, Takahashi S, Seo M, Komoda T, Awada T, Katayama S. Activating effect of momordin, extract of bitter melon (Momordica charantia L.), on the promoter of human PPARdelta.
J. Atheroscler. Thromb. Dec 22 [Epub ahead of print] (2009).
*
-
Sasaki M, Jordan P, Welbourne T, Minagar A, Joh T, Ando T, Elrod J, Alexander JS. Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha.
BMC Physiol. 5: 3 (2005).
*
-
Sasaki N, Egashira Y, Sanada H. Down-regulation of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase by polyunsaturated fatty acids in hepatocytes is not mediated by PPARalpha.
Eur. J. Nutr. 47: 80-86 (2008).
*
-
Sasso O, La Rana G, Vitiello S, Russo R, D'Agostino G, Iacono A, Russo E, Citraro R, Cuzzocrea S, Piazza PV, De Sarro G, Meli R, Calignano A. Palmitoylethanolamide modulates pentobarbital-evoked hypnotic effect in mice: involvement of allopregnanolone biosynthesis.
Eur. Neuropsychopharmacol. Oct 26 [Epub ahead of print] (2009).
-
Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, Walter J, Klockgether T, van Leuven F, Heneka MT. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma.
Proc. Natl. Acad. Sci. U.S.A. 103: 443-448 (2006).
*
-
Sastre M, Klockgether T, Heneka MT. Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms.
Int. J. Dev. Neurosci. 24: 167-176 (2006).
*
-
Satapati S, He T, Inagaki T, Potthoff M, Merritt ME, Esser V, Mangelsdorf DJ, Kliewer SA, Browning JD, Burgess SC. Partial resistance to PPARalpha agonists in Zucker diabetic fatty (ZDF) rats is associated with defective hepatic mitochondrial metabolism.
Diabetes 57: 2012-2021 (2008).
*
-
Satih S, Savinel H, Rabiau N, Fontana L, Bignon YJ, Bernard-Gallon DJ. Expression analyses of nuclear receptor genes in breast cancer cell lines exposed to soy phytoestrogens after BRCA2 knockdown by TaqMan low-density array (TLDA).
J. Mol. Signal. 4: 3 (2009).
*
-
Sato M. Peroxisome proliferator activated receptor ligands and angiogenesis.
Nippon Rinsho 63: 603-608 (2005).
-
Sato N, Kozar RA, Zou L, Weatherall JM, Attuwaybi B, Moore-Olufemi SD, Weisbrodt NW, Moore FA. Peroxisome proliferator-activated receptor gamma mediates protection against cyclooxygenase-2-induced gut dysfunction in a rodent model of mesenteric ischemia/reperfusion.
Shock 24: 462-469 (2005).
*
-
Sato O, Takanashi N, Motojima K. Third promoter and differential regulation of mouse and human fatty acid translocase/CD36 genes.
Mol. Cell. Biochem. 299: 37-43 (2007).
*
-
Sato T, Hanyu H, Akai T, Takasaki A, Sakurai H, Iwamoto T. A patient with early Alzheimer's disease who showed improvement of cognitive function and cerebral perfusion by combined therapy of nilvadipine and PPAR gamma agonists.
Nippon Ronen Igakkai Zasshi 45: 428-433 (2008).
-
Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease.
Neurobiol. Aging Nov 16 [Epub ahead of print] (2009).
-
Saubermann LJ, Nakajima A, Wada K, Zhao S, Terauchi Y, Kadowaki T, Aburatani H, Matsuhashi N, Nagai R, Blumberg RS. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis.
Inflamm. Bowel Dis. 8: 330-339 (2002).
*
-
Sauerberg P, Mogensen JP, Jeppesen L, Svensson LA, Fleckner J, Nehlin J, Wulff EM, Pettersson I. Structure-activity relationships of dimeric PPAR agonists.
Bioorg. Med. Chem. Lett. 15: 1497-1500 (2005).
*
-
Sauma L, Franck N, Paulsson JF, Westermark GT, Kjolhede P, Stralfors P, Soderstrom M, Nystrom FH. Peroxisome proliferator activated receptor gamma activity is low in mature primary human visceral adipocytes.
Diabetologia 50: 195-201 (2007).
*
-
Savkur RS, Miller AR. Investigational PPAR-gamma agonists for the treatment of type 2 diabetes.
Expert Opin. Investig. Drugs 15: 763-778 (2006).
-
Savoia C, Ebrahimian T, Lemarie CA, Paradis P, Iglarz M, Amiri F, Javeshghani D, Schiffrin EL. Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: role of oxidative stress and PRMT-1.
Clin. Sci. (Lond.) Dec 1 [Epub ahead of print] (2009).
*
-
Savoye G. Ulcerative colitis and PPARgamma ligand. Is cardiac toxicity on the other side of the coin?
Am. J. Gastroenterol. 103: 1571 (2008).
*
-
Sawai H, Liu J, Reber HA, Hines OJ, Eibl G. Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system.
Mol. Cancer Res. 4: 159-167 (2006).
*
-
Scacchi R, Pinto A, Gambina G, Rosano A, Corbo RM. The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians.
Brain Res. 1139: 1-5 (2007).
-
Scatena R, Bottoni P, Giardina B. Mitochondria, PPARs, and cancer: is receptor-independent action of PPAR agonists a key?
PPAR Res. 2008: 256251 (2008).
*
-
Scatena R, Bottoni P, Martorana GE, Vincenzoni F, Botta G, Pastore P, Giardina B. Mitochondria, ciglitazone and liver: a neglected interaction in biochemical pharmacology.
Eur. J. Pharmacol. 567: 50-58 (2007).
*
-
Scatena R, Bottoni P, Vincenzoni F, Messana I, Martorana GE, Nocca G, De Sole P, Maggiano N, Castagnola M, Giardina B. Bezafibrate induces a mitochondrial derangement in human cell lines: a PPAR-independent mechanism for a peroxisome proliferator.
Chem. Res. Toxicol. 16: 1440-1447 (2003).
*
-
Scatena R, Martorana G, Bottoni P, Giardina B. Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs).
IUBMB Life 56: 477-482 (2004).
*
-
Schachtrup C, Emmler T, Bleck B, Sandqvist A, Spener F. Functional analysis of peroxisome proliferator response element motifs in genes of fatty acid binding proteins.
Biochem. J. 382: 239-245 (2004).
*
-
Schadendorf D. Peroxisome proliferator-activating receptors: a new way to treat melanoma?
J. Invest. Dermatol. 129: 1061-1063 (2009).
*
-
Schadinger SE, Bucher NL, Schreiber BM, Farmer SR. PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes.
Am. J. Physiol. Endocrinol. Metab. 288: E1195-E1205 (2005).
*
-
Schaefer KL. PPARgamma inhibitors as novel tubulin-targeting agents.
PPAR Res. 2008: 785405 (2008).
*
-
Schaefer KL, Denevich S, Ma C, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D, Saubermann LJ. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms.
Inflamm. Bowel Dis. 11: 244-252 (2005).
*
-
Schaefer KL, Takahashi H, Morales VM, Harris G, Barton S, Osawa E, Nakajima A, Saubermann LJ. PPARgamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells.
Int. J. Cancer 120: 702-713 (2007).
*
-
Schaefer MB, Pose A, Ott J, Hecker M, Behnk A, Schulz R, Weissmann N, Gunther A, Seeger W, Mayer K. Peroxisome proliferator-activated receptor-alpha reduces inflammation and vascular leakage in a murine model of acute lung injury.
Eur. Respir. J. 32: 1344-1353 (2008).
-
Schaffler A, Weigert J, Neumeier M, Scholmerich J, Buechler C. Regulation and function of collagenous repeat containing sequence of 26-kDa protein gene product "cartonectin".
Obesity (Silver Spring) 15: 303-313 (2007).
*
-
Schafmayer C, Volzke H, Buch S, Egberts J, Spille A, von Eberstein H, Franke A, Seeger M, Hinz S, Elsharawy A, Rosskopf D, Brosch M, Krawczak M, Foelsch UR, Schafmayer A, Lammert F, Schreiber S, Faendrich F, Hampe J, Tepel J. Investigation of the Lith6 candidate genes APOBEC1 and PPARG in human gallstone disease.
Liver Int. 27: 910-919 (2007).
*
-
Schagen S, Perchuc AM, Voegeli R, Imfeld D, Schreier T, Zouboulis CC. Phospholipase stimulates lipogenesis in SZ95 sebocytes.
Exp. Dermatol. 17: 628-629 (2008).
-
Schaiff WT, Bildirici I, Cheong M, Chern PL, Nelson DM, Sadovsky Y. PPARgamma and RXR signaling regulate fatty acid uptake by primary human placental trophoblasts.
J. Clin. Endocrinol. Metab. 90: 4267-4275 (2005).
*
-
Schaiff WT, Knapp FF Jr, Barak Y, Biron-Shental T, Nelson DM, Sadovsky Y. Ligand-activated PPARgamma alters placental morphology and placental fatty acid uptake in mice.
Endocrinology 148: 3625-3634 (2007).
*
-
Schiefelbein D, Seitz O, Goren I, Dibmann JP, Schmidt H, Bachmann M, Sader R, Geisslinger G, Pfeilschifter J, Frank S. Keratinocyte-derived VEGF biosynthesis represents a pleiotropic side effect of PPARgamma agonist troglitazone but not rosiglitazone and involves activation of p38 MAPK: implications for diabetes-impaired skin repair.
Mol. Pharmacol. 74: 952-963 (2008).
*
-
Schiffrin EL. Peroxisome proliferator-activated receptors and cardiovascular remodeling.
Am. J. Physiol. Heart Circ. Physiol. 288: H1037-H1043 (2005).
*
-
Schiffrin EL, Amiri F, Benkirane K, Iglarz M, Diep QN. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension.
Hypertension 42: 664-668 (2003).
*
-
Schinner S, Kratzner R, Baun D, Dickel C, Blume R, Oetjen E. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.
Br. J. Pharmacol. 157: 736-745 (2009).
*
-
Schintu N, Frau L, Ibba M, Caboni P, Garau A, Carboni E, Carta AR. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Eur. J. Neurosci. 29: 954-963 (2009).
-
Schleser S, Ringseis R, Eder K. Conjugated linoleic acids have no effect on TNFalpha-induced adhesion molecule expression, U937 monocyte adhesion, and chemokine release in human aortic endothelial cells.
Atherosclerosis 186: 337-344 (2006).
-
Schloss JV. New targets for the treatment of vascular diseases and diabetes.
IDrugs 1: 752-753 (1998).
-
Schluter A, Barbera MJ, Iglesias R, Giralt M, Villarroya F. Phytanic acid, a novel activator of uncoupling protein-1 gene transcription and brown adipocyte differentiation.
Biochem. J. 362: 61-69 (2002).
*
-
Schmidt A, Vogel R, Rutledge SJ, Opas EE, Rodan GA, Friedman E. Cross-talk between an activator of nuclear receptors-mediated transcription and the D(1) dopamine receptor signaling pathway.
Pharmacol. Biochem. Behav. 80: 379-385 (2005).
*
-
Schmitz G, Ecker J. The opposing effects of n-3 and n-6 fatty acids.
Prog. Lipid Res. 47: 147-155 (2008).
*
-
Schmitz G, Langmann T. Metabolic learning in the intestine: adaptation to nutrition and luminal factors.
Horm. Metab. Res. 38: 452-454 (2006).
-
Schmuth M, Jiang YJ, Dubrac S, Elias PM, Feingold KR. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology.
J. Lipid Res. 49: 499-509 (2008).
*
-
Schneider JG, Schiekofer S, Eynatten MV, Schlimmer P, Dugi KA. The proline 12 alanine substitution in the PPARgamma2 gene is associated with increased extent of coronary artery disease in men.
Exp. Clin. Endocrinol. Diabetes 117: 519-521 (2009).
-
Schoonen WG, Westerink WM, Horbach GJ. High-throughput screening for analysis of in vitro toxicity.
EXS 99: 401-452 (2009).
-
Schoonjans K, Martin G, Staels B, Auwerx J. Peroxisome proliferator-activated receptors, orphans with ligands and functions.
Curr. Opin. Lipidol. 8: 159-166 (1997).
-
Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression.
J. Lipid Res. 37: 907-925 (1996).
*
-
Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation.
Biochim. Biophys. Acta 1302: 93-109 (1996).
-
Schopfer FJ, Lin Y, Baker PR, Cui T, Garcia-Barrio M, Zhang J, Chen K, Chen YE, Freeman BA. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand.
Proc. Natl. Acad. Sci. U.S.A. 102: 2340-2345 (2005).
*
-
Schote AB, Turner JD, Schiltz J, Muller CP. Nuclear receptors in human immune cells: expression and correlations.
Mol. Immunol. 44: 1436-1445 (2007).
*
-
Schrimpe AC, Wright DW. Differential gene expression mediated by 15-hydroxyeicosatetraenoic acid in LPS-stimulated RAW 264.7 cells.
Malar. J. 8: 195 (2009).
*
-
Schteingart DE. Drugs in the medical treatment of Cushing's syndrome.
Expert Opin. Emerg. Drugs 14: 661-671 (2009).
-
Schug TT, Berry DC, Shaw NS, Travis SN, Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors.
Cell 129: 723-733 (2007).
*
-
Schug TT, Berry DC, Toshkov IA, Cheng L, Nikitin AY, Noy N. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta/delta to RAR.
Proc. Natl. Acad. Sci. U.S.A. 105: 7546-7551 (2008).
*
-
Schuler M, Ali F, Chambon C, Duteil D, Bornert JM, Tardivel A, Desvergne B, Wahli W, Chambon P, Metzger D. PGC1alpha expression is controlled in skeletal muscles by PPARbeta, whose ablation results in fiber-type switching, obesity, and type 2 diabetes.
Cell. Metab. 4: 407-414 (2006).
*
-
Schultze AE, Alborn WE, Newton RK, Konrad RJ. Administration of a PPAR-alpha agonist increases serum apolipoprotein A5 levels and the apolipoprotein A5/apolipoprotein C3 ratio.
J. Lipid Res. 46: 1591-1595 (2005).
*
-
Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS. Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells.
Proteomics 7: 2603-2616 (2007).
*
-
Schumacher U, Lukacs Z, Kaltschmidt C, Freudlsperger C, Schulz D, Kompisch K, Muller R, Rudolph T, Santer R, Lorke DW, Ullrich K. High concentrations of phenylalanine stimulate peroxisome proliferator-activated receptor gamma: implications for the pathophysiology of phenylketonuria.
Neurobiol. Dis. 32: 385-390 (2008).
-
Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.
Diabetes 54: 3442-3452 (2005).
*
-
Schupp M, Cristancho AG, Lefterova MI, Hanniman EA, Briggs ER, Steger DJ, Qatanani M, Curtin JC, Schug J, Ochsner SA, McKenna NJ, Lazar MA. Re-expression of GATA2 cooperates with PPARgamma depletion to revert the adipocyte phenotype.
J. Biol. Chem. 284: 9458-9464 (2009).
*
-
Schupp M, Lefterova MI, Janke J, Leitner K, Cristancho AG, Mullican SE, Qatanani M, Szwergold N, Steger DJ, Curtin JC, Kim RJ, Suh M, Albert MR, Engeli S, Gudas LJ, Lazar MA. Retinol saturase promotes adipogenesis and is downregulated in obesity.
Proc. Natl. Acad. Sci. U.S.A. 106: 1105-1110 (2009).
*
-
Schuster H, Fagerberg B, Edwards S, Halmos T, Lopatynski J, Stender S, Birketvedt GS, Tonstad S, Gause-Nilsson I, Halldórsdóttir S, Ohman KP; for the SIR Investigators. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance.
Atherosclerosis 197: 355-362 (2008).
-
Schwab M, Reynders V, Loitsch S, Shastri YM, Steinhilber D, Schroder O, Stein J. PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells.
Carcinogenesis 29: 1407-1414 (2008).
*
-
Schwab M, Reynders V, Loitsch S, Steinhilber D, Schroder O, Stein J. The dietary histone deacetylase inhibitor sulforaphane induces human beta-defensin-2 in intestinal epithelial cells.
Immunology 125: 241-251 (2008).
*
-
Schwab M, Reynders V, Loitsch S, Steinhilber D, Stein J, Schroder O. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NFkappaB signalling.
Mol. Immunol. 44: 3625-3632 (2007).
*
-
Schwartz AV, Sellmeyer DE. Effect of thiazolidinediones on skeletal health in women with type 2 diabetes.
Expert Opin. Drug Saf. 7: 69-78 (2008).
-
Schwartz GJ, Fu J, Astarita G, Li X, Gaetani S, Campolongo P, Cuomo V, Piomelli D. The lipid messenger OEA links dietary fat intake to satiety.
Cell. Metab. 8: 281-288 (2008).
*
-
Scoditti E, Massaro M, Carluccio MA, Distante A, Storelli C, De Caterina R. PPARgamma agonists inhibit angiogenesis by suppressing PKCalpha- and CREB-mediated COX-2 expression in the human endothelium.
Cardiovasc. Res. Dec 23 [Epub ahead of print] (2009).
*
-
Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants.
Science 316: 1341-1345 (2007).
*
-
Scribner KB, Odom DP, McGrane MM. Nuclear receptor binding to the retinoic acid response elements of the phosphoenolpyruvate carboxykinase gene in vivo: effects of vitamin A deficiency.
J. Nutr. Biochem. 18: 206-214 (2007).
*
-
Seale P, Bjork B, Yang W, Kajimura S, Chin S, Kuang S, Scime A, Devarakonda S, Conroe HM, Erdjument-Bromage H, Tempst P, Rudnicki MA, Beier DR, Spiegelman BM. PRDM16 controls a brown fat/skeletal muscle switch.
Nature 454: 961-967 (2008).
*
-
Sealls W, Gonzalez M, Brosnanv MJ, Black PN, Dirusso CC. Dietary polyunsaturated fatty acids (C18:2 omega6 and C18:3 omega3) do not suppress hepatic lipogenesis.
Biochim. Biophys. Acta 1781: 406-414 (2008).
*
-
Sears DD, Hsiao G, Hsiao A, Yu JG, Courtney CH, Ofrecio JM, Chapman J, Subramaniam S. Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization.
Proc. Natl. Acad. Sci. U.S.A. 106: 18745-18750 (2009).
*
-
Seda O, Sedova L. Peroxisome proliferator-activated receptors as molecular targets in relation to obesity and type 2 diabetes.
Pharmacogenomics 8: 587-596 (2007).
-
Seda O, Sedova L. PPARs: molecular targets in the pharmacogenomics era.
Prague Med. Rep. 105: 223-236 (2004).
-
Seedorf U, Aberle J. Emerging roles of PPARdelta in metabolism.
Biochim. Biophys. Acta 1771: 1125-1131 (2007).
*
-
Seethala R, Golla R, Ma Z, Zhang H, O'Malley K, Lippy J, Cheng L, Mookhtiar K, Farrelly D, Zhang L, Hariharan N, Cheng PT. A rapid, homogeneous, fluorescence polarization binding assay for peroxisome proliferator-activated receptors alpha and gamma using a fluorescein-tagged dual PPARalpha/gamma activator.
Anal. Biochem. 363: 263-274 (2007).
*
-
Sehic A, Khuu C, Risnes S, Osmundsen H. Differential gene expression profiling of the molar tooth germ in peroxisome proliferator-activated receptor-alpha (PPAR-alpha) knockout mouse and in wild-type mouse: molar tooth phenotype of PPAR-alpha knockout mouse.
Eur. J. Oral Sci. 117: 93-104 (2009).
-
Seki N, Bujo H, Jiang M, Shibasaki M, Takahashi K, Hashimoto N, Saito Y. A potent activator of PPARalpha and gamma reduces the vascular cell recruitment and inhibits the intimal thickning in hypercholesterolemic rabbits.
Atherosclerosis 178: 1-7 (2005).
-
Selim E, Frkanec JT, Cunard R. Fibrates upregulate TRB3 in lymphocytes independent of PPARalpha by augmenting CCAAT/enhancer-binding proteinbeta (C/EBPbeta) expression.
Mol. Immunol. 44: 1218-1229 (2007).
*
-
Selva DM, Hammond GL. Peroxisome-proliferator receptor gamma represses hepatic sex hormone-binding globulin expression.
Endocrinology 150: 2183-2189 (2009).
*
-
Selvaraj RK, Klasing KC. Lutein and eicosapentaenoic acid interact to modify iNOS mRNA levels through the PPARgamma/RXR pathway in chickens and HD11 cell lines.
J. Nutr. 136: 1610-1616 (2006).
*
-
Semple RK, Chatterjee VK, O'Rahilly S. PPARgamma and human metabolic disease.
J. Clin. Invest. 116: 581-589 (2006).
*
-
Semple RK, Meirhaeghe A, Vidal-Puig AJ, Schwabe JW, Wiggins D, Gibbons GF, Gurnell M, Chatterjee VK, O'Rahilly S. A dominant negative human PPARalpha is a constitutive transcriptional co-repressor and inhibits signaling through all PPAR isoforms.
Endocrinology 146: 1871-1882 (2005).
*
-
Sen U, Rodriguez WE, Tyagi N, Kumar M, Kundu S, Tyagi SC. Ciglitazone, a PPARgamma agonist ameliorates diabetic nephropathy, in part, through homocysteine clearance.
Am. J. Physiol. Endocrinol. Metab. 295: E1205-E1212 (2008).
*
-
Sena S, Hu P, Zhang D, Wang X, Wayment B, Olsen C, Avelar E, Abel ED, Litwin SE. Impaired insulin signaling accelerates cardiac mitochondrial dysfunction after myocardial infarction.
J. Mol. Cell. Cardiol. 46: 910-918 (2009).
-
Sena S, Rasmussen IR, Wende AR, McQueen AP, Theobald HA, Wilde N, Pereira RO, Litwin SE, Berger JP, Abel ED. Cardiac hypertrophy caused by peroxisome proliferator activated receptor-gamma agonist treatment occurs independently of changes in myocardial insulin signaling.
Endocrinology 148: 6047-6053 (2007).
*
-
Senekeo-Effenberger K, Chen S, Brace-Sinnokrak E, Yueh MF, Bonzo JA, Argikar U, Kaeding J, Trottier J, Remmel RP, Ritter JK, Barbier OK, Tukey RH. Expression of the human UGT1 locus in transgenic mice by 4-chloro-6-(2,3-xylidino)-2-pyrimidinylthioacetic acid (WY-14643) and implications on drug metabolism through peroxisome proliferator-activated receptor alpha activation.
Drug Metab. Dispos. 35: 419-427 (2007).
*
-
Sener G, Sehirli AO, Gedik N, Dulger GA. Rosiglitazone, a PPAR-gamma ligand, protects against burn-induced oxidative injury of remote organs.
Burns 33: 587-593 (2007).
-
Seo YS, Kim JH, Jo NY, Choi KM, Baik SH, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH, Kim A, Yeon JE. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
J. Gastroenterol. Hepatol. 23: 102-109 (2008).
*
-
Seree E, Villard PH, Pascussi JM, Pineau T, Maurel P, Nguyen QB, Fallone F, Martin PM, Champion S, Lacarelle B, Savouret JF, Barra Y. Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites.
Gastroenterology 127: 1436-1445 (2004).
*
-
Serrano A, Del Arco I, Javier Pavon F, Macias M, Perez-Valero V, Rodriguez de Fonseca F. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
Neuropharmacology 54: 226-234 (2008).
*
-
Sertznig P, Dunlop T, Seifert M, Tilgen W, Reichrath J. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Anticancer Res. 29: 3647-3658 (2009).
-
Sertznig P, Seifert M, Tilgen W, Reichrath J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer.
J. Cell. Physiol. 212: 1-12 (2007).
*
-
Sertznig P, Seifert M, Tilgen W, Reichrath J. Cross-regulation of peroxisome proliferator-activated receptor- (PPAR) and vitamin D receptor-signaling pathways in melanoma cells.
Exp. Dermatol. 17: 626-627 (2008).
-
Sertznig P, Seifert M, Tilgen W, Reichrath J. Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases.
Am. J. Clin. Dermatol. 9: 15-31 (2008).
-
Sethi S, Ziouzenkova O, Ni H, Wagner DD, Plutzky J, Mayadas TN. Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha.
Blood 100: 1340-1346 (2002).
*
-
Seto SW, Lam TY, Leung GP, Au AL, Ngai SM, Chan SW, Kwan YW. Comparison of vascular relaxation, lipolysis and glucose uptake by peroxisome proliferator-activated receptor-gamma activation in +db/+m and +db/+db mice.
Eur. J. Pharmacol. 572: 40-48 (2007).
-
Seufert S, Coras R, Trankle C, Zlotos DP, Blumcke I, Tatenhorst L, Heneka MT, Hahnen E. PPAR gamma activators: off-target against glioma cell migration and brain invasion.
PPAR Res. 2008: 513943 (2008).
*
-
Shaat N, Lernmark A, Karlsson E, Ivarsson S, Parikh H, Berntorp K, Groop L. A variant in the transcription factor 7-like 2 (TCF7L2) gene is associated with an increased risk of gestational diabetes mellitus.
Diabetologia 50: 972-979 (2007).
*
-
Shah A, Rader DJ, Millar JS. The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans.
Atherosclerosis Dec 14 [Epub ahead of print] (2009).
-
Shah P, Mittal A, Bharatam PV. CoMFA analysis of dual/multiple PPAR activators.
Eur. J. Med. Chem. 43: 2784-2791 (2008).
-
Shah P, Mudaliar S. Pioglitazone: side effect and safety profile.
Expert Opin. Drug Saf. 9: 347-354 (2010).
-
Shah Y, Morimura K, Gonzalez F. Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally-induced colitis.
Am. J. Physiol. Gastrointest. Liver Physiol. 292: G657-G666 (2007).
*
-
Shah YM, Morimura K, Yang Q, Tanabe T, Takagi M, Gonzalez FJ. PPARalpha regulates an miRNA-mediated signaling cascade responsible for hepatocellular proliferation.
Mol. Cell. Biol. 27: 4238-4247 (2007).
*
-
Shalev A, Siegrist-Kaiser CA, Yen PM, Wahli W, Burger AG, Chin WW, Meier CA. The peroxisome proliferator-activated receptor alpha is a phosphoprotein: regulation by insulin.
Endocrinology 137: 4499-4502 (1996).
*
-
Shan W, Palkar PS, Murray IA, McDevitt EI, Kennett MJ, Kang BH, Isom HC, Perdew GH, Gonzalez FJ, Peters JM. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by down-regulating pro-inflammatory gene expression.
Toxicol. Sci. 105: 418-428 (2008).
*
-
Shankaranarayanan P, Rossin A, Khanwalkar H, Alvarez S, Alvarez R, Jacobson A, Nebbioso A, de Lera AR, Altucci L, Gronemeyer H. Growth factor-antagonized rexinoid apoptosis involves permissive PPARgamma/RXR heterodimers to activate the intrinsic death pathway by NO.
Cancer Cell 16: 220-231 (2009).
*
-
Sharifpanah F, Wartenberg M, Hannig M, Piper HM, Sauer H. Peroxisome proliferator-activated receptor alpha agonists enhance cardiomyogenesis of mouse ES cells by utilization of a reactive oxygen species-dependent mechanism.
Stem Cells 26: 64-71 (2008).
*
-
Sharma AM, Staels B. Peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism.
J. Clin. Endocrinol. Metab. 92: 386-395 (2007).
*
-
Sharma B, Salunke R, Srivastava S, Majumder C, Roy P. Effects of guggulsterone isolated from Commiphora mukul in high fat diet induced diabetic rats.
Food Chem. Toxicol. 47: 2631-2639 (2009).
*
-
She QM, Zhao J, Wang XL, Zhou CM, Shi XZ. Effect of dexamethasone on peroxisome proliferator activated receptor-gamma mRNA expression in 3T3-L1 adipocytes with the human recombinant adiponectin.
Chin. Med. J. (Engl.) 120: 155-158 (2007).
*
-
Shearer BG, Billin AN. The next generation of PPAR drugs: do we have the tools to find them?
Biochim. Biophys. Acta 1771: 1082-1093 (2007).
*
-
Shearer BG, Steger DJ, Way JM, Stanley TB, Lobe DC, Grillot DA, Iannone MA, Lazar MA, Willson TM, Billin AN. Identification and characterization of a selective PPARbeta/delta (NR1C2) antagonist.
Mol. Endocrinol. 22: 523-529 (2008).
*
-
Shelby MK, Klaassen CD. Induction of rat UDP-glucuronosyltransferases in liver and duodenum by microsomal enzyme inducers that activate various transcriptional pathways.
Drug Metab. Dispos. 34: 1772-1778 (2006).
*
-
Shen D, Deng C, Zhang M. Peroxisome proliferator-activated receptor gamma agonists inhibit the proliferation and invasion of human colon cancer cells.
Postgrad. Med. J. 83: 414-419 (2007).
*
-
Shen H, Macdonald R, Bruemmer D, Stromberg A, Daugherty A, Li XA, Toborek M, Hennig B. Zinc deficiency alters lipid metabolism in LDL receptor deficient mice treated with rosiglitazone.
J. Nutr. 137: 2339-2345 (2007).
*
-
Shen H, Oesterling E, Stromberg A, Toborek M, MacDonald R, Hennig B. Zinc deficiency induces vascular pro-inflammatory parameters associated with NF-kappaB and PPAR signaling.
J. Am. Coll. Nutr. 27: 577-587 (2008).
*
-
Shen L, Zhang Y, Wang A, Sieber-McMaster E, Chen X, Pelton P, Xu JZ, Yang M, Zhu P, Zhou L, Reuman M, Hu Z, Russell R, Gibbs AC, Ross H, Demarest K, Murray WV, Kuo GH. Synthesis and identification of [1,2,4]thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors alpha and delta.
J. Med. Chem. 50: 3954-3963 (2007).
*
-
Shen L, Zhang Y, Wang A, Sieber-McMaster E, Chen X, Pelton P, Xu JZ, Yang M, Zhu P, Zhou L, Reuman M, Hu Z, Russell R, Gibbs AC, Ross H, Demarest K, Murray WV, Kuo GH. Synthesis and structure-activity relationships of thiadiazole-derivatives as potent and orally active peroxisome proliferator-activated receptors alpha/delta dual agonists.
Bioorg. Med. Chem. 18: 1525-1529 (2008).
*
-
Shen P, Liu MH, Ng TY, Chan YH, Yong EL. Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARalpha, PPARgamma, and adipocyte differentiation in vitro.
J. Nutr. 136: 899-905 (2006).
*
-
Sheng L, Ye P, Liu YX. Atorvastatin upregulates the expression of PPAR alpha/gamma and inhibits the hypertrophy of cardiac myocytes in vitro.
Zhonghua Xin Xue Guan Bing Za Zhi 33: 1080-1084 (2005).
-
Sheng L, Ye P, Liu YX, Han CG, Zhang ZY. Peroxisome proliferator-activated receptor beta/delta activation improves angiotensin II-induced cardiac hypertrophy in vitro.
Clin. Exp. Hypertens. 30: 109-119 (2008).
-
Sheng X, Zhang Y, Gong Z, Huang C, Zang YQ. Improved insulin resistance and lipid metabolism by cinnamon extract through activation of peroxisome proliferator-activated receptors.
PPAR Res. 2008: 581348 (2008).
*
-
Shi X, Hamrick M, Isales CM. Energy balance, myostatin, and GILZ: factors regulating adipocyte differentiation in belly and bone.
PPAR Res. 2007: 92501 (2007).
*
-
Shi Z, Liu J, Guo Q, Ma X, Shen L, Xu S, Gao H, Yuan X, Zhang J. Association of TRB3 gene Q84R polymorphism with type 2 diabetes mellitus in Chinese population.
Endocrine 35: 414-419 (2009).
-
Shi-Wen X, Eastwood M, Stratton RJ, Denton CP, Leask A, Abraham DJ. Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts.
Rheumatology (Oxford) 49: 259-263 (2010).
-
Shibata N, Jishage KI, Arita M, Watanabe M, Kawase Y, Nishikawa K, Natori Y, Inoue H, Shimano H, Yamada N, Tsujimoto M, Arai H. Regulation of hepatic cholesterol synthesis by a novel protein (SPF) that accelerates cholesterol biosynthesis.
FASEB J. 20: 2642-2644 (2006).
*
-
Shibata S, Furuta K, Maeda M, Suzuki M, Oh-Hashi K, Kiuchi K, Hirata Y. (Arylthio)cyclopentenones derivatives prevent glutamate-induced HT22 cell death through a PPARgamma-dependent pathway.
Brain Res. 1296: 196-202 (2009).
-
Shibata T, Takeuchi S, Yokota S, Kakimoto K, Yonemori F, Wakitani K. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.
Br. J. Pharmacol. 130: 495-504 (2000).
*
-
Shibolet O, Podolsky DK. TLRs in the gut. IV. Negative regulation of Toll-like receptors and intestinal homeostasis: addition by subtraction.
Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1469-G1473 (2007).
*
-
Shigeto T, Yokoyama Y, Xin B, Mizunuma H. Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer.
Oncol. Rep. 18: 833-840 (2007).
*
-
Shih CC, Lin CH, Lin WL, Wu JB. Momordica charantia extract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats.
J. Ethnopharmacol. 123: 82-90 (2009).
-
Shimada T, Fujii Y, Koike T, Tabei K, Namatame T, Yamagata M, Tajima A, Yoneda M, Terano A, Hiraishi H. Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates trefoil factor family 2 (TFF2) expression in gastric epithelial cells.
Int. J. Biochem. Cell. Biol. 39: 626-637 (2007).
*
-
Shimada T, Hiraishi H. PPARgamma agonists for the diseases of gastrointestinal tract and liver.
Nippon Rinsho 68: 312-316 (2010).
-
Shimada T, Hiramatsu N, Hayakawa K, Takahashi S, Kasai A, Tagawa Y, Mukai M, Yao J, Fujii-Kuriyama Y, Kitamura M. Dual suppression of adipogenesis by cigarette smoke through activation of the aryl hydrocarbon receptor and induction of endoplasmic reticulum stress.
Am. J. Physiol. Endocrinol. Metab. 296: E721-E730 (2009).
*
-
Shimazaki N, Togashi N, Hanai M, Isoyama T, Wada K, Fujita T, Fujiwara K, Kurakata S. Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model.
Eur. J. Cancer 44: 1734-1743 (2008).
-
Shimizu M, Akter MH, Emi Y, Sato R, Yamaguchi T, Hirose F, Osumi T. Peroxisome proliferator-activated receptor subtypes differentially cooperate with other transcription factors in selective transactivation of the perilipin/PEX11alpha gene pair.
J. Biochem. (Tokyo) 139: 563-573 (2006).
*
-
Shimizu M, Moriwaki H. Synergistic effects of PPARgamma ligands and retinoids in cancer treatment.
PPAR Res. 2008: 181047 (2008).
*
-
Shimizu M, Yamashita D, Yamaguchi T, Hirose F, Osumi T. Aspects of the regulatory mechanisms of PPAR functions: analysis of a bidirectional response element and regulation by sumoylation.
Mol. Cell. Biochem. 286: 33-42 (2006).
*
-
Shimoda H, Tanaka J, Kikuchi M, Fukuda T, Ito H, Hatano T, Yoshida T. Effect of polyphenol-rich extract from walnut on diet-induced hypertriglyceridemia in mice via enhancement of fatty acid oxidation in the liver.
J. Agric. Food Chem. 57: 1786-1792 (2009).
*
-
Shimomura K, Ikeda M, Ariyama Y, Proks P, Shimomura Y, Mori M, Matsumoto S. Effect of peroxisome proliferator-activated receptor alpha ligand fenofibrate on K(v) channels in the insulin-secreting cell line HIT-T15.
Gen. Physiol. Biophys. 25: 455-460 (2006).
-
Shin DJ, Osborne TF. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha activation of CYP7A1 during food restriction and diabetes is still inhibited by small heterodimer partner.
J. Biol. Chem. 283: 15089-15096 (2008).
*
-
Shin J, Li B, Davis ME, Suh Y, Lee K. Comparative analysis of fatty acid binding protein 4 promoters: conservation of peroxisome proliferator-activated receptor binding sites.
J. Anim. Sci. 87: 3923-3934 (2009).
-
Shin M, Kim I, Inoue Y, Kimura S, Gonzalez FJ. Regulation of mouse hepatic alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase, a key enzyme in the tryptophan-nicotinamide adenine dinucleotide pathway, by hepatocyte nuclear factor 4alpha and peroxisome proliferator-activated receptor..
Mol. Pharmacol. 70: 1281-1290 (2006).
*
-
Shin S, Lee S, Kwon J, Moon S, Lee S, Lee CK, Cho K, Ha NJ, Kim K. Cordycepin suppresses expression of diabetes regulating genes by inhibition of lipopolysaccharide-induced inflammation in macrophages.
Immune Netw. 9: 98-105 (2009).
*
-
Shin SJ, Lim JH, Chung S, Youn DY, Chung HW, Kim HW, Lee JH, Chang YS, Park CW. Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats.
Hypertens. Res. 32: 835-845 (2009).
-
Shipley JM, Waxman DJ. Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b.
Toxicol. Appl. Pharmacol. 199: 275-284 (2004).
*
-
Shirai H, Oishi K, Kudo T, Shibata S, Ishida N. PPARalpha is a potential therapeutic target of drugs to treat circadian rhythm sleep disorders.
Biochem. Biophys. Res. Commun. 357: 679-682 (2007).
*
-
Shiri-Sverdlov R, Wouters K, van Gorp PJ, Gijbels MJ, Noel B, Buffat L, Staels B, Maeda N, van Bilsen M, Hofker MH. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.
J. Hepatol. 44: 732-741 (2006).
*
-
Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots.
Ann. N. Y. Acad. Sci. 1056: 206-217 (2005).
*
-
Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin.
Adv. Exp. Med. Biol. 595: 127-148 (2007).
-
Shoda J, Inada Y, Tsuji A, Kusama H, Ueda T, Ikegami T, Suzuki H, Sugiyama Y, Cohen DE, Tanaka N. Bezafibrate stimulates canalicular localization of NBD-labeled phosphatidylcholine in HepG2 cells by PPAR-mediated redistribution of ABCB4.
J. Lipid Res. 45: 1813-1825 (2004).
*
-
Shrestha UK, Karimi O, Crusius JB, Zhou F, Wang Z, Chen Z, van Bodegraven AA, Xiao J, Morre SA, Wang H, Li J, Xia B. Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease.
Inflamm. Bowel Dis. 16: 312-319 (2010).
*
-
Shrivastav S, Kino T, Cunningham T, Ichijo T, Schubert U, Heinklein P, Chrousos GP, Kopp JB. HIV-1 Vpr suppresses transcriptional activity of PPARgamma and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy.
Mol. Endocrinol. 22: 234-247 (2008).
*
-
Siddiqui AM, Cui X, Wu R, Dong W, Zhou M, Hu M, Simms HH, Wang P. The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-gamma.
Crit. Care Med. 34: 1874-1882 (2006).
-
Siest G, Jeannesson E, Marteau JB, Samara A, Marie B, Pfister M, Visvikis-Siest S. Transcription factors and drug metabolizing enzymes genes expression in lymphocytes from human healthy subjects.
Drug Metab. Dispos. 36: 182-189 (2008).
*
-
Sigmund CD. Endothelial and vascular muscle PPARgamma in arterial pressure regulation. Lessons from genetic interference and deficiency.
Hypertension Dec 28 [Epub ahead of print] (2009).
-
Sigrist S, Bedoucha M, Boelsterli UA. Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes.
Biochem. Pharmacol. 60: 67-75 (2000).
*
-
Sim FJ, Lang JK, Ali TA, Roy NS, Vates GE, Pilcher WH, Goldman SA. Statin treatment of adult human glial progenitors induces PPARgamma-mediated oligodendrocytic differentiation.
Glia 56: 954-962 (2008).
-
Sime PJ. The antifibrogenic potential of PPARgamma ligands in pulmonary fibrosis.
J. Investig. Med. 56: 534-538 (2008).
-
Simon MF, Daviaud D, Pradere JP, Gres S, Guigne C, Wabitsch M, Chun J, Valet P, Saulnier-Blache JS. Lysophosphatidic acid inhibits adipocyte differentiation via LPA1 receptor-dependent down-regulation of PPARgamma2.
J. Biol. Chem. 280: 14656-14662 (2005).
*
-
Simonini MV, Polak PE, Boullerne AI, Peters JM, Richardson JC, Feinstein DL. Regulation of oligodendrocyte progenitor cell maturation by PPARdelta: effects on bone morphogenetic proteins.
ASN Neuro. Dec 14 [Epub ahead of print] (2009).
-
Sinal CJ, Yoon M, Gonzalez FJ. Antagonism of the actions of peroxisome proliferator-activated receptor-alpha by bile acids.
J. Biol. Chem. 276: 47154-47162 (2001).
*
-
Singh JP, Kauffman R, Wang G, McClelland P, Bensch W, Bean J, Montrose C, Mantlo N, Wagle A. Identification of a novel selective PPARalpha agonist LY518674 that produces marked changes in serum lipids and apolipoprotein A-1 expression.
Mol. Pharmacol. 68: 763-768 (2005).
*
-
Singh RR, Gururaj AE, Vadlamudi RK, Kumar R. 9-cis-Retinoic acid up-regulates expression of transcriptional coregulator PELP1, a novel coactivator of the retinoid X receptor alpha pathway.
J. Biol. Chem. 281: 15394-15404 (2006).
*
-
Singh S, Bennett RG. Relaxin activates peroxisome proliferator-activated receptor gamma.
Mol. Cell. Endocrinol. Aug 24 [Epub ahead of print] (2009).
-
Singh S, Bennett RG. Relaxin family peptide receptor 1 activation stimulates peroxisome proliferator-activated receptor gamma.
Ann. N. Y. Acad. Sci. 1160: 112-116 (2009).
*
-
Sixt S, Beer S, Bluher M, Korff N, Peschel T, Sonnabend M, Teupser D, Thiery J, Adams V, Schuler G, Niebauer J. Long- but not short-term multifactorial intervention with focus on exercise training improves coronary endothelial dysfunction in diabetes mellitus type 2 and coronary artery disease.
Eur. Heart J. Sep 30 [Epub ahead of print] (2009).
-
Sjolander A, Minthon L, Bogdanovic N, Wallin A, Zetterberg H, Blennow K. The PPAR-alpha gene in Alzheimer's disease: lack of replication of earlier association.
Neurobiol. Aging 30: 666-668 (2009).
-
Skoczynska A, Dobosz T, Poreba R, Turczyn B, Derkacz A, Zoledziewska M, Jonkisz A, Lebioda A. The dependence of serum interleukin-6 level on PPAR-alpha polymorphism in men with coronary atherosclerosis.
Eur. J. Intern. Med. 16: 501-506 (2005).
-
Slattery ML, Curtin K, Wolff R, Ma KN, Sweeney C, Murtaugh M, Potter JD, Levin TR, Samowitz W. PPARgamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States).
Cancer Causes Control 17: 239-249 (2006).
*
-
Slattery ML, Murtaugh MA, Sweeney C, Ma KN, Potter JD, Caan BJ, Samowitz W. PPARgamma, energy balance, and associations with colon and rectal cancer.
Nutr. Cancer 51: 155-161 (2005).
*
-
Smahelova A. Insulin sensitizing drugs.
Vnitr. Lek. 55: 425-428 (2009).
-
Smeets PJ, de Vogel-van den Bosch HM, Willemsen PH, Stassen AP, Ayoubi T, Van der Vusse GJ, van Bilsen M. Transcriptomic analysis of PPARalpha-dependent alterations during cardiac hypertrophy.
Physiol. Genomics 36: 15-23 (2008).
*
-
Smeets PJ, Planavila A, van der Vusse GJ, van Bilsen M. Peroxisome proliferator-activated receptors and inflammation: take it to heart.
Acta Physiol (Oxf.) 191: 171-188 (2007).
*
-
Smeets PJ, Teunissen BE, Planavila A, de Vogel-van den Bosch H, Willemsen PH, van der Vusse GJ, van Bilsen M. Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by PPARalpha and PPARdelta.
J. Biol. Chem. 283: 29109-29118 (2008).
*
-
Smeets PJ, Teunissen BE, Willemsen PH, van Nieuwenhoven FA, Brouns AE, Janssen BJ, Cleutjens JP, Staels B, van der Vusse GJ, van Bilsen M. Cardiac hypertrophy is enhanced in PPARalpha-/- mice in response to chronic pressure overload.
Cardiovasc. Res. 78: 79-89 (2008).
*
-
Smith KJ, Dipreta E, Skelton H. Peroxisomes in dermatology. Part II.
J. Cutan. Med. Surg. 5: 315-322 (2001).
*
-
Smith KJ, Dipreta E, Skelton H. Peroxisomes in dermatology. Part I.
J. Cutan. Med. Surg. 5: 231-243 (2001).
*
-
Smith MR, Kantoff PW. Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer.
Invest. New Drugs 20: 195-200 (2002).
*
-
Smith SA. Peroxisome proliferator-activated receptors and the regulation of mammalian lipid metabolism.
Biochem. Soc. Trans. 30: 1086-1090 (2002).
*
-
Sobal G, Menzel EJ, Sinzinger H. Troglitazone inhibits long-term glycation and oxidation of low-density lipoprotein.
J. Cardiovasc. Pharmacol. 46: 672-680 (2005).
-
Sobrado M, Pereira MP, Ballesteros I, Hurtado O, Fernandez-Lopez D, Pradillo JM, Caso JR, Vivancos J, Nombela F, Serena J, Lizasoain I, Moro MA. Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke.
J. Neurosci. 29: 3875-3884 (2009).
-
Sokolowska M, Kowalski ML, Pawliczak R. Peroxisome proliferator-activated receptors-gamma (PPAR-gamma) and their role in immunoregulation and inflammation control.
Postepy. Hig. Med. Dosw. (Online) 59: 472-484 (2005).
-
Solaas K, Kase BF, Pham V, Bamberg K, Hunt MC, Alexson SE. Differential regulation of cytosolic and peroxisomal bile acid amidation in mouse liver: PPARalpha activation favors formation of unconjugated bile acids.
J. Lipid Res. 45: 1051-1060 (2004).
*
-
Soller M, Tautenhahn A, Brune B, Zacharowski K, John S, Link H, von Knethen A. Peroxisome proliferator-activated receptor gamma contributes to T lymphocyte apoptosis during sepsis.
J. Leukoc. Biol. 79: 235-243 (2006).
*
-
Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R, Sturmer T. A cohort study of thiazolidinediones and fractures in older adults with diabetes.
J. Clin. Endocrinol. Metab. 94: 2792-2798 (2009).
*
-
Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, Mor M, Russo R, Maccarrone M, Antonietti F, Duranti A, Tontini A, Cuzzocrea S, Tarzia G, Piomelli D. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation.
Proc. Natl. Acad. Sci. U.S.A. 106: 20966-20971 (2009).
*
-
Somm E, Schwitzgebel VM, Toulotte A, Cederroth CR, Combescure C, Nef S, Aubert ML, Huppi PS. Perinatal exposure to bisphenol A alters early adipogenesis in the rat.
Environ. Health Perspect. 117: 1549-1555 (2009).
-
Somm E, Schwitzgebel VM, Vauthay DM, Camm EJ, Chen CY, Giacobino JP, Sizonenko SV, Aubert ML, Huppi PS. Prenatal nicotine exposure alters early pancreatic islet and adipose tissue development with consequences on the control of body weight and glucose metabolism later in life.
Endocrinology 149: 6289-6299 (2008).
*
-
Son SH, Kim HK, Ji JS, Cho YS, Kim SS, Chae HS, Choi MG, Han SW, Choi KY, Chung IS, Shin OR. Expression of peroxisome proliferator-activated receptor (PPAR)gamma in Helicobacter pylori-infected gastric epithelium.
Korean J. Gastroenterol. 49: 72-78 (2007).
-
Song DH, Kang JH, Lee GS, Jeung EB, Yang MP. Upregulation of tumor necrosis factor-alpha expression by trans10-cis12 conjugated linoleic acid enhances phagocytosis of RAW macrophages via a peroxisome proliferator-activated receptor gamma-dependent pathway.
Cytokine 37: 227-235 (2007).
-
Song J, Liu H, Ressom HW, Tiwari S, Ecelbarger CM. Chronic rosiglitazone therapy normalizes expression of ACE1, SCD1 and other genes in the kidney of obese Zucker rats as determined by microarray analysis.
Exp. Clin. Endocrinol. Diabetes 116: 315-325 (2008).
-
Song SH, Hong YH, Sasaki S, Roh SG, Katoh K. Prostatic androgen-repressed message-1 as a regulator of adipocyte differentiation in the mouse.
Tohoku J. Exp. Med. 219: 311-317 (2009).
*
-
Song SH, Kwak IS, Yang BY, Lee DW, Lee SB, Lee MY. Role of rosiglitazone in lipopolysaccharide-induced peritonitis: a rat peritoneal dialysis model.
Nephrology (Carlton) 14: 155-163 (2009).
*
-
Sood HS, Hunt MJ, Tyagi SC. Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia.
Am. J. Physiol. Lung Cell. Mol. Physiol. 284: L333-L341 (2003).
*
-
Sorice GP, Folli F. A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes).
Med. Hypotheses 73: 614-618 (2009).
-
Soriguer F, Morcillo S, Cardona F, Rojo-Martinez G, de la Cruz Almaraz M, de la Soledad Ruiz de Adana M, Olveira G, Tinahones F, Esteva I. Pro12Ala polymorphism of the PPARG2 gene is associated with type 2 diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid.
J. Nutr. 136: 2325-2330 (2006).
*
-
Soska V. Nuclear receptors PPARalpha.
Vnitr. Lek. 52: 628-631 (2006).
-
Sotiropoulos KB, Clermont A, Yasuda Y, Rask-Madsen C, Mastumoto M, Takahashi J, Vecchia KD, Kondo T, Aiello LP, King GL. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain.
FASEB J. 20: 1203-1205 (2006).
*
-
Souissi IJ, Billiet L, Cuaz-Perolin C, Slimane MN, Rouis M. Matrix metalloproteinase-12 gene regulation by a PPAR alpha agonist in human monocyte-derived macrophages.
Exp. Cell Res. 314: 3405-3414 (2008).
*
-
Soumian S, Albrecht C, Davies AH, Gibbs RG. ABCA1 and atherosclerosis.
Vasc. Med. 10: 109-119 (2005).
-
Spangenburg EE, Brown DA, Johnson MS, Moore RL. Alterations in peroxisome proliferator-activated receptor mRNA expression in skeletal muscle after acute and repeated bouts of exercise.
Mol. Cell. Biochem. 332: 225-231 (2009).
*
-
Sparatore A, Godio C, Perrino E, Romeo S, Staels B, Fruchart JC, Crestani M. [4-(2H-1,2,3-Benzotriazol-2-yl)phenoxy]alkanoic acids as agonists of peroxisome proliferator-activated receptors (PPARs).
Chem. Biodivers. 3: 385-395 (2006).
-
Sparso T, Hussain MS, Andersen G, Hainerova I, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. Relationships between the functional PPARalpha Leu162Val polymorphism and obesity, type 2 diabetes, dyslipidaemia, and related quantitative traits in studies of 5799 middle-aged white people.
Mol. Genet. Metab. 90: 205-209 (2007).
*
-
Spector AA, Norris AW. Action of epoxyeicosatrienoic acids on cellular function.
Am. J. Physiol. Cell Physiol. 292: C996-C1012 (2007).
*
-
Spinelli SL, O'Brien JJ, Bancos S, Lehmann GM, Springer DL, Blumberg N, Francis CW, Taubman MB, Phipps RP. The PPAR-platelet connection: modulators of inflammation and potential cardiovascular effects.
PPAR Res. 2008: 328172 (2008).
*
-
Sporn MB, Suh N, Mangelsdorf DJ. Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs).
Trends Mol. Med. 7: 395-400 (2001).
*
-
Sprecher DL. Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta.
Am. J. Cardiol. 100: S20-S24 (2007).
*
-
Sprecher DL, Massien C, Pearce G, Billin AN, Perlstein I, Willson TM, Hassall DG, Ancellin N, Patterson SD, Lobe DC, Johnson TG. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.
Arterioscler. Thromb. Vasc. Biol. 27: 359-365 (2007).
*
-
Srivastava RA, Jahagirdar R, Azhar S, Sharma S, Bisgaier CL. Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.
Mol. Cell. Biochem. 285: 35-50 (2006).
*
-
Stachowska E, Baskiewicz-Masiuk M, Dziedziejko V, Gutowska I, Baranowska-Bosiacka I, Marchlewicz M, Dolegowska B, Wiszniewska B, Machalinski B, Chlubek D. Conjugated linoleic acid increases intracellular ROS synthesis and oxygenation of arachidonic acid in macrophages.
Nutrition 24: 187-199 (2008).
*
-
Stadlmann S, Gueth U, Wight E, Kunz-Schughart L, Hartmann A, Singer G. Expression of peroxisome proliferator activated receptor-gamma and cyclooxygenase-2 in primary and recurrent ovarian carcinoma.
J. Clin. Pathol. 60: 307-310 (2007).
-
Staels B. PPARgamma and atherosclerosis.
Curr. Med. Res. Opin. 21 Suppl. 1: S13-S20 (2005).
-
Staels B. PPAR agonists and the metabolic syndrome.
Therapie 62: 319-326 (2007).
-
Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism.
Circulation 98: 2088-2093 (1998).
*
-
Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists.
Diabetes 54: 2460-2470 (2005).
*
-
Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Nat. Clin. Pract. Cardiovasc. Med. 5: 542-553 (2008).
-
Staels B, Schoonjans K, Fruchart JC, Auwerx J. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs).
Biochimie 79: 95-99 (1997).
-
Stafslien DK, Vedvik KL, De Rosier T, Ozers MS. Analysis of ligand-dependent recruitment of coactivator peptides to RXRbeta in a time-resolved fluorescence resonance energy transfer assay.
Mol. Cell. Endocrinol. 264: 82-89 (2007).
-
Stahel PF, Smith WR, Bruchis J, Rabb CH. Peroxisome proliferator-activated receptors: "key" regulators of neuroinflammation after traumatic brain injury.
PPAR Res. 2008: 538141 (2008).
*
-
Staiger H, Haas C, Machann J, Werner R, Weisser M, Schick F, Machicao F, Stefan N, Fritsche A, Haring HU. Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans.
Diabetes 58: 579-589 (2009).
*
-
Stankov MV, Schmidt RE, Behrens GM. Combined effect of C-reactive protein and stavudine on adipogenesis.
Antivir. Ther. 14: 819-829 (2009).
-
Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH. Liver disease associated with canalicular transport defects: current and future therapies.
J. Hepatol. 52: 258-271 (2010).
*
-
Staudinger JL, Xu C, Cui YJ, Klaassen CD. Nuclear receptor-mediated regulation of carboxylesterase expression and activity.
Expert Opin. Drug Metab. Toxicol. 6: 261-271 (2010).
-
Staumont-Salle D, Abboud G, Brenuchon C, Kanda A, Roumier T, Lavogiez C, Fleury S, Remy P, Papin JP, Bertrand-Michel J, Terce F, Staels B, Delaporte E, Capron M, Dombrowicz D. Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis.
J. Allergy Clin. Immunol. 121: 962-968.e6 (2008).
*
-
Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF, Burris TP. Regulation of carbohydrate metabolism by the farnesoid X receptor.
Endocrinology 146: 984-991 (2005).
*
-
Steemburgo T, Azevedo MJ, Martinez JA. Gene-nutrient interaction and its association with obesity and diabetes mellitus.
Arq. Bras. Endocrinol. Metabol. 53: 497-508 (2009).
-
Stefan N, Schafer S, Machicao F, Machann J, Schick F, Claussen CD, Stumvoll M, Haring HU, Fritsche A. Liver fat and insulin resistance are independently associated with the -514C>T polymorphism of the hepatic lipase gene.
J. Clin. Endocrinol. Metab. 90: 4238-4243 (2005).
*
-
Stefan N, Thamer C, Staiger H, Machicao F, Machann J, Schick F, Venter C, Niess A, Laakso M, Fritsche A, Haring HU. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention.
J. Clin. Endocrinol. Metab. 92: 1827-1833 (2007).
*
-
Stefano JT, de Oliveira CP, Correa-Giannella ML, de Lima VM, de Sa SV, de Oliveira EP, de Mello ES, Giannella-Neto D, Alves VA, Carrilho FJ. Nonalcoholic steatohepatitis (NASH) in OB/OB mice treated with Yo Jyo Hen Shi Ko (YHK): effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP).
Dig. Dis. Sci. 52: 3448-3454 (2007).
*
-
Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M, Moleda P, Pilarska K. Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obese patients with type II diabetes.
J. Hum. Hypertens. 20: 684-692 (2006).
-
Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M, Pilarska K. Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes.
Arch. Med. Res. 37: 736-743 (2006).
-
Steinmetz M, Quentin T, Poppe A, Paul T, Jux C. Changes in expression levels of genes involved in fatty acid metabolism: upregulation of all three members of the PPAR family (alpha, gamma, delta) and the newly described adiponectin receptor 2, but not adiponectin receptor 1 during neonatal cardiac…
Basic Res. Cardiol. 100: 263-269 (2005).
*
-
Stene LC, Thorsby PM, Berg JP, Ronningen KS, Joner G; the Norwegian Childhood Diabetes Study Group. Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism, cod liver oil and risk of type 1 diabetes.
Pediatr. Diabetes 9: 40-45 (2008).
*
-
Sterchele PF, Sun H, Peterson RE, Vanden Heuvel JP. Regulation of peroxisome proliferator-activated receptor-alpha mRNA in rat liver.
Arch. Biochem. Biophys. 326: 281-289 (1996).
*
-
Stewart D, Javadi M, Chambers M, Gunsolly C, Gorski G, Borghaei RC. Interleukin-4 inhibition of interleukin-1-induced expression of matrix metalloproteinase-3 (MMP-3) is independent of lipoxygenase and PPARg activation in human gingival fibroblasts.
BMC Mol. Biol. 8: 12 (2007).
*
-
Stienstra R, Duval C, M 252 Ller M, Kersten S. PPARs, obesity, and inflammation.
PPAR Res. 2007: 95974 (2007).
*
-
Stienstra R, Lichtenauer-Kaligis E, Muller M. Stress- (and diet-) related regulation of hepatic nuclear receptors and its relevance for ABC-transporter functions.
Drug Metab. Rev. 36: 391-406 (2004).
*
-
Stienstra R, Mandard S, Patsouris D, Maass C, Kersten S, Muller M. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation.
Endocrinology 148: 2753-2763 (2007).
*
-
Stienstra R, Mandard S, Tan NS, Wahli W, Trautwein C, Morgan ET, Lichtenauer-Kaligis E, Kersten S, Muller M. The interleukin-1 receptor antagonist is a direct target gene of PPARalpha in liver.
J. Hepatol. 46: 869-877 (2007).
*
-
Stienstra R, Saudale F, Duval C, Keshtkar S, Groener JE, van Rooijen N, Staels B, Kersten S, Muller M. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity.
Hepatology 51: 511-522 (2010).
*
-
Still K, Grabowski P, Mackie I, Perry M, Bishop N. The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo.
Calcif. Tissue Int. 83: 285-292 (2008).
-
Stoll BA. Linkage between retinoid and fatty acid receptors: implications for breast cancer prevention.
Eur. J. Cancer Prev. 11: 319-325 (2002).
-
Stone WL, Krishnan K, Campbell SE, Qui M, Whaley SG, Yang H. Tocopherols and the treatment of colon cancer.
Ann. N. Y. Acad. Sci. 1031: 223-233 (2004).
*
-
Stoner MA, Auerbach SS, Zamule SM, Strom SC, Omiecinski CJ. Transactivation of a DR-1 PPRE by a human constitutive androstane receptor variant expressed from internal protein translation start sites.
Nucleic Acids Res. 35: 2177-2190 (2007).
*
-
Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms.
Trends Immunol. 28: 551-558 (2007).
*
-
Stulc T, Ceska R. Is it safe to combine PPAR agonists? A lesson from muraglitazar.
Med. Hypotheses 67: 669 (2006).
-
Stulc T, Ceska R. Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality?
Med. Sci. Monit. 14: RA45-RA47 (2008).
*
-
Su CG, Lewis JD. Antineoplastic and anti-inflammatory effects of PPAR ligands in colitis.
Gastroenterology 121: 1019-1021 (2001).
*
-
Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response.
J. Clin. Invest. 104: 383-389 (1999).
*
-
Su RY, Chi KH, Huang DY, Tai MH, Lin WW. 15-deoxy-Delta12,14-prostaglandin J2 up-regulates death receptor 5 gene expression in HCT116 cells: involvement of reactive oxygen species and C/EBP homologous transcription factor gene transcription.
Mol. Cancer Ther. 7: 3429-3440 (2008).
-
Su W, Bush CR, Necela BM, Calcagno SR, Murray NR, Fields AP, Thompson EA. Differential expression, distribution, and function of PPAR-gamma in the proximal and distal colon.
Physiol. Genomics 30: 342-353 (2007).
*
-
Su W, Necela BM, Fujiwara K, Kurakata S, Murray NR, Fields AP, Thompson EA. The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice.
Int. J. Cancer 123: 991-997 (2008).
*
-
Su Y, Peng SB, Li ZQ, Huang QY. Association study between PPARGC1A Thr394Thr/ Gly482Ser polymorphisms and type 2 diabetes.
Yi Chuan 30: 304-308 (2008).
-
Suardiaz M, Estivill-Torrus G, Goicoechea C, Bilbao A, Rodriguez de Fonseca F. Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain.
Pain 133: 99-110 (2007).
*
-
Subramanian S, Derosa MA, Bernal-Mizrachi C, Laffely N, Cade WT, Yarasheski KE, Cryer PE, Semenkovich CF. PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans.
Am. J. Physiol. Endocrinol. Metab. 291: E1365-E1371 (2006).
*
-
Sue YM, Chung CP, Lin H, Chau Y, Jen CY, Li HF, Chang CC, Juan SH. PPARdelta-mediated p21/p27 induction via increased CBP nuclear translocation in beraprost-induced antiproliferation of murine aortic smooth muscle cells.
Am. J. Physiol. Cell Physiol. 297: C321-C329 (2009).
*
-
Sugawara K, Olson TS, Moskaluk CA, Stevens BK, Hoang S, Kozaiwa K, Cominelli F, Ley KF, McDuffie M. Linkage to peroxisome proliferator-activated receptor-gamma in SAMP1/YitFc mice and in human Crohn's disease.
Gastroenterology 128: 351-360 (2005).
*
-
Sugden M, Caton P, Holness M. PPAR control: it's SIRTainly as easy as PGC.
J. Endocrinol. Sep 21 [Epub ahead of print] (2009).
*
-
Sugden MC, Holness MJ. Mechanisms underlying regulation of the expression and activities of the mammalian pyruvate dehydrogenase kinases.
Arch. Physiol. Biochem. 112: 139-149 (2006).
-
Sugden MC, Holness MJ. Role of nuclear receptors in the modulation of insulin secretion in lipid-induced insulin resistance.
Biochem. Soc. Trans. 36: 891-900 (2008).
*
-
Sugden MC, Zariwala MG, Holness MJ. PPARs and the orchestration of metabolic fuel selection.
Pharmacol. Res. 60: 141-150 (2009).
*
-
Sugii S, Olson P, Sears DD, Saberi M, Atkins AR, Barish GD, Hong SH, Castro GL, Yin YQ, Nelson MC, Hsiao G, Greaves DR, Downes M, Yu RT, Olefsky JM, Evans RM. PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization.
Proc. Natl. Acad. Sci. U.S.A. Dec 16 [Epub ahead of print] (2009).
*
-
Sugiyama E, Ishikawa Y, Li Y, Kagai T, Nobayashi M, Tanaka N, Kamijo Y, Yokoyama S, Hara A, Aoyama T. Eicosapentaenoic acid lowers plasma and liver cholesterol levels in the presence of peroxisome proliferators-activated receptor alpha.
Life Sci. 83: 19-28 (2008).
*
-
Sugiyama E, Tanaka N, Nakajima T, Kamijo Y, Yokoyama S, Li Y, Gonzalez FJ, Aoyama T. Haploinsufficiency in the PPARalpha and LDL receptor genes leads to gender- and age-specific obesity and hyperinsulinemia.
Biochem. Biophys. Res. Commun. 350: 370-376 (2006).
*
-
SugiyamaY, Maeda K. Assessment of inhibitory effect of many therapeutically important drugs on bile acid transport by NTCP, BSEP and other transporters.
Falk Symposium 155. XIII FALK LIVER WEEK (Part I) XIX International Bile Acid Meeting. Bile Acids: Biological Actions and Clinical Relevance, October 6 - 7, 2006 Freiburg (Germany), p. 36-37 (2006). *
-
Suhara W, Koide H, Okuzawa T, Hayashi D, Hashimoto T, Kojo H. Cow's milk increases the activities of human nuclear receptors peroxisome proliferator-activated receptors alpha and delta and retinoid X receptor alpha involved in the regulation of energy homeostasis, obesity, and inflammation.
J. Dairy Sci. 92: 4180-4187 (2009).
-
Sui Y, Zhao HL, Fan RR, Guan J, He L, Lee HM, Chan JC, Tong PC. Renin-angiotensin system activation in renal adipogenesis.
Am. J. Physiol. Renal Physiol. Nov 25 [Epub ahead of print] (2009).
*
-
Suk FM, Chen CH, Lin SY, Cheng CJ, Yen SJ, Hung LF, Liu DZ, Liang YC. 15-Deoxy-Delta(12,14)-prostaglandin J(2) inhibits fibrogenic response in human hepatoma cells.
Toxicol. Lett. 187: 22-27 (2009).
-
Suk FM, Lin SY, Chen CH, Yen SJ, Su CH, Liu DZ, Hou WC, Hung LF, Lin PJ, Liang YC. Taiwanofungus camphoratus activates peroxisome proliferator-activated receptors and induces hypotriglyceride in hypercholesterolemic rats.
Biosci. Biotechnol. Biochem. 72: 1704-1713 (2008).
*
-
Suliburk JW, Ward JL, Helmer KS, Adams SD, Zuckerbraun BS, Mercer DW. Ketamine induced hepatoprotection: the role of heme oxygenase-1.
Am. J. Physiol. Gastrointest. Liver Physiol. 296: G1360-G1369 (2009).
*
-
Sulzle A, Hirche F, Eder K. Thermally oxidized dietary fat upregulates the expression of target genes of PPAR alpha in rat liver.
J. Nutr. 134: 1375-1383 (2004).
*
-
Sumanasekera WK, Tien ES, Davis JW 2nd, Turpey R, Perdew GH, Vanden Heuvel JP. Heat shock protein-90 (Hsp90) acts as a repressor of peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARbeta activity.
Biochemistry 42: 10726-10735 (2003).
*
-
Sun F, Pan Q, Wang J, Liu S, Li Z, Yu Y. Contrary effects of BMP-2 and ATRA on adipogenesis in mouse mesenchymal fibroblasts.
Biochem. Genet. Aug 8 [Epub ahead of print] (2009).
*
-
Sun F, Xie ML, Xue J, Wang HB. Osthol regulates hepatic PPARalpha-mediated lipogenic gene expression in alcoholic fatty liver murine.
Phytomedicine Dec 28 [Epub ahead of print] (2009).
-
Sun H, Berquin IM, Owens RT, O'Flaherty JT, Edwards IJ. Peroxisome proliferator-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells.
Cancer Res. 68: 2912-2919 (2008).
*
-
Sun K, Wang Q, Huang XH. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression.
Acta Pharmacol. Sin. 27: 715-723 (2006).
*
-
Sun L, Ke Y, Zhu CY, Tang N, Tian DK, Gao YH, Zheng JP, Bian K. Inflammatory reaction versus endogenous peroxisome proliferator-activated receptors expression, re-exploring secondary organ complications of spontaneously hypertensive rats.
Chin. Med. J. (Engl.) 121: 2305-2311 (2008).
-
Sun L, Yang Z, Jin F, Zhu XQ, Qu YC, Shi XH, Wang L. The Gly482Ser variant of the PPARGC1 gene is associated with type 2 diabetes mellitus in northern Chinese, especially men.
Diabet. Med. 23: 1085-1092 (2006).
*
-
Sun WH, Chen GS, Ou XL, Yang Y, Luo C, Zhang Y, Shao Y, Xu HC, Xiao B, Xue YP, Zhou SM, Zhao QS, Ding GX. Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells.
Cancer Lett. 275: 247-255 (2009).
-
Sun X, Ritzenthaler JD, Zhong X, Zheng Y, Roman J, Han S. Nicotine stimulates PPARbeta/delta expression in human lung carcinoma cells through activation of PI3K/mTOR and suppression of AP-2alpha.
Cancer Res. 69: 6445-6453 (2009).
*
-
Sun Y, Alexander SP, Garle MJ, Gibson CL, Hewitt K, Murphy SP, Kendall DA, Bennett AJ. Cannabinoid activation of PPARalpha; a novel neuroprotective mechanism.
Br. J. Pharmacol. 152: 734-743 (2007).
*
-
Sun Y, Alexander SP, Kendall DA, Bennett AJ. Cannabinoids and PPARalpha signalling.
Biochem. Soc. Trans. 34: 1095-1097 (2006).
*
-
Sun Y, Bennett A. Cannabinoids: a new group of agonists of PPARs.
PPAR Res. 2007: 23513 (2007).
*
-
Sun Y, Zhang L, Gu HF, Han W, Ren M, Wang F, Gong B, Wang L, Guo H, Xin W, Zhao J, Gao L. Peroxisome proliferator-activated receptor-alpha regulates the expression of pancreatic/duodenal homeobox-1 in rat insulinoma (INS-1) cells and ameliorates glucose-induced insulin secretion impaired by palmitate.
Endocrinology 149: 662-671 (2008).
*
-
Sundriyal S, Bharatam PV. Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening.
Eur. J. Med. Chem. 44: 3488-3495 (2009).
-
Sung B, Park S, Yu BP, Chung HY. Modulation of PPAR in aging, inflammation, and calorie restriction.
J. Gerontol. A. Biol. Sci. Med. Sci. 59: B997-B1006 (2004).
-
Sung B, Park S, Yu BP, Chung HY. Amelioration of age-related inflammation and oxidative stress by PPARgamma activator: suppression of NF-kappaB by 2,4-thiazolidinedione.
Exp. Gerontol. 41: 590-599 (2006).
*
-
Surapureddi S, Viswakarma N, Yu S, Guo D, Rao MS, Reddy JK. PRIC320, a transcription coactivator, isolated from peroxisome proliferator-binding protein complex.
Biochem. Biophys. Res. Commun. 343: 535-543 (2006).
*
-
Surazynski A, Jarzabek K, Miltyk W, Wolczynski S, Palka J. Estrogen-dependent regulation of PPAR-gamma signaling on collagen biosynthesis in adenocarcinoma endometrial cells.
Neoplasma 56: 448-454 (2009).
-
Suruga K, Mochizuki K, Suzuki R, Goda T, Takase S. Regulation of cellular retinol-binding protein type II gene expression by arachidonic acid analogue and 9-cis retinoic acid in Caco-2 cells.
Eur. J. Biochem. 262: 70-78 (1999).
*
-
Sutanto MM, Symons MS, Cohen RN. SMRT recruitment by PPARgamma is mediated by specific residues located in its carboxy-terminal interacting domain.
Mol. Cell. Endocrinol. 259: 43-49 (2006).
-
Suzuki A, Okamoto S, Lee S, Saito K, Shiuchi T, Minokoshi Y. Leptin stimulates fatty acid oxidation and PPARalpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-activated protein kinase.
Mol. Cell. Biol. 27: 4317-4327 (2007).
*
-
Suzuki K, Takahashi K, Nishimaki-Mogami T, Kagechika H, Yamamoto M, Itabe H. Docosahexaenoic acid induces adipose differentiation-related protein through activation of retinoid X receptor in human choriocarcinoma BeWo cells.
Biol. Pharm. Bull. 32: 1177-1182 (2009).
*
-
Suzuki S, Arnold LL, Pennington KL, Kakiuchi-Kiyota S, Wei M, Wanibuchi H, Cohen SM. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.
Toxicol. Sci. 113: 349-357 (2010).
*
-
Suzuki S, Hashizume K. Do PPARgamma ligands suppress the growth of cholangiocarcinoma or the cholangiohepatitis induced by the tumor?
PPAR Res. 2008: 587401 (2008).
*
-
Suzuki ST, Zhao B, Yang J. Enhanced muscle by myostatin propeptide increases adipose tissue adiponectin, PPAR-alpha, and PPAR-gamma expressions.
Biochem. Biophys. Res. Commun. 369: 767-773 (2008).
*
-
Svacina S. Metabolic PPAR receptors and skin.
Vnitr. Lek. 52: 451-453 (2006).
-
Svacina S. New perspectives of nuclear receptors PPAR modulation.
Cas. Lek. Cesk. 143: 731-733 (2004).
-
Svacina S. Potential new antidiabetics for the next decade.
Vnitr. Lek. 55: 429-433 (2009).
-
Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, De Minicis S, Nobili L, Salzano R, Omenetti A, Pacetti D, Sigmund S, Benedetti A, Casini A. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury.
Am. J. Pathol. 169: 846-860 (2006).
*
-
Swagell CD, Henly DC, Morris CP. Regulation of human hepatocyte gene expression by fatty acids.
Biochem. Biophys. Res. Commun. 362: 374-380 (2007).
*
-
Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans.
Metab. Syndr. Relat. Disord. 6: 87-102 (2008).
-
Sweeney TR, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Decreased nuclear hormone receptor expression in the livers of mice in late pregnancy.
Am. J. Physiol. Endocrinol. Metab. 290: E1313-E1320 (2006).
*
-
Swierczynski J, Chmielewski M, Wolyniec W, Rutkowski B. Molecular mechanism of fatty acids impact on plasma lipid profile (part II).
Przegl. Lek. 64: 42-47 (2007).
-
Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, Thommesen L, Reseland JE. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPAR gamma agonist pioglitazone.
BMC Endocr. Disord. 9: 10 (2009).
*
-
Szanto A, Benko S, Szatmari I, Balint BL, Furtos I, Ruhl R, Molnar S, Csiba L, Garuti R, Calandra S, Larsson H, Diczfalusy U, Nagy L. Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor, and liver X receptor signaling in macrophages.
Mol. Cell. Biol. 24: 8154-8166 (2004).
*
-
Szanto A, Nagy L. Retinoids potentiate PPARgamma action in differentiation, gene expression and lipid metabolic processes in developing myeloid cells.
Mol. Pharmacol. 67: 1935-1943 (2005).
*
-
Szatmari I, Pap A, Ruhl R, Ma JX, Illarionov PA, Besra GS, Rajnavolgyi E, Dezso B, Nagy L. PPARgamma controls CD1d expression by turning on retinoic acid synthesis in developing human dendritic cells.
J. Exp. Med. 203: 2351-2362 (2006).
*
-
Szatmari I, Rajnavolgyi E, Nagy L. PPARgamma, a lipid-activated transcription factor as a regulator of dendritic cell function.
Ann. N. Y. Acad. Sci. 1088: 207-218 (2006).
*
-
Szatmari I, Torocsik D, Agostini M, Nagy T, Gurnell M, Barta E, Chatterjee K, Nagy L. PPARgamma regulates the function of human dendritic cells primarily by altering lipid metabolism.
Blood 110: 3271-3280 (2007).
*
-
Szatmari I, Vamosi G, Brazda P, Balint BL, Benko S, Szeles L, Jeney V, Ozvegy-Laczka C, Szanto A, Barta E, Balla J, Sarkadi B, Nagy L. Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells.
J. Biol. Chem. 281: 23812-23823 (2006).
*
-
Szeles L, Torocsik D, Nagy L. PPARgamma in immunity and inflammation: cell types and diseases.
Biochim. Biophys. Acta 1771: 1014-1030 (2007).
*
-
Szeto CC, Chow KM, Poon PY, Kwan BC, Li PK. Peroxisome proliferator-activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy.
Am. J. Nephrol. 28: 715-722 (2008).
-
Szeto CC, Li PK. Antiproteinuric and anti-inflammatory effects of thiazolidinedione.
Nephrology (Carlton) 13: 53-57 (2008).
-
Szewczyk JW, Huang S, Chin J, Tian J, Mitnaul L, Rosa RL, Peterson L, Sparrow CP, Adams AD. SAR studies: designing potent and selective LXR agonists.
Bioorg. Med. Chem. Lett. 16: 3055-3060 (2006).
*
-
Tabe Y. Molecular diagnosis of and molecular targeting therapy for leukemia.
Rinsho Byori 57: 137-145 (2009).
-
Tabe Y, Konopleva M, Kondo Y, Contractor R, Tsao T, Konoplev S, Shi Y, Ling X, Watt JC, Tsutsumi-Ishii Y, Ohsaka A, Nagaoka I, Issa JP, Kogan SC, Andreeff M. PPARgamma-active triterpenoid CDDO enhances ATRA-induced differentiation in APL.
Cancer Biol. Ther. 6: 1967-1977 (2007).
-
Tachibana K. Application of the human hepatoblastoma cell lines inducibly expressing peroxisome proliferator-activated receptors (PPARs).
Yakugaku Zasshi 127: 1223-1229 (2007).
-
Tachibana K, Anzai N, Ueda C, Katayama T, Kirino T, Takahashi R, Yamasaki D, Ishimoto K, Tanaka T, Hamakubo T, Ueda Y, Arai H, Sakai J, Kodama T, Doi T. Analysis of PPAR alpha function in human kidney cell line using siRNA.
Nucleic Acids Symp. Ser. (Oxf.) 50: 257-258 (2006).
*
-
Tachibana K, Anzai N, Ueda C, Katayama T, Yamasaki D, Kirino T, Takahashi R, Ishimoto K, Komori H, Tanaka T, Hamakubo T, Ueda Y, Arai H, Sakai J, Kodama T, Doi T. Regulation of the human PDZK1 expression by peroxisome proliferator-activated receptor alpha.
FEBS Lett. 582: 3884-3888 (2008).
*
-
Tachibana K, Kobayashi Y, Tanaka T, Tagami M, Sugiyama A, Katayama T, Ueda C, Yamasaki D, Ishimoto K, Sumitomo M, Uchiyama Y, Kohro T, Sakai J, Hamakubo T, Kodama T, Doi T. Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing PPAR isoform.
Nucl. Recept. 3: 3 (2005).
*
-
Tachibana K, Yamasaki D, Ishimoto K, Doi T. The role of PPARs in cancer.
PPAR Res. 2008: 102737 (2008).
*
-
Tachibana M, Wada K, Katayama K, Kamisaki Y, Maeyama K, Kadowaki T, Blumberg RS, Nakajima A. Activation of peroxisome proliferator-activated receptor gamma suppresses mast cell maturation involved in allergic diseases.
Allergy 63: 1136-1147 (2008).
*
-
Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, Naruse M. A selective peroxisome proliferator-activated receptor gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
Endocrinology 150: 862-870 (2009).
*
-
Tahara T, Arisawa T, Shibata T, Nakamura M, Wang F, Maruyama N, Kamiya Y, Nakamura M, Fujita H, Nagasaka M, Iwata M, Takahama K, Watanabe M, Hirata I, Nakano H. Influence of peroxisome proliferator-activated receptor (PPAR)gamma Pro12Ala polymorphism as a shared risk marker for both gastric cancer and impaired fasting glucose (IFG) in Japanese.
Dig. Dis. Sci. 53: 614-621 (2008).
*
-
Tai ES, Collins D, Robins SJ, O'Connor JJ Jr, Bloomfield HE, Ordovas JM, Schaefer EJ, Brousseau ME. The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).
Atherosclerosis 187: 153-160 (2006).
-
Tai TA, Jennermann C, Brown KK, Oliver BB, MacGinnitie MA, Wilkison WO, Brown HR, Lehmann JM, Kliewer SA, Morris DC, Graves RA. Activation of the nuclear receptor peroxisome proliferator-activated receptor gamma promotes brown adipocyte differentiation.
J. Biol. Chem. 271: 29909-29914 (1996).
*
-
Taira BR, Singer AJ, McClain SA, Lin F, Rooney J, Zimmerman T, Clark RA. Rosiglitazone, a PPAR-gamma ligand, reduces burn progression in rats.
J. Burn Care Res. 30: 499-504 (2009).
-
Takada I, Kato S. PPARs target genes.
Nippon Rinsho 63: 573-577 (2005).
-
Takada I, Kouzmenko AP, Kato S. Molecular switching of osteoblastogenesis versus adipogenesis: implications for targeted therapies.
Expert Opin. Ther. Targets 13: 593-603 (2009).
-
Takada I, Mihara M, Suzawa M, Ohtake F, Kobayashi S, Igarashi M, Youn MY, Takeyama KI, Nakamura T, Mezaki Y, Takezawa S, Yogiashi Y, Kitagawa H, Yamada G, Takada S, Minami Y, Shibuya H, Matsumoto K, Kato S. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation.
Nat. Cell Biol. 9: 1273-1285 (2007).
*
-
Takada I, Suzawa M, Matsumoto K, Kato S. Suppression of PPAR-gamma transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts.
Ann. N. Y. Acad. Sci. 1116: 182-195 (2007).
*
-
Takada I, Yu RT, Xu HE, Lambert MH, Montana VG, Kliewer SA, Evans RM, Umesono K. Alteration of a single amino acid in peroxisome proliferator-activated receptor-alpha (PPAR alpha) generates a PPAR delta phenotype.
Mol. Endocrinol. 14: 733-740 (2000).
*
-
Takagi T, Naito Y, Tomatsuri N, Handa O, Ichikawa H, Yoshida N, Yoshikawa T. Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade.
Redox. Rep. 7: 283-289 (2002).
*
-
Takahashi M, Tsuboyama-Kasaoka N, Nakatani T, Ishii M, Tsutsumi S, Aburatani H, Ezaki O. Fish oil feeding alters liver gene expressions to defend against PPARalpha activation and ROS production.
Am. J. Physiol. Gastrointest. Liver Physiol. 282: G338-G348 (2002).
*
-
Takahashi N, Goto T, Kusudo T, Moriyama T, Kawada T. The structures and functions of peroxisome proliferator-activated receptors (PPARs).
Nippon Rinsho 63: 557-564 (2005).
-
Takahashi N, Goto T, Taimatsu A, Egawa K, Katoh S, Kusudo T, Sakamoto T, Ohyane C, Lee JY, Kim YI, Uemura T, Hirai S, Kawada T. Bixin regulates mRNA expression involved in adipogenesis and enhances insulin sensitivity in 3T3-L1 adipocytes through PPARgamma activation.
Biochem. Biophys. Res. Commun. 390: 1372-1376 (2009).
*
-
Takahashi N, Kawada T. Physiological and pharmacological function of PPARs.
Nippon Yakurigaku Zasshi 117: 319-327 (2001).
-
Takahashi S, Tanaka T, Kodama T, Sakai J. Peroxisome proliferator-activated receptor delta (PPARdelta), an novel target site for drug discovery in metabolic syndrome.
Pharmacol. Res. 53: 501-507 (2006).
*
-
Takahashi T, Ono H, Ono Y, Ishimitsu T, Matsuoka H. Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1).
Int. Heart J. 48: 637-647 (2007).
-
Takahashi Y, Ide T. Effects of soy protein and isoflavone on hepatic fatty acid synthesis and oxidation and mRNA expression of uncoupling proteins and peroxisome proliferator-activated receptor gamma in adipose tissues of rats.
J. Nutr. Biochem. 19: 682-693 (2008).
*
-
Takahashi Y, Ohoka N, Hayashi H, Sato R. TRB3 suppresses adipocyte differentiation by negatively regulating PPARgamma transcriptional activity.
J. Lipid Res. 49: 880-892 (2008).
*
-
Takano H, Hasegawa H, Zou Y, Komuro I. Pleiotropic actions of PPARgamma activators thiazolidinediones in cardiovascular diseases.
Curr. Pharm. Des. 10: 2779-2786 (2004).
-
Takano H, Komuro I. PPARs and heart diseases.
Nippon Rinsho 63: 659-664 (2005).
-
Takano H, Komuro I. Peroxisome proliferator-activated receptor gamma and cardiovascular diseases.
Circ. J. 73: 214-220 (2009).
*
-
Takasawa K, Kubota N, Terauchi Y, Kadowaki T. Impact of increased PPARgamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment.
Endocr. J. 55: 767-776 (2008).
*
-
Takase S, Suruga K, Goda T. Regulation of vitamin A metabolism-related gene expression.
Br. J. Nutr. 84 Suppl. 2: S217-S221 (2000).
-
Takashima K, Ito Y, Gonzalez FJ, Nakajima T. Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and PPAR alpha-null mice.
J. Occup. Health 50: 169-180 (2008).
*
-
Takata N, Awata T, Inukai K, Watanabe M, Ohkubo T, Kurihara S, Inaba M, Katayama S. Pro12Ala substitution in peroxisome proliferator-activated receptor gamma 2 is associated with low adiponectin concentrations in young Japanese men.
Metabolism 53: 1548-1551 (2004).
*
-
Takata Y, Liu J, Yin F, Collins AR, Lyon CJ, Lee CH, Atkins AR, Downes M, Barish GD, Evans RM, Hsueh WA, Tangirala RK. PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis.
Proc. Natl. Acad. Sci. U.S.A. 105: 4277-4282 (2008).
*
-
Takayama O, Yamamoto H, Damdinsuren B, Sugita Y, Ngan CY, Xu X, Tsujino T, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M. Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology.
Br. J. Cancer 95: 889-895 (2006).
*
-
Takazawa T, Yamauchi T, Tsuchida A, Takata M, Hada Y, Iwabu M, Okada-Iwabu M, Ueki K, Kadowaki T. Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases the expression of very low density lipoprotein receptor gene in adipocytes.
J. Biol. Chem. 284: 30049-30057 (2009).
*
-
Takeda E, Arai H, Muto K, Matsuo K, Sakuma M, Fukaya M, Yamanaka-Okumura H, Yamamoto H, Taketani Y. Gene expression in low glycemic index diet - impact on metabolic control.
Forum Nutr. 60: 127-139 (2007).
-
Taketa K, Matsumura T, Yano M, Ishii N, Senokuchi T, Motoshima H, Murata Y, Kim-Mitsuyama S, Kawada T, Itabe H, Takeya M, Nishikawa T, Tsuruzoe K, Araki E. Oxidized low density lipoprotein activates peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPARgamma through MAPK-dependent COX-2 expression in macrophages.
J. Biol. Chem. 283: 9852-9862 (2008).
*
-
Takeuchi S, Matsuda T, Kobayashi S, Takahashi T, Kojima H. In vitro screening of 200 pesticides for agonistic activity via mouse peroxisome proliferator-activated receptor (PPAR)alpha and PPARgamma and quantitative analysis of in vivo induction pathway.
Toxicol. Appl. Pharmacol. 217: 235-244 (2006).
*
-
Takeyama K, Kodera Y, Suzawa M, Kato S. Peroxisome proliferator-activated receptor (PPAR) - structure, function, tissue distribution, gene expression.
Nippon Rinsho 58: 357-363 (2000).
-
Talukdar R, Saikia N, Singal DK, Tandon R. Chronic pancreatitis: evolving paradigms.
Pancreatology 6: 440-449 (2006).
-
Talukdar R, Tandon RK. Pancreatic stellate cells: new target in the treatment of chronic pancreatitis.
J. Gastroenterol. Hepatol. 23: 34-41 (2008).
*
-
Tamaki J, Iki M, Morita A, Ikeda Y, Sato Y, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H. Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study.
Osteoporos. Int. May 30 [Epub ahead of print] (2009).
*
-
Tamasi V, Juvan P, Beer M, Rozman D, Meyer U. Transcriptional activation of PPAR by phenobarbital in the absence of CAR and PXR.
Mol. Pharm. 6: 1573-1581 (2009).
*
-
Tamasi V, Miller KK, Ripp SL, Vila E, Geoghegan TE, Prough RA. Modulation of receptor phosphorylation contributes to activation of PPARalpha by dehydroepiandrosterone and other peroxisome proliferators.
Mol. Pharmacol. 73: 968-976 (2008).
*
-
Tamura K, Ono A, Miyagishima T, Nagao T, Urushidani T. Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators.
J. Toxicol. Sci. 31: 471-490 (2006).
*
-
Tan GD, Neville MJ, Liverani E, Humphreys SM, Currie JM, Dennis L, Fielding BA, Karpe F. The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank.
Diabetologia 49: 158-168 (2006).
*
-
Tan NS, Icre G, Montagner A, Heggeler BB, Wahli W, Michalik L. The nuclear hormone receptor peroxisome proliferator-activated receptor beta/delta potentiates cell chemotactism, polarization, and migration.
Mol. Cell. Biol. 27: 7161-7175 (2007).
*
-
Tan NS, Michalik L, Desvergne B, Wahli W. Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes.
J. Steroid Biochem. Mol. Biol. 93: 99-105 (2005).
-
Tan NS, Michalik L, Desvergne B, Wahli W. Genetic- or TGF-beta 1-induced changes in epidermal PPARbeta/delta expression dictate wound repair kinetics.
J. Biol. Chem. 280: 18163-18170 (2005).
*
-
Tanaka N, Aoyama T. PPAR and NASH.
Nippon Rinsho 64: 1089-1094 (2006).
-
Tanaka N, Aoyama T. Possible mechanisms of hepatitis C virus-related hepatocarcinogenesis.
Nippon Rinsho 62: 2137-2144 (2004).
-
Tanaka N, Hora K, Makishima H, Kamijo Y, Kiyosawa K, Gonzalez FJ, Aoyama T. In vivo stabilization of nuclear retinoid X receptor alpha in the presence of peroxisome proliferator-activated receptor alpha.
FEBS Lett. 543: 120-124 (2003).
*
-
Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, Hosokawa M. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats.
Cancer Res. 61: 2424-2428 (2001).
*
-
Tanaka T, Masuzaki H, Ebihara K, Ogawa Y, Yasue S, Yukioka H, Chusho H, Miyanaga F, Miyazawa T, Fujimoto M, Kusakabe T, Kobayashi N, Hayashi T, Hosoda K, Nakao K. Transgenic expression of mutant peroxisome proliferator-activated receptor gamma in liver precipitates fasting-induced steatosis but protects against high-fat diet-induced steatosis in mice.
Metabolism 54: 1490-1498 (2005).
*
-
Tanaka T, Ordovas JM, Delgado-Lista J, Perez-Jimenez F, Marin C, Perez-Martinez P, Gomez P, Lopez-Miranda J. Peroxisome proliferator-activated receptor alpha polymorphisms and postprandial lipemia in healthy men.
J. Lipid Res. 48: 1402-1408 (2007).
*
-
Tanaka T, Takeno T, Watanabe Y, Uchiyama Y, Murakami T, Yamashita H, Suzuki A, Aoi R, Iwanari H, Jiang SY, Naito M, Tachibana K, Doi T, Shulman AI, Mangelsdorf DJ, Reiter R, Auwerx J, Hamakubo T, Kodama T. The generation of monoclonal antibodies against human peroxisome proliferator-activated receptors (PPARs).
J. Atheroscler. Thromb. 9: 233-242 (2002).
*
-
Tancevski I, Wehinger A, Schgoer W, Eller P, Cuzzocrea S, Foeger B, Patsch JR, Ritsch A. Aspirin regulates expression and function of scavenger receptor-BI in macrophages: studies in primary human macrophages and in mice.
FASEB J. 20: 1328-1335 (2006).
*
-
Tang SC, Leung JC, Chan LY, Tsang AW, Lai KN. Activation of tubular epithelial cells in diabetic nephropathy and the role of the peroxisome proliferator-activated receptor-gamma agonist.
J. Am. Soc. Nephrol. 17: 1633-1643 (2006).
*
-
Tang T, Zhang J, Yin J, Staszkiewicz J, Gawronska-Kozak B, Jung DY, Ko HJ, Ong H, Kim JK, Mynatt R, Martin RJ, Keenan M, Gao Z, Ye J. Uncoupling of inflammation and insulin resistance by NF-kB in transgenic mice through elevated energy expenditure.
J. Biol. Chem. Dec 17 [Epub ahead of print] (2009).
*
-
Tang X, Guilherme A, Chakladar A, Powelka AM, Konda S, Virbasius JV, Nicoloro SM, Straubhaar J, Czech MP. An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARgamma, adipogenesis, and insulin-responsive hexose transport.
Proc. Natl. Acad. Sci. U.S.A. 103: 2087-2092 (2006).
*
-
Tang Y, Zhou L, Gunnet JW, Wines PG, Cryan EV, Demarest KT. Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A.
Biochem. Biophys. Res. Commun. 345: 29-37 (2006).
*
-
Tannehill-Gregg SH, Dominick MA, Reisinger AJ, Moehlenkamp JD, Waites CR, Stock DA, Sanderson TP, Cohen SM, Arnold LL, Schilling BE. Strain-related differences in urine composition of male rats of potential relevance to urolithiasis.
Toxicol. Pathol. 37: 293-305 (2009).
*
-
Tannehill-Gregg SH, Sanderson TP, Minnema D, Voelker R, Ulland B, Cohen SM, Arnold LL, Schilling BE, Waites CR, Dominick MA. Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.
Toxicol. Sci. 98: 258-270 (2007).
*
-
Tao H, Aakula S, Abumrad NN, Hajri T. Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates the expression and function of very low density lipoprotein receptor.
Am. J. Physiol. Endocrinol. Metab. Oct 27 [Epub ahead of print] (2009).
*
-
Tao L, Wang Y, Gao E, Zhang H, Yuan Y, Lau WB, Chan L, Koch WJ, Ma XL. Adiponectin. An indispensable molecule in rosiglitazone cardioprotection following myocardial infarction.
Circ. Res. Nov 25 [Epub ahead of print] (2009).
-
Tatenhorst L, Hahnen E, Heneka MT. Peroxisome proliferator-activated receptors (PPARs) as potential inducers of antineoplastic effects in CNS tumors.
PPAR Res. 2008: 204514 (2008).
*
-
Tavares V, Hirata RD, Rodrigues AC, Monte O, Salles JE, Scalissi N, Speranza AC, Hirata MH. Association between Pro12Ala polymorphism of the PPAR-gamma2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus.
Diabetes Obes. Metab. 7: 605-611 (2005).
-
Tawfik A, Sanders T, Kahook K, Akeel S, El-Marakby A, Al-Shabrawey M. Suppression of retinal peroxisome proliferator activated receptor-gamma in experimental diabetes and oxygen-induced retinopathy: role of NADPH oxidase.
Invest. Ophthalmol. Vis. Sci. 50: 878-884 (2009).
*
-
Tay S, Dickmann L, Dixit V, Isoherranen N. A comparison of the role of PPAR and RAR on CYP26 regulation.
Mol. Pharmacol. Nov 2 [Epub ahead of print] (2009).
*
-
Teboul M, Guillaumond F, Grechez-Cassiau A, Delaunay F. The nuclear hormone receptors family round the clock.
Mol. Endocrinol. 22: 2573-2582 (2008).
*
-
Teillon S, Calderon G, Rios M. Diminished diet-induced hyperglycemia and dyslipidemia and enhanced expression of PPARalpha and FGF-21 in mice with hepatic ablation of brain-derived neurotrophic factor.
J. Endocrinol. Jan 22 [Epub ahead of print] (2010).
*
-
Teissier E, Nohara A, Chinetti G, Paumelle R, Cariou B, Fruchart JC, Brandes R, Shah A, Staels B. Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties.
Circ. Res. 95: 1174-1182 (2004).
*
-
Tejerina S, De Pauw A, Vankoningsloo S, Houbion A, Renard P, De Longueville F, Raes M, Arnould T. Mild mitochondrial uncoupling induces 3T3-L1 adipocyte de-differentiation by a PPARgamma-independent mechanism, whereas TNFalpha-induced de-differentiation is PPARgamma-dependent.
J. Cell Sci. 122: 145-155 (2009).
*
-
Tellechea ML, Aranguren F, Perez MS, Cerrone GE, Frechtel GD, Taverna MJ. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene is associated with metabolic syndrome and surrogate measures of insulin resistance in healthy men.
Circ. J. 73: 2118-2124 (2009).
*
-
Tenenbaum A, Boyko V, Fisman EZ, Goldenberg I, Adler Y, Feinberg MS, Motro M, Tanne D, Shemesh J, Schwammenthal E, Behar S. Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?
Cardiovasc. Diabetol. 7: 18 (2008).
*
-
Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Cardiovasc. Diabetol. 4: 14 (2005).
*
-
Teoh NC, Williams J, Hartley J, Yu J, McCuskey RS, Farrell GC. Short-term therapy with peroxisome proliferation-activator receptor-alpha agonist Wy-14,643 protects murine fatty liver against ischemia-reperfusion injury.
Hepatology Nov 9 [Epub ahead of print] (2009).
*
-
Tepmongkol S, Keelawat S, Honsawek S, Ruangvejvorachai P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma.
Thyroid 18: 697-704 (2008).
-
Terauchi Y. PPARgamma and metabolic syndrome.
Rinsho Byori 55: 447-451 (2007).
-
Terauchi Y, Kadowaki T. PPAR and diabetes.
Nippon Rinsho 63: 623-629 (2005).
-
Teresi RE, Waite KA. PPARgamma, PTEN, and the fight against cancer.
PPAR Res. 2008: 932632 (2008).
*
-
Terra SG, Francone OL, Contant CF, Gao X, Lewin AJ, Nguyen TT. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Am. J. Cardiol. 102: 434-439 (2008).
-
Teruel T, Hernandez R, Benito M, Lorenzo M. Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes.
J. Biol. Chem. 278: 263-269 (2003).
*
-
Tesse A, Al-Massarani G, Wangensteen R, Reitenbach S, Martinez MC, Andriantsitohaina R. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents microparticle-induced vascular hyporeactivity through the regulation of proinflammatory proteins.
J. Pharmacol. Exp. Ther. 324: 539-547 (2008).
*
-
Tesse A, Andriantsitohaina R, Ragot T. PPARdelta activity in cardiovascular diseases: a potential pharmacological target.
PPAR Res. 2009: 745821 (2009).
*
-
Thabuis C, Tissot-Favre D, Bezelgues JB, Martin JC, Cruz-Hernandez C, Dionisi F, Destaillats F. Biological functions and metabolism of oleoylethanolamide.
Lipids 43: 887-894 (2008).
-
Thakur JK, Arthanari H, Yang F, Chau KH, Wagner G, Naar AM. Mediator subunit Gal11p/MED15 is required for fatty acid-dependent gene activation by yeast transcription factor Oaf1p.
J. Biol. Chem. 284: 4422-4428 (2009).
*
-
Tham DM, Martin-McNulty B, Wang YX, Wilson DW, Vergona R, Sullivan ME, Dole W, Rutledge JC. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs.
Physiol. Genomics 11: 21-30 (2002).
*
-
Tham DM, Wang YX, Rutledge JC. Modulation of vascular inflammation by PPARs.
Drug News Perspect. 16: 109-116 (2003).
-
Theocharis S, Giaginis C, Parasi A, Margeli A, Kakisis J, Agapitos E, Kouraklis G. Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival.
Dig. Dis. Sci. 52: 2305-2311 (2007).
*
-
Theodoropoulos G, Papaconstantinou I, Felekouras E, Nikiteas N, Karakitsos P, Panoussopoulos D, Ch Lazaris A, Patsouris E, Bramis J, Gazouli M. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer.
World J. Gastroenterol. 12: 5037-5043 (2006).
*
-
Thering BJ, Bionaz M, Loor JJ. Long-chain fatty acid effects on peroxisome proliferator-activated receptor-alpha-regulated genes in Madin-Darby bovine kidney cells: optimization of culture conditions using palmitate.
J. Dairy Sci. 92: 2027-2037 (2009).
-
Thevis M, Moller I, Thomas A, Beuck S, Rodchenkov G, Bornatsch W, Geyer H, Schanzer W. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.
Anal. Bioanal. Chem. Nov 28 [Epub ahead of print] (2009).
*
-
Thomas J, Bramlett KS, Montrose C, Foxworthy P, Eacho PI, McCann D, Cao G, Kiefer A, McCowan J, Yu KL, Grese T, Chin WW, Burris TP, Michael LF. A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha) versus liver X receptor.
J. Biol. Chem. 278: 2403-2410 (2003).
*
-
Thomassen MJ, Barna BP, Malur AG, Bonfield TL, Farver CF, Malur A, Dalrymple H, Kavuru MS, Febbraio M. ABCG1 is deficient in alveolar macrophages of GM-CSF knock-out mice and patients with pulmonary alveolar proteinosis.
J. Lipid Res. 48: 2762-2768 (2007).
*
-
Thompson PW, Bayliffe AI, Warren AP, Lamb JR. Interleukin-10 is upregulated by nanomolar rosiglitazone treatment of mature dendritic cells and human CD4+ T cells.
Cytokine 39: 184-191 (2007).
-
Thomson B, Ahrens JM, Ntambi JM, Deluca HF, Clagett-Dame M. 2-Methylene-19-nor-1alpha-hydroxyvitamin D(3) analogs inhibit adipocyte differentiation and PPARgamma2 gene transcription.
Arch. Biochem. Biophys. 460: 192-201 (2007).
*
-
Thorin-Trescases N, Thorin E. HO-1, a new target of PPARdelta with "anti-atherogenic" properties: is it the one?
Cardiovasc. Res. Jan 7 [Epub ahead of print] (2010).
*
-
Thorp E, Kuriakose G, Shah YM, Gonzalez FJ, Tabas I. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor null mice.
Circulation 116: 2182-2190 (2007).
*
-
Thulin P, Glinghammar B, Skogsberg J, Lundell K, Ehrenborg E. PPARdelta increases expression of the human apolipoprotein A-II gene in human liver cells.
Int. J. Mol. Med. 21: 819-824 (2008).
*
-
Thulin P, Rafter I, Stockling K, Tomkiewicz C, Norjavaara E, Aggerbeck M, Hellmold H, Ehrenborg E, Andersson U, Cotgreave I, Glinghammar B. PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes.
Toxicol. Appl. Pharmacol. 231: 1-9 (2008).
*
-
Tian J, Smith A, Nechtman J, Podolsky R, Aggarwal S, Snead C, Kumar S, Elgaish M, Oishi PE, Goerlach A, Fratz S, Hess J, Catravas JD, Verin AD, Fineman JR, She JX, Black SM. Effect of PPARgamma inhibition on pulmonary endothelial cell gene expression: gene profiling in pulmonary hypertension.
Physiol. Genomics Oct 13 [Epub ahead of print] (2009).
*
-
Tian L, Luo N, Klein RL, Chung BH, Garvey WT, Fu Y. Adiponectin reduces lipid accumulation in macrophage foam cells.
Atherosclerosis 202: 152-161 (2009).
-
Tien ES, Davis JW, Vanden Heuvel JP. Identification of the CREB-binding protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated receptor alpha coregulator.
J. Biol. Chem. 279: 24053-24063 (2004).
*
-
Tien ES, Hannon DB, Thompson JT, Vanden Heuvel JP. Examination of ligand-dependent coactivator recruitment by peroxisome proliferator-activated receptor-alpha (PPARalpha).
PPAR Res. 2006: 69612 (2006).
*
-
Tiesset H, Pierre M, Desseyn JL, Guery B, Beermann C, Galabert C, Gottrand F, Husson MO. Dietary (n-3) polyunsaturated fatty acids affect the kinetics of pro- and antiinflammatory responses in mice with Pseudomonas aeruginosa lung infection.
J. Nutr. 139: 82-89 (2009).
*
-
Tiwari S, Blasi ER, Heyen JR, McHarg AD, Ecelbarger CM. Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats.
Pharmacol. Res. 57: 383-392 (2008).
*
-
Tjokroprawiro A. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Acta Med. Indones. 38: 160-166 (2006).
-
Todorov VT, Desch M, Schmitt-Nilson N, Todorova A, Kurtz A. Peroxisome proliferator-activated receptor-gamma is involved in the control of renin gene expression.
Hypertension 50: 939-944 (2007).
-
Tok EC, Ertunc D, Bilgin O, Erdal EM, Kaplanoglu M, Dilek S. PPAR-gamma2 Pro12Ala polymorphism is associated with weight gain in women with gestational diabetes mellitus.
Eur. J. Obstet. Gynecol. Reprod. Biol. 129: 25-30 (2006).
-
Tomaru T, Steger DJ, Lefterova MI, Schupp M, Lazar MA. Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor gamma and CCAAT/enhancer binding proteins.
J. Biol. Chem. 284: 6116-6125 (2009).
*
-
Tomita K, Oike Y, Teratani T, Taguchi T, Noguchi M, Suzuki T, Mizutani A, Yokoyama H, Irie R, Sumimoto H, Takayanagi A, Miyashita K, Akao M, Tabata M, Tamiya G, Ohkura T, Hibi T. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice.
Hepatology 48: 458-473 (2008).
*
-
Tomkiewicz C, Muzeau F, Edgar AD, Barouki R, Aggerbeck M. Opposite regulation of the rat and human cytosolic aspartate aminotransferase genes by fibrates.
Biochem. Pharmacol. 67: 213-225 (2004).
*
-
Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, DuBois RN, Dey SK. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma.
Neoplasia 2: 483-490 (2000).
-
Tong Y, Hara A, Komatsu M, Tanaka N, Kamijo Y, Gonzalez FJ, Aoyama T. Suppression of expression of muscle-associated proteins by PPARalpha in brown adipose tissue.
Biochem. Biophys. Res. Commun. 336: 76-83 (2005).
*
-
Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma.
Annu. Rev. Biochem. 77: 289-312 (2008).
*
-
Toomey S, Harhen B, Roche HM, Fitzgerald D, Belton O. Profound resolution of early atherosclerosis with conjugated linoleic acid.
Atherosclerosis 187: 40-49 (2006).
-
Torma H, Berne B. Sodium lauryl sulphate alters the mRNA expression of lipid-metabolizing enzymes and PPAR signalling in normal human skin in vivo.
Exp. Dermatol. 18: 1010-1015 (2009).
-
Toth B, Bastug M, Mylonas I, Scholz C, Makovitzky J, Kunze S, Thaler C, Friese K, Jeschke U. Peroxisome proliferator-activated receptor-gamma in normal human pregnancy and miscarriage.
Acta Histochem. 111: 372-378 (2009).
-
Toth B, Bastug M, Scholz C, Arck P, Schulze S, Kunze S, Friese K, Jeschke U. Leptin and peroxisome proliferator-activated receptors: impact on normal and disturbed first trimester human pregnancy.
Histol. Histopathol. 23: 1465-1475 (2008).
*
-
Toth B, Hornung D, Scholz C, Djalali S, Friese K, Jeschke U. Peroxisome proliferator-activated receptors: new players in the field of reproduction.
Am. J. Reprod. Immunol. 58: 289-310 (2007).
*
-
Toth B, Jeschke U, Rogenhofer N, Scholz C, Wurfel W, Thaler CJ, Makrigiannakis A. Recurrent miscarriage: current concepts in diagnosis and treatment.
J. Reprod. Immunol. Feb 23 [Epub ahead of print] (2010).
-
Touyz RM, Schiffrin EL. Peroxisome proliferator-activated receptors in vascular biology - molecular mechanisms and clinical implications.
Vascul. Pharmacol. 45: 19-28 (2006).
*
-
Towfighi A, Ovbiagele B. Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention.
Cerebrovasc. Dis. 26: 106-112 (2008).
-
Toyama T, Kudo N, Hibino Y, Mitsumoto A, Nishikawa M, Kawashima Y. Effects of pioglitazone on stearoyl-CoA desaturase in obese Zucker fa/fa rats.
J. Pharmacol. Sci. 104: 137-145 (2007).
*
-
Toyama T, Nakamura H, Harano Y, Yamauchi N, Morita A, Kirishima T, Minami M, Itoh Y, Okanoue T. PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats.
Biochem. Biophys. Res. Commun. 324: 697-704 (2004).
*
-
Toyoda T, Kamei Y, Kato H, Sugita S, Takeya M, Suganami T, Ogawa Y. Effect of peroxisome proliferator-activated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue.
Obesity (Silver Spring) 16: 1199-1207 (2008).
*
-
Trauner M, Fickert P, Halilbasic E, Moustafa T. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Wien. Med. Wochenschr. 158: 542-548 (2008).
*
-
Trauner M, Fickert P, Lammert F, Marschall HU. ABCB4 gene mutations and primary sclerosing cholangitis.
Gastroenterology 126: 1222-1223 (2004). *
-
Tremblay F, Revett T, Huard C, Zhang Y, Tobin JF, Martinez RV, Gimeno RE. Bidirectional modulation of adipogenesis by the secreted protein CCDC80/DRO1/URB.
J. Biol. Chem. 284: 8136-8147 (2009).
*
-
Treuter E, Albrektsen T, Johansson L, Leers J, Gustafsson JA. A regulatory role for RIP140 in nuclear receptor activation.
Mol. Endocrinol. 12: 864-881 (1998).
*
-
Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, Gilliland KL, Liu W, Mauger DT, Gabbay RA, Thiboutot DM. Peroxisome proliferator-activated receptors increase human sebum production.
J. Invest. Dermatol. 126: 2002-2009 (2006).
*
-
Trombetta A, Maggiora M, Martinasso G, Cotogni P, Canuto RA, Muzio G. Arachidonic and docosahexaenoic acids reduce the growth of A549 human lung-tumor cells increasing lipid peroxidation and PPARs.
Chem. Biol. Interact. 165: 239-250 (2007).
*
-
Tsai MC, Chen L, Zhou J, Tang Z, Hsu TF, Wang Y, Shih YT, Peng HH, Wang N, Guan Y, Chien S, Chiu JJ. Shear stress induces synthetic-to-contractile phenotypic modulation in smooth muscle cells via peroxisome proliferator-activated receptor alpha/delta activations by prostacyclin released by sheared endothelial cells.
Circ. Res. 105: 471-480 (2009).
-
Tsai YS, Tsai PJ, Jiang MJ, Chou TY, Pendse A, Kim HS, Maeda N. Decreased PPARgamma expression compromises perigonadal-specific fat deposition and insulin sensitivity.
Mol. Endocrinol. 23: 1787-1798 (2009).
-
Tsai YS, Xu L, Smithies O, Maeda N. Genetic variations in peroxisome proliferator-activated receptor gamma expression affect blood pressure.
Proc. Natl. Acad. Sci. U.S.A. 106: 19084-19089 (2009).
*
-
Tsao WC, Wu HM, Chi KH, Chang YH, Lin WW. Proteasome inhibitors induce peroxisome proliferator-activated receptor transactivation through RXR accumulation and a protein kinase C-dependent pathway.
Exp. Cell Res. 304: 234-243 (2005).
*
-
Tsoyi K, Ha YM, Kim YM, Lee YS, Kim HJ, Kim HJ, Seo HG, Lee JH, Chang KC. Activation of PPAR-gamma by carbon monoxide from CORM-2 leads to the inhibition of iNOS but not COX-2 expression in LPS-stimulated macrophages.
Inflammation 32: 364-371 (2009).
*
-
Tsuchida A, Yamauchi T, Kadowaki T. Nuclear receptors as targets for drug development: molecular mechanisms for regulation of obesity and insulin resistance by peroxisome proliferator-activated receptor gamma, CREB-binding protein, and adiponectin.
J. Pharmacol. Sci. 97: 164-170 (2005).
*
-
Tsuji K, Satoh S, Mitsutake S, Murakami I, Park JJ, Li Q, Chang YT, Chung SK, Igarashi Y. Evaluation of synthetic sphingolipid analogs as ligands for peroxisome proliferator-activated receptors.
Bioorg. Med. Chem. Lett. 19: 1643-1646 (2009).
-
Tsujie M, Nakamori S, Okami J, Hayashi N, Hiraoka N, Nagano H, Dono K, Umeshita K, Sakon M, Monden M. Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway.
Exp. Cell Res. 289: 143-151 (2003).
*
-
Tsujie M, Nakamori S, Okami J, Takahashi Y, Hayashi N, Nagano H, Dono K, Umeshita K, Sakon M, Monden M. Growth inhibition of pancreatic cancer cells through activation of peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway.
Int. J. Oncol. 23: 325-331 (2003).
-
Tsukahara T, Tsukahara R, Yasuda S, Makarova N, Valentine WJ, Allison P, Yuan H, Baker DL, Li Z, Bittman R, Parrill A, Tigyi G. Different residues mediate recognition of 1-O-oleyl-lysophosphatidic acid and rosiglitazone in the ligand binding domain of PPAR1.
J. Biol. Chem. 281: 3398-3407 (2006).
*
-
Tsukamoto H, She H, Hazra S, Cheng J, Miyahara T. Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation.
J. Gastroenterol. Hepatol. 21 Suppl. 3: S102-S105 (2006).
-
Tsukuda K, Mogi M, Iwanami J, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation.
Hypertension 54: 782-787 (2009).
-
Tsunoda M, Kobayashi N, Ide T, Utsumi M, Nagasawa M, Murakami K. A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.
Am. J. Physiol. Endocrinol. Metab. 294: E833-E840 (2008).
*
-
Tsuzuki T, Kawakami Y. Tumor angiogenesis suppression by alpha-eleostearic acid, a linolenic acid isomer with a conjugated triene system, via peroxisome proliferator-activated receptor gamma.
Carcinogenesis 29: 797-806 (2008).
*
-
Tu AY, Albers JJ. Functional analysis of the transcriptional activity of the mouse phospholipid transfer protein gene.
Biochem. Biophys. Res. Commun. 287: 921-926 (2001).
*
-
Tu WL, Sun Y, Geng Y. Mechanism of PUFA in regulating of gene expression.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 24: 713-716 (2007).
-
Tudor C, Feige JN, Pingali H, Bhushan Lohray V, Wahli W, Desvergne B, Engelborghs Y, Gelman L. Association with coregulators is the major determinant governing peroxisome proliferator-activated receptor mobility in living cells.
J. Biol. Chem. 282: 4417-4426 (2007).
*
-
Tugwood JD, Aldridge TC, Lambe KG, Macdonald N, Woodyatt NJ. Peroxisome proliferator-activated receptors: structures and function.
Ann. N. Y. Acad. Sci. 804: 252-265 (1996).
*
-
Tuller ER, Beavers CT, Lou JR, Benbrook DM, Ihnat MA, Ding WQ. Docosahexaenoic acid inhibits superoxide dismutase 1 gene transcription in human cancer cells: the involvement of PPARalpha and HIF-2alpha signaling.
Mol. Pharmacol. 76: 588-595 (2009).
*
-
Tuller ER, Brock AL, Yu H, Lou JR, Benbrook DM, Ding WQ. PPARalpha signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells.
Biochem. Pharmacol. 77: 1480-1486 (2009).
*
-
Turmelle YP, Shikapwashya O, Tu S, Hruz PW, Yan Q, Rudnick DA. Rosiglitazone inhibits mouse liver regeneration.
FASEB J. 20: 2609-2611 (2006).
*
-
Tzika AA, Mintzopoulos D, Mindrinos M, Zhang J, Rahme LG, Tompkins RG. Microarray analysis suggests that burn injury results in mitochondial dysfunction in human skeletal muscle.
Int. J. Mol. Med. 24: 387-392 (2009).
-
Uchimura K, Nakamuta M, Enjoji M, Irie T, Sugimoto R, Muta T, Iwamoto H, Nawata H. Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells.
Hepatology 33: 91-99 (2001).
*
-
Uehara G, Takeda H. Relative effects of telmisartan, candesartan and losartan on alleviating arterial stiffness in patients with hypertension complicated by diabetes mellitus: an evaluation using the cardio-ankle vascular index (CAVI).
J. Int. Med. Res. 36: 1094-1102 (2008).
-
Ueno K, Sugai H, Sato H. Mechanism of sex differences and the clinical significance of PPARgamma targeted drugs.
Nippon Rinsho 68: 224-228 (2010).
-
Ueyama J, Kitaichi K, Nadai M, Iwase M, Tomyo N, Kanazawa H, Suzuki R, Takagi K, Takagi K, Hasegawa T. Effect of pioglitazone on endotoxin-induced decreases in hepatic drug-metabolizing enzyme activity and expression of CYP3A2 and CYP2C11.
Eur. J. Pharmacol. 498: 257-265 (2004).
*
-
Uji Y, Yamamoto H, Tsuchihashi H, Maeda K, Funahashi T, Shimomura I, Shimizu T, Endo Y, Tani T. Adiponectin deficiency is associated with severe polymicrobial sepsis, high inflammatory cytokine levels, and high mortality.
Surgery 145: 550-557 (2009).
-
Unno A, Takada I, Takezawa S, Oishi H, Baba A, Shimizu T, Tokita A, Yanagisawa J, Kato S. TRRAP as a hepatic coactivator of LXR and FXR function.
Biochem. Biophys. Res. Commun. 327: 933-938 (2005).
*
-
Uno K, Katagiri H, Yamada T, Ishigaki Y, Ogihara T, Imai J, Hasegawa Y, Gao J, Kaneko K, Iwasaki H, Ishihara H, Sasano H, Inukai K, Mizuguchi H, Asano T, Shiota M, Nakazato M, Oka Y. Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity.
Science 312: 1656-1659 (2006).
*
-
Urban NH, Chamberlin B, Ramage S, Roberts Z, Loria RM, Beckman MJ. Effects of alpha/beta-androstenediol immune regulating hormones on bone remodeling and apoptosis in osteoblasts.
J. Steroid Biochem. Mol. Biol. 110: 223-229 (2008).
-
Urbanska K, Pannizzo P, Grabacka M, Croul S, Del Valle L, Khalili K, Reiss K. Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines.
Int. J. Cancer 123: 1015-1024 (2008).
*
-
Usui T, Sugisaki K, Iriyama A, Yokoo S, Yamagami S, Nagai N, Ishida S, Amano S. Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor.
Invest. Ophthalmol. Vis. Sci. 49: 4370-4376 (2008).
*
-
Uthurralt J, Gordish-Dressman H, Bradbury M, Tesi-Rocha C, Devaney J, Harmon B, Reeves EK, Brandoli C, Hansen BC, Seip RL, Thompson PD, Price TB, Angelopoulos TJ, Clarkson PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF, Gordon PM, Hoffman EP. PPAR alpha L162V underlies variation in serum triglycerides and subcutaneous fat volume in young males.
BMC Med. Genet. 8: 55 (2007).
*
-
Uto H, Nakanishi C, Ido A, Hasuike S, Kusumoto K, Abe H, Numata M, Nagata K, Hayashi K, Tsubouchi H. The peroxisome proliferator-activated receptor-gamma agonist, pioglitazone, inhibits fat accumulation and fibrosis in the livers of rats fed a choline-deficient, L-amino acid-defined diet.
Hepatol. Res. 32: 235-242 (2005).
-
Vaag A, Lund SS. Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention?
Appl. Physiol. Nutr. Metab. 32: 912-920 (2007).
-
Vaccaro O, Lapice E, Monticelli A, Giacchetti M, Castaldo I, Galasso R, Pinelli M, Donnarumma G, Rivellese AA, Cocozza S, Riccardi G. Pro12Ala polymorphism of the PPARgamma2 locus modulates the relationship between energy intake and body weight in type 2 diabetic patients.
Diabetes Care 30: 1156-1161 (2007).
*
-
Vagner M, Robin JH, Zambonino-Infante JL, Tocher DR, Person-Le Ruyet J. Ontogenic effects of early feeding of sea bass (Dicentrarchus labrax) larvae with a range of dietary n-3 highly unsaturated fatty acid levels on the functioning of polyunsaturated fatty acid desaturation pathways.
Br. J. Nutr. 101: 1452-1462 (2009).
*
-
Valasek MA, Clarke SL, Repa JJ. Fenofibrate reduces intestinal cholesterol absorption via PPARalpha -dependent modulation of NPC1L1 expression in mouse.
J. Lipid Res. 48: 2725-2735 (2007).
*
-
Valles SL, Dolz-Gaiton P, Gambini J, Pallardo FV, Vina J. Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPARgamma expression in cultured astrocytes.
Brain Res. Nov 27 [Epub ahead of print] (2009).
-
van Beekum O, Brenkman AB, Grontved L, Hamers N, van den Broek NJ, Berger R, Mandrup S, Kalkhoven E. The adipogenic acetyltransferase Tip60 targets activation function 1 of peroxisome proliferator-activated receptor gamma.
Endocrinology 149: 1840-1849 (2008).
*
-
van Bilsen M, van der Vusse GJ, Gilde AJ, Lindhout M, van der Lee KA. Peroxisome proliferator-activated receptors: lipid binding proteins controlling gene expression.
Mol. Cell. Biochem. 239: 131-138 (2002).
*
-
Van Cleemput M, Heyerick A, Libert C, Swerts K, Philippe J, De Keukeleire D, Haegeman G, De Bosscher K. Hop bitter acids efficiently block inflammation independent of GRalpha, PPARalpha, or PPARgamma.
Mol. Nutr. Food Res. 53: 1143-1155 (2009).
*
-
van den Bosch HM, Bunger M, de Groot PJ, van der Meijde J, Hooiveld GJ, Muller M. Gene expression of transporters and phase I/II metabolic enzymes in murine small intestine during fasting.
BMC Genomics 8: 267 (2007).
*
-
van der Hoorn JW, Jukema JW, Havekes LM, Lundholm E, Camejo G, Rensen PC, Princen HM. The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
Br. J. Pharmacol. 156: 1067-1075 (2009).
-
van der Leij FR, Bloks VW, Grefhorst A, Hoekstra J, Gerding A, Kooi K, Gerbens F, Te Meerman G, Kuipers F. Gene expression profiling in livers of mice after acute inhibition of beta-oxidation.
Genomics 90: 680-689 (2007).
*
-
van der Meer DL, Degenhardt T, Vaisanen S, de Groot PJ, Heinaniemi M, de Vries SC, Muller M, Carlberg C, Kersten S. Profiling of promoter occupancy by PPARalpha in human hepatoma cells via ChIP-chip analysis.
Nucleic Acids Res. Jan 27 [Epub ahead of print] (2010).
*
-
van der Veen JN, Kruit JK, Havinga R, Baller JF, Chimini G, Lestavel S, Staels B, Groot PH, Groen AK, Kuipers F. Reduced cholesterol absorption upon PPARdelta activation coincides with decreased intestinal expression of NPC1L1.
J. Lipid Res. 46: 526-534 (2005).
*
-
van Doorn M, Vogels J, Tas A, van Hoogdalem EJ, Burggraaf J, Cohen A, van der Greef J. Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in type 2 diabetes mellitus patients and healthy volunteers.
Br. J. Clin. Pharmacol. 63: 562-574 (2007).
*
-
Van Gilst MR, Hadjivassiliou H, Jolly A, Yamamoto KR. Nuclear hormone receptor NHR-49 controls fat consumption and fatty acid composition in C. elegans.
PLoS Biol. 3: e53 (2005).
*
-
Van Ginderachter JA, Meerschaut S, Liu Y, Brys L, De Groeve K, Hassanzadeh Ghassabeh G, Raes G, De Baetselier P. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer.
Blood 108: 525-535 (2006).
*
-
Van Ginderachter JA, Movahedi K, Van den Bossche J, De Baetselier P. Macrophages, PPARs, and cancer.
PPAR Res. 2008: 169414 (2008).
*
-
van Neerven S, Kampmann E, Mey J. RAR/RXR and PPAR/RXR signaling in neurological and psychiatric diseases.
Prog. Neurobiol. 85: 433-451 (2008).
-
van Neerven S, Mey J. RAR/RXR and PPAR/RXR signaling in spinal cord injury.
PPAR Res. 2007: 29275 (2007).
*
-
van Raalte DH, Li M, Pritchard PH, Wasan KM. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future.
Pharm. Res. 21: 1531-1538 (2004).
-
van Westerloo DJ, Florquin S, de Boer AM, Daalhuisen J, de Vos AF, Bruno MJ, van der Poll T. Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice.
Am. J. Pathol. 166: 721-728 (2005).
*
-
Vanamala J, Glagolenko A, Yang P, Carroll RJ, Murphy ME, Newman RA, Ford JR, Braby LA, Chapkin RS, Turner ND, Lupton JR. Dietary fish oil and pectin enhance colonocyte apoptosis in part through suppression of PPARdelta/PGE2 and elevation of PGE3.
Carcinogenesis 29: 790-796 (2008).
*
-
Vanden Berghe W, Vermeulen L, Delerive P, De Bosscher K, Staels B, Haegeman G. A paradigm for gene regulation: inflammation, NF-kappaB and PPAR.
Adv. Exp. Med. Biol. 544: 181-196 (2003).
-
Vanden Heuvel JP. Peroxisome proliferator-activated receptors: a critical link among fatty acids, gene expression and carcinogenesis.
J. Nutr. 129: 575S-580S (1999).
*
-
Vanden Heuvel JP. Peroxisome proliferator-activated receptors (PPARS) and carcinogenesis.
Toxicol. Sci. 47: 1-8 (1999).
*
-
Vanden Heuvel JP. The PPAR resource page.
Biochim. Biophys. Acta 1771: 1108-1112 (2007).
*
-
Vanden Heuvel JP, Kreder D, Belda B, Hannon DB, Nugent CA, Burns KA, Taylor MJ. Comprehensive analysis of gene expression in rat and human hepatoma cells exposed to the peroxisome proliferator WY14,643.
Toxicol. Appl. Pharmacol. 188: 185-198 (2003).
*
-
Vanden Heuvel JP, Thompson JT, Frame SR, Gillies PJ. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse and rat PPARalpha, beta, gamma, LXRbeta and RXRalpha.
Toxicol. Sci. 92: 476-489 (2006).
*
-
Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, Abildgaard N, Knudsen LM, Nielsen JL, Gregersen H, Vogel U. The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT.
Bone Marrow Transplant. 43: 539-545 (2009).
-
Varga T, Nagy L. Nuclear receptors, transcription factors linking lipid metabolism and immunity: the case of peroxisome proliferator-activated receptor gamma.
Eur. J. Clin. Invest. 38: 695-707 (2008).
*
-
Varghese Z, Moorhead JF, Ruan XZ. The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy.
Kidney Int. 69: 1490-1491 (2006).
*
-
Varley CL, Southgate J. Effects of PPAR agonists on proliferation and differentiation in human urothelium.
Exp. Toxicol. Pathol. 60: 435-441 (2008).
-
Varnat F, Heggeler BB, Grisel P, Boucard N, Corthesy-Theulaz I, Wahli W, Desvergne B. PPARbeta/delta regulates Paneth cell differentiation via controlling the hedgehog signaling pathway.
Gastroenterology 131: 538-553 (2006).
*
-
Vassiliou EK, Gonzalez A, Garcia C, Tadros JH, Chakraborty G, Toney JH. Oleic acid and peanut oil high in oleic acid reverse the inhibitory effect of insulin production of the inflammatory cytokine TNF-alpha both in vitro and in vivo systems.
Lipids Health Dis. 8: 25 (2009).
*
-
Vatsyayan J, Lee SJ, Chang HY. Effects of xenobiotics and peroxisome proliferator-activated receptor-alpha on the human UDPglucose dehydrogenase gene expression.
J. Biochem. Mol. Toxicol. 19: 279-288 (2005).
*
-
Vazquez M, Roglans N, Cabrero A, Rodriguez C, Adzet T, Alegret M, Sanchez RM, Laguna JC. Bezafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue.
Mol. Cell Biochem. 216: 71-78 (2001).
*
-
Vazquez M, Silvestre JS, Prous JR. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
Methods Find. Exp. Clin. Pharmacol. 24: 515-523 (2002).
-
Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes.
Mol. Cell. Biol. 20: 1868-1876 (2000).
*
-
Vega VA, Anzulovich AC, Varas SM, Bonomi MR, Gimenez MS, Oliveros LB. Effect of nutritional vitamin A deficiency on lipid metabolism in the rat heart: its relation to PPAR gene expression.
Nutrition 25: 828-838 (2009).
*
-
Venalainen T, Molnar F, Oostenbrink C, Carlberg C, Perakyla M. Molecular mechanism of allosteric communication in the human PPARalpha-RXRalpha heterodimer.
Proteins Sep 17 [Epub ahead of print] (2009).
*
-
Venkata NG, Aung CS, Cabot PJ, Monteith GR, Roberts-Thomson SJ. PPARalpha and PPARbeta are differentially affected by ethanol and the ethanol metabolite acetaldehyde in the MCF-7 breast cancer cell line.
Toxicol. Sci. 102: 120-128 (2008).
*
-
Venkatachalam G, Kumar AP, Yue LS, Pervaiz S, Clement MV, Sakharkar MK. Computational identification and experimental validation of PPRE motifs in NHE1 and MnSOD genes of human.
BMC Genomics 10 Suppl. 3: S5 (2009).
*
-
Venkatraman MS, Chittiboyina A, Meingassner J, Ho CI, Varani J, Ellis CN, Avery MA, Pershadsingh HA, Kurtz TW, Benson SC. alpha-Lipoic acid-based PPARgamma agonists for treating inflammatory skin diseases.
Arch. Dermatol. Res. 296: 97-104 (2004).
*
-
Verdi H, Sare Koytak E, Onder O, Arslan Ergul A, Cinar K, Idilman R, Erden E, Mithat Bozdayi A, Yurdaydin C, Uzunalimoglu O, Bozkaya H. Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis.
J. Investig. Med. 53: 353-359 (2005).
-
Verges B. Clinical interest of PPARs ligands.
Diabetes Metab. 30: 7-12 (2004).
-
Verges B. Diabetic dyslipidaemia: insights for optimizing patient management.
Curr. Med. Res. Opin. 21 Suppl. 1: S29-S40 (2005).
-
Verier C, Meirhaeghe A, Bokor S, Breidenassel C, Manios Y, Molnar D, Artero EG, Nova E, De Henauw S, Moreno LA, Amouyel P, Labayen I, Bevilacqua N, Turck D, Beghin L, Dallongeville J, Gottrand F; on behalf of the HELENA study group. Breastfeeding modulates the influence of the peroxisome proliferator-activated receptor gamma (PPARG2) Pro12Ala polymorphism on adiposity in adolescents: the HELENA Cross-Sectional Study.
Diabetes Care Oct 21 [Epub ahead of print] (2009).
-
Verma S, Szmitko PE. The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis.
Can. J. Cardiol. 22 Suppl. B:12B-17B (2006).
-
Vernochet C, Davis KE, Scherer PE, Farmer SR. Mechanisms regulating repression of haptoglobin production by peroxisome proliferator-activated receptor-gamma ligands in adipocytes.
Endocrinology Dec 1 [Epub ahead of print] (2009).
*
-
Verreault M, Kaeding J, Caron P, Trottier J, Grosse L, Houssin E, Paquet S, Perreault M, Barbier O. Regulation of endobiotics glucuronidation by ligand-activated transcription factors: physiological function and therapeutic potential.
Drug Metab. Rev. Oct 15 [Epub ahead of print] (2009).
*
-
Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabiles N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P. Weight loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
Circulation 110: 3259-3269 (2004).
*
-
Vidal H. PPAR receptors: recent data.
Ann. Endocrinol. (Paris) 66: 5-9 (2005).
-
Viita H, Kinnunen K, Eriksson E, Lahteenvuo J, Babu M, Kalesnykas G, Heikura T, Laidinen S, Takalo T, Yla-Herttuala S. Intravitreal adenoviral 15-lipoxygenase-1 gene transfer prevents vascular endothelial growth factor A induced neovascularization in rabbit eyes.
Hum. Gene Ther. 20: 1679-1686 (2009).
-
Vijay SK, Mishra M, Kumar H, Tripathi K. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes.
Acta Diabetol. 46: 27-33 (2009).
-
Viles-Gonzalez JF, Choi BG, Fuster V, Badimon JJ. Peroxisome proliferator-activated receptor ligands in atherosclerosis.
Expert Opin. Investig. Drugs 13: 1393-1403 (2004).
-
Villarroya F, Bocos C, Giralt M, Ramos MP, Herrera E, Sevillano J, Gual M, Rosell M, Iglesias R. Pharmacological and gene modification-based models for studying the impact of perinatal metabolic disturbances in adult life.
Adv. Exp. Med. Biol. 646: 141-148 (2009).
-
Vimaleswaran KS, Luan J, Andersen G, Muller YL, Wheeler E, Brito EC, O'Rahilly S, Pedersen O, Baier LJ, Knowler WC, Barroso I, Wareham NJ, Loos RJ, Franks PW. The Gly482Ser genotype at the PPARGC1A gene and elevated blood pressure: a meta-analysis of 13,949 individuals.
J. Appl. Physiol. 105: 1352-1358 (2008).
*
-
Vimaleswaran KS, Radha V, Anjana M, Deepa R, Ghosh S, Majumder PP, Rao MR, Mohan V. Effect of polymorphisms in the PPARGC1A gene on body fat in Asian Indians.
Int. J. Obes. (Lond.) 30: 884-891 (2006).
*
-
Vimaleswaran KS, Radha V, Deepa R, Mohan V. Absence of association of metabolic syndrome with PPARGC1A, PPARG and UCP1 gene polymorphisms in Asian Indians.
Metab. Syndr. Relat. Disord. 5: 153-162 (2007).
-
Vimaleswaran KS, Radha V, Jayapriya MG, Ghosh S, Majumder PP, Rao MR, Mohan V. Evidence for an association with type 2 diabetes mellitus at the PPARG locus in a South Indian population.
Metabolism Oct 19 [Epub ahead of print] (2009).
*
-
Vincent-Desplanques D, Faivre-Defrance F, Wemeau JL, Vantyghem MC. Monogenic severe insulin resistance syndromes.
Rev. Med. Interne. 26: 866-873 (2005).
-
Vlaeminck-Guillem V, Laudet V, Duterque-Coquillaud M. Negative cross-talk between nuclear receptors and transcription factors: implications in inflammation and oncogenesis.
Med. Sci. (Paris) 19: 1121-1127 (2003).
-
Vogel U, Segel S, Dethlefsen C, Tjonneland A, Saber AT, Wallin H, Jensen MK, Schmidt EB, Andersen PS, Overvad K. PPARgamma Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes.
BMC Med. Genet. 10: 52 (2009).
*
-
Vohl MC, Lepage P, Gaudet D, Brewer CG, Betard C, Perron P, Houde G, Cellier C, Faith JM, Despres JP, Morgan K, Hudson TJ. Molecular scanning of the human PPARa gene: association of the L162v mutation with hyperapobetalipoproteinemia.
J. Lipid Res. 41: 945-952 (2000).
*
-
Volakakis N, Joodmardi E, Perlmann T. NR4A orphan nuclear receptors influence retinoic acid and docosahexaenoic acid signaling via up-regulation of fatty acid binding protein 5.
Biochem. Biophys. Res. Commun. 390: 1186-1191 (2009).
*
-
Volcik KA, Nettleton JA, Ballantyne CM, Boerwinkle E. Peroxisome proliferator-activated receptor-alpha genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities Study.
Am. J. Clin. Nutr. 87: 1926-1931 (2008).
*
-
Voltan S, Martines D, Elli M, Brun P, Longo S, Porzionato A, Macchi V, D'Inca R, Scarpa M, Palu G, Sturniolo GC, Morelli L, Castagliuolo I. Lactobacillus crispatus M247-derived H2O2 acts as a signal transducing molecule activating peroxisome proliferator activated receptor-gamma in the intestinal mucosa.
Gastroenterology 135: 1216-1227 (2008).
*
-
von Knethen A, Soller M, Brune B. Peroxisome proliferator-activated receptor gamma (PPARgamma) and sepsis.
Arch. Immunol. Ther. Exp. (Warsz.) 55: 19-25 (2007).
-
von Knethen A, Tzieply N, Jennewein C, Brune B. Casein-kinase-II-dependent phosphorylation of PPARgamma provokes CRM1-mediated shuttling of PPARgamma from the nucleus to the cytosol.
J. Cell Sci. Dec 21 [Epub ahead of print] (2009).
*
-
Vondrichova T, de Capretz A, Parikh H, Frenander C, Asman P, Aberg M, Groop L, Hallengren B, Lantz M. COX-2 and SCD, markers of inflammation and adipogenesis, are related to disease activity in Graves' ophthalmopathy.
Thyroid 17: 511-517 (2007).
-
Vosper H, Khoudoli GA, Graham TL, Palmer CN. Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis.
Pharmacol. Ther. 95: 47-62 (2002).
*
-
Voss KA, Liu J, Anderson SP, Dunn C, Miller JD, Owen JR, Riley RT, Bacon CW, Corton JC. Toxic effects of fumonisin in mouse liver are independent of the peroxisome proliferator-activated receptor alpha.
Toxicol. Sci. 89: 108-119 (2006).
*
-
Vrablik M, Dobiasova M, Stulc T, Kasalova Z, Dolezalova R, Prazny M, Fait T, Ceska R. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.
Neuro. Endocrinol. Lett. 29: 146-150 (2008).
-
Wachtershauser A, Loitsch SM, Stein J. PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate.
Biochem. Biophys. Res. Commun. 272: 380-385 (2000).
*
-
Wada K, Kamisaki Y. Anti-inflammatory effect of PPARgamma agonists: basics and clinical applications.
Nippon Rinsho 68: 278-283 (2010).
-
Wada K, Nakajima A, Blumberg RS. PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease.
Trends Mol. Med. 7: 329-331 (2001).
*
-
Wada S, Yamazaki T, Kawano Y, Miura S, Ezaki O. Fish oil fed prior to ethanol administration prevents acute ethanol-induced fatty liver in mice.
J. Hepatol. 49: 441-450 (2008).
-
Wagner ER, He BC, Chen L, Zuo GW, Zhang W, Shi Q, Luo Q, Luo X, Liu B, Luo J, Rastegar F, He CJ, Hu Y, Boody B, Luu HH, He TC, Deng ZL, Haydon RC. Therapeutic implications of PPARgamma in human osteosarcoma.
PPAR Res. 2010: 956427 (2010).
-
Wagner JA, Wright EC, Ennis MM, Prince M, Kochan J, Nunez DJ, Schneider B, Wang MD, Chen Y, Ghosh S, Musser BJ, Vassileva MT. Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors.
Clin. Pharmacol. Ther. 86: 619-625 (2009).
*
-
Wagner KD, Wagner N. Peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) acts as regulator of metabolism linked to multiple cellular functions.
Pharmacol. Ther. Dec 18 [Epub ahead of print] (2009).
-
Wagner N, Jehl-Pietri C, Lopez P, Murdaca J, Giordano C, Schwartz C, Gounon P, Hatem SN, Grimaldi P, Wagner KD. PPARbeta stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin.
Cardiovasc. Res. 83: 61-71 (2009).
-
Wahli W. Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing.
Swiss. Med. Wkly. 132: 83-91 (2002).
*
-
Wahli W. A gut feeling of the PXR, PPAR and NF-kappaB connection.
J. Intern. Med. 263: 613-619 (2008).
*
-
Wakabayashi KI, Okamura M, Tsutsumi S, Nishikawa N, Tanaka T, Sakakibara I, Kitakami JI, Ihara S, Hashimoto Y, Hamakubo T, Kodama T, Aburatani H, Sakai J. The peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha heterodimer targets gene of histone modification enzyme PR-Set7/Setd8 and regulates adipogenesis through a positive feedback loop.
Mol. Cell. Biol. 29: 3544-3555 (2009).
*
-
Wake DJ, Stimson RH, Tan GD, Homer NZ, Andrew R, Karpe F, Walker BR. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
J. Clin. Endocrinol. Metab. 92: 1848-1856 (2007).
*
-
Waku T, Shiraki T, Oyama T, Fujimoto Y, Maebara K, Kamiya N, Jingami H, Morikawa K. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
J. Mol. Biol. 385: 188-199 (2009).
*
-
Walcher D, Hess K, Heinz P, Petscher K, Vasic D, Kintscher U, Clemenz M, Hartge M, Raps K, Hombach V, Marx N. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.
Hypertension 51: 259-266 (2008).
-
Walczak R, Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism.
J. Lipid Res. 43: 177-186 (2002).
*
-
Walker CG, Sugden MC, Gibbons GF, Holness MJ. Peroxisome proliferator-activated receptor alpha deficiency modifies glucose handling by isolated mouse adipocytes.
J. Endocrinol. 193: 39-43 (2007).
*
-
Walker GE, Marzullo P, Verti B, Guzzaloni G, Maestrini S, Zurleni F, Liuzzi A, Di Blasio AM. Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects.
Obesity (Silver Spring) 16: 1983-1991 (2008).
*
-
Walker GE, Marzullo P, Verti B, Guzzaloni G, Maestrini S, Zurleni F, Liuzzi A, Di Blasio AM. Subcutaneous abdominal adipose tissue subcompartments: potential role in rosiglitazone effects.
Obesity (Silver Spring) 16: 1983-1991 (2008).
-
Walkey CJ, Spiegelman BM. A functional peroxisome proliferator-activated receptor-gamma ligand binding domain is not required for adipogenesis.
J. Biol. Chem. 283: 24290-24294 (2008).
*
-
Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice.
Nat. Med. 13: 1496-1503 (2007).
*
-
Wan Y, Evans RM. Rosiglitazone activation of PPARgamma suppresses fractalkine signaling.
J. Mol. Endocrinol. Oct 22 [Epub ahead of print] (2009).
-
Wan Y, Saghatelian A, Chong LW, Zhang CL, Cravatt BF, Evans RM. Maternal PPAR-gamma protects nursing neonates by suppressing the production of inflammatory milk.
Genes Dev. 21: 1895-1890 (2007).
*
-
Wan YJ, Badr MZ. Inhibition of carrageenan-induced cutaneous inflammation by PPAR agonists is dependent on hepatocyte-specific retinoid X receptor alpha.
PPAR Res. 2006: 96341 (2006).
*
-
Wan YJ, Cai Y, Lungo W, Fu P, Locker J, French S, Sucov HM. Peroxisome proliferator-activated receptor alpha-mediated pathways are altered in hepatocyte-specific retinoid X receptor alpha-deficient mice.
J. Biol. Chem. 275: 28285-28290 (2000).
*
-
Wan YJ, Morimoto M, Thurman RG, Bojes HK, French SW. Expression of the peroxisome proliferator-activated receptor gene is decreased in experimental alcoholic liver disease.
Life Sci. 56: 307-317 (1995).
-
Wan YY, Cai Y, Li J, Yuan Q, French B, Gonzalez FJ, French S. Regulation of peroxisome proliferator activated receptor alpha-mediated pathways in alcohol fed cytochrome P450 2E1 deficient mice.
Hepatol. Res. 19: 117-130 (2001).
-
Wang AG, Kim SU, Lee SH, Kim SK, Seo SB, Yu DY, Lee DS. Histone deacetylase 1 contributes to cell cycle and apoptosis.
Biol. Pharm. Bull. 28: 1966-1970 (2005).
*
-
Wang CP, Hung WC, Yu TH, Chiu CA, Lu LF, Chung FM, Hung CH, Shin SJ, Chen HJ, Lee YJ. Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history.
Exp. Clin. Endocrinol. Diabetes Feb 5 [Epub ahead of print] (2010).
-
Wang D, Dubois RN. Inflammatory mediators and nuclear receptor signaling in colorectal cancer.
Cell Cycle 6: 682-685 (2007).
*
-
Wang D, Dubois RN. Peroxisome proliferator-activated receptors and progression of colorectal cancer.
PPAR Res. 2008: 931074 (2008).
*
-
Wang D, Hirase T, Nitto T, Soma M, Node K. Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor gamma in endothelial cells.
J. Cardiol. 54: 368-374 (2009).
-
Wang D, Mann JR, Dubois RN. WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth.
Cell Cycle 3: 1512-1515 (2004).
*
-
Wang D, Wang H, Guo Y, Ning W, Katkuri S, Wahli W, Desvergne B, Dey SK, Dubois RN. Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression.
Proc. Natl. Acad. Sci. U.S.A. 103: 19069-19074 (2006).
*
-
Wang F, Gao L, Gong B, Hu J, Li M, Guan Q, Zhao J. Tissue-specific expression of PPAR mRNAs in diabetic rats and divergent effects of cilostazol.
Can. J. Physiol. Pharmacol. 86: 465-471 (2008).
*
-
Wang F, Liu H, Blanton WP, Belkina A, Lebrasseur NK, Denis GV. Brd2 disruption in mice causes severe obesity without type 2 diabetes.
Biochem. J. 425: 71-83 (2010).
*
-
Wang F, Tahara T, Arisawa T, Sakata M, Takahama K, Watanabe M, Hirata I, Nakano H. Polymorphism of peroxisome proliferator-activated receptor gamma is not associated to Japanese ulcerative colitis.
Hepatogastroenterology 55: 73-75 (2008).
-
Wang F, Tong Q. SIRT2 suppresses adipocyte differentiation by deacetylating FOXO1 and enhancing FOXO1's repressive interaction with PPARgamma.
Mol. Biol. Cell 20: 801-808 (2009).
*
-
Wang G, Zhang Z, Yu J, Zhang F, He L, Wei J, Mao J, Wang X. Antidiabetic rosiglitazone reduces soluble intercellular adhesion molecule-1 level in type 2 diabetic patients with coronary artery disease.
PPAR Res. 2008: 548178 (2008).
*
-
Wang H, Chu W, Hemphill C, Hasstedt SJ, Elbein SC. Mutation screening and association of human retinoid X receptor gamma variation with lipid levels in familial type 2 diabetes.
Mol. Genet. Metab. 76: 14-22 (2002).
*
-
Wang H, Knaub LA, Jensen DR, Jung DY, Hong EG, Ko HJ, Coates AM, Goldberg IJ, de la Houssaye BA, Janssen RC, McCurdy CE, Rahman SM, Choi CS, Choi CS, Shulman GI, Kim JK, Kim JK, Friedman JE, Eckel RH. Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues.
Diabetes 58: 116-124 (2009).
*
-
Wang H, Qiang L, Farmer SR. Identification of a domain within PPARgamma regulating expression of a group of genes containing FGF21 that are selectively repressed by SIRT1 in adipocytes.
Mol. Cell. Biol. 28: 188-200 (2008).
*
-
Wang H, Zhang Y, Yehuda-Shnaidman E, Medvedev AV, Kumar N, Daniel KW, Robidoux J, Czech MP, Mangelsdorf DJ, Collins S. Liver X receptor alpha is a transcriptional repressor of the uncoupling protein-1 gene and the brown fat phenotype.
Mol. Cell. Biol. 28: 2187-2200 (2008).
*
-
Wang HY, Cheng ML. Effects of Dan-shao-hua-xian on expression of PPAR-gamma and NF-kappa B in rat liver fibrosis.
Hepatobiliary Pancreat. Dis. Int. 7: 179-184 (2008).
*
-
Wang J, Lv X, Shi J, Hu X. Ceramide induces apoptosis via a peroxisome proliferator-activated receptor gamma-dependent pathway.
Apoptosis 11: 2043-2052 (2006).
*
-
Wang JC, Jiang P, Huang J, Qian GS. The protective effects and mechanisms of peroxisome proliferator-activated receptor-gamma agonist in rats with acute lung injury.
Zhonghua Jie He He Hu Xi Za Zhi 31: 425-430 (2008).
-
Wang JL, Yang Z, Wang R, Zhu JM. Interaction among abnormal fatty acid oxidation, endothelial function disorder, and oxidative stress in the onset of severe preeclampsia.
Zhonghua Yi Xue Za Zhi 88: 1471-1475 (2008).
-
Wang L, Huang J, Saha P, Kulkarni RN, Hu M, Kim YD, Park KG, Chan L, Rajan AS, Lee I, Moore DD. Orphan receptor small heterodimer partner is an important mediator of glucose homeostasis.
Mol. Endocrinol. 20: 2671-2681 (2006).
*
-
Wang L, Shao YY, Ballock RT. Peroxisome proliferator-activated receptor-gamma promotes adipogenic changes in growth plate chondrocytes in vitro.
PPAR Res. 2006: 67297 (2006).
*
-
Wang L, Zhang D, Swaminathan A, Xue Y, Cheng PT, Wu S, Mosqueda-Garcia R, Aurang C, Everett DW, Humphreys WG. Glucuronidation as a major metabolic clearance pathway of 14C-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection.
Drug Metab. Dispos. 34: 427-439 (2006).
*
-
Wang LH, Yang XY, Zhang X, Farrar WL. Nuclear receptors as negative modulators of STAT3 in multiple myeloma.
Cell Cycle 4: 242-245 (2005).
*
-
Wang LH, Yang XY, Zhang X, Farrar WL. Inhibition of adhesive interaction between multiple myeloma and bone marrow stromal cells by PPARgamma crosstalk with NF-kappaB and c/EBPbeta.
Blood 110: 4373-4384 (2007).
*
-
Wang M, Wang JJ, Li J, Park K, Qian X, Ma JX, Zhang SX. Pigment epithelium-derived factor (PEDF) suppresses adipogenesis via inhibition of the MAPK/ERK pathway in 3T3-L1 preadipocytes.
Am. J. Physiol. Endocrinol. Metab. 297: E1378-E1387 (2009).
*
-
Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, De Marzo AM, Isaacs WB, Drake CG, Shugart YY, Platz EA. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II.
Prostate 69: 874-885 (2009).
-
Wang MH, Zhong XY, Lin CL, Xie YK, Jia JP, Li SM, Mi C. Expression of peroxisome proliferator-activated receptor gamma in glioma.
Nan Fang Yi Ke Da Xue Xue Bao 28: 444-446 (2008).
-
Wang N. PPAR-delta in vascular pathophysiology.
PPAR Res. 2008: 164163 (2008).
*
-
Wang N, Symons JD, Zhang H, Jia Z, Gonzalez FJ, Yang T. Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone.
Toxicol. Pathol. 37: 21-27 (2009).
*
-
Wang P, Liu J, Li Y, Wu S, Luo J, Yang H, Subbiah R, Chatham J, Zhelyabovska O, Yang Q. Peroxisome proliferator-activated receptor delta is an essential transcriptional regulator for mitochondrial protection and biogenesis in adult heart.
Circ. Res. Jan 14 [Epub ahead of print] (2010).
-
Wang Q, Herrera-Ruiz D, Mathis AS, Cook TJ, Bhardwaj RK, Knipp GT. Expression of PPAR, RXR isoforms and fatty acid transporting proteins in the rat and human gastrointestinal tracts.
J. Pharm. Sci. 94: 363-372 (2005).
*
-
Wang T, Villegas S, Huang Y, White SK, Ahlem C, Lu M, Olefsky JM, Reading C, Frincke JM, Alleva D, Flores-Riveros J. Amelioration of glucose intolerance by the synthetic androstene HE3286: link to inflammatory pathways.
J. Pharmacol. Exp. Ther. Jan 12 [Epub ahead of print] (2010).
*
-
Wang T, Xu J, Yu X, Yang R, Han ZC. Peroxisome proliferator-activated receptor gamma in malignant diseases.
Crit. Rev. Oncol. Hematol. 58: 1-14 (2006).
-
Wang WM, Zhang HD, Jin YM, Zhu BB, Chen N. PPAR-gamma agonists inhibit TGF-beta1-induced chemokine expression in human tubular epithelial cells.
Acta Pharmacol. Sin. 30: 107-112 (2009).
-
Wang X, Huang G, Mei S, Qian J, Ji J, Zhang J. Over-expression of C/EBP-alpha induces apoptosis in cultured rat hepatic stellate cells depending on p53 and peroxisome proliferator-activated receptor-gamma.
Biochem. Biophys. Res. Commun. 380: 286-291 (2009).
*
-
Wang X, Wang Y, Zhao X, Andersson R, Song Z, Yang D. Potential effects of peroxisome proliferator-activated receptor activator on LPS-induced lung injury in rats.
Pulm. Pharmacol. Ther. 22: 318-325 (2009).
-
Wang XM, Chen DF. Effects of rosiglitazone on Kruppul-like factor 6(KLF6) signaling in the livers of rats with nonalcoholic fatty liver fibrosis.
Zhonghua Gan Zang Bing Za Zhi 15: 649-653 (2007).
-
Wang Y, Botolin D, Xu J, Christian B, Mitchell E, Jayaprakasam B, Nair M, Peters J, Busik J, Olson LK, Jump DB. Regulation of hepatic fatty acid elongase and desaturase expression in diabetes and obesity.
J. Lipid Res. 47: 2028-2041 (2006).
*
-
Wang Y, Feng W, Xue W, Tan Y, Hein DW, Li XK, Cai L. Inactivation of GSK-3beta by metallothionein prevents diabetes-related changes in cardiac energy metabolism, inflammation, nitrosative damage and remodeling.
Diabetes 58: 1391-1402 (2009).
*
-
Wang Y, Mu Y, Li H, Ding N, Wang Q, Wang Y, Wang S, Wang N. Peroxisome proliferator-activated receptor-gamma gene: a key regulator of adipocyte differentiation in chickens.
Poult. Sci. 87: 226-232 (2008).
-
Wang Y, Santos J, Sakurai R, Shin E, Cerny L, Torday JS, Rehan VK. Peroxisome proliferator-activated receptor gamma agonists enhance lung maturation in a neonatal rat model.
Pediatr. Res. 65: 150-155 (2009).
-
Wang Y, Torres-Gonzalez M, Tripathy S, Botolin D, Christian B, Jump DB. Elevated hepatic fatty acid elongase-5 activity affects multiple pathways controlling hepatic lipid and carbohydrate composition.
J. Lipid Res. 49: 1538-1552 (2008).
*
-
Wang Y, Wang Y, Wang DW. Bezafibrate up-regulate endothelial nitric oxide gene expressions via peroxisome proliferator-activated receptors alpha-dependent and independent pathways in cultured Bovine endothelial cells.
Zhonghua Xin Xue Guan Bing Za Zhi 34: 530-536 (2006).
-
Wang ZJ, Liu Q, Li PP, Zou CH, Shen ZF. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice.
Eur. J. Pharmacol. 580: 277-283 (2008).
*
-
Ward JE, Fernandes DJ, Taylor CC, Bonacci JV, Quan L, Stewart AG. The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation.
Pulm. Pharmacol. Ther. 19: 39-46 (2006).
-
Wargent EE, Sennitt MV, Stocker C, Mayes AE, Brown L, O'Dowd J, Wang SJ, Einerhand AW, Mohede I, Arch JR, Cawthorne MA. Prolonged treatment of genetically obese mice with conjugated linoleic acid improves glucose tolerance and lowers plasma insulin concentration: possible involvement of PPAR activation.
Lipids Health Dis. 4: 3 (2005).
*
-
Waring JF, Yang Y, Healan-Greenberg CH, Adler AL, Dickinson R, McNally T, Wang X, Weitzberg M, Xu X, Lisowski AR, Warder SE, Gu YG, Zinker BA, Blomme EA, Camp HS. Gene expression analysis in rats treated with experimental acetyl-CoA carboxylase inhibitors suggests interactions with the PPAR alpha pathway.
J. Pharmacol. Exp. Ther. 324: 507-516 (2008).
*
-
Waters SM, Kelly JP, O'Boyle P, Moloney AP, Kenny DA. Effect of level and duration of dietary n-3 polyunsaturated fatty acid supplementation on the transcriptional regulation of delta-9 desaturase in muscle of beef cattle.
J. Anim. Sci. 87: 244-252 (2009).
*
-
Watt MJ, Southgate RJ, Holmes AG, Febbraio MA. Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes.
J. Mol. Endocrinol. 33: 533-544 (2004).
*
-
Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR.
Arch. Biochem. Biophys. 369: 11-23 (1999).
*
-
Waxman DJ. Role of metabolism in the activation of dehydroepiandrosterone as a peroxisome proliferator.
J. Endocrinol. 150: S129-S147 (1996).
-
Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, Ramachandran RK, Willson TM, Kliewer SA. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues.
Endocrinology 142: 1269-1277 (2001).
*
-
Wei N, Mi MT, Wang B, Zhu JD, Zhu DP, Yuan JL. Effects of different dietary fatty acid on expression of nuclear receptor genes in breast cancer of rats.
Zhonghua Yu Fang Yi Xue Za Zhi 41: 271-276 (2007).
-
Wei Q, Jacobs DR Jr, Schreiner PJ, Siscovick DS, Steffes MW, Fornage M. Patterns of association between PPARgamma genetic variation and indices of adiposity and insulin action in African-Americans and whites: the CARDIA study.
J. Mol. Med. 84: 955-965 (2006).
*
-
Wei-Guo Z, Hui Y, Shan L, Yun Z, Wen-Cheng N, Fu-Lin Y, Fang-Yan F, Jun-Hua G, Jian-Hua Z. PPAR-gamma agonist inhibits Ang II-induced activation of dendritic cells via the MAPK and NF-kappaB pathways.
Immunol. Cell Biol. Dec 8 [Epub ahead of print] (2009).
*
-
Weinberger B, Quizon C, Vetrano AM, Archer F, Laskin JD, Laskin DL. Mechanisms mediating reduced responsiveness of neonatal neutrophils to lipoxin A4.
Pediatr. Res. 64: 393-398 (2008).
*
-
Weindl G, Schafer-Korting M, Schaller M, Korting HC. Peroxisome proliferator-activated receptors and their ligands: entry into the post-glucocorticoid era of skin treatment?
Drugs 65: 1919-1934 (2005).
-
Weiss EP, Kulaputana O, Ghiu IA, Brandauer J, Wohn CR, Phares DA, Shuldiner AR, Hagberg JM. Endurance training-induced changes in the insulin response to oral glucose are associated with the peroxisome proliferator-activated receptor-I(3)2 Pro12Ala genotype in men but not in women.
Metabolism 54: 97-102 (2005).
*
-
Wende AR, Schaeffer PJ, Parker GJ, Zechner C, Han DH, Chen MM, Hancock CR, Lehman JJ, Huss JM, McClain DA, Holloszy JO, Kelly DP. A role for the transcriptional coactivator PGC-1alpha in muscle refueling.
J. Biol. Chem. 282: 36642-36651 (2007).
*
-
Wendel AA, Purushotham A, Liu LF, Belury MA. Conjugated linoleic acid induces uncoupling protein 1 in white adipose tissue of ob/ob mice.
Lipids Sep 25 [Epub ahead of print] (2009).
-
Wenz T, Diaz F, Spiegelman BM, Moraes CT. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype.
Cell. Metab. 8: 249-256 (2008).
*
-
West NA, Haan MN, Morgenstern H. The PPAR-gamma Pro12Ala polymorphism and risk of cognitive impairment in a longitudinal study.
Neurobiol. Aging Jul 16 [Epub ahead of print] (2008).
-
Westin S, Kurokawa R, Nolte RT, Wisely GB, McInerney EM, Rose DW, Milburn MV, Rosenfeld MG, Glass CK. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators.
Nature 395: 199-202 (1998).
*
-
Weston A, Caminada D, Galicia H, Fent K. Effects of lipid-lowering pharmaceuticals bezafibrate and clofibric acid on lipid metabolism in fathead minnow (Pimephales promelas).
Environ. Toxicol. Chem. 28: 2648-2655 (2009).
-
White DB, Batayneh Z, Bachmann KA. A synergism model for PPARalpha and PXR agonist effects on HDL-cholesterol and apoA1.
Front. Biosci. (Elite Ed.) 2: 399-410 (2010).
-
Wiechers JW, Rawlings AV, Garcia C, Chesne C, Balaguer P, Nicolas JC, Corre S, Galibert MD. A new mechanism of action for skin whitening agents: binding to the peroxisome proliferator-activated receptor.
Int. J. Cosmet. Sci. 27: 123-132 (2005).
-
Wieczorek S, Knaup S, Gross WL, Epplen JT. Genetic variability of RXRB, PPARA, and PPARG in Wegener's granulomatosis.
PPAR Res. 2009: 786781 (2009).
*
-
Wiedemann A, Vocke F, Fitzgerald J, Markert U, Jeschke U, Lohse P, Toth B. Leptin gene (TTTC) microsatellite polymorphism as well as leptin receptor R223Q and PPARgamma2 P12A substitutions are not associated with hypertensive disorders in pregnancy.
Am. J. Reprod. Immunol. Jan 12 [Epub ahead of print] (2010).
-
Wierzbicki M, Chabowski A, Zendzian-Piotrowska M, Gorski J. Differential effects of in vivo PPAR alpha and gamma activation on fatty acid transport proteins expression and lipid content in rat liver.
J. Physiol. Pharmacol. 60: 99-106 (2009).
*
-
Wieser F, Waite L, Depoix C, Taylor RN. PPAR action in human placental development and pregnancy and its complications.
PPAR Res. 2008: 527048 (2008).
*
-
Wild GE, Drozdowski L, Tartaglia C, Clandinin MT, Thomson AB. Nutritional modulation of the inflammatory response in inflammatory bowel disease - from the molecular to the integrative to the clinical.
World J. Gastroenterol. 13: 1-7 (2007).
*
-
Wilding JP. The importance of free fatty acids in the development of type 2 diabetes.
Diabet. Med. 24: 934-945 (2007).
*
-
Wilding JP, Gause-Nilsson I, Persson A; On Behalf Of The Gallant 7 Study Group. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.
Diab. Vasc. Dis. Res. 4: 194-203 (2007).
-
Williams P, Marten N, Wilson V, Litten J, Corson A, Clarke L, Symonds M, Mostyn A. Influence of birth weight on gene regulators of lipid metabolism and utilisation in subcutaneous adipose tissue and skeletal muscle of neonatal pigs.
Reproduction 138: 609-617 (2009).
-
Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease.
Annu. Rev. Biochem. 70: 341-367 (2001).
*
-
Willson TM, Lehmann JM, Kliewer SA. Discovery of ligands for the nuclear peroxisome proliferator-activated receptors.
Ann. N. Y. Acad. Sci. 804: 276-283 (1996).
*
-
Winczyk K. The role of peroxisome proliferators-activated receptors (PPARgamma) in neoplasms of endocrine glands.
Endokrynol. Pol. 59: 156-167 (2008).
-
Winczyk K, Pawlikowski M. Immunohistochemical detection of PPARgamma receptors in the human pituitary adenomas: correlation with PCNA.
Folia Histochem. Cytobiol. 43: 137-141 (2005).
-
Winn RA, Van Scoyk M, Hammond M, Rodriguez K, Crossno JT Jr, Heasley LE, Nemenoff RA. Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma.
J. Biol. Chem. 281: 26943-26950 (2006).
*
-
Winzell MS, Wulff EM, Olsen GS, Sauerberg P, Gotfredsen CF, Ahren B. Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/db mice.
Eur. J. Pharmacol. 626: 297-305 (2010).
-
Wirtenberger M, Tchatchou S, Hemminki K, Schmutzhard J, Sutter C, Schmutzler RK, Meindl A, Wappenschmidt B, Kiechle M, Arnold N, Weber BH, Niederacher D, Bartram CR, Burwinkel B. Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer.
Carcinogenesis 27: 2201-2208 (2006).
*
-
Wohlfahrt G, Sipila J, Pietila LO. Field-based comparison of ligand and co-activator binding sites of nuclear receptors.
Biopolymers 91: 884-894 (2009).
-
Wohlfert EA, Nichols FC, Nevius E, Clark RB. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms.
J. Immunol. 178: 4129-4135 (2007).
*
-
Wolf CJ, Takacs ML, Schmid JE, Lau C, Abbott BD. Activation of mouse and human peroxisome proliferator-activated receptor alpha (PPARalpha) by perfluoroalkyl acids (PFAAs) of different functional groups and chain lengths.
Toxicol. Sci. 106: 162-171 (2008).
*
-
Wolf DC, Moore T, Abbott BD, Rosen MB, Das KP, Zehr RD, Lindstrom AB, Strynar MJ, Lau C. Comparative hepatic effects of perfluorooctanoic acid and WY 14,643 in PPAR-alpha knockout and wild-type mice.
Toxicol. Pathol. 36: 632-639 (2008).
*
-
Wolf G. Retinoic acid activation of peroxisome proliferation-activated receptor delta represses obesity and insulin resistance.
Nutr. Rev. 68: 67-70 (2010).
*
-
Wolf G. Retinoic acid as cause of cell proliferation or cell growth inhibition depending on activation of one of two different nuclear receptors.
Nutr. Rev. 66: 55-59 (2008).
*
-
Wolfrum C, Borrmann CM, Borchers T, Spener F. Fatty acids and hypolipidemic drugs regulate peroxisome proliferator-activated receptors alpha- and gamma-mediated gene expression via liver fatty acid binding protein: a signaling path to the nucleus.
Proc. Natl. Acad. Sci. U.S.A. 98: 2323-2328 (2001).
*
-
Wolfrum C, Stoffel M. Coactivation of Foxa2 through Pgc-1beta promotes liver fatty acid oxidation and triglyceride/VLDL secretion.
Cell. Metab. 3: 99-110 (2006).
*
-
Won HY, Min HJ, Ahn JH, Yoo SE, Bae MA, Hong JH, Hwang ES. Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation.
Biochem. Pharmacol. Nov 4 [Epub ahead of print] (2009).
*
-
Wong GW, Krawczyk SA, Kitidis-Mitrokostas C, Revett T, Gimeno R, Lodish HF. Molecular, biochemical and functional characterizations of C1q/TNF family members: adipose tissue-selective expression patterns, regulation by PPAR-gamma agonist, Cys-mediated oligomerizations, combinatorial associations and metabolic functions.
Biochem. J. 416: 161-177 (2008).
*
-
Wong J, Quinn CM, Gelissen IC, Jessup W, Brown AJ. The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation.
Atherosclerosis 196: 180-189 (2008).
-
Wood RJ. Vitamin D and adipogenesis: new molecular insights.
Nutr. Rev. 66: 40-46 (2008).
*
-
Woods CG, Burns AM, Bradford BU, Ross PK, Kosyk O, Swenberg JA, Cunningham ML, Rusyn I. WY-14,643-induced cell proliferation and oxidative stress in mouse liver are independent of NADPH oxidase.
Toxicol. Sci. 98: 366-374 (2007).
*
-
Woods CG, Heuvel JP, Rusyn I. Genomic profiling in nuclear receptor-mediated toxicity.
Toxicol. Pathol. 35: 474-494 (2007).
*
-
Wray JA, Bishop-Bailey D. Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology.
Exp. Physiol. 93: 148-154 (2008).
*
-
Wray JA, Sugden MC, Zeldin DC, Greenwood GK, Samsuddin S, Miller-Degraff L, Bradbury JA, Holness MJ, Warner TD, Bishop-Bailey D. The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo.
PLoS One 4: e7421 (2009).
*
-
Wright JJ, Kim J, Buchanan J, Boudina S, Sena S, Bakirtzi K, Ilkun O, Theobald HA, Cooksey RC, Kandror KV, Abel ED. Mechanisms for increased myocardial fatty acid utilization following short-term high fat feeding.
Cardiovasc. Res. 82: 351-360 (2009).
-
Wright MM, Schopfer FJ, Baker PR, Vidyasagar V, Powell P, Chumley P, Iles KE, Freeman BA, Agarwal A. Fatty acid transduction of nitric oxide signaling: nitrolinoleic acid potently activates endothelial heme oxygenase 1 expression.
Proc. Natl. Acad. Sci. U.S.A. 103: 4299-4304 (2006).
*
-
Wu CW, Yu J, Sung JJ. Peroxisome proliferator-activated receptor delta and gastric cancer (review).
Oncol. Rep. 22: 451-457 (2009).
-
Wu D, Ren Z, Pae M, Guo W, Cui X, Merrill AH, Meydani SN. Aging up-regulates expression of inflammatory mediators in mouse adipose tissue.
J. Immunol. 179: 4829-4839 (2007).
*
-
Wu J, Chen L, Zhang D, Huo M, Zhang X, Pu D, Guan Y. Peroxisome proliferator-activated receptors and renal diseases.
Front. Biosci. 14: 995-1009 (2009).
-
Wu J, Zhang Y, Wang N, Davis L, Yang G, Wang X, Zhu Y, Breyer MD, Guan Y. Liver X receptor alpha (LXRalpha) mediates cholesterol efflux in glomerular mesangial cells.
Am. J. Physiol. Renal Physiol. 287: F886-F895 (2004).
*
-
Wu JS, Cheung WM, Tsai YS, Chen YT, Fong WH, Tsai HD, Chen YC, Liou JY, Shyue SK, Chen JJ, Chen YE, Maeda N, Wu KK, Lin TN. Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3varepsilon upregulation.
Circulation 119: 1124-1134 (2009).
*
-
Wu JS, Lin TN, Wu KK. Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins.
J. Cell. Physiol. 220: 58-71 (2009).
*
-
Wu KK, Liou JY. Cyclooxygenase inhibitors induce colon cancer cell apoptosis via PPARdelta --> 14-3-3epsilon pathway.
Methods Mol. Biol. 512: 295-307 (2009).
-
Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes.
Nephrol. Dial. Transplant. 24: 3360-3366 (2009).
-
Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.
Am. J. Pathol. 174: 519-533 (2009).
*
-
Wu SJ, Ng LT, Wang GH, Huang YJ, Chen JL, Sun FM. Chlorophyll a, an active anti-proliferative compound of Ludwigia octovalvis, activates the CD95 (APO-1/CD95) system and AMPK pathway in 3T3-L1 cells.
Food Chem. Toxicol. Dec 3 [Epub ahead of print] (2009).
*
-
Wu W, Celestino J, Milam MR, Schmeler KM, Broaddus RR, Ellenson LH, Lu KH. Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model.
Int. J. Gynecol. Cancer 18: 329-338 (2008).
-
Wu WS, Liu GN, Huo HY, Wang FR, Zheng X, Mao D. Upregulated PGC-NRF-mtTFA expressions contributed to the development of atherosclerosis in rabbits fed with a high fat diet.
Zhonghua Xin Xue Guan Bing Za Zhi 36: 646-650 (2008).
-
Wu Y, Guo SW. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells.
Fertil. Steril. 91: S2142-S2147 (2009).
-
Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE. Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells.
Am. J. Physiol. Renal Physiol. 293: F1592-F1604 (2007).
*
-
Wunderlich FT, Luedde T, Singer S, Schmidt-Supprian M, Baumgartl J, Schirmacher P, Pasparakis M, Bruning JC. Hepatic NF-kappaB essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis.
Proc. Natl. Acad. Sci. U.S.A. 105: 1297-1302 (2008).
*
-
Xia M, Hou M, Xia X, Zhu H, Tang Z, Wang Q, Li Y, Chi D, Yu X, Zhao T, Han P, Ma J, Ling W. Anthocyanins induce cholesterol efflux from mouse peritoneal macrophages: the role of the PPARgamma-LXRalpha-ABCA1 pathway.
J. Biol. Chem. 280: 36792-36801 (2005).
*
-
Xiao J, Leung JC, Chan LY, Guo H, Lai KN. Protective effect of peroxisome proliferator-activated receptor-gamma agonists on activated renal proximal tubular epithelial cells in IgA nephropathy.
Nephrol. Dial. Transplant. 24: 2067-2077 (2009).
-
Xiao J, Leung JC, Chan LY, Tang SC, Lai KN. Crosstalk between peroxisome proliferator-activated receptor-gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy.
Clin. Immunol. 132: 266-276 (2009).
*
-
Xiao S, Anderson SP, Swanson C, Bahnemann R, Voss KA, Stauber AJ, Corton JC. Activation of peroxisome proliferator-activated receptor alpha (PPARalpha) enhances apoptosis in the mouse liver.
Toxicol. Sci. 92: 368-377 (2006).
*
-
Xiao X, Su G, Brown SN, Chen L, Ren J, Zhao P. Peroxisome proliferator-activated receptors gamma and alpha agonists stimulate cardiac glucose uptake via activation of AMP-activated protein kinase.
J. Nutr. Biochem. Jun 29 [Epub ahead of print] (2009).
*
-
Xiao Y, Xu J, Wang S, Mao C, Jin M, Ning G, Xu J, Zhang Y. Genetic ablation of steroid receptor coactivator-3 promotes PPAR-beta-mediated alternative activation of microglia in experimental autoimmune encephalomyelitis.
Glia Feb 12 [Epub ahead of print] (2010).
-
Xie L, Chang L, Guan Y, Wang X. C-reactive protein augments interleukin-8 secretion in human peripheral blood monocytes.
J. Cardiovasc. Pharmacol. 46: 690-696 (2005).
-
Xie Y, Yang Q, DePierre JW. The effects of peroxisome proliferators on global lipid homeostasis and the possible significance of these effects to other responses to these xenobiotics: an hypothesis.
Ann. N. Y. Acad. Sci. 973: 17-25 (2002).
*
-
Xing B, Xin T, Hunter RL, Bing G. Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt.
J. Neuroinflammation 5: 4 (2008).
*
-
Xita N, Lazaros L, Georgiou I, Tsatsoulis A. The Pro12Ala polymorphism of the PPAR-gamma gene is not associated with the polycystic ovary syndrome.
Hormones (Athens) 8: 267-272 (2009).
-
Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics.
Arch. Pharm. Res. 28: 249-268 (2005).
-
Xu C, Wang LL, Liu HY, Ruan CM, Zhou XB, Cao YL, Li S. A novel dual peroxisome proliferator-activated receptors alpha and gamma agonist with beneficial effects on insulin resistance and lipid metabolism.
Biotechnol. Lett. 28: 863-868 (2006).
*
-
Xu C, Wang LL, Liu HY, Zhou XB, Cao YL, Li S. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
Acta Pharmacol. Sin. 27: 223-228 (2006).
-
Xu F, Yang CC, Gomillion C, Burg KJ. Effect of ceramide on mesenchymal stem cell differentiation toward adipocytes.
Appl. Biochem. Biotechnol. Jan 23 [Epub ahead of print] (2009).
*
-
Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors.
Mol. Cell 3: 397-403 (1999).
*
-
Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors.
Proc. Natl. Acad. Sci. U.S.A. 98: 13919-13924 (2001).
*
-
Xu HE, Li Y. Ligand-dependent and -independent regulation of PPARgamma and orphan nuclear receptors.
Sci. Signal. 1: pe52 (2008).
*
-
Xu HE, Stanley TB, Montana VG, Lambert MH, Shearer BG, Cobb JE, McKee DD, Galardi CM, Plunket KD, Nolte RT, Parks DJ, Moore JT, Kliewer SA, Willson TM, Stimmel JB. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha.
Nature 415: 813-817 (2002).
*
-
Xu J, Barger SW, Drew PD. The PPAR-gamma agonist 15-deoxy-delta-prostaglandin J(2) attenuates microglial production of IL-12 family cytokines: potential relevance to Alzheimer's disease.
PPAR Res. 2008: 349185 (2008).
*
-
Xu J, Chavis JA, Racke MK, Drew PD. Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes.
J. Neuroimmunol. 176: 95-105 (2006).
-
Xu J, Drew PD. Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia.
J. Immunol. 178: 1904-1913 (2007).
*
-
Xu J, Nakamura MT, Cho HP, Clarke SD. Sterol regulatory element binding protein-1 expression is suppressed by dietary polyunsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats.
J. Biol. Chem. 274: 23577-23583 (1999).
*
-
Xu J, Racke MK, Drew PD. Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis.
J. Neurochem. 103: 1801-1810 (2007).
*
-
Xu J, Storer PD, Chavis JA, Racke MK, Drew PD. Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia.
J. Neurosci. Res. 81: 403-411 (2005).
*
-
Xu KZ, Zhu C, Kim MS, Yamahara J, Li Y. Pomegranate flower ameliorates fatty liver in an animal model of type 2 diabetes and obesity.
J. Ethnopharmacol. 123: 280-287 (2009).
-
Xu L, Han C, Lim K, Wu T. Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A2alpha/cyclooxygenase-2/prostaglandin E2 signaling pathways in human hepatocellular carcinoma cells.
Cancer Res. 66: 11859-11868 (2006).
*
-
Xu L, Han C, Wu T. A novel positive feedback loop between peroxisome proliferator-activated receptor-delta and prostaglandin E2 signaling pathways for human cholangiocarcinoma cell growth.
J. Biol. Chem. 281: 33982-33996 (2006).
*
-
Xu L, Li YM. The role of PPAR alpha in the pathogenesis of fatty liver disease.
Zhonghua Gan Zang Bing Za Zhi 13: 715-717 (2005).
-
Xu P, Zhou XJ, Chen LQ, Chen J, Xie Y, Lv LH, Hou XH. Pioglitazone attenuates the severity of sodium taurocholate-induced severe acute pancreatitis.
World J. Gastroenterol. 13: 1983-1988 (2007).
*
-
Xu XQ, Soo SY, Sun W, Zweigerdt R. Global expression profile of highly enriched cardiomyocytes derived from human embryonic stem cells.
Stem Cells 27: 2163-2174 (2009).
-
Xu Y, Agrawal S, Cook TJ, Knipp GT. Maternal di-(2-ethylhexyl)-phthalate exposure influences essential fatty acid homeostasis in rat placenta.
Placenta 29: 962-969 (2008).
-
Xu Y, Cook TJ, Knipp GT. Effects of di-(2-ethylhexyl)-phthalate (DEHP) and its metabolites on fatty acid homeostasis regulating proteins in rat placental HRP-1 trophoblast cells.
Toxicol. Sci. 84: 287-300 (2005).
*
-
Xu Y, Hubal EA, Little JC. Predicting residential exposure to phthalate plasticizer emitted from vinyl flooring: sensitivity, uncertainty, and implications for biomonitoring.
Environ. Health Perspect. 118: 253-258 (2010).
-
Xu Y, Lu L, Greyson C, Rizeq M, Nunley K, Wyatt B, Bristow MR, Long CS, Schwartz GG. The PPAR-alpha activator, fenofibrate, fails to provide myocardial protection in ischemia and reperfusion in pigs.
Am. J. Physiol. Heart Circ. Physiol. 290: H1798-H1807 (2006).
*
-
Xu Y, Stephen FR, Barbara SD. Peroxisome proliferator-activated receptor gamma interacts with CIITA x RFX5 complex to repress type I collagen gene expression.
J. Biol. Chem. 282: 26046-26056 (2007).
*
-
Xu ZK, Chen NG, Ma CY, Meng ZX, Sun YJ, Han X. Role of peroxisome proliferator-activated receptor gamma in glucose-induced insulin secretion.
Acta Biochim. Biophys. Sin. (Shanghai) 38: 1-7 (2006).
-
Xue J, Hua YN, Xie ML, Gu ZL. Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells.
Biomed. Pharmacother. Oct 17 [Epub ahead of print] (2009).
-
Yaacob NS, Kaderi MA, Norazmi MN. Differential transcriptional expression of PPARalpha, PPARgamma1, and PPARgamma2 in the peritoneal macrophages and T-cell subsets of non-obese diabetic mice.
J. Clin. Immunol. 29: 595-602 (2009).
*
-
Yacoub N, Romanowska M, Krauss S, Schweiger S, Foerster J. PPARdelta is a type 1 IFN target gene and inhibits apoptosis in T cells.
J. Invest. Dermatol. 128: 1940-1949 (2008).
*
-
Yajima H, Ikeshima E, Shiraki M, Kanaya T, Fujiwara D, Odai H, Tsuboyama-Kasaoka N, Ezaki O, Oikawa S, Kondo K. Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance.
J. Biol. Chem. 279: 33456-33462 (2004).
*
-
Yajima H, Kobayashi Y, Kanaya T, Horino Y. Identification of peroxisome-proliferator responsive element in the mouse HSL gene.
Biochem. Biophys. Res. Commun. 352: 526-531 (2007).
*
-
Yakaryilmaz F, Guliter S, Savas B, Erdem O, Ersoy R, Erden E, Akyol G, Bozkaya H, Ozenirler S. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study.
Intern. Med. J. 37: 229-235 (2007).
*
-
Yamada K, Hosokawa M, Yamada C, Watanabe R, Fujimoto S, Fujiwara H, Kunitomo M, Miura T, Kaneko T, Tsuda K, Seino Y, Inagaki N. Dietary corosolic acid ameliorates obesity and hepatic steatosis in KK-Ay mice.
Biol. Pharm. Bull. 31: 651-655 (2008).
*
-
Yamada N. Fibrates.
Nippon Rinsho 60: 962-967 (2002).
-
Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Inoue H. Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation.
Protein Pept. Lett. 15: 850-853 (2008).
-
Yamagishi S, Nakamura K, Matsui T. Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease.
Pharmacol. Res. 60: 174-178 (2009).
*
-
Yamaguchi A, Tazuma S, Nishioka T, Ohishi W, Hyogo H, Nomura S, Chayama K. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver.
Dig. Dis. Sci. 50: 1361-1371 (2005).
*
-
Yamaguchi T, Matsushita S, Motojima K, Hirose F, Osumi T. MLDP, a novel PAT family protein localized to lipid droplets and enriched in the heart, is regulated by peroxisome proliferator-activated receptor alpha.
J. Biol. Chem. 281: 14232-14240 (2006).
*
-
Yamamoto K, Itoh T, Abe D, Shimizu M, Kanda T, Koyama T, Nishikawa M, Tamai T, Ooizumi H, Yamada S. Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents.
Bioorg. Med. Chem. Lett. 15: 517-522 (2005).
*
-
Yamamoto K, Ninomiya Y, Iseki M, Nakachi Y, Kanesaki-Yatsuka Y, Yamanoue Y, Itoh T, Nishii Y, Petrovsky N, Okazaki Y. 4-Hydroxydocosahexaenoic acid, a potent peroxisome proliferator-activated receptor gamma agonist alleviates the symptoms of DSS-induced colitis.
Biochem. Biophys. Res. Commun. 367: 566-572 (2008).
*
-
Yamamoto K, Ohishi M, Ho C, Kurtz TW, Rakugi H. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
Hypertension 54: 1353-1359 (2009).
-
Yamashita A, Takada T, Nemoto K, Yamamoto G, Torii R. Transient suppression of PPARgamma directed ES cells into an osteoblastic lineage.
FEBS Lett. 580: 4121-4125 (2006).
*
-
Yamashita M. Peroxisome proliferator-activated receptor alpha-independent effects of peroxisome proliferators on cysteinyl leukotriene production in mast cells.
Eur. J. Pharmacol. 556: 172-180 (2007).
*
-
Yamashita M. PPARalpha/gamma-independent effects of PPARalpha/gamma ligands on cysteinyl leukotriene production in mast cells.
PPAR Res. 2008: 293538 (2008).
*
-
Yamauchi A, Takahashi I, Takasawa S, Nata K, Noguchi N, Ikeda T, Yoshikawa T, Shervani NJ, Suzuki I, Uruno A, Unno M, Okamoto H, Sugawara A. Thiazolidinediones inhibit REG Ialpha gene transcription in gastrointestinal cancer cells.
Biochem. Biophys. Res. Commun. 379: 743-748 (2009).
*
-
Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases.
Int. J. Obes. (Lond.) 32 Suppl. 7: S13-S18 (2008).
*
-
Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, Kadowaki T. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance.
J. Biol. Chem. 276: 41245-41254 (2001).
*
-
Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions.
Nat. Med. 13: 332-339 (2007).
*
-
Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, Komeda K, Miki H, Kubota N, Terauchi Y, Tsuchida A, Tsuboyama-Kasaoka N, Yamauchi N, Ide T, Hori W, Kato S, Fukayama M, Akanuma Y, Ezaki O, Itai A, Nagai R, Kimura S, Tobe K, Kagechika H, Shudo K, et al. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes.
J. Clin. Invest. 108: 1001-1013 (2001).
*
-
Yamazaki K, Kuromitsu J, Tanaka I. Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator-activated receptor alpha agonists.
Biochem. Biophys. Res. Commun. 290: 1114-1122 (2002).
*
-
Yamazaki K, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Kanemura N, Araki H, Tsurumi H, Kojima S, Weinstein IB, Moriwaki H. Synergistic effects of RXRalpha and PPARgamma ligands to inhibit growth in human colon cancer cells - phosphorylated RXRalpha is a critical target for colon cancer management.
Gut 56: 1557-1563 (2007).
*
-
Yamazaki T, Nakamori A, Sasaki E, Wada S, Ezaki O. Fish oil prevents sucrose-induced fatty liver but exacerbates high-safflower oil-induced fatty liver in ddy mice.
Hepatology 46: 1779-1790 (2007).
*
-
Yamazaki Y, Kawano Y, Uebayasi M. Induction of adiponectin by natural and synthetic phenolamides in mouse and human preadipocytes and its enhancement by docosahexaenoic acid.
Life Sci. 82: 290-300 (2008).
*
-
Yan H, Zhu WG, Li S, Fan FY, Sun PY, Zhu JH. Pioglitazone inhibits dendritic cell adhesion and transmigration through down-regulation of dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin.
Zhonghua Yi Xue Za Zhi 88: 835-839 (2008).
-
Yan J, Fan CL, Wo XD, Gao LP. A peroxisome proliferator response elements regulatory system in xenopus oocytes and its application.
Chin. Med. J. (Engl.) 118: 1362-1367 (2005).
-
Yan ZC, Liu DY, Zhang LL, Shen CY, Ma QL, Cao TB, Wang LJ, Nie H, Zidek W, Tepel M, Zhu ZM. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta.
Biochem. Biophys. Res. Commun. 354: 427-433 (2007).
*
-
Yan ZH, Karam WG, Staudinger JL, Medvedev A, Ghanayem BI, Jetten AM. Regulation of peroxisome proliferator-activated receptor alpha-induced transactivation by the nuclear orphan receptor TAK1/TR4.
J. Biol. Chem. 273: 10948-10957 (1998).
*
-
Yanase T, Mu YM, Nishi Y, Goto K, Nomura M, Okabe T, Takayanagi R, Nawata H. Regulation of aromatase by nuclear receptors.
J. Steroid Biochem. Mol. Biol. 79: 187-192 (2001).
-
Yang CC, Wang YC, Wei S, Lin LF, Chen CS, Lee CC, Lin CC, Chen CS. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
Cancer Res. 67: 3229-3238 (2007).
*
-
Yang CR, Lai CC. Thiazolidinediones inhibit TNF-alpha-mediated osteoclast differentiation of RAW264.7 macrophages and mouse bone marrow cells through downregulation of NFATc1.
Shock Nov 26 [Epub ahead of print] (2009).
-
Yang H, Youm YH, Dixit VD. Inhibition of thymic adipogenesis by caloric restriction is coupled with reduction in age-related thymic involution.
J. Immunol. 183: 3040-3052 (2009).
-
Yang HC, Deleuze S, Zuo Y, Potthoff SA, Ma LJ, Fogo AB. The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury.
J. Am. Soc. Nephrol. 20: 2380-2388 (2009).
-
Yang J, Chen L, Zhang X, Zhou Y, Zhang D, Huo M, Guan Y. PPARs and female reproduction: evidence from genetically manipulated mice.
PPAR Res. 2008: 723243 (2008).
*
-
Yang J, Sambandam N, Han X, Gross RW, Courtois M, Kovacs A, Febbraio M, Finck BN, Kelly DP. CD36 deficiency rescues lipotoxic cardiomyopathy.
Circ. Res. 100: 1208-1217 (2007).
*
-
Yang J, Williams RS, Kelly DP. Bcl3 interacts cooperatively with peroxisome proliferator-activated receptor gamma (PPARgamma) coactivator 1alpha to coactivate nuclear receptors estrogen-related receptor alpha and PPARalpha.
Mol. Cell Biol. 29: 4091-4102 (2009).
*
-
Yang JY, Della-Fera MA, Rayalam S, Park HJ, Ambati S, Hausman DB, Hartzell DL, Baile CA. Regulation of adipogenesis by medium-chain fatty acids in the absence of hormonal cocktail.
J. Nutr. Biochem. 20: 537-543 (2009).
*
-
Yang L, Chan CC, Kwon OS, Liu S, McGhee J, Stimpson S, Chen L, Harrington WW, Symonds W, Rockey DC. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis.
Am. J. Physiol. Gastrointest. Liver Physiol. 291: G902-G911 (2006).
*
-
Yang L, Olsson B, Pfeifer D, Jonsson JI, Zhou ZG, Jiang X, Fredriksson BA, Zhang H, Sun XF. Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell-fibronectin adhesion of colon cancer cells.
Oncogene Nov 23 [Epub ahead of print] (2009).
*
-
Yang L, Zhou ZG, Zheng XL, Wang L, Yu YY, Zhou B, Gu J, Li Y. RNA interference against peroxisome proliferator-activated receptor delta gene promotes proliferation of human colorectal cancer cells.
Dis. Colon Rectum 51: 318-328 (2008).
*
-
Yang Q, Ito S, Gonzalez FJ. Hepatocyte-restricted constitutive activation of PPAR-alpha induces hepatoproliferation but not hepatocarcinogenesis.
Carcinogenesis 28: 1171-1177 (2007).
*
-
Yang Q, Li Y. Roles of PPARs on regulating myocardial energy and lipid homeostasis.
J. Mol. Med. 85: 697-706 (2007).
*
-
Yang Q, Nagano T, Shah Y, Cheung C, Ito S, Gonzalez FJ. The PPARalpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPARalpha.
Toxicol. Sci. 101: 132-139 (2008).
*
-
Yang Q, Xie Y, Alexson SE, Nelson BD, DePierre JW. Involvement of the peroxisome proliferator-activated receptor alpha in the immunomodulation caused by peroxisome proliferators in mice.
Biochem. Pharmacol. 63: 1893-1900 (2002).
*
-
Yang Q, Yamada A, Kimura S, Peters JM, Gonzalez FJ. Alterations in skin and stratified epithelia by constitutively activated PPARalpha.
J. Invest. Dermatol. 126: 374-385 (2006).
*
-
Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius FC 3rd, Schnermann JB, Briggs JP. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney.
Am. J. Physiol. 277: F966-F973 (1999).
*
-
Yang W, Rachez C, Freedman LP. Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators.
Mol. Cell. Biol. 20: 8008-8017 (2000).
*
-
Yang WL, Frucht H. Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells.
Carcinogenesis 22: 1379-1383 (2001).
*
-
Yang XH, Liang PF, Jiang BM, Huang XY. Study on the antisense oligonucleotide against peroxisome proliferator-activated receptors promoting TNF-alpha mediated apoptosis of HaCat cells.
Zhonghua Shao Shang Za Zhi 22: 369-373 (2006).
-
Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, Farrar WL. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT.
J. Biol. Chem. 275: 4541-4544 (2000).
*
-
Yang XY, Wang LH, Farrar WL. A role for PPARgamma in the regulation of cytokines in immune cells and cancer.
PPAR Res. 2008: 961753 (2008).
*
-
Yang XY, Wang LH, Mihalic K, Xiao W, Chen T, Li P, Wahl LM, Farrar WL. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands.
J. Biol. Chem. 277: 3973-3978 (2002).
*
-
Yang Y, Gocke AR, Lovett-Racke A, Drew PD, Racke MK. PPAR alpha regulation of the immune response and autoimmune encephalomyelitis.
PPAR Res. 2008: 546753 (2008).
*
-
Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, Motoshima H, Taguchi T, Sonoda K, Kukidome D, Takuwa Y, Kawada T, Brownlee M, Nishikawa T, Araki E. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages.
Circ. Res. 100: 1442-1451 (2007).
*
-
Yao L, Li K, Zhang L, Yao S, Piao Z, Song L. Influence of the Pro12Ala polymorphism of PPAR-gamma on age at onset and sRAGE levels in Alzheimer's disease.
Brain Res. 1291: 133-139 (2009).
-
| |
